{"meta":{"query_hash":"386b2f745ddd","filters":{"venue":"Diabetes Obesity and Metabolism"},"cohort_total":602,"direct_labels_cover":1,"predictions_cover":602,"exported":602,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/386b2f745ddd","api":"https://metacan.xera.ac/api/v1/cohort?venue=Diabetes+Obesity+and+Metabolism"},"results":[{"id":"W1515030747","doi":"10.1111/j.1463-1326.2009.01044.x","title":"Antihyperglycaemic medication modifies factors of postprandial satiety in type 2 diabetes","year":2009,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University Health Centre; Diabète Québec","keywords":"Postprandial; Ghrelin; Internal medicine; Gastric emptying; Endocrinology; Medicine; Leptin; Type 2 diabetes; Crossover study; Meal; Glucagon-like peptide-1; Insulin; Area under the curve; Peptide YY; Diabetes mellitus; Gastric inhibitory polypeptide; Gastrointestinal hormone; Glucagon; Hormone; Peptide hormone; Stomach; Obesity; Neuropeptide; Receptor; Neuropeptide Y receptor","score_opus":0.017800411042103996,"score_gpt":0.22962911092852423,"score_spread":0.21182869988642022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1515030747","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991295,0.0004771259,0.000053368512,0.000013408382,0.000009689218,0.0000093256485,0.000040680392,0.000003592712,0.00026329828],"genre_scores_gemma":[0.9992606,0.00018692925,0.00011105917,0.000033065975,0.00002125741,0.0000089988,0.000110768815,0.0000022928007,0.0002650946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999848,0.00006119429,0.000014427119,0.00002695343,0.000029990342,0.00001931488],"domain_scores_gemma":[0.9993517,0.0001740475,0.00027508638,0.000035688478,0.000032376196,0.00013113659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037097302,0.00030102188,0.00041944333,0.00023565943,0.00024194157,0.00038895145,0.00012278998,0.0003284712,0.0017574045],"category_scores_gemma":[0.0010193936,0.00019421315,0.0003150528,0.00025990998,0.0001717832,0.00020623105,0.00016173445,0.00044653306,0.00012206781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028033262,0.0022632503,0.9177991,0.0001569047,0.00051908556,0.0004471227,0.00026908575,0.00018796556,0.026941251,0.000024887395,0.0001549942,0.023203082],"study_design_scores_gemma":[0.00007574932,0.0021956253,0.9969062,0.0000043367763,0.00006128934,0.000113027614,0.000028636841,0.000093696835,0.00040523135,0.000007240154,0.000105386076,0.000003478306],"about_ca_topic_score_codex":0.00062821526,"about_ca_topic_score_gemma":0.000954187,"teacher_disagreement_score":0.0017574045,"about_ca_system_score_codex":0.00016175481,"about_ca_system_score_gemma":0.00010464512,"threshold_uncertainty_score":0.005879104},"labels":[],"label_agreement":null},{"id":"W1606810773","doi":"10.1111/dom.12498","title":"One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Johnson and Johnson; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi; Merck; Takeda Pharmaceutical Company; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Medicine; Insulin degludec; Liraglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Basal insulin","score_opus":0.01926542420580191,"score_gpt":0.23143813045442665,"score_spread":0.21217270624862475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606810773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99594253,0.0021594535,0.00022133908,0.00015266828,0.0001482757,0.00041319436,0.00032246477,0.00003845728,0.0006015571],"genre_scores_gemma":[0.9927689,0.0014450328,0.00083101826,0.00040267958,0.00034488202,0.0009869225,0.0010488192,0.000018644323,0.0021532178],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999106,0.00041256787,0.000061413215,0.00018752593,0.00008022622,0.00015210445],"domain_scores_gemma":[0.9981522,0.000393453,0.00047801077,0.0002607064,0.00012262537,0.00059300044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030848768,0.0018960284,0.0033761007,0.00037264818,0.00037134418,0.0012945795,0.0008697626,0.00135451,0.0035421147],"category_scores_gemma":[0.001919718,0.0008026861,0.0031483502,0.0003163268,0.0007990717,0.0010719186,0.0005639228,0.003518585,0.0008424729],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9784742,0.0070661786,0.0014396661,0.00018697573,0.00063672854,0.00003689503,0.00004245535,0.00024006645,0.0021194078,0.000020644431,0.00025203777,0.009484759],"study_design_scores_gemma":[0.8040593,0.18428433,0.008951163,0.000038565973,0.00094208884,0.000061009618,0.000024753977,0.00032661,0.00066974777,0.00004474952,0.0005703659,0.000027192138],"about_ca_topic_score_codex":0.0005200754,"about_ca_topic_score_gemma":0.0007721323,"teacher_disagreement_score":0.0035421147,"about_ca_system_score_codex":0.00068886665,"about_ca_system_score_gemma":0.00072043866,"threshold_uncertainty_score":0.016314626},"labels":[],"label_agreement":null},{"id":"W1658549429","doi":"10.1111/dom.12032","title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials","year":2012,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":350,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Insulin degludec; Insulin glargine; Medicine; Internal medicine; Insulin; Population; Diabetes mellitus; Hypoglycemia; Relative risk; Type 1 diabetes; Randomized controlled trial; Endocrinology; Confidence interval","score_opus":0.10272121858819495,"score_gpt":0.36449144134910333,"score_spread":0.2617702227609084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1658549429","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054747157,0.9371836,0.0029737507,0.00046510698,0.000997394,0.00079645816,0.0014296578,0.00019004743,0.0012168343],"genre_scores_gemma":[0.77834696,0.20916523,0.004792634,0.0016098669,0.0006810056,0.0022083002,0.0015928224,0.00015849121,0.0014446493],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9877923,0.007929975,0.0018692802,0.0012461381,0.000825815,0.00033651938],"domain_scores_gemma":[0.9858601,0.010284154,0.0022106613,0.000783347,0.000601733,0.00025997814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016481047,0.003809813,0.016352136,0.0024028919,0.00047720547,0.0037358815,0.001672013,0.0024961804,0.0039537246],"category_scores_gemma":[0.02278338,0.0017089002,0.06639024,0.003279008,0.00066962163,0.0016109094,0.0013574046,0.003260041,0.00038908125],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016182525,0.000028626057,0.0025541892,0.032543212,0.9439761,0.00006774601,0.000028670944,0.00054947665,0.00019028563,0.000068112095,0.00029621043,0.0035148652],"study_design_scores_gemma":[0.0041452628,0.0005354938,0.0026833725,0.0014965194,0.9900031,0.000051561547,0.000018517549,0.00036671566,0.00010739905,0.00013856488,0.00043734995,0.000016184333],"about_ca_topic_score_codex":0.0042128707,"about_ca_topic_score_gemma":0.0050061406,"teacher_disagreement_score":0.016481047,"about_ca_system_score_codex":0.0017279512,"about_ca_system_score_gemma":0.0011723053,"threshold_uncertainty_score":0.087161124},"labels":[],"label_agreement":null},{"id":"W1834728684","doi":"10.1111/dom.12582","title":"Frequency of cancer events with saxagliptin in the <scp>SAVOR‐TIMI</scp> 53 trial","year":2015,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Forest Laboratories; Johnson and Johnson; Eisai; Daiichi-Sankyo; Bayer HealthCare; Hadassah Medical Organization; Gilead Sciences; Medtronic; Roche; Merck; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Pfizer; American Diabetes Association","keywords":"Saxagliptin; Medicine; TIMI; Internal medicine; Placebo; Myocardial infarction; Randomized controlled trial; Cancer; Adverse effect; Oncology; Metformin; Sitagliptin; Thrombolysis; Pathology","score_opus":0.018651721433678856,"score_gpt":0.2511753008881978,"score_spread":0.23252357945451893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834728684","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97260815,0.017647164,0.00088252185,0.0010072811,0.0003588771,0.00065669854,0.002658924,0.00006021014,0.004120257],"genre_scores_gemma":[0.9900203,0.0036571145,0.00050149363,0.0006483377,0.00035624835,0.0006335055,0.0029819834,0.000015591348,0.0011854408],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99791247,0.0014324163,0.00016777709,0.00021363558,0.00017185937,0.00010183884],"domain_scores_gemma":[0.9983187,0.00069599843,0.000522263,0.00016628878,0.00010733502,0.00018946653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042649405,0.0005002548,0.001319624,0.00017171705,0.00027080634,0.0010443203,0.0003098182,0.0011010503,0.0024785083],"category_scores_gemma":[0.002974327,0.00019157518,0.0024814964,0.00046118165,0.00032527948,0.00056816015,0.00034194934,0.0015405522,0.00024356633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88729817,0.0016369992,0.041563835,0.0029018384,0.007913972,0.00013257872,0.00011335172,0.0012688726,0.0021964596,0.0006591355,0.0052388594,0.049075868],"study_design_scores_gemma":[0.5146684,0.114977024,0.32125294,0.0011061827,0.022540385,0.0005928017,0.00022296979,0.006536179,0.0028300672,0.00276131,0.012361826,0.00014996104],"about_ca_topic_score_codex":0.00049693725,"about_ca_topic_score_gemma":0.0011264338,"teacher_disagreement_score":0.0042649405,"about_ca_system_score_codex":0.0003686355,"about_ca_system_score_gemma":0.00047106142,"threshold_uncertainty_score":0.02255541},"labels":[],"label_agreement":null},{"id":"W1874041614","doi":"10.1111/dom.12469","title":"Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Janssen Biotech; Novo Nordisk; Merck; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Metformin; Placebo; Randomized controlled trial; Type 2 diabetes; Clinical endpoint; Confidence interval; Internal medicine; Diabetes mellitus; Insulin; Endocrinology","score_opus":0.016243730977527217,"score_gpt":0.24011760220982117,"score_spread":0.22387387123229396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1874041614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990384,0.005362242,0.00048368756,0.0005379421,0.0005427259,0.0012019739,0.00045242452,0.00008897933,0.00094602857],"genre_scores_gemma":[0.990914,0.002901669,0.0009816729,0.0008382356,0.00056569034,0.001688618,0.00049995206,0.000017685301,0.0015924751],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99928504,0.00036953716,0.000072462586,0.00013796748,0.00006441723,0.00007059657],"domain_scores_gemma":[0.9990434,0.0003012011,0.00022216928,0.00008585982,0.00005894709,0.00028849774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019141082,0.001364145,0.003965382,0.0004754521,0.00034968936,0.0011747227,0.0008204217,0.0021205854,0.004154969],"category_scores_gemma":[0.0019697524,0.0008235737,0.001955333,0.00043960926,0.00086144183,0.0012969997,0.00043139872,0.002684987,0.0006972798],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9844327,0.0035438016,0.0004273041,0.00039488124,0.00062139507,0.000024986697,0.000024050634,0.00012594555,0.0015567587,0.000031555042,0.00019182161,0.0086247325],"study_design_scores_gemma":[0.95958847,0.037655886,0.0015244394,0.0000246948,0.00039787564,0.000021846501,0.00001080943,0.00030827447,0.00019841343,0.000048789643,0.00021028447,0.000010179885],"about_ca_topic_score_codex":0.0004345901,"about_ca_topic_score_gemma":0.00073392317,"teacher_disagreement_score":0.004154969,"about_ca_system_score_codex":0.00039765847,"about_ca_system_score_gemma":0.0005374018,"threshold_uncertainty_score":0.013899803},"labels":[],"label_agreement":null},{"id":"W1920830047","doi":"10.1111/dom.12589","title":"Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk; Medtronic; Sanofi-Aventis Korea Company; Janssen Research and Development; Novartis; Eli Lilly and Company","keywords":"Canagliflozin; Medicine; Placebo; Incretin; Type 2 diabetes; Sitagliptin; Glucagon-like peptide 1 receptor; Internal medicine; Pharmacology; Endocrinology; Adverse effect; Dipeptidyl peptidase-4; Urology; Agonist; Diabetes mellitus; Gastroenterology; Receptor","score_opus":0.009532739788251,"score_gpt":0.2029113262920717,"score_spread":0.1933785865038207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1920830047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881294,0.009933523,0.00018965956,0.00021510558,0.000110271314,0.00007980599,0.00013813483,0.000015932348,0.0011882402],"genre_scores_gemma":[0.9977621,0.0013150233,0.0002402638,0.00022564821,0.00014772074,0.000041092575,0.00014116826,0.0000022894146,0.00012470335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981939,0.00091707613,0.00016885412,0.00025267276,0.00037753204,0.0000899376],"domain_scores_gemma":[0.9975127,0.0013261334,0.00067033235,0.00012753489,0.00012695593,0.000236319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032883517,0.0004030483,0.0017976185,0.00043804952,0.00024068441,0.00092533155,0.00032339024,0.0010008462,0.00087571715],"category_scores_gemma":[0.0056355186,0.00030146303,0.0015078239,0.0005164226,0.00047462236,0.0005314927,0.00032418728,0.0010768351,0.00014454791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65218407,0.006533839,0.12912256,0.0015752118,0.009404875,0.00027167285,0.00021349566,0.0020351363,0.010575235,0.00010406833,0.0008457473,0.18713415],"study_design_scores_gemma":[0.13677813,0.27077293,0.5632732,0.00036986443,0.013198504,0.000987604,0.00022517335,0.0045794435,0.006452661,0.00037931965,0.002883254,0.000100033394],"about_ca_topic_score_codex":0.00045378617,"about_ca_topic_score_gemma":0.00082357874,"teacher_disagreement_score":0.0032883517,"about_ca_system_score_codex":0.0004607987,"about_ca_system_score_gemma":0.00039735608,"threshold_uncertainty_score":0.017390728},"labels":[],"label_agreement":null},{"id":"W1924115782","doi":"10.1111/dom.12574","title":"Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes","year":2015,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Novo Nordisk Fonden; Boehringer Ingelheim; F. Hoffmann-La Roche; Novo Nordisk; Intarcia Therapeutics; Biodel; GlaxoSmithKline; Osiris Therapeutics; Halozyme; Sanofi; Quest Diagnostics; Novartis; Pfizer; Orexigen Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Insulin degludec; Medicine; Liraglutide; Glycated haemoglobin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Glycated hemoglobin; Baseline (sea); Endocrinology; Insulin glargine","score_opus":0.04835495310799587,"score_gpt":0.2811609730836879,"score_spread":0.23280601997569206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924115782","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070424,0.007192889,0.00036642002,0.0001555874,0.0000823433,0.0001436561,0.00026068438,0.000027863007,0.0010663411],"genre_scores_gemma":[0.9960414,0.0016182415,0.0009682218,0.00019393896,0.00010808956,0.00012145073,0.00033675463,0.000007908389,0.000603985],"study_design_codex":"randomized_trial","study_design_gemma":"systematic_review","domain_scores_codex":[0.99942446,0.0003215136,0.000053381016,0.000084377665,0.000059814527,0.000056491335],"domain_scores_gemma":[0.9990402,0.00034146756,0.00029220892,0.00008315161,0.000043160708,0.00019977303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013462045,0.00053477567,0.0019019146,0.00020523592,0.000120114935,0.00064684596,0.00027864636,0.0004178952,0.0020315312],"category_scores_gemma":[0.0011749482,0.00024517515,0.0012189024,0.00021201692,0.0003019903,0.00047756493,0.00027591788,0.0011084102,0.00022087155],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90167934,0.003233962,0.0068598557,0.000715218,0.0031437858,0.000055166445,0.000033323115,0.00051617634,0.016476557,0.00005307122,0.00031656338,0.06691678],"study_design_scores_gemma":[0.2442344,0.6177847,0.108354434,0.0002948431,0.010042865,0.000616197,0.00012988261,0.0025513743,0.01161478,0.00025522467,0.0040613892,0.00005994429],"about_ca_topic_score_codex":0.00022298882,"about_ca_topic_score_gemma":0.00065760914,"teacher_disagreement_score":0.0020315312,"about_ca_system_score_codex":0.000217113,"about_ca_system_score_gemma":0.00034180057,"threshold_uncertainty_score":0.007119477},"labels":[],"label_agreement":null},{"id":"W1953794210","doi":"10.1111/dom.12543","title":"Durability and tolerability of dapagliflozin over 52 weeks as add‐on to metformin and sulphonylurea in type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Dapagliflozin; Placebo; Metformin; Tolerability; Medicine; Internal medicine; Adverse effect; Type 2 diabetes; Diabetes mellitus; Endocrinology; Urology; Gastroenterology","score_opus":0.015671699916392244,"score_gpt":0.2562610136405628,"score_spread":0.24058931372417056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1953794210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804866,0.0013727663,0.00014360635,0.00003714278,0.000019196495,0.00003303327,0.000080897764,0.000014294331,0.00025042408],"genre_scores_gemma":[0.9989048,0.0003643215,0.00013481324,0.00006980412,0.00004675757,0.000035681398,0.00016436235,0.000004861765,0.00027462348],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993911,0.00020622663,0.00006966979,0.00009848374,0.00015657744,0.00007795462],"domain_scores_gemma":[0.9987306,0.00039454206,0.0004367116,0.00014302605,0.00009738798,0.00019768885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021063746,0.0003475356,0.0009263743,0.00022320665,0.0001587556,0.00047341886,0.00026641082,0.0004513171,0.0011398287],"category_scores_gemma":[0.002392467,0.00021850067,0.0007824383,0.00022872988,0.00018934911,0.00045655845,0.00018355114,0.00082970463,0.00023427606],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40551946,0.013951593,0.14956756,0.00072160433,0.0017747893,0.0004053989,0.00038439693,0.002840115,0.06644143,0.000054502594,0.0008746297,0.35746452],"study_design_scores_gemma":[0.028023357,0.31344673,0.62941283,0.0001110374,0.0021577657,0.00073446456,0.0001750556,0.0039939573,0.020010756,0.00011997056,0.0017385082,0.00007562236],"about_ca_topic_score_codex":0.00034454002,"about_ca_topic_score_gemma":0.00037845207,"teacher_disagreement_score":0.0021063746,"about_ca_system_score_codex":0.00026314048,"about_ca_system_score_gemma":0.00018282207,"threshold_uncertainty_score":0.011139691},"labels":[],"label_agreement":null},{"id":"W1965490690","doi":"10.1111/j.1463-1326.2011.01451.x","title":"Regulation of glucagon secretion by zinc: lessons from the β cell‐specific Znt8 knockout mouse model","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Glucagon; Endocrinology; Internal medicine; Secretion; Paracrine signalling; Islet; Biology; Glucose homeostasis; Insulin; Enteroendocrine cell; Somatostatin; Zinc; Chemistry; Hormone; Endocrine system; Insulin resistance; Medicine; Receptor","score_opus":0.041407269805514624,"score_gpt":0.2679001325510986,"score_spread":0.226492862745584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965490690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007808829,0.9974016,0.0004519772,0.00048085616,0.000114601986,0.000003381139,0.000018370396,0.000016928509,0.0007313924],"genre_scores_gemma":[0.0027318853,0.99592006,0.00051240565,0.00022457895,0.00010673315,0.0000067048545,0.000025945557,0.0000030260833,0.00046873096],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993145,0.000009682838,0.000013675803,0.000013968814,0.000024079138,0.000007095725],"domain_scores_gemma":[0.99990416,0.000032861102,0.000019149806,0.000005216184,0.000024183973,0.0000143908255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033480418,0.0006151865,0.0010323692,0.0009934967,0.00011398677,0.00046211106,0.000734435,0.0006923223,0.0009262746],"category_scores_gemma":[0.00024469875,0.00015341018,0.00027298412,0.00081619574,0.00044155022,0.0008772555,0.00033247587,0.0012770669,0.0007784653],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033099958,0.00014535099,0.00052732334,0.010722792,0.000112960704,0.001326576,0.000066573826,0.0003153168,0.020336604,0.0039738705,0.01910218,0.9430395],"study_design_scores_gemma":[0.00013656671,0.0003618025,0.0039161765,0.0024225933,0.00026002308,0.0090176985,0.000111432855,0.00028769526,0.009059411,0.0060121864,0.96836543,0.000049096783],"about_ca_topic_score_codex":0.00061765255,"about_ca_topic_score_gemma":0.0010913481,"teacher_disagreement_score":0.0010323692,"about_ca_system_score_codex":0.0003221151,"about_ca_system_score_gemma":0.0004211192,"threshold_uncertainty_score":0.0030987263},"labels":[],"label_agreement":null},{"id":"W1965801257","doi":"10.1111/j.1463-1326.2006.00700.x","title":"Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?","year":2007,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Thiazolidinedione; Insulin; Medicine; Pioglitazone; Internal medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","score_opus":0.013346234962165197,"score_gpt":0.2751306039873413,"score_spread":0.2617843690251761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965801257","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015621322,0.96855295,0.00062724913,0.024961066,0.0022365907,0.000006659759,0.00002707532,0.000033945165,0.0019923246],"genre_scores_gemma":[0.016052091,0.95578045,0.0013595879,0.015303624,0.004965496,0.000029908635,0.00004864003,0.000016706941,0.0064435084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965477,0.00010501277,0.00004002897,0.00006205073,0.00007605217,0.000062069135],"domain_scores_gemma":[0.9995715,0.00018042061,0.000058602604,0.000027288606,0.00008561193,0.00007659492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008223468,0.00055458694,0.0013759958,0.00089840876,0.0005121964,0.002519704,0.00063493795,0.0022465012,0.0033806104],"category_scores_gemma":[0.00073834165,0.00024756714,0.000592368,0.0008945193,0.001935811,0.003973649,0.0012624051,0.004401824,0.0012928384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015894511,0.00024586188,0.0026611572,0.010547342,0.00031854952,0.0022858398,0.0014020371,0.00045993188,0.016682815,0.071862206,0.09524541,0.79669946],"study_design_scores_gemma":[0.00015738503,0.00079638115,0.0036382366,0.0028033152,0.00020783325,0.004004317,0.001624946,0.00024553706,0.0021187796,0.04401276,0.9402983,0.000092168295],"about_ca_topic_score_codex":0.001034898,"about_ca_topic_score_gemma":0.0017383265,"teacher_disagreement_score":0.0033806104,"about_ca_system_score_codex":0.00076819153,"about_ca_system_score_gemma":0.0010682696,"threshold_uncertainty_score":0.0113092065},"labels":[],"label_agreement":null},{"id":"W1966459465","doi":"10.1111/dom.12232","title":"Are bedtime nutritional strategies effective in preventing nocturnal hypoglycaemia in patients with type 1 diabetes?","year":2013,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Montreal Clinical Research Institute","funders":"American Diabetes Association","keywords":"Bedtime; Medicine; Type 1 diabetes; Type 2 diabetes; Diabetes mellitus; Medical prescription; Insulin; Regimen; Hypoglycemia; Internal medicine; Pediatrics; Intensive care medicine; Endocrinology; Pharmacology","score_opus":0.01714922819426279,"score_gpt":0.2812323911644366,"score_spread":0.2640831629701738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966459465","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011185062,0.99768615,0.00004227632,0.00062740775,0.00011823456,0.000019770776,0.000065971064,0.0000018095709,0.00032001027],"genre_scores_gemma":[0.012416504,0.98577833,0.0004065007,0.0009574999,0.00019169842,0.00006866082,0.000086650994,0.0000021059834,0.00009207603],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99827814,0.0007417578,0.0005826639,0.00013046771,0.00021749524,0.000049466245],"domain_scores_gemma":[0.992486,0.005782142,0.0012120253,0.000062757754,0.0003741229,0.00008292545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027455024,0.0005058014,0.0032189207,0.0016041548,0.00028174272,0.0020253207,0.0010871772,0.0022920282,0.0046194107],"category_scores_gemma":[0.014803019,0.000361913,0.0026234477,0.0018259907,0.00047420542,0.001888788,0.00048482645,0.0011885823,0.00040863713],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017460204,0.00014250759,0.0015061809,0.61820805,0.004931616,0.00022740787,0.00035466536,0.00009966049,0.00025393764,0.0006772771,0.003403945,0.36844876],"study_design_scores_gemma":[0.001658629,0.0018218537,0.01666263,0.84488225,0.029332247,0.0013218971,0.0016291277,0.00018981569,0.00047230904,0.0021741018,0.09976681,0.00008820711],"about_ca_topic_score_codex":0.0020093082,"about_ca_topic_score_gemma":0.0048558963,"teacher_disagreement_score":0.0046194107,"about_ca_system_score_codex":0.000664478,"about_ca_system_score_gemma":0.0019798449,"threshold_uncertainty_score":0.015453517},"labels":[],"label_agreement":null},{"id":"W1968714039","doi":"10.1111/j.1463-1326.2008.00930.x","title":"Blood pressure changes associated with sibutramine and weight management – an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes trial (SCOUT)*","year":2008,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"","keywords":"Sibutramine; Medicine; Blood pressure; Weight loss; Overweight; Post-hoc analysis; Weight management; Weight gain; Heart rate; Cardiology; Internal medicine; Diastole; Placebo; Weight change; Obesity; Anesthesia; Body weight","score_opus":0.013083279168338692,"score_gpt":0.22332250847425486,"score_spread":0.21023922930591618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968714039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948762,0.002632313,0.00027241607,0.00011533777,0.000069988986,0.0002619155,0.0012434059,0.00002746515,0.00050095166],"genre_scores_gemma":[0.9945135,0.000879336,0.00030952287,0.00017298466,0.00017857521,0.00060445676,0.002818942,0.000017751066,0.00050500105],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960956,0.0024785402,0.00027152238,0.0004415344,0.0003828893,0.00032989716],"domain_scores_gemma":[0.9928779,0.002522173,0.0022191375,0.0008886914,0.00047829535,0.0010138253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056941053,0.0015824002,0.0046535702,0.0005457212,0.0005344656,0.0012931905,0.00088095875,0.0017818154,0.0021784357],"category_scores_gemma":[0.006617643,0.0006750044,0.004423667,0.0009605844,0.0006933748,0.0008749753,0.0009893304,0.0018560137,0.00027016085],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93165505,0.0016640641,0.048684873,0.0006445813,0.008106842,0.0001056382,0.0000890906,0.00043532212,0.0012088654,0.000043664866,0.00076209445,0.006599858],"study_design_scores_gemma":[0.2578924,0.07966125,0.64175373,0.00017960771,0.015339956,0.000256361,0.00014932407,0.0022129766,0.00074658333,0.00024380763,0.001438306,0.00012572536],"about_ca_topic_score_codex":0.0014404332,"about_ca_topic_score_gemma":0.0019094534,"teacher_disagreement_score":0.0056941053,"about_ca_system_score_codex":0.0004446382,"about_ca_system_score_gemma":0.00073481473,"threshold_uncertainty_score":0.030113697},"labels":[],"label_agreement":null},{"id":"W1971679833","doi":"10.1111/j.1463-1326.2008.01022.x","title":"Prodrug delivery of novel PTP1B inhibitors to enhance insulin signalling","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Institutes of Health","keywords":"Prodrug; Insulin; Pharmacology; Population; Chemistry; Endocrinology; Internal medicine; Medicine; Biology","score_opus":0.0056008183022375245,"score_gpt":0.22662442827250262,"score_spread":0.2210236099702651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971679833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95785797,0.005918615,0.026176708,0.00034500493,0.00017261939,0.0002712594,0.00053630845,0.0002576497,0.008463819],"genre_scores_gemma":[0.97089237,0.0036735437,0.015179372,0.00014606013,0.000031715463,0.00015401609,0.00033231263,0.00003882807,0.009551683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995077,0.000007548811,0.0000032714995,0.00001395368,0.000012907345,0.000011593175],"domain_scores_gemma":[0.9999734,0.0000046480786,0.000009717955,0.0000020313273,0.0000036058561,0.000006529175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105567895,0.0003247614,0.0002624662,0.00019113091,0.000061682,0.00020196645,0.00018876018,0.00035415113,0.0012557721],"category_scores_gemma":[0.00008682384,0.000106211606,0.00012066933,0.00009479993,0.00009141054,0.00023368534,0.00013960052,0.00048724085,0.00030217462],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017621697,0.0001364018,0.00003262706,0.000101624515,0.000007150413,0.00011971188,0.000014673891,0.0011591769,0.98804396,0.0009222971,0.0002506897,0.009035389],"study_design_scores_gemma":[0.00014210561,0.0013451743,0.0004002564,0.000013484301,0.0000203917,0.00023442441,0.000009271037,0.004996256,0.98331994,0.00016375218,0.009345591,0.000009424258],"about_ca_topic_score_codex":0.00022652096,"about_ca_topic_score_gemma":0.000343661,"teacher_disagreement_score":0.0012557721,"about_ca_system_score_codex":0.00025707873,"about_ca_system_score_gemma":0.000095962125,"threshold_uncertainty_score":0.004200995},"labels":[],"label_agreement":null},{"id":"W1974288288","doi":"10.1111/dom.12052","title":"Insulin degludec: overview of a novel ultra long‐acting basal insulin","year":2012,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Western University","funders":"Novo Nordisk; National Institute for Health and Care Research","keywords":"Insulin degludec; Insulin; Dosing; Basal (medicine); Pharmacodynamics; Medicine; Endocrinology; Insulin glargine; Internal medicine; Bolus (digestion); Subcutaneous injection; Pharmacokinetics; Basal insulin; Diabetes mellitus; Type 2 diabetes; Hypoglycemia","score_opus":0.11182474375695334,"score_gpt":0.3561623482500433,"score_spread":0.24433760449308994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974288288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040062057,0.9965772,0.0005649866,0.00017789811,0.00020351972,0.00001753059,0.00003435398,0.000020531861,0.0020033484],"genre_scores_gemma":[0.00162348,0.9959377,0.00094538205,0.00019980191,0.00012889298,0.000020751766,0.00008388659,0.0000046749637,0.0010554129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979633,0.000023460863,0.000039765193,0.000047597707,0.0000746803,0.000018096744],"domain_scores_gemma":[0.99981016,0.000077088494,0.00003499983,0.000006018646,0.00005077616,0.000020992362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052679534,0.0009770297,0.0011063685,0.0024617855,0.00021405994,0.0009102438,0.00075170887,0.00079378317,0.0026481133],"category_scores_gemma":[0.00038219188,0.00046970596,0.0006849993,0.0021753584,0.00034875586,0.0014362822,0.0004506052,0.0023781746,0.0023289863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019868634,0.00019257376,0.00018030932,0.01304876,0.000083724095,0.00030870287,0.00004336537,0.00040186264,0.0040266206,0.0027002562,0.009999947,0.96881515],"study_design_scores_gemma":[0.000054750937,0.00032792467,0.00095558795,0.0021219435,0.00013434945,0.0021735365,0.000048321264,0.000267833,0.0024339843,0.001197141,0.9902503,0.00003439078],"about_ca_topic_score_codex":0.0010174331,"about_ca_topic_score_gemma":0.0011470016,"teacher_disagreement_score":0.0026481133,"about_ca_system_score_codex":0.0004687209,"about_ca_system_score_gemma":0.0005964817,"threshold_uncertainty_score":0.0088588},"labels":[],"label_agreement":null},{"id":"W1975929001","doi":"10.1111/dom.12121","title":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( <scp>GetGoal</scp> ‐P)","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"American Diabetes Association","keywords":"Lixisenatide; Placebo; Medicine; Pioglitazone; Internal medicine; Adverse effect; Metformin; Type 2 diabetes; Randomized controlled trial; Clinical endpoint; Diabetes mellitus; Endocrinology","score_opus":0.009655752413255798,"score_gpt":0.22764533074075968,"score_spread":0.21798957832750387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975929001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920946,0.0059832428,0.00024005033,0.00021806738,0.00022682751,0.00050122815,0.00019052181,0.00004660952,0.0004988431],"genre_scores_gemma":[0.994787,0.002356262,0.00069695787,0.00031703684,0.00023363616,0.0007027427,0.00021713847,0.000009489311,0.0006797388],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989396,0.0005891284,0.0001412893,0.00014816274,0.00010665667,0.00007520941],"domain_scores_gemma":[0.99838495,0.00056757464,0.00046754658,0.000092908056,0.000074044656,0.0004130072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020832533,0.0008724299,0.0034390958,0.0005743196,0.00034889387,0.0010491102,0.00068205164,0.0019019226,0.003581228],"category_scores_gemma":[0.0023529867,0.0006404781,0.0014928842,0.000407396,0.00084694446,0.0011308349,0.000392763,0.0017261879,0.0004209011],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97181994,0.0064989473,0.000541122,0.0005927545,0.00055070646,0.000021873337,0.000030673946,0.00012652285,0.0048058815,0.000034003904,0.00010950895,0.014867985],"study_design_scores_gemma":[0.73440975,0.25868347,0.0034442677,0.00007321669,0.00079218607,0.00004568772,0.00003318082,0.00043080846,0.0016729629,0.00008415399,0.00031108843,0.000019120052],"about_ca_topic_score_codex":0.00033555258,"about_ca_topic_score_gemma":0.0004849029,"teacher_disagreement_score":0.003581228,"about_ca_system_score_codex":0.0004849792,"about_ca_system_score_gemma":0.0006237309,"threshold_uncertainty_score":0.011980414},"labels":[],"label_agreement":null},{"id":"W1979078348","doi":"10.1111/dom.12393","title":"Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Tolerability; Type 2 diabetes; Placebo; Medicine; Randomized controlled trial; Pioglitazone; Clinical endpoint; Internal medicine; Diabetes mellitus; Pharmacokinetics; Pharmacology; Adverse effect; Endocrinology","score_opus":0.013940990441817559,"score_gpt":0.2524403988908831,"score_spread":0.23849940844906553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979078348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919373,0.0019158382,0.0007058768,0.00051700976,0.0005204382,0.0023508344,0.00082382007,0.00015451806,0.0010745043],"genre_scores_gemma":[0.98872036,0.0012826481,0.0015917966,0.0010212131,0.0007223832,0.0031117427,0.0010336004,0.000031826414,0.0024842962],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99865997,0.000788121,0.0000880731,0.00021338556,0.0001085448,0.00014185887],"domain_scores_gemma":[0.9982855,0.00052591815,0.0003376811,0.00021364634,0.00011793924,0.0005192951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031044688,0.001967314,0.005010515,0.0006259857,0.00047887323,0.0010781828,0.0012015674,0.0022195936,0.006033322],"category_scores_gemma":[0.0026955083,0.0012335823,0.0016451386,0.00039010542,0.0012914712,0.0013498887,0.00054412195,0.0032342563,0.0011462523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9894918,0.003942683,0.00019529591,0.00009501466,0.00026340332,0.000013548054,0.000013243582,0.00008422216,0.0014969296,0.000021040827,0.00012734876,0.004255341],"study_design_scores_gemma":[0.9624395,0.035944153,0.00084745156,0.000006343878,0.00016423484,0.000011990522,0.0000056389244,0.00020085566,0.00020584365,0.00003089491,0.00013551202,0.00000764958],"about_ca_topic_score_codex":0.0007969896,"about_ca_topic_score_gemma":0.0015934024,"teacher_disagreement_score":0.006033322,"about_ca_system_score_codex":0.000652629,"about_ca_system_score_gemma":0.0008464201,"threshold_uncertainty_score":0.020183504},"labels":[],"label_agreement":null},{"id":"W1979400849","doi":"10.1111/dom.12442","title":"<scp>GPR40</scp> agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit","year":2015,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research; Canadian Diabetes Association","keywords":"Free fatty acid receptor 1; Medicine; Type 2 diabetes; Agonist; Clinical trial; Receptor; Diabetes mellitus; Pharmacology; Bioinformatics; Internal medicine; Endocrinology; Biology","score_opus":0.031152300544292563,"score_gpt":0.2842922124606352,"score_spread":0.2531399119163426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979400849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034162856,0.9957104,0.0002480466,0.0007261473,0.00043490334,0.000007188111,0.000043810935,0.000018841914,0.0024690195],"genre_scores_gemma":[0.0015212093,0.9948953,0.00028638786,0.00065053924,0.00031712552,0.000007916612,0.00007716859,0.0000036239844,0.002240638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999093,0.000016359518,0.000012919901,0.000014249348,0.000036642585,0.000010684326],"domain_scores_gemma":[0.99989665,0.000040639046,0.000016182094,0.0000038717467,0.000028708366,0.00001383621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027914252,0.0004226213,0.0006856406,0.00080918515,0.00017696031,0.00049112464,0.0004248597,0.0006271878,0.0042122826],"category_scores_gemma":[0.00029404656,0.00010486428,0.00029702307,0.0007976365,0.00022862435,0.0007566437,0.00043346346,0.0014791328,0.0030262708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010020293,0.00004472992,0.00008565802,0.008182354,0.000060894326,0.00018370897,0.00004478853,0.000153915,0.005302181,0.0034524547,0.03804385,0.9443453],"study_design_scores_gemma":[0.000013532662,0.00008357081,0.0004542065,0.0012174316,0.000045486126,0.00090446684,0.000028247263,0.000048964703,0.00081050844,0.0013155963,0.9950694,0.00000871381],"about_ca_topic_score_codex":0.00043135986,"about_ca_topic_score_gemma":0.0010957515,"teacher_disagreement_score":0.0042122826,"about_ca_system_score_codex":0.00030328435,"about_ca_system_score_gemma":0.00038821244,"threshold_uncertainty_score":0.014091492},"labels":[],"label_agreement":null},{"id":"W1980475389","doi":"10.1111/j.1463-1326.2011.01481.x","title":"Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low‐dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Western University; Mount Sinai Hospital","funders":"","keywords":"Internal medicine; Insulin resistance; Metformin; Medicine; Endocrinology; Rosiglitazone; Type 2 diabetes; Thiazolidinedione; Insulin; Fatty liver; Placebo; Impaired glucose tolerance; Diabetes mellitus; Pathology","score_opus":0.0060665584396325635,"score_gpt":0.1889750397118429,"score_spread":0.18290848127221035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980475389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303246,0.0050179577,0.00013962833,0.0002040586,0.00005020669,0.000037774484,0.00008461176,0.000010133383,0.0014231952],"genre_scores_gemma":[0.998041,0.0009026118,0.00023628886,0.00015506298,0.000057947003,0.00003093951,0.00012461134,0.0000026581113,0.0004490267],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99934644,0.00036709468,0.00006484972,0.00006105433,0.00009393827,0.0000666525],"domain_scores_gemma":[0.9989335,0.00031406,0.00030778671,0.000101807214,0.00007729007,0.00026548695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012267779,0.00027845646,0.00097129476,0.00021226896,0.00017023302,0.00034449453,0.00020509234,0.00035850517,0.001273893],"category_scores_gemma":[0.0016627405,0.00017103855,0.000655766,0.00026591343,0.0002707431,0.0002721463,0.00017099634,0.00087546604,0.00015029029],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5075731,0.0062119267,0.074877955,0.0006120226,0.0020278771,0.00048201988,0.00018614525,0.0008864763,0.041883655,0.00024471927,0.0014620947,0.36355194],"study_design_scores_gemma":[0.054034844,0.23274054,0.69336516,0.000120171186,0.0033009124,0.0009881008,0.00017497383,0.001571392,0.009161938,0.00041757917,0.0040774904,0.000046860157],"about_ca_topic_score_codex":0.00041728493,"about_ca_topic_score_gemma":0.0025685998,"teacher_disagreement_score":0.001273893,"about_ca_system_score_codex":0.00029152175,"about_ca_system_score_gemma":0.00027994715,"threshold_uncertainty_score":0.006487906},"labels":[],"label_agreement":null},{"id":"W1982905493","doi":"10.1111/dom.12273","title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Canagliflozin; Metformin; Sitagliptin; Medicine; Placebo; Pioglitazone; Internal medicine; Type 2 diabetes; Endocrinology; Adverse effect; Urology; Diabetes mellitus; Gastroenterology; Pharmacology","score_opus":0.0058425061165601816,"score_gpt":0.20625429057641928,"score_spread":0.2004117844598591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982905493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972402,0.0017864811,0.00011987646,0.00010501319,0.00003319104,0.000119287084,0.000093414914,0.000022108146,0.00048056676],"genre_scores_gemma":[0.9980312,0.0006742465,0.00032176272,0.00021958201,0.00006320971,0.00013500346,0.00021662265,0.000004182106,0.00033417883],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995383,0.00016519878,0.000044217188,0.00010525871,0.000086833585,0.000060165083],"domain_scores_gemma":[0.99926347,0.00017952619,0.00023329906,0.00006286296,0.000042447835,0.00021849699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013182893,0.00057242595,0.0015368924,0.00031112204,0.00029234926,0.0005379974,0.00034276972,0.0007107574,0.001344745],"category_scores_gemma":[0.0015302378,0.00035365028,0.000909513,0.0003711501,0.00029248782,0.00053452264,0.0002311174,0.0011596163,0.00023083971],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8050942,0.014162442,0.04274995,0.00047254257,0.0017632898,0.00017440654,0.0001699257,0.0010894298,0.0107392715,0.000048921476,0.00088743516,0.12264824],"study_design_scores_gemma":[0.40077144,0.29551214,0.29184714,0.00009615142,0.002358564,0.0004420081,0.00013297943,0.0032159798,0.0036846518,0.00016575209,0.0017053293,0.000067879235],"about_ca_topic_score_codex":0.00064581016,"about_ca_topic_score_gemma":0.0012780707,"teacher_disagreement_score":0.0015368924,"about_ca_system_score_codex":0.0004124742,"about_ca_system_score_gemma":0.00048748683,"threshold_uncertainty_score":0.0069718957},"labels":[],"label_agreement":null},{"id":"W1982950261","doi":"10.1111/j.1463-1326.2011.01554.x","title":"Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"","keywords":"Medicine; Sibutramine; Weight loss; Internal medicine; Cardiology; Obesity","score_opus":0.02690187576765485,"score_gpt":0.24835798550674673,"score_spread":0.22145610973909188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982950261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838393,0.011699903,0.00029276533,0.00052170083,0.0001975695,0.0003102178,0.0011665241,0.00006104649,0.0019110298],"genre_scores_gemma":[0.9872383,0.0067923586,0.00054551277,0.0007536283,0.00032999736,0.00041676644,0.002374366,0.0000145407375,0.0015346406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998109,0.00008726801,0.000018629866,0.000026288335,0.00003082973,0.000026111036],"domain_scores_gemma":[0.99961394,0.000075112555,0.00013094654,0.00003211101,0.000030226409,0.000117626354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075118354,0.0005928738,0.0010111564,0.00015645992,0.0002051698,0.0005057286,0.00027610024,0.00057756086,0.002471057],"category_scores_gemma":[0.0008499221,0.00012242125,0.0009453119,0.00022658316,0.00021922456,0.0002771396,0.00030600757,0.0009660357,0.00023245443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84219176,0.004972038,0.021230744,0.0026576563,0.0068458337,0.00013290816,0.00008507094,0.00060146087,0.005272422,0.000199942,0.003625176,0.11218494],"study_design_scores_gemma":[0.69513285,0.110140085,0.17534721,0.0007014742,0.0104804775,0.00030811736,0.000078245066,0.0010803314,0.0022383675,0.0005485839,0.0039093536,0.000034850018],"about_ca_topic_score_codex":0.00078815286,"about_ca_topic_score_gemma":0.0018922393,"teacher_disagreement_score":0.002471057,"about_ca_system_score_codex":0.00022305026,"about_ca_system_score_gemma":0.00037909354,"threshold_uncertainty_score":0.008266509},"labels":[],"label_agreement":null},{"id":"W1985422490","doi":"10.1111/j.1463-1326.2009.01131.x","title":"Multiple molecular targets underlie the antidiabetic effect of <i>Nigella sativa</i> seed extract in skeletal muscle, adipocyte and liver cells","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Nigella sativa pharmacological applications","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nigella sativa; AMPK; Adipocyte; Skeletal muscle; Glucose uptake; Internal medicine; Endocrinology; Insulin; Biology; Protein kinase B; Lipid droplet; Protein kinase A; Pharmacology; Biochemistry; Signal transduction; Adipose tissue; Kinase; Medicine; Traditional medicine","score_opus":0.0063637052549147515,"score_gpt":0.2352502699697273,"score_spread":0.22888656471481256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985422490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787001,0.0122179575,0.0032432089,0.00047915362,0.00006347802,0.000056806934,0.00066470087,0.00019609132,0.0043785092],"genre_scores_gemma":[0.9892971,0.0042142486,0.0018263315,0.00021618474,0.000026010901,0.000047418933,0.00093306747,0.000015681368,0.0034239537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995136,0.000005508177,0.0000047801227,0.000012149006,0.000012505452,0.000013668512],"domain_scores_gemma":[0.9999597,0.0000043266714,0.000016965112,0.0000034642162,0.000009148196,0.0000064276896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007011132,0.00044884838,0.00031343588,0.00025108334,0.00022310345,0.00023694139,0.00024720366,0.0003967499,0.0022559778],"category_scores_gemma":[0.000044265744,0.000120568446,0.0004952356,0.00016448867,0.00017959987,0.00023493324,0.00018353714,0.00041161888,0.00038782848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036066625,0.000045510165,0.0005206021,0.00022313386,0.000023990884,0.00019608607,0.00001449152,0.000035035235,0.99586296,0.0001163164,0.00007255586,0.0025285645],"study_design_scores_gemma":[0.00012772673,0.0013666601,0.09325288,0.0000629406,0.00017493707,0.001039201,0.00011768467,0.00052697206,0.89652485,0.00030965562,0.0064801,0.000016396112],"about_ca_topic_score_codex":0.00085524353,"about_ca_topic_score_gemma":0.0017845018,"teacher_disagreement_score":0.0022559778,"about_ca_system_score_codex":0.0002781174,"about_ca_system_score_gemma":0.00021703808,"threshold_uncertainty_score":0.007547021},"labels":[],"label_agreement":null},{"id":"W1987067408","doi":"10.1111/dom.12399","title":"Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Boehringer Ingelheim","keywords":"Linagliptin; Metformin; Medicine; Type 2 diabetes; Internal medicine; Clinical endpoint; Randomized controlled trial; Population; Diabetes mellitus; Confidence interval; Gastroenterology; Adverse effect; Endocrinology; Insulin","score_opus":0.017033997711860458,"score_gpt":0.27282690052652775,"score_spread":0.25579290281466727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987067408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910382,0.0026805163,0.00035172058,0.00039879893,0.00036246862,0.0032312297,0.0006610128,0.00008938582,0.0011867536],"genre_scores_gemma":[0.98706716,0.0017904968,0.0015863292,0.000910607,0.0006031285,0.0048700226,0.0011534118,0.000020628615,0.0019981475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988254,0.0006218237,0.00010030023,0.00022808847,0.00009161916,0.00013290637],"domain_scores_gemma":[0.9983442,0.0003848702,0.0003987717,0.00014951614,0.0001072195,0.00061539194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025403232,0.0021847922,0.0048341746,0.00067322707,0.0006177341,0.0013432027,0.0013185443,0.0022237496,0.0077262144],"category_scores_gemma":[0.002311037,0.0011339156,0.0024601396,0.00050627533,0.0010880547,0.0012248614,0.00070777925,0.0031384812,0.0013993284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98830855,0.005096928,0.00042118508,0.0001796416,0.00047564192,0.000012888514,0.000018649325,0.000088911496,0.0008320363,0.000013360587,0.00013225999,0.0044199675],"study_design_scores_gemma":[0.94507986,0.053097934,0.0011440957,0.000014452535,0.00026473586,0.000013261215,0.000007106128,0.00013072282,0.00012210637,0.000020343785,0.00009823319,0.0000071735512],"about_ca_topic_score_codex":0.0010312629,"about_ca_topic_score_gemma":0.0024722842,"teacher_disagreement_score":0.0077262144,"about_ca_system_score_codex":0.0008939327,"about_ca_system_score_gemma":0.0013961444,"threshold_uncertainty_score":0.02584678},"labels":[],"label_agreement":null},{"id":"W1987329229","doi":"10.1111/j.1463-1326.2012.01564.x","title":"Acute high‐intensity interval exercise reduces the postprandial glucose response and prevalence of hyperglycaemia in patients with type 2 diabetes","year":2012,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Cardiovascular and exercise physiology","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; McMaster University","funders":"Canadian Diabetes Association","keywords":"Postprandial; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Cardiology; Meal; Endocrinology; Heart rate; Blood pressure","score_opus":0.0050670055035314954,"score_gpt":0.19853266683145238,"score_spread":0.19346566132792087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987329229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6713261,0.032645557,0.0024253835,0.24552155,0.008876483,0.0002521758,0.00059442106,0.00035218787,0.038006067],"genre_scores_gemma":[0.85305244,0.011908814,0.0023390814,0.10508994,0.0150489705,0.00021835491,0.00035478876,0.00005214096,0.011935426],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970895,0.00010472742,0.000040780447,0.000030987256,0.00008117466,0.000033358265],"domain_scores_gemma":[0.9991247,0.00045559552,0.00007825401,0.000038759274,0.00018794015,0.000114720184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000505651,0.00030813002,0.00076717325,0.00028959705,0.0003998913,0.00040866228,0.0003147637,0.0021994642,0.0015990052],"category_scores_gemma":[0.0033325916,0.00012414578,0.000238481,0.000334674,0.00025421867,0.00030676118,0.0001432574,0.0011582325,0.0008215624],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011239262,0.0025068412,0.2788364,0.00066555175,0.00022067301,0.037150133,0.00051179,0.00038565014,0.009136086,0.00078244525,0.184104,0.47446126],"study_design_scores_gemma":[0.0027236957,0.010770237,0.7941635,0.00072927837,0.0004165639,0.071411,0.0010158347,0.0045354944,0.0039996197,0.003733188,0.10639587,0.000105709],"about_ca_topic_score_codex":0.0010105006,"about_ca_topic_score_gemma":0.0021792701,"teacher_disagreement_score":0.0021994642,"about_ca_system_score_codex":0.00037088196,"about_ca_system_score_gemma":0.00024584297,"threshold_uncertainty_score":0.005349219},"labels":[],"label_agreement":null},{"id":"W1992861325","doi":"10.1111/j.1463-1326.2012.01657.x","title":"Metabolic stress, <scp>IAPP</scp> and islet amyloid","year":2012,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Islet; Proinsulin; Amyloid (mycology); Endocrinology; Internal medicine; Amylin; Prohormone; Insulin; Type 2 diabetes; Insulin resistance; Diabetes mellitus; Biology; Medicine; Hormone; Pathology","score_opus":0.02635643609017033,"score_gpt":0.2664918284569194,"score_spread":0.24013539236674905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992861325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015988696,0.99809223,0.000068372596,0.0001725486,0.00019573364,0.0000034078098,0.000014839021,0.0000073974775,0.0012855558],"genre_scores_gemma":[0.0007068882,0.99779594,0.00011268013,0.00014008833,0.00016995057,0.000003851682,0.00003618101,0.0000015520316,0.0010329142],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990535,0.000012821996,0.0000144041205,0.000015658685,0.00004179529,0.000009879896],"domain_scores_gemma":[0.99988925,0.00003330442,0.000022018463,0.0000048096117,0.000034155626,0.000016365011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023340074,0.000752811,0.00096513727,0.0016622127,0.00025633397,0.00077133917,0.0005198001,0.0007418462,0.0035378258],"category_scores_gemma":[0.0003025511,0.00020513653,0.00034096465,0.0018883025,0.00037719824,0.0010854055,0.00057594216,0.0012849272,0.003163745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078956575,0.00006661147,0.00016843474,0.011671039,0.00005247822,0.0002400355,0.00005235949,0.0001734602,0.0026025916,0.0022194174,0.032009542,0.950665],"study_design_scores_gemma":[0.000011958093,0.00005430036,0.0010839575,0.0017784463,0.000047577058,0.00210675,0.0000511415,0.000043684566,0.0005278561,0.0015934076,0.9926878,0.000013059606],"about_ca_topic_score_codex":0.00094317563,"about_ca_topic_score_gemma":0.0017479248,"teacher_disagreement_score":0.0035378258,"about_ca_system_score_codex":0.0003603653,"about_ca_system_score_gemma":0.00057799753,"threshold_uncertainty_score":0.0118352175},"labels":[],"label_agreement":null},{"id":"W1995169341","doi":"10.1111/dom.12049","title":"Components of metabolic syndrome and 5‐year change in insulin clearance – the Insulin Resistance Atherosclerosis Study","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Public Health Ontario; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Center for Research Resources; U.S. Public Health Service","keywords":"Internal medicine; Endocrinology; Insulin resistance; Medicine; Metabolic syndrome; Insulin; Waist; Glucose clamp technique; Diabetes mellitus; Blood pressure; Body mass index; Pancreatic hormone","score_opus":0.02492216230212894,"score_gpt":0.23898175043150308,"score_spread":0.21405958812937415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995169341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907697,0.0031121348,0.00055808143,0.00017850423,0.00006363223,0.00011356888,0.0038139273,0.000035517634,0.0013549273],"genre_scores_gemma":[0.99457777,0.00055722735,0.00045406507,0.00006125247,0.0000428795,0.00009541127,0.0035218997,0.000005586318,0.0006838751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992173,0.00030721718,0.0001106121,0.00014028561,0.00014511232,0.00007950575],"domain_scores_gemma":[0.99776995,0.00021380336,0.0010306983,0.00026680983,0.00028228722,0.0004365121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002242421,0.0007562141,0.00077084574,0.0006715028,0.00043834595,0.0008655096,0.0006715149,0.0008962379,0.0011968081],"category_scores_gemma":[0.0024186668,0.00043303522,0.0009867013,0.0012513895,0.00021733379,0.00056056643,0.00063843676,0.0015864416,0.0004017699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076311745,0.000114552684,0.9964839,0.000040988263,0.00085086643,0.00003615212,0.000044947607,0.00012799607,0.00016721337,0.000033895507,0.00019204429,0.0011443417],"study_design_scores_gemma":[0.000039346105,0.0002042109,0.9990151,0.000010104183,0.0001472226,0.00008711087,0.000021234704,0.00021075916,0.000034444358,0.000023824212,0.00020230196,0.000004298642],"about_ca_topic_score_codex":0.003474524,"about_ca_topic_score_gemma":0.0032361986,"teacher_disagreement_score":0.003474524,"about_ca_system_score_codex":0.00026180365,"about_ca_system_score_gemma":0.00032867608,"threshold_uncertainty_score":0.011859179},"labels":[],"label_agreement":null},{"id":"W1995308350","doi":"10.1111/j.1463-1326.2004.00460.x","title":"Current indications for pancreas or islet transplant","year":2004,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority","funders":"","keywords":"Medicine; Immunosuppression; Diabetes mellitus; Pancreas transplantation; Transplantation; Pancreas; Intensive care medicine; Islet; Internal medicine; Insulin; Surgery; Kidney transplantation; Endocrinology","score_opus":0.04992811944859253,"score_gpt":0.3487432017012347,"score_spread":0.29881508225264214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995308350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020751555,0.9870767,0.00017625092,0.0005170619,0.0005099804,0.000019599596,0.00008498475,0.000028854829,0.011379046],"genre_scores_gemma":[0.001462674,0.9926172,0.00032867808,0.00075562554,0.0003502028,0.000028586714,0.00017839983,0.000005488225,0.0042730784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997651,0.000033577406,0.00003602708,0.000036741432,0.000104576706,0.000024081972],"domain_scores_gemma":[0.99970883,0.000120322635,0.00007298639,0.000012277121,0.000047118752,0.00003852772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041282407,0.000995175,0.0013985303,0.0019460114,0.00025556795,0.0007413752,0.0009818372,0.0010786317,0.032523062],"category_scores_gemma":[0.00070659956,0.00019873258,0.00062688184,0.0022779743,0.0003936679,0.0011103811,0.00052649487,0.0011331188,0.014270534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013831558,0.00005933688,0.0002550625,0.009917466,0.00004707054,0.00036413054,0.000026919028,0.00013444465,0.00079323223,0.0012021525,0.05870448,0.9283573],"study_design_scores_gemma":[0.00007071901,0.000067659756,0.0013550405,0.005253985,0.00010342642,0.0026405512,0.000045980712,0.000024780144,0.00021662771,0.0011027323,0.9891087,0.000009781683],"about_ca_topic_score_codex":0.00083933276,"about_ca_topic_score_gemma":0.0012079242,"teacher_disagreement_score":0.032523062,"about_ca_system_score_codex":0.0003934227,"about_ca_system_score_gemma":0.00081517716,"threshold_uncertainty_score":0.10880047},"labels":[],"label_agreement":null},{"id":"W1997287686","doi":"10.1111/j.1463-1326.2004.00319.x","title":"Lack of concordance between plasma markers of cardiovascular risk and intima‐media thickness in patients with type 2 diabetes","year":2003,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cardiovascular Health and Disease Prevention","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Servier","keywords":"Medicine; Internal medicine; Diabetes mellitus; Intima-media thickness; Type 2 diabetes; Endothelial dysfunction; Waist; C-reactive protein; Atenolol; Endocrinology; Cardiology; Gastroenterology; Inflammation; Body mass index; Carotid arteries; Blood pressure","score_opus":0.009153233178156387,"score_gpt":0.22194591132386085,"score_spread":0.21279267814570446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997287686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99900705,0.00029374458,0.00011265015,0.000031609987,0.000011932517,0.0000032042783,0.00007350726,0.0000052324344,0.00046106553],"genre_scores_gemma":[0.9996692,0.00005360823,0.00006222828,0.00002509545,0.000016722914,0.0000037150494,0.00009163396,0.000001581832,0.000076287026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907136,0.00026923983,0.00012480031,0.00026178497,0.00018831962,0.000084432606],"domain_scores_gemma":[0.99555653,0.0018182843,0.0013305617,0.00034642383,0.0004528619,0.00049541495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010573852,0.0003134162,0.0005194304,0.0007580941,0.0004227607,0.0007999921,0.00036017125,0.00073912204,0.0017433157],"category_scores_gemma":[0.0049323537,0.0003369642,0.00025153955,0.00072755344,0.0005109899,0.0003526581,0.00040108533,0.0006245423,0.00033679674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019359904,0.0000197841,0.99820817,0.000009068782,0.00004289122,0.0001036172,0.000066733024,0.00002559904,0.00039532295,0.000011941283,0.000032056712,0.0008911464],"study_design_scores_gemma":[0.000013215734,0.0001151928,0.9987494,0.000005529444,0.00003544659,0.00066518603,0.000089802896,0.00013111618,0.00008670541,0.000030743005,0.000074139665,0.0000034972952],"about_ca_topic_score_codex":0.0011882166,"about_ca_topic_score_gemma":0.0011629398,"teacher_disagreement_score":0.0017433157,"about_ca_system_score_codex":0.00019353419,"about_ca_system_score_gemma":0.00020902374,"threshold_uncertainty_score":0.005831957},"labels":[],"label_agreement":null},{"id":"W1997586858","doi":"10.1111/dom.12068","title":"Newer insulin analogs: advances in basal insulin replacement","year":2013,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Diabetes Canada; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk; Amylin Pharmaceuticals; American Diabetes Association","keywords":"Insulin; Insulin degludec; Insulin lispro; Insulin analog; Medicine; Tolerability; Basal (medicine); Insulin glargine; Diabetes mellitus; Basal insulin; Type 2 diabetes; Internal medicine; Pharmacology; Endocrinology; Hypoglycemia; Human insulin; Adverse effect","score_opus":0.027297717722480054,"score_gpt":0.3221910531809734,"score_spread":0.29489333545849333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997586858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024309054,0.9979863,0.00024682688,0.00018476836,0.0001495568,0.000006905227,0.000015367648,0.000008813578,0.0011583546],"genre_scores_gemma":[0.0012225307,0.99734604,0.00047969533,0.00019107256,0.00018391677,0.000007442012,0.000034726418,0.0000024567753,0.00053198246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996635,0.000050874998,0.000061014667,0.00005564654,0.00014694015,0.000022063514],"domain_scores_gemma":[0.99972624,0.000119386415,0.000052126277,0.000011251563,0.00006755137,0.000023448863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007127567,0.00077859923,0.0013236488,0.0021598644,0.00018202957,0.0009131678,0.0007467908,0.00080756395,0.0035260797],"category_scores_gemma":[0.0006505588,0.00027622186,0.0006850012,0.002029225,0.00037262827,0.0013531239,0.00051134976,0.0023669254,0.0021711478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011882596,0.000115788345,0.0001844922,0.014093726,0.000083626284,0.00028035496,0.000050661234,0.000340329,0.0020839975,0.002388111,0.011554507,0.9687055],"study_design_scores_gemma":[0.00004855204,0.00018340099,0.00077865063,0.0030275541,0.000116067786,0.002613216,0.000046848603,0.00014837513,0.0011343526,0.0018701254,0.99001044,0.000022329456],"about_ca_topic_score_codex":0.0006451461,"about_ca_topic_score_gemma":0.00071063376,"teacher_disagreement_score":0.0035260797,"about_ca_system_score_codex":0.0004105158,"about_ca_system_score_gemma":0.000504751,"threshold_uncertainty_score":0.011795938},"labels":[],"label_agreement":null},{"id":"W1997970555","doi":"10.1111/dom.12357","title":"The interleukin‐1 receptor antagonist anakinra improves first‐phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance","year":2014,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Radboud Universiteit; Novo Nordisk Fonden; European Foundation for the Study of Diabetes","keywords":"Anakinra; Medicine; Internal medicine; Interleukin 1 receptor antagonist; Endocrinology; Placebo; Insulin; Receptor antagonist; Type 2 diabetes; Antagonist; Diabetes mellitus; Impaired glucose tolerance; Interleukin; Insulin resistance; Receptor; Cytokine","score_opus":0.004010870474421166,"score_gpt":0.1989291215263735,"score_spread":0.19491825105195232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997970555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558652,0.010084192,0.0009357879,0.024896618,0.002182826,0.00017565126,0.0001779365,0.00016615252,0.005515707],"genre_scores_gemma":[0.96638095,0.00463595,0.0011822595,0.019175595,0.003146041,0.00010865104,0.00013720404,0.000021975873,0.0052114315],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999744,0.0001376474,0.000025150088,0.000027527298,0.000041285275,0.000024464895],"domain_scores_gemma":[0.9995141,0.00029555536,0.000044135606,0.000027354234,0.00006233604,0.000056577494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005361187,0.00050336076,0.000799965,0.00019447666,0.00028295573,0.00030404664,0.00033125968,0.0012826266,0.0010898956],"category_scores_gemma":[0.0014417034,0.0001528457,0.0002703719,0.0001667534,0.00027732833,0.00029241643,0.00007315599,0.00093228504,0.00044943969],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13716966,0.0107493345,0.15739977,0.0015934624,0.00083968206,0.051809005,0.00065425795,0.0007742441,0.120002046,0.0009132234,0.060815737,0.45727962],"study_design_scores_gemma":[0.03313651,0.09395584,0.6780241,0.0004062716,0.00113343,0.07511499,0.00057939877,0.0056990515,0.040470507,0.0027024297,0.06862205,0.00015540502],"about_ca_topic_score_codex":0.0005093036,"about_ca_topic_score_gemma":0.000757442,"teacher_disagreement_score":0.0012826266,"about_ca_system_score_codex":0.00029199995,"about_ca_system_score_gemma":0.000210618,"threshold_uncertainty_score":0.0036460757},"labels":[],"label_agreement":null},{"id":"W2000297042","doi":"10.1111/j.1463-1326.2011.01444.x","title":"Incretin hormones and the expanding families of glucagon‐like sequences and their receptors","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Ottawa","keywords":"Biology; Proglucagon; Vertebrate; Subfamily; Receptor; Glucagon; Gene; Genetics; Lineage (genetic); Hormone; Evolutionary biology; Cell biology; Glucagon-like peptide-1; Endocrinology","score_opus":0.02292791986254658,"score_gpt":0.25544055628912127,"score_spread":0.2325126364265747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000297042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013401589,0.9981914,0.00014409391,0.00019361424,0.00014621307,0.000003584406,0.000013695312,0.0000089411205,0.0011645107],"genre_scores_gemma":[0.00059744867,0.9982253,0.00022321992,0.00010824052,0.00016841908,0.000005061574,0.000029250386,0.0000010128363,0.0006420373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984753,0.00002478421,0.000019743478,0.000025872738,0.00006715635,0.000014907126],"domain_scores_gemma":[0.99983716,0.000067370216,0.000027949025,0.0000066649086,0.000039405157,0.000021474432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003858202,0.00090618705,0.0011216999,0.0020047447,0.00023220012,0.0007629494,0.00076692394,0.00082236365,0.0025814788],"category_scores_gemma":[0.00046899525,0.00021685398,0.0003384418,0.0022448292,0.00055904983,0.0015031592,0.0005021007,0.0017383727,0.0023410677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007610784,0.000045157987,0.00020972965,0.006301369,0.000049224276,0.00031156305,0.00006295845,0.00026992275,0.0028903414,0.0040541925,0.01750209,0.96822727],"study_design_scores_gemma":[0.00001750172,0.00004961254,0.0010291493,0.0010094093,0.00004310494,0.0016796518,0.00005754349,0.000050302067,0.00032167774,0.0025688242,0.9931594,0.0000137170055],"about_ca_topic_score_codex":0.0007915232,"about_ca_topic_score_gemma":0.0009750694,"teacher_disagreement_score":0.0025814788,"about_ca_system_score_codex":0.0005208992,"about_ca_system_score_gemma":0.00064447866,"threshold_uncertainty_score":0.008635879},"labels":[],"label_agreement":null},{"id":"W2002728745","doi":"10.1046/j.1463-1326.2001.00030.x","title":"β‐cell deterioration – prospects for reversal or prevention","year":2001,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Adipose Tissue and Metabolism","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Mitacs; GlaxoSmithKline","keywords":"Kinesiology; Citation; Library science; Psychology; Medicine; Computer science; Medical education","score_opus":0.020029276995819523,"score_gpt":0.27297458773021227,"score_spread":0.25294531073439275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002728745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016105143,0.84100664,0.0077293576,0.11026548,0.00621826,0.00007533983,0.0002969694,0.0005041229,0.017798735],"genre_scores_gemma":[0.1857561,0.741809,0.0109328935,0.025258292,0.012997281,0.00023393141,0.00045647527,0.00008617074,0.02246983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970007,0.00007500685,0.000021996333,0.000052649895,0.000044507357,0.00010586229],"domain_scores_gemma":[0.9988053,0.00043088014,0.00016651761,0.00013055342,0.00016743739,0.00029930525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023718444,0.0007272858,0.0015171726,0.0005541198,0.00067065435,0.002749895,0.0014101812,0.0032713867,0.013269492],"category_scores_gemma":[0.002084964,0.00031489573,0.000612381,0.0004019766,0.002115795,0.0034137587,0.0011506052,0.004929941,0.0031079622],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063497196,0.0018797222,0.00972651,0.0033748955,0.00039476683,0.001238496,0.0003151461,0.002190412,0.020174442,0.10810866,0.09529986,0.7509474],"study_design_scores_gemma":[0.0014294554,0.0059170197,0.013219116,0.0027963512,0.0005943833,0.0034850938,0.0022840332,0.0021187551,0.015175197,0.1568105,0.79598373,0.000186311],"about_ca_topic_score_codex":0.0006090901,"about_ca_topic_score_gemma":0.001122083,"teacher_disagreement_score":0.013269492,"about_ca_system_score_codex":0.000538781,"about_ca_system_score_gemma":0.0018188728,"threshold_uncertainty_score":0.044390857},"labels":[],"label_agreement":null},{"id":"W2003806569","doi":"10.1111/j.1463-1326.2007.00805.x","title":"Acute effect of metformin on exercise capacity in active males","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Danone Institute of Canada; American Heart Association","keywords":"Metformin; Medicine; Placebo; Crossover study; VO2 max; Ventilatory threshold; Internal medicine; Physical exercise; Cycle ergometer; Body mass index; Diabetes mellitus; Endocrinology; Heart rate; Blood pressure","score_opus":0.007631730136959777,"score_gpt":0.23151106435240026,"score_spread":0.22387933421544048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003806569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99884784,0.00088523555,0.000047301204,0.000028645096,0.000015681077,0.000020282218,0.00004050226,0.0000043250757,0.000110188776],"genre_scores_gemma":[0.9986486,0.0005564163,0.00015819677,0.00008921936,0.00006406716,0.000039309325,0.000130955,0.0000023556393,0.00031092158],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997695,0.00010763463,0.00001751733,0.000029727022,0.000026358366,0.000049307164],"domain_scores_gemma":[0.9992495,0.00027016242,0.00017924722,0.000041378866,0.000027598171,0.0002319826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041364483,0.00047417084,0.0006341696,0.00017900339,0.00025008444,0.00033408552,0.00020706038,0.00048349245,0.0021006663],"category_scores_gemma":[0.00076979486,0.00024536246,0.0003655578,0.00012798377,0.00035389073,0.00025266447,0.00032951156,0.00073391653,0.00016847483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51469934,0.042315613,0.11661463,0.0012035312,0.0012328385,0.00055799226,0.00043619974,0.00060266873,0.20457599,0.00010707189,0.00060664007,0.11704755],"study_design_scores_gemma":[0.012798552,0.38880444,0.57156545,0.00008976443,0.00065707293,0.00037590292,0.00025278179,0.0006622429,0.023712458,0.000073421244,0.0009775262,0.000030464416],"about_ca_topic_score_codex":0.0003200385,"about_ca_topic_score_gemma":0.00057312695,"teacher_disagreement_score":0.0021006663,"about_ca_system_score_codex":0.00014380335,"about_ca_system_score_gemma":0.00016870808,"threshold_uncertainty_score":0.007027447},"labels":[],"label_agreement":null},{"id":"W2005227623","doi":"10.1111/j.1463-1326.2009.01110.x","title":"Zinc, a regulator of islet function and glucose homeostasis","year":2009,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Trace Elements in Health","field":"Nursing","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Islet; Glucose homeostasis; Zinc; Endocrinology; Internal medicine; Diabetes mellitus; Pancreas; Insulin; Homeostasis; Biology; Pancreatic islets; Regulator; Insulin resistance; Chemistry; Medicine; Biochemistry; Gene","score_opus":0.022542663804669016,"score_gpt":0.2921141168304629,"score_spread":0.2695714530257939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005227623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035758532,0.99757653,0.00020172399,0.0002343959,0.00011770003,0.0000024268988,0.000013776448,0.00001142818,0.0014845252],"genre_scores_gemma":[0.0036490527,0.99418795,0.00031213608,0.00012723473,0.00012956146,0.0000057571306,0.000023891562,0.0000019096933,0.0015623661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998857,0.000018708586,0.000016839567,0.00002191055,0.000044575645,0.000012244364],"domain_scores_gemma":[0.9999285,0.000024050056,0.000014001396,0.00000285087,0.0000191099,0.000011658209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021187526,0.00056075054,0.0008557722,0.0010318157,0.00028371887,0.0006659025,0.0005802521,0.0007429368,0.0019439101],"category_scores_gemma":[0.0002815862,0.00012103948,0.000184559,0.0014193936,0.000411016,0.00050549966,0.0005346931,0.0006576662,0.0013909399],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070815084,0.000055649056,0.0004779722,0.0063656066,0.00005795003,0.00036873293,0.00010387149,0.00025309046,0.0075491047,0.0028224709,0.018366028,0.9635088],"study_design_scores_gemma":[0.000018022813,0.00009651679,0.0024035312,0.0016354778,0.000061008544,0.0028303426,0.00016175349,0.00007968344,0.002028722,0.0034733305,0.9871946,0.000017173968],"about_ca_topic_score_codex":0.002200112,"about_ca_topic_score_gemma":0.0025546895,"teacher_disagreement_score":0.002200112,"about_ca_system_score_codex":0.00042425527,"about_ca_system_score_gemma":0.00067072595,"threshold_uncertainty_score":0.0065030456},"labels":[],"label_agreement":null},{"id":"W2005561360","doi":"10.1111/dom.12474","title":"Two dose‐ranging studies with <scp>PF</scp> ‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"Pfizer","keywords":"Metformin; Glucokinase; Activator (genetics); Type 2 diabetes; Medicine; Internal medicine; Endocrinology; Diabetes mellitus; Cancer research; Receptor","score_opus":0.018849586620283482,"score_gpt":0.2627396493139453,"score_spread":0.24389006269366179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005561360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913361,0.004615943,0.000313179,0.000283585,0.00014136037,0.0013611729,0.0004906161,0.00003338984,0.0014246365],"genre_scores_gemma":[0.9918051,0.0032592684,0.0011840158,0.00060124375,0.00023645966,0.0011365678,0.0006569784,0.000009148091,0.0011112154],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993272,0.000357955,0.00008016091,0.000095072595,0.000071373535,0.00006823232],"domain_scores_gemma":[0.99862754,0.0004299512,0.00037749458,0.000114227514,0.00009402894,0.00035677737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015121843,0.0009372918,0.0016356745,0.00044276813,0.00025912342,0.00072193146,0.0006498354,0.0013650046,0.004618025],"category_scores_gemma":[0.0016235341,0.00060243934,0.0018436717,0.0004974017,0.00068456336,0.00067341764,0.00037641104,0.0022107225,0.0004899428],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94250953,0.011372152,0.0015292689,0.00072446733,0.0016307901,0.000061843115,0.000068984526,0.00029403841,0.008118223,0.00006845356,0.0003782065,0.033243995],"study_design_scores_gemma":[0.7608617,0.22833012,0.0065777698,0.00005471679,0.0012924701,0.0000898128,0.000032183063,0.00013902932,0.0017182333,0.000077612494,0.00080249994,0.000023887109],"about_ca_topic_score_codex":0.0005464207,"about_ca_topic_score_gemma":0.0016657781,"teacher_disagreement_score":0.004618025,"about_ca_system_score_codex":0.00044462146,"about_ca_system_score_gemma":0.0006238787,"threshold_uncertainty_score":0.015448809},"labels":[],"label_agreement":null},{"id":"W2006237207","doi":"10.1046/j.1463-1326.2003.00269.x","title":"A cohort study of reproductive risk factors, weight and weight change and the development of diabetes mellitus","year":2003,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"British Heart Foundation","keywords":"Medicine; Pregnancy; Body mass index; Obstetrics; Weight gain; Diabetes mellitus; Cohort; Gynecology; Cohort study; Internal medicine; Endocrinology; Body weight","score_opus":0.01899358161751241,"score_gpt":0.24616719599321474,"score_spread":0.22717361437570233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006237207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835396,0.00025271517,0.00021009508,0.000033904194,0.000016486785,0.00004741775,0.00078666734,0.0000049746695,0.00029369144],"genre_scores_gemma":[0.9977767,0.00024752333,0.00031913747,0.000050904215,0.00002487137,0.0000641601,0.00090105116,0.0000034147374,0.0006123067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995369,0.00013410555,0.00003494075,0.00009637813,0.00010014335,0.00009761236],"domain_scores_gemma":[0.9990951,0.0001270023,0.00024105539,0.0002069549,0.00010829693,0.00022170582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092238747,0.0003475207,0.00040946697,0.000781854,0.001036573,0.0005189221,0.00035115145,0.00037225444,0.001317062],"category_scores_gemma":[0.0016567546,0.00060542906,0.0005554328,0.0009947716,0.0002698028,0.000399086,0.00045179535,0.000680724,0.0002788353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003041989,0.00012128895,0.99698156,0.000009772557,0.00015038544,0.00019467872,0.0001854752,0.000022245384,0.00033542202,0.000033660912,0.00023917595,0.0014221319],"study_design_scores_gemma":[0.000072695984,0.0005483693,0.99727243,0.000014915414,0.0001039982,0.00075402827,0.00024531616,0.00015225596,0.00010549721,0.000022979057,0.0006990931,0.000008471835],"about_ca_topic_score_codex":0.014598677,"about_ca_topic_score_gemma":0.0144911045,"teacher_disagreement_score":0.014598677,"about_ca_system_score_codex":0.00026044133,"about_ca_system_score_gemma":0.0005532633,"threshold_uncertainty_score":0.029027402},"labels":[],"label_agreement":null},{"id":"W2008804979","doi":"10.1046/j.1463-1326.2002.00164.x","title":"Animal models of insulin resistance and cardiovascular disease: some therapeutic approaches using the JCR:LA‐cp rat","year":2002,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Citation; Library science; Insulin resistance; Resistance (ecology); Medicine; Gerontology; Internal medicine; Insulin; Computer science; Biology; Ecology","score_opus":0.11004449098840965,"score_gpt":0.265879006246844,"score_spread":0.15583451525843436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008804979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009655897,0.9949303,0.0011890864,0.00050405826,0.0002834503,0.000014272804,0.000055202305,0.00004466183,0.002013421],"genre_scores_gemma":[0.002098432,0.994423,0.0016870351,0.00031462824,0.0001715456,0.000021001746,0.00008598948,0.0000070995534,0.0011913204],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985254,0.000021380534,0.0000230564,0.000033050805,0.00005058073,0.000019411063],"domain_scores_gemma":[0.99970067,0.0001173487,0.000036511123,0.000024765568,0.00008190143,0.000038952643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085453654,0.0016308205,0.001897395,0.0019188155,0.00039036377,0.000980195,0.0014949256,0.0015819729,0.0016308235],"category_scores_gemma":[0.00036564106,0.0003151961,0.00061808457,0.0018563733,0.0010941019,0.001354768,0.00040613883,0.0030138444,0.0014022546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054685527,0.00060482085,0.00034003818,0.009888827,0.00018150422,0.0007715357,0.000093336406,0.00074725086,0.051179655,0.0055599143,0.024469972,0.9056162],"study_design_scores_gemma":[0.00022281107,0.00081979844,0.0026449214,0.0019761638,0.0004929077,0.004013216,0.00012300514,0.0003368263,0.026961634,0.0048210225,0.95745367,0.00013395751],"about_ca_topic_score_codex":0.001689126,"about_ca_topic_score_gemma":0.0029732184,"teacher_disagreement_score":0.0019188155,"about_ca_system_score_codex":0.0006815042,"about_ca_system_score_gemma":0.00073680474,"threshold_uncertainty_score":0.005455613},"labels":[],"label_agreement":null},{"id":"W2010333163","doi":"10.1111/j.1463-1326.2011.01446.x","title":"Reprogramming gut and pancreas endocrine cells to treat diabetes","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Reprogramming; Endocrine system; Enteroendocrine cell; Pancreas; Diabetes mellitus; Endocrinology; Medicine; Biology; Internal medicine; Hormone; Cell; Biochemistry","score_opus":0.030644173342066042,"score_gpt":0.27875949422123475,"score_spread":0.2481153208791687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010333163","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004871699,0.9960974,0.00052647054,0.00020753303,0.00028861067,0.000008361005,0.000015958009,0.000013788055,0.0023548228],"genre_scores_gemma":[0.0013122602,0.99666935,0.0005101566,0.00017327121,0.00013549194,0.000008713367,0.000023934617,0.0000024508765,0.0011643918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998915,0.00001856792,0.000014533432,0.000019445171,0.00004433353,0.00001151694],"domain_scores_gemma":[0.9999187,0.000033760138,0.000013929912,0.0000039552183,0.000018926783,0.000010685059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029948956,0.0007392975,0.00085708685,0.0017073781,0.00021049657,0.0005817403,0.0004666999,0.0007121144,0.0028431409],"category_scores_gemma":[0.0002367815,0.00017007126,0.00035107913,0.0011896929,0.00029107436,0.00073346484,0.00047888438,0.0011932004,0.0018971981],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006318146,0.00011799102,0.00018436764,0.008055468,0.000058023372,0.00048752635,0.00006764703,0.00034227932,0.015014649,0.0025264642,0.0127089815,0.9603734],"study_design_scores_gemma":[0.000018109436,0.00012822894,0.0011275294,0.0016094354,0.00009094337,0.0033219324,0.0000719269,0.00009742379,0.0049437117,0.0014382823,0.98713416,0.000018271881],"about_ca_topic_score_codex":0.00040052898,"about_ca_topic_score_gemma":0.0008349753,"teacher_disagreement_score":0.0028431409,"about_ca_system_score_codex":0.0002967004,"about_ca_system_score_gemma":0.00036445542,"threshold_uncertainty_score":0.009511232},"labels":[],"label_agreement":null},{"id":"W2011760617","doi":"10.1111/j.1463-1326.2011.01383.x","title":"Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Ezetimibe; Statin; Medicine; Internal medicine; Diabetes mellitus; Population; Placebo; Gastroenterology; Cholesterol; Lipid profile; Endocrinology; Pharmacology","score_opus":0.059020171091089264,"score_gpt":0.3252401634328464,"score_spread":0.26621999234175714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011760617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6534419,0.3373233,0.0030177538,0.00033626423,0.00047694045,0.0015739762,0.002440765,0.00014103511,0.0012480423],"genre_scores_gemma":[0.9620226,0.03211585,0.0023266806,0.00034822396,0.00035204724,0.0008930164,0.0015888895,0.000039510058,0.0003132087],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98735446,0.007831073,0.0024415134,0.0010747921,0.0010350301,0.00026309968],"domain_scores_gemma":[0.989379,0.006324366,0.0027633165,0.0005978235,0.0006734818,0.00026207592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016494531,0.0017824722,0.010934342,0.0019968306,0.00027852898,0.0017524151,0.00072331185,0.0010682625,0.0014224389],"category_scores_gemma":[0.012868048,0.0008414765,0.016799709,0.0020760165,0.000543807,0.0008531087,0.0006816039,0.0010022961,0.00019322496],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2938803,0.00039834742,0.014880855,0.016963923,0.6407417,0.00013903319,0.00006152744,0.001576994,0.0035293105,0.000041404594,0.000395199,0.02739137],"study_design_scores_gemma":[0.08835334,0.034540858,0.05224507,0.0010532221,0.8182128,0.00027251808,0.0000854583,0.001515491,0.0019557646,0.00016882898,0.0015104483,0.00008619429],"about_ca_topic_score_codex":0.0005222798,"about_ca_topic_score_gemma":0.0012354095,"teacher_disagreement_score":0.016494531,"about_ca_system_score_codex":0.0006649649,"about_ca_system_score_gemma":0.00094923616,"threshold_uncertainty_score":0.08723247},"labels":[],"label_agreement":null},{"id":"W2011860054","doi":"10.1111/j.1463-1326.2005.00476.x","title":"Advances in pancreatic islet transplantation in humans","year":2005,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Islet; Transplantation; Islet cell transplantation; Intensive care medicine; Pancreas transplantation; Diabetes mellitus; Internal medicine; Endocrinology; Kidney transplantation","score_opus":0.019874240266731805,"score_gpt":0.29705459823772457,"score_spread":0.2771803579709928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011860054","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052726356,0.98343486,0.0017119009,0.0012320897,0.0009035906,0.000011915975,0.000021178115,0.000031877888,0.012125265],"genre_scores_gemma":[0.0038984683,0.98935974,0.0018719268,0.0009359215,0.00096817303,0.000018601502,0.000039826326,0.000007951111,0.002899308],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99967456,0.00008785372,0.000050427632,0.000048164016,0.00011527752,0.000023787115],"domain_scores_gemma":[0.99972075,0.00010600885,0.0000379441,0.000030616153,0.00007162452,0.00003312284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015229703,0.00065449666,0.00085941557,0.0010503163,0.00036723822,0.001500913,0.0005625431,0.0010562616,0.006281688],"category_scores_gemma":[0.0008935218,0.00019537286,0.00043084656,0.0012103106,0.00058676256,0.0018147246,0.00094399514,0.0016200953,0.0039694407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104891355,0.00011372512,0.00043063198,0.0044924673,0.000041493666,0.00061970804,0.00009053339,0.00026436185,0.0033266684,0.009843118,0.017414069,0.96325827],"study_design_scores_gemma":[0.000018143177,0.0001237449,0.000846927,0.0014701702,0.000042709584,0.0033077947,0.000060219652,0.00006363806,0.0013521495,0.004244563,0.9884566,0.000013262102],"about_ca_topic_score_codex":0.00035482718,"about_ca_topic_score_gemma":0.0003519031,"teacher_disagreement_score":0.006281688,"about_ca_system_score_codex":0.00044502196,"about_ca_system_score_gemma":0.0010666106,"threshold_uncertainty_score":0.021014273},"labels":[],"label_agreement":null},{"id":"W2012125528","doi":"10.1111/j.1463-1326.2012.01665.x","title":"The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of Calgary","funders":"Novo Nordisk","keywords":"Medicine; Insulin detemir; Adverse effect; Internal medicine; Insulin; Diabetes mellitus; Body mass index; Type 2 diabetes; Type 2 Diabetes Mellitus; Confidence interval; Hypoglycemia; Endocrinology; Insulin glargine","score_opus":0.019326523713890487,"score_gpt":0.31610213927775277,"score_spread":0.2967756155638623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012125528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898905,0.00068278424,0.000051973017,0.000043676562,0.000009462562,0.000021476688,0.000044278568,0.0000035684286,0.00015389318],"genre_scores_gemma":[0.99919826,0.00031292177,0.00021669774,0.00008716573,0.000023357425,0.000016567426,0.0001097975,0.0000014958811,0.000033654676],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99556845,0.002668005,0.0004898695,0.00053335755,0.000579114,0.0001611101],"domain_scores_gemma":[0.9751981,0.008695468,0.013052055,0.00081995473,0.0007796046,0.0014548232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045882696,0.00030799725,0.0006738635,0.00048374437,0.00039867134,0.001085251,0.0003604605,0.0007242247,0.00055551936],"category_scores_gemma":[0.018017044,0.0004043084,0.00074133027,0.0007102587,0.00057505415,0.0005146271,0.00046788366,0.00069711637,0.00011695904],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010187846,0.0009348144,0.9662352,0.00015857402,0.00042046313,0.00014633106,0.0002575585,0.000264774,0.00046983393,0.000010237571,0.00015922412,0.020755153],"study_design_scores_gemma":[0.0016092905,0.019391371,0.97608,0.000057979363,0.0002846201,0.0006997339,0.00033558666,0.00081071875,0.00030321357,0.000023143633,0.00037728198,0.000027238986],"about_ca_topic_score_codex":0.0010207298,"about_ca_topic_score_gemma":0.0012708978,"teacher_disagreement_score":0.0045882696,"about_ca_system_score_codex":0.0006372034,"about_ca_system_score_gemma":0.00057108345,"threshold_uncertainty_score":0.024265409},"labels":[],"label_agreement":null},{"id":"W2014308927","doi":"10.1111/j.1463-1326.2011.01521.x","title":"Blockade of kinin B <sub>1</sub> receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Endocrinology; Insulin resistance; Adipose tissue; Palmitoleic acid; Insulin; Chemistry; Linoleic acid; Biology; Fatty acid; Biochemistry; Medicine","score_opus":0.018423200554444234,"score_gpt":0.22272575889907598,"score_spread":0.20430255834463174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014308927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930636,0.0024984211,0.0023437047,0.0003159867,0.00011962877,0.00006663159,0.0004134096,0.00026654085,0.000912054],"genre_scores_gemma":[0.9876966,0.0028966807,0.0036826038,0.00023231495,0.00007008553,0.0002322598,0.0008532761,0.000060988248,0.0042752083],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997615,0.000038342994,0.000028206825,0.000045339304,0.00004837241,0.000078162804],"domain_scores_gemma":[0.9996062,0.000026307956,0.0001569025,0.00005281336,0.000034804685,0.00012300149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002914142,0.0012825656,0.0014687337,0.00063769246,0.0002496299,0.00036578436,0.000388235,0.000550683,0.0023573874],"category_scores_gemma":[0.0002043759,0.0003755945,0.0005484455,0.00030072875,0.0005010718,0.0006001859,0.00029671966,0.0021518797,0.00088161207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062549226,0.0011848632,0.0005176217,0.000117045274,0.00004924297,0.0001563536,0.000025856634,0.0001722447,0.9853674,0.000084647254,0.00020834936,0.005861623],"study_design_scores_gemma":[0.0008588708,0.019330923,0.010055893,0.00003308264,0.00019374445,0.001030811,0.00015193158,0.0015160542,0.9640889,0.00013646024,0.0025699986,0.000033276385],"about_ca_topic_score_codex":0.00063108373,"about_ca_topic_score_gemma":0.0011132499,"teacher_disagreement_score":0.0023573874,"about_ca_system_score_codex":0.00043537337,"about_ca_system_score_gemma":0.00038817953,"threshold_uncertainty_score":0.007886291},"labels":[],"label_agreement":null},{"id":"W2018366759","doi":"10.1111/j.1463-1326.2011.01509.x","title":"What matters in ADVANCE and ADVANCE‐ON","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Computer Research Institute of Montréal","funders":"Servier; U.S. Department of Veterans Affairs","keywords":"Medicine; Diabetes mellitus; Blood pressure; Disease; Type 2 diabetes; Internal medicine; Glycated haemoglobin; Intensive care medicine; Cardiology; Endocrinology","score_opus":0.0209471570295346,"score_gpt":0.28055525726273617,"score_spread":0.2596081002332016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018366759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016202928,0.63345903,0.004803904,0.21280244,0.059566032,0.0005981198,0.019071275,0.00054203236,0.05295422],"genre_scores_gemma":[0.37190127,0.18310653,0.006159083,0.28966233,0.10338637,0.0010922693,0.009720892,0.0013439697,0.0336273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9464953,0.036072973,0.004647986,0.005035713,0.0053759925,0.0023720795],"domain_scores_gemma":[0.86601764,0.09660926,0.014678893,0.009932638,0.0071611223,0.005600366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03622121,0.0015018829,0.0053551677,0.0031307628,0.0013113506,0.010529281,0.0027452088,0.0068799322,0.093824916],"category_scores_gemma":[0.14779931,0.0012058296,0.00909089,0.006380181,0.0022044259,0.009096944,0.0032149586,0.0069541144,0.008921458],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010841969,0.00035454272,0.03804866,0.06932014,0.056091808,0.001208186,0.0018520157,0.0009992638,0.0003585942,0.017858956,0.457027,0.34603882],"study_design_scores_gemma":[0.011575037,0.001018208,0.050656613,0.046110183,0.07778186,0.0022750152,0.0024494072,0.0013366794,0.0008133884,0.081933916,0.7235952,0.00045452302],"about_ca_topic_score_codex":0.0047683516,"about_ca_topic_score_gemma":0.005286246,"teacher_disagreement_score":0.093824916,"about_ca_system_score_codex":0.0017329776,"about_ca_system_score_gemma":0.005886097,"threshold_uncertainty_score":0.31387562},"labels":[],"label_agreement":null},{"id":"W2018970098","doi":"10.1111/j.1463-1326.2009.01090.x","title":"Weight and blood pressure response to weight management and sibutramine in diabetic and non‐diabetic high‐risk patients: an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes (SCOUT) trial","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; University of Alberta","funders":"Abbott Laboratories","keywords":"Sibutramine; Medicine; Diabetes mellitus; Blood pressure; Internal medicine; Weight loss; Overweight; Type 2 diabetes; Insulin; Weight management; Cardiology; Endocrinology; Obesity","score_opus":0.00492548337025824,"score_gpt":0.21812053029063191,"score_spread":0.21319504692037367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018970098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623704,0.002086157,0.00018427148,0.000086804524,0.00005669272,0.0002415214,0.00074817124,0.000013394208,0.00034606934],"genre_scores_gemma":[0.9954145,0.00086376554,0.00033278432,0.00018019124,0.00017023303,0.00050638546,0.0020953293,0.000011389989,0.0004253552],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976534,0.0014501372,0.00017728936,0.00029322406,0.00023283788,0.00019302091],"domain_scores_gemma":[0.9956292,0.0013478821,0.001200451,0.00055572094,0.00024379458,0.0010229986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046526254,0.0014830973,0.004082374,0.000481161,0.00046551935,0.0010766136,0.0007194456,0.0012533965,0.0023177068],"category_scores_gemma":[0.004041773,0.0006618438,0.0038532438,0.0008184251,0.0005869066,0.00073799555,0.0007176464,0.001678161,0.00026534894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9479759,0.0020919936,0.036525115,0.00036796008,0.0059412206,0.000057014393,0.00006501017,0.0002756259,0.00090906996,0.00003298626,0.00038465654,0.0053734328],"study_design_scores_gemma":[0.5541086,0.0842672,0.34543124,0.00013049155,0.011986916,0.00019005394,0.00014645475,0.001594246,0.00075849914,0.00021971489,0.0010643693,0.00010221518],"about_ca_topic_score_codex":0.00115332,"about_ca_topic_score_gemma":0.0019302176,"teacher_disagreement_score":0.0046526254,"about_ca_system_score_codex":0.0005084887,"about_ca_system_score_gemma":0.0007124504,"threshold_uncertainty_score":0.024605691},"labels":[],"label_agreement":null},{"id":"W2019255233","doi":"10.1111/j.1463-1326.2007.00782.x","title":"Regulation of pancreatic β‐cell function by the forkhead protein FoxO1","year":2007,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"FOXO transcription factor regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"FOXO1; Forkhead Transcription Factors; Cell growth; Biology; Internal medicine; Glucagon; Endocrinology; Cell biology; Transcription factor; Cell; Signal transduction; Medicine; Protein kinase B; Insulin; Gene; Biochemistry","score_opus":0.016804715699519863,"score_gpt":0.24815741422377421,"score_spread":0.23135269852425436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019255233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010795088,0.9928982,0.00087979104,0.00047694115,0.00029416042,0.000008220865,0.000077022276,0.000040064482,0.004246076],"genre_scores_gemma":[0.0020897454,0.99500567,0.000568592,0.00012472217,0.00011770253,0.000008331372,0.0000779288,0.0000029139767,0.0020044057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993825,0.000005646625,0.000007758225,0.000013804772,0.000026640346,0.000008020813],"domain_scores_gemma":[0.9999409,0.000011125221,0.000012394426,0.000002352207,0.000022087639,0.000011192894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019682116,0.00055757543,0.00065955863,0.0008596232,0.0002005388,0.00050991535,0.00046351395,0.00046899015,0.0026666156],"category_scores_gemma":[0.00017662637,0.00013015488,0.00018588781,0.0012193593,0.00022749863,0.00069343264,0.00036684738,0.0006430286,0.0028348877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063273794,0.000032219294,0.00023771831,0.004700654,0.000029477516,0.0002289387,0.000034156215,0.0002439463,0.010417818,0.002152682,0.01770823,0.96415085],"study_design_scores_gemma":[0.000018135472,0.00006414895,0.0017952415,0.0009015207,0.000040259252,0.0011114192,0.000047048983,0.0000955248,0.0031210352,0.0020647077,0.9907258,0.000015087891],"about_ca_topic_score_codex":0.0007720635,"about_ca_topic_score_gemma":0.000978917,"teacher_disagreement_score":0.0026666156,"about_ca_system_score_codex":0.0004595299,"about_ca_system_score_gemma":0.0005846764,"threshold_uncertainty_score":0.008920729},"labels":[],"label_agreement":null},{"id":"W2019550402","doi":"10.1111/j.1463-1326.2010.01271.x","title":"The endoplasmic reticulum stress response in the pancreatic <i>β</i> ‐cell","year":2010,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Unfolded protein response; Endoplasmic reticulum; Cell biology; Cell; Pancreatic islets; Biology; Cell type; Homeostasis; Secretion; Insulin; Endocrinology; Islet; Biochemistry","score_opus":0.01365993165459314,"score_gpt":0.25900318519561155,"score_spread":0.2453432535410184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019550402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003955757,0.9939175,0.0005078903,0.0004336866,0.0006256121,0.000009664051,0.000023189086,0.00002782664,0.0040590707],"genre_scores_gemma":[0.0013498069,0.9940953,0.0005459135,0.00033641467,0.00021904439,0.000009214913,0.00003961352,0.0000031871834,0.0034013668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999161,0.000011479249,0.000012664947,0.000015352762,0.000035876983,0.000008628116],"domain_scores_gemma":[0.9999249,0.000017737531,0.000014248062,0.00000442098,0.000025028603,0.000013568279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025758636,0.00084731984,0.000875635,0.0009162792,0.00026269475,0.0008505985,0.0005398438,0.00088683225,0.0022036845],"category_scores_gemma":[0.00016226413,0.00018313873,0.00023355235,0.0011849863,0.0005391804,0.0012573842,0.00049920945,0.001331502,0.0041166255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083772,0.00006988767,0.00019434192,0.008133581,0.000043216325,0.00033851532,0.00008196998,0.0003706328,0.014947004,0.0063467175,0.031327926,0.9380625],"study_design_scores_gemma":[0.0000094400375,0.000060906445,0.00073112064,0.0008541685,0.00002722676,0.0011368468,0.00005112765,0.000051931307,0.0017524727,0.0019414087,0.9933716,0.000011600676],"about_ca_topic_score_codex":0.00056200963,"about_ca_topic_score_gemma":0.0008330179,"teacher_disagreement_score":0.0022036845,"about_ca_system_score_codex":0.0005345461,"about_ca_system_score_gemma":0.0006078233,"threshold_uncertainty_score":0.0073720217},"labels":[],"label_agreement":null},{"id":"W2020158846","doi":"10.1111/j.1463-1326.2009.01152.x","title":"Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Merck","keywords":"Atorvastatin; Ezetimibe; Metabolic syndrome; Medicine; Tolerability; Internal medicine; Type 2 diabetes; Type 2 Diabetes Mellitus; Diabetes mellitus; Endocrinology; Gastroenterology; Acute coronary syndrome; Dyslipidemia; National Cholesterol Education Program; Cholesterol; Adverse effect; Pharmacology; Myocardial infarction","score_opus":0.009547110710946228,"score_gpt":0.22572039570497007,"score_spread":0.21617328499402386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020158846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939892,0.0036466552,0.0002472872,0.0002843304,0.00045042206,0.00044834547,0.0002309014,0.000045957004,0.0006569136],"genre_scores_gemma":[0.99605846,0.0014070686,0.00061147474,0.00029266597,0.00024281586,0.0003514635,0.00027213545,0.0000068818917,0.0007570103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990627,0.0005211009,0.00012164266,0.00012074716,0.0000614535,0.000112383976],"domain_scores_gemma":[0.99884003,0.00046186853,0.00021112755,0.0000804916,0.00007182452,0.00033467173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016015094,0.001087619,0.0033181421,0.00046741936,0.00027659556,0.0008968346,0.0005916553,0.0014219838,0.0039786384],"category_scores_gemma":[0.0026491284,0.00061203405,0.002121941,0.0003861959,0.00065947854,0.0008860911,0.00041372806,0.0023295127,0.0006112797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98660177,0.002543261,0.000617401,0.0002726153,0.0005893692,0.00002508925,0.000029739604,0.00012055307,0.0029642016,0.000023490831,0.000112143,0.0061003873],"study_design_scores_gemma":[0.71291715,0.27643746,0.005954308,0.000052757143,0.0016079881,0.00005851156,0.00005094866,0.0007301157,0.001631713,0.000102620994,0.00043405037,0.00002230106],"about_ca_topic_score_codex":0.00064703776,"about_ca_topic_score_gemma":0.0015874351,"teacher_disagreement_score":0.0039786384,"about_ca_system_score_codex":0.00039168613,"about_ca_system_score_gemma":0.0007419374,"threshold_uncertainty_score":0.013309896},"labels":[],"label_agreement":null},{"id":"W2020622760","doi":"10.1111/j.1463-1326.2008.00942.x","title":"Non‐invasive detection of transplanted pancreatic islets","year":2008,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Metabolic Technologies","keywords":"Islet; Transplantation; Medicine; Diabetes mellitus; Islet cell transplantation; Insulin; Pancreatic islets; Immune system; Clinical trial; Immune modulation; Intensive care medicine; Bioinformatics; Internal medicine; Immunology; Endocrinology; Biology","score_opus":0.01853082586857062,"score_gpt":0.252014669935761,"score_spread":0.23348384406719036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020622760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060995977,0.99572694,0.0008614729,0.0001494398,0.00018062844,0.0000074235563,0.000011752533,0.000015959242,0.0024363932],"genre_scores_gemma":[0.00239328,0.99475056,0.001009305,0.000131275,0.00009888718,0.000010991102,0.000026078693,0.0000029239818,0.0015766955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980074,0.000039158655,0.000017142162,0.00003320019,0.00009106449,0.000018673452],"domain_scores_gemma":[0.99978954,0.000107580745,0.000030550415,0.000010656671,0.000048464,0.000013205975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066751515,0.0007949856,0.001637911,0.0015383844,0.00016660766,0.00071789324,0.00095396704,0.0008312042,0.0019090435],"category_scores_gemma":[0.00042341225,0.00022302709,0.00039457562,0.0014470642,0.00044592752,0.001079571,0.00034029,0.0008000725,0.0023333202],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008185169,0.00008463587,0.00032561476,0.009287643,0.000051881092,0.00040878064,0.00004899479,0.00020028219,0.01863317,0.0018463279,0.007636267,0.96139455],"study_design_scores_gemma":[0.000031114134,0.00025019,0.0038218647,0.0025346712,0.0001718072,0.008198566,0.00016229777,0.00027501147,0.02529378,0.0023452193,0.9568697,0.000045856403],"about_ca_topic_score_codex":0.00050325686,"about_ca_topic_score_gemma":0.00067140296,"teacher_disagreement_score":0.0019090435,"about_ca_system_score_codex":0.00033732725,"about_ca_system_score_gemma":0.0004582572,"threshold_uncertainty_score":0.0063863993},"labels":[],"label_agreement":null},{"id":"W2020735006","doi":"10.1111/j.1462-8902.2004.00320.x","title":"Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide","year":2004,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Advanced Glycation End Products research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Servier","keywords":"Glycation; Gliclazide; Inhibitory postsynaptic potential; Signalling pathways; Cell biology; Chemistry; Signal transduction; Retinal; Signalling; Biochemistry; Receptor; Biology; Neuroscience; Endocrinology; Diabetes mellitus","score_opus":0.00742261289162206,"score_gpt":0.23074816652558183,"score_spread":0.22332555363395978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020735006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9571704,0.03748329,0.0021229987,0.00029572466,0.00010132183,0.00008347647,0.00039227738,0.00011070929,0.002239735],"genre_scores_gemma":[0.9771822,0.017480081,0.0022737926,0.00017465382,0.000056436045,0.00009109797,0.00055708876,0.000010608814,0.0021740757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992156,0.000018926186,0.000009513108,0.000011577303,0.000016370754,0.000022018208],"domain_scores_gemma":[0.9999441,0.000008460066,0.000015629526,0.0000044605404,0.000013461407,0.000013930158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015758646,0.0004609542,0.00037771696,0.00021605755,0.00013953133,0.00020225784,0.00018819375,0.00025476122,0.0010247203],"category_scores_gemma":[0.00009459233,0.00011646413,0.0003225561,0.00013354488,0.00019139316,0.00019948665,0.00013640146,0.0004967092,0.00028743062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001253487,0.0001258615,0.00020578886,0.00026138366,0.000023233195,0.000091904665,0.000016555756,0.000072711795,0.9938403,0.00005222127,0.00006892367,0.003987739],"study_design_scores_gemma":[0.00023425848,0.0015937585,0.011132968,0.00003053371,0.00009898038,0.00043879676,0.00005174623,0.000700283,0.9815104,0.00006484183,0.0041337293,0.000009769487],"about_ca_topic_score_codex":0.0006148557,"about_ca_topic_score_gemma":0.0009318437,"teacher_disagreement_score":0.0010247203,"about_ca_system_score_codex":0.00022888042,"about_ca_system_score_gemma":0.0003031352,"threshold_uncertainty_score":0.003428042},"labels":[],"label_agreement":null},{"id":"W2024436535","doi":"10.1111/dom.12130","title":"Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co‐morbid with insulin‐resistant type‐2 diabetes","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Heme Oxygenase-1 and Carbon Monoxide","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Internal medicine; Endocrinology; Adipocyte; Adiponectin; GLUT4; Insulin; Insulin resistance; Carbohydrate metabolism; Adipose tissue; Medicine; Biology","score_opus":0.00485499775548432,"score_gpt":0.20063222799004307,"score_spread":0.19577723023455876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024436535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750656,0.0008663519,0.0009066895,0.000080074264,0.000032342687,0.000024658504,0.00012715785,0.000057990197,0.00039826063],"genre_scores_gemma":[0.9941011,0.0013443036,0.0018354029,0.000110792455,0.000030663257,0.000080834325,0.00030636878,0.00002313344,0.0021673054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999378,0.000010921426,0.000005169209,0.00001380458,0.000012753508,0.000019596273],"domain_scores_gemma":[0.999902,0.000007696853,0.000034992165,0.000010325648,0.0000067477954,0.00003816184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011672462,0.0004822088,0.00045667923,0.0003606973,0.00014954593,0.00016221618,0.0001689159,0.00023771121,0.0012610058],"category_scores_gemma":[0.00007214741,0.00013782538,0.0002112008,0.0001629872,0.00027801373,0.00021623871,0.00016465689,0.00082640717,0.00013937574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048420574,0.0010409398,0.00048281936,0.00010143175,0.000023644156,0.000102794016,0.000025645768,0.000080371836,0.9879602,0.000051740008,0.00007696442,0.0052113673],"study_design_scores_gemma":[0.0010511267,0.016650695,0.02240526,0.00003692172,0.00014162982,0.0004981959,0.00014760705,0.0011369465,0.9541743,0.00016198836,0.003573614,0.000021659112],"about_ca_topic_score_codex":0.0002100044,"about_ca_topic_score_gemma":0.00041983818,"teacher_disagreement_score":0.0012610058,"about_ca_system_score_codex":0.00012042092,"about_ca_system_score_gemma":0.00014461575,"threshold_uncertainty_score":0.004218459},"labels":[],"label_agreement":null},{"id":"W2026751220","doi":"10.1111/j.1463-1326.2010.01312.x","title":"Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study","year":2010,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Postprandial; Insulin; Internal medicine; Impaired glucose tolerance; Medicine; Endocrinology; Meal; Buccal administration; Diabetes mellitus; Insulin resistance; Pharmacology","score_opus":0.00887560486675868,"score_gpt":0.24891153818066994,"score_spread":0.24003593331391126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026751220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630874,0.0023693952,0.00014865566,0.00008060046,0.00005281287,0.00030123294,0.00014526235,0.000010639276,0.0005826069],"genre_scores_gemma":[0.9940959,0.0022969325,0.00048526737,0.00036689176,0.00020575544,0.0004028984,0.00040107055,0.000006273173,0.001739114],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996475,0.00015121324,0.00002249643,0.000060473903,0.000056434794,0.00006186026],"domain_scores_gemma":[0.99968255,0.00005364096,0.0000733185,0.000038714916,0.000031375894,0.000120537225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00122044,0.0008751666,0.0017088221,0.00024038351,0.00037510908,0.0006797846,0.00036941475,0.0009775367,0.0031755734],"category_scores_gemma":[0.00056648575,0.00048374484,0.0010616508,0.00034364202,0.00055073807,0.00037903426,0.00035508335,0.0012522127,0.00058822014],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8705942,0.035153568,0.033880282,0.0009965203,0.0015268862,0.00018999462,0.00013873815,0.00011989989,0.018242879,0.00008120836,0.00038492223,0.038690902],"study_design_scores_gemma":[0.1927952,0.6313241,0.16712815,0.00009588371,0.0023957512,0.00034509526,0.00018721611,0.0004203303,0.0025512262,0.00011057132,0.0026005807,0.000045965335],"about_ca_topic_score_codex":0.00090064923,"about_ca_topic_score_gemma":0.0011116952,"teacher_disagreement_score":0.0031755734,"about_ca_system_score_codex":0.0002807664,"about_ca_system_score_gemma":0.00055085914,"threshold_uncertainty_score":0.010623395},"labels":[],"label_agreement":null},{"id":"W2029664649","doi":"10.1111/j.1463-1326.2007.00747.x","title":"PPAR‐alpha: therapeutic role in diabetes‐related cardiovascular disease","year":2007,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Diabetes mellitus; Medicine; Disease; Statin; Clinical trial; Internal medicine; Clinical endpoint; Fenofibrate; Cause of death; Type 2 diabetes; Bioinformatics; Intensive care medicine; Endocrinology; Biology","score_opus":0.015527915947265011,"score_gpt":0.25681104126673754,"score_spread":0.24128312531947252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029664649","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014252913,0.9976935,0.00013396742,0.000373188,0.0003173797,0.000005405234,0.000009946983,0.000009477936,0.0013147409],"genre_scores_gemma":[0.00074486836,0.9977042,0.00024001377,0.00027666753,0.00021964514,0.000008022127,0.000015988386,0.0000016754111,0.0007890039],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998093,0.000040594055,0.000024477415,0.00003027092,0.000073977724,0.000021338466],"domain_scores_gemma":[0.9997632,0.00010818142,0.000029076038,0.000009367657,0.000057839883,0.000032428034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008218489,0.0010143926,0.0016186915,0.001737945,0.000380509,0.0009694397,0.0011885603,0.0017127874,0.0036065748],"category_scores_gemma":[0.0005762626,0.000258271,0.0004458291,0.0020995173,0.0008071624,0.0013390712,0.0006207388,0.0028353664,0.0032971825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020450256,0.00015172042,0.00016515415,0.006482078,0.00007689308,0.0003421437,0.000058583923,0.00035507663,0.0019438084,0.004006252,0.03114543,0.95506823],"study_design_scores_gemma":[0.00008157062,0.0001861138,0.00096817967,0.002092042,0.00007575079,0.0020909589,0.00005688777,0.00009289442,0.0004958356,0.0030091566,0.9908319,0.000018649163],"about_ca_topic_score_codex":0.0006017955,"about_ca_topic_score_gemma":0.0012959797,"teacher_disagreement_score":0.0036065748,"about_ca_system_score_codex":0.0005154656,"about_ca_system_score_gemma":0.00064631755,"threshold_uncertainty_score":0.012065232},"labels":[],"label_agreement":null},{"id":"W2031730303","doi":"10.1111/dom.12428","title":"Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Janssen Research and Development; American Heart Association","keywords":"Canagliflozin; Medicine; Placebo; Blood pressure; Internal medicine; Type 2 diabetes; Endocrinology; Diabetes mellitus; Regimen; Adverse effect; Gastroenterology","score_opus":0.004615864103886198,"score_gpt":0.20171394092333242,"score_spread":0.19709807681944622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031730303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974654,0.0018915444,0.00008479614,0.00006115097,0.000026142461,0.00006681532,0.000061445484,0.000011614783,0.00033098846],"genre_scores_gemma":[0.9980096,0.0009583175,0.0002000273,0.00020898128,0.000074612704,0.000090777976,0.00019334744,0.00000199625,0.00026243116],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997023,0.0000917407,0.00003313253,0.0000566617,0.00006221165,0.000054004406],"domain_scores_gemma":[0.9994923,0.00009521806,0.00016673181,0.000028665765,0.000038231352,0.0001788645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011798257,0.0004331698,0.0014031329,0.00031837236,0.00033474228,0.0004469199,0.00027114945,0.00057193055,0.0008805388],"category_scores_gemma":[0.0010935966,0.0002737462,0.0008559724,0.00038151606,0.00026837562,0.0004575821,0.00024249233,0.00089184573,0.00016023505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58479667,0.025859034,0.17955212,0.0008111307,0.0036908588,0.0003820203,0.00028683402,0.0019909742,0.015712883,0.0000513681,0.0014059312,0.18546025],"study_design_scores_gemma":[0.15486456,0.2779394,0.55652404,0.000121116165,0.003206868,0.0005586501,0.00015414157,0.0021404775,0.002462756,0.00008721924,0.0018796267,0.000061149476],"about_ca_topic_score_codex":0.0009534127,"about_ca_topic_score_gemma":0.0018430823,"teacher_disagreement_score":0.0014031329,"about_ca_system_score_codex":0.0003325827,"about_ca_system_score_gemma":0.00037695759,"threshold_uncertainty_score":0.006239593},"labels":[],"label_agreement":null},{"id":"W2032883705","doi":"10.1111/dom.12134","title":"A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; University of Calgary; Centre for Family Medicine; McMaster University; Canadian Heart Research Centre; Hamilton Health Sciences; Western University; University of Toronto; Population Health Research Institute; Université Laval; Université de Montréal; University of British Columbia; Montreal Clinical Research Institute; St. Michael's Hospital","funders":"Merck Canada","keywords":"Medicine; Type 2 Diabetes Mellitus; Primary care; Blood pressure; Diabetes mellitus; Internal medicine; Disease; Type 2 diabetes; Intensive care medicine; Physical therapy; Family medicine; Endocrinology","score_opus":0.006035245437309562,"score_gpt":0.228748609499203,"score_spread":0.22271336406189343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032883705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941831,0.0011517105,0.00006289085,0.0005873379,0.000020026273,0.000047395606,0.0012741528,0.0000063946186,0.0026670177],"genre_scores_gemma":[0.9983883,0.00047195068,0.00015142052,0.00015930402,0.000011118843,0.0000115324965,0.00060055184,0.0000016163593,0.0002043525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856025,0.000117313924,0.00010884804,0.00019628873,0.00068556395,0.00033178815],"domain_scores_gemma":[0.9973078,0.0002175426,0.0007221789,0.00004144373,0.0009614196,0.0007496911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067643635,0.0002403189,0.00040558286,0.0008508429,0.0016768881,0.00094136887,0.000824029,0.000535698,0.0016481479],"category_scores_gemma":[0.00449911,0.00025395246,0.00041565485,0.0023834389,0.00038905715,0.00035298974,0.00057453016,0.0005373286,0.000116484225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012029648,0.00006280761,0.9895906,0.000087286244,0.000056944304,0.00009764593,0.00068853644,0.000090019224,0.00010070163,0.000030176858,0.0008664235,0.008208484],"study_design_scores_gemma":[0.000008930966,0.000047263686,0.9989249,0.000023318187,0.000015100621,0.00006592322,0.0005173514,0.000097642136,0.0000144671485,0.0000065965824,0.00027328506,0.0000051514057],"about_ca_topic_score_codex":0.9437662,"about_ca_topic_score_gemma":0.9652312,"teacher_disagreement_score":0.9437662,"about_ca_system_score_codex":0.01312612,"about_ca_system_score_gemma":0.011849469,"threshold_uncertainty_score":0.113129914},"labels":[],"label_agreement":null},{"id":"W2033185429","doi":"10.1111/j.1463-1326.2012.01673.x","title":"Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Weight loss; Exenatide; Medicine; Placebo; Weight change; Sitagliptin; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Gastroenterology; Obesity","score_opus":0.05835125910981301,"score_gpt":0.2946800038701167,"score_spread":0.23632874476030372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033185429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8541399,0.13187449,0.0025407975,0.00080005266,0.00016918502,0.0038940522,0.004881938,0.00015514395,0.0015443384],"genre_scores_gemma":[0.96961546,0.017968858,0.0028495847,0.0010259888,0.00014493206,0.003250559,0.004648358,0.000063983716,0.00043231354],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9828924,0.011545912,0.0019627498,0.0010808727,0.0021791917,0.0003388481],"domain_scores_gemma":[0.97876096,0.011598352,0.0070654727,0.0010260422,0.0008869025,0.00066227437],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.021991163,0.0010548427,0.0048042918,0.0010465697,0.00043028794,0.001699688,0.000897569,0.0013566349,0.0016789911],"category_scores_gemma":[0.020243973,0.0005656263,0.008337087,0.001824052,0.0008000234,0.00093664863,0.0008003715,0.0016439501,0.00021743763],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77292174,0.001681169,0.03572626,0.015666258,0.08769018,0.00029558977,0.0003062152,0.0014746685,0.0040596686,0.00016124792,0.0020121373,0.07800487],"study_design_scores_gemma":[0.49522218,0.13280231,0.21752013,0.0029296512,0.13685696,0.0009342881,0.00024095629,0.0020897933,0.0023626257,0.00047617618,0.008382968,0.00018202703],"about_ca_topic_score_codex":0.0007109166,"about_ca_topic_score_gemma":0.0019626794,"teacher_disagreement_score":0.9951957,"about_ca_system_score_codex":0.0010633295,"about_ca_system_score_gemma":0.0015087668,"threshold_uncertainty_score":0.116301775},"labels":[],"label_agreement":null},{"id":"W2034171544","doi":"10.1111/j.1463-1326.2011.01362.x","title":"Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Sitagliptin; Postprandial; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus; Insulin","score_opus":0.010168186497145333,"score_gpt":0.21106722708303688,"score_spread":0.20089904058589156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034171544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932707,0.005627964,0.0000900895,0.00013140649,0.00005674444,0.000043547323,0.000075045384,0.000020272853,0.0006843123],"genre_scores_gemma":[0.9964921,0.002051318,0.00033438372,0.00037245717,0.000103638136,0.00006986007,0.00023736151,0.000003676874,0.00033523832],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976295,0.00011020394,0.000038135873,0.000025948484,0.000038738013,0.00002398051],"domain_scores_gemma":[0.9995221,0.00017927712,0.000111403955,0.000017285702,0.000026125312,0.00014388394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007263308,0.00048574372,0.0011380992,0.00021442538,0.00023871052,0.00038128227,0.00016593054,0.00054581143,0.0011999067],"category_scores_gemma":[0.00087840774,0.00017057799,0.0005033075,0.00024009674,0.00019814433,0.0002053994,0.00017419951,0.00081334374,0.00018383682],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43949503,0.01361317,0.23540647,0.0016223859,0.0028913193,0.0013720727,0.0003724086,0.00096367433,0.051176455,0.00007879954,0.0017739413,0.25123426],"study_design_scores_gemma":[0.031288706,0.19781289,0.75739866,0.00015174075,0.0016999954,0.001499519,0.00027119435,0.0014409597,0.0052955025,0.000090155074,0.0030097826,0.000040911455],"about_ca_topic_score_codex":0.00026646798,"about_ca_topic_score_gemma":0.0005322291,"teacher_disagreement_score":0.0011999067,"about_ca_system_score_codex":0.00015984394,"about_ca_system_score_gemma":0.00020108966,"threshold_uncertainty_score":0.004014075},"labels":[],"label_agreement":null},{"id":"W2037395799","doi":"10.1111/dom.12226","title":"Composite endpoints in trials of type‐2 diabetes","year":2013,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sitagliptin; Medicine; Saxagliptin; Type 2 diabetes; Exenatide; Linagliptin; Dapagliflozin; Liraglutide; Vildagliptin; Internal medicine; Diabetes mellitus; Clinical trial; Randomized controlled trial; Endocrinology","score_opus":0.056287142802563854,"score_gpt":0.32216846093570106,"score_spread":0.2658813181331372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037395799","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007454505,0.99861693,0.00031211192,0.00022394945,0.00017602216,0.00019358874,0.00008755462,0.000007768803,0.0003076531],"genre_scores_gemma":[0.0025087665,0.99256974,0.002583906,0.0007545057,0.00021578495,0.0010120941,0.00020427088,0.000011433162,0.00013947717],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9453537,0.030701237,0.014160687,0.0020577237,0.007356539,0.00037021618],"domain_scores_gemma":[0.86294454,0.112590246,0.01746729,0.0017747388,0.0046322267,0.000591034],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.04767252,0.0021527593,0.010668117,0.013192897,0.0005923722,0.0036527938,0.0022853664,0.003067325,0.006328448],"category_scores_gemma":[0.08414989,0.0010127163,0.006627967,0.01602305,0.0015157582,0.002943627,0.0022028908,0.0034730646,0.00083261804],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003943801,0.00003486217,0.00036216003,0.68066627,0.0056121554,0.000058636142,0.00015177732,0.00021178003,0.00022107702,0.002496977,0.006173774,0.30361617],"study_design_scores_gemma":[0.0013513017,0.0005711819,0.003984778,0.6982372,0.02550433,0.00052911404,0.0002914496,0.0002665103,0.00048609456,0.0073911175,0.26127943,0.000107519816],"about_ca_topic_score_codex":0.0017154327,"about_ca_topic_score_gemma":0.0034316205,"teacher_disagreement_score":0.9523275,"about_ca_system_score_codex":0.0031279903,"about_ca_system_score_gemma":0.008001862,"threshold_uncertainty_score":0.25211942},"labels":[],"label_agreement":null},{"id":"W2039664878","doi":"10.1111/j.1463-1326.2012.01637.x","title":"Effect of anti‐ <scp>IL</scp> ‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Adipokines, Inflammation, and Metabolic Diseases","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Particle Physics","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Medicine; Canakinumab; Metformin; Internal medicine; Placebo; Insulin; Sulfonylurea; Type 2 diabetes; Endocrinology; Diabetes mellitus; Impaired glucose tolerance; Insulin resistance","score_opus":0.008338072323909101,"score_gpt":0.2653110258040003,"score_spread":0.2569729534800912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039664878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788088,0.013651581,0.00051287323,0.00069176144,0.00090015924,0.0026875378,0.0006786488,0.00014307907,0.001925431],"genre_scores_gemma":[0.98624086,0.0059489016,0.001015265,0.0008866598,0.0008049274,0.0025301115,0.0007063141,0.000023454686,0.0018435087],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99888057,0.00064339506,0.000100121506,0.0001761274,0.00008627219,0.0001134785],"domain_scores_gemma":[0.9981993,0.0007480734,0.00046852496,0.00012406734,0.00011676965,0.00034341431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027103324,0.0017467063,0.00404478,0.0004767667,0.0003975565,0.0012639427,0.0009651171,0.0024736056,0.005981646],"category_scores_gemma":[0.003150479,0.0007565507,0.0024576224,0.0005056375,0.0012233165,0.0009326222,0.0003689651,0.00248705,0.00080677716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98879015,0.0015825484,0.00026952891,0.0006525395,0.0009464262,0.000017155053,0.00001383486,0.00009581615,0.0009624094,0.000023054263,0.00019553467,0.006450937],"study_design_scores_gemma":[0.97368175,0.024460968,0.0008222352,0.000031246225,0.00053876056,0.000013062324,0.0000053170456,0.00010965357,0.00017701367,0.00002763791,0.00012716024,0.0000051559696],"about_ca_topic_score_codex":0.0008115882,"about_ca_topic_score_gemma":0.00130246,"teacher_disagreement_score":0.005981646,"about_ca_system_score_codex":0.0007563485,"about_ca_system_score_gemma":0.000903189,"threshold_uncertainty_score":0.02001065},"labels":[],"label_agreement":null},{"id":"W2040535327","doi":"10.1111/j.1463-1326.2005.00556.x","title":"Reduced left ventricular mass after treatment of obese patients with sibutramine: an echocardiographic multicentre study","year":2006,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton General Hospital","funders":"","keywords":"Sibutramine; Medicine; Placebo; Blood pressure; Body mass index; Cardiology; Internal medicine; Heart rate; Body surface area; Obesity; Weight loss; Left ventricular hypertrophy; Endocrinology","score_opus":0.004058364162573455,"score_gpt":0.21969718355831136,"score_spread":0.2156388193957379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040535327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988386,0.0006705721,0.00007254607,0.000040230374,0.000019102328,0.00011215835,0.00011180742,0.000005758199,0.00012926484],"genre_scores_gemma":[0.9982333,0.00038651144,0.0002651008,0.00019377643,0.00010228532,0.00017971109,0.00047053245,0.0000036343476,0.00016503551],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99867576,0.0007176153,0.00013585213,0.00016766509,0.00017045264,0.00013259721],"domain_scores_gemma":[0.9982338,0.00030966464,0.00051640737,0.00018906075,0.0001237587,0.0006272022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021225207,0.0011954478,0.0026051681,0.00053160463,0.00068735017,0.00073122286,0.00057749695,0.0012847241,0.0014407206],"category_scores_gemma":[0.002096243,0.000640947,0.0019460217,0.0007033478,0.0007209727,0.00042188726,0.00050689245,0.0008543656,0.00034006525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6683268,0.017215747,0.2613913,0.00069002155,0.0056349374,0.00085307343,0.0004191773,0.00048127162,0.01893057,0.000047006066,0.00058912585,0.025420958],"study_design_scores_gemma":[0.14498636,0.20586137,0.6408988,0.00007823288,0.0037167813,0.0010614032,0.00016217667,0.00059669686,0.0015949414,0.000049892016,0.00091213215,0.00008113649],"about_ca_topic_score_codex":0.0010598,"about_ca_topic_score_gemma":0.0016595561,"teacher_disagreement_score":0.0026051681,"about_ca_system_score_codex":0.00048300464,"about_ca_system_score_gemma":0.0007626274,"threshold_uncertainty_score":0.011225104},"labels":[],"label_agreement":null},{"id":"W2041239330","doi":"10.1111/j.1463-1326.2011.01404.x","title":"High‐density lipoprotein‐cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Eli Lilly and Company","keywords":"Pioglitazone; Medicine; Internal medicine; Blood pressure; Myocardial infarction; Post-hoc analysis; Type 2 diabetes; Cholesterol; Placebo; Cardiology; Stroke (engine); Diabetes mellitus; Endocrinology","score_opus":0.018707300552375503,"score_gpt":0.22895393290745122,"score_spread":0.21024663235507574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041239330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979869,0.00068399723,0.0002372386,0.00012961449,0.000033431235,0.000030063116,0.00018210369,0.000009788738,0.0007068129],"genre_scores_gemma":[0.99865556,0.00024987833,0.00019013713,0.00013377664,0.0000410157,0.00004372332,0.00019246648,0.0000018022004,0.000491572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995908,0.00018669254,0.00003055253,0.000068037436,0.00006211798,0.00006186389],"domain_scores_gemma":[0.99883765,0.00051381264,0.00026274685,0.000112400994,0.000054655622,0.00021872614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016787514,0.00032111982,0.00047871188,0.00015345657,0.00014944871,0.0005022867,0.00021500373,0.00050120126,0.0016559095],"category_scores_gemma":[0.0017061244,0.00019426816,0.0005508166,0.0002336882,0.00021199933,0.00020651166,0.00027504563,0.0009068901,0.00017341446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36748537,0.0135630015,0.39631906,0.0010572064,0.004151534,0.00079919084,0.00042764933,0.0021579675,0.02903208,0.0007359605,0.001626161,0.18264483],"study_design_scores_gemma":[0.013451066,0.124571815,0.83764744,0.00013261376,0.0060776235,0.0005817264,0.00023684013,0.003335759,0.009363601,0.0017881657,0.00276049,0.000052888427],"about_ca_topic_score_codex":0.000644639,"about_ca_topic_score_gemma":0.0010822249,"teacher_disagreement_score":0.0016787514,"about_ca_system_score_codex":0.00015756347,"about_ca_system_score_gemma":0.00036302154,"threshold_uncertainty_score":0.008878171},"labels":[],"label_agreement":null},{"id":"W2041310907","doi":"10.1111/j.1463-1326.2012.01613.x","title":"Factors influencing initial choice of insulin therapy in a large international non‐interventional study of people with type 2 diabetes","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Sanofi","keywords":"Type 2 diabetes; Medicine; Insulin; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.15798927200610685,"score_gpt":0.38128961406848283,"score_spread":0.22330034206237598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041310907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929416,0.00013007224,0.000041412295,0.000087823384,0.0000040630116,0.0000083265,0.0002041914,7.8571435e-7,0.00022903818],"genre_scores_gemma":[0.9994585,0.0000679584,0.00005938866,0.00004580875,0.000006265778,0.00000943503,0.00026911436,8.7885917e-7,0.000082695224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999089,0.0004521891,0.00008627621,0.00012832027,0.00012273411,0.00012143051],"domain_scores_gemma":[0.9963398,0.00072697917,0.0019118648,0.00016926306,0.00025740513,0.0005947325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016011983,0.00024103138,0.0003602449,0.0006621169,0.00077472365,0.00096302974,0.00034744566,0.0005849843,0.0015228812],"category_scores_gemma":[0.0053364486,0.00026853534,0.00055762223,0.001202583,0.00031332477,0.00044306263,0.00047303722,0.00084581866,0.0001888448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093459625,0.00007305988,0.99918,0.0000038678354,0.0000279815,0.000025220805,0.000073026305,0.00001594231,0.000022560336,0.000006937819,0.00006551632,0.00041237284],"study_design_scores_gemma":[0.00001324667,0.000049628685,0.99944955,0.0000053249773,0.000018059818,0.00004271024,0.0002128384,0.00012253874,0.000010536008,0.000012959091,0.00005977303,0.0000028197471],"about_ca_topic_score_codex":0.02261168,"about_ca_topic_score_gemma":0.028370894,"teacher_disagreement_score":0.02261168,"about_ca_system_score_codex":0.000517804,"about_ca_system_score_gemma":0.0004975769,"threshold_uncertainty_score":0.04496014},"labels":[],"label_agreement":null},{"id":"W2041447975","doi":"10.1111/j.1463-1326.2009.01157.x","title":"Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Endocrinology; Internal medicine; Agonist; Receptor; Nuclear receptor; Appetite; Peroxisome proliferator-activated receptor; Knockout mouse; Weight loss; Chemistry; Activator (genetics); Biology; Medicine; Transcription factor; Obesity; Biochemistry","score_opus":0.005075044985849484,"score_gpt":0.20881025495313071,"score_spread":0.20373520996728123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041447975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868515,0.0023072734,0.006374332,0.000591561,0.0001242906,0.00011844237,0.0014002497,0.0005332533,0.0016990326],"genre_scores_gemma":[0.96951956,0.004000962,0.0091547035,0.0006664251,0.00008043096,0.000564272,0.0022274586,0.00032038396,0.013465792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99952614,0.00006336147,0.00006346131,0.00013446936,0.00010691743,0.00010559816],"domain_scores_gemma":[0.9995802,0.00003454568,0.00017355914,0.00004662442,0.000026934806,0.00013809498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004608925,0.0008818834,0.0007107103,0.0009756971,0.0003780365,0.00053562527,0.0006176137,0.00063107925,0.0031034462],"category_scores_gemma":[0.00018933485,0.0005831226,0.0008526719,0.00045650426,0.0008433758,0.0005548772,0.0004540012,0.0018976921,0.0009919722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017495684,0.0003717228,0.000452912,0.00009548935,0.000020990914,0.000110681096,0.00002950166,0.00006365593,0.9942305,0.00013557207,0.00011679088,0.0026225613],"study_design_scores_gemma":[0.0007010165,0.0056764744,0.01156245,0.00007930549,0.00017262068,0.0010261915,0.00018199734,0.0013477557,0.9711953,0.00031424107,0.00771319,0.000029360952],"about_ca_topic_score_codex":0.00043989744,"about_ca_topic_score_gemma":0.0008124939,"teacher_disagreement_score":0.0031034462,"about_ca_system_score_codex":0.00048307373,"about_ca_system_score_gemma":0.00040353404,"threshold_uncertainty_score":0.010381997},"labels":[],"label_agreement":null},{"id":"W2043193063","doi":"10.1111/j.1463-1326.2007.00811.x","title":"Effect of chronic rosiglitazone, metformin and glyburide treatment on β‐cell mass, function and insulin sensitivity in mZDF rats","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Mitacs","keywords":"Rosiglitazone; Internal medicine; Endocrinology; Metformin; Insulin; Medicine; Diabetes mellitus","score_opus":0.005642407623199774,"score_gpt":0.22515794906489622,"score_spread":0.21951554144169644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043193063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820423,0.0008299686,0.00040945024,0.00005654534,0.00002157825,0.00001493442,0.00019353772,0.000034826775,0.00023502884],"genre_scores_gemma":[0.9935681,0.0014913265,0.0016028624,0.00011656446,0.000026737744,0.00009513051,0.0005697398,0.000030859243,0.0024987205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998357,0.000016347789,0.000019384655,0.000043425054,0.000033179134,0.000051890427],"domain_scores_gemma":[0.99964845,0.00003006473,0.000118869204,0.000043082582,0.000027712647,0.00013187292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001716933,0.00064112793,0.00055803615,0.00063531986,0.000210007,0.00028744625,0.00028471331,0.00043775214,0.0010306474],"category_scores_gemma":[0.00015158804,0.00026854608,0.00045825043,0.00021358594,0.00038728278,0.00038554022,0.00027560344,0.0011960252,0.00020808775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066469284,0.00052359555,0.0017616849,0.00007240983,0.000039995222,0.000121175115,0.000044300235,0.00010795292,0.98550767,0.000058858,0.000055485893,0.005059982],"study_design_scores_gemma":[0.00057241623,0.013862631,0.03941616,0.000027624745,0.00022573305,0.00051431236,0.00027212067,0.0010280221,0.94090134,0.00019569077,0.0029371057,0.000046749316],"about_ca_topic_score_codex":0.0011134519,"about_ca_topic_score_gemma":0.0015511025,"teacher_disagreement_score":0.0011134519,"about_ca_system_score_codex":0.00028388362,"about_ca_system_score_gemma":0.00023486739,"threshold_uncertainty_score":0.0034478903},"labels":[],"label_agreement":null},{"id":"W2043551382","doi":"10.1111/dom.12456","title":"Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer","year":2015,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Heritage Foundation for Medical Research","keywords":"Observational study; Medicine; Adverse effect; Confounding; Intensive care medicine; Clinical trial; Diabetes mellitus; Randomized controlled trial; Internal medicine; Endocrinology","score_opus":0.01702600455774621,"score_gpt":0.2704242773177059,"score_spread":0.2533982727599597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043551382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012720551,0.99063617,0.000076654804,0.008255079,0.0007455866,0.0000017358633,0.000009216468,0.000001938031,0.00014636797],"genre_scores_gemma":[0.0027211634,0.98731637,0.00018113705,0.006427016,0.0032222988,0.0000068939016,0.000018853809,0.000003977199,0.000102213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99326587,0.0026264086,0.0012589147,0.00085519376,0.0017750936,0.00021849356],"domain_scores_gemma":[0.9482209,0.044240844,0.0026322892,0.0007182891,0.0036316116,0.00055602373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016008088,0.0009844848,0.004112104,0.0032832357,0.0011612417,0.00340771,0.0017273123,0.0052492293,0.0023241031],"category_scores_gemma":[0.026484959,0.0005512788,0.0019039107,0.004719975,0.005518826,0.006229263,0.00221564,0.006787039,0.000537262],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042415154,0.00006863036,0.0009073548,0.057182606,0.00095960015,0.00038525087,0.0010618934,0.00042736655,0.0005866301,0.028673159,0.05531034,0.85401297],"study_design_scores_gemma":[0.00017356704,0.00030790808,0.004105189,0.11705228,0.0017264939,0.0025431712,0.0024815726,0.0003335465,0.00040839304,0.055929955,0.8147542,0.00018371764],"about_ca_topic_score_codex":0.0022842274,"about_ca_topic_score_gemma":0.0027842685,"teacher_disagreement_score":0.016008088,"about_ca_system_score_codex":0.0022416455,"about_ca_system_score_gemma":0.005104366,"threshold_uncertainty_score":0.084659934},"labels":[],"label_agreement":null},{"id":"W2045272891","doi":"10.1111/j.1463-1326.2012.01658.x","title":"Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function","year":2012,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Glycemic; Natural history; Context (archaeology); Insulin; Type 2 diabetes; Diabetes mellitus; Term (time); Intensive care medicine; Type 2 Diabetes Mellitus; Endocrinology; Internal medicine","score_opus":0.03544990856842906,"score_gpt":0.2801399588414883,"score_spread":0.24469005027305923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045272891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009089982,0.99931586,0.000049778555,0.00008728372,0.00007527514,0.0000023606192,0.00000694843,0.0000028647298,0.00036870438],"genre_scores_gemma":[0.00042917364,0.9991172,0.00010187995,0.000071794515,0.000054204716,0.0000030227916,0.000010747289,6.5629877e-7,0.00021138463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985373,0.000030088173,0.000024970059,0.000021757058,0.000056268695,0.000013174746],"domain_scores_gemma":[0.999808,0.00009574321,0.000033573728,0.000006577163,0.000041717798,0.0000143386615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056844205,0.0008176215,0.0013658024,0.0015317628,0.00020959011,0.0007394236,0.000783696,0.0008727176,0.0024815649],"category_scores_gemma":[0.00054028316,0.00020152038,0.00049714476,0.0022711686,0.00037798026,0.0009530299,0.00050185405,0.001428345,0.0015998945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010820344,0.00008884485,0.00013913645,0.018730987,0.000102144295,0.0001671044,0.000038408252,0.00021936257,0.0011193369,0.0013112223,0.012325338,0.96564984],"study_design_scores_gemma":[0.00005830908,0.00023864511,0.0021325494,0.008408894,0.00027325645,0.0028199605,0.00010213108,0.0001362368,0.0007662699,0.0021362768,0.9828964,0.000030989962],"about_ca_topic_score_codex":0.00084758596,"about_ca_topic_score_gemma":0.0014994129,"teacher_disagreement_score":0.0024815649,"about_ca_system_score_codex":0.00041866215,"about_ca_system_score_gemma":0.0005922305,"threshold_uncertainty_score":0.008301616},"labels":[],"label_agreement":null},{"id":"W2045790951","doi":"10.1111/dom.12348","title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"American Heart Association","keywords":"Canagliflozin; Medicine; Placebo; Internal medicine; Kidney disease; Renal function; Diabetes mellitus; Empagliflozin; Urology; Type 2 diabetes; Endocrinology; Gastroenterology; Pathology","score_opus":0.003466919050973172,"score_gpt":0.19398320196770036,"score_spread":0.19051628291672718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045790951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948547,0.003944139,0.00020797407,0.000106764266,0.000045568784,0.00017564454,0.00011192257,0.000024856874,0.0005284348],"genre_scores_gemma":[0.9967771,0.0014201719,0.00047568738,0.00029720739,0.00011703789,0.00019220525,0.00024593182,0.0000043588484,0.00047035018],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953747,0.00016399469,0.000051674626,0.000097827506,0.00008741347,0.00006155387],"domain_scores_gemma":[0.9995322,0.00013056773,0.00015415935,0.000031820775,0.00003240753,0.000118819335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013614823,0.00046820444,0.0017152816,0.00028369477,0.00020218958,0.00043042455,0.00030099836,0.0005896113,0.001390062],"category_scores_gemma":[0.0010831666,0.0002254488,0.0007457181,0.00036231658,0.00026482245,0.00043330484,0.00022383235,0.0010280757,0.00020328155],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.724295,0.021604318,0.036662556,0.001095366,0.0024388684,0.00018146484,0.00014004488,0.0017544393,0.019082742,0.00004667586,0.0010181925,0.19168036],"study_design_scores_gemma":[0.3228944,0.44023845,0.22079714,0.00012953758,0.002395889,0.00060985173,0.00011367434,0.0036368454,0.0062677185,0.00012266723,0.002734355,0.00005943215],"about_ca_topic_score_codex":0.000510997,"about_ca_topic_score_gemma":0.00094953144,"teacher_disagreement_score":0.0017152816,"about_ca_system_score_codex":0.00031915976,"about_ca_system_score_gemma":0.0003817098,"threshold_uncertainty_score":0.0072003007},"labels":[],"label_agreement":null},{"id":"W2047199620","doi":"10.1111/dom.12391","title":"Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Placebo; Tolerability; Pioglitazone; Medicine; Type 2 diabetes; Randomized controlled trial; Clinical endpoint; Internal medicine; Diabetes mellitus; Adverse effect; Endocrinology","score_opus":0.016460300769629517,"score_gpt":0.25187791448215346,"score_spread":0.23541761371252395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047199620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98313177,0.008065658,0.0009371615,0.001011,0.0009394863,0.0031059575,0.0010748535,0.00016247945,0.0015715876],"genre_scores_gemma":[0.9851511,0.003312298,0.0026746984,0.0013082152,0.0008916294,0.0032862504,0.0012237441,0.000031947533,0.0021202052],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99814546,0.0012663229,0.00014359549,0.00020291096,0.00012220215,0.00011950793],"domain_scores_gemma":[0.99729675,0.0012263833,0.00053458597,0.0002554896,0.00013408961,0.000552638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003750014,0.0014272511,0.0037069216,0.0005979343,0.00046090438,0.0008457332,0.0010411057,0.0023739631,0.006346019],"category_scores_gemma":[0.0036882102,0.00083557423,0.0019952927,0.0004669382,0.0012232815,0.0009458101,0.00041726028,0.0030126455,0.0008052564],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98732877,0.002802205,0.00020456362,0.0002561876,0.0006473919,0.00001931585,0.0000181613,0.00008878422,0.0015603695,0.00004064493,0.00019325978,0.0068404605],"study_design_scores_gemma":[0.97566575,0.023258036,0.0004461492,0.000009938765,0.00020584736,0.000010475807,0.0000038872467,0.00010542158,0.0001423598,0.000026130378,0.000121137055,0.000004890695],"about_ca_topic_score_codex":0.0009960429,"about_ca_topic_score_gemma":0.0019095979,"teacher_disagreement_score":0.006346019,"about_ca_system_score_codex":0.0005776085,"about_ca_system_score_gemma":0.00093461206,"threshold_uncertainty_score":0.021229565},"labels":[],"label_agreement":null},{"id":"W2048930008","doi":"10.1111/j.1463-1326.2009.01114.x","title":"Lipid receptors and islet function: therapeutic implications?","year":2009,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Diabetes Canada","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Free fatty acid receptor 1; Receptor; G protein-coupled receptor; Enteroendocrine cell; Insulin; Secretion; Biology; Cell biology; Beta cell; Endocrinology; Islet; Internal medicine; Hormone; Agonist; Endocrine system; Biochemistry; Medicine","score_opus":0.03198999510827581,"score_gpt":0.2871956774012498,"score_spread":0.25520568229297397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048930008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007801877,0.9976452,0.000066000575,0.00073070853,0.0003747341,0.000002012045,0.0000071456766,0.0000046353734,0.0010914758],"genre_scores_gemma":[0.0006946425,0.9969597,0.00013244676,0.0005525899,0.000466079,0.0000048172005,0.000012400588,0.0000013691991,0.0011759271],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998621,0.000036963997,0.000015846203,0.000022418237,0.00004532272,0.000017361246],"domain_scores_gemma":[0.9998673,0.00005460729,0.000016730566,0.000008004052,0.00003342836,0.000019975232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055671384,0.0009849408,0.0017098254,0.0012653936,0.0003066001,0.0012943354,0.0008457586,0.0016856769,0.005843904],"category_scores_gemma":[0.00061357016,0.00023620742,0.00038870386,0.0015414321,0.0007614662,0.0020613256,0.0006908225,0.0020273777,0.004250458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016364866,0.00008654913,0.00014225977,0.006877272,0.00005363211,0.00046714226,0.00008020273,0.00028818555,0.002034904,0.007115313,0.05338078,0.9293102],"study_design_scores_gemma":[0.000033893466,0.000069669404,0.00041839737,0.0017220371,0.000037622234,0.0015074736,0.0000884123,0.000050560586,0.00023135511,0.0035645931,0.9922639,0.000012193528],"about_ca_topic_score_codex":0.0006912855,"about_ca_topic_score_gemma":0.0013194953,"teacher_disagreement_score":0.005843904,"about_ca_system_score_codex":0.0005539229,"about_ca_system_score_gemma":0.00056769245,"threshold_uncertainty_score":0.019549847},"labels":[],"label_agreement":null},{"id":"W2049014431","doi":"10.1111/j.1463-1326.2009.01130.x","title":"Dietary supplementation of n‐3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA‐cp rat","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Heart and Stroke Foundation of Canada","keywords":"Postprandial; Polyunsaturated fatty acid; Internal medicine; Endocrinology; Medicine; Weight gain; Food science; Body weight; Chemistry; Biochemistry; Fatty acid; Diabetes mellitus","score_opus":0.008729512213517438,"score_gpt":0.2680526397257535,"score_spread":0.2593231275122361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049014431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675107,0.00089190295,0.0008293166,0.00021576456,0.00005130501,0.000031212337,0.0005670797,0.00014437587,0.0005179696],"genre_scores_gemma":[0.98471874,0.0021220092,0.004312348,0.00031293932,0.00006997539,0.00025180008,0.0021115309,0.00014566527,0.005954969],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997477,0.000025122707,0.00003048732,0.00006472237,0.000052542196,0.000079375175],"domain_scores_gemma":[0.9990694,0.000052973453,0.00033756215,0.00012126322,0.00010966749,0.00030919584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003700056,0.0011964171,0.0010197612,0.0011843115,0.00039523555,0.00043050724,0.0005929311,0.00089277636,0.0017633237],"category_scores_gemma":[0.00029426982,0.0004325222,0.00058040227,0.00044580852,0.0007384124,0.00062275556,0.00043605623,0.0019565178,0.00058877096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009886739,0.0016723044,0.00070438645,0.00012626628,0.000042625055,0.00011716498,0.000047645328,0.00008092201,0.98320454,0.00006190728,0.00018728893,0.0038680893],"study_design_scores_gemma":[0.0014964457,0.030853352,0.03652131,0.00010693641,0.00035311288,0.00080713374,0.0003488371,0.0015858758,0.9235762,0.00022445562,0.0040390072,0.00008742516],"about_ca_topic_score_codex":0.0022636359,"about_ca_topic_score_gemma":0.0023742453,"teacher_disagreement_score":0.0022636359,"about_ca_system_score_codex":0.0004186496,"about_ca_system_score_gemma":0.0006092126,"threshold_uncertainty_score":0.005898893},"labels":[],"label_agreement":null},{"id":"W2049459857","doi":"10.1111/j.1463-1326.2005.00503.x","title":"Degradation in insulin sensitivity with increasing severity of the metabolic syndrome in obese postmenopausal women","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Université de Montréal","funders":"Canadian Institutes of Health Research; University of Ottawa","keywords":"Metabolic syndrome; Internal medicine; Endocrinology; Insulin resistance; Medicine; Insulin; Insulin sensitivity; Homeostasis; Obesity; Postmenopausal women; Blood pressure; Glucose clamp technique; Glucose homeostasis","score_opus":0.004994784289080499,"score_gpt":0.1951152510699209,"score_spread":0.19012046678084038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049459857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990388,0.00058530254,0.000056258395,0.000025059948,0.00000365545,0.000007004011,0.000067660636,0.0000031720597,0.00021307073],"genre_scores_gemma":[0.99957925,0.00012951969,0.00009335832,0.000025719366,0.000006635567,0.0000053869967,0.000075742,7.650922e-7,0.00008363815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983764,0.000044454173,0.000020741478,0.000039386618,0.00003363231,0.000024096265],"domain_scores_gemma":[0.99917775,0.00010324788,0.00044850336,0.000054205364,0.000100928126,0.000115480514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044430053,0.00023555901,0.0002745282,0.00040202888,0.00021219772,0.00036498145,0.00014995031,0.00035643045,0.00079380476],"category_scores_gemma":[0.0017192487,0.00019321391,0.00026374025,0.0003642447,0.00020271674,0.00017782804,0.0002783097,0.00043251747,0.00014809554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031738085,0.000027248476,0.99615127,0.00001277326,0.000059891197,0.00009118784,0.000063602565,0.000027455826,0.001374813,0.0000075332205,0.000029878634,0.0018369165],"study_design_scores_gemma":[0.000004283294,0.00009843405,0.9995158,0.000002192189,0.00001563562,0.00019157336,0.000031305237,0.000031494765,0.00005749525,0.000008462202,0.000042169777,0.0000011299411],"about_ca_topic_score_codex":0.0013741198,"about_ca_topic_score_gemma":0.0016738671,"teacher_disagreement_score":0.0013741198,"about_ca_system_score_codex":0.00011851428,"about_ca_system_score_gemma":0.00010178879,"threshold_uncertainty_score":0.002732277},"labels":[],"label_agreement":null},{"id":"W2051243940","doi":"10.1111/dom.12188","title":"Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Empagliflozin; Metformin; Pioglitazone; Placebo; Medicine; Type 2 diabetes; Tolerability; Internal medicine; Clinical endpoint; Urology; Diabetes mellitus; Adverse effect; Randomized controlled trial; Gastroenterology; Endocrinology","score_opus":0.0066711662358415694,"score_gpt":0.21346407052343266,"score_spread":0.2067929042875911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051243940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984003,0.0057631363,0.0003866114,0.00037985278,0.00055465836,0.0015184226,0.00040846318,0.00009333753,0.0010555261],"genre_scores_gemma":[0.9902352,0.0038902918,0.0009061033,0.00078455644,0.0007693542,0.0016445479,0.0005047938,0.00001472048,0.0012505865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991524,0.00046860435,0.000082726525,0.00012339436,0.000088562876,0.00008420769],"domain_scores_gemma":[0.998982,0.00034607138,0.00025489417,0.00007629394,0.00006065965,0.00028011418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020524168,0.0013335395,0.0031516592,0.00050913903,0.00038128448,0.0010300203,0.0008753542,0.0019471684,0.0044332766],"category_scores_gemma":[0.0020266224,0.00069293816,0.0021066843,0.0004331471,0.0008990005,0.00083084224,0.00038209773,0.002825375,0.0005097526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97881544,0.005825591,0.00067475834,0.0005680133,0.0011825669,0.00003341175,0.000022838309,0.00011413667,0.0012973342,0.000023129413,0.00021924035,0.011223596],"study_design_scores_gemma":[0.9510817,0.045257073,0.002097957,0.00003164063,0.0007258956,0.000023928034,0.000009741275,0.00020364624,0.00033996225,0.000026292115,0.00019439808,0.000007813163],"about_ca_topic_score_codex":0.0005549997,"about_ca_topic_score_gemma":0.0011748357,"teacher_disagreement_score":0.0044332766,"about_ca_system_score_codex":0.0004752351,"about_ca_system_score_gemma":0.0006838581,"threshold_uncertainty_score":0.014830768},"labels":[],"label_agreement":null},{"id":"W2052854039","doi":"10.1111/j.1463-1326.2005.00540.x","title":"Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Population Health Research Institute; University Health Network; Hamilton Health Sciences; University of Toronto; Western University","funders":"","keywords":"Medicine; Metformin; Rosiglitazone; Impaired glucose tolerance; Diabetes mellitus; Type 2 diabetes; Internal medicine; Population; Context (archaeology); Insulin resistance; Placebo; Randomized controlled trial; Physical therapy; Endocrinology; Environmental health; Alternative medicine","score_opus":0.032253905362539456,"score_gpt":0.3165672046368674,"score_spread":0.2843132992743279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052854039","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5908853,0.021372955,0.015092196,0.0048724352,0.0028995227,0.31283998,0.018610485,0.00035208577,0.03307506],"genre_scores_gemma":[0.6892492,0.0060138796,0.034516603,0.0036800182,0.0011454338,0.24871002,0.0065665296,0.0000990173,0.0100193005],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98344857,0.011766744,0.0006268428,0.0011034227,0.0017706604,0.0012837996],"domain_scores_gemma":[0.9962578,0.0010842858,0.0005857173,0.00048008715,0.00081596326,0.00077607605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019252798,0.004223492,0.0059948033,0.0009382635,0.0017322099,0.00170544,0.0018500243,0.002419476,0.009624158],"category_scores_gemma":[0.012862681,0.0011536166,0.004614688,0.0024280408,0.0017227762,0.0010644342,0.0017800989,0.0024476862,0.0006525534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93406636,0.0069172177,0.0073135206,0.0014127833,0.0048159007,0.000060491016,0.00018198996,0.0015059947,0.0004238358,0.0019672038,0.004447787,0.03688697],"study_design_scores_gemma":[0.92262274,0.041629545,0.0178605,0.0002597711,0.00646466,0.000035973466,0.00010473724,0.0027020501,0.00018651909,0.0016023192,0.0064097573,0.00012133892],"about_ca_topic_score_codex":0.18487257,"about_ca_topic_score_gemma":0.20725758,"teacher_disagreement_score":0.81512743,"about_ca_system_score_codex":0.0072465306,"about_ca_system_score_gemma":0.018743316,"threshold_uncertainty_score":0.367593},"labels":[],"label_agreement":null},{"id":"W2053986195","doi":"10.1111/j.1463-1326.2005.00483.x","title":"X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Orlistat; Weight loss; Reduction (mathematics); Energy expenditure; Medicine; Obesity; Internal medicine; Mathematics","score_opus":0.012144126247191632,"score_gpt":0.24892018903349084,"score_spread":0.2367760627862992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053986195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987494,0.00068014563,0.00006194577,0.00006144601,0.00002418232,0.00011704925,0.00007133152,0.000012214258,0.0002224123],"genre_scores_gemma":[0.9978283,0.0005958386,0.0004252705,0.00019644138,0.00008140409,0.00019508747,0.0002699681,0.0000036663594,0.00040409958],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997222,0.00013593314,0.00002531589,0.000035979043,0.00004528666,0.00003531216],"domain_scores_gemma":[0.99939156,0.00012402744,0.00021732044,0.000030441077,0.000019166824,0.00021741973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009411451,0.0006606269,0.0014280037,0.00030437292,0.00021130411,0.00038447548,0.00044178238,0.000715644,0.0016960043],"category_scores_gemma":[0.0008941039,0.00030139866,0.00063927704,0.00025733572,0.00047933398,0.00035455296,0.00027961345,0.00096814655,0.00033160695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87085843,0.016098324,0.045755886,0.0004478677,0.0008388099,0.00012082946,0.000070230475,0.00038575337,0.015606209,0.00004178607,0.00039825955,0.04937762],"study_design_scores_gemma":[0.2760331,0.48182046,0.23517753,0.00005828359,0.0008981752,0.00045170233,0.0000767958,0.0016127045,0.0029709358,0.00010891799,0.00075602846,0.00003549767],"about_ca_topic_score_codex":0.00046940183,"about_ca_topic_score_gemma":0.0011804276,"teacher_disagreement_score":0.0016960043,"about_ca_system_score_codex":0.000243132,"about_ca_system_score_gemma":0.00034286059,"threshold_uncertainty_score":0.005673647},"labels":[],"label_agreement":null},{"id":"W2055789597","doi":"10.1111/j.1463-1326.2011.01469.x","title":"The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Type 2 diabetes; Diabetes mellitus; Insulin; Value (mathematics); Medicine; Endocrinology; Computer science","score_opus":0.04938534273080385,"score_gpt":0.30595648186038643,"score_spread":0.25657113912958257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055789597","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005750091,0.9854822,0.000054511478,0.011626953,0.0023568012,0.000002088947,0.000009502878,0.0000026619384,0.0004077754],"genre_scores_gemma":[0.0010428431,0.9844173,0.00016829262,0.010266108,0.0036560467,0.000007682659,0.000014423199,0.0000027586866,0.0004245953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786097,0.0007999469,0.00033865633,0.00017688947,0.0007551146,0.00006842153],"domain_scores_gemma":[0.9913338,0.00625347,0.00088722,0.00015084451,0.0012416458,0.00013295235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004214205,0.0007479414,0.0023795734,0.001182375,0.00037228,0.001615452,0.0013948333,0.0047130473,0.0018250679],"category_scores_gemma":[0.01097938,0.00026110167,0.0011481532,0.0020164454,0.0015162389,0.0026044014,0.0006594788,0.005174018,0.0010529984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028164836,0.00004392087,0.00035124787,0.034038067,0.0003425992,0.0006376664,0.00017119614,0.00020564235,0.00080925156,0.00782169,0.24913572,0.7061614],"study_design_scores_gemma":[0.00012296895,0.00018375395,0.0012639508,0.033944458,0.00042063286,0.0028365424,0.00021871678,0.00012291479,0.00030662466,0.007531063,0.95300955,0.000038806575],"about_ca_topic_score_codex":0.0014872497,"about_ca_topic_score_gemma":0.0026924363,"teacher_disagreement_score":0.0047130473,"about_ca_system_score_codex":0.0010207716,"about_ca_system_score_gemma":0.002144207,"threshold_uncertainty_score":0.02228713},"labels":[],"label_agreement":null},{"id":"W2057340863","doi":"10.1111/j.1463-1326.2011.01476.x","title":"Long in the shade, glucagon re‐occupies centre court","year":2011,"lang":"en","type":"editorial","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"Servier","keywords":"Glucagon; Political science; Medicine; Internal medicine; Insulin","score_opus":0.011931717840016485,"score_gpt":0.23642520831703215,"score_spread":0.22449349047701567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057340863","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021932542,0.022473233,0.0069072573,0.45112383,0.13537084,0.00006029775,0.00045936558,0.0010871637,0.38032484],"genre_scores_gemma":[0.030956322,0.010069425,0.0037030543,0.18508042,0.032360688,0.00005991169,0.00029593756,0.0017905793,0.7356837],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649173,0.000663722,0.00013511747,0.00092487625,0.0013443466,0.00044025382],"domain_scores_gemma":[0.99541205,0.0009029393,0.00027121496,0.0004609872,0.0014615882,0.0014912173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021304798,0.00083763374,0.0011013572,0.0011482172,0.008152808,0.01393355,0.0015036946,0.005845977,0.13301739],"category_scores_gemma":[0.010886937,0.0003845774,0.0006364741,0.00084514834,0.010593234,0.008281319,0.005443773,0.015808834,0.07898919],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006177171,0.000016916718,0.00016687559,0.00009672821,0.000013120587,0.00025469862,0.0018874438,0.000029322075,0.0007644691,0.07262266,0.8843194,0.03976656],"study_design_scores_gemma":[0.0000026826397,0.000007963194,0.00004749065,0.00005724228,0.0000017568249,0.00008243808,0.00056004,0.000008997684,0.000077436096,0.003811346,0.99533635,0.000006348569],"about_ca_topic_score_codex":0.0067598154,"about_ca_topic_score_gemma":0.01138552,"teacher_disagreement_score":0.13301739,"about_ca_system_score_codex":0.0028254276,"about_ca_system_score_gemma":0.003325374,"threshold_uncertainty_score":0.44498748},"labels":[],"label_agreement":null},{"id":"W2059296389","doi":"10.1111/j.1463-1326.2008.00895.x","title":"PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample*","year":2008,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"Sanofi","keywords":"Medicine; Overweight; Body mass index; Prospective cohort study; Waist; Obesity; Abdominal obesity; Cohort; Population; Internal medicine; Demography; Environmental health","score_opus":0.03108563416204404,"score_gpt":0.3229494165215878,"score_spread":0.2918637823595438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059296389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955326,0.00026460082,0.00078228756,0.000080764126,0.000020908454,0.0010093653,0.040474948,0.00004116512,0.001999881],"genre_scores_gemma":[0.90708923,0.00032591226,0.0021803048,0.00034175804,0.000068618276,0.0035762861,0.083101444,0.0000537394,0.003262663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931157,0.00024662414,0.00006564678,0.00016181705,0.00010715935,0.00010709028],"domain_scores_gemma":[0.9983903,0.000120878736,0.00042152658,0.00045689518,0.00031162568,0.00029881587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016098567,0.0008965202,0.00054541935,0.001182406,0.0007402498,0.0009402766,0.00086875627,0.0006989228,0.0025086792],"category_scores_gemma":[0.0018978737,0.0005888257,0.0006694526,0.0018047919,0.00031226047,0.000770888,0.0015161283,0.00076866307,0.0011587567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016887039,0.0003117134,0.99264854,0.0000371368,0.00016296697,0.00012503823,0.00012640012,0.00009393994,0.00040863012,0.000076181896,0.0027869956,0.0015338331],"study_design_scores_gemma":[0.00033113602,0.00048420866,0.99506664,0.000021512105,0.00014031469,0.0002668483,0.00031503194,0.00021895752,0.00012570267,0.000046898076,0.0029695963,0.000013170494],"about_ca_topic_score_codex":0.02228174,"about_ca_topic_score_gemma":0.02253171,"teacher_disagreement_score":0.02228174,"about_ca_system_score_codex":0.00055188994,"about_ca_system_score_gemma":0.000827947,"threshold_uncertainty_score":0.044304073},"labels":[],"label_agreement":null},{"id":"W2059493545","doi":"10.1111/dom.12173","title":"Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Diabetes Foundation; Government of Alberta; Canadian Diabetes Association","keywords":"Gliclazide; Medicine; Nested case-control study; Internal medicine; Type 2 diabetes; Cardiology; Diabetes mellitus; Acute coronary syndrome; Case-control study; Myocardial infarction; Insulin; Endocrinology","score_opus":0.005065744187496018,"score_gpt":0.2004459440936458,"score_spread":0.19538019990614977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059493545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993936,0.00013622764,0.000089810186,0.00001929009,0.000006949554,0.000016889873,0.00019685276,0.0000022602492,0.00013820753],"genre_scores_gemma":[0.999416,0.00006293374,0.00012490018,0.000023120345,0.000008455775,0.000014422658,0.00025274573,0.0000015848403,0.000095794974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894196,0.00023799001,0.000088749824,0.00040165777,0.00021041057,0.00011932393],"domain_scores_gemma":[0.99837,0.00026714246,0.0005434582,0.00027495666,0.000247229,0.00029730133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010391645,0.00048394155,0.000551355,0.00082549115,0.0009455587,0.0009046303,0.0008123716,0.0006624411,0.00087235094],"category_scores_gemma":[0.0025601913,0.00066172425,0.0009672172,0.0009857983,0.00059982075,0.00027114968,0.00041326132,0.00065964257,0.00011712477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048335438,0.000103675426,0.99807113,0.000009127783,0.00028074335,0.00016871457,0.00013641817,0.000033311426,0.00029576998,0.00001801894,0.00007551365,0.00032413512],"study_design_scores_gemma":[0.00009606323,0.00022014923,0.99821126,0.000008147142,0.00021790233,0.0003688272,0.0001885124,0.0004414107,0.00006320562,0.0000218117,0.00015372147,0.000008959522],"about_ca_topic_score_codex":0.12604307,"about_ca_topic_score_gemma":0.10132704,"teacher_disagreement_score":0.12604307,"about_ca_system_score_codex":0.0013099512,"about_ca_system_score_gemma":0.00088408525,"threshold_uncertainty_score":0.25061888},"labels":[],"label_agreement":null},{"id":"W2059631102","doi":"10.1111/dom.12070","title":"A nine country study of the burden of non‐severe nocturnal hypoglycaemic events on diabetes management and daily function","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Diabetes mellitus; Medicine; Nap; Diabetes management; Feeling; Nocturnal; Type 1 diabetes; Insulin; Type 2 diabetes; Gerontology; Demography; Pediatrics; Internal medicine; Endocrinology; Psychology","score_opus":0.007226952094115496,"score_gpt":0.22237118938662737,"score_spread":0.21514423729251186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059631102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898547,0.000110718036,0.000038060087,0.000045223474,0.0000050168624,0.000012007233,0.00039414663,7.846436e-7,0.0004085986],"genre_scores_gemma":[0.99930775,0.00014179367,0.000052055635,0.000042588472,0.0000040360833,0.00001594663,0.00031905767,7.86171e-7,0.00011598407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992416,0.0004082501,0.000083539606,0.000077734505,0.00007143804,0.00011744122],"domain_scores_gemma":[0.9982495,0.0003898443,0.0007149371,0.000106965046,0.0001706892,0.00036810618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012778358,0.00021341779,0.0002830577,0.0006316244,0.0005138999,0.0007335645,0.00020583639,0.0003089463,0.0015305381],"category_scores_gemma":[0.0024771623,0.00026048603,0.00051697646,0.0011850218,0.0002151157,0.00058652466,0.0006362673,0.0005235468,0.00020350148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005119286,0.000045919845,0.9985677,0.000012692322,0.00004582972,0.000069220216,0.00034123805,0.000016166923,0.00004092231,0.0000142852305,0.00009390519,0.0007007609],"study_design_scores_gemma":[0.000008405961,0.00009459431,0.998398,0.00001272275,0.000019634605,0.00010457742,0.0011021481,0.000043989978,0.000012910096,0.000007406768,0.00019246273,0.0000032218686],"about_ca_topic_score_codex":0.013360918,"about_ca_topic_score_gemma":0.01439923,"teacher_disagreement_score":0.013360918,"about_ca_system_score_codex":0.00033603754,"about_ca_system_score_gemma":0.00030247265,"threshold_uncertainty_score":0.026566267},"labels":[],"label_agreement":null},{"id":"W2060050338","doi":"10.1111/dom.12075","title":"Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from <scp>INSPIRE ME IAA</scp>","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Canadian Institutes of Health Research; Sanofi","keywords":"Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Insulin; Endocrinology; Abdominal obesity; Prospective cohort study; Adipose tissue; Metabolic syndrome","score_opus":0.0205073153259742,"score_gpt":0.24985739572334184,"score_spread":0.22935008039736765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060050338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972696,0.0002480863,0.000105143146,0.000040066934,0.000005633296,0.000023915298,0.0018695209,0.0000057169236,0.00043243953],"genre_scores_gemma":[0.99605656,0.000102046026,0.00024198135,0.000046765945,0.000012419237,0.000036444286,0.0033144522,0.0000030712808,0.00018613822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994035,0.00017637815,0.000100670775,0.00015693728,0.000110545916,0.00005195592],"domain_scores_gemma":[0.9982534,0.00026195886,0.000865949,0.000111033914,0.00026934437,0.00023835684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010924522,0.000344226,0.00044263093,0.0010137467,0.00035861882,0.00056403433,0.0005119406,0.0006077468,0.0011300758],"category_scores_gemma":[0.0022508265,0.00039575453,0.000625013,0.0013227232,0.0001591565,0.00046488811,0.0005311126,0.00067117164,0.00030177934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068767615,0.000016904203,0.9994844,0.000004136304,0.000042500244,0.000007488043,0.000012786432,0.000015410164,0.000033336273,0.0000016888515,0.000058896956,0.00025361954],"study_design_scores_gemma":[0.000010249516,0.00003872549,0.9997019,0.0000024691442,0.000017672071,0.000045553905,0.00003230764,0.000093771254,0.000013670238,0.0000025850536,0.000039490675,0.0000015961922],"about_ca_topic_score_codex":0.009389445,"about_ca_topic_score_gemma":0.010543627,"teacher_disagreement_score":0.009389445,"about_ca_system_score_codex":0.00034100626,"about_ca_system_score_gemma":0.00023247482,"threshold_uncertainty_score":0.018669605},"labels":[],"label_agreement":null},{"id":"W2061883499","doi":"10.1111/dom.12262","title":"A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp>: <scp>VICTOZA ADD‐ON</scp>)","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk; American Diabetes Association","keywords":"Insulin degludec; Medicine; Internal medicine; Insulin aspart; Endocrinology; Lira; Metformin; Insulin; Basal insulin; Type 2 diabetes; Hypoglycemia; Diabetes mellitus; Insulin glargine","score_opus":0.021593007188927805,"score_gpt":0.2575520745690506,"score_spread":0.2359590673801228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061883499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460065,0.0028625322,0.0002339741,0.00023394488,0.0002619216,0.0005913967,0.00022906406,0.00005742828,0.00092922937],"genre_scores_gemma":[0.9940995,0.0019612047,0.00094418804,0.00036169303,0.00023088916,0.00071090006,0.00032430678,0.000013845621,0.0013536301],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99916697,0.00048956653,0.00006877784,0.00013769434,0.000056376255,0.000080706675],"domain_scores_gemma":[0.9988207,0.00046237922,0.00023018739,0.00007947601,0.000045954832,0.00036126873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012122281,0.0013608575,0.0029778243,0.0004065012,0.00024148848,0.0009957161,0.0010059888,0.0015465748,0.005152564],"category_scores_gemma":[0.0018677892,0.0007751077,0.0022968745,0.0003583866,0.00071203907,0.0010069588,0.0004273415,0.002513403,0.00075922476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98594135,0.0034735491,0.00018798103,0.00023924773,0.00047565892,0.000012388848,0.00002166478,0.00010875658,0.0011515376,0.000020097563,0.00008809796,0.008279631],"study_design_scores_gemma":[0.803398,0.19090346,0.002783184,0.00005201343,0.001275061,0.00003328872,0.00003956528,0.00057226047,0.00058102974,0.0000786392,0.0002647573,0.000018777391],"about_ca_topic_score_codex":0.001292312,"about_ca_topic_score_gemma":0.0024801912,"teacher_disagreement_score":0.005152564,"about_ca_system_score_codex":0.00073898886,"about_ca_system_score_gemma":0.00091086497,"threshold_uncertainty_score":0.017237008},"labels":[],"label_agreement":null},{"id":"W2063476025","doi":"10.1111/dom.12465","title":"Incretin‐based medications for type 2 diabetes: an overview of reviews","year":2015,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Systematic review; Checklist; Cochrane Library; Observational study; MEDLINE; Randomized controlled trial; Incretin; Internal medicine; Type 2 diabetes; Diabetes mellitus; Psychology; Endocrinology","score_opus":0.16725277773619593,"score_gpt":0.4005807717538717,"score_spread":0.23332799401767576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063476025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015646458,0.9991279,0.000103266764,0.00019704402,0.0000961752,0.00012249989,0.00009384297,0.0000063096304,0.000096481206],"genre_scores_gemma":[0.0024272457,0.9956033,0.0009994422,0.00030193364,0.00009804463,0.0004158643,0.000100953555,0.0000040838836,0.000049155577],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97762907,0.0073440266,0.00930849,0.0012897954,0.0038782284,0.00055041886],"domain_scores_gemma":[0.93361527,0.044459037,0.013209455,0.0008018612,0.007326485,0.0005878348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021360992,0.0027117196,0.009791053,0.023727078,0.00082137063,0.0039797514,0.002655276,0.0027632313,0.0033785065],"category_scores_gemma":[0.0704097,0.0019886098,0.009635076,0.02007942,0.00083737035,0.003712544,0.0022535257,0.00200953,0.0004891812],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017440622,0.00002368275,0.000596787,0.9116616,0.005987758,0.00006855054,0.00019422178,0.00012969004,0.00019542762,0.00043229252,0.0030051924,0.07753039],"study_design_scores_gemma":[0.00017970701,0.00018661105,0.0026676112,0.9244679,0.03461778,0.00034929762,0.00019518234,0.00012707262,0.00016919209,0.0005210486,0.0364792,0.000039345636],"about_ca_topic_score_codex":0.008832945,"about_ca_topic_score_gemma":0.02161427,"teacher_disagreement_score":0.023727078,"about_ca_system_score_codex":0.0058053774,"about_ca_system_score_gemma":0.014555981,"threshold_uncertainty_score":0.1129691},"labels":[],"label_agreement":null},{"id":"W2065380980","doi":"10.1111/j.1463-1326.2012.01602.x","title":"Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Novo Nordisk","keywords":"Medicine; Insulin; Insulin detemir; Metformin; Diabetes mellitus; Internal medicine; Observational study; Type 2 Diabetes Mellitus; Type 2 diabetes; Cohort; Basal insulin; Endocrinology","score_opus":0.022650359943830196,"score_gpt":0.29206289434808774,"score_spread":0.26941253440425755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065380980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930641,0.004498381,0.000505721,0.00016252663,0.000026826525,0.000055197794,0.00093328743,0.000012522194,0.000741344],"genre_scores_gemma":[0.99744284,0.0007527057,0.0007325585,0.00014951741,0.000046979727,0.000048761955,0.0005683371,0.000005684127,0.00025256787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976666,0.0010488465,0.0003568082,0.00047786275,0.00031995916,0.00013005013],"domain_scores_gemma":[0.9894937,0.0024916714,0.006432954,0.0003851365,0.00043405508,0.00076245435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034095838,0.00026958503,0.00073483726,0.00082387077,0.00028286644,0.0010574602,0.00047745087,0.00077074143,0.0013604072],"category_scores_gemma":[0.0074004466,0.0003919913,0.0007281778,0.0019613851,0.00023616577,0.0008466795,0.00054348726,0.00066817674,0.00031836113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029381393,0.00011597962,0.9860719,0.00016438565,0.00035064804,0.000047120593,0.00014377282,0.000059704267,0.00024257835,0.00003327911,0.0001393066,0.009693187],"study_design_scores_gemma":[0.00013346084,0.0013394345,0.9966107,0.00006019758,0.00021548086,0.00025214907,0.00018133923,0.00043140232,0.0001313901,0.000051704657,0.0005809761,0.000011849854],"about_ca_topic_score_codex":0.0014447902,"about_ca_topic_score_gemma":0.0020585055,"teacher_disagreement_score":0.0034095838,"about_ca_system_score_codex":0.0003853565,"about_ca_system_score_gemma":0.0005052983,"threshold_uncertainty_score":0.018031776},"labels":[],"label_agreement":null},{"id":"W2066046508","doi":"10.1111/j.1463-1326.2010.01251.x","title":"A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin","year":2010,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Professional Engineers Ontario","funders":"Amylin Pharmaceuticals; Eli Lilly and Company","keywords":"Exenatide; Placebo; Metformin; Medicine; Internal medicine; Clinical endpoint; Type 2 diabetes; Nausea; Adverse effect; Gastroenterology; Diabetes mellitus; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.008773329220469896,"score_gpt":0.23759637324484778,"score_spread":0.2288230440243779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066046508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935926,0.0051960316,0.00051901734,0.00042439302,0.00093897496,0.0017865459,0.0005161541,0.00010046441,0.0011592604],"genre_scores_gemma":[0.98864836,0.0032974354,0.001259648,0.00081092224,0.0007856584,0.0022122061,0.0006654189,0.000019634024,0.0023007276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99905163,0.00050945184,0.00008617167,0.00018842996,0.000061857,0.00010240365],"domain_scores_gemma":[0.99879694,0.00039493796,0.00023505204,0.00009214835,0.000080098216,0.00040074644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022709083,0.0017958559,0.0043921946,0.0005999586,0.0006070605,0.0012355956,0.0010715439,0.0024681685,0.00684831],"category_scores_gemma":[0.0018259882,0.0009344046,0.0016600476,0.0004525341,0.0017200944,0.001328386,0.0004524036,0.0032466268,0.0010570986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9901218,0.0037892726,0.00013920937,0.00030258362,0.0003102881,0.000015569958,0.000015054124,0.00005072512,0.001693887,0.000024274943,0.00011015298,0.0034271637],"study_design_scores_gemma":[0.9405282,0.057818923,0.0007394186,0.000018103452,0.00023855333,0.000013960489,0.0000103945795,0.000115665964,0.00033108622,0.000023523291,0.00015544916,0.000006630312],"about_ca_topic_score_codex":0.0007692427,"about_ca_topic_score_gemma":0.001195063,"teacher_disagreement_score":0.00684831,"about_ca_system_score_codex":0.0005798026,"about_ca_system_score_gemma":0.0009773034,"threshold_uncertainty_score":0.02290988},"labels":[],"label_agreement":null},{"id":"W2067359845","doi":"10.1046/j.1463-1326.2001.00033.x","title":"PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone","year":2001,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Citation; Rosiglitazone; Type 2 diabetes; Medicine; Library science; Diabetes mellitus; Endocrinology; Computer science","score_opus":0.01218761175316994,"score_gpt":0.257524190039947,"score_spread":0.24533657828677705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067359845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070198155,0.998216,0.00012103837,0.0005910297,0.0005663119,0.0000032309852,0.000010561066,0.000006476225,0.00041524315],"genre_scores_gemma":[0.00024744915,0.9983798,0.00017789725,0.000413101,0.00033229214,0.0000042545576,0.000012583918,0.0000012167237,0.00043134217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977237,0.000049251612,0.000043786833,0.000032411022,0.000084223306,0.000017998293],"domain_scores_gemma":[0.9995726,0.00021937567,0.00004498685,0.000012431132,0.000110259054,0.00004037686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010062763,0.0009729183,0.0024443294,0.001434271,0.0003437064,0.0011140673,0.0011722444,0.0014407405,0.0022211052],"category_scores_gemma":[0.0009907853,0.00030941996,0.00050881953,0.0021374454,0.00050123327,0.0017488103,0.0004583769,0.0030240214,0.00186469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035380485,0.000091917456,0.00014037409,0.009873241,0.00011419267,0.00036845802,0.000059465343,0.00027557503,0.0016456154,0.0024886993,0.06914226,0.9154463],"study_design_scores_gemma":[0.000101267506,0.00016275892,0.00056700193,0.0025105046,0.0001632419,0.0011060509,0.00007552005,0.000074305986,0.00033307855,0.0016839548,0.9932001,0.000022179594],"about_ca_topic_score_codex":0.0015120786,"about_ca_topic_score_gemma":0.0040322538,"teacher_disagreement_score":0.0024443294,"about_ca_system_score_codex":0.00052047434,"about_ca_system_score_gemma":0.0009232827,"threshold_uncertainty_score":0.007430315},"labels":[],"label_agreement":null},{"id":"W2070814970","doi":"10.1111/j.1463-1326.2004.00441.x","title":"Abdominal obesity predicts declining insulin sensitivity in non‐obese normoglycaemics: the Insulin Resistance Atherosclerosis Study (IRAS)","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute","keywords":"Waist; Body mass index; Medicine; Overweight; Internal medicine; Insulin resistance; Obesity; Abdominal obesity; Circumference; Endocrinology; Diabetes mellitus","score_opus":0.010801282965756092,"score_gpt":0.22976389815845097,"score_spread":0.2189626151926949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070814970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876046,0.00045735016,0.0000925969,0.000056585533,0.000011127592,0.000012220418,0.00018744874,0.0000073960014,0.00041494833],"genre_scores_gemma":[0.9989838,0.00017291089,0.00018384917,0.000035509693,0.000028453713,0.000012346646,0.00041066547,0.0000030702824,0.00016933588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996319,0.00015164528,0.000045080225,0.00007075604,0.000060182076,0.000040527055],"domain_scores_gemma":[0.99809843,0.00034947577,0.00074581674,0.00018667978,0.00014193494,0.00047770477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016367774,0.00052031735,0.00046722672,0.0007716391,0.00037142937,0.0008325613,0.00028605195,0.0007206014,0.0012884359],"category_scores_gemma":[0.0023499385,0.0004793162,0.00048701174,0.00068640494,0.00036452888,0.0004281354,0.0005562651,0.0011405,0.00030580457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040002193,0.000065073444,0.99841404,0.000010528072,0.00011197199,0.000041241285,0.000033996836,0.000028920316,0.00020249787,0.0000136508825,0.00006355704,0.00061449077],"study_design_scores_gemma":[0.000017592663,0.00018286577,0.99935275,0.0000045825195,0.000045215904,0.00015520239,0.000035450656,0.000112909336,0.000022902419,0.000017065466,0.000051215422,0.000002243184],"about_ca_topic_score_codex":0.0013999923,"about_ca_topic_score_gemma":0.00153053,"teacher_disagreement_score":0.0016367774,"about_ca_system_score_codex":0.00011290574,"about_ca_system_score_gemma":0.00018901,"threshold_uncertainty_score":0.008656204},"labels":[],"label_agreement":null},{"id":"W2072396082","doi":"10.1111/dom.12359","title":"Effect of sitagliptin therapy on triglyceride‐rich lipoprotein kinetics in patients with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval; Centre hospitalier de l'Université Laval","funders":"Merck","keywords":"Sitagliptin; Internal medicine; Endocrinology; Apolipoprotein B; Very low-density lipoprotein; Triglyceride; Placebo; Crossover study; Type 2 diabetes; Chemistry; Cholesterol; Medicine; Lipoprotein; Insulin; Diabetes mellitus","score_opus":0.003847252317263479,"score_gpt":0.20169237514221577,"score_spread":0.19784512282495229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072396082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972191,0.002097537,0.00009509922,0.000060992494,0.000037407302,0.000034212055,0.00005979169,0.000015364916,0.00038039076],"genre_scores_gemma":[0.9980426,0.0008260694,0.00029307813,0.0002113293,0.00007495173,0.00006132066,0.00020026907,0.0000053544813,0.00028492842],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997558,0.00010940865,0.00003543402,0.00003618058,0.00003716465,0.000026053112],"domain_scores_gemma":[0.9994855,0.00019823923,0.00010472448,0.00002626049,0.000023857421,0.00016138962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006357321,0.00060200144,0.0014449656,0.00020341767,0.00023056364,0.00046643172,0.00016484132,0.0006600825,0.0013290598],"category_scores_gemma":[0.000933589,0.00024634416,0.00054766715,0.00019992043,0.00020962872,0.00028869256,0.00014879378,0.00077340624,0.00021944393],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5990722,0.013820363,0.15106279,0.0008812775,0.002664783,0.0011628083,0.00033591423,0.0012371656,0.093690805,0.00008370439,0.0008910333,0.13509715],"study_design_scores_gemma":[0.058666553,0.26791543,0.65530807,0.00010403148,0.0018008024,0.0014174636,0.00026074788,0.0023391666,0.00969694,0.00013623266,0.0022931148,0.00006145267],"about_ca_topic_score_codex":0.00021287274,"about_ca_topic_score_gemma":0.0003684709,"teacher_disagreement_score":0.0014449656,"about_ca_system_score_codex":0.00017559584,"about_ca_system_score_gemma":0.00019571985,"threshold_uncertainty_score":0.004446149},"labels":[],"label_agreement":null},{"id":"W2074091547","doi":"10.1111/dom.12114","title":"Flexibly timed once‐daily dosing with degludec: a new ultra‐long‐acting basal insulin","year":2013,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk Canada","keywords":"Insulin degludec; Dosing; Medicine; Insulin glargine; Basal insulin; Insulin; Basal (medicine); Insulin detemir; Type 2 diabetes; Diabetes mellitus; Endocrinology; Internal medicine; Hypoglycemia; Intensive care medicine","score_opus":0.04250271054545744,"score_gpt":0.31296317966676435,"score_spread":0.2704604691213069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074091547","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69085616,0.11983527,0.1445212,0.0027943365,0.0025688997,0.0006114464,0.0014027549,0.002715489,0.034694467],"genre_scores_gemma":[0.8591996,0.033929527,0.08883647,0.0025288102,0.00041122688,0.00032341195,0.0016315628,0.00019056247,0.012948846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998677,0.000023607843,0.000011423371,0.000029267681,0.000052917934,0.0000150282285],"domain_scores_gemma":[0.99994195,0.000008982789,0.000013116319,0.000007518827,0.000009247645,0.000019174013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000195796,0.00023110572,0.0003179932,0.00028199403,0.000106011765,0.00056751905,0.0005503991,0.00032624754,0.0011590305],"category_scores_gemma":[0.00018214123,0.00014091723,0.00031173992,0.00020179918,0.00016104811,0.0005387959,0.00032891365,0.0012570741,0.00066331506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00596285,0.0016087991,0.0017020665,0.0007845062,0.00007313703,0.00065159844,0.000110700385,0.0010807153,0.29655132,0.0019973977,0.006739463,0.6827376],"study_design_scores_gemma":[0.0045937803,0.030029876,0.02113011,0.0006285426,0.00046300632,0.028512213,0.00020165075,0.038268518,0.4601397,0.0020615507,0.41359675,0.00037426484],"about_ca_topic_score_codex":0.00030108934,"about_ca_topic_score_gemma":0.00035029763,"teacher_disagreement_score":0.0011590305,"about_ca_system_score_codex":0.00021314874,"about_ca_system_score_gemma":0.00015614278,"threshold_uncertainty_score":0.0038774014},"labels":[],"label_agreement":null},{"id":"W2075427448","doi":"10.1111/j.1463-1326.2007.00788.x","title":"New insights into the molecular mechanisms of priming of insulin exocytosis","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Connaught Fund; University of Toronto","keywords":"Exocytosis; Insulin; Vesicle; Priming (agriculture); Secretion; Cell biology; Munc-18; Biology; Glucose homeostasis; Exocyst; Secretory Vesicle; Docking (animal); Endocrinology; Biochemistry; Insulin resistance; Medicine; Membrane; Synaptic vesicle","score_opus":0.008944835475021524,"score_gpt":0.22527132123076596,"score_spread":0.21632648575574442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075427448","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24776615,0.6252404,0.089359686,0.018364387,0.0019021084,0.000077607714,0.00032045896,0.0007251185,0.0162441],"genre_scores_gemma":[0.6189215,0.3371635,0.03277448,0.00290058,0.0020706523,0.000096378884,0.00029055067,0.00006479229,0.0057175164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981123,0.000033540997,0.000018091905,0.00003915828,0.00005246832,0.000045571272],"domain_scores_gemma":[0.99974626,0.00009895566,0.000041919087,0.000030218825,0.000034947334,0.00004763355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075208466,0.00063105696,0.0007854601,0.0006521956,0.00037126613,0.0015005613,0.0007360577,0.0011573221,0.0015255765],"category_scores_gemma":[0.00045425294,0.00028352928,0.0007222982,0.00040175745,0.0015034197,0.0039615817,0.0007531562,0.0022677395,0.0004465392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011435846,0.0003251603,0.0024846965,0.0024654863,0.00014334102,0.002585882,0.0006507174,0.004461416,0.64184326,0.14973213,0.002977385,0.19118698],"study_design_scores_gemma":[0.00036497138,0.0015318126,0.023342887,0.000962287,0.0004724842,0.0078040212,0.0014531445,0.044870492,0.41383687,0.2750702,0.22997738,0.00031348027],"about_ca_topic_score_codex":0.0002266588,"about_ca_topic_score_gemma":0.0002253175,"teacher_disagreement_score":0.0015255765,"about_ca_system_score_codex":0.0007067369,"about_ca_system_score_gemma":0.0005314985,"threshold_uncertainty_score":0.005127728},"labels":[],"label_agreement":null},{"id":"W2077038286","doi":"10.1111/dom.12090","title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":486,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Mitsubishi Tanabe Pharma Corporation; European Foundation for the Study of Diabetes; American Society of Nephrology; American Diabetes Association","keywords":"Canagliflozin; Medicine; Renal function; Placebo; Kidney disease; Internal medicine; Type 2 diabetes; Urology; Diabetes mellitus; Creatinine; Endocrinology; Empagliflozin; Blood urea nitrogen; Gastroenterology","score_opus":0.0051452716821656095,"score_gpt":0.20177999333681063,"score_spread":0.19663472165464502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077038286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98802185,0.009223971,0.00037873152,0.0002851771,0.00008951674,0.00033332585,0.0002530059,0.00003554216,0.0013789061],"genre_scores_gemma":[0.9962739,0.0018369156,0.0005111357,0.00037420186,0.00016009857,0.0001769173,0.00032211735,0.000003868679,0.00034085018],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99953365,0.00020787612,0.000043403576,0.00006675017,0.000109407076,0.000038994862],"domain_scores_gemma":[0.9992361,0.00028031963,0.00024255962,0.00003691962,0.00006534913,0.00013872221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020301193,0.00028255754,0.0010965384,0.00022398413,0.00018903216,0.0004309285,0.00022221096,0.0006128878,0.0015040524],"category_scores_gemma":[0.0016564525,0.00011971428,0.00065595855,0.0002624882,0.0003202091,0.00024172736,0.0001638475,0.0009062004,0.00018693437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6842289,0.012921828,0.04988523,0.0014586117,0.0020520706,0.0001996573,0.00016354029,0.0011357436,0.020470124,0.00011002751,0.0019369182,0.22543733],"study_design_scores_gemma":[0.3006301,0.394167,0.28285977,0.0002619204,0.0033430841,0.00073790556,0.00012987113,0.0032321871,0.008966739,0.0003318356,0.0052881786,0.000051396953],"about_ca_topic_score_codex":0.00052762823,"about_ca_topic_score_gemma":0.00088640396,"teacher_disagreement_score":0.0020301193,"about_ca_system_score_codex":0.00030021768,"about_ca_system_score_gemma":0.00048398747,"threshold_uncertainty_score":0.010736406},"labels":[],"label_agreement":null},{"id":"W2081134608","doi":"10.1111/j.1463-1326.2009.01050.x","title":"Improved cardiovascular health following a progressive walking and dietary intervention for type 2 diabetes","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Heart Rate Variability and Autonomic Control","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pedometer; Medicine; Blood pressure; Body mass index; Type 2 diabetes; Confidence interval; Physical therapy; Randomized controlled trial; Diabetes mellitus; Internal medicine; Physical activity; Endocrinology","score_opus":0.015579853308000543,"score_gpt":0.27486392050602765,"score_spread":0.2592840671980271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081134608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750584,0.0011196663,0.000194848,0.00009719038,0.000057910405,0.00046294916,0.00009324068,0.000030092042,0.00043823078],"genre_scores_gemma":[0.9928847,0.0015205598,0.0019791122,0.00037247466,0.00017818772,0.0018448982,0.00028758822,0.0000067816204,0.00092570356],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999468,0.00022303151,0.000052457013,0.00009463366,0.00007129739,0.0000906248],"domain_scores_gemma":[0.99957985,0.00011541455,0.000110647394,0.00002523263,0.00002226016,0.00014648252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008251537,0.0007457649,0.0013811318,0.0004014931,0.00025951653,0.00037138158,0.0005070613,0.0009595599,0.0030603558],"category_scores_gemma":[0.0013335363,0.0002900209,0.0008191789,0.00032994602,0.00026769,0.00028786008,0.00042225665,0.0010258602,0.00021831512],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5601567,0.12200998,0.007908357,0.0032458296,0.0027959128,0.00015092157,0.00020589978,0.0015019065,0.0101516275,0.00009800369,0.0006780924,0.29109678],"study_design_scores_gemma":[0.40829137,0.48428637,0.100191,0.00031325984,0.0018261798,0.00013594078,0.00007876275,0.0014114935,0.0022259224,0.00015038221,0.0010560559,0.00003322897],"about_ca_topic_score_codex":0.0010383046,"about_ca_topic_score_gemma":0.0015233954,"teacher_disagreement_score":0.0030603558,"about_ca_system_score_codex":0.00021967254,"about_ca_system_score_gemma":0.00039644702,"threshold_uncertainty_score":0.010237932},"labels":[],"label_agreement":null},{"id":"W2081199780","doi":"10.1111/dom.12271","title":"Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2‐year trial in insulin‐naïve patients with type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Medicine; Insulin glargine; Insulin degludec; Insulin; Internal medicine; Diabetes mellitus; Metformin; Hypoglycemia; Population; Type 2 diabetes; Endocrinology","score_opus":0.007403713643261174,"score_gpt":0.22060987078041594,"score_spread":0.21320615713715477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081199780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959436,0.002385025,0.00015543921,0.0002083431,0.0001584137,0.0004266675,0.0002015181,0.000028051983,0.00049292267],"genre_scores_gemma":[0.99402314,0.0017858668,0.00061757385,0.0005607113,0.0003689508,0.0008927171,0.0005760573,0.000010607128,0.0011643786],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989549,0.00061659166,0.00006762683,0.0001471323,0.00006346134,0.0001502122],"domain_scores_gemma":[0.9990545,0.00027231334,0.00017460811,0.000089399175,0.000041970256,0.00036731624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029733428,0.0014838568,0.0029525512,0.0004305101,0.00027847532,0.0011929043,0.0008032779,0.0014960542,0.0030447778],"category_scores_gemma":[0.0015627942,0.0007240753,0.0023029998,0.0005693932,0.00081041316,0.0011093293,0.0005007287,0.0027585824,0.00042144652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9808735,0.0076887347,0.0009938908,0.00019063514,0.0004724722,0.000029072864,0.000034481807,0.00019853945,0.0014787775,0.000023026225,0.00014500321,0.007871706],"study_design_scores_gemma":[0.8235481,0.1667346,0.007900279,0.00002608537,0.00055122626,0.000027782618,0.00003101871,0.0005689118,0.00028203597,0.000057119534,0.00025353712,0.000019256537],"about_ca_topic_score_codex":0.0010575872,"about_ca_topic_score_gemma":0.0019280069,"teacher_disagreement_score":0.0030447778,"about_ca_system_score_codex":0.00066252786,"about_ca_system_score_gemma":0.0006756815,"threshold_uncertainty_score":0.015724778},"labels":[],"label_agreement":null},{"id":"W2081216702","doi":"10.1111/dom.12126","title":"Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Alberta Innovates - Health Solutions; Canadian Diabetes Association","keywords":"Acute coronary syndrome; Medicine; Internal medicine; Cardiology; Diabetes mellitus; Myocardial infarction; Endocrinology","score_opus":0.004917858367688996,"score_gpt":0.2118756143606785,"score_spread":0.20695775599298952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081216702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99793744,0.00074715144,0.0000557982,0.00040242885,0.000022609922,0.0000038802204,0.00025847295,0.0000033301137,0.000568854],"genre_scores_gemma":[0.99897385,0.00042804654,0.00005134136,0.000115785755,0.00004896556,0.0000032453906,0.00024603604,0.0000012002932,0.00013157359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995414,0.00009356273,0.00006472939,0.00009908324,0.00008936925,0.00011185388],"domain_scores_gemma":[0.99631965,0.00049800845,0.002322202,0.00012811236,0.00020161687,0.0005303631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006545403,0.00026569676,0.0004660288,0.0007590649,0.00046816983,0.00095065834,0.00035610015,0.0011934715,0.0027096688],"category_scores_gemma":[0.0046343086,0.0002770852,0.000742912,0.0013399886,0.00044661734,0.0008927572,0.00041476678,0.0010522562,0.0003752157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065567045,0.000020113795,0.9987577,0.000006563665,0.00004781272,0.000057673475,0.000047231086,0.000012631831,0.0000569727,0.000009027536,0.000046961643,0.00087177503],"study_design_scores_gemma":[0.000006263897,0.00006782787,0.9992747,0.00001110289,0.000051530547,0.00019271146,0.0001575279,0.00007365131,0.000023864472,0.000045008797,0.00009188258,0.000003985074],"about_ca_topic_score_codex":0.004825223,"about_ca_topic_score_gemma":0.0051615867,"teacher_disagreement_score":0.004825223,"about_ca_system_score_codex":0.00019516956,"about_ca_system_score_gemma":0.0002878269,"threshold_uncertainty_score":0.009594321},"labels":[],"label_agreement":null},{"id":"W2082809017","doi":"10.1111/j.1463-1326.2007.00753.x","title":"Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Diabetes Canada; Canadian Diabetes Association; American Diabetes Association","keywords":"Medicine; Rosiglitazone; Glimepiride; Regimen; Internal medicine; Fixed-dose combination; Adiponectin; Type 2 diabetes; Adverse effect; Gastroenterology; Clinical endpoint; Diabetes mellitus; Pharmacology; Endocrinology; Insulin resistance; Insulin; Randomized controlled trial","score_opus":0.006522453057879444,"score_gpt":0.21743710933162655,"score_spread":0.21091465627374711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082809017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532885,0.011519428,0.00028656778,0.00026054127,0.00016088401,0.00036618215,0.0002579409,0.00008106445,0.0017383735],"genre_scores_gemma":[0.99426323,0.0027485294,0.0007914613,0.0005340849,0.00021854343,0.00026704813,0.000575079,0.000009250185,0.0005926793],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994203,0.00021156836,0.0000668604,0.0001284494,0.000112644535,0.00006027317],"domain_scores_gemma":[0.9991667,0.00020380042,0.00021875354,0.000053794534,0.000056924117,0.00029996943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009949537,0.0006815237,0.0027790507,0.00040124916,0.00045845253,0.00073107344,0.000717659,0.00083624333,0.0025154997],"category_scores_gemma":[0.0016623354,0.00042867791,0.0010423259,0.00047443353,0.0003451803,0.0004222969,0.00023659375,0.0015122758,0.00046738927],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54207754,0.017034272,0.063531876,0.001658405,0.0051423204,0.0006674241,0.0002558363,0.0020709056,0.022471368,0.000099294324,0.0025815344,0.34240916],"study_design_scores_gemma":[0.2379926,0.40801805,0.33294055,0.0003936466,0.0044501987,0.0018022103,0.00018401232,0.002304995,0.0043950505,0.00016435349,0.007250378,0.00010396215],"about_ca_topic_score_codex":0.00093850575,"about_ca_topic_score_gemma":0.0031062665,"teacher_disagreement_score":0.0027790507,"about_ca_system_score_codex":0.0007187976,"about_ca_system_score_gemma":0.0005977591,"threshold_uncertainty_score":0.008415163},"labels":[],"label_agreement":null},{"id":"W2083415436","doi":"10.1111/j.1463-1326.2011.01493.x","title":"Achieving a clinically relevant composite outcome of an HbA1c of &lt;7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Merck Sharp and Dohme; Novo Nordisk","keywords":"Liraglutide; Medicine; Sitagliptin; Glimepiride; Exenatide; Type 2 diabetes; Internal medicine; Weight loss; Rosiglitazone; Weight gain; Placebo; Diabetes mellitus; Endocrinology; Obesity","score_opus":0.16090406437223578,"score_gpt":0.39536483810216133,"score_spread":0.23446077372992555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083415436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11709433,0.8701115,0.0055257324,0.0009396809,0.00089620054,0.0010002516,0.0023972066,0.00028558463,0.0017493897],"genre_scores_gemma":[0.9134458,0.07733901,0.0036953895,0.0010955431,0.00038665975,0.0011268118,0.0017474879,0.00011752486,0.0010457829],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98280644,0.012340038,0.002080733,0.0014949464,0.0009250405,0.00035265126],"domain_scores_gemma":[0.98685,0.009192037,0.0019305034,0.0010519233,0.00065624464,0.00031929385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0232429,0.003550221,0.017019985,0.0033893646,0.0005038626,0.00361724,0.002078816,0.002199483,0.003019416],"category_scores_gemma":[0.02538468,0.0016450116,0.056992862,0.0038292005,0.00069630495,0.0014568571,0.0014886531,0.0025723614,0.00040628714],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013486319,0.000025642361,0.0028958756,0.018868202,0.9607047,0.00006998431,0.000029227745,0.00093116495,0.00024233854,0.00006337092,0.00032741952,0.002355797],"study_design_scores_gemma":[0.0026498588,0.000358979,0.0025613846,0.00084381684,0.99246275,0.000048933176,0.00001789216,0.00044929612,0.000104352344,0.00013369099,0.00035073253,0.000018328517],"about_ca_topic_score_codex":0.0044588214,"about_ca_topic_score_gemma":0.006863758,"teacher_disagreement_score":0.0232429,"about_ca_system_score_codex":0.0018421523,"about_ca_system_score_gemma":0.0013314412,"threshold_uncertainty_score":0.122921705},"labels":[],"label_agreement":null},{"id":"W2084414747","doi":"10.1111/j.1463-1326.2007.00781.x","title":"Role of the M <sub>3</sub> muscarinic acetylcholine receptor in β‐cell function and glucose homeostasis","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health","keywords":"Internal medicine; Endocrinology; Muscarinic acetylcholine receptor; Glucose homeostasis; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Insulin; Muscarinic acetylcholine receptor M1; Biology; Beta cell; Acetylcholine; Receptor; Chemistry; Insulin resistance; Medicine; Islet","score_opus":0.005872598525084818,"score_gpt":0.20151721148713791,"score_spread":0.1956446129620531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084414747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962781,0.028703908,0.003994082,0.00054609065,0.000052961303,0.00001566613,0.00012307672,0.0000938505,0.0036894635],"genre_scores_gemma":[0.9885196,0.008109412,0.0018979618,0.00018705602,0.000023322995,0.00001489833,0.000087456276,0.000012454338,0.0011479193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999349,0.000013762596,0.0000056655717,0.000009667259,0.000014797179,0.000021202204],"domain_scores_gemma":[0.9999186,0.000011459906,0.000032038075,0.0000069088783,0.0000080304135,0.000023007136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020906121,0.00030854333,0.00028315975,0.00016755094,0.00015418172,0.00040360732,0.00022582142,0.00041016328,0.00068272895],"category_scores_gemma":[0.00014830864,0.00010116331,0.00020467877,0.000078979196,0.00029426417,0.00025645888,0.00024343678,0.00039416077,0.00037212844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039819628,0.000032859247,0.0016799684,0.000080150596,0.00002085202,0.0004961833,0.000031158732,0.0001037393,0.9849296,0.0009742771,0.00015712103,0.011095901],"study_design_scores_gemma":[0.00014824695,0.0013229342,0.090220645,0.00009878298,0.0001921769,0.006005182,0.00019360826,0.0018360072,0.8803722,0.0027057398,0.016868621,0.000035851892],"about_ca_topic_score_codex":0.00046852723,"about_ca_topic_score_gemma":0.0004658714,"teacher_disagreement_score":0.00068272895,"about_ca_system_score_codex":0.0002588698,"about_ca_system_score_gemma":0.00022358855,"threshold_uncertainty_score":0.0022839904},"labels":[],"label_agreement":null},{"id":"W2086380056","doi":"10.1111/j.1463-1326.2012.01607.x","title":"Utility of non‐high‐density lipoprotein cholesterol in assessing incident type 2 diabetes risk","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; Mount Sinai Hospital; Western University; University of Toronto","funders":"Canadian Institutes of Health Research; Genentech","keywords":"Type 2 diabetes; High-density lipoprotein; Diabetes mellitus; Cholesterol; Medicine; Internal medicine; Endocrinology","score_opus":0.010115458745603783,"score_gpt":0.24145201480239845,"score_spread":0.23133655605679465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086380056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98445475,0.006704667,0.0021511952,0.00034698995,0.00009271266,0.00014371044,0.0015574537,0.000065901186,0.004482575],"genre_scores_gemma":[0.99435943,0.0014807081,0.0024380956,0.00007832359,0.000059317324,0.00004100551,0.0007505098,0.0000055728697,0.0007871263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825376,0.00070464995,0.00018051367,0.00019858721,0.0005490432,0.00011333172],"domain_scores_gemma":[0.9966252,0.0009849073,0.0009800632,0.00017680625,0.0008479924,0.0003850264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004454256,0.0007852745,0.00053388183,0.0015329228,0.00048002353,0.0011811812,0.000766639,0.0006856178,0.0008053005],"category_scores_gemma":[0.0065543717,0.00021661054,0.00050139,0.0014012761,0.0004061156,0.00044439497,0.0005104177,0.00094109355,0.00040059673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015009103,0.000035416364,0.9941704,0.000034794408,0.00009439483,0.000024936093,0.000029351986,0.00008302287,0.00014013443,0.00001275495,0.00008916045,0.005135593],"study_design_scores_gemma":[0.000017934744,0.0002396324,0.9973936,0.000048473714,0.0001633202,0.0002419072,0.00008266285,0.001133396,0.00025370737,0.000052604322,0.00036277878,0.000010075823],"about_ca_topic_score_codex":0.026875423,"about_ca_topic_score_gemma":0.049988464,"teacher_disagreement_score":0.026875423,"about_ca_system_score_codex":0.0005524481,"about_ca_system_score_gemma":0.0010740575,"threshold_uncertainty_score":0.053438008},"labels":[],"label_agreement":null},{"id":"W2088106139","doi":"10.1111/j.1463-1326.2009.01179.x","title":"Errors in patient perception of caloric deficit required for weight loss—observations from the Diet Plate Trial <sup>*</sup>","year":2009,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diet and metabolism studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Caloric theory; Weight loss; Calorie; Medicine; Caloric intake; Obesity; Population; Diabetes mellitus; Gerontology; Physical therapy; Environmental health; Internal medicine; Endocrinology","score_opus":0.027690046632202273,"score_gpt":0.24396540182944704,"score_spread":0.21627535519724478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088106139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946649,0.0005877467,0.00067927374,0.0004933412,0.00003325221,0.00015674111,0.0007099954,0.00003839912,0.0026363183],"genre_scores_gemma":[0.99788046,0.0001893884,0.00050400995,0.0004211225,0.000034107394,0.0001570449,0.00052033144,0.000012144931,0.00028139353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99153155,0.0054010265,0.0013096662,0.00036193454,0.0012096755,0.00018614775],"domain_scores_gemma":[0.9174788,0.05366907,0.019331401,0.0033888763,0.0048283176,0.0013035269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007709617,0.0003253254,0.0005377272,0.00044041226,0.00045930434,0.000830969,0.00044322544,0.0009637333,0.0012658644],"category_scores_gemma":[0.05246523,0.0002542257,0.00052848697,0.0005299043,0.00048080223,0.0008228344,0.0005051695,0.001519629,0.0006792772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02223806,0.0018451455,0.891533,0.00036956498,0.0006633994,0.00075204007,0.0052100243,0.0009791886,0.0018249077,0.00012631204,0.0070527163,0.06740566],"study_design_scores_gemma":[0.0010986675,0.015838299,0.96904063,0.00012378646,0.0002856827,0.0015203657,0.002098379,0.0026900587,0.0026484022,0.00017027167,0.004349495,0.00013591978],"about_ca_topic_score_codex":0.0016982373,"about_ca_topic_score_gemma":0.0015270959,"teacher_disagreement_score":0.007709617,"about_ca_system_score_codex":0.0005958737,"about_ca_system_score_gemma":0.00036430915,"threshold_uncertainty_score":0.040772855},"labels":[],"label_agreement":null},{"id":"W2095497214","doi":"10.1111/j.1463-1326.2006.00639.x","title":"A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes","year":2006,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk","keywords":"Insulin aspart; Medicine; Insulin; Diabetes mellitus; Internal medicine; Endocrinology; Type 2 diabetes; Metformin; Regular insulin; Human insulin; Hypoglycemia","score_opus":0.009411476953642984,"score_gpt":0.224953700820747,"score_spread":0.21554222386710403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095497214","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807703,0.0015045545,0.00009608494,0.000011057321,0.00001460498,0.0000144456635,0.000038193095,0.0000032564378,0.00024065662],"genre_scores_gemma":[0.99882,0.0006356061,0.00022793676,0.00006754229,0.000025475501,0.00001224991,0.0001148611,0.0000014136876,0.00009493684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996246,0.00017884861,0.000057457164,0.000047755104,0.000066782035,0.000024604034],"domain_scores_gemma":[0.9988682,0.00047250098,0.0002964913,0.000056850153,0.00007121975,0.0002347668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009247886,0.00025140314,0.00063233485,0.00018772886,0.0001266544,0.00036354415,0.000108148,0.00023816606,0.00074409245],"category_scores_gemma":[0.0019004914,0.0001015136,0.00030379946,0.00023623016,0.00015471867,0.00026602525,0.00015300333,0.00020129971,0.00010485268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.271745,0.002035554,0.6316817,0.0006602744,0.0015108527,0.0007377679,0.00032412508,0.0005656833,0.013351156,0.00008127755,0.0002861241,0.07702054],"study_design_scores_gemma":[0.008574605,0.15046407,0.8288654,0.00007284893,0.0014889151,0.0024576494,0.00048222675,0.0016026675,0.0037173848,0.00009669885,0.0021420184,0.00003556921],"about_ca_topic_score_codex":0.00024514733,"about_ca_topic_score_gemma":0.0003114295,"teacher_disagreement_score":0.0009247886,"about_ca_system_score_codex":0.00013918914,"about_ca_system_score_gemma":0.00012359524,"threshold_uncertainty_score":0.004890859},"labels":[],"label_agreement":null},{"id":"W2095923443","doi":"10.1111/j.1463-1326.2012.01642.x","title":"Autocrine regulation of insulin secretion","year":2012,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Alberta","funders":"Diabetes Research and Wellness Foundation; National Institute for Health and Care Research; Wellcome Trust","keywords":"Autocrine signalling; Paracrine signalling; Insulin; Secretion; Endocrinology; Biology; Internal medicine; Receptor; Cell biology; Biochemistry; Medicine","score_opus":0.032236669992980777,"score_gpt":0.28058472244380017,"score_spread":0.2483480524508194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095923443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033141032,0.99678314,0.00040385805,0.00019462162,0.00020854101,0.000006183487,0.000024480854,0.00001958741,0.002028151],"genre_scores_gemma":[0.0023431578,0.99577194,0.00029878723,0.00015685945,0.0001881138,0.000011919298,0.000039523406,0.0000028921222,0.0011868551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975795,0.00003957776,0.000032302607,0.00004216363,0.00009976566,0.000028245055],"domain_scores_gemma":[0.99985707,0.000046215697,0.000028314502,0.0000074761047,0.00003996844,0.000020865918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040529566,0.00084299286,0.001320879,0.0013875914,0.00021366701,0.0011054466,0.0007341481,0.0008213365,0.0024354754],"category_scores_gemma":[0.00033954968,0.00020616029,0.00036537816,0.0013276158,0.00053501583,0.0010827235,0.0007486245,0.0012951524,0.0023423198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001386128,0.0000866976,0.00036374945,0.013328834,0.00008773964,0.00067065196,0.00008092326,0.0003199513,0.011738046,0.005223284,0.018670546,0.94929105],"study_design_scores_gemma":[0.000022043536,0.0000750867,0.0013288148,0.00140828,0.000063975094,0.0029772755,0.00006234239,0.000106828265,0.0033608438,0.0024183656,0.9881566,0.0000194009],"about_ca_topic_score_codex":0.00044859154,"about_ca_topic_score_gemma":0.00047651978,"teacher_disagreement_score":0.0024354754,"about_ca_system_score_codex":0.00056008185,"about_ca_system_score_gemma":0.0006132828,"threshold_uncertainty_score":0.008147478},"labels":[],"label_agreement":null},{"id":"W2096349641","doi":"10.1111/j.1463-1326.2011.01410.x","title":"Differentiating short‐ and long‐term effects of diet in the obese mouse using <sup>1</sup> H‐nuclear magnetic resonance metabolomics","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Fondation pour la Recherche Médicale; Canadian Diabetes Association; Heart and Stroke Foundation of Canada","keywords":"Metabolomics; Metabolite; Obesity; Weaning; Endocrinology; Internal medicine; Biology; Medicine; Bioinformatics","score_opus":0.011486685281290604,"score_gpt":0.21068095048047064,"score_spread":0.19919426519918004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096349641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487394,0.0007603935,0.0032535652,0.00016863231,0.000028445116,0.000015816307,0.00044899175,0.00005718541,0.0003930163],"genre_scores_gemma":[0.9828419,0.0018049129,0.010094737,0.00035456073,0.00004469275,0.00010428049,0.0010540503,0.000113170354,0.003587809],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99980515,0.000031010757,0.000017484139,0.00005866859,0.00004879319,0.000038892053],"domain_scores_gemma":[0.99959534,0.00005010267,0.00016311166,0.00004618932,0.000036486326,0.000108758846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041084524,0.00048840314,0.0003970791,0.0006364144,0.00014619132,0.00047738376,0.00017426828,0.00039503083,0.0006669928],"category_scores_gemma":[0.00021503451,0.0002653656,0.00026977554,0.00027321326,0.00046341878,0.00040255106,0.00026577202,0.00085733394,0.00018082747],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000792294,0.000029884282,0.0008206274,0.000016564549,0.000008791846,0.000018706796,0.000011378873,0.00001798646,0.9966979,0.000027084434,0.000015989406,0.0015427973],"study_design_scores_gemma":[0.00006659148,0.0016774666,0.06810974,0.000014523299,0.000086620465,0.00024463702,0.000098168915,0.00056856545,0.9277427,0.00020460374,0.0011586546,0.000027827367],"about_ca_topic_score_codex":0.00038640198,"about_ca_topic_score_gemma":0.0015036508,"teacher_disagreement_score":0.0006669928,"about_ca_system_score_codex":0.00022558299,"about_ca_system_score_gemma":0.00017490819,"threshold_uncertainty_score":0.0022313595},"labels":[],"label_agreement":null},{"id":"W2099670937","doi":"10.1111/dom.12494","title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( <scp>EASE</scp> ‐1)","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Placebo; Medicine; Insulin; Type 2 diabetes; Clinical endpoint; Internal medicine; Diabetes mellitus; Randomized controlled trial; Adverse effect; Endocrinology","score_opus":0.013638609868025108,"score_gpt":0.2461924121162025,"score_spread":0.23255380224817737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099670937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98725826,0.005940951,0.00055505545,0.00054768956,0.0006918894,0.0029177924,0.0006684768,0.00012689707,0.0012931194],"genre_scores_gemma":[0.9819629,0.00508596,0.001951415,0.0012653456,0.001062663,0.004869548,0.0010666705,0.000020766543,0.0027145473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999485,0.0002459972,0.00004473401,0.00010836937,0.000048013877,0.00006790966],"domain_scores_gemma":[0.99934226,0.00018299243,0.00018963801,0.000050154125,0.00004277087,0.00019219644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014835487,0.001441956,0.003304479,0.00045453795,0.00034237144,0.000965547,0.0008315409,0.0017691507,0.006337528],"category_scores_gemma":[0.0013791885,0.00066309766,0.0015938045,0.00046250524,0.0008910763,0.0008270228,0.00036109332,0.0025508734,0.00074697833],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98274165,0.004129183,0.00035920047,0.0004885594,0.0005566332,0.0000196861,0.000015689904,0.00012642462,0.0016042844,0.000023010094,0.0002709583,0.009664709],"study_design_scores_gemma":[0.97141147,0.026864469,0.0010662117,0.000017187274,0.00020162787,0.000012192612,0.0000044837225,0.00012600966,0.00014386816,0.000014762295,0.00013285191,0.000004968692],"about_ca_topic_score_codex":0.0007396963,"about_ca_topic_score_gemma":0.0017100233,"teacher_disagreement_score":0.006337528,"about_ca_system_score_codex":0.0004999978,"about_ca_system_score_gemma":0.00091307826,"threshold_uncertainty_score":0.021201134},"labels":[],"label_agreement":null},{"id":"W2102844230","doi":"10.1111/j.1463-1326.2005.00533.x","title":"Elevated C‐reactive protein in Native Canadian children: an ominous early complication of childhood obesity","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Adipokines, Inflammation, and Metabolic Diseases","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Western University; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Medicine; Adiponectin; Internal medicine; Interquartile range; Metabolic syndrome; Population; C-reactive protein; Insulin resistance; Obesity; Endocrinology; Childhood obesity; Waist; National Health and Nutrition Examination Survey; Overweight; Inflammation; Environmental health","score_opus":0.006843874011588902,"score_gpt":0.21939738582308943,"score_spread":0.21255351181150053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102844230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737895,0.0005827079,0.000072023366,0.0002572871,0.000011025083,0.000014493096,0.00043360714,0.0000078258245,0.0012419447],"genre_scores_gemma":[0.9990097,0.0003648514,0.00015518419,0.000057669986,0.000009551766,0.0000039384545,0.00020342103,0.0000017876637,0.00019387796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943644,0.000032478212,0.00002469818,0.000076588665,0.0002508486,0.00017902516],"domain_scores_gemma":[0.99929774,0.00005186552,0.00024736152,0.000020430383,0.00020881124,0.00017384565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028659246,0.0003880822,0.00029053842,0.0008586567,0.0017133435,0.0006967072,0.0005310324,0.00043544747,0.0010333646],"category_scores_gemma":[0.0011049102,0.0002390777,0.00020357987,0.0017011353,0.00071329315,0.00023353429,0.00041465828,0.00068878493,0.00011383263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040464143,0.000018228862,0.99548584,0.000023163897,0.000012066802,0.00076607545,0.00042475612,0.000030231302,0.00029816348,0.000047154947,0.0004054588,0.0024483446],"study_design_scores_gemma":[0.0000030993297,0.000020244177,0.99729115,0.000013368136,0.0000088493325,0.0012912262,0.00083933555,0.00008785975,0.00006206059,0.000018872872,0.00035823195,0.000005638857],"about_ca_topic_score_codex":0.89568514,"about_ca_topic_score_gemma":0.9272059,"teacher_disagreement_score":0.10431486,"about_ca_system_score_codex":0.0058031594,"about_ca_system_score_gemma":0.008619043,"threshold_uncertainty_score":0.20985836},"labels":[],"label_agreement":null},{"id":"W2103828712","doi":"10.1111/j.1463-1326.2008.00994.x","title":"Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","year":2008,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":294,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute for Health and Care Research","keywords":"Vildagliptin; Glimepiride; Medicine; Metformin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Type 2 Diabetes Mellitus; Hypoglycemia; Confidence interval; Randomized controlled trial; Gastroenterology; Endocrinology","score_opus":0.009903568371051009,"score_gpt":0.2167715782832629,"score_spread":0.2068680099122119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103828712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980217,0.0007657006,0.00027705246,0.000084525156,0.00006390658,0.00030698543,0.00016778507,0.000033916098,0.0002783812],"genre_scores_gemma":[0.99712557,0.0003650813,0.00065956014,0.0002224583,0.00010574455,0.0006294314,0.00033323112,0.000011658994,0.0005472075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984092,0.00085027755,0.00018154681,0.00027509703,0.00012418718,0.00015974719],"domain_scores_gemma":[0.99799335,0.00064537243,0.0006219036,0.00028493963,0.000073432464,0.00038108235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030006818,0.0011201586,0.0034984513,0.0003530495,0.0003599447,0.00085558876,0.00066348515,0.0012962926,0.0026160183],"category_scores_gemma":[0.003217189,0.00076320354,0.0024249938,0.00027679635,0.00080660457,0.0009604329,0.00046011418,0.0019808768,0.00048647306],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9637317,0.0059920372,0.003055449,0.00021978766,0.00081904756,0.0000477008,0.00005775536,0.00044298472,0.008221407,0.000020211277,0.0001898816,0.017202014],"study_design_scores_gemma":[0.5639215,0.39799258,0.032008503,0.000033733904,0.0012600633,0.00009105583,0.000038421967,0.0010106389,0.0029839126,0.00008381212,0.00052327005,0.000052394145],"about_ca_topic_score_codex":0.0002664893,"about_ca_topic_score_gemma":0.0004895145,"teacher_disagreement_score":0.0034984513,"about_ca_system_score_codex":0.00057976897,"about_ca_system_score_gemma":0.000561604,"threshold_uncertainty_score":0.01586926},"labels":[],"label_agreement":null},{"id":"W2106144638","doi":"10.1111/j.1463-1326.2009.01057.x","title":"Home telehealth for diabetes management: a systematic review and meta‐analysis","year":2009,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Telehealth; Medicine; MEDLINE; Telemedicine; Randomized controlled trial; Confidence interval; Meta-analysis; Health care; Quality of life (healthcare); Telecare; Diabetes mellitus; Family medicine; Population; Physical therapy; Nursing; Internal medicine","score_opus":0.044979311744765896,"score_gpt":0.35528001117062386,"score_spread":0.310300699425858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106144638","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034375787,0.99522036,0.00034984743,0.00017204852,0.00010247116,0.00026368257,0.00024348167,0.000016909928,0.00019347551],"genre_scores_gemma":[0.11484902,0.880685,0.0018463677,0.0006309244,0.00023315815,0.0011198455,0.0004054453,0.000015858457,0.00021433189],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993244,0.0038185674,0.0014238026,0.0005600886,0.00076311786,0.00019048587],"domain_scores_gemma":[0.9818823,0.014297791,0.0023533932,0.00034965607,0.00089696917,0.00021992244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010739178,0.0019776057,0.015366705,0.005153153,0.00054734986,0.0022985188,0.0020376698,0.0019906682,0.0044721444],"category_scores_gemma":[0.027593879,0.0010256598,0.025099125,0.0066667963,0.0005856055,0.0013902315,0.0009901159,0.0017212468,0.00024209291],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029008116,0.00008874325,0.0029412585,0.47481528,0.49081606,0.00014793454,0.000085736996,0.0005899714,0.00014302309,0.00012739481,0.00093044044,0.026413368],"study_design_scores_gemma":[0.0017479872,0.0005615973,0.004437033,0.052654475,0.93787706,0.00014515761,0.000064087755,0.0003148769,0.00013568686,0.00019314421,0.00184147,0.000027374217],"about_ca_topic_score_codex":0.0069198306,"about_ca_topic_score_gemma":0.012544962,"teacher_disagreement_score":0.015366705,"about_ca_system_score_codex":0.0024807823,"about_ca_system_score_gemma":0.0031924646,"threshold_uncertainty_score":0.05679488},"labels":[],"label_agreement":null},{"id":"W2107562831","doi":"10.1111/j.1463-1326.2010.01233.x","title":"Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study","year":2010,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute for Health and Care Research","keywords":"Vildagliptin; Glimepiride; Medicine; Metformin; Diabetes mellitus; Internal medicine; Type 2 diabetes; Gastroenterology; Endocrinology","score_opus":0.008943048231581338,"score_gpt":0.22399462829677433,"score_spread":0.21505158006519298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107562831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957819,0.0028095415,0.00021776749,0.00011666641,0.00015091953,0.00031179152,0.00021702424,0.000030659587,0.00036376243],"genre_scores_gemma":[0.994769,0.0019961724,0.0005937966,0.00037781065,0.00049936684,0.00030196528,0.0005586875,0.000016984664,0.0008861408],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99757344,0.0013828862,0.0002251252,0.00033295184,0.00025382885,0.00023183304],"domain_scores_gemma":[0.99700123,0.00094284985,0.0009061576,0.00045961942,0.00014752774,0.00054262514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051418645,0.0015011537,0.0038504275,0.000652628,0.00035675667,0.0013238443,0.0011395812,0.0021364337,0.0035770857],"category_scores_gemma":[0.0030758316,0.0008819137,0.0034661153,0.0005124852,0.0014642334,0.0015079482,0.00040764245,0.00269024,0.000663647],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9559749,0.016477408,0.0012575622,0.00044793158,0.0016730464,0.00007876077,0.00005315085,0.00016887454,0.007723633,0.00003341741,0.00021644664,0.015894828],"study_design_scores_gemma":[0.54275775,0.44170856,0.01111614,0.0000410098,0.0017078416,0.0001211819,0.000031474054,0.00032721178,0.0016242407,0.000061209576,0.00046953105,0.000033840748],"about_ca_topic_score_codex":0.00051484007,"about_ca_topic_score_gemma":0.00080904557,"teacher_disagreement_score":0.0051418645,"about_ca_system_score_codex":0.0008165914,"about_ca_system_score_gemma":0.0006985791,"threshold_uncertainty_score":0.027193129},"labels":[],"label_agreement":null},{"id":"W2111447866","doi":"10.1111/j.1463-1326.2008.01026.x","title":"Effect of antiobesity medications in patients with type 2 diabetes mellitus","year":2009,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Orlistat; Medicine; Sibutramine; Weight loss; Liraglutide; Diabetes mellitus; Type 2 Diabetes Mellitus; Rimonabant; Exenatide; Type 2 diabetes; Phentermine; Management of obesity; Incretin; Internal medicine; Obesity; Endocrinology; Antagonist","score_opus":0.008592925378184008,"score_gpt":0.2911010331813722,"score_spread":0.2825081078031882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111447866","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026307732,0.9982653,0.00006284443,0.0001260125,0.00008408881,0.000004789762,0.000013977281,0.0000055627906,0.0011743339],"genre_scores_gemma":[0.0019580487,0.9968727,0.0002267395,0.0002055595,0.0001131254,0.000007814053,0.0000267584,0.0000011607775,0.0005879546],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998436,0.00003508853,0.000024944813,0.000018348039,0.00006802829,0.000009966137],"domain_scores_gemma":[0.9998041,0.000087498585,0.000043619002,0.0000056608073,0.000045557517,0.000013576554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003479092,0.00063293596,0.0015324185,0.0012002769,0.0001667065,0.00049476826,0.00052961754,0.0006283913,0.004178264],"category_scores_gemma":[0.00056008104,0.00015447116,0.0005441632,0.0013562604,0.00015276208,0.00049463834,0.00029916648,0.0009149418,0.0018166889],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014444065,0.00011476388,0.0004949113,0.015389875,0.00019166162,0.00045087177,0.000043397125,0.00010633509,0.0010188571,0.00047831648,0.015240634,0.96632606],"study_design_scores_gemma":[0.00021101968,0.0004814091,0.009545233,0.011316153,0.0009915277,0.008642393,0.0001398239,0.00017615304,0.0013029372,0.0013914289,0.9657677,0.000034167002],"about_ca_topic_score_codex":0.0007718123,"about_ca_topic_score_gemma":0.0015231865,"teacher_disagreement_score":0.004178264,"about_ca_system_score_codex":0.00019171825,"about_ca_system_score_gemma":0.000412723,"threshold_uncertainty_score":0.013977647},"labels":[],"label_agreement":null},{"id":"W2113206514","doi":"10.1111/dom.12529","title":"Islet amyloid inhibitors improve glucose homeostasis in a transgenic mouse model of type 2 diabetes","year":2015,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Islet; Amyloid (mycology); Genetically modified mouse; Glucose homeostasis; Endocrinology; Internal medicine; In vivo; Type 2 diabetes; Transgene; Diabetes mellitus; Apoptosis; Insulin; Secretion; Biology; Chemistry; Medicine; Biochemistry; Insulin resistance","score_opus":0.01756434275765166,"score_gpt":0.22753389156601977,"score_spread":0.2099695488083681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113206514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42209318,0.06602397,0.01352017,0.3728375,0.02517332,0.0006135266,0.0009038262,0.0037692287,0.09506533],"genre_scores_gemma":[0.70783466,0.04519238,0.01150634,0.15926306,0.020066647,0.00038826675,0.00060069613,0.00021735263,0.054930493],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998179,0.000048778504,0.000016332693,0.00001869387,0.000074712756,0.000023598139],"domain_scores_gemma":[0.99963737,0.00016563892,0.000046506248,0.000027234066,0.00007188885,0.00005140546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045842564,0.00063936383,0.00076286506,0.00032972213,0.0003052005,0.00052485266,0.0003131357,0.0028545044,0.0013597691],"category_scores_gemma":[0.0010341997,0.00013505084,0.00038773235,0.00016602548,0.0003142887,0.00040337213,0.00018407816,0.0024497316,0.0011428522],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058117304,0.0027957174,0.008989046,0.0010521009,0.00019206184,0.112643674,0.000343108,0.0013981401,0.20080395,0.00903555,0.29910707,0.3578278],"study_design_scores_gemma":[0.0030610824,0.009191216,0.020716527,0.000630511,0.00043315132,0.12513234,0.00025186225,0.01297534,0.09253458,0.015502104,0.71939397,0.00017730154],"about_ca_topic_score_codex":0.00022576845,"about_ca_topic_score_gemma":0.00043332364,"teacher_disagreement_score":0.0028545044,"about_ca_system_score_codex":0.0005359552,"about_ca_system_score_gemma":0.00018342026,"threshold_uncertainty_score":0.0045488477},"labels":[],"label_agreement":null},{"id":"W2113411572","doi":"10.1111/j.1463-1326.2010.01254.x","title":"Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin","year":2010,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Merck Canada","keywords":"Sitagliptin; Medicine; Metformin; Internal medicine; Insulin; Placebo; Sitagliptin Phosphate; Endocrinology; Diabetes mellitus; Beta cell; Insulin resistance; Type 2 diabetes; Pharmacology; Islet","score_opus":0.0534038358896754,"score_gpt":0.3209368514847031,"score_spread":0.2675330155950277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113411572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987356,0.00020377291,0.00019326604,0.00004080206,0.000035364723,0.00050002156,0.000052243653,0.000008467774,0.00023044847],"genre_scores_gemma":[0.9956864,0.00037272292,0.001423689,0.00022222346,0.00019173895,0.0012719515,0.0003689248,0.000009855442,0.0004524435],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99899524,0.0005345652,0.000078640725,0.0001399502,0.00008135687,0.00017026668],"domain_scores_gemma":[0.99801755,0.00047692866,0.0001558042,0.00033834018,0.00010231862,0.00090899464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002759194,0.0014636451,0.002153164,0.00045703963,0.00075500226,0.0008109648,0.0008764872,0.00088315987,0.0029785084],"category_scores_gemma":[0.0013624097,0.00058670103,0.001628482,0.0004990101,0.0018465864,0.001198101,0.00082690787,0.0031984309,0.00047149608],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6343811,0.24211626,0.01278761,0.00026654187,0.00053632975,0.0004454245,0.00043636764,0.0007529973,0.07668605,0.00012156249,0.00029619873,0.031173563],"study_design_scores_gemma":[0.033876106,0.9521316,0.010774015,0.000008002804,0.00013346686,0.00008843192,0.00006376472,0.00023532467,0.0024635403,0.0000331738,0.00017715123,0.000015417365],"about_ca_topic_score_codex":0.00092381594,"about_ca_topic_score_gemma":0.0008565179,"teacher_disagreement_score":0.0029785084,"about_ca_system_score_codex":0.00050144567,"about_ca_system_score_gemma":0.0011913588,"threshold_uncertainty_score":0.014592171},"labels":[],"label_agreement":null},{"id":"W2113724447","doi":"10.1111/j.1463-1326.2011.01495.x","title":"Interleukin‐15 treatment improves glucose homeostasis and insulin sensitivity in obese mice","year":2011,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Glucose homeostasis; Insulin sensitivity; Homeostasis; Endocrinology; Internal medicine; Insulin; Medicine; Insulin resistance","score_opus":0.012434354174829427,"score_gpt":0.2041513459036775,"score_spread":0.19171699172884807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113724447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941163,0.0017677431,0.0015451318,0.00033368164,0.00011854667,0.000028459692,0.0005415627,0.00016946,0.0013791501],"genre_scores_gemma":[0.9896355,0.0017792255,0.0032703502,0.00031325244,0.000038505415,0.00007999985,0.00089485856,0.000056690373,0.0039316593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997204,0.000059333564,0.000042375446,0.000048790684,0.00005665926,0.00007241676],"domain_scores_gemma":[0.9997224,0.00002507339,0.00009400625,0.000030263007,0.00001583668,0.000112297865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028467938,0.000554057,0.0005036151,0.0006143824,0.00014847206,0.00038860086,0.0002885335,0.00047756356,0.0012638734],"category_scores_gemma":[0.00015284934,0.00026076136,0.00040322106,0.00026480682,0.0003644561,0.00029919588,0.00019357774,0.0013576567,0.0003322959],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022200972,0.00063153973,0.00044463217,0.00008529958,0.000031832962,0.00007454066,0.000035708938,0.00018337552,0.9911946,0.00015246635,0.00014107434,0.0048049157],"study_design_scores_gemma":[0.000526873,0.0072692665,0.009139811,0.00004873301,0.00010448219,0.00034121252,0.00010742331,0.0015622139,0.9764416,0.00026035061,0.00417531,0.000022710316],"about_ca_topic_score_codex":0.00044733268,"about_ca_topic_score_gemma":0.00070207205,"teacher_disagreement_score":0.0012638734,"about_ca_system_score_codex":0.0002514621,"about_ca_system_score_gemma":0.00027407735,"threshold_uncertainty_score":0.004228115},"labels":[],"label_agreement":null},{"id":"W2114506972","doi":"10.1111/dom.12444","title":"<scp>LEADER</scp> 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the <scp>L</scp> iraglutide <scp>E</scp> ffect and <scp>A</scp> ction in <scp>D</scp> iabetes: <scp>E</scp> valuation of cardiovascular outcome <scp>R</scp> esults ( <scp>LEADER</scp> ) trial: preliminary observations","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novartis Pharma; Novo Nordisk Fonden; Astellas Pharma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Orexigen Therapeutics; F. Hoffmann-La Roche; Novo Nordisk; Medicines Company; Intarcia Therapeutics; GlaxoSmithKline; Osiris Therapeutics; Halozyme; Sanofi; St. Jude Medical; MannKind Corporation; Pfizer","keywords":"Medicine; Calcitonin; Gerontology; Internal medicine","score_opus":0.04427697335830322,"score_gpt":0.2587140336290045,"score_spread":0.2144370602707013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114506972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465007,0.0013055519,0.00009083394,0.00022118597,0.000031626987,0.00038211784,0.002377633,0.000036858073,0.00090409175],"genre_scores_gemma":[0.9894009,0.0010934474,0.0007454985,0.00064685347,0.00013583983,0.0010751602,0.0052976236,0.000016475708,0.0015882748],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995995,0.00018591862,0.00003068317,0.00007590234,0.0000579026,0.000050122948],"domain_scores_gemma":[0.9994104,0.00008594659,0.00016714177,0.000049078146,0.000054732038,0.00023276085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013031643,0.0006661894,0.0011547833,0.0001877172,0.00030861804,0.0007021647,0.00036877012,0.0007498461,0.0035111096],"category_scores_gemma":[0.0010432662,0.00033041154,0.00084077084,0.0004652295,0.00036716598,0.00038833328,0.00046749847,0.0012248637,0.00061692245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79829943,0.0066695055,0.11894387,0.0009041746,0.0023835711,0.00021310161,0.00024332652,0.00055535056,0.007055466,0.00011847438,0.008406678,0.05620696],"study_design_scores_gemma":[0.5482249,0.111946195,0.32733527,0.00015524703,0.0034745615,0.0003598085,0.00021789497,0.0010377765,0.002139862,0.00025108983,0.0047709476,0.00008640693],"about_ca_topic_score_codex":0.0020202769,"about_ca_topic_score_gemma":0.0037889637,"teacher_disagreement_score":0.0035111096,"about_ca_system_score_codex":0.00040150608,"about_ca_system_score_gemma":0.000658218,"threshold_uncertainty_score":0.0117458105},"labels":[],"label_agreement":null},{"id":"W2117505171","doi":"10.1111/dom.12187","title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Astellas Pharma; AstraZeneca","keywords":"Dapagliflozin; Medicine; Placebo; Insulin; Adverse effect; Diabetes mellitus; Type 2 diabetes; Population; Internal medicine; Urology; Endocrinology","score_opus":0.0043399929951399956,"score_gpt":0.19137911585337625,"score_spread":0.18703912285823626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117505171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931746,0.0057518994,0.00020463819,0.00011384705,0.000044849978,0.00011027165,0.000098046396,0.000010742274,0.0004909423],"genre_scores_gemma":[0.9973143,0.0016268243,0.00034181454,0.00020092784,0.000097321215,0.00011087118,0.00014156697,0.0000016533863,0.00016468007],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999584,0.00018578848,0.000052349205,0.00006185721,0.00007600358,0.000040016632],"domain_scores_gemma":[0.9993216,0.000213663,0.00026331097,0.00003370949,0.000040445295,0.00012723697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015706507,0.00023689057,0.0009838655,0.00022298265,0.00019764507,0.00047118717,0.00016358367,0.00040306404,0.0008662566],"category_scores_gemma":[0.0016515236,0.0001652374,0.00049147377,0.0003017546,0.00017997084,0.00035721916,0.00019315258,0.00061589375,0.00012557414],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5208618,0.006905672,0.19089447,0.0009434929,0.0016237983,0.00034441764,0.00019154085,0.00094918045,0.009044899,0.00008383045,0.0015953659,0.26656157],"study_design_scores_gemma":[0.13469444,0.2525155,0.5962463,0.00025210477,0.0025016307,0.0011342849,0.00018244924,0.0043357774,0.0035658944,0.00022252284,0.0042909444,0.00005830721],"about_ca_topic_score_codex":0.00028634066,"about_ca_topic_score_gemma":0.00055380276,"teacher_disagreement_score":0.0015706507,"about_ca_system_score_codex":0.000276599,"about_ca_system_score_gemma":0.00029202277,"threshold_uncertainty_score":0.008306503},"labels":[],"label_agreement":null},{"id":"W2120771901","doi":"10.1111/j.1463-1326.2005.00541.x","title":"Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (&gt;60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rosiglitazone; Medicine; Glipizide; Tolerability; Placebo; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Gastroenterology; Insulin; Endocrinology; Adverse effect; Alternative medicine","score_opus":0.005432125892819263,"score_gpt":0.2292860588156759,"score_spread":0.22385393292285663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120771901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662566,0.0022308126,0.000094717885,0.00012953971,0.00010944714,0.00017332459,0.000102250786,0.000025898207,0.00050837157],"genre_scores_gemma":[0.9964552,0.0013420115,0.0005772415,0.0005301526,0.00021324425,0.00017426413,0.0002601979,0.000008085187,0.00043957122],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990445,0.00059152953,0.00006704989,0.00011520608,0.0000811751,0.000100548845],"domain_scores_gemma":[0.99801683,0.00077378633,0.00038374125,0.00016177779,0.00006328709,0.0006006144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021341953,0.0012715419,0.0031184352,0.00029724828,0.00025594956,0.00087576517,0.0006818044,0.0013673792,0.002274772],"category_scores_gemma":[0.0026385442,0.0005049278,0.0025671073,0.0002557615,0.0005481529,0.00066156726,0.0004042916,0.0021650326,0.0003566169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9425689,0.015082015,0.0036422499,0.0003060284,0.0010827633,0.000068342866,0.000068044945,0.00031532394,0.002481903,0.000028743512,0.00021969598,0.03413599],"study_design_scores_gemma":[0.5998714,0.37231323,0.023816457,0.00006544949,0.0018543472,0.00008719681,0.000050675095,0.0005920139,0.0007700602,0.00007197508,0.00047968447,0.000027518327],"about_ca_topic_score_codex":0.000728403,"about_ca_topic_score_gemma":0.0014541543,"teacher_disagreement_score":0.0031184352,"about_ca_system_score_codex":0.0003882369,"about_ca_system_score_gemma":0.00048253342,"threshold_uncertainty_score":0.011286795},"labels":[],"label_agreement":null},{"id":"W2120993742","doi":"10.1111/dom.12238","title":"Intensification of medication and glycaemic control among patients with type 2 diabetes – the <scp>ADVANCE</scp> trial","year":2013,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Diabetes mellitus; Odds ratio; Confidence interval; Type 2 diabetes; Internal medicine; Randomized controlled trial; Insulin; Logistic regression; Endocrinology","score_opus":0.004643060273135869,"score_gpt":0.1916671397977088,"score_spread":0.18702407952457292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120993742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922994,0.005476648,0.00012561398,0.00036061037,0.00010775734,0.00022446716,0.00030860116,0.000013017474,0.0010839518],"genre_scores_gemma":[0.99293846,0.003082011,0.0007117563,0.00057883427,0.0005347772,0.00035137497,0.0011125945,0.000004155,0.0006860964],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99928564,0.00048278365,0.000047295678,0.000074254276,0.000061509265,0.000048577756],"domain_scores_gemma":[0.9987754,0.00038797085,0.0004526151,0.000099830664,0.000053491945,0.00023073672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018889146,0.00053643406,0.0012847296,0.00019129811,0.00017651929,0.00059144536,0.0003883631,0.0006318396,0.002203586],"category_scores_gemma":[0.0018093643,0.00020550596,0.00146867,0.00029645753,0.0002985183,0.00042374595,0.0003387383,0.0015421375,0.00012866706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8915923,0.0067629167,0.03312778,0.0017059621,0.00664706,0.00009545813,0.00007018866,0.0015760193,0.0013054318,0.00024000873,0.0020673606,0.054809548],"study_design_scores_gemma":[0.71412367,0.1274031,0.14178641,0.0004802528,0.00854906,0.00028000935,0.000066409935,0.0033204746,0.0007109471,0.0004773164,0.0027637722,0.00003860933],"about_ca_topic_score_codex":0.00085710036,"about_ca_topic_score_gemma":0.0014629554,"teacher_disagreement_score":0.002203586,"about_ca_system_score_codex":0.00030327338,"about_ca_system_score_gemma":0.0006425373,"threshold_uncertainty_score":0.009989679},"labels":[],"label_agreement":null},{"id":"W2128093058","doi":"10.1111/dom.12290","title":"Pronounced reduction of postprandial glucagon by lixisenatide: a meta‐analysis of randomized clinical trials","year":2014,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi","keywords":"Lixisenatide; Postprandial; Meta-analysis; Randomized controlled trial; Glucagon; Medicine; Internal medicine; Reduction (mathematics); Endocrinology; Diabetes mellitus; Type 2 diabetes; Insulin; Mathematics; Liraglutide","score_opus":0.0973132919649313,"score_gpt":0.40441716668855515,"score_spread":0.3071038747236239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128093058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040737323,0.9553776,0.0012639017,0.00040657978,0.00038266153,0.00032763585,0.0008893312,0.000084124775,0.0005308034],"genre_scores_gemma":[0.7180794,0.27294394,0.0035072716,0.0015435233,0.00044160796,0.0009516702,0.0017046584,0.00008207075,0.0007458861],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99008256,0.0058795363,0.0019869443,0.0011749679,0.0006091916,0.00026687523],"domain_scores_gemma":[0.98797554,0.00853583,0.0020559572,0.00060793804,0.0006168389,0.00020782143],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01333741,0.0029686817,0.015670288,0.0025112198,0.0005294611,0.0031228035,0.0015036903,0.0020603382,0.003389007],"category_scores_gemma":[0.017439885,0.0014847894,0.041109785,0.0033151426,0.0006422229,0.0012437186,0.0009046247,0.0018673615,0.00028583469],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014315738,0.000036100755,0.0042220554,0.049734022,0.9249264,0.00008292551,0.000025134439,0.0005569567,0.00048246075,0.000053434633,0.00029937903,0.0052653938],"study_design_scores_gemma":[0.0026795762,0.0004123335,0.0037055712,0.0017304184,0.99047905,0.00005235085,0.000013926404,0.00018483098,0.0001490252,0.00008923066,0.00049123383,0.000012380944],"about_ca_topic_score_codex":0.0029792986,"about_ca_topic_score_gemma":0.005191631,"teacher_disagreement_score":0.9843297,"about_ca_system_score_codex":0.0014439746,"about_ca_system_score_gemma":0.0012188596,"threshold_uncertainty_score":0.07053578},"labels":[],"label_agreement":null},{"id":"W2133819196","doi":"10.1111/j.1463-1326.2007.00837.x","title":"Metabolomic profiling of dietary‐induced insulin resistance in the high fat–fed C57BL/6J mouse","year":2008,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Metabolomics; Insulin resistance; Metabolite; Internal medicine; Metabolome; Endocrinology; Biology; Insulin; Bioinformatics; Medicine","score_opus":0.014542742527578145,"score_gpt":0.22092888525878343,"score_spread":0.20638614273120529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133819196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917829,0.00067071,0.005001786,0.00010843877,0.000019300584,0.00004589192,0.0018194853,0.0001412199,0.00041025536],"genre_scores_gemma":[0.9797881,0.0012745993,0.012222538,0.00026454122,0.000020846728,0.00014817413,0.0028958875,0.000120675824,0.0032647192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982435,0.000022389233,0.000013697244,0.000062989,0.000049113736,0.000027516622],"domain_scores_gemma":[0.9997669,0.000027465647,0.00007746381,0.000030389554,0.000036900252,0.0000608112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033847857,0.0005310974,0.00045227684,0.00097425864,0.0002019135,0.00036013382,0.00016074388,0.00035752408,0.0005347566],"category_scores_gemma":[0.00018954184,0.00023144887,0.00034858746,0.0003768873,0.00029152175,0.00019039826,0.00018603764,0.00070345006,0.00017901276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043771532,0.000043698557,0.0010508067,0.000016442595,0.000015966558,0.000029322522,0.000012170567,0.000054653734,0.99728405,0.000020001049,0.000026336933,0.0010087481],"study_design_scores_gemma":[0.00009491797,0.0026445528,0.17236952,0.000024958936,0.00022901436,0.00054567034,0.00011528508,0.0038382527,0.81800234,0.0002577081,0.0018417069,0.00003607665],"about_ca_topic_score_codex":0.0005115014,"about_ca_topic_score_gemma":0.0010331991,"teacher_disagreement_score":0.00097425864,"about_ca_system_score_codex":0.00019743016,"about_ca_system_score_gemma":0.00013574958,"threshold_uncertainty_score":0.0017900467},"labels":[],"label_agreement":null},{"id":"W2135041172","doi":"10.1111/j.1463-1326.2006.00625.x","title":"Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3‐L1 pre‐adipocytes and adipocytes","year":2006,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Adipokines, Inflammation, and Metabolic Diseases","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Internal medicine; Endocrinology; Adipocyte; Hormone; Adipokine; 3T3-L1; Insulin; Endogeny; Chemistry; Biology; Adipose tissue; Insulin resistance; Medicine","score_opus":0.0047910215498751475,"score_gpt":0.21167569187205765,"score_spread":0.2068846703221825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135041172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876924,0.0048012286,0.002854206,0.00016682757,0.00003729935,0.000032749726,0.0015341396,0.00010105594,0.002780018],"genre_scores_gemma":[0.98312193,0.0029031732,0.0031246776,0.00016610057,0.000031912357,0.000120951416,0.0029809999,0.0000790865,0.0074712294],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981433,0.000020951127,0.000011954796,0.000054012417,0.000048904,0.0000499167],"domain_scores_gemma":[0.9998888,0.000025167288,0.000030970852,0.000008969112,0.000018629558,0.000027545888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014214299,0.00034754755,0.00023656397,0.0004081651,0.00032209148,0.00053770596,0.00021680168,0.00031019413,0.0025092068],"category_scores_gemma":[0.0001296071,0.0002466753,0.00039071092,0.00040478812,0.00040147585,0.00034122446,0.00025955166,0.0006436764,0.0007917213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033698132,0.00001689457,0.00034677028,0.000022338489,0.0000040811037,0.00006247258,0.00003526706,0.000025866162,0.9980902,0.000046846635,0.000028391683,0.000983911],"study_design_scores_gemma":[0.00006375815,0.00050866546,0.08446234,0.000018387052,0.000042636846,0.0007875172,0.00026840725,0.00065535115,0.906755,0.00013777145,0.006274917,0.000025340665],"about_ca_topic_score_codex":0.0022137645,"about_ca_topic_score_gemma":0.0032816913,"teacher_disagreement_score":0.0025092068,"about_ca_system_score_codex":0.0005495153,"about_ca_system_score_gemma":0.00023238108,"threshold_uncertainty_score":0.008394122},"labels":[],"label_agreement":null},{"id":"W2135287300","doi":"10.1111/j.1463-1326.2009.01125.x","title":"Insulin use and increased risk of mortality in type 2 diabetes: a cohort study","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Medicine; Hazard ratio; Insulin; Confidence interval; Proportional hazards model; Diabetes mellitus; Type 2 diabetes; Population; Internal medicine; Cohort; Cohort study; Demography; Endocrinology; Environmental health","score_opus":0.012697734058363311,"score_gpt":0.23904757741599467,"score_spread":0.22634984335763136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135287300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99846077,0.0004223807,0.00007872851,0.000045353652,0.000012816177,0.00001218222,0.0007480849,0.0000037751176,0.00021575141],"genre_scores_gemma":[0.9983271,0.00043092284,0.0001416394,0.00004079946,0.000024509469,0.000016231736,0.0007955114,0.0000025789368,0.00022061614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941003,0.00016921632,0.00006132888,0.00014534616,0.000115948824,0.00009815855],"domain_scores_gemma":[0.998519,0.00022841505,0.0006445892,0.00017612345,0.00015955798,0.00027240138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009801376,0.0004593256,0.00043868157,0.0007653061,0.00043188382,0.0009055505,0.00054352486,0.0006168487,0.0011061043],"category_scores_gemma":[0.0023426865,0.0005046906,0.00083933154,0.0014067193,0.00021841358,0.00045509654,0.00044633195,0.0008748982,0.00019201207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022680656,0.00004624474,0.9987494,0.0000071036307,0.00023542692,0.000050860628,0.000032690637,0.000030175883,0.000081552236,0.0000055695286,0.00005629114,0.00047780373],"study_design_scores_gemma":[0.00002529643,0.000096144104,0.9992508,0.0000070469214,0.000100346486,0.00016443589,0.000058522714,0.00016017699,0.000024075394,0.000010385326,0.00009822297,0.000004439147],"about_ca_topic_score_codex":0.01865804,"about_ca_topic_score_gemma":0.018590007,"teacher_disagreement_score":0.01865804,"about_ca_system_score_codex":0.00042061048,"about_ca_system_score_gemma":0.00046767472,"threshold_uncertainty_score":0.037098885},"labels":[],"label_agreement":null},{"id":"W2143906026","doi":"10.1046/j.1463-1326.2000.00107.x","title":"Optimizing insulin delivery: assessment of three strategies in intensive diabetes management","year":2000,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Insulin; Dietary management; Meal; Medicine; Diabetes mellitus; Type 2 diabetes; Metabolic control analysis; Basal insulin; Endocrinology; Internal medicine","score_opus":0.01525380925888541,"score_gpt":0.2711590562942703,"score_spread":0.25590524703538486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143906026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953401,0.0008253949,0.0019887947,0.00012794051,0.000012183877,0.0006473111,0.000036067184,0.000021474147,0.001000739],"genre_scores_gemma":[0.9898246,0.0005685279,0.008137917,0.0001251642,0.00002794144,0.00096940517,0.00009058278,0.0000024726796,0.00025347312],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990097,0.0004885502,0.00012375027,0.000088401976,0.00023541103,0.00005413617],"domain_scores_gemma":[0.99825484,0.00077667413,0.00050511735,0.00008131084,0.00009785863,0.0002841461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017749462,0.000655483,0.00056372205,0.0003994857,0.00016094402,0.0005216448,0.00044090586,0.0006495577,0.0008775456],"category_scores_gemma":[0.0042460505,0.00022630054,0.00038472534,0.00023999422,0.00029288323,0.00042988494,0.00042847855,0.0004563307,0.000101577614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05194062,0.030020213,0.15311283,0.0020353762,0.001103345,0.00008321168,0.0006018563,0.009491467,0.008628791,0.00040774758,0.0005866514,0.7419878],"study_design_scores_gemma":[0.028356332,0.31102106,0.62110925,0.0006164023,0.0016027723,0.00054557825,0.0008113459,0.022143653,0.008336173,0.0016846624,0.0036495058,0.00012332125],"about_ca_topic_score_codex":0.000327738,"about_ca_topic_score_gemma":0.0004224106,"teacher_disagreement_score":0.0017749462,"about_ca_system_score_codex":0.00038782923,"about_ca_system_score_gemma":0.0004263688,"threshold_uncertainty_score":0.009386957},"labels":[],"label_agreement":null},{"id":"W2144790234","doi":"10.1111/j.1463-1326.2007.00725.x","title":"Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Ezetimibe; Simvastatin; Medicine; Atorvastatin; Type 2 diabetes; Pharmacology; Apolipoprotein B; Internal medicine; Statin; Cholesterol; Endocrinology; Diabetes mellitus","score_opus":0.006956152334018997,"score_gpt":0.218371969766574,"score_spread":0.211415817432555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144790234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305034,0.004578081,0.00015678366,0.0003564643,0.00025648315,0.00038354966,0.00024122433,0.00005953254,0.0009174981],"genre_scores_gemma":[0.99486625,0.0017937031,0.00065800385,0.00074657873,0.00026972996,0.0005474052,0.0003280434,0.0000106734515,0.0007796415],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99920887,0.00042734685,0.00008435569,0.00012296185,0.000051615538,0.0001049361],"domain_scores_gemma":[0.9988914,0.00041104323,0.00024090767,0.000051890933,0.00004677362,0.00035796067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014546902,0.0011245405,0.0033489608,0.000316503,0.00031452373,0.00081767485,0.0006826216,0.0015572321,0.0038601866],"category_scores_gemma":[0.0015433047,0.0005534147,0.0018930555,0.00032180204,0.00065686094,0.0006074778,0.00029850067,0.001907053,0.0005920149],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9780164,0.005114788,0.0007768752,0.0003040922,0.0006823439,0.000027699967,0.00002500265,0.00016046033,0.0021692785,0.000025557933,0.00022654663,0.012470973],"study_design_scores_gemma":[0.8540553,0.13827707,0.004721766,0.000034299526,0.0010403827,0.00004702626,0.000024068237,0.00062352873,0.00070575695,0.00007889609,0.000373684,0.000018240295],"about_ca_topic_score_codex":0.00067430775,"about_ca_topic_score_gemma":0.0012347909,"teacher_disagreement_score":0.0038601866,"about_ca_system_score_codex":0.00045465192,"about_ca_system_score_gemma":0.0008497532,"threshold_uncertainty_score":0.012913585},"labels":[],"label_agreement":null},{"id":"W2145434394","doi":"10.1111/j.1463-1326.2005.00502.x","title":"Insulin increases gelatinase activity in rat glomerular mesangial cells via ERK‐ and PI‐3 kinase‐dependent signalling","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Gelatinase; MAPK/ERK pathway; Diabetic nephropathy; Kinase; Matrix metalloproteinase; Internal medicine; Insulin; Endocrinology; Chemistry; Extracellular matrix; Mesangial cell; Cell biology; LY294002; Extracellular; Intracellular; Kidney; Phosphatidylinositol; Biology; Medicine","score_opus":0.004888362261122881,"score_gpt":0.19834206982431354,"score_spread":0.19345370756319066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145434394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98976874,0.004076648,0.0032856644,0.00015501902,0.000051540046,0.00003659054,0.00044208404,0.00016216397,0.002021463],"genre_scores_gemma":[0.98953575,0.0029108238,0.0039966293,0.0000925375,0.000022681874,0.000065373,0.0007136219,0.000020778061,0.0026418422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998846,0.000017763461,0.000014796038,0.000021916669,0.000031389212,0.000029605471],"domain_scores_gemma":[0.9998981,0.00001656536,0.000025436737,0.00001570508,0.000009553215,0.000034718858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020019988,0.0004889451,0.00025720548,0.00035515628,0.00010631485,0.00024670732,0.00013381333,0.00019551672,0.0013033735],"category_scores_gemma":[0.000109268774,0.00017478848,0.0003416113,0.00026154294,0.00019844969,0.00024717159,0.00018412116,0.00060392753,0.0004104528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019703906,0.0000548672,0.00016162147,0.00003272108,0.0000043234168,0.000038260438,0.00000798538,0.000021587974,0.99865794,0.000028257467,0.000018816872,0.00077657367],"study_design_scores_gemma":[0.000080557766,0.00059062324,0.018027807,0.000009014623,0.000033085507,0.0002102629,0.000027842198,0.00069147913,0.9788929,0.00006544218,0.0013629687,0.000007909805],"about_ca_topic_score_codex":0.00074658013,"about_ca_topic_score_gemma":0.0011643586,"teacher_disagreement_score":0.0013033735,"about_ca_system_score_codex":0.0002292329,"about_ca_system_score_gemma":0.00019538515,"threshold_uncertainty_score":0.004360199},"labels":[],"label_agreement":null},{"id":"W2146309429","doi":"10.1111/j.1463-1326.2011.01496.x","title":"Variations in tissue selectivity amongst insulin secretagogues: a systematic review","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Cardiac Ischemia and Reperfusion","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Repaglinide; Sulfonylurea receptor; Nateglinide; Glibenclamide; Glipizide; Insulin; Tolbutamide; Glimepiride; Receptor; Chemistry; Pharmacology; Secretagogue; Internal medicine; Gliclazide; Sulfonylurea; Endocrinology; Glucokinase; Medicine; Diabetes mellitus; Metformin; Type 2 diabetes","score_opus":0.0181915316227047,"score_gpt":0.2811520338139581,"score_spread":0.2629605021912534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146309429","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014559041,0.99712616,0.00013490599,0.00017529704,0.000047582944,0.00015998863,0.0006557135,0.000007680794,0.00023680601],"genre_scores_gemma":[0.015612395,0.98253274,0.00055326073,0.00038760278,0.000042588657,0.00030778916,0.00045392907,0.000006646078,0.000102984624],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99508214,0.001142625,0.002434097,0.00047885228,0.00069441623,0.00016777706],"domain_scores_gemma":[0.96858215,0.022854999,0.0055223387,0.0003227381,0.0024125725,0.00030524048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005559099,0.0014028036,0.009902976,0.013829224,0.0004317778,0.002292231,0.0019063362,0.0014400766,0.0051699723],"category_scores_gemma":[0.02659522,0.0008670544,0.007036007,0.016620565,0.0009038695,0.0022008123,0.0016028944,0.0008218987,0.0004896048],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003400338,0.000011207222,0.0011073792,0.9462686,0.009229353,0.00013372424,0.00014201432,0.00007153798,0.00023414337,0.00012534596,0.0010839052,0.041252714],"study_design_scores_gemma":[0.00046286132,0.0003523225,0.009468228,0.8246924,0.13943769,0.0008439985,0.00048481848,0.000086506494,0.00045797258,0.0003241911,0.02332986,0.000059196715],"about_ca_topic_score_codex":0.006069713,"about_ca_topic_score_gemma":0.018452175,"teacher_disagreement_score":0.013829224,"about_ca_system_score_codex":0.0028233242,"about_ca_system_score_gemma":0.0068232664,"threshold_uncertainty_score":0.029399693},"labels":[],"label_agreement":null},{"id":"W2154268206","doi":"10.1111/j.1463-1326.2012.01576.x","title":"Liraglutide: from clinical trials to clinical practice","year":2012,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk; Eli Lilly and Company","keywords":"Liraglutide; Exenatide; Medicine; Tolerability; Sitagliptin; Regimen; Nausea; Clinical trial; Type 2 diabetes; Internal medicine; Pharmacology; Diabetes mellitus; Adverse effect; Endocrinology","score_opus":0.270250484376392,"score_gpt":0.4984562156673189,"score_spread":0.22820573129092692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154268206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048861704,0.6986796,0.013101588,0.22793207,0.017999355,0.0037262002,0.0018250583,0.0011941991,0.030655783],"genre_scores_gemma":[0.08267424,0.5131789,0.05909131,0.29402447,0.026938517,0.01123418,0.0026773412,0.0008715012,0.009309542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9481008,0.037824597,0.00451578,0.0020359436,0.0066933054,0.00082954357],"domain_scores_gemma":[0.93487257,0.033583142,0.0069687157,0.004425312,0.011871278,0.008278997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0773684,0.0014728045,0.004641335,0.0019973798,0.0007839559,0.010457213,0.003561683,0.00724293,0.014811227],"category_scores_gemma":[0.12052266,0.00089227717,0.0016132931,0.0025558188,0.0034377608,0.0067733885,0.004256553,0.008155574,0.007892526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077617117,0.00044599225,0.00076575653,0.008788534,0.00046509752,0.0001609328,0.00022109783,0.00034902612,0.0007831978,0.008647073,0.18409082,0.78752065],"study_design_scores_gemma":[0.028874338,0.008492299,0.0034523925,0.056461547,0.0015314393,0.0006086735,0.00042517149,0.0015894953,0.0013067939,0.049821034,0.84723514,0.00020164774],"about_ca_topic_score_codex":0.0010470399,"about_ca_topic_score_gemma":0.0011437557,"teacher_disagreement_score":0.0773684,"about_ca_system_score_codex":0.0046115215,"about_ca_system_score_gemma":0.009246758,"threshold_uncertainty_score":0.40916812},"labels":[],"label_agreement":null},{"id":"W2154517237","doi":"10.1111/j.1463-1326.2009.01129.x","title":"The response to short‐term intensive insulin therapy in type 2 diabetes","year":2009,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Diabetes mellitus; Type 2 diabetes; Insulin; Area under the curve; Gastroenterology; Endocrinology","score_opus":0.01483040254068376,"score_gpt":0.25882040029228304,"score_spread":0.24398999775159927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154517237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980147,0.0015534243,0.000103172366,0.000047350266,0.000016622062,0.000011800325,0.00003934451,0.0000057369743,0.00020784861],"genre_scores_gemma":[0.99893874,0.0004477028,0.00019095108,0.00008777314,0.000055026492,0.000021493084,0.0001413292,0.0000021986152,0.000114841234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994635,0.00027827016,0.000067967296,0.000060494494,0.000086510365,0.000043291973],"domain_scores_gemma":[0.99804026,0.0008256068,0.00064158323,0.00006141303,0.00010748392,0.00032373183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011894238,0.00033074626,0.0005444018,0.00022665922,0.00015351526,0.00040913103,0.00022724933,0.00047305864,0.0006531818],"category_scores_gemma":[0.0023754702,0.00008792121,0.0003825989,0.00026149632,0.00019228102,0.00018721225,0.00021290012,0.0005139237,0.00012410257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026181785,0.0011730862,0.88965964,0.00028608998,0.00048650088,0.00039726854,0.00017261587,0.00047986096,0.0067776255,0.000017097775,0.0004166556,0.07395164],"study_design_scores_gemma":[0.00033442458,0.008485113,0.9883669,0.000034071734,0.00016252918,0.0006776223,0.00011172012,0.0006347492,0.0008506849,0.000027952652,0.0003028226,0.000011480654],"about_ca_topic_score_codex":0.00027730982,"about_ca_topic_score_gemma":0.00031267814,"teacher_disagreement_score":0.0011894238,"about_ca_system_score_codex":0.00018292789,"about_ca_system_score_gemma":0.00011120872,"threshold_uncertainty_score":0.006290376},"labels":[],"label_agreement":null},{"id":"W2155334088","doi":"10.1111/j.1463-1326.2011.01450.x","title":"Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?","year":2011,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; Medical Research Council; National Institute for Health and Care Research; Canada Research Chairs; Wellcome Trust","keywords":"Paracrine signalling; Glucagon; Secretion; Internal medicine; Endocrinology; Depolarization; Islet; Somatostatin; Blood sugar regulation; Biology; Cell biology; Chemistry; Insulin; Receptor; Medicine","score_opus":0.0281236078666534,"score_gpt":0.2748657014297744,"score_spread":0.246742093563121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155334088","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012141237,0.9987207,0.00014161904,0.00032360427,0.00020337557,0.0000014003347,0.0000059246395,0.0000046429473,0.00047723443],"genre_scores_gemma":[0.0007280359,0.99838245,0.00012831333,0.0001916732,0.0002517909,0.000003123715,0.0000077624245,8.856951e-7,0.00030602457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998362,0.000034725123,0.000025865615,0.000030301137,0.000054000462,0.000018842919],"domain_scores_gemma":[0.9997825,0.00009962226,0.000033375996,0.000010546937,0.000047306472,0.000026610198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063950644,0.0008548798,0.0018180955,0.0009710805,0.00022762167,0.0010064553,0.0008860801,0.0010609006,0.0018730466],"category_scores_gemma":[0.00058506406,0.00021292045,0.00032836912,0.0014215343,0.00092925166,0.0023664504,0.0005295537,0.0015177794,0.0014410898],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010792793,0.00005430664,0.0004950963,0.014075134,0.00011051539,0.0005536655,0.0001331642,0.00023774132,0.004019323,0.008291636,0.019674966,0.9522465],"study_design_scores_gemma":[0.0000324317,0.00015881218,0.001918221,0.0039833435,0.00015233933,0.0042815423,0.0002732569,0.00011092471,0.0013539414,0.006251252,0.98144895,0.000034895187],"about_ca_topic_score_codex":0.00044339657,"about_ca_topic_score_gemma":0.00070221326,"teacher_disagreement_score":0.0018730466,"about_ca_system_score_codex":0.0005935277,"about_ca_system_score_gemma":0.00070166535,"threshold_uncertainty_score":0.0062659383},"labels":[],"label_agreement":null},{"id":"W2158090662","doi":"10.1111/j.1463-1326.2007.00808.x","title":"Rosiglitazone prevents diabetes by increasing beta‐cell mass in an animal model of type 2 diabetes characterized by reduced beta‐cell mass at birth","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University","funders":"","keywords":"Rosiglitazone; Endocrinology; Internal medicine; Offspring; Medicine; Diabetes mellitus; Impaired glucose tolerance; Type 2 diabetes; Beta cell; Glucose homeostasis; Impaired fasting glucose; Insulin resistance; Pregnancy; Biology; Islet","score_opus":0.011883686419659237,"score_gpt":0.23034477125844519,"score_spread":0.21846108483878596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158090662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854585,0.005713178,0.004034313,0.00048418905,0.0002680133,0.0002164357,0.0008102194,0.00040858262,0.0026065547],"genre_scores_gemma":[0.96198,0.012192399,0.009789682,0.0004170753,0.00014597924,0.0007292756,0.0016831778,0.00009920583,0.012963168],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997708,0.00003066242,0.000026499067,0.000046528112,0.000084138475,0.00004136943],"domain_scores_gemma":[0.99971443,0.0000240791,0.0001171295,0.000044298296,0.000021773081,0.00007821482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023632817,0.000833627,0.0005881021,0.00085464556,0.00029045893,0.00038745784,0.0005408479,0.0008604058,0.0015513955],"category_scores_gemma":[0.00016389592,0.00028776733,0.00044481392,0.00037167853,0.00034018685,0.0003153879,0.00020579321,0.002236181,0.00046390452],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024038379,0.0011392342,0.0008036348,0.00017739706,0.00004252992,0.00017375646,0.000028797716,0.000091714675,0.986347,0.00017705023,0.00015858213,0.008456504],"study_design_scores_gemma":[0.00095277163,0.016249575,0.020187931,0.00013927062,0.00024264684,0.00082433276,0.00010282381,0.0007130686,0.95121896,0.00026080414,0.009073624,0.000034157994],"about_ca_topic_score_codex":0.00048833917,"about_ca_topic_score_gemma":0.0012461607,"teacher_disagreement_score":0.0015513955,"about_ca_system_score_codex":0.00027959,"about_ca_system_score_gemma":0.0004976703,"threshold_uncertainty_score":0.0051898956},"labels":[],"label_agreement":null},{"id":"W2161963078","doi":"10.1111/dom.12340","title":"Gut microbiota, nutrient sensing and energy balance","year":2014,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Health Canada; University of Toronto; Eidgenössische Technische Hochschule Zürich","keywords":"Gut flora; Gut–brain axis; Enteroendocrine cell; Gastrointestinal tract; Microbiome; Nutrient sensing; Paracrine signalling; Endocrine system; Autocrine signalling; Enteric nervous system; Biology; Medicine; Glucagon-like peptide-1; Neuroscience; Bioinformatics; Immunology; Hormone; Cell biology; Internal medicine; Endocrinology; Signal transduction; Diabetes mellitus; Type 2 diabetes; Receptor","score_opus":0.008222028108562434,"score_gpt":0.24559260304440103,"score_spread":0.2373705749358386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161963078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008294547,0.9981958,0.000078157034,0.000373709,0.00031485484,0.0000025930783,0.000009086555,0.0000054757384,0.00093730673],"genre_scores_gemma":[0.0007804754,0.9978137,0.0000983493,0.00017192563,0.00033604263,0.0000044680787,0.000018342196,0.0000011182475,0.00077544077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982077,0.00003577708,0.000022202761,0.00002702845,0.00006911843,0.000025108593],"domain_scores_gemma":[0.9997904,0.00007407064,0.000029825442,0.000006974267,0.000060340244,0.000038552032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004697843,0.0010358923,0.0012687824,0.0017098987,0.00039672927,0.0012367176,0.0009766634,0.0016107277,0.0040036784],"category_scores_gemma":[0.00068575726,0.00025932436,0.0003276402,0.0017248843,0.0007304345,0.0014419669,0.0009514875,0.0019986017,0.0024404086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008362378,0.00007394737,0.00025851576,0.010509605,0.000082669954,0.00030204825,0.000084824496,0.00030650682,0.0017544336,0.0067467205,0.043718353,0.9360787],"study_design_scores_gemma":[0.000011311216,0.000050390317,0.0009935552,0.0022424744,0.000042325155,0.0011524333,0.00006948236,0.00005542565,0.00025800345,0.003740572,0.99136907,0.0000149400785],"about_ca_topic_score_codex":0.0012499582,"about_ca_topic_score_gemma":0.0018946021,"teacher_disagreement_score":0.0040036784,"about_ca_system_score_codex":0.0008261439,"about_ca_system_score_gemma":0.001276229,"threshold_uncertainty_score":0.0133936405},"labels":[],"label_agreement":null},{"id":"W2164258738","doi":"10.1111/dom.12431","title":"Dipeptidyl peptidase‐4 inhibitors and the risk of community‐acquired pneumonia in patients with type 2 diabetes","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Société Francophone du Diabète","keywords":"Medicine; Community-acquired pneumonia; Pneumonia; Odds ratio; Internal medicine; Diabetes mellitus; Dipeptidyl peptidase-4; Incidence (geometry); Cohort study; Cohort; Logistic regression; Type 2 diabetes; Confidence interval; Intensive care medicine; Endocrinology","score_opus":0.00890503614945085,"score_gpt":0.2122461691177736,"score_spread":0.20334113296832276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164258738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604636,0.0029280994,0.000097519296,0.00012381922,0.000028524792,0.0000088061315,0.0003483313,0.0000037958555,0.00041476227],"genre_scores_gemma":[0.9987325,0.0006666872,0.00012652834,0.000055164655,0.000033395743,0.000008615882,0.00028658743,0.0000014324104,0.000089127025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993243,0.00024380375,0.000085759646,0.0001374447,0.0001273789,0.00008135162],"domain_scores_gemma":[0.9974669,0.00063724304,0.0013010603,0.00012817454,0.0001816682,0.00028493252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010674578,0.00027865698,0.0004667315,0.00060022675,0.0002960861,0.00073254283,0.00037245336,0.0006039243,0.0010285155],"category_scores_gemma":[0.0043417183,0.00031977898,0.00082054414,0.0010415824,0.0001861718,0.00037276486,0.00027377438,0.00097496953,0.00010896278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019643463,0.00004220511,0.99851936,0.000018560679,0.00013792513,0.000048140122,0.00001295276,0.000029695231,0.000046815585,0.0000059499985,0.00006428689,0.00087766175],"study_design_scores_gemma":[0.00002865523,0.00012255959,0.99900395,0.000022327911,0.00010912044,0.00023277715,0.000053325333,0.00029127795,0.000024188392,0.000021384567,0.000086395325,0.000004135877],"about_ca_topic_score_codex":0.0067183673,"about_ca_topic_score_gemma":0.006035902,"teacher_disagreement_score":0.0067183673,"about_ca_system_score_codex":0.00034734732,"about_ca_system_score_gemma":0.000369398,"threshold_uncertainty_score":0.013358533},"labels":[],"label_agreement":null},{"id":"W2164465462","doi":"10.1111/j.1463-1326.2006.00578.x","title":"Synergistic effects of conjugated linoleic acid and chromium picolinate improve vascular function and renal pathophysiology in the insulin‐resistant JCR:LA‐ <i>cp</i> rat","year":2006,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chromium effects and bioremediation","field":"Environmental Science","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Ministry of Agriculture and Forestry; University of Alberta","funders":"University of Alberta","keywords":"Pathophysiology; Conjugated linoleic acid; Chromium; Chemistry; Internal medicine; Endocrinology; Insulin; Medicine; Renal function; Insulin resistance; Linoleic acid; Biochemistry; Fatty acid","score_opus":0.0015027588222001757,"score_gpt":0.15605655249945857,"score_spread":0.1545537936772584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164465462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808705,0.00059702987,0.0006043159,0.00010644254,0.00002750223,0.00002157662,0.0001508415,0.00007429675,0.00033103593],"genre_scores_gemma":[0.99317473,0.001001708,0.0025848018,0.00017518096,0.00003249977,0.00007850171,0.00047566925,0.00005707729,0.0024197716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999655,0.000051310515,0.000035633155,0.0000978924,0.0000665567,0.00009359711],"domain_scores_gemma":[0.99920684,0.00004678732,0.00030447228,0.00008940002,0.00006505943,0.00028747538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031307127,0.0010314476,0.0010319189,0.0008893886,0.00032979503,0.00042950912,0.0006000232,0.00083339115,0.001107512],"category_scores_gemma":[0.0002891887,0.0004651758,0.00066902494,0.00040908382,0.0007288449,0.0005518771,0.00031831532,0.0017300113,0.00028804815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010125267,0.0014522937,0.0006981348,0.00009348788,0.00005566005,0.00012238097,0.00003871738,0.000099155346,0.9844023,0.00005756002,0.0000754573,0.002779552],"study_design_scores_gemma":[0.00083199574,0.034849137,0.014465367,0.00003451764,0.00035266046,0.0006448581,0.00016871229,0.0010775126,0.94584805,0.00011633594,0.0015698487,0.00004091354],"about_ca_topic_score_codex":0.001256289,"about_ca_topic_score_gemma":0.0015279666,"teacher_disagreement_score":0.001256289,"about_ca_system_score_codex":0.0004371977,"about_ca_system_score_gemma":0.0004869781,"threshold_uncertainty_score":0.0037050247},"labels":[],"label_agreement":null},{"id":"W2166886145","doi":"10.1111/dom.12527","title":"Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the <scp>AWARD</scp> ‐1 and <scp>AWARD</scp> ‐3 clinical trials","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Type 2 Diabetes Mellitus; Liraglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.07220703135005108,"score_gpt":0.3189510850167525,"score_spread":0.24674405366670144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166886145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840059,0.009416206,0.00037725954,0.00035040712,0.000054722797,0.00025638973,0.0037749892,0.000015196451,0.0017489156],"genre_scores_gemma":[0.99411124,0.0021532637,0.00033056515,0.00026109387,0.000042853706,0.0002616747,0.002595815,0.000004305839,0.00023918091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971854,0.0015367961,0.0004262131,0.00013155992,0.0006116865,0.00010832202],"domain_scores_gemma":[0.9939605,0.002187593,0.002652246,0.00013750653,0.00058607094,0.00047613593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052051586,0.00024849412,0.0010518418,0.0005069127,0.00024319782,0.0005959152,0.00028248914,0.00053762755,0.0016686416],"category_scores_gemma":[0.0056501776,0.00018782374,0.002313302,0.001445598,0.00019478955,0.00038509266,0.000412929,0.0006358227,0.00015372442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032865062,0.00080914295,0.90207446,0.0018397797,0.004941451,0.00005693849,0.000354654,0.0004127099,0.0005644614,0.000051312396,0.0015952485,0.054434687],"study_design_scores_gemma":[0.003168037,0.0047149393,0.9880597,0.0001492577,0.0015518807,0.00012731004,0.00018811795,0.0004919362,0.00019031527,0.00003438642,0.0013007104,0.000023389595],"about_ca_topic_score_codex":0.0017254297,"about_ca_topic_score_gemma":0.002562256,"teacher_disagreement_score":0.0052051586,"about_ca_system_score_codex":0.00036331237,"about_ca_system_score_gemma":0.0003455738,"threshold_uncertainty_score":0.02752781},"labels":[],"label_agreement":null},{"id":"W2171070862","doi":"10.1111/j.1463-1326.2005.00524.x","title":"Glucose control with insulin results in reduction of NF‐κB‐binding activity in mononuclear blood cells of patients with recently manifested type 1 diabetes","year":2005,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Advanced Glycation End Products research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Diabetes Gesellschaft; Heart and Stroke Foundation of Canada","keywords":"Electrophoretic mobility shift assay; Western blot; Internal medicine; Endocrinology; Transcription factor; Peripheral blood mononuclear cell; Insulin; P50; NF-κB; Cytoplasm; Diabetes mellitus; Oxidative stress; Glycation; Biology; Molecular biology; Chemistry; Medicine; Biochemistry; In vitro; Gene; Inflammation","score_opus":0.005343959516033108,"score_gpt":0.21513854388560483,"score_spread":0.2097945843695717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171070862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99925464,0.0004669933,0.00009667692,0.000018125065,0.000006981787,0.0000029248606,0.000034197186,0.0000044976036,0.000114877876],"genre_scores_gemma":[0.9994815,0.00015713793,0.00010549632,0.00002969214,0.000013350636,0.00000481845,0.00009175466,0.0000019921256,0.00011427853],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986494,0.000029521183,0.00001707418,0.000048750153,0.000019075655,0.000020718064],"domain_scores_gemma":[0.99974424,0.000043650558,0.00010636639,0.000015254651,0.000023219784,0.00006727293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015246886,0.00032360796,0.00035028392,0.00026702593,0.0003082966,0.00032348986,0.00011451187,0.00030571537,0.0011240104],"category_scores_gemma":[0.0005478517,0.00015728321,0.00018607987,0.00027491403,0.00014511995,0.00012668858,0.000117623626,0.00034436598,0.00018255015],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056527285,0.00049284514,0.9085651,0.00012244022,0.0001520082,0.002619657,0.00043634372,0.00010548969,0.065955676,0.000027806975,0.0002665261,0.015603376],"study_design_scores_gemma":[0.00009451927,0.0016263012,0.9891038,0.00001584718,0.000098313096,0.005368486,0.00025651773,0.00019487669,0.0026817124,0.000025989953,0.0005260828,0.0000074781774],"about_ca_topic_score_codex":0.00038102665,"about_ca_topic_score_gemma":0.0004004217,"teacher_disagreement_score":0.0011240104,"about_ca_system_score_codex":0.00016408184,"about_ca_system_score_gemma":0.000068346046,"threshold_uncertainty_score":0.0037602186},"labels":[],"label_agreement":null},{"id":"W2171901801","doi":"10.1111/dom.12021","title":"Metformin directly inhibits ghrelin secretion through <scp>AMP</scp> ‐activated protein kinase in rat primary gastric cells","year":2012,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Research Nova Scotia; Canadian Institutes of Health Research; Dalhousie University; Heart and Stroke Foundation of Canada","keywords":"Metformin; AMPK; Ghrelin; Internal medicine; Endocrinology; Orexigenic; Protein kinase A; AMP-activated protein kinase; Secretion; Activator (genetics); Chemistry; Biology; Kinase; Medicine; Hormone; Diabetes mellitus; Receptor; Biochemistry; Neuropeptide","score_opus":0.01653617338224082,"score_gpt":0.2241903325024524,"score_spread":0.2076541591202116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171901801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923929,0.0030514502,0.0014225508,0.00021716404,0.0001277281,0.000035474455,0.00059719285,0.0001286333,0.0020268243],"genre_scores_gemma":[0.98519945,0.0050783963,0.0040492266,0.00013742216,0.000053407144,0.00013130698,0.0018382019,0.000031709962,0.0034807972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998568,0.000025224077,0.000021300299,0.000019860974,0.00003518359,0.00004152842],"domain_scores_gemma":[0.99994826,0.000013504746,0.000012527854,0.000008124602,0.0000054021684,0.000012179409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021808087,0.0004200267,0.00035408512,0.00028798304,0.00021619457,0.0002208006,0.00023642529,0.0002021753,0.001573205],"category_scores_gemma":[0.00009536497,0.0002428255,0.00043343432,0.00020959553,0.00022686334,0.00015483097,0.00015603397,0.0006266225,0.00048447325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068313105,0.0001258737,0.00017292588,0.00008771835,0.000015217804,0.00006966657,0.000015574613,0.000091592185,0.99677306,0.000091120055,0.0001795083,0.0016946488],"study_design_scores_gemma":[0.00017638359,0.00165944,0.0055284183,0.000009504166,0.00004195795,0.00015705545,0.000028648466,0.0009884278,0.98888856,0.000057752903,0.0024572634,0.00000669159],"about_ca_topic_score_codex":0.0012237664,"about_ca_topic_score_gemma":0.0027733082,"teacher_disagreement_score":0.001573205,"about_ca_system_score_codex":0.00033058453,"about_ca_system_score_gemma":0.0003546505,"threshold_uncertainty_score":0.0052629113},"labels":[],"label_agreement":null},{"id":"W2207970920","doi":"10.1111/dom.12624","title":"Patient‐reported outcome results in patients with type 2 diabetes treated with once‐weekly dulaglutide: data from the <scp>AWARD</scp> phase <scp>III</scp> clinical trial programme","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Exenatide; Medicine; Checklist; Type 2 diabetes; Diabetes mellitus; Internal medicine; Quality of life (healthcare); Physical therapy; Psychology; Endocrinology; Nursing","score_opus":0.08649019103364348,"score_gpt":0.31850987965368993,"score_spread":0.23201968862004646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2207970920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931203,0.0027370686,0.00020464126,0.000074258,0.000022071094,0.00016122605,0.0026888098,0.000013517418,0.0009782661],"genre_scores_gemma":[0.99476093,0.00054739113,0.00024682865,0.000098265584,0.000041535593,0.00023692928,0.003753767,0.0000052672144,0.00030914933],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99796045,0.0010493767,0.0003299662,0.00018892752,0.00035439117,0.000116826915],"domain_scores_gemma":[0.99188083,0.003035191,0.0033532383,0.00033742294,0.00067395926,0.00071934896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004842598,0.00038411116,0.0013819003,0.0005939677,0.00022165845,0.00066781393,0.00036025333,0.0006329302,0.0010298677],"category_scores_gemma":[0.0044569448,0.00015359564,0.0019165346,0.0009898097,0.00019582252,0.0005674679,0.00033018264,0.0009246481,0.00017488135],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13583566,0.003267742,0.8028287,0.0012601367,0.0072360425,0.00024735252,0.00032734338,0.0016181131,0.0025059653,0.000054867323,0.0013369807,0.043481052],"study_design_scores_gemma":[0.0064761513,0.02252109,0.9666027,0.0000514073,0.0018651405,0.00021127444,0.00009762911,0.0006718707,0.00056741724,0.000037053076,0.00085248746,0.000045816098],"about_ca_topic_score_codex":0.0007503941,"about_ca_topic_score_gemma":0.0011554577,"teacher_disagreement_score":0.004842598,"about_ca_system_score_codex":0.00030856096,"about_ca_system_score_gemma":0.00029503417,"threshold_uncertainty_score":0.025610387},"labels":[],"label_agreement":null},{"id":"W2267584932","doi":"10.1111/dom.12642","title":"Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12‐month data from the <scp>OpT2mise</scp> randomized trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Medtronic; Novo Nordisk; Sanofi; Eli Lilly and Company","keywords":"Medicine; Insulin pump; Randomization; Randomized controlled trial; Type 2 diabetes; Insulin; Type 1 diabetes; Clinical endpoint; Diabetes mellitus; Internal medicine; Surgery; Anesthesia; Endocrinology","score_opus":0.031649223401205066,"score_gpt":0.2752478400027025,"score_spread":0.24359861660149745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267584932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890022,0.008092702,0.00031181693,0.0004183238,0.00031962388,0.0003999311,0.00063254853,0.0000448936,0.00077793334],"genre_scores_gemma":[0.9920141,0.003501378,0.00076014514,0.000568703,0.00043788244,0.0007273278,0.00101531,0.000014171636,0.0009610441],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99893004,0.0006515552,0.00009885149,0.00014528022,0.00008354366,0.00009067567],"domain_scores_gemma":[0.9984843,0.00054445374,0.00044785542,0.00011097268,0.00007447561,0.00033791587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022320366,0.001042387,0.0030925793,0.0003308926,0.000278202,0.0011912385,0.00060487166,0.0013215799,0.0039836187],"category_scores_gemma":[0.0020391808,0.00041591818,0.0023488018,0.00041211376,0.000544136,0.0007799932,0.00038686697,0.0021161635,0.0004237177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9849902,0.0014274224,0.0013981666,0.00038687172,0.0016197583,0.000016683323,0.000015088867,0.00015511946,0.0006233072,0.000028891205,0.00022022272,0.009118248],"study_design_scores_gemma":[0.94238204,0.04457765,0.00966128,0.000078058125,0.0020457082,0.000039061182,0.000020581108,0.0005076131,0.0002787553,0.000092017945,0.00030304375,0.0000141543505],"about_ca_topic_score_codex":0.00086095487,"about_ca_topic_score_gemma":0.0011768237,"teacher_disagreement_score":0.0039836187,"about_ca_system_score_codex":0.00044095208,"about_ca_system_score_gemma":0.0005159712,"threshold_uncertainty_score":0.013326526},"labels":[],"label_agreement":null},{"id":"W2291499225","doi":"10.1111/dom.12658","title":"Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Seven Oaks General Hospital; Manitoba Health; University of Manitoba; Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research; Western University; Institute for Clinical Evaluative Sciences; London Health Sciences Centre; Lawson Health Research Institute","keywords":"Medicine; Gliclazide; Kidney disease; Metformin; Internal medicine; Diabetes mellitus; Sitagliptin; Rosiglitazone; Thiazolidinedione; Medical prescription; Type 2 diabetes; Glibenclamide; Pioglitazone; Dialysis; Renal function; Population; Saxagliptin; Nephrology; Endocrinology; Pharmacology","score_opus":0.00432910448264221,"score_gpt":0.20576289492310285,"score_spread":0.20143379044046064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291499225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828672,0.002099561,0.000093969174,0.00051050703,0.000015903579,0.000017026989,0.013246327,0.000016088192,0.0011335122],"genre_scores_gemma":[0.9921665,0.0010303142,0.00015774762,0.00018161212,0.00002010536,0.000018066761,0.0059275054,0.0000042713928,0.0004937834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999185,0.000061196486,0.00015630542,0.00015812695,0.00024954276,0.00018976934],"domain_scores_gemma":[0.99694806,0.00012088936,0.0015199154,0.00006401665,0.00095297466,0.00039408193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061850116,0.00021336591,0.0003455387,0.0013368535,0.00046929088,0.00075504684,0.0007872461,0.00061255926,0.0011032168],"category_scores_gemma":[0.0021735716,0.00022116888,0.0006666022,0.0033381998,0.00033206947,0.00051001576,0.0005256249,0.00051009795,0.00021961515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000453062,0.000010332186,0.99815065,0.000030230038,0.00004536206,0.000020377993,0.00007820173,0.000041050513,0.000082559214,0.000011803588,0.00032091554,0.0011632389],"study_design_scores_gemma":[0.0000017990617,0.000008020364,0.99953043,0.000007936182,0.00000857656,0.00002739904,0.000088323555,0.000063849795,0.000017300807,0.0000016364091,0.00024333366,0.0000014665712],"about_ca_topic_score_codex":0.7445087,"about_ca_topic_score_gemma":0.81218565,"teacher_disagreement_score":0.7445087,"about_ca_system_score_codex":0.0055535287,"about_ca_system_score_gemma":0.004632855,"threshold_uncertainty_score":0.5139919},"labels":[],"label_agreement":null},{"id":"W2301357986","doi":"10.1111/dom.12661","title":"Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( <scp>BEGIN</scp> : <scp>ADD TO GLP</scp> ‐1 <scp>S</scp> tudy)","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Placebo; Metformin; Insulin degludec; Type 2 diabetes; Internal medicine; Diabetes mellitus; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.0085891965301117,"score_gpt":0.23521407583377166,"score_spread":0.22662487930365996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301357986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308854,0.0039906586,0.0002349312,0.00031093688,0.0004150432,0.00086741836,0.00022289195,0.00007177156,0.0007978008],"genre_scores_gemma":[0.9921715,0.0028267484,0.0011634617,0.00071794994,0.0003991726,0.0010141258,0.000375701,0.000015295996,0.0013160259],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994252,0.0003105512,0.00006330609,0.00010084612,0.000039329614,0.00006093198],"domain_scores_gemma":[0.9991436,0.0002669897,0.00023628992,0.00006586939,0.000042975655,0.00024423227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014945278,0.001240448,0.002629326,0.0003994592,0.0003345936,0.0011182091,0.0006829281,0.0016750244,0.0035238955],"category_scores_gemma":[0.001812764,0.00072435034,0.0018271132,0.00035630426,0.0008168233,0.00086091296,0.00035651473,0.002428101,0.00054943305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97973824,0.0049087196,0.00042911366,0.0004882944,0.0005604998,0.000022553388,0.00002940215,0.00013251267,0.00217387,0.000021565751,0.00017579485,0.011319405],"study_design_scores_gemma":[0.89882493,0.097286984,0.0019695344,0.000045655772,0.00055368495,0.000028262177,0.000020029152,0.0003612563,0.0005907967,0.000033640707,0.00027105527,0.000014219927],"about_ca_topic_score_codex":0.00073034706,"about_ca_topic_score_gemma":0.0013966729,"teacher_disagreement_score":0.0035238955,"about_ca_system_score_codex":0.00048946735,"about_ca_system_score_gemma":0.0007387851,"threshold_uncertainty_score":0.011788547},"labels":[],"label_agreement":null},{"id":"W2311186584","doi":"10.1111/dom.12666","title":"Long‐term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; AstraZeneca (Canada); St. Michael's Hospital","funders":"National Institutes of Health; Servier; National Institute of General Medical Sciences; Intarcia Therapeutics; Sanofi; MannKind Corporation; AstraZeneca","keywords":"Dapagliflozin; Medicine; Type 2 Diabetes Mellitus; Disease; Diabetes mellitus; Term (time); Internal medicine; Type 2 diabetes; Intensive care medicine; Endocrinology","score_opus":0.005550549728598769,"score_gpt":0.19105456191078776,"score_spread":0.18550401218218898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311186584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823883,0.015925521,0.00045076478,0.00016713057,0.00006284562,0.00010447519,0.00026321175,0.000020455374,0.0006171424],"genre_scores_gemma":[0.9969068,0.001658814,0.00036823493,0.00022323037,0.00011414232,0.00009950126,0.00045741608,0.0000027384374,0.00016916697],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99892235,0.00046845136,0.00016899926,0.00016469129,0.00019385637,0.00008173128],"domain_scores_gemma":[0.99762964,0.0008101575,0.0009430393,0.0001626407,0.00015532343,0.00029912117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004502127,0.00038507042,0.00178281,0.00024586736,0.00025507013,0.00063743454,0.00034301472,0.00056605856,0.0010104005],"category_scores_gemma":[0.0033974277,0.00021967755,0.001170418,0.00037392572,0.00028007955,0.0006861871,0.00032292318,0.0009993775,0.00012397389],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5016706,0.008176397,0.20244393,0.0022262514,0.011228633,0.00023526314,0.00023176565,0.0017864939,0.016680473,0.00008122084,0.0012250673,0.25401378],"study_design_scores_gemma":[0.07273593,0.21072099,0.6978431,0.00036053703,0.007956471,0.0008145259,0.00013213842,0.0022680082,0.0043799547,0.00020739301,0.0025177703,0.00006317968],"about_ca_topic_score_codex":0.00034060044,"about_ca_topic_score_gemma":0.00070756645,"teacher_disagreement_score":0.004502127,"about_ca_system_score_codex":0.00034573954,"about_ca_system_score_gemma":0.0004856731,"threshold_uncertainty_score":0.02380985},"labels":[],"label_agreement":null},{"id":"W2335878298","doi":"10.1111/dom.12640","title":"Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Agonist; Pharmacology; Internal medicine; Exenatide; Type 2 diabetes; Gastroenterology; Endocrinology; Receptor; Diabetes mellitus","score_opus":0.0069009306933684855,"score_gpt":0.22579742792270516,"score_spread":0.21889649722933668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335878298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849725,0.0008255178,0.0001079435,0.000032037507,0.000007103023,0.000013827616,0.000055458888,0.000004552438,0.0004562796],"genre_scores_gemma":[0.9995096,0.00019522637,0.000083640945,0.000053051557,0.000011893676,0.0000071415807,0.00006674417,0.0000012067968,0.000071477785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993943,0.00024117381,0.00008953642,0.00008947701,0.0001383494,0.000047122034],"domain_scores_gemma":[0.99837226,0.00044894472,0.00082634465,0.00007800448,0.000098946686,0.00017556365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084214826,0.00012710555,0.0004947258,0.00030161944,0.00022169015,0.000410228,0.00012266453,0.0002801004,0.00075484684],"category_scores_gemma":[0.0023786216,0.0001361617,0.00029050102,0.0003548231,0.00014828856,0.00033763304,0.00016800352,0.00043119394,0.00008663867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00206358,0.00018859007,0.9797651,0.00004464982,0.000102626786,0.00026421735,0.00007557525,0.000074658376,0.0023502712,0.000017415658,0.00013003379,0.014923285],"study_design_scores_gemma":[0.00015836857,0.0022214095,0.9946976,0.000012068326,0.000082076265,0.0015466332,0.00008060961,0.0002957087,0.0004468753,0.000025658206,0.00042771755,0.0000053764215],"about_ca_topic_score_codex":0.00042123903,"about_ca_topic_score_gemma":0.000678153,"teacher_disagreement_score":0.00084214826,"about_ca_system_score_codex":0.0001670322,"about_ca_system_score_gemma":0.00017261766,"threshold_uncertainty_score":0.0044537783},"labels":[],"label_agreement":null},{"id":"W2336303226","doi":"10.1111/dom.12678","title":"Antiresorptive therapy and newly diagnosed diabetes in women: a historical cohort study","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; McGill University; University of Manitoba","funders":"World Health Organization; Amgen","keywords":"Medicine; Diabetes mellitus; Cohort; Internal medicine; Confidence interval; Cohort study; Body mass index; Osteoporosis; Hazard ratio; Bone mineral; Endocrinology","score_opus":0.017910708368926196,"score_gpt":0.2711527590035123,"score_spread":0.2532420506345861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336303226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798644,0.000479258,0.0000833359,0.000051347928,0.0000091110605,0.000022518972,0.00081783725,0.0000034269399,0.00054664933],"genre_scores_gemma":[0.9984962,0.0004594321,0.00009065323,0.00005094102,0.000016053045,0.000014971105,0.000610309,0.0000021516971,0.00025921525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99959,0.00008550385,0.000032805103,0.0001437179,0.00007201588,0.000076013384],"domain_scores_gemma":[0.9992331,0.000089849396,0.00026761318,0.00010619913,0.00009951788,0.00020368026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008361967,0.00031114282,0.00031579947,0.0007333031,0.0008238967,0.0006399015,0.00049672154,0.00041320384,0.0016186251],"category_scores_gemma":[0.0014856204,0.00045204363,0.00048606936,0.001126701,0.0003556059,0.00041233227,0.0004347921,0.0005673316,0.00025219034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017462783,0.00005250914,0.99873286,0.000009976935,0.0000952148,0.0000827164,0.00007978478,0.000019400906,0.000101270016,0.000020685708,0.000093974304,0.0005370484],"study_design_scores_gemma":[0.000042094776,0.00024062034,0.9984567,0.000014973855,0.00013030713,0.00030843387,0.00018499742,0.00015109924,0.000033987788,0.000026326692,0.00040535795,0.000005122758],"about_ca_topic_score_codex":0.049244132,"about_ca_topic_score_gemma":0.0474965,"teacher_disagreement_score":0.049244132,"about_ca_system_score_codex":0.0005696548,"about_ca_system_score_gemma":0.00056484964,"threshold_uncertainty_score":0.097914994},"labels":[],"label_agreement":null},{"id":"W2341277771","doi":"10.1111/dom.12679","title":"Gastrointestinal safety across the albiglutide development programme","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline","keywords":"Liraglutide; Placebo; Tolerability; Medicine; Nausea; Vomiting; Internal medicine; Gastroenterology; Adverse effect; Type 2 diabetes; Endocrinology; Diabetes mellitus","score_opus":0.013575770224160314,"score_gpt":0.23616941183591605,"score_spread":0.22259364161175574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341277771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5358205,0.07721765,0.035433017,0.040053286,0.003751502,0.019106628,0.017108688,0.008666952,0.26284176],"genre_scores_gemma":[0.72735715,0.029722575,0.04552418,0.024419993,0.0029138485,0.007913855,0.032254625,0.0011550473,0.12873867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99757856,0.0009694936,0.00014398457,0.00021787785,0.00090710004,0.00018294911],"domain_scores_gemma":[0.99620456,0.00045087523,0.00064598536,0.00032005503,0.001518149,0.00086032663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006749,0.00040054292,0.000490819,0.0007157142,0.00046840063,0.0010781253,0.00086522923,0.00097605324,0.010047222],"category_scores_gemma":[0.0052830926,0.000227997,0.00063779304,0.0005053149,0.00036374887,0.00062472327,0.0010696036,0.0014697578,0.0030126183],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012405167,0.0019072979,0.010319875,0.0014680913,0.00022181896,0.00046408668,0.00020100099,0.0006690152,0.02718621,0.0014443159,0.06608683,0.87762624],"study_design_scores_gemma":[0.010873075,0.025555808,0.053625442,0.0010705299,0.00064486667,0.0023039798,0.000104744526,0.0014434791,0.026751505,0.000932958,0.8766253,0.000068401714],"about_ca_topic_score_codex":0.0013662004,"about_ca_topic_score_gemma":0.0018868903,"teacher_disagreement_score":0.010047222,"about_ca_system_score_codex":0.0010532446,"about_ca_system_score_gemma":0.0027995193,"threshold_uncertainty_score":0.035692573},"labels":[],"label_agreement":null},{"id":"W2387599933","doi":"10.1111/dom.12684","title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"Janssen Research and Development; Roche; Novartis; Novo Nordisk; Sanofi; GlaxoSmithKline; Merck; Bristol-Myers Squibb; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Amgen; Pfizer","keywords":"Canagliflozin; Sitagliptin; Metformin; Medicine; Sitagliptin Phosphate; Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Pharmacology","score_opus":0.006258163269643421,"score_gpt":0.20136252006855904,"score_spread":0.1951043567989156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2387599933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967623,0.002420129,0.00014510163,0.00007357405,0.000036312857,0.0001510321,0.000076780314,0.000014382004,0.0003203323],"genre_scores_gemma":[0.997931,0.00088336045,0.00042378402,0.00022402132,0.0000739539,0.00014137162,0.00018517672,0.000002567016,0.00013468116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992557,0.00032993063,0.00011788747,0.00011589466,0.00013331318,0.000047246886],"domain_scores_gemma":[0.9987386,0.00048682076,0.00038366733,0.0000974852,0.000072306604,0.00022125462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016964313,0.0005005799,0.0017535565,0.00028215995,0.00017015383,0.0005161202,0.00042319982,0.0006970682,0.0013800195],"category_scores_gemma":[0.0024401613,0.00025466576,0.0009746161,0.0003127953,0.00043668723,0.0005425455,0.00026621885,0.0011646992,0.00018223432],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8415411,0.012871139,0.024167616,0.0010595595,0.002839597,0.00013145918,0.00014888238,0.0015069477,0.01416885,0.00006530344,0.0005078959,0.10099168],"study_design_scores_gemma":[0.45731032,0.44650543,0.08528096,0.00012468618,0.0024135378,0.0004168802,0.00009973097,0.0033734804,0.0031158559,0.00013536829,0.0011760418,0.000047797166],"about_ca_topic_score_codex":0.0003408785,"about_ca_topic_score_gemma":0.000580105,"teacher_disagreement_score":0.0017535565,"about_ca_system_score_codex":0.00033412533,"about_ca_system_score_gemma":0.00032557733,"threshold_uncertainty_score":0.008971751},"labels":[],"label_agreement":null},{"id":"W2388825372","doi":"10.1111/dom.12689","title":"Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global <scp>HAT</scp> study","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Science and Engineering Research Board; Novo Nordisk; National Institute for Health and Care Research; Boehringer Ingelheim; Medtronic; Sanofi; Medpace; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Insulin; Type 2 diabetes; Type 1 diabetes; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.009119883461574484,"score_gpt":0.23512112988095865,"score_spread":0.22600124641938416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2388825372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982948,0.00027300956,0.000049119622,0.000020480871,0.00000704658,0.000011669971,0.0011144271,0.0000031635213,0.00022633243],"genre_scores_gemma":[0.99819714,0.00021239476,0.000065661,0.00002644227,0.000010185308,0.000021824626,0.0013449731,0.0000024292797,0.00011893367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992725,0.00026474585,0.0000988602,0.0001687267,0.00010786538,0.000087386456],"domain_scores_gemma":[0.99795085,0.00030837877,0.0011626135,0.00013060094,0.00017356781,0.00027397368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010608642,0.00054785673,0.0005754985,0.0008646486,0.0003463287,0.00084388256,0.00045586962,0.00065890467,0.0008203775],"category_scores_gemma":[0.0018431811,0.0006574096,0.00086259266,0.0015499229,0.00031280005,0.0006043299,0.0007374644,0.00068638206,0.00022509269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009560949,0.000023854935,0.9991955,0.000011721164,0.000065362925,0.000030242094,0.0000753167,0.000028349114,0.000032153912,0.0000027948527,0.00007486626,0.00036426194],"study_design_scores_gemma":[0.000021906853,0.00013938031,0.9991623,0.00000790901,0.000038330316,0.0001228974,0.00026749368,0.00010719363,0.000022140366,0.0000050040926,0.00010046025,0.0000049928426],"about_ca_topic_score_codex":0.009975367,"about_ca_topic_score_gemma":0.0076560755,"teacher_disagreement_score":0.009975367,"about_ca_system_score_codex":0.00030265123,"about_ca_system_score_gemma":0.0002388731,"threshold_uncertainty_score":0.019834638},"labels":[],"label_agreement":null},{"id":"W2463959854","doi":"10.1111/dom.12736","title":"Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes ( <scp>LIRA‐SWITCH</scp> ): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novo Nordisk","keywords":"Liraglutide; Sitagliptin; Medicine; Clinical endpoint; Metformin; Type 2 diabetes; Sitagliptin Phosphate; Internal medicine; Weight loss; Randomized controlled trial; Urology; Endocrinology; Gastroenterology; Diabetes mellitus; Obesity","score_opus":0.014695607301590724,"score_gpt":0.2412439360185757,"score_spread":0.22654832871698496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463959854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651873,0.0013720307,0.00016321619,0.00016836783,0.000115090625,0.0006820052,0.00033574417,0.000044961736,0.0005999611],"genre_scores_gemma":[0.9951031,0.0009932868,0.00054604345,0.0005018136,0.00024672478,0.0011010201,0.00063878525,0.000010420998,0.0008587856],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999361,0.0003094572,0.00005807014,0.00012872224,0.0000635676,0.00007923332],"domain_scores_gemma":[0.999041,0.00023526423,0.0003112144,0.0000840781,0.00005662227,0.0002718639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001673792,0.001182834,0.0020624492,0.00028864387,0.00033204033,0.00090738625,0.0005924473,0.0016042412,0.0040957048],"category_scores_gemma":[0.0011961841,0.0004790008,0.0016948363,0.0002620174,0.000738929,0.00054368156,0.00025914417,0.0019760733,0.0006955973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97944045,0.005260445,0.0009801608,0.00032730715,0.0006600292,0.000023060087,0.000030942854,0.00016912851,0.0027428116,0.000021407137,0.00027521234,0.010069073],"study_design_scores_gemma":[0.9209264,0.073879585,0.0037121433,0.000024457939,0.000420861,0.000033001263,0.000012236335,0.00025119775,0.000508732,0.000033619854,0.00018754814,0.000010249146],"about_ca_topic_score_codex":0.0007808015,"about_ca_topic_score_gemma":0.0012753255,"teacher_disagreement_score":0.0040957048,"about_ca_system_score_codex":0.0005418861,"about_ca_system_score_gemma":0.00075647817,"threshold_uncertainty_score":0.0137014985},"labels":[],"label_agreement":null},{"id":"W2466620119","doi":"10.1111/dom.12687","title":"Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and &lt;65 years","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Gerontology; Exenatide; Endocrinology","score_opus":0.005353490245852348,"score_gpt":0.19682980196859595,"score_spread":0.1914763117227436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466620119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96831053,0.029164314,0.00034930138,0.00016331972,0.00010076837,0.00015966596,0.00056511484,0.000030690175,0.0011562259],"genre_scores_gemma":[0.99611485,0.0025311126,0.00023321448,0.00023606663,0.0000875155,0.000077592056,0.0005280423,0.0000041278313,0.00018735952],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992625,0.00032845297,0.00011916478,0.00013569712,0.0001017166,0.00005253423],"domain_scores_gemma":[0.998453,0.00046538367,0.000664847,0.000097707016,0.0001295739,0.00018944126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027583058,0.0003237533,0.0017919163,0.0002515722,0.00022263892,0.000830038,0.00023006099,0.00048528926,0.0011882144],"category_scores_gemma":[0.0025301243,0.00017612369,0.002053379,0.00041055158,0.00017832214,0.00046679468,0.00020091084,0.0006878246,0.00012922368],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46526796,0.002729871,0.20874031,0.0042786296,0.03097134,0.00037275086,0.00041275186,0.002394368,0.015771976,0.00015009567,0.0021792508,0.26673073],"study_design_scores_gemma":[0.12189605,0.12543988,0.724912,0.00051695545,0.017952386,0.0011104349,0.00023547655,0.0014268522,0.0022759084,0.00021811276,0.003941133,0.000074817835],"about_ca_topic_score_codex":0.0007926006,"about_ca_topic_score_gemma":0.0019454317,"teacher_disagreement_score":0.0027583058,"about_ca_system_score_codex":0.00040984616,"about_ca_system_score_gemma":0.00040276657,"threshold_uncertainty_score":0.014587522},"labels":[],"label_agreement":null},{"id":"W2467997778","doi":"10.1111/dom.12739","title":"Glucocorticoid‐induced hyperglycaemia in respiratory disease: a systematic review and meta‐analysis","year":2016,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Medical Research Council Canada","keywords":"Glucocorticoid; Placebo; Relative risk; Medicine; Meta-analysis; Diabetes mellitus; Confidence interval; Internal medicine; Randomized controlled trial; Endocrinology; Pathology","score_opus":0.041734381447298144,"score_gpt":0.3250469359214884,"score_spread":0.2833125544741903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467997778","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014815668,0.9977653,0.00017244653,0.000087046705,0.00007272838,0.000101827616,0.00017525807,0.0000096644335,0.00013415351],"genre_scores_gemma":[0.054500684,0.9431421,0.0009359916,0.00041858194,0.00013783532,0.000349724,0.000329271,0.000011354856,0.0001743833],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994965,0.0024577556,0.001366536,0.00043229072,0.0005884241,0.00019004427],"domain_scores_gemma":[0.9891027,0.008369915,0.001496087,0.00025252992,0.00065003574,0.00012870248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007888838,0.002208125,0.013945918,0.004088992,0.00048358418,0.0024471774,0.0015147879,0.0017692181,0.0032937825],"category_scores_gemma":[0.02103969,0.0010836239,0.023421505,0.005322831,0.00051179354,0.0011424952,0.0010821646,0.0016473391,0.0002326804],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016646596,0.000025688667,0.0022043232,0.63031584,0.34043628,0.00015010276,0.00007763693,0.0004966662,0.00020361728,0.0001818356,0.0011069662,0.023136355],"study_design_scores_gemma":[0.00064891623,0.00024735727,0.0043495228,0.0601981,0.92962325,0.00021198869,0.000051516596,0.00018382363,0.00015252644,0.00028205718,0.004022026,0.000028847913],"about_ca_topic_score_codex":0.006835327,"about_ca_topic_score_gemma":0.015484103,"teacher_disagreement_score":0.013945918,"about_ca_system_score_codex":0.0024240194,"about_ca_system_score_gemma":0.002867445,"threshold_uncertainty_score":0.04172069},"labels":[],"label_agreement":null},{"id":"W2494432242","doi":"10.1111/dom.12741","title":"One‐year efficacy and safety of saxagliptin add‐on in patients receiving dapagliflozin and metformin","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"AstraZeneca","keywords":"Saxagliptin; Dapagliflozin; Placebo; Metformin; Medicine; Internal medicine; Adverse effect; Glycated haemoglobin; Type 2 diabetes; Diabetes mellitus; Endocrinology; Sitagliptin; Insulin","score_opus":0.009020959823222884,"score_gpt":0.21245615479370644,"score_spread":0.20343519497048357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494432242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99859446,0.00085844327,0.000057435078,0.00004895514,0.000031602445,0.00004667827,0.0000997045,0.000007686142,0.0002550992],"genre_scores_gemma":[0.9986349,0.00040119284,0.00011316596,0.00013041034,0.000072809664,0.000056403383,0.00035265632,0.0000017467063,0.00023668687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99918693,0.00032238427,0.00009627237,0.00014017583,0.00013148498,0.00012277016],"domain_scores_gemma":[0.99763715,0.0007474953,0.00061791955,0.00017075168,0.00011355102,0.0007130786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030366036,0.000596991,0.0020040292,0.0004181351,0.00032643828,0.00078140665,0.0003356836,0.0009313328,0.0014856912],"category_scores_gemma":[0.0031607163,0.00038660056,0.0023299018,0.00029040023,0.0003992871,0.0007673381,0.00039023953,0.0018332273,0.00022770587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8694323,0.009312358,0.06275126,0.0002624216,0.0025324284,0.00018693232,0.00013366307,0.0010375908,0.004228881,0.0000673608,0.00043113896,0.04962364],"study_design_scores_gemma":[0.13803196,0.37479734,0.47302502,0.0001431484,0.0052503846,0.00040830747,0.00018440024,0.004168654,0.0027033004,0.00020564243,0.00097552326,0.00010621312],"about_ca_topic_score_codex":0.00057754293,"about_ca_topic_score_gemma":0.00077295833,"teacher_disagreement_score":0.0030366036,"about_ca_system_score_codex":0.0005834525,"about_ca_system_score_gemma":0.00063020317,"threshold_uncertainty_score":0.01605928},"labels":[],"label_agreement":null},{"id":"W2516863452","doi":"10.1111/dom.12786","title":"Sitagliptin and risk of fractures in type 2 diabetes: <scp>R</scp> esults from the <scp>TECOS</scp> trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; University of Alberta; St. Michael's Hospital","funders":"Merck Sharp and Dohme; Novo Nordisk; University of Alberta; National Institute for Health and Care Research; Novartis; Bayer; AstraZeneca; Endocrine Society; GlaxoSmithKline; Amgen","keywords":"Medicine; Sitagliptin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.013809678897011743,"score_gpt":0.271004348771971,"score_spread":0.25719466987495926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516863452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97372097,0.019639524,0.00040347097,0.0008683708,0.00026840257,0.00035031306,0.0021903296,0.000020027517,0.0025386203],"genre_scores_gemma":[0.987823,0.0060866824,0.00053951994,0.0005775852,0.00048097275,0.00041630203,0.0028653755,0.000010662749,0.001199934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99922335,0.0004235446,0.00009209595,0.00008681021,0.00011741108,0.00005673607],"domain_scores_gemma":[0.99871254,0.0004474307,0.0004258814,0.00010148704,0.00011836906,0.0001943163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027065675,0.00050464924,0.00084859005,0.00017898546,0.000189287,0.0009090075,0.00028522464,0.00065439,0.0023019218],"category_scores_gemma":[0.002568232,0.00022426172,0.0010469207,0.0003731455,0.00024830655,0.00024894517,0.00025544103,0.00071589253,0.00022771435],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67386055,0.0020117094,0.22890021,0.0032613103,0.013668051,0.00026924667,0.00011977033,0.0010649175,0.0031695268,0.00031616006,0.00788309,0.06547554],"study_design_scores_gemma":[0.34567088,0.03292247,0.578747,0.0009931705,0.026396701,0.00070940016,0.00021082703,0.0032565831,0.0020276576,0.000983675,0.0079975035,0.00008419271],"about_ca_topic_score_codex":0.001316596,"about_ca_topic_score_gemma":0.0030343842,"teacher_disagreement_score":0.0027065675,"about_ca_system_score_codex":0.0002013145,"about_ca_system_score_gemma":0.0005535516,"threshold_uncertainty_score":0.014313877},"labels":[],"label_agreement":null},{"id":"W2517814663","doi":"10.1111/dom.12749","title":"Ezetimibe increases intestinal expression of the <scp>LDL</scp> receptor gene in dyslipidaemic men with insulin resistance","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Ezetimibe; Endocrinology; PCSK9; Internal medicine; LDL receptor; Insulin resistance; Cholesterol; Familial hypercholesterolemia; HMG-CoA reductase; Liver X receptor; Chemistry; Medicine; Insulin; Biology; Reductase; Lipoprotein; Biochemistry; Transcription factor; Nuclear receptor; Gene","score_opus":0.005997450683939614,"score_gpt":0.19873182551777488,"score_spread":0.19273437483383526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517814663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982377,0.0013486827,0.000112638896,0.000050122206,0.000014224958,0.00001586992,0.000037019745,0.000011789419,0.00017181474],"genre_scores_gemma":[0.9985671,0.000576998,0.00027751384,0.0001073773,0.00002920019,0.00002094995,0.000067821085,0.0000028351,0.00035023424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99988353,0.00004992439,0.000008233821,0.000019457779,0.000022844324,0.00001599935],"domain_scores_gemma":[0.99981326,0.00006046046,0.00006545632,0.000009266273,0.000012405662,0.00003918656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034741187,0.0003032115,0.00065375166,0.00015668596,0.000117259995,0.00022424675,0.0001063895,0.0003038826,0.0014215331],"category_scores_gemma":[0.0004893431,0.00024853987,0.00022635733,0.00013190003,0.00020591117,0.0001224642,0.00010355211,0.00036392958,0.00014889298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17103769,0.0024206645,0.10008502,0.00070685643,0.00092182134,0.0005301337,0.00026489806,0.00047048723,0.6597773,0.00007148371,0.0005081528,0.063205466],"study_design_scores_gemma":[0.014190205,0.07377152,0.85884535,0.000043897657,0.0011365666,0.00083738856,0.00023752586,0.0011765725,0.047597256,0.0000793603,0.0020610671,0.000023369677],"about_ca_topic_score_codex":0.00032833687,"about_ca_topic_score_gemma":0.0006120991,"teacher_disagreement_score":0.0014215331,"about_ca_system_score_codex":0.00013122636,"about_ca_system_score_gemma":0.00007749249,"threshold_uncertainty_score":0.0047555566},"labels":[],"label_agreement":null},{"id":"W2528138059","doi":"10.1111/dom.12805","title":"Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: <scp>a</scp> systematic review and meta‐analysis","year":2016,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Boehringer Ingelheim; Amgen","keywords":"Dulaglutide; Exenatide; Medicine; Liraglutide; Internal medicine; Type 2 diabetes; Basal (medicine); Sitagliptin; Meta-analysis; Lixisenatide; Randomized controlled trial; Glucagon-like peptide 1 receptor; Diabetes mellitus; Endocrinology; Insulin; Receptor; Agonist","score_opus":0.03299279135512655,"score_gpt":0.2840780141662557,"score_spread":0.25108522281112916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528138059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056877076,0.9911006,0.0005516991,0.00029859165,0.00027540888,0.00080419984,0.0007983943,0.00004484232,0.0004384808],"genre_scores_gemma":[0.20448154,0.78542244,0.0028652435,0.0015644346,0.0004456889,0.0032253223,0.0012528966,0.000050589042,0.0006917489],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.990413,0.005209387,0.0023457932,0.0007988938,0.0009875516,0.00024544788],"domain_scores_gemma":[0.9853814,0.010915527,0.0023167683,0.00035290784,0.000825019,0.00020835927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013087096,0.002590409,0.0181564,0.004141708,0.0005454294,0.0032574432,0.0018611274,0.0022024822,0.005701675],"category_scores_gemma":[0.026951356,0.0012313096,0.033999838,0.0053204405,0.0006609531,0.0015127222,0.0012395456,0.0017214491,0.00037575318],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029806516,0.000024594114,0.001497944,0.44198418,0.54421216,0.000071422844,0.000049370035,0.0003547984,0.000204997,0.00010637437,0.000663017,0.007850518],"study_design_scores_gemma":[0.001781592,0.00028206574,0.0021085,0.033268664,0.9605312,0.00006855367,0.00003222716,0.00019975664,0.00011460802,0.00015266787,0.001441751,0.000018385665],"about_ca_topic_score_codex":0.006927653,"about_ca_topic_score_gemma":0.013685313,"teacher_disagreement_score":0.0181564,"about_ca_system_score_codex":0.003125003,"about_ca_system_score_gemma":0.0035459641,"threshold_uncertainty_score":0.06921202},"labels":[],"label_agreement":null},{"id":"W2528767427","doi":"10.1111/dom.12789","title":"Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use","year":2016,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Cegep Edouard Montpetit; Montreal Children's Hospital; McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Novo Nordisk; Boehringer Ingelheim; Roche","keywords":"Medicine; Artificial pancreas; Safety profile; Pancreas; Intensive care medicine; Internal medicine; Diabetes mellitus; Endocrinology; Adverse effect; Type 1 diabetes","score_opus":0.020082468594124773,"score_gpt":0.25199060281501506,"score_spread":0.2319081342208903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528767427","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035194985,0.99162745,0.00082969834,0.0019103546,0.0002981899,0.000012892146,0.00006982907,0.000012751161,0.0017194265],"genre_scores_gemma":[0.029216217,0.96424973,0.0022476914,0.0016449355,0.0013795873,0.0000509379,0.00017026956,0.000012597208,0.0010280502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990662,0.0003589356,0.00019614617,0.00009946216,0.00023347244,0.00004587062],"domain_scores_gemma":[0.99781656,0.0013632589,0.00046866343,0.00006607824,0.00019029327,0.00009509886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023575502,0.00031911413,0.0009774109,0.00062382425,0.0001995325,0.0012803687,0.00035777962,0.00071646384,0.0021730743],"category_scores_gemma":[0.0026238682,0.00010890845,0.00073045044,0.0006807555,0.0005526032,0.0011298077,0.00054411107,0.0013731865,0.00065841497],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013717662,0.00009823548,0.0029238544,0.011024318,0.0002677401,0.0006618768,0.00009711119,0.00026253652,0.004309045,0.0036536749,0.0058528497,0.969477],"study_design_scores_gemma":[0.00045351387,0.006857864,0.02348743,0.018788774,0.001968211,0.01870027,0.0006043946,0.00071704906,0.013337946,0.01235115,0.9025892,0.00014421296],"about_ca_topic_score_codex":0.00021008651,"about_ca_topic_score_gemma":0.0003304226,"teacher_disagreement_score":0.0023575502,"about_ca_system_score_codex":0.00036704206,"about_ca_system_score_gemma":0.0006134312,"threshold_uncertainty_score":0.0124681},"labels":[],"label_agreement":null},{"id":"W2529164329","doi":"10.1111/dom.12794","title":"Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes ( <scp>EVIDENCE</scp> ): A double‐blind, randomized, placebo‐controlled clinical trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; Université de Montréal; Montreal Clinical Research Institute; University of Guelph; University of Toronto","funders":"Public Health Agency of Canada; Dairy Farmers of Canada","keywords":"Medicine; Internal medicine; Prediabetes; Glycated hemoglobin; Postprandial; Endocrinology; Type 2 diabetes; Insulin resistance; Placebo; Vitamin D and neurology; Impaired fasting glucose; Insulin; Diabetes mellitus; Glucose tolerance test; Impaired glucose tolerance","score_opus":0.024996536740296546,"score_gpt":0.33947994664678444,"score_spread":0.3144834099064879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529164329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856683,0.007455218,0.00043555544,0.00062275503,0.0007268024,0.003206665,0.0004737103,0.00010542332,0.0013055789],"genre_scores_gemma":[0.9865637,0.0040688626,0.001390333,0.0011501265,0.0006566044,0.0035135397,0.0004695864,0.00001345938,0.0021737337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99924123,0.00040208703,0.000081947685,0.00011892485,0.000073016156,0.00008276829],"domain_scores_gemma":[0.9990631,0.0002983487,0.00018039043,0.00005717418,0.00008782845,0.00031319977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019205716,0.0012158551,0.0030142455,0.00053400756,0.0006860328,0.0010969312,0.00083280326,0.0030183354,0.00456069],"category_scores_gemma":[0.001902368,0.00081454706,0.0015229905,0.00038998586,0.0010636217,0.0006280419,0.00039876314,0.002064072,0.0006395089],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9833333,0.005650578,0.00048459548,0.0005577271,0.00052361924,0.000021681824,0.000021979411,0.00005501793,0.0018586987,0.00002056666,0.0002197349,0.007252504],"study_design_scores_gemma":[0.9266472,0.07029097,0.0017981244,0.000043554133,0.0004040035,0.00002071598,0.000012311584,0.00015307897,0.00034822265,0.00004192249,0.00023150128,0.000008462056],"about_ca_topic_score_codex":0.0012414473,"about_ca_topic_score_gemma":0.0016048775,"teacher_disagreement_score":0.00456069,"about_ca_system_score_codex":0.00038728854,"about_ca_system_score_gemma":0.0010035641,"threshold_uncertainty_score":0.015257001},"labels":[],"label_agreement":null},{"id":"W2544950685","doi":"10.1111/dom.12816","title":"Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase <scp>II</scp> and <scp>III</scp> clinical trials","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Merck Sharp and Dohme; European Association for the Study of Diabetes; Novo Nordisk; Amgen","keywords":"Dulaglutide; Medicine; Insulin glargine; Renal function; Internal medicine; Placebo; Type 2 diabetes; Urology; Endocrinology; Exenatide; Gastroenterology; Diabetes mellitus","score_opus":0.01698268501004133,"score_gpt":0.2805988584911671,"score_spread":0.26361617348112576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544950685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549215,0.03616585,0.00072963437,0.0009673305,0.000525947,0.0016243348,0.0013188518,0.00020834219,0.0035382488],"genre_scores_gemma":[0.9862834,0.0075566065,0.0010165606,0.0014715891,0.00022120758,0.001060189,0.0010630897,0.000028016097,0.0012992681],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9992337,0.00045730776,0.00007724542,0.00008234315,0.00006158013,0.00008788585],"domain_scores_gemma":[0.9988796,0.00032821912,0.0003068651,0.00006548269,0.000105068524,0.00031485784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002662362,0.0007072853,0.002695084,0.000288041,0.00032364717,0.0011251663,0.0004903633,0.0010185796,0.0021938924],"category_scores_gemma":[0.0022112401,0.0003328793,0.0022563536,0.00037670665,0.00029045617,0.0007405783,0.00025512412,0.0020748333,0.00031617063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81388384,0.0077433805,0.0058546895,0.003615681,0.006005579,0.00015527148,0.00015702778,0.0012859317,0.00819393,0.00016439412,0.0049272543,0.14801298],"study_design_scores_gemma":[0.795738,0.16150585,0.03214653,0.0003332242,0.0030354646,0.00022692297,0.000084994565,0.0013785913,0.0013284311,0.00033964482,0.0038249528,0.00005735662],"about_ca_topic_score_codex":0.00059154653,"about_ca_topic_score_gemma":0.0021082659,"teacher_disagreement_score":0.002695084,"about_ca_system_score_codex":0.00045214623,"about_ca_system_score_gemma":0.0005853357,"threshold_uncertainty_score":0.014080048},"labels":[],"label_agreement":null},{"id":"W2548551915","doi":"10.1111/dom.12818","title":"Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL‐6 production in skeletal muscle and reduces insulin resistance in obese diabetic <i>db/db</i> mice","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Adipokines, Inflammation, and Metabolic Diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Montreal Heart Institute","funders":"","keywords":"Metformin; Insulin resistance; Internal medicine; Endocrinology; Insulin; Medicine; Skeletal muscle; Diabetes mellitus; Glucose clamp technique; Glucose uptake; Type 2 diabetes; Pancreatic hormone","score_opus":0.009844989439245503,"score_gpt":0.21901720320158327,"score_spread":0.20917221376233777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548551915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608254,0.0009433596,0.001651009,0.00013312844,0.000109535315,0.00010087354,0.0003353203,0.000083776606,0.00056052115],"genre_scores_gemma":[0.98808146,0.0020461348,0.006503081,0.00020264521,0.0000785008,0.00027312414,0.0008752066,0.000031220727,0.0019086676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998591,0.000014208928,0.000023626291,0.000031936324,0.000027946518,0.000043293832],"domain_scores_gemma":[0.9998698,0.000009683377,0.000043748103,0.000010378012,0.000008154081,0.00005821241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019288479,0.00079040433,0.0008520757,0.00056273455,0.00026287438,0.00045717903,0.00044379872,0.00077949866,0.0014796717],"category_scores_gemma":[0.00011579605,0.000257536,0.0005855436,0.0003206582,0.00042141418,0.00049804477,0.00025937974,0.001657923,0.00027838402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037973057,0.0009981634,0.00022420057,0.00010143419,0.00003585013,0.000060417107,0.00001556961,0.00006305338,0.9913714,0.00006046051,0.00005185195,0.0032203475],"study_design_scores_gemma":[0.0013549433,0.021834418,0.004459144,0.000025903144,0.00023123204,0.00029044514,0.000058261405,0.0005410144,0.969061,0.000044072778,0.0020811849,0.00001833196],"about_ca_topic_score_codex":0.00048069525,"about_ca_topic_score_gemma":0.0010274182,"teacher_disagreement_score":0.0014796717,"about_ca_system_score_codex":0.00028038013,"about_ca_system_score_gemma":0.00033703842,"threshold_uncertainty_score":0.0049500465},"labels":[],"label_agreement":null},{"id":"W2550794647","doi":"10.1111/dom.12821","title":"Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: <scp>A B</scp> ayesian meta‐analysis of survival data","year":2016,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Simon Fraser University; MD Precision (Canada); Precision Nanosystems (Canada); University of British Columbia","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Hazard ratio; Observational study; Placebo; Randomized controlled trial; Relative risk; Myocardial infarction; Stroke (engine); Confidence interval; Sitagliptin; Type 2 diabetes; Diabetes mellitus; Pharmacology; Insulin; Endocrinology; Metformin","score_opus":0.07167600119653196,"score_gpt":0.3062117333737652,"score_spread":0.23453573217723328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550794647","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017749732,0.97914267,0.0010506408,0.00040747735,0.0003371886,0.0003003935,0.0005931382,0.000037720372,0.00038102912],"genre_scores_gemma":[0.42806044,0.56125504,0.0052449694,0.0014328696,0.00068575656,0.0012953802,0.0013351216,0.000045076085,0.0006451847],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99004304,0.0061046276,0.0019113127,0.0007765968,0.00092402654,0.00024034042],"domain_scores_gemma":[0.9892398,0.0076266187,0.0017716167,0.00046387574,0.00073921273,0.00015889168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014967705,0.002454237,0.012081152,0.005457652,0.0005044965,0.0027307966,0.0011547013,0.0018916125,0.0025375772],"category_scores_gemma":[0.020014217,0.0011474201,0.048936702,0.0045300615,0.0005138115,0.0010793168,0.0012197752,0.0016678078,0.00020265143],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032737954,0.00003031179,0.004936015,0.098062485,0.8846219,0.00007067417,0.000032566295,0.0005171316,0.00026446927,0.00008240754,0.00045029973,0.007657903],"study_design_scores_gemma":[0.0010049094,0.00030762207,0.0048186956,0.007131262,0.9852384,0.000067671106,0.000021047388,0.00032112675,0.00013034198,0.00014254887,0.00080165284,0.000014778523],"about_ca_topic_score_codex":0.0043723676,"about_ca_topic_score_gemma":0.008433651,"teacher_disagreement_score":0.014967705,"about_ca_system_score_codex":0.0016243476,"about_ca_system_score_gemma":0.0021109188,"threshold_uncertainty_score":0.07915777},"labels":[],"label_agreement":null},{"id":"W2560424376","doi":"10.1111/dom.12815","title":"Predictors of outcomes in patients with type 2 diabetes in the lixisenatide <scp>GetGoal</scp> clinical trials","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Boehringer Ingelheim; Novo Nordisk; Merck; Sanofi; Roche; GlaxoSmithKline; Janssen Pharmaceuticals; AstraZeneca","keywords":"Medicine; Lixisenatide; Type 2 diabetes; Internal medicine; Placebo; Basal insulin; Basal (medicine); Clinical endpoint; Diabetes mellitus; Insulin; Randomized controlled trial; Glycated hemoglobin; Endocrinology","score_opus":0.02459821376528614,"score_gpt":0.2894897659217755,"score_spread":0.26489155215648935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560424376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8562559,0.13488679,0.0023511904,0.0012285403,0.00030448553,0.0006333816,0.0022827585,0.000039142844,0.0020177567],"genre_scores_gemma":[0.98946476,0.0065938523,0.00094841816,0.0004227152,0.00025049536,0.0005338525,0.0016345195,0.000011568282,0.00013981768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9754142,0.017580535,0.0034705242,0.0013211292,0.0017690576,0.00044446014],"domain_scores_gemma":[0.9671661,0.017446684,0.0120674865,0.0012713624,0.0012752956,0.0007730612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027200555,0.0007128667,0.003125765,0.0008822477,0.00039104014,0.0018458123,0.00052423944,0.0010389546,0.0008065177],"category_scores_gemma":[0.02840342,0.0003849194,0.0045317435,0.0025153859,0.0004545893,0.00086480763,0.0008260293,0.0013783782,0.00009845834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09161284,0.00037188217,0.77689886,0.007038365,0.083166964,0.00023739139,0.0002172368,0.0012893693,0.0008071152,0.00021590856,0.0017932192,0.036350917],"study_design_scores_gemma":[0.01929751,0.011031255,0.8857493,0.0018022986,0.072510965,0.00067420205,0.00031952647,0.0028629221,0.0010544941,0.0010152264,0.0035861793,0.000096213196],"about_ca_topic_score_codex":0.00055842486,"about_ca_topic_score_gemma":0.001096751,"teacher_disagreement_score":0.027200555,"about_ca_system_score_codex":0.0003652937,"about_ca_system_score_gemma":0.00083294295,"threshold_uncertainty_score":0.143852},"labels":[],"label_agreement":null},{"id":"W2563073900","doi":"10.1111/dom.12851","title":"Comparison of exposure response relationship of atrasentan between <scp>N</scp> orth <scp>A</scp> merican and <scp>A</scp> sian populations","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AbbVie","keywords":"Albuminuria; Pharmacodynamics; Placebo; Internal medicine; Medicine; Urology; Type 2 diabetes; Diabetic nephropathy; Endocrinology; Pharmacology; Chemistry; Diabetes mellitus; Pharmacokinetics; Pathology","score_opus":0.035551766309733314,"score_gpt":0.3031542375120466,"score_spread":0.2676024712023133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563073900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986797,0.00050937315,0.00016235991,0.00001826549,0.0000180393,0.00008011348,0.000106858584,0.0000036770296,0.00042156733],"genre_scores_gemma":[0.99871695,0.00025733808,0.00021843374,0.000048622627,0.000028509228,0.000119154356,0.00015573342,0.0000023431792,0.0004529973],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9988631,0.0006492863,0.00009693312,0.00018912132,0.00013623755,0.00006533059],"domain_scores_gemma":[0.9982374,0.0008136834,0.00048931653,0.00014314437,0.00011980536,0.00019660927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00193554,0.00036837938,0.000747864,0.0002144659,0.00010648978,0.00027192922,0.00020058143,0.00034083542,0.0019627933],"category_scores_gemma":[0.0018653488,0.00020619626,0.000919845,0.00021645447,0.00026006193,0.00021982926,0.00017398935,0.00044991268,0.00014676999],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83065295,0.005309735,0.089329705,0.00063997565,0.0045917127,0.000101959544,0.0002939227,0.0010097106,0.033089127,0.00012427465,0.00034328358,0.034513656],"study_design_scores_gemma":[0.03497787,0.4340012,0.514118,0.000040115603,0.003970803,0.00023335055,0.0002605993,0.0019221832,0.008360133,0.0002306392,0.0018306946,0.000054312655],"about_ca_topic_score_codex":0.00061294937,"about_ca_topic_score_gemma":0.00090956764,"teacher_disagreement_score":0.0019627933,"about_ca_system_score_codex":0.00021048471,"about_ca_system_score_gemma":0.00024089677,"threshold_uncertainty_score":0.010236263},"labels":[],"label_agreement":null},{"id":"W2563196695","doi":"10.1111/dom.12840","title":"Metformin in adults with type 1 diabetes: <scp>D</scp> esign and methods of <scp>REducing</scp> with <scp>MetfOrmin V</scp> ascular <scp>A</scp> dverse <scp>L</scp> esions ( <scp>REMOVAL</scp> ): <scp>A</scp> n international multicentre trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; St Joseph's Health Care","funders":"Steno Diabetes Center Copenhagen; Merck KGaA; British Heart Foundation; Juvenile Diabetes Research Foundation United Kingdom","keywords":"Metformin; Medicine; Pharmacology; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.01383300333938595,"score_gpt":0.27210012046824994,"score_spread":0.25826711712886397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563196695","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9118869,0.07062125,0.000991038,0.002559952,0.0014306922,0.0062015303,0.0011010227,0.00009241821,0.0051152357],"genre_scores_gemma":[0.95911306,0.026412483,0.0030486372,0.002879197,0.00087867805,0.0047154096,0.0008542775,0.0000141134415,0.0020840857],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99931395,0.00038377047,0.00009062258,0.00008214958,0.00007600942,0.0000535311],"domain_scores_gemma":[0.9994549,0.00012750103,0.00019448799,0.000031151987,0.000038431783,0.0001535248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018781,0.00065760635,0.0011445764,0.0003960225,0.0003036243,0.0006609572,0.00048312478,0.0011858145,0.0035585368],"category_scores_gemma":[0.0015977374,0.00029569142,0.0011956601,0.00042986567,0.00039554952,0.0005065304,0.00034480257,0.0014123067,0.00032394845],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8210517,0.014232871,0.0051053693,0.0051169,0.002111132,0.00006759146,0.000075922544,0.00031536588,0.003936377,0.00032211354,0.0023650185,0.1452996],"study_design_scores_gemma":[0.8523199,0.12324961,0.016151864,0.00066875963,0.0022910568,0.00008708435,0.000055905133,0.00042026007,0.0010967198,0.0002534419,0.0033814122,0.000024026296],"about_ca_topic_score_codex":0.0009201922,"about_ca_topic_score_gemma":0.002546012,"teacher_disagreement_score":0.0035585368,"about_ca_system_score_codex":0.00039009275,"about_ca_system_score_gemma":0.0008820835,"threshold_uncertainty_score":0.011904538},"labels":[],"label_agreement":null},{"id":"W2563362161","doi":"10.1111/dom.12864","title":"The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy","year":2016,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Ion Transport and Channel Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institutes of Health; Novo Nordisk; Kyowa Hakko Kirin; Boehringer Ingelheim; AstraZeneca; Amgen","keywords":"Medicine; Urology; Type 2 diabetes; Albuminuria; Placebo; Diabetic nephropathy; Metabolite; Diabetes mellitus; Population; Internal medicine; Renal function; Urine; Urinary system; Gastroenterology; Endocrinology; Pharmacology; Pathology","score_opus":0.0016736962902884887,"score_gpt":0.1643762295613279,"score_spread":0.16270253327103942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563362161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440306,0.004505297,0.00015768265,0.00008807006,0.00002827407,0.00006226329,0.00011870441,0.000010772499,0.00062578195],"genre_scores_gemma":[0.9978515,0.0010108975,0.0005014543,0.00013572315,0.000037861417,0.000029757382,0.0001545231,0.0000028993786,0.00027534115],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99912804,0.00048915215,0.00009561716,0.00011121612,0.00009871534,0.00007719144],"domain_scores_gemma":[0.99867344,0.0004704363,0.00045775846,0.0000727573,0.0001080806,0.00021754528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019166332,0.00050978805,0.0019724607,0.00025102877,0.0002246403,0.00048899965,0.00024426566,0.00038743863,0.0009832053],"category_scores_gemma":[0.001930734,0.00020704912,0.0014734414,0.00031100016,0.00019569763,0.00032495838,0.0002929008,0.0007970265,0.00010624797],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51952076,0.009137728,0.26348814,0.0015113868,0.009041555,0.00037944387,0.00031241533,0.0021245813,0.03924017,0.000106864376,0.0004709496,0.15466608],"study_design_scores_gemma":[0.02037154,0.1669512,0.7935753,0.00009820179,0.0055280174,0.0003403453,0.00018137039,0.0015749867,0.00909884,0.00018757474,0.0020376788,0.000054985594],"about_ca_topic_score_codex":0.0005683426,"about_ca_topic_score_gemma":0.0017236384,"teacher_disagreement_score":0.0019724607,"about_ca_system_score_codex":0.00027024536,"about_ca_system_score_gemma":0.00041450773,"threshold_uncertainty_score":0.010136247},"labels":[],"label_agreement":null},{"id":"W2573794142","doi":"10.1111/dom.12873","title":"Dual role of interleukin‐1β in islet amyloid formation and its β‐cell toxicity: <scp>I</scp> mplications for type 2 diabetes and islet transplantation","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Islet; Downregulation and upregulation; Amyloid (mycology); Apoptosis; Cell biology; Transplantation; Chemistry; Endocrinology; Internal medicine; Biology; Insulin; Medicine; Biochemistry","score_opus":0.015709173806033722,"score_gpt":0.2499304910447204,"score_spread":0.23422131723868667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573794142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979761,0.0065541617,0.006360577,0.00051913987,0.0002862291,0.00027906234,0.0014039385,0.0005114848,0.0043244227],"genre_scores_gemma":[0.9839246,0.0034065612,0.006523286,0.00023611629,0.00014209485,0.0005320942,0.0013449498,0.00014372541,0.003746619],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995957,0.000078434314,0.00007161481,0.000078499565,0.00011063215,0.00006520677],"domain_scores_gemma":[0.99970657,0.00004992098,0.00009465291,0.000052299427,0.000024327454,0.000072271294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031103278,0.0009832638,0.00064280315,0.0005764117,0.00030270056,0.0006877237,0.0004560324,0.00074412505,0.0023957288],"category_scores_gemma":[0.00021664794,0.00020618978,0.0004939493,0.00051352044,0.00058118027,0.00040643534,0.00023466976,0.0018596451,0.00067718484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000653719,0.0002643716,0.00014941183,0.00013068646,0.00001819405,0.00023817134,0.000026422325,0.00010676302,0.9949303,0.00021511795,0.00026520618,0.0030015623],"study_design_scores_gemma":[0.00016930209,0.0009509222,0.0015513854,0.000022158436,0.0000589764,0.0008599157,0.000026295205,0.0005759549,0.9921239,0.00008068186,0.0035709557,0.000009562015],"about_ca_topic_score_codex":0.0002750611,"about_ca_topic_score_gemma":0.00041392844,"teacher_disagreement_score":0.0023957288,"about_ca_system_score_codex":0.0003370836,"about_ca_system_score_gemma":0.00035900742,"threshold_uncertainty_score":0.0080145},"labels":[],"label_agreement":null},{"id":"W2574266291","doi":"10.1111/dom.12874","title":"Physician step prescription and monitoring to improve <scp>ARTERial</scp> health ( <scp>SMARTER</scp> ): A randomized controlled trial in patients with type 2 diabetes and hypertension","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cardiovascular Health and Disease Prevention","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute; Jewish General Hospital; Concordia University; St Mary's Hospital Centre; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University; Heart and Stroke Foundation of Canada","keywords":"Medicine; Diabetes mellitus; Medical prescription; Type 2 diabetes; Randomized controlled trial; Internal medicine; Physical therapy; Emergency medicine; Endocrinology","score_opus":0.0074259383247465985,"score_gpt":0.23239505501288055,"score_spread":0.22496911668813394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574266291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870991,0.007984076,0.00032677082,0.0006833666,0.00054549624,0.0017553612,0.00042569474,0.000077027835,0.0011030072],"genre_scores_gemma":[0.98771614,0.004508639,0.0013811968,0.001141353,0.00080443424,0.002721254,0.00042592591,0.000010483018,0.0012905725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99926144,0.00037236064,0.00007525532,0.00011925412,0.000069200105,0.00010238823],"domain_scores_gemma":[0.9990596,0.00029705506,0.00022851692,0.000052802,0.00005158947,0.0003103648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001463117,0.0008774348,0.0026059737,0.00048344518,0.00046332026,0.00096360745,0.0007149421,0.00181081,0.004910688],"category_scores_gemma":[0.001967079,0.00056558964,0.0019353338,0.0005582795,0.0007307735,0.0007834563,0.00043666558,0.0026229776,0.0003579688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96524984,0.012125558,0.0014885213,0.0010715513,0.0016533936,0.00003253813,0.00004795305,0.00018737228,0.00055661355,0.00006276047,0.00043769417,0.017086184],"study_design_scores_gemma":[0.95548034,0.03860213,0.0042310758,0.00007219609,0.0009062905,0.000016691854,0.000025285033,0.00030981743,0.00010208651,0.000060293507,0.00018547052,0.000008316082],"about_ca_topic_score_codex":0.002182267,"about_ca_topic_score_gemma":0.00422427,"teacher_disagreement_score":0.004910688,"about_ca_system_score_codex":0.0004905169,"about_ca_system_score_gemma":0.0010221184,"threshold_uncertainty_score":0.016427875},"labels":[],"label_agreement":null},{"id":"W2574678721","doi":"10.1111/dom.12832","title":"Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 ( <scp>DPP</scp> ‐4) inhibitor omarigliptin or the once‐daily <scp>DPP</scp> ‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Sitagliptin; Medicine; Sitagliptin Phosphate; Metformin; Internal medicine; Randomized controlled trial; Dipeptidyl peptidase-4 inhibitor; Confidence interval; Dipeptidyl peptidase-4; Adverse effect; Type 2 diabetes; Gastroenterology; Saxagliptin; Diabetes mellitus; Pharmacology; Endocrinology; Insulin","score_opus":0.02663838770768699,"score_gpt":0.2781004863912154,"score_spread":0.25146209868352837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574678721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824349,0.0031374802,0.0010566924,0.0009728647,0.0012995941,0.007546207,0.0014019635,0.00012892623,0.0020214242],"genre_scores_gemma":[0.9760786,0.0018285186,0.0029933855,0.0016719641,0.0010132033,0.011120027,0.0016878824,0.000030725794,0.0035755855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978404,0.0014041326,0.00015670169,0.00031769412,0.00011610516,0.00016500911],"domain_scores_gemma":[0.99521184,0.0019786241,0.0009951476,0.00040512613,0.00029178514,0.0011175292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040739453,0.002149529,0.0049679037,0.0005060445,0.00070579664,0.0013185467,0.0013671806,0.003042661,0.011337162],"category_scores_gemma":[0.005102083,0.0010268727,0.0025682002,0.00057532685,0.0021540874,0.0014730197,0.0006641045,0.0037815953,0.0014763803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.994787,0.0024125038,0.00014506424,0.00014059037,0.00033177432,0.000008398578,0.000010304166,0.0000717476,0.00038884665,0.000024537372,0.00010657979,0.0015725786],"study_design_scores_gemma":[0.973161,0.025955187,0.0003004819,0.000009229068,0.00021038984,0.0000073546034,0.0000050687386,0.00014939903,0.00007024913,0.00003908633,0.00008772988,0.0000047163057],"about_ca_topic_score_codex":0.0010341455,"about_ca_topic_score_gemma":0.0016731676,"teacher_disagreement_score":0.011337162,"about_ca_system_score_codex":0.0010487644,"about_ca_system_score_gemma":0.002061814,"threshold_uncertainty_score":0.037926555},"labels":[],"label_agreement":null},{"id":"W2577069570","doi":"10.1111/dom.12880","title":"Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas, single‐hormone artificial pancreas, or sensor‐augmented pump therapy in adults with type 1 diabetes: <scp>A</scp> n open‐label, randomised, crossover, controlled trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital; Université de Montréal; McGill University Health Centre; Montreal Clinical Research Institute; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Artificial pancreas; Hormone; Medicine; Endocrinology; Internal medicine; Insulin; Diabetes mellitus; Glucagon; Pancreas; Crossover study; Type 2 diabetes; Hormone therapy; Type 1 diabetes; Pathology; Cancer","score_opus":0.028269055082034904,"score_gpt":0.27093403592543575,"score_spread":0.24266498084340085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577069570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937915,0.00282562,0.00028103,0.00021578411,0.00031728437,0.0015914754,0.00029932384,0.000044134482,0.000633868],"genre_scores_gemma":[0.9920474,0.0020094945,0.0011094668,0.0004065109,0.00042797156,0.0027239511,0.00033191429,0.000009484619,0.00093373336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99932003,0.00032591444,0.00006974248,0.00014298863,0.000060783324,0.00008058821],"domain_scores_gemma":[0.99887556,0.00036199283,0.0002333413,0.00007306465,0.00006696457,0.00038901326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011838935,0.0013409249,0.0035622197,0.0003962557,0.0004599125,0.00087827834,0.00070724013,0.0017709924,0.0053654816],"category_scores_gemma":[0.0017162691,0.00063435634,0.0019025158,0.00046226816,0.00091341225,0.00068687444,0.00044954766,0.0020007247,0.00049335754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9826433,0.0064873532,0.0006063313,0.0005990005,0.0005551897,0.000019205716,0.000033657518,0.00010410343,0.0008739542,0.000022056516,0.00016707386,0.007888648],"study_design_scores_gemma":[0.9269353,0.0704111,0.0019445505,0.000026007387,0.00024419624,0.000014334564,0.000014766788,0.00014808709,0.00013100947,0.000027091957,0.000097093056,0.00000636187],"about_ca_topic_score_codex":0.001838206,"about_ca_topic_score_gemma":0.002321746,"teacher_disagreement_score":0.0053654816,"about_ca_system_score_codex":0.00061098725,"about_ca_system_score_gemma":0.00097683,"threshold_uncertainty_score":0.017949343},"labels":[],"label_agreement":null},{"id":"W2582426955","doi":"10.1111/dom.12892","title":"Safety and efficacy of <scp>IDegLira</scp> titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: <scp>DUAL VI</scp> randomized clinical trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk; European Foundation for the Study of Diabetes; American Diabetes Association","keywords":"Medicine; Type 2 diabetes; Metformin; Pioglitazone; Liraglutide; Internal medicine; Adverse effect; Diabetes mellitus; Randomized controlled trial; Gastroenterology; Insulin; Urology; Endocrinology","score_opus":0.01647658566892487,"score_gpt":0.2755543898933128,"score_spread":0.259077804224388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582426955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937383,0.0023376122,0.00044589033,0.000244678,0.00026521122,0.0014863331,0.00039960776,0.00006629237,0.0010160493],"genre_scores_gemma":[0.9914824,0.0012825974,0.0015909895,0.0006159204,0.00049580727,0.0025409614,0.00066444336,0.000019662048,0.0013073437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983986,0.00090664654,0.00013941209,0.00029207583,0.00014126749,0.00012206668],"domain_scores_gemma":[0.997969,0.00062742404,0.0006456639,0.00021016152,0.000108894026,0.0004389754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030737782,0.0016713613,0.004001996,0.00045291492,0.00031749424,0.0011786051,0.0008188515,0.0020225095,0.0046234117],"category_scores_gemma":[0.0026041314,0.00084906403,0.0024476375,0.0003861153,0.0010250981,0.0010302303,0.00043168868,0.002811189,0.00076809566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.985557,0.0029102487,0.0005236635,0.00025175812,0.00054613844,0.000014188032,0.000016842952,0.00015837023,0.001787177,0.000025638683,0.00013564699,0.008073362],"study_design_scores_gemma":[0.93892187,0.058517918,0.0013377491,0.000019221055,0.00034703102,0.000020563191,0.0000066773937,0.00030069027,0.00032546214,0.000060476807,0.00013173495,0.0000106792695],"about_ca_topic_score_codex":0.00044164364,"about_ca_topic_score_gemma":0.0008243175,"teacher_disagreement_score":0.0046234117,"about_ca_system_score_codex":0.00059157243,"about_ca_system_score_gemma":0.0007113449,"threshold_uncertainty_score":0.016255915},"labels":[],"label_agreement":null},{"id":"W2583128854","doi":"10.1111/dom.12896","title":"Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"National Health and Medical Research Council; Deakin University","keywords":"Skeletal muscle; Endocrinology; Internal medicine; Corepressor; Insulin; Cardiac function curve; Cardiac muscle; Glucose uptake; Beta oxidation; In vivo; Medicine; Metabolism; Biology; Gene expression; Heart failure; Biochemistry; Gene","score_opus":0.011553266496461776,"score_gpt":0.2606076476147208,"score_spread":0.24905438111825906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583128854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287075,0.0023327132,0.0017803422,0.00015932499,0.00007899233,0.00006435305,0.00089414994,0.000186791,0.0016326949],"genre_scores_gemma":[0.98481166,0.0033421027,0.0033662568,0.00017543626,0.000047657715,0.000114401264,0.0017128602,0.000057617905,0.006371879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987507,0.00001814919,0.000017125267,0.000027671256,0.000031906,0.00002997434],"domain_scores_gemma":[0.99984443,0.000010272429,0.0000621504,0.000012262147,0.000012818795,0.000058061843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018625843,0.00077657006,0.0004492752,0.00044971312,0.00016446703,0.00026849052,0.00028906824,0.0003541837,0.002326102],"category_scores_gemma":[0.00011101621,0.00017878726,0.00027903903,0.00026327747,0.0002858606,0.00030991036,0.00020036868,0.0007827612,0.00034048728],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011957047,0.00015724519,0.00015576636,0.00006549818,0.000013351482,0.000032590026,0.000009549538,0.000054836273,0.996024,0.000047273625,0.000046964553,0.0021972354],"study_design_scores_gemma":[0.00028579193,0.0053876736,0.00864851,0.000020782041,0.000091436545,0.0001701241,0.00004908366,0.0005617196,0.98213744,0.000047796944,0.0025887669,0.000010822355],"about_ca_topic_score_codex":0.00051430735,"about_ca_topic_score_gemma":0.0013404066,"teacher_disagreement_score":0.002326102,"about_ca_system_score_codex":0.00021270069,"about_ca_system_score_gemma":0.00020993133,"threshold_uncertainty_score":0.007781565},"labels":[],"label_agreement":null},{"id":"W2586129535","doi":"10.1111/dom.12902","title":"Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: <scp>H</scp> igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Exenatide; Liraglutide; Medicine; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Gastroenterology; Endocrinology; Insulin glargine; Diabetes mellitus; Urology; Agonist; Receptor","score_opus":0.013362450733565802,"score_gpt":0.2128715142048029,"score_spread":0.19950906347123712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586129535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995403,0.00011145785,0.000038896433,0.000025278407,0.0000022179001,0.0000059290946,0.00012912591,0.0000012589146,0.0001454282],"genre_scores_gemma":[0.9995901,0.000053629043,0.00005571371,0.00003315814,0.0000035520793,0.00000773471,0.00018285513,8.191072e-7,0.000072457886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941146,0.00014472588,0.00012364077,0.00014236721,0.00010383654,0.00007385195],"domain_scores_gemma":[0.99894494,0.00013134864,0.0006825897,0.00005096839,0.000054427204,0.0001357768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068778987,0.00011697845,0.0002958358,0.00067355344,0.00023459057,0.0004443664,0.00022415782,0.00036383627,0.00092924153],"category_scores_gemma":[0.0018828292,0.00013981875,0.00057990325,0.0010416092,0.00012540517,0.00033541775,0.0002790933,0.0003248862,0.00013559252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028493349,0.00007234989,0.9971213,0.000009210001,0.00007959392,0.00002622592,0.000058697606,0.000048186732,0.000110138026,0.0000074914997,0.00005920155,0.0021227272],"study_design_scores_gemma":[0.000023241082,0.00020142054,0.9991345,0.0000071469385,0.000026688502,0.00010792529,0.0001259483,0.00025030234,0.000036238496,0.000013625305,0.00006956229,0.0000035782589],"about_ca_topic_score_codex":0.0041855816,"about_ca_topic_score_gemma":0.0055773146,"teacher_disagreement_score":0.0041855816,"about_ca_system_score_codex":0.0003090108,"about_ca_system_score_gemma":0.0002505202,"threshold_uncertainty_score":0.008322477},"labels":[],"label_agreement":null},{"id":"W2586360876","doi":"10.1111/dom.12858","title":"Chronic liraglutide therapy induces an enhanced endogenous glucagon‐like peptide‐1 secretory response in early type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Liraglutide; Incretin; Medicine; Internal medicine; Endocrinology; Glucagon-like peptide-1; Endogeny; Type 2 diabetes; Context (archaeology); Placebo; Glucagon; Diabetes mellitus; Hormone; Area under the curve; Glucagon-like peptide 1 receptor; Receptor; Agonist; Biology","score_opus":0.025454983720309386,"score_gpt":0.25834506315053946,"score_spread":0.23289007943023007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586360876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99869543,0.00083429867,0.0001296139,0.000027609263,0.0000110799365,0.00002354345,0.000035507368,0.000009646515,0.00023331458],"genre_scores_gemma":[0.9980977,0.0006454759,0.00042653267,0.00013308125,0.000023673456,0.00006682817,0.00013298522,0.0000054073676,0.00046820863],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99984324,0.0000562201,0.000017912798,0.000021018695,0.000025623343,0.00003594533],"domain_scores_gemma":[0.9998524,0.000029969631,0.000036968755,0.000017170014,0.0000067038322,0.000056837827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042319275,0.00029880847,0.00085366936,0.00015226864,0.00014052178,0.00040827194,0.00017100612,0.0003487015,0.00094604975],"category_scores_gemma":[0.00024651497,0.00018321663,0.0003891434,0.00017057,0.00030819935,0.00021469913,0.0001906513,0.0008914095,0.00019338679],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1135841,0.00864001,0.025425635,0.000594685,0.00026134806,0.0005405413,0.00019191368,0.00043082974,0.7696976,0.000102680904,0.0005190238,0.080011666],"study_design_scores_gemma":[0.018354177,0.2945442,0.576248,0.00015033936,0.0005843372,0.0024664449,0.00029162035,0.0015566612,0.10122283,0.00024232615,0.004266808,0.00007235023],"about_ca_topic_score_codex":0.0005204302,"about_ca_topic_score_gemma":0.0011698512,"teacher_disagreement_score":0.00094604975,"about_ca_system_score_codex":0.00024774706,"about_ca_system_score_gemma":0.0002434057,"threshold_uncertainty_score":0.0031648278},"labels":[],"label_agreement":null},{"id":"W2588151434","doi":"10.1111/dom.12904","title":"Treatment with the glucagon receptor antagonist <scp>LY2409021</scp> increases ambulatory blood pressure in patients with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Internal medicine; Placebo; Blood pressure; Ambulatory blood pressure; Endocrinology; Type 2 diabetes; Glycemic; Glycated hemoglobin; Crossover study; Lipid profile; Mean arterial pressure; Ambulatory; Diabetes mellitus; Gastroenterology; Insulin; Heart rate","score_opus":0.00583972582482539,"score_gpt":0.20114962719925142,"score_spread":0.19530990137442603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588151434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943395,0.0044938824,0.00015720757,0.00016125906,0.000084736224,0.00009784904,0.00012245672,0.000045708974,0.00049731595],"genre_scores_gemma":[0.99638605,0.0019910717,0.00054718216,0.00032899884,0.00015313661,0.00010083752,0.00021370666,0.0000068390823,0.00027224727],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971277,0.00014655285,0.000035258792,0.00003728833,0.00004244983,0.00002566025],"domain_scores_gemma":[0.999529,0.00013786159,0.00016438178,0.000023538441,0.00002201752,0.00012314046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007381739,0.00042988616,0.0013339727,0.00014803342,0.00013240497,0.00038603562,0.00025523992,0.00044595133,0.0016858107],"category_scores_gemma":[0.0007990215,0.00021596404,0.00058569846,0.00020038645,0.00022593081,0.0002828872,0.00014319677,0.0008905313,0.00028848872],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70520186,0.016367357,0.020120427,0.0015670029,0.002522802,0.0003265371,0.00012535616,0.0007881786,0.087879464,0.00008300824,0.00176934,0.1632487],"study_design_scores_gemma":[0.349118,0.4652424,0.17016141,0.00012749518,0.0015110525,0.00092636474,0.00011526492,0.0020050413,0.0083716065,0.0001413042,0.0022286207,0.000051404593],"about_ca_topic_score_codex":0.0002957667,"about_ca_topic_score_gemma":0.0006448587,"teacher_disagreement_score":0.0016858107,"about_ca_system_score_codex":0.0001833213,"about_ca_system_score_gemma":0.00025214296,"threshold_uncertainty_score":0.005639553},"labels":[],"label_agreement":null},{"id":"W2588974371","doi":"10.1111/dom.12909","title":"Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp>","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Ezetimibe; PCSK9; Medicine; Statin; Internal medicine; Adverse effect; Diabetes mellitus; Gastroenterology; Urology; Pharmacology; Endocrinology; Cholesterol; Lipoprotein; LDL receptor","score_opus":0.008596369459351293,"score_gpt":0.23169539415642734,"score_spread":0.22309902469707604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588974371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964737,0.0020750475,0.00013389031,0.00010586012,0.000033872537,0.00027943964,0.0004066901,0.000013133239,0.00047836793],"genre_scores_gemma":[0.9968272,0.0008182895,0.00035030083,0.00034893097,0.00009422479,0.00024357403,0.0009214005,0.000005642096,0.0003903934],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99952924,0.0002025878,0.00006262772,0.00008419174,0.000058539354,0.00006277063],"domain_scores_gemma":[0.9990363,0.0001724891,0.00027986692,0.00007059004,0.00009867832,0.00034208357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013113187,0.0007698903,0.0015260115,0.0002892298,0.00023772934,0.0008451105,0.00031569804,0.00057295465,0.0016381292],"category_scores_gemma":[0.0010259701,0.0003409126,0.0020523593,0.00029730977,0.0003185937,0.0003574583,0.00027339018,0.0013256902,0.00024074383],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85945654,0.0073324954,0.051304035,0.0010635012,0.0077395462,0.0002310529,0.00012398521,0.0004864645,0.027213633,0.00007234912,0.0013029923,0.04367331],"study_design_scores_gemma":[0.5153054,0.20203511,0.2588892,0.000110533525,0.012533377,0.0006472861,0.00011106715,0.0017623373,0.0055561364,0.00011702524,0.0028612816,0.00007111966],"about_ca_topic_score_codex":0.00079139613,"about_ca_topic_score_gemma":0.0020156251,"teacher_disagreement_score":0.0016381292,"about_ca_system_score_codex":0.0005053005,"about_ca_system_score_gemma":0.00065506203,"threshold_uncertainty_score":0.0069350004},"labels":[],"label_agreement":null},{"id":"W2591690224","doi":"10.1111/dom.12930","title":"Lixisenatide reduces glycaemic variability in insulin‐treated patients with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi","keywords":"Postprandial; Medicine; Lixisenatide; Internal medicine; Placebo; Diabetes mellitus; Insulin; Basal (medicine); Body mass index; Area under the curve; Type 2 diabetes; Endocrinology; Type 1 diabetes; Basal insulin","score_opus":0.009965807097266683,"score_gpt":0.24702719551059987,"score_spread":0.23706138841333319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591690224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9333361,0.06379671,0.0008934652,0.000277465,0.00013840034,0.00029147128,0.00046677477,0.000060494127,0.00073916535],"genre_scores_gemma":[0.99199957,0.006519119,0.00065016065,0.00018190949,0.00009565008,0.000114715534,0.000301141,0.000006978931,0.00013074065],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9976088,0.0015274157,0.00042081278,0.00017651705,0.00019850282,0.000067987676],"domain_scores_gemma":[0.9973617,0.0009785237,0.0012127684,0.00018332113,0.000113795424,0.00014992445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004220423,0.0006678537,0.0036752475,0.0007748164,0.00019220679,0.00077430526,0.00039117085,0.0006350272,0.0007652317],"category_scores_gemma":[0.0050757728,0.0004058451,0.0033561222,0.0009341002,0.00026017032,0.0005075415,0.00042511514,0.00077336025,0.00007613333],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6178071,0.002903786,0.07834944,0.005836123,0.09197931,0.0002818351,0.00017850533,0.0025190902,0.0084563065,0.00009880533,0.0010231434,0.19056661],"study_design_scores_gemma":[0.26177797,0.17000757,0.48810536,0.0007614026,0.06580938,0.00081100053,0.00024658846,0.004973845,0.003868665,0.00056445034,0.0029311758,0.0001426384],"about_ca_topic_score_codex":0.00050002406,"about_ca_topic_score_gemma":0.0011276342,"teacher_disagreement_score":0.004220423,"about_ca_system_score_codex":0.00040443675,"about_ca_system_score_gemma":0.00040199462,"threshold_uncertainty_score":0.022320032},"labels":[],"label_agreement":null},{"id":"W2600127085","doi":"10.1111/dom.12958","title":"Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Sitagliptin; Medicine; Internal medicine; Endocrinology; Placebo; Metformin; Glycated hemoglobin; Type 2 diabetes; Glucagon receptor; Blood pressure; Lipid profile; Glucagon-like peptide 1 receptor; Glucagon; Diabetes mellitus; Insulin; Receptor","score_opus":0.008540022634781116,"score_gpt":0.21006093675243936,"score_spread":0.20152091411765824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600127085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958877,0.0031363915,0.00010952224,0.00015712398,0.00003062155,0.000037406946,0.00007776562,0.00002398231,0.00053949107],"genre_scores_gemma":[0.9977118,0.0012249326,0.00032208918,0.00025996834,0.000088661836,0.000043380274,0.00016668194,0.0000037001948,0.00017872815],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99982893,0.00007564396,0.000023058625,0.000021468726,0.00003372159,0.000017239257],"domain_scores_gemma":[0.9996444,0.000082269355,0.00016558733,0.000013658662,0.000016677015,0.00007738381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045418664,0.00030231092,0.0007881254,0.00012491705,0.00012224952,0.00029041685,0.00016972491,0.0003047588,0.0011913287],"category_scores_gemma":[0.0005586495,0.00012869087,0.00034734383,0.00017074395,0.00021408913,0.00019686922,0.00010350353,0.0005789232,0.00024264982],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39492747,0.012484969,0.090996884,0.0017406626,0.002600479,0.0009213393,0.00023740588,0.0015922582,0.14933068,0.00018036428,0.0033410813,0.34164643],"study_design_scores_gemma":[0.16242799,0.41595566,0.38450554,0.00020540076,0.0016201398,0.0043691555,0.00022760328,0.004319256,0.021258805,0.00026057754,0.004776401,0.00007348844],"about_ca_topic_score_codex":0.00022562212,"about_ca_topic_score_gemma":0.00068031764,"teacher_disagreement_score":0.0011913287,"about_ca_system_score_codex":0.0001742151,"about_ca_system_score_gemma":0.00020533398,"threshold_uncertainty_score":0.0039853454},"labels":[],"label_agreement":null},{"id":"W2604384839","doi":"10.1111/dom.12960","title":"Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus‐basal insulin regimens: <scp>A</scp> n analysis from the <scp>OpT2mise</scp> randomized trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Glycemic; Medicine; Type 1 diabetes; Insulin; Insulin pump; Diabetes mellitus; Randomized controlled trial; Internal medicine; Bolus (digestion); Type 2 diabetes; Basal (medicine); Univariate analysis; Endocrinology; Gastroenterology; Multivariate analysis; Anesthesia","score_opus":0.01044846833486708,"score_gpt":0.22614072643318736,"score_spread":0.2156922580983203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604384839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959806,0.0029976482,0.00020082438,0.00014660125,0.0000743589,0.00008862844,0.00017142299,0.0000082801,0.00033158626],"genre_scores_gemma":[0.9980216,0.0008101068,0.0003148491,0.00016804303,0.00009042515,0.00008485735,0.00034149698,0.0000022953188,0.00016630399],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99913377,0.0005427159,0.0000890854,0.00008589757,0.00008545618,0.000063167034],"domain_scores_gemma":[0.9984176,0.0007463741,0.0004700472,0.00010035686,0.000050324088,0.00021528806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018079213,0.00049578777,0.0014081274,0.00021424064,0.00016264954,0.0007290752,0.00026512993,0.0005373089,0.0014279962],"category_scores_gemma":[0.0020595,0.00022241275,0.0029645788,0.00041613376,0.0003194295,0.00033423718,0.00020869476,0.0010878599,0.000087056884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87634826,0.0024264813,0.07429061,0.0008752527,0.009746571,0.000081336686,0.000044306078,0.0007110829,0.0025474695,0.00010322369,0.0005887429,0.03223666],"study_design_scores_gemma":[0.49021372,0.09931734,0.3802485,0.00021904368,0.022405116,0.000264817,0.00011168404,0.0039124647,0.0013879613,0.0005501487,0.001301284,0.00006797853],"about_ca_topic_score_codex":0.0005023544,"about_ca_topic_score_gemma":0.0010382734,"teacher_disagreement_score":0.0018079213,"about_ca_system_score_codex":0.00020911446,"about_ca_system_score_gemma":0.00046705682,"threshold_uncertainty_score":0.00956136},"labels":[],"label_agreement":null},{"id":"W2606062157","doi":"10.1111/dom.12980","title":"Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the <scp>LixiLan‐O</scp> trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide ( <scp>iGlarLixi</scp> ) vs insulin glargine and lixisenatide monocomponents","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Medicine; Lixisenatide; Insulin glargine; Glycated hemoglobin; Body mass index; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Basal insulin","score_opus":0.03690419666737692,"score_gpt":0.32483341390899106,"score_spread":0.28792921724161413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606062157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564385,0.0030191268,0.00009776691,0.00014176859,0.000066204346,0.00017173738,0.00018777522,0.0000053940475,0.0006663171],"genre_scores_gemma":[0.9977627,0.00075935124,0.00020852768,0.00017815578,0.00007758541,0.00022353136,0.0004000014,0.000004079846,0.000386039],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99847287,0.0009917021,0.00011644463,0.00014649972,0.000111086396,0.0001614461],"domain_scores_gemma":[0.9980077,0.0009823971,0.00031831063,0.00010675816,0.00008249601,0.0005023595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037890177,0.0006467427,0.0024922227,0.00022644667,0.00018192582,0.0008681203,0.00043569595,0.0010038973,0.0020053897],"category_scores_gemma":[0.0028031894,0.00026573273,0.0025342747,0.0003393634,0.0004574633,0.00077010057,0.000329608,0.0017671107,0.000176205],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9705171,0.0022740583,0.009519614,0.00030709914,0.0020597568,0.00003563587,0.000030812727,0.00039929617,0.0014014903,0.000044080065,0.0002000737,0.013211018],"study_design_scores_gemma":[0.42495614,0.4329242,0.12597997,0.00018430474,0.00949337,0.00014382003,0.00012528173,0.0028345136,0.001905563,0.00035828806,0.0010295792,0.000065009815],"about_ca_topic_score_codex":0.0007343202,"about_ca_topic_score_gemma":0.0015510619,"teacher_disagreement_score":0.0037890177,"about_ca_system_score_codex":0.0004439572,"about_ca_system_score_gemma":0.0007905998,"threshold_uncertainty_score":0.020038486},"labels":[],"label_agreement":null},{"id":"W2607405121","doi":"10.1111/dom.12983","title":"Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from <scp>TECOS</scp>","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Merck","keywords":"Medicine; Sitagliptin; Kidney disease; Sitagliptin Phosphate; Internal medicine; Diabetes mellitus; Cohort; Adverse effect; Type 2 diabetes; Population; Surgery; Endocrinology","score_opus":0.006523128332024438,"score_gpt":0.21133195236320448,"score_spread":0.20480882403118006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607405121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995119,0.00156882,0.00020441796,0.00016260934,0.000028675879,0.00012154278,0.0012650249,0.000009155699,0.0015207641],"genre_scores_gemma":[0.9968766,0.00042994047,0.00020066946,0.00021039488,0.00007017374,0.0001142397,0.0017450792,0.0000033545002,0.00034953747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902105,0.00031096372,0.00013574546,0.00016138109,0.00027379868,0.00009699524],"domain_scores_gemma":[0.9972458,0.00048702484,0.0015079005,0.00014250133,0.00026393385,0.0003529573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028453358,0.0002671311,0.00059664913,0.00035794015,0.00033186658,0.0006923883,0.00018243444,0.0004351514,0.002779743],"category_scores_gemma":[0.0032723679,0.00011696283,0.0011971627,0.0006475118,0.00021949144,0.00034406243,0.00042493947,0.0006058294,0.00018511541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08420483,0.0010251452,0.8578208,0.0008458107,0.0023241246,0.00012569755,0.000144498,0.0004195956,0.00243794,0.00013998737,0.0016998673,0.04881176],"study_design_scores_gemma":[0.0050320034,0.008269924,0.9826105,0.00012512549,0.0010509363,0.00029348477,0.00007875432,0.0003879804,0.00062227383,0.00018771636,0.001321018,0.000020242513],"about_ca_topic_score_codex":0.0011352316,"about_ca_topic_score_gemma":0.0021797079,"teacher_disagreement_score":0.0028453358,"about_ca_system_score_codex":0.0003011637,"about_ca_system_score_gemma":0.0007366802,"threshold_uncertainty_score":0.015047729},"labels":[],"label_agreement":null},{"id":"W2607581455","doi":"10.1111/dom.12986","title":"Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment","year":2017,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Medicine; Lixisenatide; Type 2 diabetes; Internal medicine; Diabetes mellitus; Intensive care medicine; Endocrinology; Liraglutide","score_opus":0.017480152213805566,"score_gpt":0.2692898192023451,"score_spread":0.25180966698853957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607581455","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77255344,0.21416514,0.0021648433,0.0011821993,0.00078358623,0.0021409558,0.002571233,0.00011855666,0.0043200348],"genre_scores_gemma":[0.98628753,0.010079611,0.0010604482,0.0005361541,0.00026294802,0.0004927178,0.00066136237,0.0000122795955,0.0006069931],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609226,0.0025692051,0.00056973647,0.00034954236,0.0002992684,0.00011996478],"domain_scores_gemma":[0.9933122,0.004118301,0.0016546802,0.00030654576,0.000407341,0.00020093565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00980239,0.0010683016,0.004240278,0.00062842754,0.0002887862,0.0012119602,0.0006028935,0.0008948611,0.0026545338],"category_scores_gemma":[0.008321596,0.00044244828,0.00939039,0.0006133,0.00045423102,0.00081747153,0.00048576205,0.0011873529,0.00023639982],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7366593,0.000958771,0.021646889,0.023428157,0.15714656,0.00013529995,0.00012623797,0.0014845835,0.0029656747,0.00013048825,0.00077036803,0.054547757],"study_design_scores_gemma":[0.37004083,0.19785874,0.10139372,0.0030567024,0.30951107,0.0007287696,0.00022707871,0.0031964327,0.005363585,0.0009033428,0.007571242,0.0001485274],"about_ca_topic_score_codex":0.0005795405,"about_ca_topic_score_gemma":0.001582984,"teacher_disagreement_score":0.00980239,"about_ca_system_score_codex":0.00065328233,"about_ca_system_score_gemma":0.0008656857,"threshold_uncertainty_score":0.051840603},"labels":[],"label_agreement":null},{"id":"W2611973976","doi":"10.1111/dom.12963","title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; Novo Nordisk","keywords":"Medicine; Liraglutide; Randomized controlled trial; Phase (matter); Weight management; Internal medicine; Weight loss; Type 2 diabetes; Endocrinology; Diabetes mellitus; Obesity","score_opus":0.014177553145384573,"score_gpt":0.27153404159708555,"score_spread":0.257356488451701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611973976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49230614,0.48651975,0.0028715082,0.003202156,0.0009934604,0.0047022183,0.0042313384,0.00035907736,0.0048143477],"genre_scores_gemma":[0.87439036,0.11124207,0.002757751,0.003483621,0.0009747772,0.003631417,0.0024115832,0.000056101824,0.0010522439],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618405,0.0023003756,0.00064283237,0.0003641631,0.00035933603,0.00014920032],"domain_scores_gemma":[0.9928254,0.0026811738,0.0033129433,0.00033758132,0.00050438073,0.00033841745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0080575,0.0012361842,0.0033298242,0.00072617154,0.0003662584,0.0015390312,0.0007755894,0.0017295866,0.0034172435],"category_scores_gemma":[0.009662338,0.00044139472,0.006425496,0.0009874866,0.00095833465,0.0008896857,0.0003361332,0.0015793721,0.0003912208],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78845185,0.0021770564,0.004717269,0.024843995,0.041546963,0.00015076672,0.00014810252,0.0006996966,0.0043626754,0.00029943194,0.003948661,0.12865357],"study_design_scores_gemma":[0.85767525,0.06551656,0.022811478,0.003489365,0.04234936,0.0003123965,0.00008683695,0.00060189766,0.0015580952,0.00074777333,0.004762563,0.000088393914],"about_ca_topic_score_codex":0.0008097991,"about_ca_topic_score_gemma":0.002135849,"teacher_disagreement_score":0.0080575,"about_ca_system_score_codex":0.00094901095,"about_ca_system_score_gemma":0.0012814618,"threshold_uncertainty_score":0.04261267},"labels":[],"label_agreement":null},{"id":"W2621101635","doi":"10.1111/dom.13028","title":"Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Population Health Research Institute; Université Laval; University of Toronto; Hamilton Health Sciences; McMaster University","funders":"Regeneron Pharmaceuticals; Novo Nordisk; Sanofi; Servier; Amgen; Pfizer; AstraZeneca; Duke Clinical Research Institute; Eli Lilly and Company; Mylan; GlaxoSmithKline","keywords":"Medicine","score_opus":0.02342545171499733,"score_gpt":0.2439605460816667,"score_spread":0.22053509436666938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621101635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7924514,0.006738875,0.010152642,0.0014977098,0.0006557152,0.14592944,0.027668983,0.0001125539,0.014792741],"genre_scores_gemma":[0.6730001,0.0013199722,0.0111173745,0.0043989886,0.00031482455,0.28729045,0.009873153,0.000058923386,0.01262628],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9961022,0.0013093245,0.00036236658,0.0010335449,0.0005044128,0.0006880567],"domain_scores_gemma":[0.9986274,0.00024135859,0.00026542076,0.00014582553,0.00031053007,0.00040942853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004897096,0.0018329892,0.0021993187,0.0009855734,0.0014163926,0.0009507209,0.0012433312,0.0020673226,0.015918855],"category_scores_gemma":[0.0048556617,0.0011861575,0.0013070357,0.0012663123,0.001062451,0.0011646077,0.00075626525,0.0021144815,0.0037925579],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50826144,0.07701892,0.2816421,0.0033105684,0.002740756,0.0016020915,0.0032120333,0.0013757591,0.00859545,0.003215083,0.0171742,0.09185155],"study_design_scores_gemma":[0.19010788,0.26834035,0.46793464,0.0010467471,0.002466538,0.0015098077,0.003096781,0.0030846226,0.0022841769,0.009940028,0.04966316,0.0005252086],"about_ca_topic_score_codex":0.0034134034,"about_ca_topic_score_gemma":0.0038070162,"teacher_disagreement_score":0.015918855,"about_ca_system_score_codex":0.0012412895,"about_ca_system_score_gemma":0.003020876,"threshold_uncertainty_score":0.05325389},"labels":[],"label_agreement":null},{"id":"W2669035283","doi":"10.1111/dom.13040","title":"Glycemic Improvement with a Fixed‐dose combination of <scp>DPP</scp> ‐4 inhibitor + metformin in patients with Type 2 diabetes ( <scp>GIFT</scp> study)","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"","keywords":"Metformin; Medicine; Fixed-dose combination; Type 2 diabetes; Pill; Glycemic; Formulary; Diabetes mellitus; Internal medicine; Pharmacology; Endocrinology","score_opus":0.006730278868638191,"score_gpt":0.21396269146593078,"score_spread":0.20723241259729258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2669035283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990702,0.00048072744,0.000023137683,0.000032936405,0.000014080863,0.000024224324,0.000091892,0.0000033627284,0.00025940707],"genre_scores_gemma":[0.9988955,0.00031674484,0.00017521497,0.00011450032,0.000038283266,0.000022914286,0.00028416558,0.0000010557875,0.00015164488],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99953556,0.00019585056,0.00004962775,0.00006990896,0.0000894853,0.000059558693],"domain_scores_gemma":[0.99924755,0.00014749073,0.0002819586,0.000057127934,0.000049837563,0.0002161355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097177416,0.00024344328,0.00069603557,0.00027268913,0.00026756572,0.00046639726,0.00026452597,0.0003631979,0.0007702198],"category_scores_gemma":[0.0013141187,0.00017107069,0.0007804448,0.0005239005,0.00017155879,0.00028628224,0.00023830483,0.00071147137,0.00011106872],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14177546,0.011106023,0.75243896,0.00038615667,0.0020871966,0.00022575824,0.00019616087,0.00054930657,0.0037176271,0.00004325213,0.0011091706,0.086364925],"study_design_scores_gemma":[0.013767935,0.06734128,0.9155579,0.00003585492,0.00083117664,0.00022752998,0.00012621775,0.0007066574,0.00049645244,0.000043702625,0.0008428551,0.000022559909],"about_ca_topic_score_codex":0.003596609,"about_ca_topic_score_gemma":0.00719405,"teacher_disagreement_score":0.003596609,"about_ca_system_score_codex":0.0006049979,"about_ca_system_score_gemma":0.0005654904,"threshold_uncertainty_score":0.0071513653},"labels":[],"label_agreement":null},{"id":"W2715646815","doi":"10.1111/dom.13043","title":"Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the <scp>DUAL V</scp> randomized trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Insulin degludec; Type 2 diabetes; Insulin glargine; Internal medicine; Weight loss; Insulin; Body mass index; Post-hoc analysis; Basal (medicine); Diabetes mellitus; Endocrinology; Gastroenterology; Obesity","score_opus":0.00983911403288233,"score_gpt":0.2613156423722514,"score_spread":0.25147652833936907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2715646815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843615,0.009815094,0.00055761595,0.0005614148,0.00048970344,0.0011125171,0.0005216238,0.00013430024,0.0024461471],"genre_scores_gemma":[0.99157023,0.0036139386,0.0010697499,0.0008348149,0.00033448578,0.00079152704,0.0005340212,0.000023222787,0.001227895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999203,0.00051568815,0.000057469424,0.00008075124,0.000056336048,0.00008685754],"domain_scores_gemma":[0.99933666,0.00023027115,0.00016712546,0.00004277116,0.000034785775,0.00018839494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024096083,0.0011589576,0.0024102163,0.0003494158,0.00023472344,0.0010013722,0.0004910764,0.000963457,0.0023403338],"category_scores_gemma":[0.0014760105,0.0004448964,0.0021694524,0.00033409218,0.0005853773,0.00067403086,0.00029636399,0.0023145613,0.00030535416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9732755,0.0019719242,0.0008424438,0.0005901153,0.0013449311,0.000037599904,0.000028653754,0.00030682486,0.0021954663,0.00009617904,0.00059189723,0.01871841],"study_design_scores_gemma":[0.9341896,0.059076104,0.002804405,0.00008636264,0.0015186864,0.000059853097,0.000022283097,0.00072093174,0.000685139,0.00013714196,0.0006825504,0.000017031358],"about_ca_topic_score_codex":0.0008505471,"about_ca_topic_score_gemma":0.002088454,"teacher_disagreement_score":0.0024102163,"about_ca_system_score_codex":0.0006285653,"about_ca_system_score_gemma":0.0007251291,"threshold_uncertainty_score":0.012743354},"labels":[],"label_agreement":null},{"id":"W2728705426","doi":"10.1111/dom.13052","title":"The challenges of achieving postprandial glucose control using closed‐loop systems in patients with type 1 diabetes","year":2017,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Children's Hospital; Université de Montréal; Montreal Clinical Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; National Institutes of Health; Juvenile Diabetes Research Foundation International","keywords":"Medicine; Postprandial; Type 2 diabetes; Closed loop; Diabetes mellitus; Internal medicine; Endocrinology; Control engineering","score_opus":0.04845112612589183,"score_gpt":0.3107202422090482,"score_spread":0.2622691160831564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728705426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0553383,0.8002066,0.09340336,0.03462217,0.0021290553,0.000173147,0.00035845704,0.00064519496,0.013123728],"genre_scores_gemma":[0.3637149,0.5320497,0.07901092,0.016755972,0.0036599822,0.0005469949,0.0005470039,0.00018112222,0.0035334085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980394,0.0009501299,0.00023237793,0.00021807622,0.00046378069,0.00009629643],"domain_scores_gemma":[0.9964635,0.002261522,0.0003895671,0.00015607917,0.0006243557,0.00010497484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035124246,0.0005233398,0.0012582451,0.00030221842,0.00023801193,0.0019727722,0.00087970175,0.0011377805,0.0016208614],"category_scores_gemma":[0.0063352883,0.00020775152,0.0006748925,0.00047789715,0.00059410156,0.0014569279,0.00093083346,0.002061211,0.0008129067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012324238,0.00023402477,0.0041863164,0.004769452,0.00021116703,0.0005182415,0.00036398688,0.0043793716,0.0057145776,0.0047591333,0.008295459,0.96533585],"study_design_scores_gemma":[0.00097168685,0.0128729325,0.04674657,0.019777477,0.0015554434,0.0119396085,0.0032450226,0.0462759,0.039522525,0.0776138,0.7388438,0.00063528726],"about_ca_topic_score_codex":0.0012284619,"about_ca_topic_score_gemma":0.0009098709,"teacher_disagreement_score":0.0035124246,"about_ca_system_score_codex":0.0005042283,"about_ca_system_score_gemma":0.0009437573,"threshold_uncertainty_score":0.018575728},"labels":[],"label_agreement":null},{"id":"W2735625114","doi":"10.1111/dom.12935","title":"Improving glycaemic control in type 2 diabetes: <scp>S</scp> timulate insulin secretion or provide beta‐cell rest?","year":2017,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; European Commission; BC Children's Hospital; Canadian Diabetes Association","keywords":"Beta cell; Type 2 diabetes; Insulin; Medicine; Diabetes mellitus; Endocrinology; BETA (programming language); Internal medicine; Bioinformatics; Islet; Biology; Computer science","score_opus":0.032774083468979066,"score_gpt":0.28816430992586856,"score_spread":0.25539022645688947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735625114","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012611768,0.99153477,0.0004168052,0.0032699788,0.0013702641,0.000016881464,0.000088414345,0.000032679196,0.0020090386],"genre_scores_gemma":[0.0058235335,0.9871273,0.00068107387,0.0029747502,0.0013411652,0.000034403864,0.00011913693,0.000011253629,0.0018873541],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977785,0.000066151515,0.00003421137,0.000029888508,0.00007317858,0.000018707693],"domain_scores_gemma":[0.999824,0.00007364361,0.000031077718,0.000008469011,0.00004574219,0.000017061242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052883365,0.00042256006,0.00080076087,0.00049327855,0.00012153887,0.0007492119,0.00050002144,0.0006655986,0.003963196],"category_scores_gemma":[0.0007691529,0.00008227075,0.0004668639,0.00056441186,0.0003205815,0.0008896955,0.00032602804,0.0011421508,0.0014495068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037425166,0.000063515385,0.00018488555,0.02069209,0.0002590957,0.00017278054,0.00011788724,0.00020104191,0.0033252796,0.0046875468,0.046362914,0.9235586],"study_design_scores_gemma":[0.00013638452,0.0005219713,0.001438991,0.008883004,0.0003412422,0.0008330867,0.00013393334,0.0001936292,0.0017104755,0.004768707,0.981006,0.000032522625],"about_ca_topic_score_codex":0.0005514115,"about_ca_topic_score_gemma":0.0013362856,"teacher_disagreement_score":0.003963196,"about_ca_system_score_codex":0.0002896429,"about_ca_system_score_gemma":0.00046896978,"threshold_uncertainty_score":0.013258219},"labels":[],"label_agreement":null},{"id":"W2738470483","doi":"10.1111/dom.13063","title":"Beyond glycaemic control: A cross‐over, double‐blinded, 24‐week intervention with liraglutide in type 1 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Novo Nordisk","keywords":"Medicine; Liraglutide; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.016842916185050797,"score_gpt":0.27087693168449756,"score_spread":0.25403401549944676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738470483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925921,0.0026282563,0.00061817886,0.00024931278,0.00025651985,0.002776573,0.00022557045,0.00007372596,0.0005798106],"genre_scores_gemma":[0.98305607,0.0023751778,0.003588608,0.000659165,0.0002908504,0.0080979075,0.0003170016,0.000020279309,0.0015949947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99890196,0.000628131,0.000117206764,0.00017542593,0.00008964521,0.000087661414],"domain_scores_gemma":[0.9991897,0.00018022669,0.00025668152,0.000081114005,0.000075525415,0.00021678703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024903268,0.0010536481,0.0021067006,0.0004018488,0.0005849891,0.00065093033,0.0007317042,0.0017767779,0.002538001],"category_scores_gemma":[0.0018039682,0.0005362115,0.00081908755,0.00032293488,0.00063142483,0.00057735166,0.0003928626,0.0011977798,0.00043027542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90243036,0.03795504,0.0007158496,0.0011402054,0.000652026,0.000029906221,0.00013403881,0.00023729296,0.012382209,0.00003529703,0.00041902874,0.04386881],"study_design_scores_gemma":[0.7000052,0.28653508,0.008901726,0.00010774993,0.00063849613,0.00003317433,0.00003765373,0.00037040154,0.0023515737,0.000066368244,0.0009284431,0.000024176903],"about_ca_topic_score_codex":0.00080941257,"about_ca_topic_score_gemma":0.0015593212,"teacher_disagreement_score":0.002538001,"about_ca_system_score_codex":0.000456055,"about_ca_system_score_gemma":0.00091520697,"threshold_uncertainty_score":0.013170242},"labels":[],"label_agreement":null},{"id":"W2738689849","doi":"10.1111/dom.13069","title":"Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"Canadian Diabetes Association","keywords":"Glucagon; Internal medicine; Endocrinology; Crossover study; Nasal administration; Chemistry; Glucose clamp technique; Triglyceride; Medicine; Placebo; Insulin; Pancreatic hormone; Cholesterol; Pharmacology; Insulin resistance","score_opus":0.014209217674613837,"score_gpt":0.25399865322804516,"score_spread":0.23978943555343132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738689849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991418,0.00039962406,0.000222023,0.000012018862,0.000015442389,0.00005041566,0.000025672072,0.0000050892136,0.00012781691],"genre_scores_gemma":[0.9987845,0.00018000712,0.00059582887,0.000054891738,0.000033821787,0.00006749571,0.000049615246,0.0000034742707,0.00023038634],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996228,0.0001878426,0.00002117282,0.00007271223,0.000049789665,0.00004554231],"domain_scores_gemma":[0.9991966,0.000326397,0.00016620898,0.00007545639,0.000041443767,0.00019395824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010862605,0.00047342764,0.00064902677,0.0001287067,0.00022931992,0.00028086762,0.00016748226,0.00044513674,0.0013348516],"category_scores_gemma":[0.0012942435,0.00029022532,0.0002198255,0.00015054429,0.000520682,0.00027219145,0.00017953532,0.00053624494,0.00013064167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5853355,0.016986813,0.061990246,0.000731182,0.00038330513,0.0003493573,0.00049033953,0.0005376693,0.2815348,0.00010380578,0.00016771938,0.051389407],"study_design_scores_gemma":[0.008105073,0.6576393,0.27750766,0.000028171078,0.0005017406,0.00032835928,0.00032347886,0.0008893108,0.053725936,0.00009689097,0.0008262082,0.000027820075],"about_ca_topic_score_codex":0.00025336354,"about_ca_topic_score_gemma":0.00028282384,"teacher_disagreement_score":0.0013348516,"about_ca_system_score_codex":0.00015292967,"about_ca_system_score_gemma":0.00022563503,"threshold_uncertainty_score":0.005744815},"labels":[],"label_agreement":null},{"id":"W2739009446","doi":"10.1111/dom.13064","title":"Insights into optimal basal insulin titration in type 2 diabetes: <scp>R</scp> esults of a quantitative survey","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Winnipeg Regional Health Authority","funders":"Sanofi","keywords":"Titration; Medicine; Basal insulin; Type 2 diabetes; Diabetes mellitus; Endocrinology; Chemistry","score_opus":0.03238971050280456,"score_gpt":0.3042466098995466,"score_spread":0.27185689939674207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739009446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530834,0.00010654538,0.00028818933,0.0010767088,0.0000149308535,0.00011852005,0.00072342466,0.0000113954675,0.0023518568],"genre_scores_gemma":[0.9977404,0.00018906733,0.00054121786,0.0005231817,0.000016472268,0.00019092747,0.00047063682,0.000004022676,0.0003242698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953141,0.002757011,0.0005055431,0.00021677793,0.0007743829,0.00043204523],"domain_scores_gemma":[0.9826518,0.008332343,0.00374498,0.00044714016,0.0026420334,0.0021816418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010199003,0.00015858766,0.00022549824,0.0007971681,0.00051812344,0.0013164066,0.0002937008,0.00049486494,0.0018637743],"category_scores_gemma":[0.021871647,0.00017091677,0.00044261236,0.00083801855,0.00043590722,0.0011798842,0.0012157654,0.0007298406,0.0002534684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011724229,0.00039242816,0.9303634,0.00037662522,0.0000781043,0.00014250836,0.027920177,0.00021772433,0.00031972898,0.00024462296,0.0049830563,0.034844324],"study_design_scores_gemma":[0.000028757164,0.00049537397,0.944353,0.00023396102,0.000021638714,0.00012669333,0.047732674,0.00076404033,0.00013010796,0.00014073982,0.00594582,0.000027379527],"about_ca_topic_score_codex":0.006961215,"about_ca_topic_score_gemma":0.005735277,"teacher_disagreement_score":0.010199003,"about_ca_system_score_codex":0.001322521,"about_ca_system_score_gemma":0.0020195665,"threshold_uncertainty_score":0.05393809},"labels":[],"label_agreement":null},{"id":"W2746628081","doi":"10.1111/dom.13086","title":"Effect of once‐weekly dulaglutide on glycated haemoglobin ( <scp>HbA1c</scp> ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline <scp>HbA1c</scp>","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Internal medicine; Diabetes mellitus; Confidence interval; Glycated hemoglobin; Type 2 diabetes; Gastroenterology; Glycated haemoglobin; Adverse effect; Endocrinology; Liraglutide","score_opus":0.01035491514470968,"score_gpt":0.23737268121278995,"score_spread":0.22701776606808027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746628081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95112634,0.046031922,0.00034622822,0.00030575506,0.00032211674,0.00022771637,0.0006246844,0.00008620986,0.00092909375],"genre_scores_gemma":[0.99245644,0.005298519,0.00037863106,0.00045218898,0.00013234775,0.00017489807,0.00040222413,0.000012952559,0.00069178373],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9989104,0.0005337868,0.00013134647,0.00022588034,0.00010586436,0.00009275982],"domain_scores_gemma":[0.99836487,0.000562172,0.0006072109,0.00012225875,0.000112886075,0.00023055502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002415519,0.0008338697,0.0040687444,0.00039121145,0.00019877276,0.0009884071,0.0005161662,0.00090043165,0.0021155002],"category_scores_gemma":[0.0033157398,0.00047632807,0.004275187,0.00044037867,0.0003251056,0.0006805459,0.00035609098,0.0011784869,0.00022180792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84594345,0.0017842203,0.011439284,0.0037000293,0.04079905,0.00009931136,0.00012166304,0.0008258373,0.004938032,0.0000671214,0.0011320756,0.0891498],"study_design_scores_gemma":[0.47875318,0.2372717,0.20067331,0.0010215001,0.07194846,0.00061602634,0.00024784915,0.0025909734,0.0035251284,0.00045288136,0.0027439645,0.00015503436],"about_ca_topic_score_codex":0.0012342257,"about_ca_topic_score_gemma":0.0036688887,"teacher_disagreement_score":0.0040687444,"about_ca_system_score_codex":0.00057984353,"about_ca_system_score_gemma":0.0005279067,"threshold_uncertainty_score":0.012774646},"labels":[],"label_agreement":null},{"id":"W2751490170","doi":"10.1111/dom.13008","title":"Monoacylglycerol signalling and ABHD6 in health and disease","year":2017,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Monoacylglycerol lipase; Signalling; Disease; Medicine; Biology; Cell biology; Internal medicine; Receptor","score_opus":0.05611425341355459,"score_gpt":0.36023134853831,"score_spread":0.30411709512475543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751490170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023319605,0.99072474,0.00066427223,0.00080045755,0.00042525178,0.000009899212,0.00010066391,0.000028515211,0.004914209],"genre_scores_gemma":[0.017426271,0.97529435,0.00064526545,0.00043072025,0.00039543965,0.000015102849,0.0001571821,0.0000057980315,0.00562988],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991834,0.000015537205,0.000009488705,0.000015996935,0.000022178832,0.000018361316],"domain_scores_gemma":[0.99995804,0.000010196992,0.000007151677,0.0000017657636,0.000013527087,0.000009342804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019740418,0.0005006166,0.00046885895,0.0007680148,0.0003541371,0.0008573949,0.00033826908,0.00079936034,0.00378449],"category_scores_gemma":[0.00017717086,0.00011634946,0.00024755887,0.00076854485,0.0003473695,0.0005510915,0.0006134927,0.0009317438,0.0012698289],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007837659,0.000100206285,0.0007932948,0.015099857,0.00015106864,0.001102603,0.0004237928,0.0007670231,0.05354618,0.032100152,0.022028584,0.87310356],"study_design_scores_gemma":[0.000019431103,0.00012742833,0.0024013987,0.00125141,0.00010089933,0.0013464256,0.00019081721,0.00022673076,0.006827985,0.008585552,0.97889155,0.000030317355],"about_ca_topic_score_codex":0.0013149838,"about_ca_topic_score_gemma":0.0021879568,"teacher_disagreement_score":0.00378449,"about_ca_system_score_codex":0.0006580044,"about_ca_system_score_gemma":0.0007327582,"threshold_uncertainty_score":0.012660325},"labels":[],"label_agreement":null},{"id":"W2752834631","doi":"10.1111/dom.13010","title":"Metabolomics applied to islet nutrient sensing mechanisms","year":2017,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Alberta","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Metabolomics; Islet; Insulin; Secretion; Computational biology; Biology; Bioinformatics; Chemistry; Computer science; Cell biology; Biochemistry; Endocrinology","score_opus":0.04656412140846029,"score_gpt":0.3038742621995362,"score_spread":0.25731014079107595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752834631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020832804,0.997358,0.0004465625,0.00030336133,0.00027744783,0.0000048469183,0.00002687436,0.000015277921,0.0013591698],"genre_scores_gemma":[0.0011352565,0.99750936,0.00033848212,0.00015103263,0.00025490296,0.0000050940516,0.000037583668,0.0000022377146,0.000565982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998129,0.000029418808,0.000021727765,0.00003962133,0.00007525643,0.00002123337],"domain_scores_gemma":[0.99974984,0.00009715546,0.000038349088,0.000012342381,0.00007712415,0.000025232303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006026915,0.0011651415,0.0012925873,0.0032748436,0.0002969868,0.001295008,0.0007320445,0.0009941303,0.0032986482],"category_scores_gemma":[0.00064265827,0.00028979787,0.0006422856,0.0028261838,0.0005759403,0.0014675139,0.0011744407,0.0016109102,0.0018843594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008855059,0.00007248901,0.0004251922,0.01654343,0.00016707448,0.0003523324,0.0000820946,0.00058637065,0.006967223,0.009138847,0.022210002,0.94336635],"study_design_scores_gemma":[0.000011385834,0.00007072447,0.0015356847,0.0028204746,0.00013706964,0.0015113537,0.000083342224,0.00035408774,0.0032073597,0.006752833,0.98347175,0.00004381886],"about_ca_topic_score_codex":0.0009914067,"about_ca_topic_score_gemma":0.0011656892,"teacher_disagreement_score":0.0032986482,"about_ca_system_score_codex":0.0007127924,"about_ca_system_score_gemma":0.0009300661,"threshold_uncertainty_score":0.011035025},"labels":[],"label_agreement":null},{"id":"W2753333999","doi":"10.1111/dom.13104","title":"Metformin extended‐release versus immediate‐release: <scp>A</scp> n international, randomized, double‐blind, head‐to‐head trial in pharmacotherapy‐naïve patients with type 2 diabetes","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"AstraZeneca","keywords":"Metformin; Medicine; Type 2 diabetes; Randomized controlled trial; Placebo; Clinical endpoint; Internal medicine; Adverse effect; Diabetes mellitus; Pharmacotherapy; Gastroenterology; Endocrinology; Pharmacology","score_opus":0.023221334526631464,"score_gpt":0.3015745698871178,"score_spread":0.27835323536048634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753333999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98494047,0.0075308853,0.0006017249,0.0005055784,0.0004986579,0.0023749527,0.0009829721,0.00013430376,0.0024303144],"genre_scores_gemma":[0.98370945,0.004817428,0.002188439,0.0009886096,0.0005342755,0.0032965003,0.0009986508,0.000029885327,0.0034367093],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996524,0.00020390685,0.000023131195,0.000052897056,0.000027467164,0.000040231444],"domain_scores_gemma":[0.99944514,0.00014102687,0.00014629916,0.000037422822,0.000029146815,0.00020093973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013072342,0.001195749,0.0021637762,0.00028430726,0.0002949141,0.00071722554,0.00066461385,0.00097325206,0.0067586987],"category_scores_gemma":[0.001195364,0.0004858815,0.0012540569,0.00033124926,0.00062874355,0.0007305928,0.00036384337,0.0018260628,0.00072384457],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9786904,0.0029634547,0.00028322497,0.00062719616,0.00047492413,0.00002159866,0.000019342884,0.00012720391,0.0023827169,0.000058753816,0.00053191715,0.01381917],"study_design_scores_gemma":[0.96638906,0.031144895,0.0012521056,0.00003490026,0.00027956773,0.000029341747,0.000009365932,0.00021594507,0.00025010988,0.0000506079,0.00033480005,0.000009304999],"about_ca_topic_score_codex":0.00070520357,"about_ca_topic_score_gemma":0.0023175385,"teacher_disagreement_score":0.0067586987,"about_ca_system_score_codex":0.00042520286,"about_ca_system_score_gemma":0.00074982684,"threshold_uncertainty_score":0.022610068},"labels":[],"label_agreement":null},{"id":"W2753736324","doi":"10.1111/dom.13001","title":"Recent new insights into the role of SNARE and associated proteins in insulin granule exocytosis","year":2017,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Exocytosis; Cell biology; Lipid bilayer fusion; Munc-18; SNARE complex; Biology; Granule (geology); Vesicle fusion; Secretion; Chemistry; Vesicle; Synaptic vesicle; Membrane; Biochemistry","score_opus":0.03377539440660406,"score_gpt":0.2831373104046554,"score_spread":0.24936191599805133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753736324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017121457,0.9977787,0.00017643282,0.00032135478,0.00024700272,0.0000033532672,0.000018423949,0.0000105654035,0.001272957],"genre_scores_gemma":[0.0006259388,0.99808073,0.00019175676,0.00017332505,0.00025469507,0.0000038150047,0.00002571377,0.0000014053475,0.0006426068],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998851,0.000014407097,0.00001881098,0.000023747536,0.00004349737,0.000014456494],"domain_scores_gemma":[0.99978393,0.00008202363,0.000030090148,0.0000071512495,0.000060811653,0.00003606643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043711936,0.0008249572,0.00093059853,0.0021656519,0.00027042296,0.0009877858,0.00055965787,0.0010637343,0.003577106],"category_scores_gemma":[0.00046969653,0.00025953163,0.00037572664,0.00242425,0.0005097033,0.0020042907,0.00091174373,0.001621722,0.0018773287],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011412937,0.00008315942,0.00018425951,0.015556418,0.00007592533,0.0003621338,0.00009760225,0.00054148515,0.0042671505,0.0072697205,0.024073014,0.94737494],"study_design_scores_gemma":[0.000010622975,0.000059347753,0.0005778124,0.0013351297,0.00006208633,0.0007799326,0.00006868806,0.00009735522,0.00046378214,0.0033462849,0.9931821,0.000016871207],"about_ca_topic_score_codex":0.00063945464,"about_ca_topic_score_gemma":0.00094674097,"teacher_disagreement_score":0.003577106,"about_ca_system_score_codex":0.0005089139,"about_ca_system_score_gemma":0.00089745433,"threshold_uncertainty_score":0.011966646},"labels":[],"label_agreement":null},{"id":"W2754397244","doi":"10.1111/dom.13112","title":"Insulin resistance and cardiovascular outcomes in the <scp>ORIGIN</scp> trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Sanofi","keywords":"Medicine; Insulin glargine; Insulin resistance; Insulin; Internal medicine; Hazard ratio; Myocardial infarction; Endocrinology; Randomization; Stroke (engine); Basal (medicine); Diabetes mellitus; Randomized controlled trial; Hypoglycemia; Confidence interval","score_opus":0.017958814643979578,"score_gpt":0.24971910115584622,"score_spread":0.23176028651186664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754397244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94476795,0.032871455,0.00081241253,0.0027658204,0.00071962446,0.0014265779,0.0023981237,0.0000964975,0.014141587],"genre_scores_gemma":[0.9791734,0.0074725486,0.0014847876,0.002104141,0.00079249864,0.0023084974,0.0026949744,0.00003422675,0.0039349897],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998889,0.00076169765,0.000058117883,0.00009842939,0.00009931818,0.000093421804],"domain_scores_gemma":[0.9990988,0.0002525641,0.0002636545,0.000093300456,0.00007569231,0.00021593849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023383074,0.0005924885,0.0012196121,0.00018193119,0.0003190098,0.0013452433,0.00037662516,0.0009481077,0.0039521884],"category_scores_gemma":[0.0028414042,0.00022540752,0.001322841,0.00037258226,0.0004200339,0.00051247573,0.0005463554,0.002177391,0.00038522005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85729015,0.0035503572,0.029004043,0.006503112,0.008569941,0.00024579544,0.00015545932,0.0008996604,0.0021481197,0.0013563768,0.015131512,0.07514552],"study_design_scores_gemma":[0.7699332,0.045696273,0.14888045,0.0022985965,0.013642694,0.00051759253,0.0001825062,0.0026276247,0.0012186306,0.0030063023,0.011893905,0.00010227014],"about_ca_topic_score_codex":0.0011447317,"about_ca_topic_score_gemma":0.0016862063,"teacher_disagreement_score":0.0039521884,"about_ca_system_score_codex":0.00038454492,"about_ca_system_score_gemma":0.00094852416,"threshold_uncertainty_score":0.0132213235},"labels":[],"label_agreement":null},{"id":"W2756174617","doi":"10.1111/dom.13114","title":"Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Medicine; Internal medicine; Type 2 diabetes; Endocrinology; Placebo; Type 1 diabetes; Cholesterol; Insulin; Diabetes mellitus; PCSK9; Population; Apolipoprotein B; Lipoprotein; Apolipoprotein A1; LDL receptor","score_opus":0.010753474393634945,"score_gpt":0.23046606069594383,"score_spread":0.2197125863023089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756174617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98858786,0.0061431145,0.00026280325,0.0007008813,0.0003441999,0.001246685,0.00061140436,0.000047705642,0.0020552657],"genre_scores_gemma":[0.99041814,0.0028417548,0.0007942934,0.0011205596,0.0004602848,0.0016006593,0.0008808817,0.00001157818,0.0018718549],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993993,0.00034133144,0.00004827725,0.00009422751,0.00004777422,0.00006907599],"domain_scores_gemma":[0.99921644,0.00016615269,0.00026498153,0.00005293443,0.000054816584,0.0002446361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015966241,0.0012675287,0.0019518555,0.0003214531,0.00041295693,0.0010791621,0.0005384835,0.001346751,0.0040625776],"category_scores_gemma":[0.0018851048,0.00042448746,0.0016555414,0.0002658232,0.00072122354,0.0005939688,0.00035710356,0.0019123608,0.0004929916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.982357,0.0022655267,0.0023306122,0.0005590064,0.0010924037,0.000035916793,0.000027255373,0.00013232982,0.0011296074,0.000065549684,0.00056822685,0.009436537],"study_design_scores_gemma":[0.9639509,0.026926616,0.006250244,0.00007197974,0.0013546485,0.000070011294,0.000019660796,0.00038578163,0.00029943432,0.000107916894,0.0005496995,0.000013100236],"about_ca_topic_score_codex":0.0011463598,"about_ca_topic_score_gemma":0.002391219,"teacher_disagreement_score":0.0040625776,"about_ca_system_score_codex":0.00056191103,"about_ca_system_score_gemma":0.0007383079,"threshold_uncertainty_score":0.013590634},"labels":[],"label_agreement":null},{"id":"W2765113122","doi":"10.1111/dom.13134","title":"Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: <scp>A</scp> randomized clinical trial","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); GDI Integrated Facility Services (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Nasal congestion; Decongestant; Concomitant; Nasal decongestant; Pharmacodynamics; Common cold; Pseudoephedrine; Anesthesia; Adverse effect; rhinorrhea; Mucous membrane of nose; Nausea; Pharmacokinetics; Nose; Internal medicine; Surgery; Pathology; Immunology","score_opus":0.031824790788710894,"score_gpt":0.3455311865108615,"score_spread":0.31370639572215064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765113122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954477,0.0014528366,0.00017977037,0.0001626618,0.00018147708,0.0017842804,0.0002822303,0.000024984827,0.00048417383],"genre_scores_gemma":[0.99399394,0.00088151736,0.00067343435,0.00042876427,0.00031312727,0.002377893,0.00036552185,0.000008939086,0.00095679366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99913305,0.0004164765,0.00006964509,0.0001630269,0.00008753624,0.00013021583],"domain_scores_gemma":[0.9984553,0.00032685016,0.0004085078,0.000114387985,0.00012429564,0.00057074724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001975321,0.0012326597,0.0025600877,0.00029133368,0.00049727724,0.0010197831,0.0006653392,0.001862876,0.0039109765],"category_scores_gemma":[0.0017132302,0.0006418815,0.0017127931,0.00030299247,0.0010364249,0.0009291928,0.000402031,0.0019289982,0.0005080296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9835428,0.0067109466,0.0011438334,0.0002512623,0.0004245034,0.00003132912,0.000027814916,0.000072768795,0.0027464884,0.000018177667,0.00016088056,0.004869121],"study_design_scores_gemma":[0.6538637,0.33511552,0.008485868,0.00003131852,0.0006784079,0.000050671624,0.00004351539,0.00032501743,0.00080175104,0.000069548274,0.00051030173,0.000024362249],"about_ca_topic_score_codex":0.0008448138,"about_ca_topic_score_gemma":0.0020610245,"teacher_disagreement_score":0.0039109765,"about_ca_system_score_codex":0.0006543772,"about_ca_system_score_gemma":0.0013109577,"threshold_uncertainty_score":0.013083577},"labels":[],"label_agreement":null},{"id":"W2771026854","doi":"10.1111/dom.13163","title":"Systemic use of antibiotics and risk of diabetes in adults: <scp>A</scp> nested case‐control study of <scp>Alberta's Tomorrow Project</scp>","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Antibiotic Use and Resistance","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Alberta Health; Alberta Cancer Foundation; University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Medicine; Diabetes mellitus; Antibiotics; Odds ratio; Confounding; Nested case-control study; Logistic regression; Cohort study; Cohort; Internal medicine; Observational study; Environmental health; Endocrinology","score_opus":0.008924027519172439,"score_gpt":0.21627883491594938,"score_spread":0.20735480739677695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771026854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996734,0.00039765422,0.00019941987,0.00010340903,0.0000143340685,0.000097353855,0.0018861968,0.000008787336,0.0005588513],"genre_scores_gemma":[0.9965634,0.0002609874,0.00066476775,0.00014181927,0.000016959459,0.0000665934,0.0017568424,0.000004259009,0.0005243654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990501,0.00012571711,0.000058048645,0.00026600508,0.0003239843,0.00017620064],"domain_scores_gemma":[0.9987551,0.000081475424,0.0002941038,0.00013471155,0.00041340705,0.00032123944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009139682,0.0005133856,0.000428832,0.000827919,0.0020669657,0.0010390353,0.0012194145,0.0005718831,0.00091497623],"category_scores_gemma":[0.0012818695,0.0005948203,0.0006736276,0.0017819393,0.0006370892,0.00018433812,0.0005035506,0.0007211833,0.0001266335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002058611,0.00009279303,0.9966574,0.000023371686,0.00019446292,0.00014209625,0.00022855324,0.000046061385,0.00038056608,0.00004570825,0.0007665814,0.0012165171],"study_design_scores_gemma":[0.0000702718,0.000070337235,0.9983543,0.000025070498,0.00015665371,0.0001596306,0.00025204878,0.0003015122,0.00008212988,0.000023874096,0.0004958047,0.000008374508],"about_ca_topic_score_codex":0.934425,"about_ca_topic_score_gemma":0.9398469,"teacher_disagreement_score":0.065575,"about_ca_system_score_codex":0.0077690445,"about_ca_system_score_gemma":0.008246578,"threshold_uncertainty_score":0.1319223},"labels":[],"label_agreement":null},{"id":"W2774952602","doi":"10.1111/dom.13179","title":"Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Novo Nordisk; Sanofi","keywords":"Medicine; Insulin; Logistic regression; Diabetes mellitus; Regimen; Internal medicine; Observational study; Type 2 diabetes; Hypoglycemia; Body mass index; Univariate analysis; Type 1 diabetes; Prospective cohort study; Pediatrics; Endocrinology; Multivariate analysis","score_opus":0.023378684042730295,"score_gpt":0.31488547563110575,"score_spread":0.29150679158837545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774952602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998565,0.00018093316,0.00005215414,0.000037819504,0.000006203012,0.000010818081,0.00097404985,0.0000015973645,0.00017146033],"genre_scores_gemma":[0.9983518,0.00009958127,0.000063166735,0.000023775337,0.00001157933,0.000017874825,0.0013270173,0.0000022170932,0.00010301194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914217,0.00032908402,0.00011839514,0.00014411648,0.00014331906,0.00012292375],"domain_scores_gemma":[0.9968437,0.0006026603,0.0015877605,0.00024984495,0.00022551749,0.0004905232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014333561,0.0003812074,0.0005308325,0.0010401758,0.00049501145,0.0008294169,0.0005191158,0.0005865034,0.0016574229],"category_scores_gemma":[0.0042164526,0.0003393521,0.0016165198,0.0019444885,0.00025909697,0.0005227572,0.0012026752,0.0008586621,0.00018363095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017209629,0.000014504731,0.9992711,0.000008431223,0.00006979589,0.000025346711,0.0000406938,0.000024511108,0.000017629332,0.000003540696,0.0000594758,0.00029277834],"study_design_scores_gemma":[0.00001291704,0.000055853656,0.9995239,0.0000063268126,0.00003750266,0.000045767723,0.00012465731,0.00010168007,0.00000628564,0.00000789258,0.00007416052,0.0000030963397],"about_ca_topic_score_codex":0.014463484,"about_ca_topic_score_gemma":0.013013905,"teacher_disagreement_score":0.014463484,"about_ca_system_score_codex":0.00041756846,"about_ca_system_score_gemma":0.000435061,"threshold_uncertainty_score":0.028758585},"labels":[],"label_agreement":null},{"id":"W2782920834","doi":"10.1111/dom.13217","title":"<scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca","keywords":"Medicine; TIMI; Baseline (sea); Internal medicine; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.01928314700339614,"score_gpt":0.2485237473738867,"score_spread":0.22924060037049054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782920834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672975,0.0019538666,0.0019020349,0.00093372,0.00016000532,0.0014241324,0.022827212,0.00005250745,0.0034490263],"genre_scores_gemma":[0.97675586,0.00042527093,0.0021017662,0.0015327467,0.00021723531,0.005565665,0.0107206125,0.000038747345,0.0026420385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992524,0.00021210086,0.00009743597,0.00018802799,0.00014998177,0.00010002399],"domain_scores_gemma":[0.99931014,0.00010518641,0.00033435444,0.000047799673,0.00009498053,0.000107513166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013970926,0.00044536314,0.0005787602,0.00042145798,0.00041411296,0.00043147724,0.00027350124,0.0006646522,0.0067074685],"category_scores_gemma":[0.002265794,0.00019603941,0.0005046295,0.0006143083,0.00026785771,0.0005387705,0.0002605757,0.00054676825,0.0018588135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07102792,0.0024577382,0.8432913,0.00104084,0.00093432126,0.0002881266,0.000538216,0.00041106858,0.0037706904,0.00044255366,0.027207421,0.048589878],"study_design_scores_gemma":[0.009253587,0.009624937,0.9542549,0.00025460508,0.0006089117,0.0010839658,0.0003266811,0.0010252682,0.0009850734,0.0010947832,0.021425338,0.000061900726],"about_ca_topic_score_codex":0.0006749739,"about_ca_topic_score_gemma":0.0005283114,"teacher_disagreement_score":0.0067074685,"about_ca_system_score_codex":0.00025863026,"about_ca_system_score_gemma":0.00046308758,"threshold_uncertainty_score":0.022438705},"labels":[],"label_agreement":null},{"id":"W2785139619","doi":"10.1111/dom.13172","title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","year":2017,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":294,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk; Novo Nordisk Fonden; Steno Diabetes Center Copenhagen","keywords":"Medicine; Semaglutide; Glycated haemoglobin; Diabetic retinopathy; Glycated hemoglobin; Ophthalmology; Diabetes mellitus; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.007429259347866054,"score_gpt":0.2222728373629661,"score_spread":0.21484357801510004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785139619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53079104,0.39974695,0.0019091999,0.02088323,0.0009203879,0.002027932,0.021898178,0.000456619,0.021366533],"genre_scores_gemma":[0.91072226,0.058356836,0.005017111,0.008647991,0.0010430557,0.0019939758,0.008540174,0.000074928386,0.00560362],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976809,0.0014438817,0.00020709819,0.00013790373,0.00045665022,0.00007355819],"domain_scores_gemma":[0.99424064,0.0023736984,0.0019290468,0.00018036227,0.00086850085,0.00040766966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005422783,0.00033563562,0.0008772953,0.0003864355,0.00016649363,0.00066235045,0.00069050264,0.0013627113,0.0040342403],"category_scores_gemma":[0.008889376,0.0001496592,0.0010486346,0.00094635313,0.00021282848,0.000332384,0.00023735697,0.0006636885,0.0005322785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2750387,0.002123278,0.1247059,0.019593637,0.008375933,0.00026388766,0.0003566813,0.0010995356,0.0022697796,0.00127557,0.086931534,0.4779656],"study_design_scores_gemma":[0.208841,0.07594514,0.602762,0.008360428,0.023072721,0.0013206318,0.000291325,0.0029069737,0.0019509017,0.0028753693,0.071532026,0.00014147995],"about_ca_topic_score_codex":0.0036305024,"about_ca_topic_score_gemma":0.0065755374,"teacher_disagreement_score":0.005422783,"about_ca_system_score_codex":0.0005583371,"about_ca_system_score_gemma":0.0013469554,"threshold_uncertainty_score":0.028678775},"labels":[],"label_agreement":null},{"id":"W2787959738","doi":"10.1111/dom.13257","title":"Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Ezetimibe; Medicine; Internal medicine; Dyslipidemia; PCSK9; Population; Type 2 diabetes; Fenofibrate; Gastroenterology; Endocrinology; Clinical endpoint; Statin; Randomized controlled trial; Cholesterol; Diabetes mellitus; Apolipoprotein B; Lipoprotein; Apolipoprotein A1; LDL receptor","score_opus":0.009826980854002007,"score_gpt":0.25888975585096974,"score_spread":0.24906277499696772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787959738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98843,0.006237898,0.00029624611,0.00080714154,0.00052934163,0.0009922312,0.0006090905,0.000060954542,0.0020371587],"genre_scores_gemma":[0.9912476,0.0024472864,0.00082252367,0.0011828752,0.00041040813,0.0012448838,0.000686238,0.000010219948,0.001948064],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994592,0.00029218209,0.000044067656,0.00009425149,0.00003954511,0.00007069991],"domain_scores_gemma":[0.99951303,0.00011464783,0.00012621922,0.00003481332,0.00003632251,0.00017498202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012003175,0.001169952,0.0021407166,0.00031986772,0.00030467688,0.0009703097,0.0005856002,0.0010574517,0.004869598],"category_scores_gemma":[0.0016434077,0.00043419257,0.0016458804,0.00027305415,0.0005304605,0.0006508891,0.00048997666,0.0015975846,0.00044995814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9858641,0.0018744512,0.0011862837,0.00059436494,0.0013361191,0.000031228235,0.000026328129,0.00015367617,0.0007237409,0.00007713054,0.000457134,0.007675467],"study_design_scores_gemma":[0.9715152,0.021010706,0.004117123,0.000069592534,0.0018149831,0.000041771433,0.00003005864,0.00056439074,0.00020715375,0.00014295962,0.00047427582,0.00001170061],"about_ca_topic_score_codex":0.0014837189,"about_ca_topic_score_gemma":0.0031640036,"teacher_disagreement_score":0.004869598,"about_ca_system_score_codex":0.0005919086,"about_ca_system_score_gemma":0.00064266956,"threshold_uncertainty_score":0.016290486},"labels":[],"label_agreement":null},{"id":"W2789501252","doi":"10.1111/dom.13278","title":"Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Diabetes Canada; McGill University Health Centre; Montreal Clinical Research Institute; University of Manitoba; Eli Lilly (Canada)","funders":"","keywords":"Medicine; Adverse effect; Continuous glucose monitoring; Type 2 diabetes; Prospective cohort study; Type 1 diabetes; Population; Glucagon; Diabetes mellitus; Internal medicine; Anesthesia; Pediatrics; Insulin; Endocrinology","score_opus":0.05040934713875908,"score_gpt":0.3324586729810634,"score_spread":0.28204932584230435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789501252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948319,0.0024571477,0.0004307059,0.000065387045,0.000053749303,0.0016235026,0.00018230522,0.000012279126,0.00034300672],"genre_scores_gemma":[0.9926307,0.0021593377,0.0024759916,0.000379595,0.00015340827,0.0015615772,0.00042440474,0.000006704222,0.00020820371],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99705124,0.0020371298,0.00032581022,0.00024017577,0.0002404478,0.00010524171],"domain_scores_gemma":[0.99452126,0.0022848616,0.0017900347,0.0003398402,0.00039737878,0.00066654594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006276876,0.0007584167,0.0011942242,0.00031713303,0.00039729112,0.0007081297,0.0005047481,0.00085723394,0.0017285264],"category_scores_gemma":[0.0052664047,0.000437589,0.0015349187,0.00051983254,0.00080817833,0.00077323715,0.00028390338,0.001071933,0.00022711785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6923788,0.105334006,0.07684758,0.0038715964,0.0048412085,0.00033145392,0.0007041804,0.000993088,0.015032716,0.00015664392,0.0006850648,0.098823674],"study_design_scores_gemma":[0.12043299,0.8303175,0.045574233,0.000075464246,0.0010119224,0.0001643616,0.00016746913,0.00041417673,0.000980239,0.000027889544,0.0008023006,0.000031351316],"about_ca_topic_score_codex":0.0006552822,"about_ca_topic_score_gemma":0.0015328235,"teacher_disagreement_score":0.006276876,"about_ca_system_score_codex":0.0003738318,"about_ca_system_score_gemma":0.0012362513,"threshold_uncertainty_score":0.033195674},"labels":[],"label_agreement":null},{"id":"W2789883359","doi":"10.1111/dom.13225","title":"One‐year weight losses in the Tianjin Gestational Diabetes Mellitus Prevention Programme: A randomized clinical trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Dalhousie University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; European Foundation for the Study of Diabetes","keywords":"Medicine; Weight loss; Overweight; Randomized controlled trial; Gestational diabetes; Waist; Obesity; Body mass index; Physical therapy; Weight management; Diabetes mellitus; Internal medicine; Pregnancy; Gestation; Endocrinology","score_opus":0.04090900994013091,"score_gpt":0.33869323593667217,"score_spread":0.29778422599654125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789883359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844221,0.007620387,0.00044524545,0.0007622277,0.0006829281,0.0044846246,0.00039652493,0.000080766404,0.0011051783],"genre_scores_gemma":[0.9817485,0.0042053913,0.0013820869,0.0009857614,0.0004332664,0.009213521,0.000427545,0.000008002772,0.0015959257],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99878186,0.00060781336,0.00011726981,0.00022143984,0.00010705302,0.00016459652],"domain_scores_gemma":[0.9992778,0.00016675168,0.00020827686,0.0000604678,0.000043624656,0.00024316338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017343757,0.00095535547,0.0029001723,0.0005378361,0.0005479285,0.00083421264,0.0009331008,0.002179458,0.0043220506],"category_scores_gemma":[0.0022821636,0.0005631996,0.0020017219,0.00057857874,0.0008204819,0.0007313772,0.0005528811,0.0019926785,0.00035630545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9436985,0.013542572,0.0016969626,0.0022277008,0.001975185,0.000049373477,0.00008589439,0.00029658346,0.0010792919,0.00009723944,0.00044227447,0.03480833],"study_design_scores_gemma":[0.9522336,0.04042699,0.005319714,0.00010742986,0.0011162132,0.000016349015,0.000025875588,0.0002283037,0.000153008,0.00006486203,0.00029482628,0.000012710922],"about_ca_topic_score_codex":0.0019258877,"about_ca_topic_score_gemma":0.002983216,"teacher_disagreement_score":0.0043220506,"about_ca_system_score_codex":0.00072195556,"about_ca_system_score_gemma":0.0012686055,"threshold_uncertainty_score":0.014458716},"labels":[],"label_agreement":null},{"id":"W2789984616","doi":"10.1111/dom.13274","title":"Role of bicarbonate supplementation on urine uric acid crystals and diabetic tubulopathy in adults with type 1 diabetes","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Urine; Urine osmolality; Medicine; Internal medicine; Creatinine; Endocrinology; Sodium bicarbonate; Tubulopathy; Kidney disease; Type 1 diabetes; Microalbuminuria; Uric acid; Diabetes mellitus; Urology; Chemistry","score_opus":0.004463709535323452,"score_gpt":0.20985914966493777,"score_spread":0.2053954401296143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789984616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967229,0.0024767376,0.000033917313,0.00012386529,0.00005262879,0.00016085268,0.00009711502,0.0000068644117,0.00032504945],"genre_scores_gemma":[0.99782795,0.00084903487,0.00025703156,0.00023823118,0.00006627641,0.00016934235,0.00011772251,0.0000020683476,0.0004722847],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996037,0.0002021503,0.00004625001,0.00004488471,0.000038990045,0.0000641373],"domain_scores_gemma":[0.99914646,0.0002077415,0.00015145808,0.000038215865,0.000069962305,0.0003861448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011922318,0.00057264837,0.0017754431,0.00015566914,0.0004009133,0.0006351471,0.00029987496,0.0010776925,0.0018634604],"category_scores_gemma":[0.0015778284,0.00029129587,0.0010536124,0.00018745859,0.00028773522,0.00046674014,0.00042470603,0.00093651743,0.00017366829],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8518758,0.031255934,0.043923263,0.0009888104,0.0015019035,0.00013482815,0.00031548494,0.00039807888,0.012593424,0.00003715895,0.0005335512,0.05644175],"study_design_scores_gemma":[0.07487667,0.7275236,0.18856749,0.00021022999,0.0021615592,0.000129504,0.00023755095,0.0009546099,0.0037938638,0.00007876591,0.0014301721,0.000036018595],"about_ca_topic_score_codex":0.0012000874,"about_ca_topic_score_gemma":0.002481049,"teacher_disagreement_score":0.0018634604,"about_ca_system_score_codex":0.00031411948,"about_ca_system_score_gemma":0.00058617984,"threshold_uncertainty_score":0.006305158},"labels":[],"label_agreement":null},{"id":"W2790059086","doi":"10.1111/dom.13235","title":"Effect of proprotein convertase subtilisin/kexin type 9 ( <scp>PCSK9</scp> ) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: <scp>A</scp> systematic review and meta‐analysis","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Capital Health","keywords":"Medicine; PCSK9; Internal medicine; Alirocumab; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Kexin; Publication bias; Subgroup analysis; Confidence interval; Gastroenterology; Endocrinology; Cholesterol; LDL receptor; Lipoprotein","score_opus":0.020657028541026294,"score_gpt":0.28550547619983746,"score_spread":0.26484844765881116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790059086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005321067,0.99330467,0.0002764737,0.00014814385,0.00019090778,0.00028637072,0.0002430784,0.000014706172,0.00021465037],"genre_scores_gemma":[0.17395885,0.8199614,0.0019230208,0.001110867,0.0004179629,0.0015128884,0.0005418709,0.000023985163,0.00054912665],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9934163,0.0029492069,0.0019976068,0.000682662,0.00073260046,0.00022171701],"domain_scores_gemma":[0.985025,0.011450852,0.002159887,0.00031341778,0.0008554319,0.00019533293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0106526865,0.0025253622,0.01881865,0.004104813,0.00052519824,0.0033035323,0.0017423185,0.0027017018,0.0033602957],"category_scores_gemma":[0.022536984,0.0012349673,0.030400021,0.004599176,0.000660835,0.0013353786,0.0011286691,0.0017522092,0.0002370564],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039334847,0.000039546852,0.0019133489,0.45553488,0.5260105,0.00010334695,0.00006559935,0.00036601245,0.00030706194,0.00011725652,0.00046866032,0.011140293],"study_design_scores_gemma":[0.0010819663,0.00032544474,0.0022067828,0.021795074,0.97299844,0.00007135681,0.000030077874,0.000124348,0.00012869092,0.00012178716,0.0011002816,0.000015607766],"about_ca_topic_score_codex":0.005523476,"about_ca_topic_score_gemma":0.010700666,"teacher_disagreement_score":0.01881865,"about_ca_system_score_codex":0.002144459,"about_ca_system_score_gemma":0.0030085638,"threshold_uncertainty_score":0.056337476},"labels":[],"label_agreement":null},{"id":"W2790160447","doi":"10.1111/dom.13251","title":"Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Merck","keywords":"Extension (predicate logic); Term (time); Medicine; Physical therapy; Internal medicine; Computer science; Physics","score_opus":0.007645441871384784,"score_gpt":0.22841082766575554,"score_spread":0.22076538579437077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790160447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119616,0.004458511,0.0002164234,0.00036874137,0.00011057073,0.0008577501,0.00072239956,0.000042320553,0.0020271235],"genre_scores_gemma":[0.9909739,0.0021837754,0.00083049765,0.00095802016,0.00028554484,0.0011500184,0.0012882641,0.000012550225,0.0023173888],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993173,0.00030579188,0.0000584435,0.00012101243,0.00010755886,0.00008989048],"domain_scores_gemma":[0.9990489,0.00016411755,0.00029558208,0.000079808946,0.000078475336,0.00033306004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020028653,0.00069696095,0.0021518439,0.00019418205,0.00030194712,0.0008016171,0.0005495991,0.001049719,0.0040708915],"category_scores_gemma":[0.0012746153,0.00032502037,0.0011417179,0.00028447536,0.00043879953,0.0005188383,0.00031642153,0.0014883406,0.0006778428],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88587815,0.012206197,0.013229373,0.0010623466,0.002480619,0.00016412065,0.00016785186,0.00037439654,0.0129008675,0.000115090035,0.0020281419,0.0693927],"study_design_scores_gemma":[0.79863954,0.14943774,0.04667707,0.00013760128,0.0013891906,0.00016212327,0.000052398034,0.0004915634,0.0009269218,0.00007538275,0.001976806,0.000033560973],"about_ca_topic_score_codex":0.0014368609,"about_ca_topic_score_gemma":0.0044872067,"teacher_disagreement_score":0.0040708915,"about_ca_system_score_codex":0.00065329915,"about_ca_system_score_gemma":0.001025441,"threshold_uncertainty_score":0.013618469},"labels":[],"label_agreement":null},{"id":"W2790892243","doi":"10.1111/dom.13293","title":"Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: <scp>A</scp> 1‐year randomized study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"GlaxoSmithKline","keywords":"Rosiglitazone; Internal medicine; Endocrinology; Medicine; Blood pressure; Agonist; Type 2 diabetes; Insulin resistance; Diastole; Diabetes mellitus; Insulin; Receptor","score_opus":0.0047547713575161795,"score_gpt":0.2151233258842722,"score_spread":0.210368554526756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790892243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960044,0.0027349307,0.00008870285,0.0001235749,0.00013040924,0.0003580884,0.00021134269,0.000020964731,0.00032755692],"genre_scores_gemma":[0.9953863,0.0018583424,0.00028828997,0.00043458768,0.0002455615,0.00035988443,0.000490802,0.0000047118783,0.00093158643],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995472,0.00014478019,0.000052140007,0.00008998021,0.00006635673,0.00009946384],"domain_scores_gemma":[0.9994081,0.000081225415,0.00015619323,0.000053960102,0.000059259564,0.00024131218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011970452,0.0009207421,0.0021723257,0.0004271114,0.0005094303,0.0008535856,0.0005687697,0.0015309572,0.0024077285],"category_scores_gemma":[0.00065027556,0.0005564802,0.0019969305,0.00051966956,0.00038745266,0.0003992991,0.00032014257,0.0017020021,0.0003939196],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9242439,0.023886418,0.016647633,0.0006029149,0.003766774,0.00009522737,0.0000483942,0.00020899506,0.0053645894,0.000036395144,0.00045472872,0.024644034],"study_design_scores_gemma":[0.545932,0.31815806,0.1278969,0.000106367224,0.0045104916,0.00012943105,0.00007105431,0.00052683626,0.0014164704,0.00006131805,0.0011560889,0.00003486621],"about_ca_topic_score_codex":0.001988164,"about_ca_topic_score_gemma":0.00443014,"teacher_disagreement_score":0.0024077285,"about_ca_system_score_codex":0.00043983373,"about_ca_system_score_gemma":0.0007903757,"threshold_uncertainty_score":0.008054674},"labels":[],"label_agreement":null},{"id":"W2791007077","doi":"10.1111/dom.13236","title":"Two‐year trial of intermittent insulin therapy vs metformin for the preservation of β‐cell function after initial short‐term intensive insulin induction in early type 2 diabetes","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Metformin; Medicine; Insulin; Type 2 diabetes; Internal medicine; Randomized controlled trial; Diabetes mellitus; Endocrinology","score_opus":0.0340578647877229,"score_gpt":0.2946610893769653,"score_spread":0.2606032245892424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791007077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971227,0.0012046684,0.00018154473,0.00026518415,0.00023876583,0.00034496246,0.00015203838,0.000034760025,0.00045543342],"genre_scores_gemma":[0.994921,0.00075179996,0.00072951574,0.0006651178,0.0003249362,0.0008754093,0.000380817,0.000010262167,0.0013410287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993793,0.000307398,0.0000401352,0.00012296301,0.00004591896,0.000104269406],"domain_scores_gemma":[0.9983485,0.00046299348,0.00032854048,0.00017364226,0.000067967194,0.00061833306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018455118,0.0011403423,0.0025122366,0.00034892128,0.0004394425,0.0011188361,0.0010657635,0.0016176932,0.0046462673],"category_scores_gemma":[0.0018046673,0.00050845084,0.0016195001,0.00034559553,0.0009567309,0.0011473212,0.0005332174,0.0038383845,0.0005959314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9816275,0.007960867,0.0004507812,0.000114705756,0.0003172908,0.000017898443,0.000022366185,0.00014247317,0.00097494136,0.000036008812,0.00016940292,0.008165808],"study_design_scores_gemma":[0.81406724,0.17991804,0.0043055583,0.00003649208,0.0003228096,0.000029146175,0.000025380274,0.00053154456,0.0004120374,0.00009987188,0.00023442548,0.000017488264],"about_ca_topic_score_codex":0.0008156492,"about_ca_topic_score_gemma":0.0014374171,"teacher_disagreement_score":0.0046462673,"about_ca_system_score_codex":0.0006974197,"about_ca_system_score_gemma":0.0009202093,"threshold_uncertainty_score":0.015543342},"labels":[],"label_agreement":null},{"id":"W2791162071","doi":"10.1111/dom.13301","title":"Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; University of Toronto; Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"Dapagliflozin; Albuminuria; Urology; Medicine; Internal medicine; Excretion; Endocrinology; Urinary system; Placebo; Renal function; Diabetes mellitus; Type 2 diabetes; Pathology","score_opus":0.0032171069287916525,"score_gpt":0.20101722841888417,"score_spread":0.19780012149009252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791162071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745053,0.0017283206,0.0003037241,0.000064173575,0.00005413355,0.00007069225,0.000082196675,0.000016671802,0.00022951326],"genre_scores_gemma":[0.99784994,0.00063714193,0.00063581165,0.00010776186,0.00007249127,0.00010541424,0.00011955232,0.0000055473247,0.00046639377],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99960667,0.00019674082,0.00003921839,0.00005121544,0.000047627356,0.00005855684],"domain_scores_gemma":[0.99916637,0.00043394184,0.00013630465,0.00006581344,0.000046582853,0.00015107289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015072203,0.0005227181,0.001804755,0.00017967525,0.00009406522,0.0004398482,0.0001918556,0.00034607196,0.00080936286],"category_scores_gemma":[0.0010406505,0.00020352784,0.0010690953,0.0001442827,0.0003160796,0.00039200686,0.00020664834,0.0010469197,0.00007237219],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7843886,0.008868451,0.011417727,0.001101562,0.0037513734,0.000102132646,0.00010949472,0.0027856803,0.101535514,0.00012543591,0.0005711657,0.08524282],"study_design_scores_gemma":[0.07683636,0.65725845,0.14961839,0.000099387675,0.008342093,0.00018072079,0.00008673626,0.007713501,0.09656128,0.00026736147,0.0029798734,0.000055854194],"about_ca_topic_score_codex":0.00039740113,"about_ca_topic_score_gemma":0.000962622,"teacher_disagreement_score":0.001804755,"about_ca_system_score_codex":0.0002590303,"about_ca_system_score_gemma":0.000352271,"threshold_uncertainty_score":0.007971048},"labels":[],"label_agreement":null},{"id":"W2791740462","doi":"10.1111/dom.13137","title":"Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Incretin; Medicine; Glucagon-like peptide 1 receptor; Agonist; Exenatide; Type 2 diabetes; Dipeptidyl peptidase; Internal medicine; Dipeptidyl peptidase-4 inhibitor; Pharmacology; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Adverse effect; Weight loss; Diabetes mellitus; Liraglutide; Alogliptin; Meta-analysis; Endocrinology; Receptor; Chemistry; Obesity; Biochemistry; Enzyme","score_opus":0.12533389312906065,"score_gpt":0.40361008164803713,"score_spread":0.2782761885189765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791740462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024377722,0.9705301,0.0017488842,0.00038729748,0.0005217981,0.000704066,0.0011029365,0.00008970303,0.00053759344],"genre_scores_gemma":[0.61487293,0.37156057,0.0054986957,0.0018099964,0.0006241826,0.0026080334,0.002151444,0.00013696638,0.0007370692],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97045046,0.017548528,0.006557215,0.002810241,0.0020681843,0.0005653209],"domain_scores_gemma":[0.96723104,0.0246991,0.0049114437,0.0012633988,0.0013980764,0.00049700803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028159836,0.0039863326,0.027655516,0.00617841,0.00062760606,0.004446963,0.0027278804,0.0030788672,0.0036655786],"category_scores_gemma":[0.040912908,0.0020530117,0.069174185,0.006656989,0.0009720942,0.002254227,0.0016587772,0.0028688714,0.00040061527],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005231047,0.000019118213,0.002094601,0.054732542,0.93475443,0.000044970093,0.00002377041,0.00044811988,0.0001223894,0.000045915906,0.0001684306,0.0023147473],"study_design_scores_gemma":[0.0015258569,0.00019828358,0.0014928861,0.0025239973,0.9935662,0.00002997351,0.00001500647,0.00020541313,0.000071539376,0.000088931294,0.00026982458,0.00001205184],"about_ca_topic_score_codex":0.004223458,"about_ca_topic_score_gemma":0.0063826996,"teacher_disagreement_score":0.028159836,"about_ca_system_score_codex":0.0027615803,"about_ca_system_score_gemma":0.0021720538,"threshold_uncertainty_score":0.14892524},"labels":[],"label_agreement":null},{"id":"W2792803451","doi":"10.1111/dom.13289","title":"Effects of intranasal insulin on endogenous glucose production in insulin‐resistant men","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"Diabetes Canada","keywords":"Endogeny; Insulin; Nasal administration; Production (economics); Insulin resistance; Internal medicine; Endocrinology; Medicine; Economics; Pharmacology; Macroeconomics","score_opus":0.013039616732076015,"score_gpt":0.21678708344737418,"score_spread":0.20374746671529817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792803451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992791,0.00038305364,0.00009626124,0.000016215203,0.000023344033,0.000046349334,0.00002774241,0.0000092146465,0.00011877089],"genre_scores_gemma":[0.99854845,0.0003802929,0.00042804627,0.00007074018,0.000052072017,0.00008572633,0.000073271156,0.0000061407372,0.00035532913],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996911,0.00013557845,0.000026101437,0.000062230356,0.000037314487,0.00004773242],"domain_scores_gemma":[0.99953556,0.00013968632,0.00008919869,0.00005261478,0.000020311016,0.00016263594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007191443,0.0006533879,0.0013406784,0.00021505049,0.00031350373,0.00037854354,0.00027521298,0.00060826633,0.0012394241],"category_scores_gemma":[0.0008495435,0.00047912323,0.00053359667,0.0002121429,0.0005490873,0.00043142235,0.00022111427,0.0010452728,0.00018731333],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70964575,0.032373387,0.0072270483,0.0004160486,0.0005606549,0.00023444642,0.0002956789,0.00038612046,0.20163931,0.00005684218,0.00017989607,0.046984863],"study_design_scores_gemma":[0.044746704,0.8636836,0.06621006,0.000023640496,0.00061143626,0.00021187757,0.00014309869,0.0008628782,0.022804005,0.00006884426,0.00060170196,0.000032089807],"about_ca_topic_score_codex":0.0005160664,"about_ca_topic_score_gemma":0.0008032657,"teacher_disagreement_score":0.0013406784,"about_ca_system_score_codex":0.00017982266,"about_ca_system_score_gemma":0.00026879043,"threshold_uncertainty_score":0.004146278},"labels":[],"label_agreement":null},{"id":"W2793672077","doi":"10.1111/dom.13245","title":"Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"AbbVie","keywords":"Medicine; Diabetic nephropathy; Clinical trial; Protocol (science); Urology; Sonar; Diabetes mellitus; Internal medicine; Alternative medicine; Endocrinology; Pathology; Artificial intelligence","score_opus":0.04565872220495022,"score_gpt":0.3243476603241468,"score_spread":0.2786889381191966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793672077","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001128871,0.0011950735,0.0058122827,0.0012158698,0.0019123547,0.9817292,0.0037420595,0.0001649829,0.0030992632],"genre_scores_gemma":[0.001995287,0.00037620068,0.007055038,0.0008997892,0.00033198658,0.98777544,0.0007629799,0.000016133263,0.00078714587],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9437428,0.039518215,0.005730367,0.004564386,0.0043390826,0.002105082],"domain_scores_gemma":[0.9790045,0.0055131447,0.0030328978,0.0033199328,0.0059028654,0.0032266376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07213033,0.005467908,0.0060873493,0.0025538795,0.0043980116,0.005123882,0.00376794,0.007725366,0.047988992],"category_scores_gemma":[0.050730404,0.0029863166,0.003827964,0.0035354665,0.004524953,0.0034946315,0.002318511,0.01217204,0.02054676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5571588,0.0106457,0.0039939145,0.04558624,0.0028249947,0.0011277602,0.0020123569,0.0037643814,0.008142213,0.053747278,0.18502237,0.12597398],"study_design_scores_gemma":[0.4520471,0.018488303,0.007888553,0.015389426,0.0022952477,0.00058178994,0.00048170346,0.0044300593,0.0023664802,0.026301658,0.4692603,0.00046932462],"about_ca_topic_score_codex":0.0015625003,"about_ca_topic_score_gemma":0.0031123902,"teacher_disagreement_score":0.07213033,"about_ca_system_score_codex":0.004056834,"about_ca_system_score_gemma":0.018012308,"threshold_uncertainty_score":0.3814662},"labels":[],"label_agreement":null},{"id":"W2793793620","doi":"10.1111/dom.13252","title":"Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"European Foundation for the Study of Diabetes; Eli Lilly and Company; American Diabetes Association","keywords":"Medicine; Dulaglutide; Subgroup analysis; Diabetes mellitus; Glycated haemoglobin; Internal medicine; Type 2 diabetes; Endocrinology; Meta-analysis; Liraglutide","score_opus":0.007338434889576477,"score_gpt":0.23898001209343775,"score_spread":0.23164157720386128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793793620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692917,0.027472107,0.0004432628,0.0001924404,0.00023608128,0.0004244289,0.0007969369,0.000030149517,0.0011129527],"genre_scores_gemma":[0.99473286,0.0032761989,0.00028628268,0.00025131015,0.00017197934,0.00018514055,0.0007221622,0.000010108769,0.0003639919],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99817276,0.0009106741,0.00029698387,0.00030591624,0.00016293235,0.00015076382],"domain_scores_gemma":[0.99875367,0.00053658953,0.0003704317,0.00013153882,0.000065382264,0.00014241358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031261037,0.0009823182,0.004946235,0.000738004,0.00019077605,0.001312307,0.0005677119,0.0009110899,0.0019136438],"category_scores_gemma":[0.0023193527,0.0004839604,0.008998163,0.00086120097,0.0004357394,0.00076954695,0.00049683446,0.0011223204,0.00021088205],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89727837,0.0007137442,0.022287752,0.00239911,0.047879707,0.00020755736,0.00007472058,0.0007108399,0.002646277,0.00009032968,0.00049291505,0.025218574],"study_design_scores_gemma":[0.50761443,0.12291552,0.17735495,0.00072591595,0.18105048,0.00063580537,0.00030823398,0.0030700027,0.00200839,0.0007798399,0.0033818937,0.00015453609],"about_ca_topic_score_codex":0.00063410547,"about_ca_topic_score_gemma":0.0019821434,"teacher_disagreement_score":0.004946235,"about_ca_system_score_codex":0.0005166748,"about_ca_system_score_gemma":0.00055136473,"threshold_uncertainty_score":0.0165326},"labels":[],"label_agreement":null},{"id":"W2794876887","doi":"10.1111/dom.13311","title":"Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: <scp>R</scp> esults from the <scp>ADVANCE‐ON</scp> study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Japan Society for the Promotion of Science; National Health and Medical Research Council; Medical Research Council; Servier","keywords":"Waist-to-height ratio; Medicine; Hazard ratio; Waist; Body mass index; Waist–hip ratio; Internal medicine; Stroke (engine); Myocardial infarction; Confidence interval; Type 2 diabetes; Proportional hazards model; Diabetes mellitus; Demography; Obesity; Cardiology; Endocrinology","score_opus":0.008693423885560053,"score_gpt":0.19630004390657316,"score_spread":0.1876066200210131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794876887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955889,0.0019217645,0.00024128554,0.00009717851,0.000033638713,0.000045877052,0.0012022309,0.0000068602517,0.00086219586],"genre_scores_gemma":[0.9967205,0.0005874498,0.00051375607,0.000062441366,0.00006366416,0.00004968352,0.0017135771,0.0000046739783,0.00028426215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989335,0.00051181955,0.00012488845,0.00017579674,0.00020242363,0.000051537423],"domain_scores_gemma":[0.9961714,0.0012278236,0.0011091192,0.00050381944,0.0004955111,0.000492287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00386501,0.0006295518,0.0006810137,0.0006420338,0.0002492444,0.0009368905,0.00044165397,0.00054035423,0.0011239852],"category_scores_gemma":[0.0038739445,0.00028984123,0.0011943756,0.00089246087,0.00017035204,0.00036916864,0.0005073739,0.00088085217,0.00016575705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004794217,0.00017011675,0.987531,0.000088933855,0.0010789807,0.00007755773,0.00006138294,0.00011391977,0.0003166527,0.00001935963,0.0003648333,0.0053830473],"study_design_scores_gemma":[0.0006663823,0.0015610078,0.9947048,0.000048400238,0.0014697649,0.00018310567,0.00008363816,0.00047777453,0.00022157966,0.000040398976,0.00052565505,0.00001754041],"about_ca_topic_score_codex":0.0030294014,"about_ca_topic_score_gemma":0.005137264,"teacher_disagreement_score":0.00386501,"about_ca_system_score_codex":0.0001830305,"about_ca_system_score_gemma":0.00031079713,"threshold_uncertainty_score":0.02044034},"labels":[],"label_agreement":null},{"id":"W2795033409","doi":"10.1111/dom.13315","title":"Baseline characteristics and enrichment results from the <scp>SONAR</scp> trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"AbbVie","keywords":"Medicine; Baseline (sea); Fishery","score_opus":0.012679675476472616,"score_gpt":0.23919566503437067,"score_spread":0.22651598955789806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795033409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975814,0.0075237444,0.00073446747,0.00073450815,0.00009618436,0.001009319,0.0042575877,0.000038720715,0.0058471807],"genre_scores_gemma":[0.9872119,0.0013918233,0.00054451486,0.0011453461,0.00018132458,0.0018529877,0.0056420825,0.000019271303,0.0020108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989987,0.0004988328,0.000113801674,0.00013757743,0.00014506772,0.00010597937],"domain_scores_gemma":[0.9989442,0.0004055843,0.00032576983,0.00008920442,0.00006840708,0.00016689644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022240216,0.00042647854,0.0009759979,0.000156864,0.00021057564,0.0005135449,0.00023390354,0.00062037114,0.004321472],"category_scores_gemma":[0.0017830051,0.00014725362,0.0007700433,0.00034617356,0.0003270485,0.00050484453,0.00018169299,0.0008752716,0.00065152586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7882754,0.0027134228,0.09372021,0.0026251834,0.005080034,0.00040307821,0.00013331311,0.0021159078,0.009944589,0.0007673403,0.01401552,0.08020599],"study_design_scores_gemma":[0.3557553,0.13981019,0.4502559,0.0009331142,0.01009916,0.0017243347,0.00021599153,0.0028618553,0.009227982,0.0027610105,0.02619564,0.00015955116],"about_ca_topic_score_codex":0.00019016385,"about_ca_topic_score_gemma":0.00047685145,"teacher_disagreement_score":0.004321472,"about_ca_system_score_codex":0.0002616754,"about_ca_system_score_gemma":0.00048136723,"threshold_uncertainty_score":0.014456809},"labels":[],"label_agreement":null},{"id":"W2799866020","doi":"10.1111/dom.13359","title":"Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Nederlands Herseninstituut; Medical Research Council; Université de Lausanne; Rosetrees Trust; Medical Research Council Canada; Wellcome Trust","keywords":"Glucokinase; Internal medicine; Endocrinology; Arc (geometry); Arcuate nucleus; Glucose homeostasis; Insulin; Medicine; Homeostasis; Diabetes mellitus; Hypothalamus; Insulin resistance","score_opus":0.01026146709295816,"score_gpt":0.2214207674067677,"score_spread":0.21115930031380953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799866020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99254614,0.0021390754,0.0034090327,0.00012503465,0.00003213364,0.000013254153,0.00011194039,0.000078675825,0.0015446272],"genre_scores_gemma":[0.995602,0.0012648149,0.0019493254,0.000041360694,0.000015900774,0.0000133195945,0.000082674575,0.00001714998,0.0010134763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999536,0.000005884522,0.0000025821412,0.0000150051455,0.000009543437,0.000013381065],"domain_scores_gemma":[0.99995005,0.0000055045825,0.000017449558,0.0000045011975,0.0000051045436,0.000017434586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055675133,0.00024882416,0.00019693119,0.00012451068,0.00009541545,0.00030514348,0.0001658739,0.00011934896,0.0008936653],"category_scores_gemma":[0.00006639145,0.00007479457,0.0001519297,0.00010323365,0.00041901352,0.00021320667,0.00015345452,0.00032694222,0.00015676368],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011936794,0.000044196797,0.0034577223,0.00009111974,0.000024465397,0.00015244137,0.00003207288,0.0003273016,0.98804164,0.0004765501,0.00007299771,0.006085664],"study_design_scores_gemma":[0.00016748051,0.0009216125,0.090492845,0.000029737974,0.00014138152,0.00080660504,0.00018549846,0.002782725,0.8995804,0.00080643885,0.0040638624,0.000021434047],"about_ca_topic_score_codex":0.0008965394,"about_ca_topic_score_gemma":0.00087892724,"teacher_disagreement_score":0.0008965394,"about_ca_system_score_codex":0.00040528429,"about_ca_system_score_gemma":0.00029269423,"threshold_uncertainty_score":0.0029895902},"labels":[],"label_agreement":null},{"id":"W2801318333","doi":"10.1111/dom.13337","title":"A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; Credit Valley Hospital; Health Sciences Centre; McGill University; University of Toronto; Jewish General Hospital; McGill University Health Centre; Sunnybrook Health Science Centre; LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Sanofi; Merck; Boehringer Ingelheim; AstraZeneca","keywords":"Basal insulin; Type 2 diabetes; Basal (medicine); Insulin; Diabetes mellitus; Medicine; Intensive care medicine; Computer science; Process (computing); Risk analysis (engineering); Algorithm; Endocrinology","score_opus":0.049416641570814795,"score_gpt":0.32308235014969566,"score_spread":0.27366570857888084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801318333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045504302,0.9648245,0.008408421,0.016327173,0.0027211965,0.00055147446,0.0003957851,0.00019161856,0.0061246403],"genre_scores_gemma":[0.004345611,0.94624686,0.03804562,0.007125252,0.0009576177,0.000576645,0.0005411649,0.000021675785,0.0021396335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998615,0.00046955538,0.0003981308,0.00013007512,0.00032317865,0.000064088534],"domain_scores_gemma":[0.99880016,0.0005267733,0.00022039046,0.000029168425,0.00035308997,0.00007051764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029346393,0.0016819736,0.0016525468,0.003002441,0.00055827474,0.0018450868,0.0020940874,0.0021628488,0.005273834],"category_scores_gemma":[0.0045210286,0.00041706045,0.0019644492,0.0020231872,0.0006737239,0.0023565746,0.0014048978,0.0039089634,0.0026112935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012106897,0.000106235624,0.00052154646,0.034621503,0.0002970299,0.0002772994,0.00017466635,0.0007967174,0.00034282682,0.009763345,0.06610565,0.8868722],"study_design_scores_gemma":[0.00021754115,0.00024857107,0.0022543105,0.0758342,0.001333524,0.0020451725,0.0003194644,0.0010382663,0.00043727882,0.016063143,0.90011215,0.00009638666],"about_ca_topic_score_codex":0.0018626695,"about_ca_topic_score_gemma":0.004907643,"teacher_disagreement_score":0.005273834,"about_ca_system_score_codex":0.0014427733,"about_ca_system_score_gemma":0.004365181,"threshold_uncertainty_score":0.017642796},"labels":[],"label_agreement":null},{"id":"W2802498945","doi":"10.1111/dom.13346","title":"Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Foundation; Medical Research Council; National Institute for Health and Care Research; Medical Research Council Canada; Wellcome Trust","keywords":"Medicine; Metformin; Medical prescription; Diabetes mellitus; Drug; Type 2 diabetes; Drug class; Clinical trial; Pharmacology; Internal medicine; Endocrinology","score_opus":0.008734570265024708,"score_gpt":0.22983335037809052,"score_spread":0.22109878011306583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802498945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9419446,0.0056788377,0.00056293164,0.0020578895,0.000068611684,0.000045437344,0.046383947,0.000049575905,0.003208211],"genre_scores_gemma":[0.98179597,0.0019920748,0.0004451376,0.00025675414,0.00006244376,0.00006195322,0.014646694,0.000019293253,0.0007195007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707747,0.00050673075,0.00089037174,0.0006702777,0.0005267561,0.00032835512],"domain_scores_gemma":[0.9837982,0.0019565215,0.009914995,0.0004819611,0.0030673682,0.00078090845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013993611,0.00025117243,0.0005207207,0.0023192447,0.00026682846,0.0009774459,0.0007341796,0.000395035,0.003263873],"category_scores_gemma":[0.013433708,0.00033658472,0.00084464275,0.0048156264,0.00039861776,0.0013781361,0.0013914217,0.0006276706,0.0006542061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001939975,0.000017834574,0.98618364,0.0004323564,0.0002592453,0.0001957125,0.0011956856,0.0004814075,0.00017764393,0.00038895605,0.0035879859,0.006885504],"study_design_scores_gemma":[0.0000066312305,0.000028847639,0.9964675,0.00011651205,0.000033571057,0.00017228645,0.0005210881,0.0002842252,0.000056665398,0.00004477556,0.0022579234,0.000010071998],"about_ca_topic_score_codex":0.16926353,"about_ca_topic_score_gemma":0.1513737,"teacher_disagreement_score":0.16926353,"about_ca_system_score_codex":0.002378067,"about_ca_system_score_gemma":0.0012078489,"threshold_uncertainty_score":0.3365566},"labels":[],"label_agreement":null},{"id":"W2803237745","doi":"10.1111/dom.13370","title":"P465L‐PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Northern British Columbia","funders":"FP7 Health; Wellcome; Medical Research Council; European Commission; Horizon 2020 Framework Programme; Wellcome Trust","keywords":"Internal medicine; Endocrinology; Insulin resistance; Very low-density lipoprotein; Steatosis; Fatty liver; Pathophysiology; Bezafibrate; Biology; Mutant; Lipoprotein; Gene; Medicine; Insulin; Cholesterol; Biochemistry; Disease","score_opus":0.010230307488901745,"score_gpt":0.24301585354469507,"score_spread":0.23278554605579332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803237745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947271,0.0006668871,0.0018087452,0.00018245523,0.00007479376,0.00005650157,0.0012017827,0.0001923984,0.0010892464],"genre_scores_gemma":[0.9917972,0.00073369994,0.0018748813,0.0001327466,0.000045741486,0.000112723224,0.0014287966,0.000078703255,0.0037955523],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99952257,0.00008279239,0.000082460945,0.00011348604,0.00012897604,0.00006980733],"domain_scores_gemma":[0.99973494,0.000028959901,0.0000984148,0.000028135579,0.000014088888,0.0000954739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024413108,0.0010313616,0.00059127226,0.00060738466,0.00034382637,0.00034777605,0.00035255018,0.0007096832,0.0045396793],"category_scores_gemma":[0.0001710131,0.00034212918,0.0007935449,0.00030348598,0.000491455,0.00026234335,0.00041576184,0.0009032686,0.0013457752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006375385,0.00015195552,0.00048686418,0.00003663033,0.00001683971,0.0005986975,0.00001744988,0.00005099663,0.99684167,0.0000639249,0.00008950828,0.0010079425],"study_design_scores_gemma":[0.00036899818,0.0036372875,0.017460447,0.000037864087,0.000107420135,0.008636449,0.000102748134,0.0013115725,0.9644015,0.00011214329,0.0037928163,0.000030739247],"about_ca_topic_score_codex":0.0004808632,"about_ca_topic_score_gemma":0.00050374714,"teacher_disagreement_score":0.0045396793,"about_ca_system_score_codex":0.0002344374,"about_ca_system_score_gemma":0.00022596658,"threshold_uncertainty_score":0.015186727},"labels":[],"label_agreement":null},{"id":"W2803567790","doi":"10.1111/dom.13374","title":"The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double‐blind, randomized, controlled, acute feeding, equivalence trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diet, Metabolism, and Disease","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Saskatchewan; St. Michael's Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research","keywords":"Postprandial; Type 2 diabetes; Randomized controlled trial; Fructose; Medicine; Double blind; Internal medicine; Carbohydrate metabolism; Endocrinology; Diabetes mellitus; Food science; Chemistry; Placebo","score_opus":0.012708680500046518,"score_gpt":0.27247261180939797,"score_spread":0.25976393130935144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803567790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903313,0.0037544235,0.0006709116,0.00036885592,0.0006677258,0.002789376,0.00038681968,0.00007847414,0.0009521642],"genre_scores_gemma":[0.98636043,0.0026501955,0.002369139,0.0009417347,0.0008942551,0.0046982854,0.00047428263,0.00002673661,0.0015850733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980268,0.0012394367,0.0001670717,0.0002799024,0.00014351943,0.00014334243],"domain_scores_gemma":[0.99777776,0.0008005056,0.0005010138,0.0001966496,0.0001421147,0.00058190944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026128774,0.0018132405,0.004605568,0.0006217717,0.00061881775,0.0012378189,0.00138223,0.002875939,0.0049389927],"category_scores_gemma":[0.0036998559,0.0009567145,0.001708161,0.00051140384,0.0016587141,0.001611224,0.0006283787,0.0027853623,0.00066487456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9852924,0.0070140534,0.00013513508,0.00030734303,0.00029765224,0.000011563451,0.000017313116,0.00005824117,0.0010413332,0.00002354952,0.00009575031,0.005705627],"study_design_scores_gemma":[0.91544104,0.08286457,0.00077748793,0.000021463758,0.00023602607,0.000010552563,0.000010002605,0.00013222815,0.00031105638,0.000045985445,0.00013987444,0.000009806585],"about_ca_topic_score_codex":0.0007645328,"about_ca_topic_score_gemma":0.0010152628,"teacher_disagreement_score":0.0049389927,"about_ca_system_score_codex":0.00063308707,"about_ca_system_score_gemma":0.0010798784,"threshold_uncertainty_score":0.016522586},"labels":[],"label_agreement":null},{"id":"W2803715345","doi":"10.1111/dom.13384","title":"Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Ezetimibe; PCSK9; Medicine; Internal medicine; Placebo; Diabetes mellitus; Statin; Endocrinology; Lipoprotein; Cholesterol; LDL receptor; Apolipoprotein A1; Pathology","score_opus":0.03600435787991747,"score_gpt":0.29793487863960166,"score_spread":0.2619305207596842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803715345","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96593195,0.026895268,0.0009032056,0.0006725908,0.0001310575,0.0010442485,0.0023855092,0.000066562614,0.0019695521],"genre_scores_gemma":[0.9874177,0.006159562,0.0014412015,0.0007422467,0.000118198914,0.0010113093,0.0024116188,0.000023438552,0.00067469536],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969111,0.00213316,0.00024819135,0.00034854378,0.00020408907,0.00015501968],"domain_scores_gemma":[0.99722844,0.00097450323,0.00095074234,0.00023294587,0.0002647948,0.00034858374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071474845,0.0008807552,0.003046744,0.00031737293,0.00047788394,0.0011901248,0.00047977283,0.0005390913,0.002783849],"category_scores_gemma":[0.005639362,0.0004217037,0.003916477,0.00047907844,0.0005648327,0.00080305524,0.00081259536,0.001405731,0.00019085428],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9137935,0.0008970878,0.022545673,0.003919185,0.017753152,0.000074953634,0.00017768404,0.0008107284,0.0039032768,0.00019948158,0.0024576513,0.03346764],"study_design_scores_gemma":[0.7372269,0.046794247,0.16105974,0.00087090133,0.04049237,0.00049235614,0.00019192894,0.0021060202,0.0022612836,0.0010035634,0.0074009104,0.00009980243],"about_ca_topic_score_codex":0.0015053729,"about_ca_topic_score_gemma":0.005738125,"teacher_disagreement_score":0.0071474845,"about_ca_system_score_codex":0.00062023994,"about_ca_system_score_gemma":0.0015032643,"threshold_uncertainty_score":0.037800014},"labels":[],"label_agreement":null},{"id":"W2803721928","doi":"10.1111/dom.13351","title":"Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim Japan; Eli Lilly and Company","keywords":"Empagliflozin; Placebo; Medicine; Pharmacodynamics; Insulin; Internal medicine; Randomized controlled trial; Diabetes mellitus; Pharmacokinetics; Type 2 diabetes; Endocrinology","score_opus":0.03184946405653108,"score_gpt":0.3047898708028425,"score_spread":0.27294040674631137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803721928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868666,0.005346042,0.00074927876,0.0005020729,0.000361643,0.0044545466,0.0005910491,0.00007058616,0.0010581979],"genre_scores_gemma":[0.9804575,0.0043952423,0.0029032335,0.0011353622,0.00063077605,0.007917196,0.0009128915,0.000018761082,0.0016290122],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99885595,0.00062180596,0.00009973061,0.00022339908,0.00009182219,0.000107271495],"domain_scores_gemma":[0.9990126,0.0001885042,0.00026397593,0.00008824766,0.00012743585,0.00031917857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038497818,0.0018095572,0.0038216414,0.0003164849,0.00051151647,0.0008716023,0.0007794567,0.0018912228,0.00335455],"category_scores_gemma":[0.002104919,0.0008382174,0.0021507507,0.00044979583,0.0008413001,0.0010855461,0.00043435572,0.0021128685,0.00045247303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9714264,0.008784203,0.0010482577,0.0009736912,0.0015308973,0.000030484514,0.000068822315,0.00011044084,0.0032155493,0.00002281339,0.0003859754,0.012402486],"study_design_scores_gemma":[0.93272305,0.06086742,0.004316492,0.000035095385,0.0012872496,0.000018383997,0.000015470885,0.00016349669,0.0002562273,0.000022128559,0.0002831775,0.000011883305],"about_ca_topic_score_codex":0.0009277853,"about_ca_topic_score_gemma":0.0023662704,"teacher_disagreement_score":0.0038497818,"about_ca_system_score_codex":0.00059924193,"about_ca_system_score_gemma":0.0014754392,"threshold_uncertainty_score":0.020359814},"labels":[],"label_agreement":null},{"id":"W2804740558","doi":"10.1111/dom.13373","title":"Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta‐analysis","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Neurological Disorders and Treatments","field":"Neuroscience","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; Brain and Cognition Discovery Foundation; University Health Network","funders":"Allergan; China Scholarship Council; University of Toronto","keywords":"Medicine; Sitagliptin; Placebo; Metformin; Meta-analysis; Rosiglitazone; Pioglitazone; Randomized controlled trial; Liraglutide; Cochrane Library; Internal medicine; Linagliptin; MEDLINE; Pharmacology; Diabetes mellitus; Type 2 diabetes; Insulin; Endocrinology; Alternative medicine; Pathology","score_opus":0.12507677845945644,"score_gpt":0.36149428675023887,"score_spread":0.23641750829078242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804740558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034471864,0.9949746,0.00034908607,0.000111306945,0.00008780987,0.00044395242,0.00030771017,0.000012423517,0.00026598014],"genre_scores_gemma":[0.11253506,0.881866,0.0022771095,0.0005507043,0.00017531039,0.0016477047,0.0006338852,0.000017394768,0.00029679257],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98907566,0.0058363946,0.002920299,0.0007238032,0.0012204294,0.00022337059],"domain_scores_gemma":[0.9807622,0.014821102,0.0026276507,0.00041058255,0.0011699571,0.00020843458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015270347,0.002356431,0.016383694,0.006882842,0.00057206216,0.0027659736,0.0017496072,0.0018401588,0.0036891778],"category_scores_gemma":[0.035162266,0.0010932981,0.022807084,0.0069159647,0.00067098776,0.0016012624,0.0014995472,0.0015880119,0.00024076932],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020864862,0.000031240575,0.0018886874,0.5453762,0.43232983,0.000078024124,0.00009205482,0.00026692648,0.00016703746,0.00017418862,0.00047377107,0.017035533],"study_design_scores_gemma":[0.0010892571,0.0002539258,0.0028210639,0.04216556,0.9507319,0.00011331607,0.00005817973,0.00015234319,0.00012756797,0.00026936794,0.0021930444,0.000024599653],"about_ca_topic_score_codex":0.005004625,"about_ca_topic_score_gemma":0.012946095,"teacher_disagreement_score":0.016383694,"about_ca_system_score_codex":0.0028740554,"about_ca_system_score_gemma":0.0034626173,"threshold_uncertainty_score":0.08075833},"labels":[],"label_agreement":null},{"id":"W2807363782","doi":"10.1111/dom.13396","title":"Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical endpoint; Sitagliptin; Placebo; Exenatide; Internal medicine; Adverse effect; Weight gain; Weight loss; Dulaglutide; Hypoglycemia; Gastroenterology; Diabetes mellitus; Clinical trial; Insulin; Endocrinology; Obesity; Liraglutide; Body weight","score_opus":0.02843823787394919,"score_gpt":0.3032648852547078,"score_spread":0.2748266473807586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807363782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665663,0.01192444,0.0012801668,0.0013645724,0.0003804567,0.004735355,0.004492602,0.00016986654,0.009086057],"genre_scores_gemma":[0.96984655,0.005297144,0.003874522,0.001469643,0.00063362997,0.008990556,0.005384129,0.000049894898,0.0044539873],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99878305,0.0007900763,0.00009956198,0.00010874345,0.00012401848,0.000094479925],"domain_scores_gemma":[0.99860305,0.0003761205,0.00035842572,0.00012479322,0.00014959942,0.00038801174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004607927,0.00080475473,0.0015713067,0.0002620309,0.00029976948,0.00083610264,0.0005793535,0.00086073414,0.008075047],"category_scores_gemma":[0.004121678,0.00022440654,0.0017334587,0.00047708923,0.00052032777,0.0008164871,0.0006745562,0.0015763412,0.0006836613],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91762364,0.0045986967,0.0050290152,0.0020053082,0.0016099565,0.00007946975,0.00013157731,0.0005829214,0.0019534042,0.00041510514,0.00554613,0.060424797],"study_design_scores_gemma":[0.7450968,0.21967651,0.02078891,0.00057891523,0.0019518415,0.00031006237,0.00011068839,0.0009304914,0.0012595302,0.0006847992,0.008573532,0.000037888112],"about_ca_topic_score_codex":0.00068818784,"about_ca_topic_score_gemma":0.001458243,"teacher_disagreement_score":0.008075047,"about_ca_system_score_codex":0.0003712796,"about_ca_system_score_gemma":0.0013268745,"threshold_uncertainty_score":0.027013779},"labels":[],"label_agreement":null},{"id":"W2807732548","doi":"10.1111/dom.13413","title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Dapagliflozin; Medicine; Placebo; Renal function; Kidney disease; Type 2 diabetes; Internal medicine; Urology; Clinical endpoint; Adverse effect; Randomization; Diabetes mellitus; Gastroenterology; Randomized controlled trial; Endocrinology","score_opus":0.005970261016607593,"score_gpt":0.21811641055821412,"score_spread":0.21214614954160654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807732548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98602,0.008276371,0.00049740815,0.000492193,0.00009789775,0.00043966918,0.0013794558,0.00003516922,0.0027617149],"genre_scores_gemma":[0.993763,0.0024037724,0.0005185799,0.0006977976,0.00027669492,0.0003148164,0.0011669984,0.000009713067,0.00084858044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990722,0.00054794014,0.00005492211,0.00010719071,0.0001655377,0.00005214287],"domain_scores_gemma":[0.9991258,0.00031894422,0.00023433629,0.000086576605,0.000078520294,0.00015599313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021831694,0.00061906286,0.0024284963,0.00021933223,0.00022065348,0.0006932476,0.00040906685,0.0007242917,0.0022456378],"category_scores_gemma":[0.002895137,0.0002640875,0.0017952969,0.00031823156,0.00035797566,0.00049294624,0.0005249602,0.0012517353,0.0003819451],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83369225,0.010300812,0.038638312,0.001203765,0.0071903476,0.0001442568,0.00013069058,0.0016061348,0.006567184,0.0003586544,0.0041177697,0.09604982],"study_design_scores_gemma":[0.6305483,0.16853699,0.17288299,0.00023453492,0.009899941,0.000544171,0.00009626914,0.0051264847,0.002842228,0.0007349452,0.008443979,0.000109072666],"about_ca_topic_score_codex":0.00031971585,"about_ca_topic_score_gemma":0.00079599605,"teacher_disagreement_score":0.0024284963,"about_ca_system_score_codex":0.00033940372,"about_ca_system_score_gemma":0.00042742887,"threshold_uncertainty_score":0.011545837},"labels":[],"label_agreement":null},{"id":"W2808271763","doi":"10.1111/dom.13353","title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"ExxonMobil Research and Engineering Company; Novo Nordisk","keywords":"Semaglutide; Nausea; Weight loss; Vomiting; Medicine; Sitagliptin; Type 2 diabetes; Placebo; Internal medicine; Dulaglutide; Adverse effect; Gastroenterology; Exenatide; Liraglutide; Diabetes mellitus; Obesity; Endocrinology","score_opus":0.019855582552365737,"score_gpt":0.2665220678581215,"score_spread":0.24666648530575574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808271763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95634335,0.036964085,0.0005063607,0.00060618116,0.00030039556,0.0012344621,0.0006342869,0.00012479788,0.003286104],"genre_scores_gemma":[0.98850375,0.008155229,0.0006047836,0.0005109365,0.00021537085,0.0007011579,0.0006090723,0.0000100185825,0.0006895525],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9991986,0.00045503213,0.00013679375,0.00006646746,0.00008350678,0.00005962277],"domain_scores_gemma":[0.999243,0.00023775498,0.00029406545,0.00005136593,0.000067968955,0.000105699924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020681766,0.00073105976,0.0017407385,0.00030232128,0.00022815922,0.0007530528,0.00040831434,0.0007907516,0.0032876641],"category_scores_gemma":[0.0022225787,0.0003284646,0.0023732472,0.00038586545,0.0003593671,0.00048781736,0.00027690217,0.0010049839,0.00024413271],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8871437,0.0026709884,0.008404975,0.0073503135,0.011009378,0.00016246538,0.00015469785,0.00044529192,0.006627488,0.00025360758,0.0018871181,0.07389002],"study_design_scores_gemma":[0.7615791,0.17948839,0.037941854,0.0009989676,0.011877796,0.00040037453,0.0001525649,0.0007370865,0.0025768038,0.0005024993,0.0037048657,0.00003964895],"about_ca_topic_score_codex":0.0005429097,"about_ca_topic_score_gemma":0.0022903841,"teacher_disagreement_score":0.0032876641,"about_ca_system_score_codex":0.00033649665,"about_ca_system_score_gemma":0.0005187545,"threshold_uncertainty_score":0.010998368},"labels":[],"label_agreement":null},{"id":"W2809389718","doi":"10.1111/dom.13445","title":"Impact of macronutrient content of meals on postprandial glucose control in the context of closed‐loop insulin delivery: <scp>A</scp> randomized cross‐over study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Fonds de recherche du Québec – Nature et technologies; Canadian Institutes of Health Research","keywords":"Postprandial; Insulin; Medicine; Meal; Context (archaeology); Internal medicine; Endocrinology; Crossover study; Area under the curve; Carbohydrate; Bolus (digestion); Biology","score_opus":0.019508385797295462,"score_gpt":0.29934680326126195,"score_spread":0.2798384174639665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809389718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770737,0.00034306312,0.0003153993,0.00005501167,0.00013227422,0.0011100991,0.00008767146,0.000020362007,0.00022871463],"genre_scores_gemma":[0.993222,0.00040865646,0.002455114,0.00032714067,0.00023200912,0.0023243376,0.00022032374,0.000013313579,0.0007971147],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99813277,0.0010533733,0.00017329343,0.00025588355,0.0002175507,0.00016723006],"domain_scores_gemma":[0.9977137,0.0007584484,0.00053304154,0.00024120744,0.00020434729,0.0005492315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028348162,0.0010100405,0.0024378248,0.00034258302,0.00047041394,0.0010373173,0.0008417732,0.0016956354,0.002643113],"category_scores_gemma":[0.0027176673,0.0007649296,0.0012878708,0.00034895886,0.0011046907,0.0007476987,0.000563472,0.0016203375,0.00027304635],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9597662,0.024945885,0.00068328436,0.0003166725,0.0005761191,0.000017322847,0.000034948825,0.0001495648,0.005103566,0.000031019008,0.00010197616,0.008273416],"study_design_scores_gemma":[0.406298,0.58085006,0.008047494,0.00003548694,0.0010162066,0.000019912635,0.000032026106,0.0005801394,0.0026687074,0.000072303395,0.00035515672,0.000024440158],"about_ca_topic_score_codex":0.0011732471,"about_ca_topic_score_gemma":0.0013249877,"teacher_disagreement_score":0.0028348162,"about_ca_system_score_codex":0.0005596707,"about_ca_system_score_gemma":0.001301046,"threshold_uncertainty_score":0.014992118},"labels":[],"label_agreement":null},{"id":"W2809681611","doi":"10.1111/dom.13377","title":"Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Canadian VIGOUR Centre; University of Alberta","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research","keywords":"Medicine; Type 2 diabetes; Hazard ratio; Sitagliptin; Internal medicine; Aspirin; Diabetes mellitus; Myocardial infarction; Stroke (engine); Angina; Disease; Proportional hazards model; Confidence interval; Endocrinology","score_opus":0.007154820336780577,"score_gpt":0.19809272029479205,"score_spread":0.19093789995801147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809681611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9027919,0.08131522,0.0010231625,0.0038778833,0.0005685458,0.000100679696,0.0041339323,0.00002753488,0.0061610923],"genre_scores_gemma":[0.9645957,0.028711569,0.0005645686,0.0017156403,0.0008358725,0.00008522516,0.002532426,0.00002633815,0.000932822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885964,0.0003898113,0.00013848957,0.00016380035,0.00036186437,0.000086412096],"domain_scores_gemma":[0.99581075,0.0020951144,0.0010565725,0.00022905204,0.0005965833,0.00021198523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004085719,0.00022858949,0.00040849848,0.0006645081,0.00020281361,0.00060701655,0.00022836076,0.00037026146,0.0009641203],"category_scores_gemma":[0.0073147337,0.00015794269,0.000646211,0.0010182589,0.00023568707,0.00036698068,0.0003857875,0.00041198163,0.00013986208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015544376,0.00007770927,0.95030713,0.0002954372,0.00041483107,0.0002350001,0.00039506448,0.00006328321,0.00025694724,0.00012481427,0.003325227,0.04295022],"study_design_scores_gemma":[0.00014764811,0.00034402823,0.9890927,0.00024983633,0.000374123,0.0008708652,0.00038641976,0.000082162485,0.00018257546,0.00008235798,0.008168871,0.000018371573],"about_ca_topic_score_codex":0.0039873174,"about_ca_topic_score_gemma":0.0025433588,"teacher_disagreement_score":0.004085719,"about_ca_system_score_codex":0.00025919013,"about_ca_system_score_gemma":0.0006833757,"threshold_uncertainty_score":0.021607637},"labels":[],"label_agreement":null},{"id":"W2810651762","doi":"10.1111/dom.13448","title":"Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; McGill University; University of Alberta; McGill University Health Centre","funders":"Government of Canada","keywords":"Metformin; Medicine; Exacerbation; Hazard ratio; Confidence interval; Diabetes mellitus; Proportional hazards model; Internal medicine; Heart failure; Type 2 diabetes; Population; Cumulative dose; Endocrinology; Environmental health","score_opus":0.009007983188584895,"score_gpt":0.21779254340710125,"score_spread":0.20878456021851635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810651762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519664,0.0031836813,0.0007361449,0.00022390681,0.000020786953,0.000015913532,0.0002746615,0.000008087337,0.00034020448],"genre_scores_gemma":[0.99898595,0.00032310668,0.0002939575,0.000052428662,0.000036236666,0.000008075067,0.00023097715,0.0000022318452,0.00006709752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996452,0.0021598556,0.00025096515,0.00045983234,0.0003838915,0.00029338896],"domain_scores_gemma":[0.9825362,0.011413063,0.003928445,0.0010282155,0.00037597347,0.00071811414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009170264,0.0005567441,0.00082768826,0.00067859876,0.00027833067,0.0013401284,0.00073171395,0.00096946,0.0015970394],"category_scores_gemma":[0.019338375,0.00039277403,0.0031396467,0.00073075545,0.00039047914,0.0010838174,0.0011950465,0.0012696082,0.000109135806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005052833,0.00017053467,0.9820386,0.00012063289,0.0023309714,0.00011068903,0.00007305947,0.0029104247,0.00012732697,0.00013559588,0.00007476884,0.00685455],"study_design_scores_gemma":[0.00024361919,0.0025554446,0.97578865,0.000101800724,0.0021489724,0.00034579003,0.00018373986,0.017394407,0.00017870654,0.00065820385,0.00037398393,0.000026619899],"about_ca_topic_score_codex":0.0026335744,"about_ca_topic_score_gemma":0.0032674975,"teacher_disagreement_score":0.009170264,"about_ca_system_score_codex":0.0005254591,"about_ca_system_score_gemma":0.0005876018,"threshold_uncertainty_score":0.048497558},"labels":[],"label_agreement":null},{"id":"W2881018690","doi":"10.1111/dom.13460","title":"The effects of kisspeptin on β‐cell function, serum metabolites and appetite in humans","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Hypothalamic control of reproductive hormones","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Medical Research Council; Medical Research Council Canada; Biotechnology and Biological Sciences Research Council; Rosetrees Trust; Imperial College London; Diabetes UK; National Institute for Health and Care Research; Wellcome Trust","keywords":"Medicine; Kisspeptin; Appetite; Endocrinology; Internal medicine; Pharmacology; Function (biology); Hypothalamus; Genetics","score_opus":0.0036731325301247028,"score_gpt":0.20235299383027328,"score_spread":0.19867986130014859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2881018690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781637,0.01851468,0.0005097518,0.00019721681,0.00005249141,0.000020284291,0.00025282602,0.000015599162,0.002273343],"genre_scores_gemma":[0.99416804,0.0045884885,0.00044340832,0.00017494308,0.00003294986,0.00001768506,0.00012686686,0.0000048055217,0.0004427599],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999312,0.000027528067,0.0000053094413,0.000016095522,0.000011614894,0.000008276602],"domain_scores_gemma":[0.9999312,0.00001936849,0.000020706262,0.000007997392,0.000004428549,0.000016207829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032782456,0.00017527399,0.00035036844,0.00013991116,0.00013872606,0.00031635698,0.000054341996,0.00022081805,0.001158287],"category_scores_gemma":[0.000253981,0.00010403461,0.00020104615,0.000106748215,0.00024183985,0.00019593588,0.00013329678,0.0002663313,0.00015336192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044023976,0.00146561,0.22617641,0.0015872782,0.0012096791,0.0025844106,0.0006266143,0.0011132864,0.49751592,0.0012816854,0.0027094015,0.21970573],"study_design_scores_gemma":[0.0005760135,0.020567404,0.91203886,0.00013654862,0.0005865487,0.0055139842,0.00047923118,0.0008058502,0.043504596,0.0011403708,0.014606527,0.000043986827],"about_ca_topic_score_codex":0.00016730095,"about_ca_topic_score_gemma":0.00017745268,"teacher_disagreement_score":0.001158287,"about_ca_system_score_codex":0.000118253854,"about_ca_system_score_gemma":0.00010464073,"threshold_uncertainty_score":0.003874898},"labels":[],"label_agreement":null},{"id":"W2883282832","doi":"10.1111/dom.13470","title":"Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild‐to‐moderate renal impairment","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health; University of Alberta Hospital; University of Alberta; Alberta Health Services","funders":"Servier; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Novo Nordisk; Valeant Pharmaceuticals International; Sanofi; American Diabetes Association","keywords":"Medicine; Insulin glargine; Type 2 diabetes; Type 1 diabetes; Internal medicine; Continuous glucose monitoring; Diabetes mellitus; Insulin; Endocrinology","score_opus":0.015610115476800567,"score_gpt":0.2655334214507449,"score_spread":0.2499233059739443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883282832","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16827813,0.8247077,0.0016297108,0.000994318,0.0011392708,0.0002962966,0.0006863799,0.00010704923,0.002161183],"genre_scores_gemma":[0.8818214,0.113094255,0.0013035536,0.0015309937,0.00086181174,0.00024787485,0.00042621416,0.000031411553,0.00068253925],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965113,0.0021501998,0.00049508724,0.0004446213,0.00024899654,0.00014975476],"domain_scores_gemma":[0.9947371,0.0037094997,0.0010270472,0.00020692828,0.00015911167,0.00016024587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007052193,0.00164479,0.007719377,0.0011444798,0.00025715056,0.0019209187,0.00075610064,0.0017834175,0.002692791],"category_scores_gemma":[0.009201841,0.00095171377,0.022841727,0.0013202105,0.00059163646,0.00097428885,0.0007403007,0.0025035215,0.00023238329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21844903,0.0003863456,0.008549684,0.059317283,0.6433942,0.00023558897,0.00012407446,0.001988291,0.0017661593,0.00028079576,0.0011574634,0.0643511],"study_design_scores_gemma":[0.063590325,0.014510264,0.025684673,0.0046290183,0.88467914,0.00028713065,0.000106981664,0.0010502686,0.0007092486,0.0010885531,0.0036000432,0.00006438534],"about_ca_topic_score_codex":0.0019700262,"about_ca_topic_score_gemma":0.002802891,"teacher_disagreement_score":0.007719377,"about_ca_system_score_codex":0.0005390676,"about_ca_system_score_gemma":0.0005642846,"threshold_uncertainty_score":0.037296057},"labels":[],"label_agreement":null},{"id":"W2887023054","doi":"10.1111/dom.13483","title":"3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF) prevents high fat diet‐induced insulin resistance via maintenance of hepatic lipid homeostasis","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Insulin resistance; Internal medicine; Lipid metabolism; FGF21; Endocrinology; Fatty liver; Beta oxidation; Fatty acid; Lipid droplet; Chemistry; Fish oil; Lipotoxicity; Biology; Biochemistry; Insulin; Fibroblast growth factor; Medicine; Receptor","score_opus":0.008596861381035804,"score_gpt":0.2335609512493906,"score_spread":0.2249640898683548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887023054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98966,0.0052591874,0.00266893,0.00028630914,0.00007759422,0.0000807743,0.0005535196,0.00018913613,0.0012245202],"genre_scores_gemma":[0.9848187,0.0045340746,0.0053948704,0.00017082867,0.000057856352,0.000115966955,0.00082479545,0.00003200874,0.004050867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998814,0.000019571115,0.000008752242,0.000023347415,0.000032851993,0.000034097],"domain_scores_gemma":[0.9998965,0.000009992685,0.000044794957,0.000008282079,0.000010292371,0.000030107862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001476763,0.0006222661,0.0003481856,0.0005962205,0.00019133861,0.00017508892,0.0002484361,0.00042475888,0.0016262617],"category_scores_gemma":[0.00007829941,0.00014345985,0.0003354836,0.00025710056,0.00029951666,0.00023404162,0.00015798847,0.00085975335,0.00037176782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012477423,0.0002739123,0.00019683364,0.000087789005,0.000012608848,0.000049839204,0.000005928649,0.00006205819,0.9929611,0.00004754438,0.00006671042,0.0049878573],"study_design_scores_gemma":[0.000264831,0.003868706,0.005212441,0.00002094803,0.00005806491,0.00024536424,0.000020442072,0.00038009745,0.98688996,0.00003877552,0.0029919585,0.0000083372315],"about_ca_topic_score_codex":0.00040464022,"about_ca_topic_score_gemma":0.00077175786,"teacher_disagreement_score":0.0016262617,"about_ca_system_score_codex":0.00021752909,"about_ca_system_score_gemma":0.00025498745,"threshold_uncertainty_score":0.0054403543},"labels":[],"label_agreement":null},{"id":"W2889776606","doi":"10.1111/dom.13528","title":"The association of basal insulin treatment versus standard care with outcomes in anti‐GAD positive and negative subjects: A post‐hoc analysis of the ORIGIN trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Sanofi","keywords":"Insulin glargine; Medicine; Hazard ratio; Internal medicine; Confidence interval; Placebo; Incidence (geometry); Post-hoc analysis; Diabetes mellitus; Myocardial infarction; Randomized controlled trial; Stroke (engine); Gastroenterology; Insulin; Endocrinology; Hypoglycemia","score_opus":0.004122859864936471,"score_gpt":0.22987035766844277,"score_spread":0.2257474978035063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889776606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268895,0.0039595864,0.0005697317,0.00023419995,0.00044510144,0.0003884225,0.00068941154,0.000038136353,0.0009864437],"genre_scores_gemma":[0.9955302,0.0008144748,0.00056509697,0.00026965296,0.0002518478,0.00058417016,0.0006928336,0.000032189208,0.0012595226],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99448806,0.0040764264,0.00027087328,0.0004990785,0.0002118711,0.00045374705],"domain_scores_gemma":[0.9930508,0.0047136447,0.00071122777,0.0006488318,0.0002897444,0.00058573706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070124227,0.0015638667,0.0054574497,0.0003283679,0.0003382497,0.0017455968,0.0011054645,0.0014376041,0.0036983043],"category_scores_gemma":[0.008183826,0.00056983455,0.007197102,0.00044428214,0.0008007533,0.0012183082,0.0009942936,0.0031371326,0.00035476344],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98659176,0.00043210696,0.0025051842,0.0002766471,0.0077626533,0.000031403353,0.00002992468,0.0001492446,0.00038547112,0.000046314934,0.00020671338,0.0015824646],"study_design_scores_gemma":[0.7167218,0.15955566,0.05980274,0.00019461046,0.054907292,0.00012267247,0.00024463126,0.0042158067,0.0016626543,0.00075966195,0.001703612,0.0001088327],"about_ca_topic_score_codex":0.0013538316,"about_ca_topic_score_gemma":0.0015918828,"teacher_disagreement_score":0.0070124227,"about_ca_system_score_codex":0.0006073904,"about_ca_system_score_gemma":0.0007932369,"threshold_uncertainty_score":0.037085712},"labels":[],"label_agreement":null},{"id":"W2889838690","doi":"10.1111/dom.13401","title":"Islet prohormone processing in health and disease","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Children's Hospital; Juvenile Diabetes Research Foundation International","keywords":"Proglucagon; Prohormone; Prohormone convertase; Proinsulin; Islet; Endocrinology; Enteroendocrine cell; Internal medicine; Amylin; Glucose homeostasis; Insulin; Glucagon; Biology; Type 2 diabetes; Hormone; Medicine; Insulin resistance; Diabetes mellitus; Glucagon-like peptide-1; Endocrine system","score_opus":0.029852731100373127,"score_gpt":0.3060687038235041,"score_spread":0.276215972723131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889838690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024509162,0.9413184,0.0020300553,0.008274363,0.0028053382,0.000027771523,0.00073662057,0.00018803102,0.020110304],"genre_scores_gemma":[0.27319136,0.6888815,0.0048099286,0.007063449,0.0067593358,0.00012813235,0.0020981885,0.00011484406,0.016953241],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962103,0.00008657286,0.000044834153,0.00008819571,0.00009408326,0.000065208485],"domain_scores_gemma":[0.9995795,0.00006720451,0.00009628568,0.000032646807,0.00009937698,0.00012501082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091739645,0.0005910114,0.00074850896,0.00096307334,0.00040693444,0.0021151206,0.0005707942,0.0012843143,0.0043195207],"category_scores_gemma":[0.001042973,0.00018763472,0.00038951845,0.0011538562,0.00084789173,0.00082129345,0.0013711125,0.0016395982,0.0021844534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023189588,0.00030587244,0.033348247,0.006063606,0.00067254185,0.0063450425,0.0012587182,0.0008729948,0.03179468,0.03604975,0.10251996,0.77844965],"study_design_scores_gemma":[0.00018508888,0.0006372469,0.0782557,0.004185272,0.0005217683,0.014162467,0.0008874626,0.0006817893,0.004342763,0.044242438,0.85177004,0.00012795936],"about_ca_topic_score_codex":0.00088806136,"about_ca_topic_score_gemma":0.00053528947,"teacher_disagreement_score":0.0043195207,"about_ca_system_score_codex":0.0006136427,"about_ca_system_score_gemma":0.00075619394,"threshold_uncertainty_score":0.014450252},"labels":[],"label_agreement":null},{"id":"W2890415448","doi":"10.1111/dom.13522","title":"Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research; Lundbeckfonden; Steno Diabetes Center Copenhagen","keywords":"Medicine; Glucagon-like peptide-1; Antipsychotic; Glucagon-like peptide 1 receptor; Meta-analysis; Pharmacology; Internal medicine; Diabetes mellitus; Endocrinology; Receptor; Schizophrenia (object-oriented programming); Type 2 diabetes; Agonist; Psychiatry","score_opus":0.14773646459709897,"score_gpt":0.3460003284333762,"score_spread":0.19826386383627723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890415448","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045062173,0.99310017,0.0007122511,0.00019300258,0.00015467074,0.00051347585,0.00056227,0.0000330776,0.00022481676],"genre_scores_gemma":[0.14689471,0.84520286,0.0030057153,0.0010114267,0.0002062175,0.0022437877,0.0010160623,0.000040221563,0.00037891243],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9919464,0.004038292,0.0022429738,0.0007878497,0.0007610174,0.00022346179],"domain_scores_gemma":[0.98711956,0.009175443,0.0021218378,0.0004106002,0.0009862815,0.00018629742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012711206,0.0026386431,0.021106929,0.0053101853,0.00061717944,0.0028948216,0.0020729327,0.0023543583,0.0038585328],"category_scores_gemma":[0.026842887,0.001466839,0.03376477,0.0059908754,0.000740185,0.0016347021,0.0014014835,0.0017886703,0.0003393589],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020063769,0.000028972228,0.0017215135,0.43780905,0.5481326,0.0000939784,0.00006611821,0.00032237018,0.00021349847,0.00010385055,0.0004609652,0.009040729],"study_design_scores_gemma":[0.00070541183,0.0001955724,0.0016674112,0.026266377,0.9695323,0.0000697959,0.00003120852,0.00011181596,0.00008235943,0.00012375176,0.0011967135,0.000017216355],"about_ca_topic_score_codex":0.0062355506,"about_ca_topic_score_gemma":0.015025379,"teacher_disagreement_score":0.021106929,"about_ca_system_score_codex":0.002434359,"about_ca_system_score_gemma":0.00391774,"threshold_uncertainty_score":0.067224145},"labels":[],"label_agreement":null},{"id":"W2891590598","doi":"10.1111/dom.13387","title":"Islet stress, degradation and autoimmunity","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"Diabetes Fonds; Juvenile Diabetes Research Foundation United States of America","keywords":"Endoplasmic-reticulum-associated protein degradation; Unfolded protein response; Endoplasmic reticulum; Proteasome; Autoimmunity; Protein degradation; Cell biology; Immune system; Biology; Ubiquitin; Inflammation; Context (archaeology); Translation (biology); Immunology; Biochemistry; Messenger RNA","score_opus":0.013411365750661654,"score_gpt":0.262544797419163,"score_spread":0.24913343166850133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891590598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014046412,0.99806625,0.000087021406,0.00026047917,0.00029405768,0.0000021277133,0.000010251109,0.000007039044,0.0011323319],"genre_scores_gemma":[0.0009799787,0.9976508,0.00010888132,0.0001705387,0.00019912531,0.0000039220777,0.000018559025,0.000001516023,0.0008665958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987745,0.000020988027,0.000019366615,0.000021990125,0.000044329696,0.000015952117],"domain_scores_gemma":[0.99989295,0.00003891398,0.000018359622,0.00000511668,0.00002784597,0.00001677439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027984174,0.00065187586,0.0006818163,0.0014607232,0.00034494261,0.0009728043,0.00050314993,0.0010237772,0.0028968703],"category_scores_gemma":[0.00038356686,0.00018397094,0.00027888874,0.0013678677,0.00040403462,0.0010434858,0.00065997086,0.0013940352,0.0016636178],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007744193,0.000070732385,0.00022405124,0.0129023185,0.0000603813,0.00042121497,0.0001276519,0.0003169079,0.002955837,0.008294911,0.04043202,0.9341166],"study_design_scores_gemma":[0.000006390128,0.00004833558,0.00064483745,0.0016255635,0.00002782339,0.0016404737,0.000050799175,0.000036926573,0.00038046407,0.0028340332,0.9926951,0.000009329922],"about_ca_topic_score_codex":0.00067537796,"about_ca_topic_score_gemma":0.0009978728,"teacher_disagreement_score":0.0028968703,"about_ca_system_score_codex":0.00052295654,"about_ca_system_score_gemma":0.0007693443,"threshold_uncertainty_score":0.009691},"labels":[],"label_agreement":null},{"id":"W2893097539","doi":"10.1111/dom.13547","title":"Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Liraglutide; Medicine; Placebo; Quality of life (healthcare); EQ-5D; Visual analogue scale; Confidence interval; Physical therapy; Clinical trial; Type 2 diabetes; Internal medicine; Diabetes mellitus; Gerontology; Health related quality of life; Alternative medicine; Nursing; Endocrinology","score_opus":0.03952394011067687,"score_gpt":0.3006571993597987,"score_spread":0.2611332592491218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893097539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671085,0.0074897376,0.00029025885,0.000835075,0.0002230668,0.000651325,0.0010531419,0.000032124055,0.0027144302],"genre_scores_gemma":[0.99054015,0.0021211787,0.0005928612,0.0010317776,0.00042600848,0.0016966119,0.002076337,0.0000068300465,0.0015082406],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998607,0.00089430186,0.00009317222,0.00015582309,0.00013683326,0.0001129783],"domain_scores_gemma":[0.99914944,0.0002081949,0.0002766206,0.00006485673,0.000098349185,0.00020251122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003121201,0.00046680312,0.0016082198,0.0001650176,0.00032802118,0.000868137,0.0003729691,0.00085052924,0.0027190812],"category_scores_gemma":[0.0025630046,0.00016657812,0.0013257324,0.00025536213,0.0003076624,0.00063720945,0.0004961603,0.0013006892,0.00042714173],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74320364,0.0067289793,0.14896426,0.0026924966,0.006501563,0.00020241785,0.00027914593,0.00075283565,0.0019767992,0.00036196224,0.006290258,0.08204565],"study_design_scores_gemma":[0.53983074,0.17611462,0.258669,0.0010339647,0.009977317,0.00036583524,0.00048011405,0.0021035266,0.0012458717,0.0009777546,0.009111376,0.00008986899],"about_ca_topic_score_codex":0.0004930287,"about_ca_topic_score_gemma":0.0010371795,"teacher_disagreement_score":0.003121201,"about_ca_system_score_codex":0.00026028123,"about_ca_system_score_gemma":0.00050036685,"threshold_uncertainty_score":0.016506672},"labels":[],"label_agreement":null},{"id":"W2894644761","doi":"10.1111/dom.13553","title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University Health Network; University of Toronto; Toronto General Hospital; LMC Diabetes & Endocrinology (Canada); Heart and Stroke Foundation","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Type 2 diabetes; Baseline (sea); Diabetes mellitus; Internal medicine; Endocrinology; Liraglutide","score_opus":0.011917956048650204,"score_gpt":0.20899184292867204,"score_spread":0.19707388688002184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894644761","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8339048,0.041131176,0.008051577,0.0049148323,0.0014620605,0.08092101,0.011729284,0.00023532208,0.017649978],"genre_scores_gemma":[0.8455059,0.009294388,0.022278287,0.0061316993,0.0023602953,0.099257775,0.0094205085,0.000072170216,0.0056790295],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616325,0.0026691027,0.00021516567,0.00035487814,0.00043266357,0.00016499417],"domain_scores_gemma":[0.9982041,0.00048198018,0.0005076167,0.00017575132,0.0002145917,0.0004160032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009238606,0.0012756517,0.0020792482,0.00030431838,0.0005451605,0.001262193,0.0009173003,0.0020448861,0.0041641043],"category_scores_gemma":[0.0048795673,0.00046109728,0.0013851488,0.0006812824,0.0010033265,0.0008591626,0.0005064855,0.0019317238,0.001206229],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8892263,0.007510725,0.027793996,0.0042617833,0.0023032734,0.0002491702,0.00020312973,0.0013675067,0.006401891,0.0018616057,0.0069162385,0.0519044],"study_design_scores_gemma":[0.825035,0.10730818,0.04154009,0.0007352028,0.0030222095,0.00039709607,0.000075881195,0.001650309,0.0015987626,0.0014976074,0.017024128,0.000115510746],"about_ca_topic_score_codex":0.00029599297,"about_ca_topic_score_gemma":0.0007557883,"teacher_disagreement_score":0.009238606,"about_ca_system_score_codex":0.0005069748,"about_ca_system_score_gemma":0.00170877,"threshold_uncertainty_score":0.048859},"labels":[],"label_agreement":null},{"id":"W2894644940","doi":"10.1111/dom.13549","title":"Effect of selenium supplementation on changes in HbA1c: Results from a multiple‐dose, randomized controlled trial","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Selenium in Biological Systems","field":"Nursing","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Odense Universitetshospital; Kræftens Bekæmpelse","keywords":"Medicine; Selenium; Randomized controlled trial; Internal medicine","score_opus":0.011326318039326008,"score_gpt":0.26467763241626463,"score_spread":0.25335131437693864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894644940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93840605,0.04689159,0.0018804244,0.0014943077,0.0021507298,0.005580778,0.0012724414,0.00019425427,0.002129367],"genre_scores_gemma":[0.97331625,0.012672571,0.002918577,0.0013136134,0.00096268463,0.006205328,0.00072341436,0.00003774062,0.0018497378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99538594,0.0027955354,0.00058822177,0.00067663094,0.0003551519,0.00019861435],"domain_scores_gemma":[0.9965329,0.0016174605,0.000942576,0.0002726967,0.0002708893,0.00036353196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050920653,0.0017799421,0.0073710047,0.00061812135,0.0006775354,0.001751136,0.0014043113,0.0034144465,0.0066403584],"category_scores_gemma":[0.0064167073,0.0009149009,0.0047121663,0.00075944077,0.0011588328,0.0013117503,0.00054331374,0.0022327781,0.0006438813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9879596,0.0012379551,0.00026754927,0.0017684367,0.003576276,0.000019339384,0.000018646315,0.00009310159,0.00051606185,0.000030055151,0.00014754762,0.0043653073],"study_design_scores_gemma":[0.97586536,0.019421108,0.0011046223,0.00013959479,0.002918728,0.0000138075275,0.000010119593,0.00012908425,0.00013160912,0.000055960398,0.00019857363,0.000011443775],"about_ca_topic_score_codex":0.00089187553,"about_ca_topic_score_gemma":0.0015731083,"teacher_disagreement_score":0.0073710047,"about_ca_system_score_codex":0.0008484133,"about_ca_system_score_gemma":0.001153376,"threshold_uncertainty_score":0.026929736},"labels":[],"label_agreement":null},{"id":"W2894980769","doi":"10.1111/dom.13552","title":"Personalized risk‐based screening for diabetic retinopathy: A multivariate approach versus the use of stratification rules","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Engineering and Physical Sciences Research Council; Medical Research Council Canada; Medical Research Council; National Institute for Health and Care Research","keywords":"Multivariate statistics; Confidence interval; Multivariate analysis; Diabetic retinopathy; Stratification (seeds); Risk stratification; Medicine; Diabetes mellitus; Artificial intelligence; Mathematics; Statistics; Internal medicine; Computer science","score_opus":0.07209137526660578,"score_gpt":0.2937419889729786,"score_spread":0.22165061370637282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894980769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69282323,0.0043329806,0.28837538,0.0052908855,0.00028552406,0.0004156681,0.004836883,0.0010558675,0.002583566],"genre_scores_gemma":[0.95980406,0.00042704208,0.036972255,0.0003026132,0.00021253279,0.00008626976,0.0017161529,0.00003463149,0.00044437803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960576,0.002263428,0.00026350655,0.000918572,0.00029209603,0.00020480267],"domain_scores_gemma":[0.9884644,0.008115542,0.0014754554,0.00083087856,0.0006547387,0.00045909983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068799714,0.0015819028,0.0024104912,0.002535577,0.00043933716,0.001927851,0.0012271444,0.0010088062,0.0010873833],"category_scores_gemma":[0.014198138,0.00042495911,0.002195932,0.0012169605,0.00044710637,0.0011618531,0.0013608173,0.0022282668,0.00032537317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025451877,0.00084925676,0.592464,0.00032393954,0.0024813702,0.00039833906,0.00031703027,0.19911402,0.0019427264,0.0018933251,0.0035936313,0.1940771],"study_design_scores_gemma":[0.00009311993,0.00052451674,0.051424123,0.00011804615,0.0005516266,0.0002227755,0.000099464094,0.9389462,0.0006384644,0.0063282317,0.0009821334,0.00007135335],"about_ca_topic_score_codex":0.007138543,"about_ca_topic_score_gemma":0.0075754267,"teacher_disagreement_score":0.007138543,"about_ca_system_score_codex":0.00062639924,"about_ca_system_score_gemma":0.0010401862,"threshold_uncertainty_score":0.03638518},"labels":[],"label_agreement":null},{"id":"W2895653157","doi":"10.1111/dom.13550","title":"Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Bayer","keywords":"Medicine; Diabetes mellitus; Macrovascular disease; Diabetic retinopathy; Referral; Disease; Stroke (engine); Nephropathy; Intensive care medicine; Retinopathy; Type 2 diabetes; Internal medicine; Family medicine","score_opus":0.03245947634275809,"score_gpt":0.3370501022343341,"score_spread":0.30459062589157604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895653157","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046743496,0.99830085,0.000072759976,0.00036426913,0.000118657226,0.000107957894,0.0004137906,0.0000042300735,0.00015018575],"genre_scores_gemma":[0.013221406,0.9846332,0.00046304904,0.0008909843,0.00012007503,0.00028237785,0.00029830562,0.0000053585386,0.000085237676],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9909146,0.003193733,0.0035643878,0.00064145913,0.0013958049,0.00029009386],"domain_scores_gemma":[0.9541415,0.034292728,0.0078148525,0.0005765804,0.0028078926,0.00036638955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009325206,0.0012113738,0.007337052,0.009757689,0.00056011224,0.0026873322,0.0015723634,0.0018944083,0.0047848565],"category_scores_gemma":[0.055681325,0.0011757044,0.009019806,0.011548451,0.0007452161,0.00220729,0.0013511614,0.0014584096,0.00029387113],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011308379,0.000010663246,0.001739822,0.9579395,0.01179556,0.000077675264,0.000107845335,0.000090071815,0.0000618888,0.00020815447,0.0025002882,0.025355436],"study_design_scores_gemma":[0.00022996243,0.00011620999,0.0075415913,0.8847709,0.08973969,0.00036343082,0.00022015483,0.00009956381,0.00007493442,0.00044792757,0.01636131,0.000034338835],"about_ca_topic_score_codex":0.017625183,"about_ca_topic_score_gemma":0.048299987,"teacher_disagreement_score":0.017625183,"about_ca_system_score_codex":0.003497298,"about_ca_system_score_gemma":0.012468933,"threshold_uncertainty_score":0.049317002},"labels":[],"label_agreement":null},{"id":"W2896703135","doi":"10.1111/dom.13556","title":"The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; University of Toronto; Juvenile Diabetes Research Foundation International","keywords":"Effective renal plasma flow; Medicine; Renal function; Internal medicine; Endocrinology; Tamm–Horsfall protein; Type 2 diabetes; Albuminuria; Type 1 diabetes; Lipocalin; Diabetes mellitus; Urology; Kidney; Renal blood flow","score_opus":0.012173041915362885,"score_gpt":0.22912827455064302,"score_spread":0.21695523263528013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896703135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466395,0.0011212438,0.000102264545,0.00012917552,0.000011413858,0.00002146001,0.0030454393,0.0000051166853,0.00089982076],"genre_scores_gemma":[0.9977691,0.0003638868,0.000107858104,0.00006188663,0.000011540435,0.000009170124,0.0014205269,0.000001787178,0.00025414076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994331,0.00005784384,0.000045298828,0.000121233235,0.00020824945,0.00013428743],"domain_scores_gemma":[0.9988049,0.00007745418,0.0003005637,0.000056041652,0.00045577818,0.00030524711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008624648,0.00039541663,0.00048734515,0.0007782922,0.0009782326,0.00066926307,0.00052979775,0.00040558793,0.0009494983],"category_scores_gemma":[0.0016322014,0.00019488132,0.00045988723,0.0017815068,0.00027691456,0.0002010519,0.00061386754,0.00064721936,0.0001261377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007364831,0.000011947729,0.9983461,0.000012375909,0.00006523329,0.0000158609,0.00010135609,0.000021942107,0.00006810348,0.000010732103,0.0001645969,0.0011081335],"study_design_scores_gemma":[0.0000020148198,0.000009806144,0.9997482,0.0000028117,0.000017540593,0.000014546656,0.000054329903,0.000029317229,0.0000067585615,0.0000027103106,0.000110351546,0.0000016083317],"about_ca_topic_score_codex":0.78892857,"about_ca_topic_score_gemma":0.82603365,"teacher_disagreement_score":0.21107143,"about_ca_system_score_codex":0.0024373005,"about_ca_system_score_gemma":0.0020022658,"threshold_uncertainty_score":0.4246289},"labels":[],"label_agreement":null},{"id":"W2897347858","doi":"10.1111/dom.13412","title":"Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"Personalized medicine; Medicine; Precision medicine; Intensive care medicine; Disease; Alternative medicine; Health care; Clinical Practice; Diabetes mellitus; MEDLINE; Family medicine; Bioinformatics; Pathology","score_opus":0.04989399605290109,"score_gpt":0.3150990897770885,"score_spread":0.26520509372418744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897347858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040681753,0.9675606,0.0009153814,0.02449043,0.0008931091,0.00002497397,0.00003064349,0.000011938703,0.005666068],"genre_scores_gemma":[0.0072204657,0.98355144,0.0014476485,0.0063797305,0.00043061806,0.00003523622,0.000033044336,0.0000040830128,0.000897664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970203,0.0017395521,0.0002772722,0.00013934876,0.00061762414,0.0002058964],"domain_scores_gemma":[0.9960312,0.0026701873,0.0002504805,0.000077086675,0.00075947965,0.00021145908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051719174,0.0005197857,0.0009316133,0.0013523413,0.00067796104,0.0028227994,0.001078921,0.0029838474,0.0033411346],"category_scores_gemma":[0.0066963076,0.00019363938,0.0008733752,0.0018320568,0.00095181353,0.0028716717,0.0018385996,0.003140351,0.00075640256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054135555,0.00007735718,0.0004918813,0.040427823,0.00022324924,0.0006555137,0.0019558354,0.00046585704,0.00071771233,0.034771916,0.052582998,0.86757576],"study_design_scores_gemma":[0.000012408868,0.000048374633,0.00060091645,0.026144661,0.00015234134,0.000938846,0.0014346702,0.00010388144,0.00022694249,0.008790542,0.9615237,0.000022695365],"about_ca_topic_score_codex":0.0019818603,"about_ca_topic_score_gemma":0.004256306,"teacher_disagreement_score":0.0051719174,"about_ca_system_score_codex":0.0013597155,"about_ca_system_score_gemma":0.0056271614,"threshold_uncertainty_score":0.027351975},"labels":[],"label_agreement":null},{"id":"W2898326314","doi":"10.1111/dom.13565","title":"Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; European Foundation for the Study of Diabetes; American Diabetes Association; Novo Nordisk; Australian Diabetes Society; National Institute for Health and Care Research","keywords":"Medicine; Insulin degludec; Insulin glargine; Type 2 diabetes; Internal medicine; Population; Intermittent fasting; Post-hoc analysis; Endocrinology; Diabetes mellitus","score_opus":0.01045146279439519,"score_gpt":0.2432358781708654,"score_spread":0.2327844153764702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898326314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052215,0.007273359,0.0004933518,0.00013205492,0.00017699944,0.00027639628,0.0004903942,0.000033449647,0.00060179405],"genre_scores_gemma":[0.9964394,0.001269054,0.00042665118,0.00016164646,0.00020120162,0.00028006258,0.00070566474,0.000016315642,0.0004999302],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99509996,0.0034548652,0.0004178378,0.00050317706,0.00030107496,0.00022316264],"domain_scores_gemma":[0.98965913,0.006907072,0.0017273873,0.0009288172,0.0003018835,0.0004756351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007829168,0.0011795217,0.003898219,0.00045055346,0.00026882402,0.0014746401,0.0006677614,0.0010968554,0.002643118],"category_scores_gemma":[0.0065550203,0.00040967818,0.0075706216,0.0005604487,0.0005909027,0.0009623606,0.00052330334,0.0017128265,0.0001862849],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9412298,0.0005294208,0.018554594,0.0008913886,0.026006259,0.000076755015,0.00006243198,0.0005078141,0.0014237119,0.00003531217,0.0003648778,0.010317634],"study_design_scores_gemma":[0.43896523,0.212887,0.25931522,0.0003845854,0.07573773,0.0005371808,0.0003050185,0.005436903,0.0032606828,0.00053462543,0.002467364,0.0001684612],"about_ca_topic_score_codex":0.00046493308,"about_ca_topic_score_gemma":0.00092102244,"teacher_disagreement_score":0.007829168,"about_ca_system_score_codex":0.00037059744,"about_ca_system_score_gemma":0.0005204282,"threshold_uncertainty_score":0.04140514},"labels":[],"label_agreement":null},{"id":"W2899757702","doi":"10.1111/dom.13578","title":"Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient‐level pooled analysis of EDITION 1, 2 and 3","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Sanofi","keywords":"Insulin glargine; Medicine; Type 2 diabetes; Insulin; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.013394377525270841,"score_gpt":0.2520523750613682,"score_spread":0.23865799753609734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899757702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6073378,0.34485462,0.022701468,0.0005037737,0.0017838087,0.0018244003,0.016809888,0.0005358292,0.0036482976],"genre_scores_gemma":[0.97421277,0.0119849,0.0057718316,0.0005026181,0.0003261954,0.0014484258,0.0043650377,0.00014490842,0.0012433489],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9718739,0.018700708,0.0035903645,0.003424426,0.001848542,0.0005621194],"domain_scores_gemma":[0.97462296,0.0152982725,0.0051962114,0.003564422,0.0010418233,0.00027633712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03137037,0.0020416356,0.0076989797,0.0029427903,0.00022717047,0.0024557668,0.0010900404,0.0019177437,0.0021640665],"category_scores_gemma":[0.025438767,0.0011069725,0.042627055,0.0033989311,0.00052276766,0.0010292482,0.0012568041,0.0016143195,0.000313317],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056005556,0.00007620627,0.048647255,0.011717033,0.8704459,0.00018518204,0.0001276361,0.0013693152,0.0013183253,0.00017144678,0.0010486646,0.008887624],"study_design_scores_gemma":[0.0076992833,0.005679624,0.14004889,0.0011767152,0.83612573,0.00040946528,0.00016900158,0.0026356105,0.001068422,0.0004933275,0.004345329,0.00014852466],"about_ca_topic_score_codex":0.0020252147,"about_ca_topic_score_gemma":0.0022220574,"teacher_disagreement_score":0.03137037,"about_ca_system_score_codex":0.00051666243,"about_ca_system_score_gemma":0.0006183644,"threshold_uncertainty_score":0.16590434},"labels":[],"label_agreement":null},{"id":"W2900447792","doi":"10.1111/dom.13573","title":"CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital; University of Waterloo; McGill University Health Centre; University of British Columbia; Diabetes Canada; University of Toronto; University of Manitoba","funders":"Mitsubishi Tanabe Pharma Corporation; European Foundation for the Study of Diabetes; Diabetes Canada; Janssen Research and Development; American Diabetes Association","keywords":"Canagliflozin; Medicine; Glycated hemoglobin; Clinical endpoint; Type 2 Diabetes Mellitus; Regimen; Internal medicine; Weight loss; Diabetes mellitus; Adverse effect; Type 2 diabetes; Body mass index; Blood pressure; Renal function; Weight change; Surgery; Endocrinology; Clinical trial; Obesity","score_opus":0.012931836768372841,"score_gpt":0.2841871140611043,"score_spread":0.27125527729273147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900447792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6138113,0.023365362,0.0021585857,0.007953734,0.00039760247,0.0022678075,0.29622763,0.0006575064,0.0531604],"genre_scores_gemma":[0.8945657,0.0069114408,0.003995936,0.0018416541,0.00016993575,0.0007094452,0.086679876,0.00009808974,0.0050279046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948697,0.0005440534,0.00041510139,0.00058479706,0.0030972662,0.00048911595],"domain_scores_gemma":[0.9760969,0.0017241674,0.0040855687,0.000714286,0.014648686,0.0027303935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043907394,0.00044975532,0.00089227804,0.0026265825,0.0013506371,0.0014908051,0.0016904629,0.0005786976,0.004538815],"category_scores_gemma":[0.015903667,0.0003387431,0.0006396787,0.008350221,0.00047404427,0.0005114175,0.00069204386,0.0006013168,0.00046457603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00424156,0.00032700354,0.7392343,0.0017059299,0.0010627651,0.00014064931,0.0003733335,0.0016660624,0.00030732123,0.0010098951,0.12751308,0.12241814],"study_design_scores_gemma":[0.0013319534,0.0003128415,0.9697565,0.00033496198,0.00053907547,0.000117716445,0.00016379321,0.0022449722,0.00023169677,0.00008165481,0.02481776,0.00006713559],"about_ca_topic_score_codex":0.98625004,"about_ca_topic_score_gemma":0.9881121,"teacher_disagreement_score":0.037129357,"about_ca_system_score_codex":0.037129357,"about_ca_system_score_gemma":0.071404055,"threshold_uncertainty_score":0.26939362},"labels":[],"label_agreement":null},{"id":"W2900763157","doi":"10.1111/dom.13580","title":"Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi","keywords":"Lixisenatide; Insulin glargine; Medicine; Internal medicine; Hypoglycemia; Endocrinology; Glycated haemoglobin; Basal insulin; Type 2 diabetes; Diabetes mellitus; Exenatide","score_opus":0.007540714160374208,"score_gpt":0.24378613251231127,"score_spread":0.23624541835193705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900763157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936964,0.0041339616,0.0006244299,0.000109888766,0.000052652747,0.00006817255,0.000120562996,0.00009378457,0.0011002063],"genre_scores_gemma":[0.99626994,0.0015691074,0.001072122,0.00015642866,0.000047947186,0.00004354863,0.00029122084,0.000016648162,0.0005330062],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996131,0.00014349386,0.000051273535,0.000058592635,0.00009215121,0.0000414546],"domain_scores_gemma":[0.99981993,0.00003898152,0.000068696885,0.000029046896,0.000008086836,0.000035364483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005808574,0.0004151163,0.001038977,0.00041387696,0.000071069335,0.00048171263,0.0004195019,0.00026096852,0.0016803608],"category_scores_gemma":[0.00043267934,0.00016073085,0.0005928687,0.00035655484,0.00024025106,0.0004057625,0.00020723062,0.0008853063,0.00025761017],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3063924,0.01014906,0.011895273,0.0013939079,0.0040695793,0.00046684348,0.00014242594,0.0036895492,0.17496522,0.0004387578,0.0017819982,0.48461506],"study_design_scores_gemma":[0.15499912,0.51199263,0.21156591,0.0003413839,0.004715131,0.0038782617,0.00031865784,0.012845255,0.08392457,0.00065695803,0.014589181,0.00017288436],"about_ca_topic_score_codex":0.00016443394,"about_ca_topic_score_gemma":0.00036151387,"teacher_disagreement_score":0.0016803608,"about_ca_system_score_codex":0.0002625771,"about_ca_system_score_gemma":0.00015799027,"threshold_uncertainty_score":0.0056214333},"labels":[],"label_agreement":null},{"id":"W2901294588","doi":"10.1111/dom.13588","title":"Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"NIHR Leicester Biomedical Research Centre; Novo Nordisk; National Institute for Health and Care Research","keywords":"Medicine; Real world data; Real world evidence; Internal medicine; Data science","score_opus":0.09797833499607542,"score_gpt":0.4307543182501102,"score_spread":0.3327759832540348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901294588","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49339128,0.42627317,0.009162316,0.003230204,0.0023892708,0.005206148,0.037623744,0.00012199698,0.022601832],"genre_scores_gemma":[0.89504033,0.059767686,0.0060554957,0.0031194957,0.0011655831,0.0064225025,0.027527452,0.00009306794,0.0008084013],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9585611,0.023098951,0.010760624,0.0027547223,0.004313582,0.0005110341],"domain_scores_gemma":[0.9196848,0.043103974,0.020647237,0.005027374,0.010087361,0.0014491794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047001332,0.001048246,0.0029801643,0.0075741718,0.00076832116,0.002956559,0.0015017177,0.0014248217,0.0061882315],"category_scores_gemma":[0.08401945,0.0005430238,0.005320738,0.008179117,0.0010625442,0.0031620492,0.0028890907,0.0013592857,0.0005521207],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03315392,0.0007605824,0.48610133,0.15124951,0.21228388,0.0009069575,0.0039185965,0.00070568005,0.0011099974,0.0045040054,0.019235412,0.08607009],"study_design_scores_gemma":[0.011688608,0.005659987,0.75490224,0.0382466,0.1329518,0.0020497981,0.0037582554,0.0005526541,0.00059927447,0.0020841467,0.04721739,0.00028935817],"about_ca_topic_score_codex":0.002078186,"about_ca_topic_score_gemma":0.0058440845,"teacher_disagreement_score":0.047001332,"about_ca_system_score_codex":0.0011898386,"about_ca_system_score_gemma":0.0020297775,"threshold_uncertainty_score":0.24856979},"labels":[],"label_agreement":null},{"id":"W2901474773","doi":"10.1111/dom.13595","title":"Identification of autoimmune type 1 diabetes and multiple organ‐specific autoantibodies in adult‐onset non‐insulin‐requiring diabetes in China: A population‐based multicentre nationwide survey","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"National Natural Science Foundation of China","keywords":"Autoantibody; Medicine; Internal medicine; Type 1 diabetes; Diabetes mellitus; Odds ratio; Population; Glutamate decarboxylase; Immunology; Endocrinology; Antibody; Biology","score_opus":0.005816497401431077,"score_gpt":0.22151566020856475,"score_spread":0.21569916280713367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901474773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989808,0.00009047063,0.00005353873,0.000024584553,0.0000025069642,0.0000138582145,0.0006531799,0.0000027315546,0.00017834113],"genre_scores_gemma":[0.9990416,0.00006831881,0.000062851876,0.00003440486,0.000004500806,0.000012664653,0.0006527093,5.9773424e-7,0.00012233392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956685,0.0000827012,0.000063548076,0.00012984246,0.000092776005,0.00006430249],"domain_scores_gemma":[0.9992849,0.000045735756,0.00026492996,0.0000681466,0.00012896162,0.00020727531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006157192,0.00036753542,0.00036101675,0.00075108657,0.00044410216,0.0003245463,0.0004208267,0.00039589152,0.00076734944],"category_scores_gemma":[0.0007582858,0.0003110669,0.00038363942,0.0012584643,0.00022706263,0.00041803866,0.00040387327,0.0002971066,0.00013081059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011588955,0.000012704717,0.9994485,0.0000053768795,0.000019057496,0.000023427865,0.000035245408,0.000011304152,0.00013429142,0.0000030899384,0.000039205413,0.0002562509],"study_design_scores_gemma":[0.0000015716206,0.000015109134,0.9997942,0.0000013072056,0.0000066622706,0.000036939287,0.000043962016,0.000053824926,0.0000134709335,0.0000020998943,0.000030021118,8.816884e-7],"about_ca_topic_score_codex":0.04463464,"about_ca_topic_score_gemma":0.044360418,"teacher_disagreement_score":0.04463464,"about_ca_system_score_codex":0.0005645264,"about_ca_system_score_gemma":0.00061550504,"threshold_uncertainty_score":0.08874965},"labels":[],"label_agreement":null},{"id":"W2904088434","doi":"10.1111/dom.13603","title":"Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Exenatide; Dulaglutide; Liraglutide; Medicine; Discontinuation; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus","score_opus":0.014719400181179777,"score_gpt":0.22701795383515339,"score_spread":0.2122985536539736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904088434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995378,0.00015967159,0.00001794766,0.000020587242,0.0000022874756,0.0000035898468,0.00019303411,8.0158924e-7,0.00006428334],"genre_scores_gemma":[0.9994941,0.00007543043,0.000030417328,0.000018970886,0.000005307809,0.0000055368027,0.00032870143,4.979564e-7,0.000040981024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993333,0.00019814953,0.00012164916,0.00015452238,0.00012236951,0.000069965645],"domain_scores_gemma":[0.99776125,0.00031781135,0.0014953918,0.0000899638,0.00009246034,0.00024317461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010219282,0.00017106139,0.00041573466,0.0005836533,0.0002804491,0.00064440654,0.00029122204,0.00041706522,0.00079163554],"category_scores_gemma":[0.0024708032,0.00021986532,0.00082516513,0.0010015387,0.00017771497,0.00042982062,0.00029689932,0.0005531433,0.00008666511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045069068,0.00006636684,0.99842274,0.000012472922,0.00014007371,0.000016862332,0.000024143537,0.000043684206,0.000038187638,0.0000055502546,0.000045172703,0.0007340093],"study_design_scores_gemma":[0.000039229835,0.00030704978,0.9989833,0.0000076271886,0.00007564056,0.00007398926,0.00008399775,0.00035120235,0.000021056912,0.000009499706,0.00004418762,0.000003326287],"about_ca_topic_score_codex":0.005577756,"about_ca_topic_score_gemma":0.005788122,"teacher_disagreement_score":0.005577756,"about_ca_system_score_codex":0.00047506523,"about_ca_system_score_gemma":0.00026615922,"threshold_uncertainty_score":0.011090577},"labels":[],"label_agreement":null},{"id":"W2905361067","doi":"10.1111/dom.13613","title":"The effects of incretin‐based therapies on β‐cell function and insulin resistance in type 2 diabetes: A systematic review and network meta‐analysis combining 360 trials","year":2018,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"China Scholarship Council; Cambridge Trust; National Natural Science Foundation of China; National Institute for Health and Care Research","keywords":"Medicine; Incretin; Insulin resistance; Type 2 diabetes; Internal medicine; Placebo; Meta-analysis; Subgroup analysis; Cochrane Library; Lixisenatide; Insulin; Randomized controlled trial; Diabetes mellitus; Confidence interval; Sitagliptin; Exenatide; Gastroenterology; Endocrinology; Pathology","score_opus":0.034934140937823266,"score_gpt":0.2901301820123201,"score_spread":0.25519604107449684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905361067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009255528,0.98806655,0.00090798264,0.00016041478,0.00017512718,0.00053018756,0.00065769244,0.000031931675,0.0002146583],"genre_scores_gemma":[0.26659492,0.72238094,0.004761579,0.0010290643,0.00033507723,0.002820549,0.0015644362,0.00006112644,0.00045240068],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98444253,0.007801611,0.0044574267,0.0015015313,0.0014647223,0.00033211117],"domain_scores_gemma":[0.97755015,0.016783722,0.0033616151,0.0007007828,0.0013369217,0.00026691705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018507902,0.003289757,0.025312116,0.0077536586,0.00081460027,0.0034093068,0.0020735937,0.0025596274,0.0033018102],"category_scores_gemma":[0.03176682,0.0018257613,0.04794746,0.0087620085,0.0007779566,0.001874371,0.0018310403,0.0018566508,0.0003498636],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028178806,0.000027105261,0.002458644,0.21831462,0.7691307,0.00008816225,0.000047646085,0.00047199483,0.00022005434,0.000054459117,0.00023206625,0.0061366237],"study_design_scores_gemma":[0.00070313836,0.00014169177,0.0014617777,0.008002815,0.9889626,0.000044552737,0.00001672757,0.00012087139,0.000057890404,0.00006444919,0.00041244217,0.000011177578],"about_ca_topic_score_codex":0.0049414705,"about_ca_topic_score_gemma":0.010351603,"teacher_disagreement_score":0.025312116,"about_ca_system_score_codex":0.0025597163,"about_ca_system_score_gemma":0.0032535256,"threshold_uncertainty_score":0.097880304},"labels":[],"label_agreement":null},{"id":"W2905455723","doi":"10.1111/dom.13617","title":"Stability of insulin and C‐peptide measurement with long‐term frozen storage of serum: Implications for diabetes research studies","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Concordance; Insulin; Analyte; Reproducibility; Diabetes mellitus; C-peptide; Peptide; Concordance correlation coefficient; Confidence interval; Internal medicine; Medicine; Chemistry; Endocrinology; Chromatography; Biochemistry; Mathematics; Statistics","score_opus":0.12108253350561021,"score_gpt":0.3616008749532017,"score_spread":0.2405183414475915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905455723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7852346,0.104871005,0.08941595,0.009516127,0.0022607031,0.0009411712,0.0011915124,0.00025469513,0.006314382],"genre_scores_gemma":[0.95153147,0.0066674356,0.037380002,0.0018678103,0.00068871793,0.0004998002,0.0004752188,0.00007126021,0.00081828283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.95937204,0.02667026,0.0040940144,0.0029137796,0.006468255,0.00048177835],"domain_scores_gemma":[0.8522352,0.083919145,0.027298862,0.0143375285,0.020812208,0.0013970629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1002515,0.00064822927,0.0012257898,0.001064769,0.0012710987,0.003222245,0.0016624042,0.0012858032,0.00078660913],"category_scores_gemma":[0.1465063,0.00046463957,0.0007263744,0.0024062248,0.0025272293,0.002087098,0.001024896,0.001510336,0.00027033503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00968904,0.0012399835,0.6682372,0.0023487639,0.0018605661,0.0010474811,0.0054644803,0.005002994,0.06494596,0.0052662143,0.0049734144,0.22992395],"study_design_scores_gemma":[0.0002968445,0.006950045,0.8216148,0.0023505646,0.0025869135,0.0033919322,0.002591635,0.02125103,0.10568992,0.011740904,0.021198126,0.00033727055],"about_ca_topic_score_codex":0.005323379,"about_ca_topic_score_gemma":0.0041138562,"teacher_disagreement_score":0.1002515,"about_ca_system_score_codex":0.0019849157,"about_ca_system_score_gemma":0.002385744,"threshold_uncertainty_score":0.53018695},"labels":[],"label_agreement":null},{"id":"W2911886982","doi":"10.1111/dom.13666","title":"Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novo Nordisk","keywords":"Medicine; Insulin glargine; Type 2 diabetes; Liraglutide; Insulin; Clinical endpoint; Internal medicine; Adverse effect; Diabetes mellitus; Gastroenterology; Hazard ratio; Randomized controlled trial; Confidence interval; Endocrinology","score_opus":0.014451675164902306,"score_gpt":0.2782371434809578,"score_spread":0.2637854683160555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911886982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921846,0.0032763889,0.00031644673,0.00039732744,0.00045394068,0.0018901936,0.0004156259,0.00008042858,0.0009851845],"genre_scores_gemma":[0.9918469,0.0019365035,0.0011436152,0.0007829041,0.0005027329,0.0018650944,0.00045473044,0.000019588331,0.0014479079],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987596,0.0007242411,0.00010945965,0.00019429432,0.00008913836,0.0001232325],"domain_scores_gemma":[0.9985228,0.00053283473,0.0003502947,0.00010593677,0.00007690207,0.0004112773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027681985,0.0017085766,0.0035707771,0.0005286076,0.0003909112,0.0013713783,0.0010475587,0.0020995452,0.0070418995],"category_scores_gemma":[0.002579061,0.00096358504,0.0024242592,0.00045248255,0.0013153452,0.0010760347,0.00053387653,0.0030851655,0.0009148756],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99086666,0.0031039943,0.0001960713,0.00020396628,0.00039288562,0.000013343977,0.000014422625,0.00005857659,0.0010461689,0.000016641045,0.00008143333,0.0040058973],"study_design_scores_gemma":[0.93875587,0.059303664,0.0007604175,0.00002213266,0.00052993913,0.000015694855,0.000010993167,0.00015879657,0.00027701928,0.00003976333,0.000117705364,0.000008073797],"about_ca_topic_score_codex":0.00086616457,"about_ca_topic_score_gemma":0.0014937622,"teacher_disagreement_score":0.0070418995,"about_ca_system_score_codex":0.00080010534,"about_ca_system_score_gemma":0.0009393181,"threshold_uncertainty_score":0.023557484},"labels":[],"label_agreement":null},{"id":"W2912391401","doi":"10.1111/dom.13656","title":"Association between allopurinol and cardiovascular outcomes and all‐cause mortality in diabetes: A retrospective, population‐based cohort study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; Women's College Hospital","funders":"Department of Medicine, University of Toronto; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Allopurinol; Hazard ratio; Interquartile range; Internal medicine; Proportional hazards model; Population; Retrospective cohort study; Diabetes mellitus; Cumulative incidence; Myocardial infarction; Stroke (engine); Cohort; Surgery; Confidence interval; Endocrinology","score_opus":0.01298370599253307,"score_gpt":0.251498737171857,"score_spread":0.23851503117932393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912391401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965624,0.00039819992,0.00019145831,0.0000540592,0.000009877885,0.000032569566,0.0023162216,0.0000059207796,0.0004291701],"genre_scores_gemma":[0.99808407,0.0002443782,0.00018644011,0.000055185224,0.000010746706,0.000017948734,0.0011557704,0.0000022983538,0.0002432085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938595,0.00008327468,0.00005838957,0.0001914316,0.00016811557,0.00011289521],"domain_scores_gemma":[0.99869055,0.000083342384,0.0005036231,0.00019788765,0.0003247145,0.00019995276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007394074,0.00026808484,0.0003517307,0.00058194605,0.00076405425,0.0007596912,0.000589256,0.00035589212,0.00089992775],"category_scores_gemma":[0.001593249,0.00034468656,0.00048558076,0.001559734,0.00032708782,0.0002671204,0.00037807,0.000475558,0.00018234854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050658153,0.000010533299,0.99927086,0.000007150941,0.00006783395,0.000030952066,0.000035309753,0.000012043031,0.00008440759,0.000007183991,0.00009332027,0.0003299067],"study_design_scores_gemma":[0.000010949133,0.00004378321,0.99925977,0.0000074181685,0.000054231998,0.00013131236,0.000091598704,0.000079286445,0.000021715,0.00000870902,0.0002880741,0.0000031830475],"about_ca_topic_score_codex":0.29919693,"about_ca_topic_score_gemma":0.33756292,"teacher_disagreement_score":0.29919693,"about_ca_system_score_codex":0.001533885,"about_ca_system_score_gemma":0.0017864421,"threshold_uncertainty_score":0.59491086},"labels":[],"label_agreement":null},{"id":"W2912733453","doi":"10.1111/dom.13649","title":"Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Eli Lilly and Company","keywords":"Population; Medicine; Generalizability theory; Clinical trial; Type 2 diabetes; Internal medicine; Myocardial infarction; Population study; Diabetes mellitus; Demography; Endocrinology; Statistics; Environmental health","score_opus":0.027593446234962127,"score_gpt":0.2704935831468206,"score_spread":0.24290013691185847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912733453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93624395,0.030446483,0.011177963,0.0050864695,0.0006757159,0.0013429113,0.0041983747,0.0001386196,0.010689569],"genre_scores_gemma":[0.9945803,0.0012937166,0.0008380018,0.0017172074,0.00023015334,0.00028222788,0.00088002003,0.000018867146,0.0001594475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8731125,0.091491535,0.014834447,0.012316264,0.006936771,0.0013085318],"domain_scores_gemma":[0.83653355,0.10851308,0.025799967,0.019748889,0.0077250907,0.0016794564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1046985,0.00048822234,0.0016184034,0.002476505,0.0005040927,0.0021266493,0.0012514056,0.0012800992,0.0017813075],"category_scores_gemma":[0.2186185,0.00045882715,0.0028425679,0.0025520762,0.0013856482,0.0014551268,0.002144305,0.001272304,0.00023401353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035021403,0.0001155282,0.9413182,0.00068036787,0.010651167,0.00018944446,0.0005361131,0.0017674449,0.00047746964,0.0005120437,0.0018230316,0.03842697],"study_design_scores_gemma":[0.0011020388,0.0020019133,0.98063,0.00048845925,0.006164595,0.00044185255,0.00060826825,0.002566101,0.00035641246,0.0016345435,0.003971795,0.00003404463],"about_ca_topic_score_codex":0.00399608,"about_ca_topic_score_gemma":0.004068692,"teacher_disagreement_score":0.1046985,"about_ca_system_score_codex":0.0007755359,"about_ca_system_score_gemma":0.0009173571,"threshold_uncertainty_score":0.5537052},"labels":[],"label_agreement":null},{"id":"W2913495096","doi":"10.1111/dom.13665","title":"Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; University Health Network; Toronto General Hospital; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Juvenile Diabetes Research Foundation Canada","keywords":"Internal medicine; Arterial stiffness; Effective renal plasma flow; Medicine; Pulse wave velocity; Aldosterone; Renal function; Cardiology; Plasma renin activity; Hemodynamics; Uric acid; Diabetes mellitus; Endocrinology; Renin–angiotensin system; Renal blood flow; Blood pressure","score_opus":0.006673999725667458,"score_gpt":0.2039932729642124,"score_spread":0.19731927323854495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913495096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929357,0.0003951144,0.00004454275,0.000016085934,0.0000035493802,0.0000022680033,0.00009392713,0.0000019239685,0.0001490797],"genre_scores_gemma":[0.9996238,0.00009686549,0.000054444456,0.000013835206,0.00000967101,0.0000033093213,0.00012251125,8.050237e-7,0.00007469019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974436,0.0000619205,0.000036226054,0.00007432501,0.000047124246,0.000036121317],"domain_scores_gemma":[0.998601,0.00031723335,0.00062560936,0.00008052223,0.00010560169,0.0002700968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006392371,0.00029482358,0.00037179867,0.00058370363,0.0003091838,0.000531242,0.00021542337,0.00046555957,0.00078307453],"category_scores_gemma":[0.0018064994,0.0002533027,0.00033566135,0.00052665174,0.00022740473,0.0003712863,0.00031238256,0.00059781974,0.0001193838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010510938,0.000018410354,0.9991308,0.000003943299,0.000038753376,0.000024112343,0.00002700305,0.000015815025,0.000115227136,0.0000035544888,0.000010868782,0.00050649577],"study_design_scores_gemma":[0.0000020695152,0.000074054224,0.99963355,0.0000018480647,0.000018530865,0.00011631114,0.00003817194,0.000068644134,0.000019522928,0.0000051752168,0.000020986612,0.000001083021],"about_ca_topic_score_codex":0.0020008353,"about_ca_topic_score_gemma":0.0025357518,"teacher_disagreement_score":0.0020008353,"about_ca_system_score_codex":0.00016695641,"about_ca_system_score_gemma":0.00012699967,"threshold_uncertainty_score":0.003978312},"labels":[],"label_agreement":null},{"id":"W2913976280","doi":"10.1111/dom.13661","title":"Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Diabetes Canada; University of Toronto","funders":"Banting and Best Diabetes Centre, University of Toronto","keywords":"Overweight; Medicine; Resting energy expenditure; Crossover study; Appetite; Internal medicine; Endocrinology; Glucagon; Placebo; Nasal administration; Insulin; Adverse effect; Energy expenditure; Obesity; Pharmacology","score_opus":0.007308227490843986,"score_gpt":0.21075641737255282,"score_spread":0.20344818988170885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913976280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99878424,0.0008556126,0.00009202897,0.000026457192,0.00003446002,0.000028232296,0.000032690124,0.000010318591,0.00013607097],"genre_scores_gemma":[0.99817693,0.0007890519,0.00043590213,0.000096067066,0.0000737881,0.0000462099,0.00010599505,0.000004978538,0.00027106924],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998746,0.000043725584,0.000014233072,0.000020614378,0.000025200865,0.000021730017],"domain_scores_gemma":[0.9997563,0.00007194767,0.0000817694,0.000013894985,0.000011095071,0.00006499391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035982684,0.00039748204,0.00074663246,0.0001289792,0.00013201643,0.0002962044,0.00018379456,0.00032868577,0.0013572016],"category_scores_gemma":[0.0005137498,0.00023020188,0.00020747281,0.00012799684,0.0003632185,0.0003331752,0.00015497646,0.0006994985,0.00016853122],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55274904,0.01998176,0.010423258,0.0010281658,0.0005725968,0.000301432,0.00022519648,0.0002706993,0.3405116,0.000056178018,0.0004076514,0.07347252],"study_design_scores_gemma":[0.05195275,0.7818188,0.122599326,0.00007910654,0.00054889097,0.0005506878,0.0003063584,0.00066976174,0.040367026,0.00009203469,0.0009851045,0.000030076842],"about_ca_topic_score_codex":0.00030772018,"about_ca_topic_score_gemma":0.00066996383,"teacher_disagreement_score":0.0013572016,"about_ca_system_score_codex":0.00013564774,"about_ca_system_score_gemma":0.00015565356,"threshold_uncertainty_score":0.0045402646},"labels":[],"label_agreement":null},{"id":"W2914178425","doi":"10.1111/dom.13644","title":"Dimorphic autoantigenic and protective effects of Reg2 peptide in the treatment of diabetic β‐cell loss","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China; Canadian Diabetes Association","keywords":"Medicine; Islet; Internal medicine; Endocrinology; Diabetes mellitus; Antibody; CD8; Streptozocin; Streptozotocin; Insulin; Immune system; Immunology","score_opus":0.0052837459271437865,"score_gpt":0.204439386754619,"score_spread":0.19915564082747522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914178425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481803,0.0033151838,0.00075197994,0.00007108829,0.000053227337,0.00003511532,0.000095691496,0.0000805128,0.00077918445],"genre_scores_gemma":[0.9947962,0.0022899585,0.0013238463,0.000120978424,0.000047895763,0.000044271506,0.00023466688,0.000015742991,0.0011264912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999409,0.000012747905,0.0000051784623,0.000011439578,0.000012735098,0.000017043558],"domain_scores_gemma":[0.99995553,0.0000034774387,0.000013544984,0.0000054465404,0.000004221761,0.000017822415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016442296,0.0004205688,0.00032568973,0.00023769918,0.00007681452,0.00016391829,0.00019458591,0.00023652246,0.00094032637],"category_scores_gemma":[0.00007135509,0.00007835005,0.0002165354,0.00011443645,0.0001886026,0.00016840031,0.000115781586,0.0005951932,0.00019897262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002597357,0.0007959411,0.00040713258,0.00025444804,0.00003122435,0.00022998189,0.00002202126,0.00016830007,0.97858995,0.00009805104,0.00014089704,0.016664632],"study_design_scores_gemma":[0.0013491628,0.028199669,0.012513938,0.000038210586,0.00020332301,0.0019728811,0.000058953174,0.0007925701,0.94620216,0.00013992643,0.008511471,0.000017702947],"about_ca_topic_score_codex":0.00007494665,"about_ca_topic_score_gemma":0.00011256175,"teacher_disagreement_score":0.00094032637,"about_ca_system_score_codex":0.00006577162,"about_ca_system_score_gemma":0.00011423115,"threshold_uncertainty_score":0.0031456947},"labels":[],"label_agreement":null},{"id":"W2914902752","doi":"10.1111/dom.13642","title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre","funders":"Amgen","keywords":"Medicine; Metformin; Type 2 diabetes; Kidney disease; Internal medicine; Diabetes mellitus; Disease; Endocrinology","score_opus":0.005217562185070648,"score_gpt":0.18397353790726192,"score_spread":0.17875597572219126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914902752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480116,0.0038168784,0.00011972385,0.00015597163,0.00003837604,0.000023261424,0.00048959797,0.0000034778002,0.0005516062],"genre_scores_gemma":[0.9981438,0.0008277459,0.00014738148,0.00010746289,0.000062134925,0.00002515266,0.00048962055,0.000001158304,0.00019564819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992471,0.00029984338,0.000112793765,0.00011494177,0.00014554021,0.00007975683],"domain_scores_gemma":[0.9981914,0.00038229488,0.0010454396,0.00007974258,0.000105977284,0.00019509743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012955064,0.00025482438,0.00060195156,0.000548104,0.00037113787,0.0006790507,0.00026832827,0.00060577743,0.0013629029],"category_scores_gemma":[0.003061837,0.0002453882,0.000953697,0.0010725331,0.0001535851,0.00039209056,0.00043046742,0.00073865766,0.00013238817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001512354,0.00014037568,0.9937928,0.00007346274,0.0004948982,0.000048887945,0.000021257543,0.00005549666,0.000085122345,0.000016355198,0.00013874462,0.003620283],"study_design_scores_gemma":[0.00015131307,0.0004696425,0.9982309,0.000027803075,0.0003205058,0.00015723525,0.000034691162,0.00027791347,0.00004232878,0.000044991295,0.0002371043,0.000005578467],"about_ca_topic_score_codex":0.0015965725,"about_ca_topic_score_gemma":0.0025494704,"teacher_disagreement_score":0.0015965725,"about_ca_system_score_codex":0.0002554537,"about_ca_system_score_gemma":0.00030606447,"threshold_uncertainty_score":0.006851375},"labels":[],"label_agreement":null},{"id":"W2915555967","doi":"10.1111/dom.13677","title":"Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; Novo Nordisk","keywords":"Liraglutide; Medicine; Mace; Insulin glargine; Hazard ratio; Insulin degludec; Internal medicine; Type 2 diabetes; Diabetes mellitus; Insulin; Proportional hazards model; Endocrinology; Myocardial infarction; Confidence interval; Percutaneous coronary intervention","score_opus":0.009402614858056152,"score_gpt":0.20513423684962048,"score_spread":0.19573162199156433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915555967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895181,0.0072733215,0.0005468915,0.0001303758,0.000061009425,0.000105503335,0.0014429779,0.000023857367,0.0008980719],"genre_scores_gemma":[0.9960057,0.00095824705,0.00033401052,0.00018261226,0.00009914376,0.000083238105,0.001848771,0.000013194192,0.00047505257],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973205,0.0014636477,0.00023360789,0.0005238957,0.00027041134,0.00018806256],"domain_scores_gemma":[0.99789774,0.00082454784,0.00056118006,0.0003462415,0.0001422233,0.00022809731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033281045,0.0007811937,0.0024617363,0.000437941,0.00021745256,0.001475234,0.0004876472,0.00069932116,0.00148481],"category_scores_gemma":[0.0036979795,0.00047011182,0.003944374,0.0005792776,0.00042576808,0.00059935247,0.00057235424,0.0010580502,0.00018785115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5481789,0.0010676585,0.35889953,0.0021189048,0.045493342,0.00033131437,0.00016136243,0.00086578866,0.006857998,0.00025546382,0.0022356142,0.033534054],"study_design_scores_gemma":[0.042896114,0.028570915,0.8887931,0.00014993269,0.03130051,0.00083231024,0.00013534365,0.0016959255,0.0017582693,0.00037846554,0.0033841159,0.00010493954],"about_ca_topic_score_codex":0.00107381,"about_ca_topic_score_gemma":0.0013915462,"teacher_disagreement_score":0.0033281045,"about_ca_system_score_codex":0.000422582,"about_ca_system_score_gemma":0.00034092268,"threshold_uncertainty_score":0.017600894},"labels":[],"label_agreement":null},{"id":"W2916549936","doi":"10.1111/dom.13675","title":"Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Cilag; Esperion Therapeutics; Servier; Sanofi; Kowa Company; Novo Nordisk; Medicines Company; European Foundation for the Study of Diabetes; AstraZeneca; Eli Lilly and Company; Amgen; Pfizer; Steno Diabetes Center Copenhagen; American Diabetes Association","keywords":"Medicine; Insulin degludec; Liraglutide; Basal insulin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Basal (medicine); Insulin; Endocrinology","score_opus":0.003049679341641157,"score_gpt":0.17336434118006108,"score_spread":0.17031466183841992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916549936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667459,0.023814308,0.0019716807,0.00045619454,0.0007857103,0.0012763132,0.0015545497,0.00021879104,0.003176537],"genre_scores_gemma":[0.9920712,0.0026959523,0.001786468,0.00037500152,0.0001742059,0.0007217839,0.00076899683,0.00003204282,0.00137432],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9979876,0.0013032986,0.00018463773,0.00023716681,0.000112879905,0.0001743385],"domain_scores_gemma":[0.99879384,0.00068556814,0.00021899393,0.00010322023,0.0000719982,0.00012629596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038386781,0.0014485512,0.0054109916,0.0004219396,0.00013308508,0.0013495261,0.00072505925,0.0007778454,0.004549181],"category_scores_gemma":[0.0030065947,0.00054573524,0.00616094,0.0003346159,0.00040238508,0.0008989237,0.00046157485,0.0019342538,0.00059541303],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9722739,0.0006224783,0.0011483772,0.0012506931,0.010841911,0.000034727178,0.000018495728,0.00053455576,0.002138459,0.000054608416,0.00028681228,0.010795029],"study_design_scores_gemma":[0.74996066,0.18347526,0.016498413,0.0002856501,0.040390365,0.00019986401,0.00009426234,0.0029975127,0.0033663332,0.0003357838,0.0023275563,0.000068326495],"about_ca_topic_score_codex":0.0005182405,"about_ca_topic_score_gemma":0.0010812687,"teacher_disagreement_score":0.0054109916,"about_ca_system_score_codex":0.00047534407,"about_ca_system_score_gemma":0.00048280417,"threshold_uncertainty_score":0.020301104},"labels":[],"label_agreement":null},{"id":"W2917974791","doi":"10.1111/dom.13674","title":"Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute; Hamilton General Hospital; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Hazard ratio; Insulin glargine; Internal medicine; Placebo; Randomized controlled trial; Diabetes mellitus; Incidence (geometry); Type 2 diabetes; Confidence interval; Endocrinology","score_opus":0.006510270591356861,"score_gpt":0.24503217935952357,"score_spread":0.2385219087681667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917974791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97492665,0.02009164,0.0006340281,0.0007755787,0.0005296215,0.00064641854,0.0007814499,0.0000408104,0.0015738725],"genre_scores_gemma":[0.99206805,0.0041150963,0.0006277696,0.00062564615,0.0003861142,0.000577145,0.00066409406,0.000011739415,0.0009242289],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99801767,0.0014658573,0.000121205594,0.00015647893,0.000103129,0.00013566579],"domain_scores_gemma":[0.9981712,0.00094420114,0.0003017549,0.00018576952,0.00009858582,0.00029840635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029743311,0.0010903941,0.003560389,0.00027723686,0.00023789622,0.0013138991,0.0005570586,0.0011766792,0.0027873379],"category_scores_gemma":[0.003734054,0.00032173825,0.004577076,0.0003660083,0.00052296155,0.00059059216,0.0006179311,0.0026603572,0.00029067253],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9823523,0.00085062895,0.0019446715,0.00069755653,0.0052259625,0.00003441002,0.000029754976,0.00023797636,0.00047038976,0.000083068364,0.00023560818,0.007837695],"study_design_scores_gemma":[0.9119946,0.047808226,0.020202491,0.00030123658,0.016022708,0.00006641668,0.00007702486,0.0016337148,0.00042431723,0.00061511766,0.00081163406,0.00004255624],"about_ca_topic_score_codex":0.0012317648,"about_ca_topic_score_gemma":0.0015957952,"teacher_disagreement_score":0.003560389,"about_ca_system_score_codex":0.00058054476,"about_ca_system_score_gemma":0.0006378605,"threshold_uncertainty_score":0.015729964},"labels":[],"label_agreement":null},{"id":"W2918318471","doi":"10.1111/dom.13680","title":"Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Amgen","keywords":"Evolocumab; Medicine; Placebo; Atorvastatin; Internal medicine; Statin; Type 2 diabetes; PCSK9; Gastroenterology; Diabetes mellitus; Cholesterol; Endocrinology; Lipoprotein; Apolipoprotein A1","score_opus":0.014141394061538503,"score_gpt":0.2587694760928445,"score_spread":0.244628082031306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918318471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848098,0.008970767,0.00021748318,0.00054805225,0.00042627947,0.0012875281,0.0010920708,0.0000407614,0.0026071377],"genre_scores_gemma":[0.9879354,0.0027609142,0.000765557,0.0011994522,0.0003810103,0.0013246764,0.0014579537,0.000020402482,0.004154586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989379,0.00063785946,0.0000581991,0.00015614595,0.000079197736,0.00013063589],"domain_scores_gemma":[0.998809,0.00026054255,0.0003804562,0.00010837532,0.000090776986,0.0003509633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023858277,0.0011239086,0.002457784,0.00023364878,0.0002970797,0.000938281,0.0005989105,0.0012764011,0.0066623576],"category_scores_gemma":[0.0022127894,0.00059365184,0.0016335159,0.00028904152,0.00067659334,0.00074024627,0.000456718,0.0015018056,0.00083193637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9867964,0.0010598633,0.0024999431,0.00043914505,0.0012230141,0.000055605306,0.00004348005,0.00012970794,0.00093023817,0.00007120455,0.0006476973,0.0061036767],"study_design_scores_gemma":[0.95554674,0.030696416,0.01109163,0.000075218675,0.00089093915,0.00008500315,0.000039154114,0.00018077246,0.00015285617,0.000076672244,0.001149079,0.00001559918],"about_ca_topic_score_codex":0.0013989441,"about_ca_topic_score_gemma":0.0042365994,"teacher_disagreement_score":0.0066623576,"about_ca_system_score_codex":0.0007633163,"about_ca_system_score_gemma":0.0008516399,"threshold_uncertainty_score":0.022287846},"labels":[],"label_agreement":null},{"id":"W2919371810","doi":"10.1111/dom.13687","title":"Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Exeter Clinical Research Facility; Medical Research Council; National Institute for Health and Care Research; Medical Research Council Canada; Department of Health and Social Care; Wellcome Trust","keywords":"Medicine; Discontinuation; Type 2 diabetes; Metformin; Medical prescription; Blood pressure; Weight loss; Diabetes mellitus; Population; Internal medicine; Confidence interval; Endocrinology; Pharmacology; Obesity","score_opus":0.012478294501780693,"score_gpt":0.23634766540505767,"score_spread":0.22386937090327697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919371810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853893,0.0012262648,0.00018693124,0.00010960525,0.00001287817,0.000032878725,0.012558865,0.000018075496,0.00046517773],"genre_scores_gemma":[0.99064434,0.00053992734,0.00017717056,0.00009269225,0.00001892503,0.000044712295,0.008323536,0.000007222622,0.00015135396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663025,0.0006828681,0.0008326477,0.00083514437,0.00064611045,0.00037305398],"domain_scores_gemma":[0.99056154,0.001219329,0.0053299586,0.00080582197,0.0014987708,0.00058458815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020156528,0.00031260063,0.0006391762,0.0024144056,0.00051799254,0.0012107856,0.0006208254,0.00057004753,0.0009407681],"category_scores_gemma":[0.005588915,0.00060407835,0.0010382754,0.0053215935,0.00047944504,0.0010054422,0.0010231097,0.0006726698,0.0004390598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065895474,0.000011270184,0.9988446,0.000028052971,0.00010432391,0.000037438665,0.000064805965,0.000043885677,0.000033439905,0.0000068026175,0.00022167899,0.00053781684],"study_design_scores_gemma":[0.0000048087845,0.000043167063,0.9991302,0.000014592224,0.000040680072,0.00016505845,0.00015572271,0.00014110564,0.000035781297,0.000005329381,0.00026000445,0.0000036808467],"about_ca_topic_score_codex":0.068241514,"about_ca_topic_score_gemma":0.060924347,"teacher_disagreement_score":0.068241514,"about_ca_system_score_codex":0.0016858203,"about_ca_system_score_gemma":0.0015980926,"threshold_uncertainty_score":0.1356886},"labels":[],"label_agreement":null},{"id":"W2919787870","doi":"10.1111/dom.13682","title":"Trial design and baseline data for LIRA‐PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GRi Simulations (Canada); Surrey Memorial Hospital","funders":"Novo Nordisk; American Diabetes Association","keywords":"Medicine; Liraglutide; Clinical endpoint; Randomized controlled trial; Type 2 diabetes; Metformin; Overweight; Internal medicine; Diabetes mellitus; Glycated hemoglobin; Pediatrics; Insulin; Obesity; Endocrinology","score_opus":0.02199204367663652,"score_gpt":0.26251990096163225,"score_spread":0.24052785728499573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919787870","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69127697,0.0138844885,0.011630157,0.008609822,0.0041234237,0.24929573,0.007190912,0.00072639075,0.013262067],"genre_scores_gemma":[0.6676355,0.002302815,0.014038102,0.0056923027,0.001675864,0.29974174,0.0030230463,0.00007641699,0.005814163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9893072,0.008288111,0.0005356785,0.0009458323,0.00043643298,0.00048664364],"domain_scores_gemma":[0.9950133,0.0020982854,0.0011723399,0.00049355254,0.00034637813,0.0008761357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010825262,0.0029022691,0.0047207815,0.0006329918,0.0009442326,0.001865821,0.0014689546,0.004974992,0.013839771],"category_scores_gemma":[0.01287356,0.0010951535,0.0029814197,0.00072715833,0.0020919084,0.0023892815,0.0008650825,0.0040652156,0.0021342125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9892279,0.00214484,0.00059233926,0.0009149315,0.0009432519,0.000057814937,0.00004573486,0.00022158737,0.0004790406,0.00037449363,0.0010080662,0.0039899917],"study_design_scores_gemma":[0.97928613,0.018031964,0.0004539492,0.00006109972,0.0004810045,0.000031362277,0.000011166547,0.00033112537,0.00008978954,0.00030749093,0.00090298685,0.000012027119],"about_ca_topic_score_codex":0.0004211439,"about_ca_topic_score_gemma":0.0007163375,"teacher_disagreement_score":0.013839771,"about_ca_system_score_codex":0.00080565666,"about_ca_system_score_gemma":0.0020820769,"threshold_uncertainty_score":0.057250142},"labels":[],"label_agreement":null},{"id":"W2921421880","doi":"10.1111/dom.13699","title":"Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Institutes of Health; Novo Nordisk","keywords":"Insulin degludec; Insulin glargine; Medicine; Insulin; Diabetes mellitus; Endocrinology; Internal medicine; Pediatrics; Hypoglycemia","score_opus":0.007635116727159678,"score_gpt":0.21004748691954406,"score_spread":0.20241237019238437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921421880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98454857,0.014126036,0.00015577514,0.00012758243,0.00009359928,0.00007967643,0.00023214324,0.000008660296,0.0006279861],"genre_scores_gemma":[0.99514776,0.0032077455,0.0002930044,0.00034138866,0.00015832244,0.00006840997,0.00046586394,0.0000041082985,0.0003132543],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991872,0.00047236076,0.00007415433,0.000109166685,0.000091050264,0.000066097295],"domain_scores_gemma":[0.99871945,0.00054986565,0.00038537505,0.000058109956,0.000065221975,0.00022193656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025046675,0.00049614254,0.001386462,0.00026542155,0.00014280174,0.0007506068,0.00024265748,0.00067629036,0.001365868],"category_scores_gemma":[0.0021430005,0.0001886508,0.002063841,0.00033387475,0.00031457862,0.0004933331,0.00027811396,0.0009850815,0.00013477051],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86913747,0.0027382313,0.04697156,0.0017067565,0.004271825,0.00011187937,0.00008293999,0.0008221732,0.0056243856,0.00009405666,0.00068346254,0.06775521],"study_design_scores_gemma":[0.35636577,0.33840257,0.28425485,0.00050101173,0.010435771,0.0007285966,0.00017318044,0.0019749932,0.0032925846,0.00034327208,0.0034358897,0.00009146334],"about_ca_topic_score_codex":0.00039254775,"about_ca_topic_score_gemma":0.0006699948,"teacher_disagreement_score":0.0025046675,"about_ca_system_score_codex":0.00031871343,"about_ca_system_score_gemma":0.00032057078,"threshold_uncertainty_score":0.013246059},"labels":[],"label_agreement":null},{"id":"W2921562138","doi":"10.1111/dom.13698","title":"Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Liraglutide; Medicine; Diabetes mellitus; Mace; Internal medicine; Type 2 diabetes; Post-hoc analysis; Lixisenatide; Diabetic nephropathy; Endocrinology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.0253702906421352,"score_gpt":0.3092381997192483,"score_spread":0.2838679090771131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921562138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897696,0.0042739995,0.0010560717,0.00025641543,0.00015823712,0.00071979826,0.002220422,0.00004786495,0.0014975898],"genre_scores_gemma":[0.9921314,0.0007087634,0.0009826821,0.00027402554,0.00019474085,0.0013878499,0.0025293024,0.000043060696,0.0017481422],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9932601,0.0042331764,0.0006077101,0.00065672665,0.0007194252,0.00052291976],"domain_scores_gemma":[0.986006,0.008937202,0.002284955,0.0012038421,0.00084386906,0.0007241333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014065036,0.0009314056,0.0030547017,0.00035913748,0.0003200159,0.0014230581,0.00079177675,0.0007068679,0.0034995005],"category_scores_gemma":[0.010339442,0.00032983278,0.005846005,0.00061530975,0.0005331587,0.001279878,0.0007620887,0.0018228603,0.000290284],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90425706,0.0007651681,0.046996854,0.0016119607,0.026705949,0.00021144767,0.00017150863,0.0014998462,0.0026242898,0.00027571584,0.0019028549,0.012977333],"study_design_scores_gemma":[0.22142284,0.20124905,0.47887573,0.00049288117,0.06895088,0.0006298535,0.00048569046,0.011088113,0.005546098,0.0013550273,0.00968615,0.00021774745],"about_ca_topic_score_codex":0.0005601691,"about_ca_topic_score_gemma":0.0010238059,"teacher_disagreement_score":0.014065036,"about_ca_system_score_codex":0.000428365,"about_ca_system_score_gemma":0.0011688409,"threshold_uncertainty_score":0.074383914},"labels":[],"label_agreement":null},{"id":"W2921595130","doi":"10.1111/dom.13692","title":"Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Colorado Clinical and Translational Sciences Institute; Canadian Institutes of Health Research; National Institutes of Health; Novo Nordisk Fonden; University of Toronto; National Institute of Diabetes and Digestive and Kidney Diseases; University of Colorado; ZonMw; Fondation Leducq; University Health Network; Horizon Pharmaceuticals; Diabetes Canada; Eli Lilly and Company; AstraZeneca; Canadian Diabetes Association; International Society for Pediatric and Adolescent Diabetes; Novo Nordisk; Thrasher Research Fund; Sanofi","keywords":"Cotransporter; Medicine; Internal medicine; Endocrinology; Sodium; Chemistry","score_opus":0.044988646982151256,"score_gpt":0.28159246317917935,"score_spread":0.23660381619702808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921595130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000860038,0.9986413,0.00003476731,0.0006992987,0.0002189469,0.0000018076329,0.000011960954,0.0000036508084,0.0003022522],"genre_scores_gemma":[0.0004478558,0.99861515,0.00007782504,0.0004395769,0.00015181543,0.000002989416,0.000016221515,9.1208824e-7,0.00024764112],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998355,0.00003572476,0.00002940057,0.000026703994,0.000054328175,0.000018238054],"domain_scores_gemma":[0.999691,0.00016011711,0.00004899604,0.000008240671,0.00006799528,0.000023652752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006421026,0.0005779198,0.0016011273,0.00091104774,0.00019261701,0.0008882542,0.00075001415,0.0009763783,0.0033438222],"category_scores_gemma":[0.0008034946,0.00016582519,0.0006942582,0.0011863139,0.0003705528,0.0013396963,0.0003809547,0.002027064,0.0013073208],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013477035,0.00006286391,0.00015657133,0.021961408,0.00020629076,0.00009579387,0.000048999897,0.000134248,0.00071619655,0.003006095,0.04057802,0.93289876],"study_design_scores_gemma":[0.0000896448,0.00017506814,0.0013180092,0.01220173,0.00043247876,0.0009773977,0.0001143315,0.00010683356,0.0002644035,0.003431349,0.98086506,0.00002363591],"about_ca_topic_score_codex":0.0007862996,"about_ca_topic_score_gemma":0.0022553778,"teacher_disagreement_score":0.0033438222,"about_ca_system_score_codex":0.0003943239,"about_ca_system_score_gemma":0.0008705167,"threshold_uncertainty_score":0.0111861825},"labels":[],"label_agreement":null},{"id":"W2921878115","doi":"10.1111/dom.13695","title":"Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"OPKO Health (Canada)","funders":"Eli Lilly and Company","keywords":"Placebo; Medicine; Tolerability; Gastrin; Nausea; Agonist; Internal medicine; Adverse effect; Vomiting; Insulin; Endocrinology; Gastroenterology; Receptor","score_opus":0.009621001642796896,"score_gpt":0.23406959652495235,"score_spread":0.22444859488215546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921878115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998218,0.0009171565,0.00010979673,0.000056148252,0.00009071297,0.00008123041,0.000071353155,0.000033001215,0.00042263998],"genre_scores_gemma":[0.9971698,0.00070135365,0.00039851118,0.00014145428,0.0001978952,0.0001017914,0.00027564366,0.000009654797,0.0010038947],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997969,0.000073695715,0.000022446833,0.000030017623,0.000025410913,0.000051550698],"domain_scores_gemma":[0.9996313,0.00010290853,0.00007839343,0.000039651473,0.000011410664,0.00013626042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003907441,0.00056630676,0.0018391459,0.00018789252,0.0001439621,0.00048965384,0.0003703052,0.00072036654,0.0039027077],"category_scores_gemma":[0.0004936064,0.00027774536,0.0005758349,0.000121790275,0.00038877278,0.00049439253,0.0002353453,0.0015870557,0.000559844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5638166,0.017117532,0.0023920943,0.0007911977,0.0007864426,0.00045851336,0.00008339067,0.00044885444,0.32608327,0.000096240736,0.0006057042,0.08732011],"study_design_scores_gemma":[0.2051341,0.6936668,0.04083813,0.00008340266,0.0011889741,0.0009281312,0.00013428714,0.0010354166,0.054030996,0.00011675841,0.0027820487,0.000060947674],"about_ca_topic_score_codex":0.00018988102,"about_ca_topic_score_gemma":0.00058924814,"teacher_disagreement_score":0.0039027077,"about_ca_system_score_codex":0.000145774,"about_ca_system_score_gemma":0.00032197847,"threshold_uncertainty_score":0.013055861},"labels":[],"label_agreement":null},{"id":"W2928618472","doi":"10.1111/dom.13732","title":"Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Sanofi","keywords":"Medicine; Intensive care medicine; Randomized controlled trial; Continuous glucose monitoring; Basal insulin; Hypoglycemia; Adverse effect; Clinical trial; Clinical Practice; Gold standard (test); Diabetes mellitus; Insulin; Type 2 diabetes; Internal medicine; Type 1 diabetes; Physical therapy; Endocrinology","score_opus":0.35035989989894034,"score_gpt":0.5040464253399498,"score_spread":0.15368652544100947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928618472","genre_codex":"review","genre_gemma":"review","domain_codex":"methods","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002500471,0.585414,0.08242923,0.27037066,0.03893811,0.010243847,0.0024020642,0.0009055398,0.00679598],"genre_scores_gemma":[0.057325214,0.27925807,0.34028545,0.23348422,0.031178018,0.05006712,0.0045253956,0.0013855495,0.0024910453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.106852055,0.4829484,0.3354645,0.017337015,0.05544311,0.001954929],"domain_scores_gemma":[0.038067024,0.80202264,0.044894025,0.038214236,0.0735872,0.0032149092],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.762456,0.0033144304,0.025579764,0.014597435,0.0053943936,0.02628278,0.023606135,0.019260155,0.0039932397],"category_scores_gemma":[0.86292726,0.0058166916,0.019177876,0.013938648,0.016416948,0.02491183,0.012649319,0.031985518,0.0031334204],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020990118,0.0001999409,0.0043922095,0.33014396,0.014239215,0.0004832349,0.008461773,0.0019695058,0.0012081605,0.035590976,0.11110311,0.49010885],"study_design_scores_gemma":[0.0023361843,0.0006602043,0.0061413054,0.5961405,0.007995154,0.00075011625,0.0031809425,0.0027384183,0.0014385355,0.10773184,0.27030307,0.000583705],"about_ca_topic_score_codex":0.004464975,"about_ca_topic_score_gemma":0.0048798383,"teacher_disagreement_score":0.237544,"about_ca_system_score_codex":0.019550303,"about_ca_system_score_gemma":0.03853171,"threshold_uncertainty_score":0.29293412},"labels":[],"label_agreement":null},{"id":"W2929722478","doi":"10.1111/dom.13726","title":"First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Merck Canada; Gilead Sciences; European Foundation for the Study of Diabetes; AstraZeneca; Eli Lilly and Company; Amgen; Pfizer; Novo Nordisk; Valeant Pharmaceuticals International; Sanofi; American Diabetes Association","keywords":"Medicine; Continuous glucose monitoring; Type 2 diabetes; Population; Type 1 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Environmental health","score_opus":0.00903000549003959,"score_gpt":0.24710264616660313,"score_spread":0.23807264067656353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929722478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99937963,0.00013071859,0.00008881005,0.000013617696,0.0000028985453,0.000020146581,0.00010834493,0.0000017139558,0.0002541127],"genre_scores_gemma":[0.99929166,0.000102171754,0.000248943,0.000033797292,0.0000064451183,0.000013051308,0.00018213077,0.0000013314466,0.00012041117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991365,0.0002853798,0.00006725601,0.00015563727,0.00026255313,0.000092648545],"domain_scores_gemma":[0.99599934,0.00080713566,0.0014367186,0.0002123374,0.0012388107,0.0003056749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015185695,0.00030731442,0.00030791917,0.00027734102,0.00042854188,0.0005687602,0.00027026108,0.00039512198,0.0008394583],"category_scores_gemma":[0.0046644565,0.00017049504,0.000360741,0.00030676645,0.00021139925,0.00039928293,0.00028259744,0.0004765227,0.00014984241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041614298,0.00018245379,0.9949934,0.000019385678,0.000044227865,0.00003588756,0.00018063036,0.000026509288,0.00053623645,0.0000052389346,0.00005135887,0.0035086095],"study_design_scores_gemma":[0.000017764614,0.00303817,0.9957955,0.000009279244,0.00006150881,0.00016955243,0.00024774743,0.00015195625,0.00030230687,0.0000032640378,0.00019915232,0.0000037934412],"about_ca_topic_score_codex":0.01468242,"about_ca_topic_score_gemma":0.018635623,"teacher_disagreement_score":0.01468242,"about_ca_system_score_codex":0.0005751372,"about_ca_system_score_gemma":0.0005703393,"threshold_uncertainty_score":0.029193878},"labels":[],"label_agreement":null},{"id":"W2932567006","doi":"10.1111/dom.13729","title":"Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin‐treated type 2 diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Zafgen; Abbott Diabetes Care; Dexcom; Novo Nordisk; Sanofi; MannKind Corporation; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Type 2 diabetes; Bolus (digestion); Diabetes mellitus; Insulin; Nocturnal; Endocrinology; Cardiology","score_opus":0.013117985935490897,"score_gpt":0.25184387476242776,"score_spread":0.23872588882693685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2932567006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99860746,0.0005049159,0.00035785572,0.000045833163,0.000044259035,0.000111074885,0.000094956384,0.000012417247,0.00022112684],"genre_scores_gemma":[0.9984847,0.0001684683,0.0006987134,0.000051965508,0.000037750553,0.00015329036,0.00013596713,0.000004997686,0.00026424133],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971861,0.0022311124,0.00015250346,0.00018323939,0.00015098011,0.00009608463],"domain_scores_gemma":[0.99307764,0.005168442,0.00090408616,0.00039217033,0.00013599622,0.00032169145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041041095,0.0005265624,0.0017712235,0.00017957436,0.00012280613,0.0005005133,0.00040512357,0.0005499846,0.0014259443],"category_scores_gemma":[0.0064994926,0.0002488768,0.0020370637,0.00023766769,0.00031579676,0.00042590447,0.00028319456,0.001014224,0.00009909091],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92244136,0.0032396687,0.03944779,0.00034248637,0.0052233567,0.000036181027,0.000074396565,0.0013976721,0.0026426732,0.00007002253,0.00021567801,0.024868721],"study_design_scores_gemma":[0.21932976,0.36765808,0.37103072,0.00014608081,0.014138946,0.00017536087,0.00016536811,0.020582035,0.0049875425,0.00064509566,0.0010430327,0.000097938406],"about_ca_topic_score_codex":0.00045972026,"about_ca_topic_score_gemma":0.0005823,"teacher_disagreement_score":0.0041041095,"about_ca_system_score_codex":0.00024780942,"about_ca_system_score_gemma":0.00040717467,"threshold_uncertainty_score":0.021704853},"labels":[],"label_agreement":null},{"id":"W2933543441","doi":"10.1111/dom.13730","title":"Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital; University of Manitoba","funders":"Canadian Society of Endocrinology and Metabolism; Novo Nordisk; Diabetes Canada","keywords":"Insulin degludec; Medicine; Insulin glargine; Diabetes mellitus; Continuous glucose monitoring; Type 2 diabetes; Pediatrics; Quartile; Stroke (engine); Internal medicine; Intensive care medicine; Type 1 diabetes; Endocrinology; Confidence interval","score_opus":0.007903825763419092,"score_gpt":0.21875281386762596,"score_spread":0.21084898810420688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933543441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966368,0.010968118,0.003052621,0.0028153125,0.00011415932,0.0008629561,0.008541673,0.000057616697,0.007219465],"genre_scores_gemma":[0.9917847,0.0019507246,0.0023369167,0.0003521413,0.000024701856,0.00013344799,0.0026260973,0.000012819152,0.0007784205],"study_design_codex":"simulation_or_modeling","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988398,0.00048632157,0.000043432632,0.00015092718,0.00021611137,0.00026340978],"domain_scores_gemma":[0.9980572,0.0008899191,0.00032359382,0.00005014068,0.0002854145,0.0003937376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029672931,0.0012005062,0.0014648562,0.0008340143,0.0007056934,0.0023078674,0.0013490096,0.0009473405,0.0026513215],"category_scores_gemma":[0.007129417,0.00048335304,0.0040242933,0.0012243318,0.0007254211,0.0006235924,0.0009041525,0.0016535296,0.00013644608],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07840769,0.0028908465,0.12845208,0.00494202,0.014455856,0.00083306653,0.00042167178,0.59645504,0.0024065631,0.0127359,0.023054697,0.13494453],"study_design_scores_gemma":[0.029230438,0.01667446,0.19335535,0.0024997194,0.01456518,0.0009371387,0.00086382387,0.7160653,0.0020781597,0.0074723866,0.015546087,0.0007120331],"about_ca_topic_score_codex":0.7775792,"about_ca_topic_score_gemma":0.80747133,"teacher_disagreement_score":0.22242081,"about_ca_system_score_codex":0.036397144,"about_ca_system_score_gemma":0.025309099,"threshold_uncertainty_score":0.44746137},"labels":[],"label_agreement":null},{"id":"W2936097160","doi":"10.1111/dom.13751","title":"Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Medicine; Insulin glargine; Morning; Randomized controlled trial; Type 2 diabetes; Insulin; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.01267882740177082,"score_gpt":0.24844079432213162,"score_spread":0.2357619669203608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936097160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889529,0.0042137224,0.00067649264,0.000462647,0.0005495652,0.0033430594,0.00053381163,0.00011120048,0.0011565684],"genre_scores_gemma":[0.98828495,0.001989579,0.0021256518,0.00084721606,0.00063028093,0.0044367146,0.00049492123,0.000022458338,0.0011681851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99887854,0.00068182615,0.00008812716,0.00016875978,0.00008397693,0.000098808494],"domain_scores_gemma":[0.99817467,0.00063345535,0.0005881851,0.0001244501,0.00009809969,0.00038122066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002531109,0.0013542629,0.0030848547,0.0004540631,0.00042007235,0.0011438205,0.00095191825,0.0018708273,0.005541686],"category_scores_gemma":[0.0031173786,0.000797409,0.0020408127,0.0004784489,0.00095337373,0.0010675371,0.0003730925,0.0027604273,0.00073798536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9875408,0.0034961589,0.0002968602,0.00029030995,0.00042903886,0.000009346097,0.00001490399,0.00008242795,0.00081093353,0.000017214155,0.00016189186,0.006850306],"study_design_scores_gemma":[0.9292329,0.0684497,0.0013761816,0.000025950301,0.00031329485,0.000012270008,0.000009021798,0.00025539735,0.00016574135,0.000040783954,0.00010976418,0.000009088647],"about_ca_topic_score_codex":0.0005417818,"about_ca_topic_score_gemma":0.0010825745,"teacher_disagreement_score":0.005541686,"about_ca_system_score_codex":0.000748285,"about_ca_system_score_gemma":0.00092112954,"threshold_uncertainty_score":0.018538773},"labels":[],"label_agreement":null},{"id":"W2939788581","doi":"10.1111/dom.13646","title":"Residual cardiovascular risk among people with diabetes","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network","funders":"","keywords":"Residual risk; Medicine; Diabetes mellitus; Disease; Type 2 diabetes; Atherosclerotic cardiovascular disease; Cardiovascular health; Environmental health; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.014250612439845042,"score_gpt":0.23154158952086837,"score_spread":0.21729097708102332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939788581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007580998,0.99869365,0.000044285152,0.00025355787,0.0001950523,0.000002358659,0.000021287353,0.000004371546,0.00070966914],"genre_scores_gemma":[0.00044222997,0.9988949,0.00005433771,0.00016472193,0.0001656964,0.0000034171399,0.000023908377,6.478531e-7,0.00025019218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999814,0.00003792383,0.000032810385,0.000031425392,0.00006638293,0.000017552726],"domain_scores_gemma":[0.9997814,0.000112269365,0.00003234024,0.0000050127164,0.000050844283,0.000018160095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004677842,0.00063601026,0.0011316771,0.0015532788,0.00022969957,0.00086848193,0.00047479974,0.0008175249,0.0036629254],"category_scores_gemma":[0.00073150126,0.00016039434,0.0005206828,0.0014265513,0.00023463015,0.00071457704,0.00058575097,0.0013583268,0.001476717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063842424,0.00003445171,0.00031526462,0.01860292,0.00014036744,0.000096862175,0.00005545452,0.0001178984,0.00036444466,0.0023294103,0.030642536,0.9472366],"study_design_scores_gemma":[0.000025155665,0.0000899753,0.002392352,0.015079119,0.0003542951,0.0014136331,0.0000962417,0.000080584075,0.00019424326,0.0024335675,0.9778155,0.000025170399],"about_ca_topic_score_codex":0.0012717515,"about_ca_topic_score_gemma":0.0021198946,"teacher_disagreement_score":0.0036629254,"about_ca_system_score_codex":0.00037102573,"about_ca_system_score_gemma":0.00081259967,"threshold_uncertainty_score":0.012253642},"labels":[],"label_agreement":null},{"id":"W2942519534","doi":"10.1111/dom.13754","title":"Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Acute kidney injury; Kidney disease; Hazard ratio; Internal medicine; Placebo; Randomized controlled trial; Meta-analysis; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Adverse effect; Relative risk; Confidence interval; Endocrinology; Pathology","score_opus":0.0784109921710881,"score_gpt":0.33839555872688576,"score_spread":0.25998456655579766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942519534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042056786,0.994651,0.00032885594,0.00014618803,0.000098982295,0.00009371518,0.0002493931,0.000018062705,0.0002081805],"genre_scores_gemma":[0.1440412,0.85220104,0.0014177609,0.00065105414,0.00022646193,0.00038240553,0.0007242758,0.00003052138,0.00032525058],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99447423,0.0031453362,0.0011995417,0.0005008712,0.0004913768,0.00018867914],"domain_scores_gemma":[0.9898935,0.0076886765,0.0012897598,0.00030070177,0.00066759204,0.00015980388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009084766,0.0022074003,0.012124755,0.0026973728,0.0003717262,0.0020864278,0.0013951057,0.0012554026,0.0025884495],"category_scores_gemma":[0.016778354,0.00083953154,0.020224253,0.0045045833,0.00035054836,0.0010884539,0.0010547312,0.002018914,0.0001946451],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060648653,0.000038441787,0.0042833374,0.24843757,0.708794,0.000125285,0.00006681191,0.00080302084,0.00026219623,0.00021214302,0.0015975378,0.0293149],"study_design_scores_gemma":[0.0012107539,0.0002490403,0.0055161323,0.012654622,0.97694004,0.0000981176,0.00003088412,0.00030918902,0.00015517331,0.0003354091,0.00248039,0.00002026819],"about_ca_topic_score_codex":0.0042095073,"about_ca_topic_score_gemma":0.008653716,"teacher_disagreement_score":0.012124755,"about_ca_system_score_codex":0.0014750242,"about_ca_system_score_gemma":0.0016699457,"threshold_uncertainty_score":0.048045397},"labels":[],"label_agreement":null},{"id":"W2943127375","doi":"10.1111/dom.13762","title":"Weight loss enhances cardiac energy metabolism and function in heart failure associated with obesity","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cardiovascular Function and Risk Factors","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Heart and Stroke Foundation of Canada","keywords":"Heart failure; Internal medicine; Medicine; Endocrinology; Weight loss; Cardiac function curve; Ventricle; Muscle hypertrophy; Beta oxidation; Cardiac hypertrophy; Obesity; Metabolism","score_opus":0.0036187875414610826,"score_gpt":0.18304957692986853,"score_spread":0.17943078938840745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943127375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782443,0.0010742282,0.0005594255,0.00009336381,0.00003370097,0.000014455581,0.00008333365,0.000030748266,0.0002863173],"genre_scores_gemma":[0.9967518,0.0010823397,0.00060830195,0.00016610775,0.00005481284,0.000048721435,0.00028530395,0.000019912137,0.0009828007],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99990547,0.000018333134,0.000007996713,0.000016960552,0.000017075328,0.000034152887],"domain_scores_gemma":[0.9997727,0.000021030568,0.000073541574,0.000021899134,0.00001552228,0.000095314936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022183289,0.0005261314,0.00052148866,0.00026372162,0.00013310817,0.00030530585,0.00016184969,0.00027817467,0.0012182855],"category_scores_gemma":[0.0001536935,0.0001772572,0.0003251561,0.00011264098,0.00029049136,0.00027019178,0.00030357452,0.0011173579,0.00018467288],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004529669,0.00054993056,0.0017752941,0.00008385968,0.000049934173,0.000076264645,0.000018672068,0.000059005524,0.9874992,0.0000334419,0.00010347726,0.00522126],"study_design_scores_gemma":[0.0016104553,0.036417145,0.44686934,0.00013163283,0.0004818346,0.0014627975,0.0003424731,0.0028094272,0.50610465,0.00040483402,0.0033049611,0.00006044583],"about_ca_topic_score_codex":0.00026640293,"about_ca_topic_score_gemma":0.00038468905,"teacher_disagreement_score":0.0012182855,"about_ca_system_score_codex":0.000108603854,"about_ca_system_score_gemma":0.00010200285,"threshold_uncertainty_score":0.004075587},"labels":[],"label_agreement":null},{"id":"W2943453646","doi":"10.1111/dom.13755","title":"Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Servier; National Health and Medical Research Council; National Institutes of Health; Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Blood pressure; Diabetes mellitus; Glycated hemoglobin; Type 2 diabetes; Proportional hazards model; Endocrinology","score_opus":0.030216539972744108,"score_gpt":0.307938708642132,"score_spread":0.2777221686693879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943453646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604356,0.0016258814,0.00021358268,0.00016981624,0.00007223951,0.00016199944,0.00073158275,0.000018545283,0.0009627867],"genre_scores_gemma":[0.9954293,0.00057693187,0.0007320327,0.00023167717,0.00028264095,0.00036097498,0.0016132081,0.000007509562,0.0007655978],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99869764,0.0007227651,0.00008195123,0.00024696413,0.00015349043,0.00009725214],"domain_scores_gemma":[0.9970788,0.00090798456,0.001166718,0.00033193885,0.00015652835,0.00035809842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028710302,0.0006476534,0.001660691,0.00017404727,0.00018920383,0.0007537284,0.0004766622,0.00085323275,0.0024159544],"category_scores_gemma":[0.0045506065,0.0002979039,0.0013776848,0.00030199636,0.00036379308,0.00078015146,0.00062071066,0.0014654526,0.00023665128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89336973,0.0025443968,0.07857454,0.00070385623,0.0038733291,0.00009744417,0.000088771245,0.0011475267,0.002159143,0.00026692665,0.001499021,0.015675284],"study_design_scores_gemma":[0.22404568,0.14347176,0.6046021,0.00041587758,0.011086345,0.000565955,0.00017933098,0.0064232745,0.003079215,0.001385039,0.004616165,0.00012936252],"about_ca_topic_score_codex":0.00034425716,"about_ca_topic_score_gemma":0.00049790356,"teacher_disagreement_score":0.0028710302,"about_ca_system_score_codex":0.00018924713,"about_ca_system_score_gemma":0.00032081903,"threshold_uncertainty_score":0.015183687},"labels":[],"label_agreement":null},{"id":"W2945166916","doi":"10.1111/dom.13611","title":"A safety update on sodium glucose co‐transporter 2 inhibitors","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Canagliflozin; Medicine; Empagliflozin; Dapagliflozin; Randomized controlled trial; Incidence (geometry); Internal medicine; Adverse effect; Diabetes mellitus; Observational study; Acute kidney injury; Placebo; Amputation; Surgery; Type 2 diabetes; Endocrinology; Pathology","score_opus":0.020074418725650908,"score_gpt":0.27450870267141614,"score_spread":0.2544342839457652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945166916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035998847,0.7600794,0.0051552793,0.118820325,0.022395477,0.0006187966,0.008791263,0.0009086713,0.07963087],"genre_scores_gemma":[0.020864664,0.8019253,0.008654368,0.097712375,0.026057974,0.0009404528,0.011889746,0.000308318,0.03164678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99673116,0.00096085324,0.00065984303,0.00019491868,0.0013058777,0.00014746218],"domain_scores_gemma":[0.98483676,0.0058223982,0.0023551001,0.0004286419,0.0059523582,0.0006047244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052448786,0.0007585269,0.001977088,0.0016869869,0.0006066082,0.0023601537,0.0018234956,0.0037466947,0.017377015],"category_scores_gemma":[0.016078454,0.00033304945,0.0021454848,0.0019943472,0.00044267144,0.0018422288,0.0008696968,0.004573204,0.0061830757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000655511,0.00012010299,0.00047908654,0.007060414,0.00031028467,0.0002231104,0.00005799621,0.00018814496,0.0007034604,0.0029746408,0.37809628,0.609131],"study_design_scores_gemma":[0.0003668138,0.00043311695,0.0013853902,0.0071713426,0.00046984953,0.00062691903,0.000035342124,0.0001345331,0.00032521156,0.002225112,0.9867993,0.000027176058],"about_ca_topic_score_codex":0.0020158994,"about_ca_topic_score_gemma":0.004361591,"teacher_disagreement_score":0.017377015,"about_ca_system_score_codex":0.0010668677,"about_ca_system_score_gemma":0.0021263964,"threshold_uncertainty_score":0.058131933},"labels":[],"label_agreement":null},{"id":"W2945971750","doi":"10.1111/dom.13789","title":"Authors' reply to: “The role of long‐term effects of allopurinol on cardiovascular outcomes and all‐cause mortality in diabetes”","year":2019,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; Women's College Hospital","funders":"","keywords":"Medicine; Diabetes mellitus; Endocrinology","score_opus":0.0073494023102385255,"score_gpt":0.22618286081185815,"score_spread":0.21883345850161962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945971750","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039672104,0.0009993997,0.000037912934,0.9812201,0.01637632,0.0000055485657,0.00007900551,0.00001667518,0.00086831965],"genre_scores_gemma":[0.0035346374,0.00096769986,0.000098488024,0.9599505,0.0330158,0.000021362186,0.000041863877,0.00001215865,0.0023574803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982828,0.0005140997,0.00029098138,0.00024885396,0.00040608356,0.00025727725],"domain_scores_gemma":[0.9922117,0.0043322938,0.0007179298,0.0002035284,0.0017107466,0.0008238744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024388013,0.0006190691,0.001065367,0.0006718337,0.0024937822,0.002279182,0.0013853777,0.03288524,0.006343669],"category_scores_gemma":[0.021922305,0.000619644,0.000957008,0.0007614691,0.0016311612,0.0026571709,0.0010968648,0.024446277,0.0059793633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009446033,0.000026179056,0.0011808483,0.000051897452,0.000019244058,0.0013812179,0.000105978266,0.000039386614,0.000095331474,0.0008408145,0.99043745,0.005727261],"study_design_scores_gemma":[0.00031821593,0.00014547119,0.0044097467,0.0007054296,0.000098300065,0.005969762,0.00086561905,0.0005454845,0.0005804576,0.008410716,0.9777641,0.00018681936],"about_ca_topic_score_codex":0.0036134885,"about_ca_topic_score_gemma":0.004251608,"teacher_disagreement_score":0.03288524,"about_ca_system_score_codex":0.0022578805,"about_ca_system_score_gemma":0.0029620556,"threshold_uncertainty_score":0.021221638},"labels":[],"label_agreement":null},{"id":"W2950136952","doi":"10.1111/dom.13811","title":"Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health; Lunenfeld-Tanenbaum Research Institute; Health Sciences Centre; St Joseph's Health Care; University of Toronto; Western University; Sunnybrook Health Science Centre; LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi; AstraZeneca","keywords":"Medicine; Empagliflozin; Diabetic ketoacidosis; Dapagliflozin; Diabetes mellitus; Type 2 diabetes; Type 1 diabetes; Insulin; Canagliflozin; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.026315365111541193,"score_gpt":0.2924846575457922,"score_spread":0.266169292434251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950136952","genre_codex":"review","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001246937,0.98023236,0.001271482,0.004758144,0.0019608121,0.0019434908,0.0007024021,0.000054811957,0.007829609],"genre_scores_gemma":[0.0035661226,0.9793946,0.004258226,0.004642125,0.0004329613,0.0020797479,0.0011978474,0.000013915455,0.004414523],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993299,0.0002442014,0.00016341366,0.000040971205,0.00018312092,0.000038326765],"domain_scores_gemma":[0.99936956,0.00026779986,0.00015171815,0.000021281961,0.00014124463,0.00004830994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024360837,0.00074457336,0.0011823474,0.0013394208,0.00022019763,0.0007008146,0.0010512227,0.0013138427,0.0039258953],"category_scores_gemma":[0.002082162,0.00022925192,0.0014361584,0.0008939902,0.00031958483,0.0009924698,0.0008011051,0.002167501,0.0013484065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007819278,0.00024438076,0.00011618368,0.07048704,0.00030262876,0.000097519376,0.00005438906,0.00028308516,0.0013649026,0.0055286465,0.05610103,0.8646383],"study_design_scores_gemma":[0.0011859264,0.00054619426,0.0021178464,0.0496814,0.0010812059,0.00043619575,0.000049115588,0.00017856773,0.00086457824,0.0030816817,0.94074285,0.00003438435],"about_ca_topic_score_codex":0.0011763962,"about_ca_topic_score_gemma":0.002452026,"teacher_disagreement_score":0.0039258953,"about_ca_system_score_codex":0.0007799924,"about_ca_system_score_gemma":0.0031394255,"threshold_uncertainty_score":0.013133407},"labels":[],"label_agreement":null},{"id":"W2954115740","doi":"10.1111/dom.13820","title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Ontario Drug Policy Research Network; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Dapagliflozin; Hazard ratio; Diabetes mellitus; Internal medicine; Cohort study; Population; Incidence (geometry); Urinary system; Cohort; Retrospective cohort study; Confidence interval; Type 2 diabetes; Endocrinology","score_opus":0.0042578219873595285,"score_gpt":0.1978892058495821,"score_spread":0.1936313838622226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954115740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987907,0.00038893905,0.000045198314,0.00003659308,0.000006787928,0.000009161165,0.0004478175,0.0000021304845,0.00027260257],"genre_scores_gemma":[0.9991352,0.0002405628,0.000047376085,0.000046439374,0.000013394886,0.000007298052,0.00033039303,8.6630274e-7,0.00017848371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968266,0.00005385933,0.000031235995,0.00008056272,0.000083275096,0.00006842795],"domain_scores_gemma":[0.9994223,0.00004845895,0.0002566891,0.000047251153,0.00007272455,0.0001526322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000404732,0.0002903025,0.00045866537,0.0005869069,0.0005716008,0.0006591222,0.0002919078,0.00043673575,0.0009324289],"category_scores_gemma":[0.0010014514,0.00042989044,0.00055555406,0.0013750532,0.00025956132,0.0003814146,0.00031325157,0.00058025983,0.00015757352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004219142,0.000017631393,0.9994804,0.000003537637,0.00004348943,0.000024042949,0.000037930127,0.0000067917995,0.00005384043,0.0000036936658,0.000035755456,0.00025075965],"study_design_scores_gemma":[0.000008710213,0.00004274869,0.99961394,0.0000036051856,0.000027154816,0.00008645888,0.000078673824,0.00004259795,0.000007484216,0.000004782212,0.00008244663,0.0000014334968],"about_ca_topic_score_codex":0.066968955,"about_ca_topic_score_gemma":0.073266625,"teacher_disagreement_score":0.066968955,"about_ca_system_score_codex":0.00060043734,"about_ca_system_score_gemma":0.00056638854,"threshold_uncertainty_score":0.13315827},"labels":[],"label_agreement":null},{"id":"W2954462466","doi":"10.1111/dom.13824","title":"Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Novo Nordisk; Sanofi; Pfizer; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Diabetes mellitus; Weight management; Type 2 diabetes; Randomized controlled trial; Internal medicine; Body mass index; Overweight; Endocrinology","score_opus":0.003699516871405874,"score_gpt":0.22044988878038713,"score_spread":0.21675037190898125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954462466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985408,0.004783593,0.0010501398,0.00053540984,0.0002511283,0.005766039,0.000983411,0.00008908328,0.0011332218],"genre_scores_gemma":[0.98038805,0.0039353943,0.0027380704,0.0013152335,0.000436647,0.007540211,0.0012568936,0.00002879332,0.0023606583],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991209,0.00046239732,0.000072654104,0.00015274851,0.00008401581,0.00010736525],"domain_scores_gemma":[0.9988188,0.00029954486,0.00035819624,0.000104072285,0.00008739303,0.00033195954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002581006,0.0012831202,0.0030279935,0.00033503858,0.00038434705,0.0009797721,0.00075792504,0.0015875583,0.0046594823],"category_scores_gemma":[0.0020470659,0.00065585197,0.0016615797,0.00043247087,0.0010141776,0.0010537821,0.00040400095,0.001882667,0.0006675441],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9669057,0.011080068,0.0010356919,0.00049304,0.0008504582,0.000036892703,0.00003628428,0.0002170187,0.0035473565,0.00003925257,0.00036912956,0.015389078],"study_design_scores_gemma":[0.898047,0.09815574,0.0022089276,0.000026558824,0.00040497718,0.000032351087,0.00001502127,0.0002442467,0.00035009804,0.000049136637,0.00045678634,0.000009236957],"about_ca_topic_score_codex":0.00060718897,"about_ca_topic_score_gemma":0.0012784397,"teacher_disagreement_score":0.0046594823,"about_ca_system_score_codex":0.0006805343,"about_ca_system_score_gemma":0.0012574669,"threshold_uncertainty_score":0.015587509},"labels":[],"label_agreement":null},{"id":"W2954546034","doi":"10.1111/dom.13826","title":"Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Term (time); Insulin; Glucagon-like peptide-1; Internal medicine; Intensive care medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus","score_opus":0.02133313376193959,"score_gpt":0.2495910649470088,"score_spread":0.2282579311850692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954546034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87282085,0.116882585,0.0006833191,0.0022678336,0.0006593076,0.00045064627,0.0018954135,0.00007793798,0.0042620744],"genre_scores_gemma":[0.9706759,0.022455068,0.00095435174,0.0015205557,0.0008552979,0.0004693189,0.0017938529,0.000021989541,0.0012535885],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99639845,0.0025514863,0.00032574288,0.00027580265,0.0002984573,0.00015002683],"domain_scores_gemma":[0.99444157,0.0028633096,0.0014112224,0.00036699697,0.00040828978,0.0005086179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056132907,0.00088131556,0.003528971,0.00033162528,0.00029549585,0.0012051286,0.0007055774,0.0010998884,0.005159746],"category_scores_gemma":[0.0063336887,0.00032945658,0.0041488865,0.0004231637,0.00079561386,0.0009820408,0.00063959544,0.0018061951,0.0005935104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9107526,0.0010707073,0.0077251815,0.00524975,0.021063663,0.00008154237,0.0000999442,0.00046359707,0.000974576,0.00016547191,0.0019304942,0.050422516],"study_design_scores_gemma":[0.78189766,0.10649092,0.051709633,0.0029466196,0.046940807,0.00040260976,0.00019719164,0.0012497881,0.0010824419,0.0008421351,0.0061370786,0.00010311621],"about_ca_topic_score_codex":0.0005095988,"about_ca_topic_score_gemma":0.0011465002,"teacher_disagreement_score":0.0056132907,"about_ca_system_score_codex":0.000544338,"about_ca_system_score_gemma":0.0007234611,"threshold_uncertainty_score":0.029686332},"labels":[],"label_agreement":null},{"id":"W2956359130","doi":"10.1111/dom.13831","title":"Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi; Ministerio de Fomento","keywords":"Glomerular hyperfiltration; Renal function; Medicine; Kidney disease; Diabetes mellitus; Nephron; Risk factor; Disease; Internal medicine; Intensive care medicine; Endocrinology; Diabetic nephropathy","score_opus":0.034576305812519345,"score_gpt":0.28683598987509923,"score_spread":0.25225968406257987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956359130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000101331076,0.99870527,0.00005749401,0.00030862278,0.00018499406,0.000003781253,0.000037165202,0.0000054618336,0.0005958887],"genre_scores_gemma":[0.00039265622,0.9990783,0.000079776226,0.000116434814,0.00012563806,0.0000037624925,0.000039538405,6.274475e-7,0.00016321459],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99977344,0.000040770676,0.0000495419,0.000036265646,0.00008021553,0.000019736102],"domain_scores_gemma":[0.9996184,0.00017456428,0.00007474346,0.000007720426,0.00009512578,0.000029527839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005103097,0.0007550321,0.0015483128,0.0027341153,0.00024111826,0.00087811315,0.0007027575,0.0007367911,0.0034189585],"category_scores_gemma":[0.00092387974,0.00018348586,0.00075332774,0.0026497145,0.00028842545,0.0007139529,0.00052428467,0.001415095,0.0012630618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108497035,0.00007660266,0.00095372146,0.03450843,0.00038314023,0.00016955443,0.00006452572,0.00023864352,0.0005039682,0.0023090441,0.044355914,0.9163279],"study_design_scores_gemma":[0.000030499225,0.00010889514,0.0043857633,0.018629497,0.0006987447,0.0017710362,0.0000976395,0.00015339228,0.00020944756,0.0024085438,0.9714679,0.000038535443],"about_ca_topic_score_codex":0.001596267,"about_ca_topic_score_gemma":0.002856761,"teacher_disagreement_score":0.0034189585,"about_ca_system_score_codex":0.0005159176,"about_ca_system_score_gemma":0.0013143396,"threshold_uncertainty_score":0.011437535},"labels":[],"label_agreement":null},{"id":"W2965202731","doi":"10.1111/dom.13852","title":"Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Dapagliflozin; Medicine; Propensity score matching; Population; Observational study; Type 2 diabetes; TIMI; Internal medicine; Diabetes mellitus; Inclusion and exclusion criteria; Emergency medicine; Endocrinology; Environmental health; Myocardial infarction; Alternative medicine","score_opus":0.04937953159987543,"score_gpt":0.29813904196884766,"score_spread":0.24875951036897223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965202731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99795157,0.00061012246,0.000102592465,0.00007716043,0.00002361673,0.000018116853,0.00084881135,0.0000029394062,0.00036514527],"genre_scores_gemma":[0.9979417,0.00019103904,0.00008433601,0.00012288945,0.00003388519,0.000032973017,0.0014527533,0.0000031812688,0.0001371352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832267,0.0005631831,0.0002513018,0.00047333882,0.0002395317,0.00014982393],"domain_scores_gemma":[0.9965077,0.0006710449,0.0020339934,0.0003202483,0.00016174697,0.0003052577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020604853,0.00028682538,0.0009129106,0.000529617,0.00042877355,0.0013656619,0.0004231534,0.00069682836,0.0017953671],"category_scores_gemma":[0.0049088025,0.00040393564,0.0017745941,0.0012017157,0.0002755643,0.00061347656,0.00043140774,0.0009917718,0.00022229274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010613843,0.00044177994,0.9814984,0.00012974643,0.0023053708,0.00009950795,0.00007539337,0.00014615135,0.00025435557,0.0000754635,0.0007957376,0.003564273],"study_design_scores_gemma":[0.0010776137,0.0010232689,0.9947797,0.000036570178,0.0010951099,0.00028275864,0.00012262643,0.0008154263,0.00007722226,0.00013750009,0.00053431286,0.000017880682],"about_ca_topic_score_codex":0.0023917581,"about_ca_topic_score_gemma":0.0022005653,"teacher_disagreement_score":0.0023917581,"about_ca_system_score_codex":0.00035419097,"about_ca_system_score_gemma":0.00040218548,"threshold_uncertainty_score":0.01089704},"labels":[],"label_agreement":null},{"id":"W2965229115","doi":"10.1111/dom.13839","title":"Glucagon‐like peptide‐2 mobilizes lipids from the intestine by a systemic nitric oxide‐independent mechanism","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Chylomicron; Internal medicine; Endocrinology; Nitric oxide; Triglyceride; Omega-N-Methylarginine; Medicine; Chemistry; Lipoprotein; Nitric oxide synthase; Very low-density lipoprotein; Cholesterol","score_opus":0.006032439116310421,"score_gpt":0.19833749693419228,"score_spread":0.19230505781788185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965229115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998511,0.00056737085,0.00038387158,0.00008043293,0.000017565946,0.000036788373,0.000020878928,0.0000058790097,0.0003761477],"genre_scores_gemma":[0.99801326,0.00033188134,0.00095871725,0.00014882893,0.00003606245,0.00008931494,0.000036711175,0.000001975998,0.00038318452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992,0.00003607698,0.0000042681695,0.000019559293,0.000009277829,0.000010742556],"domain_scores_gemma":[0.99992216,0.000021204462,0.000025449384,0.000008601926,0.000004277245,0.000018226749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003299897,0.00029430486,0.0002908635,0.000061379644,0.00012237536,0.00019477971,0.00014408967,0.0003051624,0.0014220909],"category_scores_gemma":[0.00022184305,0.00012207677,0.00014202986,0.000040199247,0.00038521213,0.00016981087,0.00015490658,0.00042260234,0.00011330664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0579321,0.0032046593,0.047943406,0.00067640684,0.00015259156,0.0009869426,0.00020355546,0.0003834626,0.8439519,0.00035218318,0.00034763894,0.04386512],"study_design_scores_gemma":[0.011583069,0.19420981,0.42868844,0.00018647531,0.0004364909,0.005150229,0.00081666076,0.0038460412,0.34716105,0.0010634781,0.0068126987,0.000045561843],"about_ca_topic_score_codex":0.00012494373,"about_ca_topic_score_gemma":0.0001617343,"teacher_disagreement_score":0.0014220909,"about_ca_system_score_codex":0.00015652274,"about_ca_system_score_gemma":0.00015652992,"threshold_uncertainty_score":0.0047573447},"labels":[],"label_agreement":null},{"id":"W2971769159","doi":"10.1111/dom.13874","title":"Cardiovascular outcomes trials in type 2 diabetes: Time to include young adults","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Pediatrics; Gerontology; Endocrinology","score_opus":0.011434455576190002,"score_gpt":0.24030736058747618,"score_spread":0.22887290501128618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971769159","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050219554,0.15685998,0.0024416107,0.7538292,0.052562352,0.0055465233,0.003153171,0.00018674748,0.02039845],"genre_scores_gemma":[0.1474729,0.20779264,0.023460569,0.41036263,0.1303233,0.056531273,0.0043706973,0.00036460184,0.01932145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9288525,0.05005787,0.012298414,0.0012560351,0.005520594,0.0020146605],"domain_scores_gemma":[0.77326477,0.12494672,0.028930414,0.0069567906,0.029435059,0.03646634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08417915,0.0008689128,0.0046467655,0.0008156896,0.001323185,0.005303995,0.0020410584,0.007829775,0.021101141],"category_scores_gemma":[0.21298066,0.0009201549,0.002202783,0.0019827122,0.0009809742,0.006741023,0.0037225378,0.006947476,0.0036075464],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026807128,0.00046075005,0.0074119894,0.027953323,0.002038126,0.00045913173,0.00088507216,0.0003729265,0.0006221223,0.0049458146,0.53694,0.39110368],"study_design_scores_gemma":[0.073226064,0.005031795,0.04552239,0.118805945,0.0034388388,0.00061236176,0.0018479665,0.0009789728,0.00053861213,0.011770162,0.7379801,0.00024685674],"about_ca_topic_score_codex":0.0024317235,"about_ca_topic_score_gemma":0.011315231,"teacher_disagreement_score":0.08417915,"about_ca_system_score_codex":0.0021369236,"about_ca_system_score_gemma":0.012816561,"threshold_uncertainty_score":0.4451872},"labels":[],"label_agreement":null},{"id":"W2972107819","doi":"10.1111/dom.13876","title":"Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Empagliflozin; Type 2 diabetes; Diabetes mellitus; Internal medicine; Dapagliflozin; Adverse effect; Canagliflozin; Placebo; Endocrinology","score_opus":0.004777926649296908,"score_gpt":0.21199667970781733,"score_spread":0.20721875305852042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972107819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8548583,0.133783,0.000778991,0.0013531509,0.00064617646,0.00013052768,0.0014113806,0.000028933146,0.007009555],"genre_scores_gemma":[0.9784526,0.017048059,0.00046204915,0.0013330469,0.00046673656,0.00011980216,0.0004912338,0.000014838417,0.0016116546],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99878293,0.00070440717,0.00014127849,0.00014060346,0.0000942525,0.00013637726],"domain_scores_gemma":[0.99852765,0.0008807186,0.00030588382,0.00007428767,0.000047900823,0.00016353678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002685563,0.00060162606,0.0019464059,0.0005801329,0.00018064909,0.0008178564,0.00015998665,0.000584037,0.0030968809],"category_scores_gemma":[0.003378012,0.00030942526,0.0033140508,0.00052354456,0.00025708412,0.0004676587,0.00042277074,0.0008837428,0.00029263285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48418954,0.0010065341,0.2592499,0.0044084857,0.03731713,0.0007748664,0.00059716054,0.0010671833,0.008038688,0.00074698724,0.0031492328,0.19945426],"study_design_scores_gemma":[0.034814086,0.07088913,0.7821283,0.0016422605,0.07742013,0.0010130572,0.0011505071,0.0019102595,0.0060424404,0.0028948074,0.019942366,0.000152671],"about_ca_topic_score_codex":0.000751797,"about_ca_topic_score_gemma":0.0020350504,"teacher_disagreement_score":0.0030968809,"about_ca_system_score_codex":0.00022816575,"about_ca_system_score_gemma":0.00032638537,"threshold_uncertainty_score":0.014202774},"labels":[],"label_agreement":null},{"id":"W2979521390","doi":"10.1111/dom.13893","title":"Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population‐based cohort study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Boehringer Ingelheim Stiftung","keywords":"Glimepiride; Medicine; Hazard ratio; Incidence (geometry); Type 2 diabetes; Internal medicine; Myocardial infarction; Stroke (engine); Gliclazide; Diabetes mellitus; Proportional hazards model; Population; Confidence interval; Cohort study; Cardiology; Endocrinology; Insulin","score_opus":0.011605204755857614,"score_gpt":0.23999813862626526,"score_spread":0.22839293387040766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979521390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815696,0.00030869612,0.0001332193,0.000028062976,0.0000145169115,0.000022957274,0.001099156,0.0000030655885,0.00023329534],"genre_scores_gemma":[0.99812096,0.00026156637,0.00014018716,0.000041034305,0.000024263401,0.000028850129,0.0012172979,0.000002956268,0.00016286595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998779,0.00036011476,0.00014187429,0.00038330376,0.00021476278,0.00012086814],"domain_scores_gemma":[0.997895,0.0002407011,0.0009776526,0.0004026165,0.0002031274,0.00028088447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019839646,0.000437975,0.0006243016,0.00080490386,0.0004142851,0.0010039868,0.000554127,0.00073409005,0.0012674158],"category_scores_gemma":[0.0033508854,0.00048970745,0.0014862092,0.0014516127,0.000248478,0.0005644073,0.0005014619,0.00091700366,0.00024777255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001246972,0.00010367285,0.9961598,0.00002485402,0.0011149385,0.00008620072,0.000050139322,0.00006447104,0.00021187477,0.000018205677,0.000108223714,0.00081061345],"study_design_scores_gemma":[0.00012986935,0.00045586785,0.9983485,0.000008142529,0.00035293016,0.00018769638,0.00007224059,0.00021779473,0.000042659896,0.000019319452,0.0001565923,0.000008375114],"about_ca_topic_score_codex":0.0068369913,"about_ca_topic_score_gemma":0.005977516,"teacher_disagreement_score":0.0068369913,"about_ca_system_score_codex":0.00038171414,"about_ca_system_score_gemma":0.00037650703,"threshold_uncertainty_score":0.013594389},"labels":[],"label_agreement":null},{"id":"W2982015658","doi":"10.1111/dom.13901","title":"Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto","funders":"Genentech; HLS Therapeutics; Ipsen; Novo Nordisk; Intarcia Therapeutics; Sanofi; GlaxoSmithKline; Roche Diabetes Care; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Insulin degludec; Insulin glargine; Titration; Insulin; Medicine; Hypoglycemia; Internal medicine; Endocrinology; Chemistry; Inorganic chemistry","score_opus":0.008804360340932764,"score_gpt":0.21409659241442822,"score_spread":0.20529223207349545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982015658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99646723,0.002104209,0.00021284496,0.00006749562,0.000042503718,0.0002139996,0.00018889109,0.000012340256,0.0006903988],"genre_scores_gemma":[0.9981591,0.00039514448,0.00024762435,0.0002727117,0.00008262946,0.000105121486,0.0003918495,0.0000065535783,0.0003393211],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973218,0.0015605972,0.00019046936,0.00029877602,0.0003639745,0.00026443068],"domain_scores_gemma":[0.99684024,0.0010117784,0.0009926995,0.0004121775,0.0001956528,0.0005474582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005902431,0.0004940475,0.0017434923,0.00027880393,0.00026308777,0.00097227056,0.00045662568,0.0009027778,0.001970164],"category_scores_gemma":[0.0029794672,0.0003160799,0.0020576576,0.00027372272,0.00060552603,0.0006786456,0.0004401816,0.0011236361,0.00030823462],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85933715,0.0059501296,0.0809806,0.0010920359,0.0065976847,0.00014248436,0.00022910058,0.000211474,0.011381814,0.00012024985,0.00074288115,0.03321434],"study_design_scores_gemma":[0.17394201,0.32825065,0.48443615,0.00016466623,0.0067075053,0.0003656257,0.00027315877,0.0005877779,0.00240649,0.0002704966,0.002504763,0.00009066594],"about_ca_topic_score_codex":0.00031094352,"about_ca_topic_score_gemma":0.0004635374,"teacher_disagreement_score":0.005902431,"about_ca_system_score_codex":0.00032096557,"about_ca_system_score_gemma":0.00053177366,"threshold_uncertainty_score":0.03121537},"labels":[],"label_agreement":null},{"id":"W2993540759","doi":"10.1111/dom.13938","title":"Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Manitoba; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Baseline (sea); Internal medicine; Cardiology; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.00789071885382023,"score_gpt":0.20363925178007017,"score_spread":0.19574853292624994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993540759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9103745,0.07470165,0.0023047829,0.0043602707,0.0004272395,0.000118319105,0.00135737,0.000069174916,0.0062866258],"genre_scores_gemma":[0.9954122,0.0019999533,0.00030455308,0.0011846705,0.00039336318,0.0000354986,0.00029267388,0.0000121189805,0.0003649853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924159,0.0047493954,0.00040319338,0.00086298055,0.0009967043,0.0005717645],"domain_scores_gemma":[0.9789651,0.013545348,0.004181715,0.0018674663,0.0007864434,0.000653859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013936713,0.0005026701,0.0022398033,0.00037360005,0.00028456244,0.0012338156,0.0007851379,0.0018500094,0.0022919409],"category_scores_gemma":[0.025311964,0.0005413337,0.0038507297,0.00067998254,0.00072910334,0.0011488643,0.00049423514,0.0020863751,0.0003123063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10005984,0.0009827984,0.69837594,0.001382707,0.025260724,0.00044173785,0.00026267482,0.0017650796,0.0023264557,0.0010116642,0.0029659749,0.16516449],"study_design_scores_gemma":[0.00212518,0.002536015,0.9843412,0.00012017275,0.0068355775,0.0001658656,0.000055734996,0.0010501534,0.00046709756,0.0008800285,0.0013873406,0.000035528145],"about_ca_topic_score_codex":0.0011843138,"about_ca_topic_score_gemma":0.0014138961,"teacher_disagreement_score":0.013936713,"about_ca_system_score_codex":0.00038434172,"about_ca_system_score_gemma":0.0006000155,"threshold_uncertainty_score":0.073705256},"labels":[],"label_agreement":null},{"id":"W2995051978","doi":"10.1111/dom.13943","title":"Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near‐normoglycaemia","year":2019,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research","keywords":"Mount; Medicine; Exenatide; Diabetes mellitus; Metformin; Family medicine; Gerontology; Library science; History; Type 2 diabetes; Engineering; Endocrinology","score_opus":0.012862102025733136,"score_gpt":0.24962455513296092,"score_spread":0.2367624531072278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995051978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91342556,0.026113702,0.00029376155,0.039606467,0.0064939763,0.00018639422,0.000544088,0.00005041086,0.013285566],"genre_scores_gemma":[0.9632117,0.006417021,0.0006332176,0.020596493,0.0067795124,0.00012037584,0.00026535333,0.000014308343,0.0019618657],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953735,0.0002280361,0.00006292962,0.000058749836,0.00005445398,0.000058486705],"domain_scores_gemma":[0.99796116,0.0013901674,0.00014170432,0.000086351174,0.00009749827,0.00032306102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010543042,0.0003715464,0.0017413591,0.00034903208,0.00048686087,0.0007553775,0.00060216465,0.002405971,0.0027813932],"category_scores_gemma":[0.0039953887,0.00018139249,0.0013026065,0.0005335568,0.00041424623,0.00069234037,0.00024204513,0.0020364977,0.0003447963],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62973356,0.00947895,0.029481363,0.001069688,0.0015368263,0.014196044,0.0002949218,0.0008958519,0.00489783,0.0010832513,0.02223802,0.28509364],"study_design_scores_gemma":[0.23156747,0.23204076,0.4334644,0.0010737864,0.006247112,0.025642963,0.0015111475,0.006886588,0.0035461495,0.0047891485,0.05289613,0.000334335],"about_ca_topic_score_codex":0.0014013768,"about_ca_topic_score_gemma":0.0029494294,"teacher_disagreement_score":0.0027813932,"about_ca_system_score_codex":0.0010355464,"about_ca_system_score_gemma":0.00050267606,"threshold_uncertainty_score":0.009304702},"labels":[],"label_agreement":null},{"id":"W2996036402","doi":"10.1111/dom.13946","title":"The importance of the initial period of basal insulin titration in people with diabetes","year":2019,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Health Sciences Centre; Winnipeg Regional Health Authority","funders":"Department of Health and Social Care; National Institute for Health and Care Research; Sanofi","keywords":"Basal insulin; Basal (medicine); Period (music); Titration; Insulin; Diabetes mellitus; Endocrinology; Medicine; Chemistry; Type 2 diabetes; Art; Inorganic chemistry","score_opus":0.026442326779344324,"score_gpt":0.3023705261040479,"score_spread":0.2759281993247036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996036402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007081093,0.99906975,0.00004309605,0.00023043128,0.00012835844,0.0000036831168,0.0000075964726,0.0000027668684,0.00044356004],"genre_scores_gemma":[0.0006964091,0.9987581,0.00010578977,0.00018876954,0.00008445363,0.000005509637,0.000010283369,8.96346e-7,0.00014986726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937075,0.0002011161,0.0001500087,0.00006712119,0.0001754974,0.000035498215],"domain_scores_gemma":[0.9991155,0.00061753416,0.00012037617,0.000016278502,0.00010385619,0.000026350295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001027994,0.0005642817,0.0015153851,0.0014120975,0.0002447893,0.0013503934,0.00074853713,0.0013080904,0.0023562552],"category_scores_gemma":[0.0022856242,0.000261343,0.00091938855,0.0015523806,0.00049006444,0.0012298791,0.0005714589,0.0018938694,0.00095454114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013035326,0.0000464155,0.00022228016,0.059620555,0.0001974585,0.00015961485,0.00015716469,0.00016236577,0.00042707124,0.0020337796,0.016516892,0.92032605],"study_design_scores_gemma":[0.00006082511,0.0001878304,0.0024255896,0.041214567,0.0005664146,0.0021912279,0.000264249,0.000110162844,0.00038631188,0.0025514695,0.95000654,0.000034849465],"about_ca_topic_score_codex":0.0017949765,"about_ca_topic_score_gemma":0.0025555342,"teacher_disagreement_score":0.0023562552,"about_ca_system_score_codex":0.00062356505,"about_ca_system_score_gemma":0.0012224307,"threshold_uncertainty_score":0.007882476},"labels":[],"label_agreement":null},{"id":"W2996554586","doi":"10.1111/dom.13945","title":"Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy","year":2019,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Boehringer Ingelheim (Canada); Mount Sinai Hospital","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Insulin; Population; Diabetes mellitus; Placebo; Type 2 diabetes; Type 1 diabetes; Internal medicine; Endocrinology","score_opus":0.026340575980382454,"score_gpt":0.3030969097098147,"score_spread":0.2767563337294322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996554586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415474,0.0008477801,0.047949664,0.0006380717,0.00007289033,0.00044684033,0.0015261985,0.00010475168,0.0068665477],"genre_scores_gemma":[0.9877506,0.0002810114,0.010063919,0.00010936508,0.000014352281,0.00035440738,0.00045960752,0.000012528314,0.00095422723],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99926823,0.00048123076,0.00003321825,0.000075949865,0.00006916508,0.00007213344],"domain_scores_gemma":[0.9949575,0.0041180076,0.0003735008,0.0001988709,0.0002661915,0.00008594263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022720257,0.0006523096,0.0012406666,0.00033017035,0.0002252333,0.00084274553,0.0010544338,0.0010024427,0.0022929998],"category_scores_gemma":[0.0051698396,0.0003944077,0.0021187167,0.0003381417,0.00035305723,0.00041724718,0.0004005307,0.001242331,0.00016269437],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005743518,0.00020311115,0.0029527822,0.00012645795,0.00016258688,0.000048256286,0.000026827182,0.99162537,0.00070811884,0.0010518037,0.00017434462,0.0023460556],"study_design_scores_gemma":[0.00036167487,0.0007487002,0.002166661,0.000027300039,0.00021084341,0.000027161983,0.000017331327,0.9942173,0.0007371186,0.00096960587,0.0004996895,0.000016672146],"about_ca_topic_score_codex":0.010940831,"about_ca_topic_score_gemma":0.0053015756,"teacher_disagreement_score":0.010940831,"about_ca_system_score_codex":0.0012968607,"about_ca_system_score_gemma":0.0014488858,"threshold_uncertainty_score":0.021754265},"labels":[],"label_agreement":null},{"id":"W2998275298","doi":"10.1111/dom.13955","title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Cardiology; Intensive care medicine; Endocrinology; Liraglutide","score_opus":0.01189550944405662,"score_gpt":0.22508104765261885,"score_spread":0.21318553820856223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998275298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739733,0.02342855,0.00030461128,0.00023661893,0.000069899674,0.00013084809,0.00042159684,0.00004863031,0.0013860016],"genre_scores_gemma":[0.99131596,0.006268745,0.0008597781,0.0003613093,0.0001557234,0.00009280278,0.00057505106,0.0000057723346,0.0003648334],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995815,0.00020182798,0.000042754153,0.00006415288,0.00007226784,0.0000375727],"domain_scores_gemma":[0.99928766,0.00026633288,0.00024040615,0.000045257133,0.000046840127,0.000113570444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001955923,0.00045386903,0.0013846112,0.00032585528,0.00012330001,0.0005226105,0.0002838855,0.0005037553,0.0012566155],"category_scores_gemma":[0.0016410274,0.00017043816,0.0011116088,0.00038229083,0.0002715947,0.00050026865,0.00025944776,0.00074959465,0.000119768854],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65873295,0.004581406,0.037847605,0.004262548,0.012442773,0.00020660504,0.00012947853,0.002329196,0.015025411,0.00035315743,0.00210388,0.26198503],"study_design_scores_gemma":[0.28997442,0.32594618,0.34952277,0.00063752383,0.015590042,0.0011000895,0.00019346828,0.004138276,0.006507981,0.0011295748,0.0051543787,0.00010531013],"about_ca_topic_score_codex":0.00047337104,"about_ca_topic_score_gemma":0.0018518912,"teacher_disagreement_score":0.001955923,"about_ca_system_score_codex":0.0002193864,"about_ca_system_score_gemma":0.00029327415,"threshold_uncertainty_score":0.0103440285},"labels":[],"label_agreement":null},{"id":"W3004835181","doi":"10.1111/dom.13991","title":"Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Hazard ratio; Mace; Internal medicine; Uric acid; Type 2 diabetes; Placebo; Diabetic nephropathy; Confidence interval; Diabetes mellitus; Cardiology; Endocrinology; Myocardial infarction; Kidney; Percutaneous coronary intervention","score_opus":0.017860684801858918,"score_gpt":0.23375872892902466,"score_spread":0.21589804412716573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004835181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900322,0.007990785,0.0003984426,0.00013156307,0.00006362472,0.000113366004,0.0007573423,0.000018576904,0.0004941505],"genre_scores_gemma":[0.9965354,0.0011366433,0.0003304756,0.00015627393,0.0001445437,0.00016656292,0.0011746932,0.000006058867,0.0003493059],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99864286,0.0008660118,0.00009900296,0.00016139109,0.00011686912,0.000113839385],"domain_scores_gemma":[0.99875283,0.0004583562,0.000366232,0.00019227993,0.000079844685,0.00015040886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003364498,0.0008564831,0.0025176445,0.00031595575,0.00019796814,0.0009834016,0.00046407277,0.0005663881,0.00079054636],"category_scores_gemma":[0.0020774435,0.00031949254,0.0033560663,0.0004872583,0.000278623,0.00050247106,0.00058298087,0.0011827388,0.00011952697],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5410563,0.0019789822,0.33989987,0.0028118992,0.073584355,0.00027303473,0.00011944657,0.0015129566,0.003941179,0.00023947218,0.0017260341,0.032856442],"study_design_scores_gemma":[0.078476,0.033810023,0.81746507,0.00019992655,0.061436474,0.00044888805,0.00014291526,0.0031300224,0.0014923562,0.00064805895,0.002660151,0.00009004815],"about_ca_topic_score_codex":0.0006523864,"about_ca_topic_score_gemma":0.0015148938,"teacher_disagreement_score":0.003364498,"about_ca_system_score_codex":0.00023891202,"about_ca_system_score_gemma":0.00032222294,"threshold_uncertainty_score":0.017793417},"labels":[],"label_agreement":null},{"id":"W3006085306","doi":"10.1111/dom.13997","title":"Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca; American Diabetes Association","keywords":"Saxagliptin; Medicine; Dapagliflozin; Glimepiride; Metformin; Type 2 diabetes; Pharmacology; Fixed-dose combination; Diabetes mellitus; Internal medicine; Urology; Endocrinology; Sitagliptin","score_opus":0.014505288255022824,"score_gpt":0.22342156750597997,"score_spread":0.20891627925095715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006085306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669063,0.0016947526,0.00017063491,0.00018847364,0.00012681162,0.00038021166,0.00028506314,0.000029096494,0.00043442802],"genre_scores_gemma":[0.9961021,0.00093373604,0.00049456686,0.00038361622,0.00030493017,0.0005486372,0.0005987702,0.000010987482,0.00062269135],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99883574,0.0005656231,0.00012466586,0.00024237874,0.00010632751,0.00012525312],"domain_scores_gemma":[0.99828184,0.00042884896,0.0004974927,0.00016716254,0.000097122684,0.00052761374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002576098,0.0016896406,0.0036815351,0.0004528046,0.00038826463,0.0014807176,0.0009775884,0.0017115329,0.0041438816],"category_scores_gemma":[0.0019650243,0.0009660513,0.0027351545,0.00041623213,0.0011056224,0.0012100801,0.00052250666,0.0030456348,0.00075777515],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.981926,0.0048648296,0.0012170527,0.00025225434,0.0011372521,0.000020891877,0.000029680916,0.0001620983,0.0026406725,0.00001756446,0.00016920202,0.0075625153],"study_design_scores_gemma":[0.9072326,0.085949,0.004629174,0.000024233676,0.0010050338,0.000034927125,0.000018991395,0.00039663241,0.0004978841,0.000038065926,0.00015765839,0.000015802712],"about_ca_topic_score_codex":0.00058373675,"about_ca_topic_score_gemma":0.0012372284,"teacher_disagreement_score":0.0041438816,"about_ca_system_score_codex":0.00075345946,"about_ca_system_score_gemma":0.0007141202,"threshold_uncertainty_score":0.013862729},"labels":[],"label_agreement":null},{"id":"W3008335290","doi":"10.1111/dom.14011","title":"Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"","keywords":"Medicine; Dapagliflozin; Diabetes mellitus; Internal medicine; Myocardial infarction; Mace; Type 2 diabetes; Hazard ratio; Stroke (engine); Cardiology; TIMI; Percutaneous coronary intervention; Endocrinology; Confidence interval","score_opus":0.01415808740807647,"score_gpt":0.20265518379180927,"score_spread":0.1884970963837328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008335290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99019426,0.006039607,0.0003538463,0.00020888909,0.00008099027,0.000090716385,0.0020099054,0.000016125396,0.0010056982],"genre_scores_gemma":[0.9945439,0.0010527963,0.00031978916,0.00021764905,0.00016776852,0.00012542894,0.0032057883,0.00000788995,0.0003589739],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99873966,0.0006079938,0.00011760992,0.00019866321,0.00021136843,0.00012478673],"domain_scores_gemma":[0.9975362,0.001103738,0.0006865802,0.00022343075,0.000113037895,0.0003369713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00381987,0.0006517364,0.0020002068,0.0003723192,0.0001717683,0.0008833509,0.00039870932,0.0005075756,0.0018438271],"category_scores_gemma":[0.0031974367,0.0003019152,0.003870845,0.0006115877,0.0002819631,0.00054879166,0.0005356082,0.0011626446,0.00014869704],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57464373,0.0008966908,0.34411368,0.0019057414,0.0297611,0.00033866163,0.000098411285,0.0027935314,0.0028064072,0.00031312573,0.0037745254,0.03855434],"study_design_scores_gemma":[0.071212165,0.018031266,0.8724746,0.00018758448,0.028847378,0.00053160416,0.000111531706,0.0046984153,0.0006659656,0.0006000974,0.0025414643,0.00009796079],"about_ca_topic_score_codex":0.0007018904,"about_ca_topic_score_gemma":0.0014197356,"teacher_disagreement_score":0.00381987,"about_ca_system_score_codex":0.00028904455,"about_ca_system_score_gemma":0.00044746939,"threshold_uncertainty_score":0.020201623},"labels":[],"label_agreement":null},{"id":"W3009238663","doi":"10.1111/dom.14017","title":"Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute for Health and Care Research","keywords":"Empagliflozin; Medicine; Internal medicine; Cardiology; Myocardial infarction; Risk factor; Heart failure; Type 2 diabetes; Diabetes mellitus; Relative risk; Hazard ratio; Confidence interval; Endocrinology","score_opus":0.05443718887107603,"score_gpt":0.23978317151922038,"score_spread":0.18534598264814434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009238663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95193905,0.002229096,0.0381411,0.0014546639,0.00030911696,0.0006868804,0.0010999931,0.00024026277,0.0038997398],"genre_scores_gemma":[0.99462163,0.00018406693,0.003282921,0.00051958713,0.00005119701,0.00032811446,0.00038487746,0.000028424183,0.00059906975],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99079204,0.0074207415,0.0002238485,0.0008245677,0.00048159304,0.00025729495],"domain_scores_gemma":[0.96985966,0.026341574,0.0016190044,0.0016308965,0.00034769817,0.0002012075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03740431,0.00072123966,0.0015219135,0.00015592822,0.0001324508,0.0010430461,0.0010592903,0.000941529,0.002198099],"category_scores_gemma":[0.036108978,0.00047307153,0.004627407,0.00016036192,0.00055381045,0.00083001895,0.00046301054,0.0014971722,0.0002747542],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35266685,0.003770818,0.16168545,0.0034246473,0.049749564,0.0013272855,0.00077297486,0.2831693,0.013659059,0.008809885,0.0075809336,0.113383256],"study_design_scores_gemma":[0.054106515,0.07358512,0.20303114,0.00045532885,0.034241013,0.00082592,0.00031283015,0.5790045,0.018136142,0.024509275,0.011513539,0.00027869342],"about_ca_topic_score_codex":0.0008156671,"about_ca_topic_score_gemma":0.00066077046,"teacher_disagreement_score":0.03740431,"about_ca_system_score_codex":0.00037670735,"about_ca_system_score_gemma":0.0009895359,"threshold_uncertainty_score":0.1978153},"labels":[],"label_agreement":null},{"id":"W3010351291","doi":"10.1111/dom.14020","title":"Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Placebo; Medicine; Type 2 diabetes; Adverse effect; Clinical endpoint; Metformin; Internal medicine; Randomized controlled trial; Diabetes mellitus; Randomization; Gastroenterology; Endocrinology; Insulin","score_opus":0.012231868217493709,"score_gpt":0.24304934158717661,"score_spread":0.23081747336968292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010351291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259055,0.0033620219,0.0005772362,0.00038078518,0.00019453779,0.0017882132,0.0004386783,0.00007543455,0.00059253693],"genre_scores_gemma":[0.98882675,0.0021049678,0.0022988594,0.0009020355,0.00044858895,0.0032527226,0.0007656316,0.00003045212,0.0013699476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986154,0.00079590356,0.00013020162,0.00021100782,0.0001247625,0.00012266132],"domain_scores_gemma":[0.9979296,0.00064973853,0.000570478,0.00021530107,0.00016502322,0.00047001304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003569644,0.0015085873,0.0039897626,0.00045569867,0.0004594537,0.0009961022,0.00087981747,0.0025308188,0.0040293117],"category_scores_gemma":[0.003169834,0.00094185333,0.002007907,0.00040693465,0.0010161066,0.0016017953,0.00040113268,0.0028258788,0.00068138115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9446136,0.021221397,0.001029105,0.00051698333,0.000789832,0.00004654565,0.000067164525,0.00026894856,0.006210625,0.000024495646,0.00034233317,0.024869023],"study_design_scores_gemma":[0.86279005,0.13289917,0.0028243721,0.00001937906,0.00031513406,0.000036044963,0.000015020833,0.00022093845,0.00058376364,0.000032849122,0.00024816341,0.000015123304],"about_ca_topic_score_codex":0.000331661,"about_ca_topic_score_gemma":0.00066651904,"teacher_disagreement_score":0.0040293117,"about_ca_system_score_codex":0.00059896585,"about_ca_system_score_gemma":0.00090238906,"threshold_uncertainty_score":0.01887834},"labels":[],"label_agreement":null},{"id":"W3010648955","doi":"10.1111/dom.14032","title":"Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Dosing; Pharmacokinetics; Placebo; Postprandial; Pharmacodynamics; Type 2 diabetes; Diabetes mellitus; Anesthesia; Urology; Internal medicine; Endocrinology","score_opus":0.019440194938486713,"score_gpt":0.2527941115982972,"score_spread":0.23335391665981048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010648955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877325,0.009291786,0.00089329755,0.00027045506,0.000079502424,0.00044836334,0.00026448167,0.000033224707,0.0009863708],"genre_scores_gemma":[0.9945346,0.0023201937,0.0014852992,0.0004409448,0.00013336992,0.00028739683,0.00028260352,0.000008794913,0.0005067015],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985051,0.0010501922,0.00014339607,0.00011162693,0.00012941986,0.00006023429],"domain_scores_gemma":[0.9971174,0.0015917902,0.0006664933,0.0001656867,0.00016509363,0.00029349863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031482035,0.0006425281,0.0017210615,0.0003133911,0.0002463538,0.0005265245,0.00031118494,0.00090332935,0.0016495256],"category_scores_gemma":[0.0040831743,0.00040255563,0.0011581767,0.0004548617,0.0004346009,0.0006933566,0.00018702046,0.0011891639,0.00019355651],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7619629,0.016789783,0.042312063,0.0018843145,0.0034954266,0.0004951847,0.0002884629,0.002249922,0.047751676,0.00013871457,0.0008151441,0.12181641],"study_design_scores_gemma":[0.20724188,0.6718194,0.0969708,0.00010664741,0.0025633534,0.001028513,0.00016981368,0.0018238835,0.013928332,0.00020788393,0.0040560444,0.00008345106],"about_ca_topic_score_codex":0.00030435086,"about_ca_topic_score_gemma":0.00052625453,"teacher_disagreement_score":0.0031482035,"about_ca_system_score_codex":0.00040839237,"about_ca_system_score_gemma":0.00042560435,"threshold_uncertainty_score":0.016649485},"labels":[],"label_agreement":null},{"id":"W3011497856","doi":"10.1111/dom.14026","title":"Glucose and protein metabolic responses to an energy‐ but not protein‐ restricted diet in type 2 diabetes","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Muscle metabolism and nutrition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Diabetes mellitus","score_opus":0.01207265938748419,"score_gpt":0.2212107678357456,"score_spread":0.2091381084482614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011497856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999428,0.00025563032,0.000070803566,0.000023221428,0.000012159636,0.000010530235,0.000053562948,0.0000033308665,0.0001427399],"genre_scores_gemma":[0.9985312,0.00026719374,0.00035178958,0.0001088781,0.000031065963,0.00004500689,0.00025299468,0.0000036960469,0.00040801748],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998547,0.000059575552,0.000013849518,0.000023433253,0.000023557388,0.00002490316],"domain_scores_gemma":[0.99980444,0.00004745803,0.000033548382,0.00002096871,0.000016074646,0.00007758361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051221834,0.00040125856,0.0004211162,0.00015020749,0.00014308389,0.00026170458,0.00014624165,0.00033057004,0.0009884919],"category_scores_gemma":[0.00043301316,0.00018484096,0.00028701575,0.00019773461,0.00018583854,0.00015244646,0.00017286949,0.00065421825,0.00010699637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20630595,0.019024553,0.31433025,0.0005605533,0.0010410729,0.00087087794,0.00031874486,0.0010870392,0.40738618,0.00009530609,0.00060883036,0.048370652],"study_design_scores_gemma":[0.0017032981,0.03646515,0.94500256,0.000021294929,0.00031937842,0.00043037624,0.00018524671,0.00097278063,0.014280758,0.000055816694,0.00054940465,0.000014071251],"about_ca_topic_score_codex":0.0009260076,"about_ca_topic_score_gemma":0.0010476655,"teacher_disagreement_score":0.0009884919,"about_ca_system_score_codex":0.0001478014,"about_ca_system_score_gemma":0.0001540734,"threshold_uncertainty_score":0.003306806},"labels":[],"label_agreement":null},{"id":"W3013330267","doi":"10.1111/dom.14015","title":"Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: <i>Post hoc</i> analysis of the EMPA‐REG OUTCOME trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; McGill University; University of Toronto; McGill University Health Centre; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences","keywords":"Empagliflozin; Medicine; Internal medicine; Myocardial infarction; Post-hoc analysis; Placebo; Diabetes mellitus; Heart failure; Cardiology; Type 2 diabetes; Hazard ratio; Confidence interval; Endocrinology","score_opus":0.017965382220222717,"score_gpt":0.2772640766944761,"score_spread":0.2592986944742534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013330267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157083,0.0037514102,0.00065061264,0.00034206168,0.0002548266,0.0005541061,0.00107352,0.000075998665,0.0017266634],"genre_scores_gemma":[0.99452907,0.0010878072,0.0006183848,0.0004627027,0.00036704852,0.0006429657,0.0012651313,0.000013098698,0.0010137976],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99906904,0.0005734443,0.000053455293,0.0001402751,0.00006736734,0.00009644268],"domain_scores_gemma":[0.99912065,0.00025923122,0.0002592547,0.00010311555,0.00006970649,0.00018806667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002444432,0.0014021551,0.0024915067,0.00023334734,0.0001875258,0.0010698823,0.00055254926,0.0007638868,0.0017910199],"category_scores_gemma":[0.0016736024,0.00041813788,0.0028689054,0.00021705213,0.0004917851,0.0005869846,0.00042259047,0.0017528748,0.0003208374],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9720457,0.0022207976,0.0060922178,0.0004207099,0.0057441853,0.000027195512,0.000021733122,0.0004852306,0.0018819467,0.00007504168,0.0009842581,0.010001002],"study_design_scores_gemma":[0.8045729,0.11697316,0.05771663,0.000118415766,0.0141662145,0.0001037717,0.000051736104,0.002813223,0.0017281491,0.00034124055,0.001364534,0.000050124752],"about_ca_topic_score_codex":0.0006438408,"about_ca_topic_score_gemma":0.001214077,"teacher_disagreement_score":0.0024915067,"about_ca_system_score_codex":0.00030754393,"about_ca_system_score_gemma":0.00044493712,"threshold_uncertainty_score":0.012927532},"labels":[],"label_agreement":null},{"id":"W3014351387","doi":"10.1111/dom.14043","title":"Differential glycaemic control with basal insulin glargine 300 <scp>U/mL</scp> versus degludec 100 <scp>U/mL</scp> according to kidney function in type 2 diabetes: A subanalysis from the <scp>BRIGHT</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Insulin degludec; Medicine; Renal function; Insulin glargine; Internal medicine; Urology; Diabetes mellitus; Type 2 diabetes; Confidence interval; Endocrinology; Kidney disease; Gastroenterology; Randomized controlled trial; Type 1 diabetes","score_opus":0.014324296476900424,"score_gpt":0.22038638604777686,"score_spread":0.20606208957087643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014351387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906737,0.006633439,0.0003119156,0.0002381078,0.00013585709,0.00031674898,0.0006254947,0.000020613243,0.0010441444],"genre_scores_gemma":[0.99727684,0.00089102634,0.00033201306,0.0002893851,0.00009396034,0.00024161628,0.0004997559,0.0000058476016,0.0003696431],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998882,0.0006783992,0.00010820261,0.0001569835,0.00008294259,0.000091388996],"domain_scores_gemma":[0.99899274,0.00040492995,0.0002657132,0.0001231594,0.000051253348,0.00016228182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023911097,0.0007464105,0.002625914,0.00021832781,0.00021087864,0.0009918762,0.00039940377,0.00063069834,0.0023886657],"category_scores_gemma":[0.001850595,0.0003099402,0.00335265,0.0003414052,0.00045146636,0.0004711883,0.0003749586,0.0013132254,0.0002273603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97485715,0.00073772727,0.004707411,0.0006795692,0.0077166893,0.000017679158,0.000033557273,0.00020901913,0.0016914613,0.00006801471,0.00044946902,0.008832114],"study_design_scores_gemma":[0.829087,0.06989866,0.06451484,0.00031602825,0.030451186,0.00010893133,0.0001327405,0.0015758547,0.0017685737,0.00084655976,0.001238075,0.000061452294],"about_ca_topic_score_codex":0.0006159407,"about_ca_topic_score_gemma":0.0015737818,"teacher_disagreement_score":0.002625914,"about_ca_system_score_codex":0.00036476008,"about_ca_system_score_gemma":0.0004186404,"threshold_uncertainty_score":0.012645602},"labels":[],"label_agreement":null},{"id":"W3014409190","doi":"10.1111/dom.14041","title":"Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Agence Nationale de la Recherche; AstraZeneca","keywords":"Dapagliflozin; Medicine; Placebo; Type 2 diabetes; Adverse effect; Internal medicine; Diabetic ketoacidosis; Diabetes mellitus; Population; Renal function; Urology; Endocrinology; Insulin","score_opus":0.021327916295630935,"score_gpt":0.25585816195749583,"score_spread":0.2345302456618649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014409190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305516,0.0036798005,0.00052987126,0.00011265812,0.000022196713,0.00010652726,0.0018232159,0.000015356896,0.00065512006],"genre_scores_gemma":[0.9952258,0.00077476655,0.00032037607,0.00018591985,0.00008233936,0.00012189131,0.0031124642,0.0000070376173,0.0001693643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970721,0.0014832672,0.00029115754,0.0004573665,0.0005425354,0.00015360287],"domain_scores_gemma":[0.99385417,0.0024208,0.0021911233,0.00067671,0.00036713274,0.00049013813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007249766,0.0006915504,0.0015666471,0.00084384764,0.00023423116,0.00093610573,0.00043008945,0.00054604816,0.0016493897],"category_scores_gemma":[0.005612333,0.00030046393,0.0036150652,0.0010290679,0.0003278599,0.00045485175,0.0006480495,0.0010328803,0.00016912911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10881525,0.00050771376,0.8439452,0.0005636098,0.018424172,0.00021535213,0.00015139769,0.0009616276,0.0017544862,0.00010896617,0.0011294805,0.023422673],"study_design_scores_gemma":[0.0070313034,0.0067008534,0.97633773,0.000048879883,0.0069563617,0.00027288945,0.00006778835,0.0010360614,0.00037136432,0.00015739634,0.0009854013,0.0000340399],"about_ca_topic_score_codex":0.00059595035,"about_ca_topic_score_gemma":0.00087005564,"teacher_disagreement_score":0.007249766,"about_ca_system_score_codex":0.00029337648,"about_ca_system_score_gemma":0.000390055,"threshold_uncertainty_score":0.038340926},"labels":[],"label_agreement":null},{"id":"W3014701587","doi":"10.1111/dom.13965","title":"What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?","year":2020,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"","keywords":"Medicine; Empagliflozin; Canagliflozin; Clinical trial; Intensive care medicine; Internal medicine; Albuminuria; Clinical endpoint; Type 2 diabetes; Renal function; Diabetes mellitus; Endocrinology","score_opus":0.23986227727852943,"score_gpt":0.36642641467798515,"score_spread":0.1265641373994557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014701587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024876455,0.88692343,0.0038869204,0.0959786,0.0078075975,0.00017249017,0.0012972789,0.00007398192,0.0013720125],"genre_scores_gemma":[0.06053923,0.6941788,0.014826795,0.17710689,0.049089078,0.0011708123,0.0020388933,0.0003036238,0.0007459232],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.8218854,0.10303345,0.04554106,0.011794022,0.015401174,0.002344827],"domain_scores_gemma":[0.19898179,0.68546206,0.039205514,0.026168723,0.04585259,0.0043293308],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.32859755,0.0017741008,0.0093006585,0.0049201194,0.0013383018,0.011347107,0.0060364455,0.007944808,0.009561608],"category_scores_gemma":[0.5762386,0.0017663949,0.011077617,0.008095185,0.0049920348,0.014682007,0.0046171285,0.011325958,0.001748523],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005318135,0.00027078832,0.03691776,0.1666131,0.03905779,0.00039188977,0.0020396472,0.0015397826,0.00042041473,0.01822988,0.104116835,0.625084],"study_design_scores_gemma":[0.0040707556,0.002254588,0.07024657,0.36829913,0.061346304,0.0014553043,0.0023673351,0.0025957339,0.0008119605,0.075850524,0.40994605,0.0007557965],"about_ca_topic_score_codex":0.007461095,"about_ca_topic_score_gemma":0.009816739,"teacher_disagreement_score":0.32859755,"about_ca_system_score_codex":0.0039873063,"about_ca_system_score_gemma":0.010625704,"threshold_uncertainty_score":0.82795876},"labels":[],"label_agreement":null},{"id":"W3014973577","doi":"10.1111/dom.14050","title":"Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Novo Nordisk","keywords":"Liraglutide; Appetite; Medicine; Overweight; Crossover study; Placebo; Type 2 diabetes; Internal medicine; Endocrinology; Insulin; Diabetes mellitus; Obesity","score_opus":0.0086374462452065,"score_gpt":0.22145787819047297,"score_spread":0.21282043194526648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014973577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995197,0.0038236172,0.000085873755,0.00011156948,0.000058734477,0.00019994008,0.00010105835,0.000024157303,0.00039803426],"genre_scores_gemma":[0.9962089,0.0018525963,0.0005820701,0.0002130556,0.0000705451,0.00032306294,0.00016382874,0.0000055999158,0.0005804252],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997063,0.00014703812,0.000033343964,0.00004801622,0.000033932483,0.00003126305],"domain_scores_gemma":[0.99957556,0.00011440706,0.00013726637,0.000021855845,0.00002400331,0.00012701069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072551786,0.0006017473,0.0014551107,0.00023986427,0.00026919463,0.00040639602,0.00037733957,0.00094340125,0.0019673372],"category_scores_gemma":[0.001033982,0.00030172264,0.000678665,0.00024057519,0.00040218548,0.00033057822,0.0002048664,0.0010354212,0.00027848702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8615461,0.022120908,0.007913677,0.0019711147,0.001291034,0.000102033504,0.00016366351,0.00042424293,0.024741318,0.000024120714,0.00044136736,0.07926049],"study_design_scores_gemma":[0.28384078,0.58684397,0.116904005,0.000215895,0.0022882996,0.00023882533,0.00014331998,0.00094922306,0.0070066457,0.00006716735,0.0014485668,0.000053328582],"about_ca_topic_score_codex":0.00092456356,"about_ca_topic_score_gemma":0.0017920067,"teacher_disagreement_score":0.0019673372,"about_ca_system_score_codex":0.00031611093,"about_ca_system_score_gemma":0.00030780173,"threshold_uncertainty_score":0.0065814257},"labels":[],"label_agreement":null},{"id":"W3021285140","doi":"10.1111/dom.14082","title":"Sodium‐glucose co‐transporter‐2 inhibitors and the risk of urosepsis: A multi‐site, prevalent new‐user cohort study","year":2020,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Kidney Stones and Urolithiasis Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Saskatchewan Health Quality Council; University of Manitoba; Manitoba Health; Health Sciences Centre; Institut National d'Excellence en Santé et en Services Sociaux; University of Calgary; McGill University Health Centre; Institute for Clinical Evaluative Sciences; McGill University; Jewish General Hospital; Sunnybrook Health Science Centre; Sinai Health System; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Dapagliflozin; Medicine; Empagliflozin; Hazard ratio; Internal medicine; Proportional hazards model; Confidence interval; Type 2 diabetes; Canagliflozin; Cohort; Diabetes mellitus; Endocrinology","score_opus":0.017826730922764,"score_gpt":0.28436987930530844,"score_spread":0.26654314838254445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021285140","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513197,0.002527012,0.00050726987,0.00004454207,0.000032128195,0.00009543831,0.0014900146,0.000006702738,0.00016496016],"genre_scores_gemma":[0.9978023,0.0007386568,0.00035532686,0.000067041416,0.000028200642,0.000059698992,0.0008013529,0.0000037040506,0.00014367377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998197,0.00064604584,0.00022562948,0.0004893199,0.00028860653,0.00015351475],"domain_scores_gemma":[0.9968742,0.00059976033,0.0011716528,0.000589271,0.0004163378,0.00034884395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032455763,0.0006320607,0.0011318712,0.0010518207,0.0005529011,0.0012318833,0.000775572,0.00091720646,0.0012135966],"category_scores_gemma":[0.004258989,0.0006844798,0.003982308,0.0018321587,0.00024136854,0.0004709539,0.00064215774,0.00066306005,0.00015819377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048369938,0.00019405414,0.97169286,0.0002917076,0.019013533,0.00016024812,0.00009660509,0.00020559908,0.00045236284,0.000042653333,0.00025344553,0.0027599444],"study_design_scores_gemma":[0.0016921266,0.0011524009,0.9763699,0.000099589,0.017733725,0.00044374855,0.00016585088,0.0013281965,0.00023104776,0.000060050483,0.00068643707,0.00003684034],"about_ca_topic_score_codex":0.026583225,"about_ca_topic_score_gemma":0.027491305,"teacher_disagreement_score":0.026583225,"about_ca_system_score_codex":0.00086942327,"about_ca_system_score_gemma":0.0008581133,"threshold_uncertainty_score":0.05285698},"labels":[],"label_agreement":null},{"id":"W3021290569","doi":"10.1111/dom.14079","title":"The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Sun Pharma; Novo Nordisk; Valeant Pharmaceuticals International; American Heart Association; Sanofi; HLS Therapeutics; Amgen; AstraZeneca; Eli Lilly and Company","keywords":"Semaglutide; Liraglutide; Mace; Medicine; Diabetic nephropathy; Internal medicine; Nephropathy; Blood pressure; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Endocrinology; Placebo; Cardiology","score_opus":0.011967852273858442,"score_gpt":0.245136943228653,"score_spread":0.23316909095479457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021290569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8745671,0.11733433,0.0014295238,0.0011653355,0.0003162876,0.0010100268,0.0018366207,0.00005632591,0.0022844214],"genre_scores_gemma":[0.9854455,0.009542723,0.001040551,0.0008496617,0.0002808992,0.00080947194,0.0013697147,0.000023880686,0.00063760707],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98935753,0.0077212434,0.0011547487,0.00076426566,0.0006191916,0.000383062],"domain_scores_gemma":[0.9913492,0.0055104815,0.0017046891,0.000621116,0.0004760849,0.0003382654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01274631,0.0010666898,0.0059144995,0.0005231258,0.00027847983,0.0014804596,0.0007077165,0.0011319051,0.0014987662],"category_scores_gemma":[0.013065742,0.00044747666,0.008406683,0.0010655092,0.0006335636,0.0011357496,0.0005458193,0.0017018417,0.00017620887],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7955362,0.0004589287,0.017468851,0.008585839,0.12996532,0.00018850433,0.00017039177,0.0013201765,0.0026875027,0.000327536,0.0014716598,0.041818965],"study_design_scores_gemma":[0.43922254,0.096990116,0.14011827,0.0020154486,0.3049611,0.00068468583,0.00037564657,0.003926512,0.0021848278,0.0025902847,0.0067561916,0.00017432358],"about_ca_topic_score_codex":0.00067146117,"about_ca_topic_score_gemma":0.0014269386,"teacher_disagreement_score":0.01274631,"about_ca_system_score_codex":0.0006313373,"about_ca_system_score_gemma":0.0009457758,"threshold_uncertainty_score":0.067409694},"labels":[],"label_agreement":null},{"id":"W3021808388","doi":"10.1111/dom.14077","title":"<scp>iGlarLixi</scp> effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the <scp>LixiLan‐L</scp> study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Type 2 diabetes; Lixisenatide; Basal insulin; Metformin; Medicine; Insulin glargine; Basal (medicine); Internal medicine; Insulin; Endocrinology; Diabetes mellitus; Gastroenterology","score_opus":0.00812366234545442,"score_gpt":0.20665570532734998,"score_spread":0.19853204298189556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021808388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956233,0.001944456,0.00027755677,0.00025204508,0.00013528405,0.0004333885,0.00056893734,0.000050600767,0.0007145192],"genre_scores_gemma":[0.9954116,0.001094283,0.00076217594,0.00039991547,0.00017355183,0.00044197426,0.0009227233,0.000021503396,0.0007722306],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99813217,0.0012336251,0.00013548299,0.00018829409,0.000093700386,0.00021670676],"domain_scores_gemma":[0.99760133,0.0010613572,0.0004549035,0.00028725583,0.00015196795,0.00044316667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040639862,0.001285,0.003192392,0.00033602875,0.00028470624,0.0012173599,0.00053668395,0.0007795551,0.0034579656],"category_scores_gemma":[0.0021875612,0.00040527154,0.005900093,0.00038382874,0.00078639924,0.00073829945,0.0004189123,0.002246515,0.00043299186],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9661262,0.0050749816,0.0026655886,0.0004459083,0.0041244435,0.000059038386,0.000044981807,0.00043021014,0.0032756391,0.000044710487,0.0006587003,0.017049804],"study_design_scores_gemma":[0.52587074,0.43233645,0.028159454,0.00007904944,0.008365248,0.00009675304,0.00011313195,0.0012715334,0.0021930218,0.0001501105,0.0013047382,0.00005976874],"about_ca_topic_score_codex":0.00082245894,"about_ca_topic_score_gemma":0.0020458302,"teacher_disagreement_score":0.0040639862,"about_ca_system_score_codex":0.00065126823,"about_ca_system_score_gemma":0.0010236293,"threshold_uncertainty_score":0.02149266},"labels":[],"label_agreement":null},{"id":"W3025648277","doi":"10.1111/dom.14084","title":"Goal achievement of <scp>HbA1c</scp> and <scp>LDL‐</scp> cholesterol in a randomized trial comparing colesevelam with ezetimibe: <scp>GOAL‐RCT</scp>","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"","keywords":"Ezetimibe; Medicine; Internal medicine; Gastroenterology; Randomized controlled trial; Type 2 diabetes; Discontinuation; Cholesterol; Statin; Endocrinology; Diabetes mellitus","score_opus":0.01245808594523028,"score_gpt":0.2262069639989136,"score_spread":0.2137488780536833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025648277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98531264,0.0036354198,0.00076672673,0.00078662526,0.0004900906,0.0062248516,0.0008394086,0.00007679961,0.0018674983],"genre_scores_gemma":[0.9879488,0.0012902598,0.0019625642,0.000686291,0.0003182368,0.006058669,0.00064590154,0.000015145135,0.0010741915],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975944,0.0015297582,0.000235812,0.00028469323,0.00016848963,0.00018674378],"domain_scores_gemma":[0.99794406,0.0005930922,0.00050561444,0.00013163942,0.00019159818,0.000633913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003197178,0.0014128018,0.003584258,0.0004051074,0.00041303688,0.001381718,0.00061336136,0.0020514317,0.005393838],"category_scores_gemma":[0.003859079,0.00076105056,0.0033182164,0.00044508537,0.0008620683,0.0009644052,0.00070552627,0.002259815,0.0005288725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9908153,0.0024995278,0.00045453868,0.00037311556,0.0015043241,0.000012638096,0.000020793008,0.00010652271,0.000883844,0.000049659364,0.00016934924,0.0031104384],"study_design_scores_gemma":[0.9584956,0.036975842,0.0020007093,0.000051300598,0.0014919791,0.000012576968,0.000019702877,0.00030322553,0.00028164173,0.0001065289,0.00024929355,0.000011550856],"about_ca_topic_score_codex":0.0013957988,"about_ca_topic_score_gemma":0.00285875,"teacher_disagreement_score":0.005393838,"about_ca_system_score_codex":0.00079452514,"about_ca_system_score_gemma":0.0017176954,"threshold_uncertainty_score":0.018044174},"labels":[],"label_agreement":null},{"id":"W3028818452","doi":"10.1111/dom.14103","title":"Sex‐specific associations between cardiovascular risk factors and myocardial infarction in patients with type 2 diabetes: The <scp>ADVANCE‐ON</scp> study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; Servier; University of New South Wales","keywords":"Medicine; Hazard ratio; Internal medicine; Body mass index; Myocardial infarction; Diabetes mellitus; Proportional hazards model; Blood pressure; Type 2 diabetes; Relative risk; Cohort; Cohort study; Risk factor; Confidence interval; Demography; Endocrinology","score_opus":0.017986675731275714,"score_gpt":0.24065019938256754,"score_spread":0.22266352365129183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028818452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980026,0.0005689026,0.000079229365,0.0000599787,0.000022826067,0.000017911807,0.00079382333,0.0000031683344,0.00045160565],"genre_scores_gemma":[0.997837,0.00029822823,0.00012486565,0.000077571,0.000086336055,0.000024797508,0.0012767822,0.0000030514473,0.00027140265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996087,0.00012897917,0.000038448547,0.000101581885,0.00007979019,0.000042443793],"domain_scores_gemma":[0.99878246,0.00017472761,0.00047221198,0.0002200965,0.00010897219,0.00024160495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012904592,0.0004983855,0.000572033,0.00034802879,0.0003242797,0.00072176085,0.000382439,0.0006410103,0.0011987453],"category_scores_gemma":[0.0014503456,0.00035001407,0.00090768887,0.00067257846,0.00019702771,0.00035113786,0.00041297346,0.00093386753,0.00016999911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019400083,0.00007302585,0.99562776,0.000030601735,0.00045675208,0.00007628086,0.000035460605,0.000035492812,0.00021950176,0.000017160519,0.0002610467,0.0012268942],"study_design_scores_gemma":[0.0002624576,0.00034534853,0.99823296,0.000010562546,0.00033044367,0.00027153752,0.000045999157,0.00013604283,0.000058276844,0.000028488726,0.00027229293,0.0000055095825],"about_ca_topic_score_codex":0.0022455992,"about_ca_topic_score_gemma":0.0030915975,"teacher_disagreement_score":0.0022455992,"about_ca_system_score_codex":0.000150599,"about_ca_system_score_gemma":0.0002530847,"threshold_uncertainty_score":0.006824672},"labels":[],"label_agreement":null},{"id":"W3031038558","doi":"10.1111/dom.14102","title":"Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel","year":2020,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Merck Sharp and Dohme; TrigoCare International; Hebrew University of Jerusalem; Mylan; KU Leuven; Teva Pharmaceutical Industries; Novo Nordisk; Sanofi; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Type 2 diabetes; Medicine; Metformin; Intensive care medicine; Expert opinion; Diabetes mellitus; Diabetes treatment; Endocrinology","score_opus":0.03341292104257114,"score_gpt":0.27084942317275323,"score_spread":0.23743650213018208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031038558","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00141676,0.4767311,0.010270007,0.47862884,0.020556556,0.0006526143,0.0008533839,0.000240515,0.010650294],"genre_scores_gemma":[0.03369802,0.53457934,0.08250805,0.3075242,0.027874812,0.0026957013,0.004093127,0.00023646021,0.006790268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9869153,0.0058956295,0.003411346,0.0008447882,0.0022793324,0.00065359974],"domain_scores_gemma":[0.97906554,0.0071781254,0.0022421344,0.00039651466,0.009702523,0.0014151636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027681438,0.0012247838,0.0030899635,0.002162956,0.0010221018,0.003931962,0.0052106306,0.008559715,0.0037462763],"category_scores_gemma":[0.03533092,0.00056079146,0.0041808956,0.0017278213,0.00120927,0.0035733213,0.0032477274,0.00889286,0.0028397432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023801776,0.00010008702,0.0015639664,0.01554265,0.0007790375,0.00049222383,0.0006483691,0.00081225653,0.00061972777,0.007207472,0.44395143,0.5280447],"study_design_scores_gemma":[0.00049689575,0.00014203171,0.0026853448,0.060493167,0.001264336,0.00073812273,0.00062907743,0.00090716133,0.00035234276,0.013277439,0.91887385,0.000140328],"about_ca_topic_score_codex":0.0037132371,"about_ca_topic_score_gemma":0.005500015,"teacher_disagreement_score":0.027681438,"about_ca_system_score_codex":0.002762569,"about_ca_system_score_gemma":0.009951911,"threshold_uncertainty_score":0.1463952},"labels":[],"label_agreement":null},{"id":"W3033072901","doi":"10.1111/dom.14111","title":"Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte <scp>ATP</scp> homeostasis during substrate challenge","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cholesterol and Lipid Metabolism","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada","keywords":"Carbohydrate-responsive element-binding protein; Glucokinase; Internal medicine; Endocrinology; Glucose homeostasis; Hepatocyte; Homeostasis; Medicine; Cell biology; Biochemistry; Biology; Transcription factor; Gene; Insulin resistance; In vitro; Insulin","score_opus":0.01643195933039404,"score_gpt":0.2234258433639886,"score_spread":0.20699388403359456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033072901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972474,0.0008032494,0.0007714842,0.00010759578,0.000040781695,0.000020346024,0.0003682231,0.00011955035,0.00052128354],"genre_scores_gemma":[0.99511236,0.0007757754,0.0013010459,0.00011229609,0.000023619985,0.000045000004,0.0008722481,0.000028477236,0.0017292622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998448,0.000015697025,0.00001873044,0.00003635266,0.000031853015,0.000052572614],"domain_scores_gemma":[0.99983037,0.000011627686,0.00006727051,0.000016456006,0.000012807495,0.000061566265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011582409,0.0005928574,0.00054020877,0.00029584032,0.000118401214,0.00035204738,0.00022905834,0.00025842665,0.0016784646],"category_scores_gemma":[0.00009255308,0.0001373883,0.00030879787,0.00021261105,0.00037400148,0.0002966939,0.00017496641,0.0009819985,0.00043952375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014953198,0.00014395855,0.00037938516,0.00005172277,0.000010461093,0.000044130637,0.000007153944,0.00005259258,0.9959649,0.000025661977,0.000058052294,0.0017667294],"study_design_scores_gemma":[0.00019454931,0.00486038,0.009243511,0.000011911271,0.00004371821,0.00022696992,0.000050480372,0.0003164941,0.9838157,0.000031182142,0.0011969621,0.000008124958],"about_ca_topic_score_codex":0.00059690565,"about_ca_topic_score_gemma":0.0010748059,"teacher_disagreement_score":0.0016784646,"about_ca_system_score_codex":0.00027595364,"about_ca_system_score_gemma":0.00026870563,"threshold_uncertainty_score":0.0056150556},"labels":[],"label_agreement":null},{"id":"W3034401538","doi":"10.1111/dom.14117","title":"Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian <scp>LMC</scp> diabetes registry ( <scp>SPARE</scp> study)","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Semaglutide; Medicine; Exenatide; Type 2 diabetes; Internal medicine; Liraglutide; Diabetes mellitus; Retrospective cohort study; Glucagon-like peptide 1 receptor; Cohort; Endocrinology; Agonist","score_opus":0.011871058071430296,"score_gpt":0.22199252926547053,"score_spread":0.21012147119404023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034401538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901805,0.00073805446,0.00006062359,0.0001088185,0.000010264044,0.00008656247,0.008189687,0.000007877172,0.0006176305],"genre_scores_gemma":[0.9923273,0.0005190457,0.00022005137,0.00016588693,0.000016722204,0.00006589691,0.0064119576,0.000004492517,0.0002687913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866426,0.00021592816,0.00011117054,0.00027334795,0.0005164384,0.00021880248],"domain_scores_gemma":[0.99708563,0.00019914446,0.0013411603,0.00018273806,0.0007559446,0.0004354463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011603195,0.00040832735,0.0005906476,0.00084776327,0.0008686557,0.0009948864,0.00080533116,0.0005096603,0.00080449827],"category_scores_gemma":[0.0031005854,0.00036552883,0.0008834713,0.003907703,0.0003719935,0.00039301845,0.0006184322,0.00068645104,0.00018199053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000655348,0.000067593566,0.9957677,0.00006264399,0.00020556047,0.000040926123,0.00010934177,0.000058599868,0.00005976397,0.000017688433,0.0006261541,0.0023286701],"study_design_scores_gemma":[0.00007487052,0.00010562494,0.9989618,0.000019750309,0.0000964349,0.00004817955,0.000119875156,0.00015374024,0.000018505403,0.0000074241225,0.00038623766,0.0000075900766],"about_ca_topic_score_codex":0.80870444,"about_ca_topic_score_gemma":0.81670743,"teacher_disagreement_score":0.19129556,"about_ca_system_score_codex":0.005643305,"about_ca_system_score_gemma":0.0049625817,"threshold_uncertainty_score":0.38484424},"labels":[],"label_agreement":null},{"id":"W3035236623","doi":"10.1111/dom.14044","title":"Postprandial hyperglycaemia following insulin suspensions by the artificial pancreas: Implications for bolus calculators","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital; McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Postprandial; Insulin; Medicine; Bolus (digestion); Artificial pancreas; Internal medicine; Meal; Diabetes mellitus; Endocrinology; Regular insulin; Type 1 diabetes; Hypoglycemia","score_opus":0.02744931408699795,"score_gpt":0.2776482186697307,"score_spread":0.25019890458273275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035236623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930438,0.0042173997,0.0011656334,0.00029176206,0.00005953317,0.000023374947,0.00005457447,0.000017584316,0.0011262347],"genre_scores_gemma":[0.99822086,0.000822318,0.000630571,0.00008173583,0.00007120856,0.000009341911,0.000039365288,0.000009821595,0.00011482417],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99640876,0.0017052459,0.00050051115,0.00038309424,0.0008613298,0.00014109677],"domain_scores_gemma":[0.96590334,0.021860829,0.0087760575,0.0017157394,0.0011568327,0.0005871694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004969759,0.00039211617,0.0007686063,0.0006670627,0.0002741756,0.0015859463,0.000586717,0.000565318,0.0009981223],"category_scores_gemma":[0.03274539,0.00029867946,0.0006738635,0.000829477,0.0008502079,0.0011241415,0.00043078986,0.00090641977,0.00014790728],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004510123,0.00016342443,0.95720375,0.00029511005,0.0001864672,0.0012888968,0.00034574853,0.00026608494,0.0020051529,0.0001496107,0.00013927867,0.033446338],"study_design_scores_gemma":[0.000059519298,0.0024826922,0.9895531,0.00018049244,0.0003103839,0.0037203769,0.0005146874,0.0011261279,0.001362042,0.00020766827,0.000456146,0.000026684074],"about_ca_topic_score_codex":0.00072107645,"about_ca_topic_score_gemma":0.0006010732,"teacher_disagreement_score":0.004969759,"about_ca_system_score_codex":0.0003471354,"about_ca_system_score_gemma":0.00043965745,"threshold_uncertainty_score":0.026282907},"labels":[],"label_agreement":null},{"id":"W3036174462","doi":"10.1111/dom.14118","title":"γ‐aminobutyric acid stimulates β‐cell proliferation through the <scp>mTORC1</scp> / <scp>p70S6K</scp> pathway, an effect amplified by <scp>Ly49</scp> , a novel γ‐aminobutyric acid type A receptor positive allosteric modulator","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Cell growth; mTORC1; Receptor; Cell biology; PI3K/AKT/mTOR pathway; Aminobutyric acid; Cell; Chemistry; Endocrinology; Internal medicine; Signal transduction; Biology; Biochemistry; Medicine","score_opus":0.014909305773513138,"score_gpt":0.22535702520054504,"score_spread":0.21044771942703192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036174462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930419,0.0027582415,0.0014491169,0.0001872763,0.000051143637,0.00002505325,0.0003487482,0.00011124594,0.0020273705],"genre_scores_gemma":[0.99480224,0.0020375652,0.0011612166,0.000086793,0.000020284158,0.00004208049,0.00027040232,0.00002356363,0.0015559177],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993265,0.00001211971,0.000007752666,0.000012605401,0.000017436145,0.000017517481],"domain_scores_gemma":[0.9999546,0.000007647393,0.000015365245,0.0000048833044,0.0000044521207,0.000013099783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097487566,0.00030671028,0.00022355487,0.00014973071,0.00010293581,0.00023459594,0.00011907478,0.0001832189,0.0022279846],"category_scores_gemma":[0.00006357194,0.00012414057,0.00025363787,0.000104944804,0.00016159387,0.00012753255,0.00013084763,0.0004831842,0.0005067555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018935306,0.000019758832,0.00009329217,0.000036485653,0.0000064533374,0.000020023343,0.0000025561235,0.000028434819,0.9986975,0.000025160998,0.00003952745,0.0008415298],"study_design_scores_gemma":[0.00004438548,0.00045868318,0.0038006017,0.000008183098,0.000020324294,0.00012940529,0.00001763029,0.000531134,0.9936215,0.000024219118,0.0013408836,0.0000028428753],"about_ca_topic_score_codex":0.00029377925,"about_ca_topic_score_gemma":0.0006143803,"teacher_disagreement_score":0.0022279846,"about_ca_system_score_codex":0.00015837731,"about_ca_system_score_gemma":0.0001681508,"threshold_uncertainty_score":0.007453382},"labels":[],"label_agreement":null},{"id":"W3038205043","doi":"10.1111/dom.14123","title":"The effect of referral to an open‐group behavioural weight‐management programme on the relative risk of normoglycaemia, non‐diabetic hyperglycaemia and type 2 diabetes: Secondary analysis of the <scp>WRAP</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Education","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada; Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Relative risk; Body mass index; Diabetes mellitus; Confidence interval; Type 2 diabetes; Internal medicine; Weight management; Randomized controlled trial; Overweight; Endocrinology","score_opus":0.018876471789053214,"score_gpt":0.25316372148879035,"score_spread":0.23428724969973713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038205043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98856676,0.0066229175,0.00031511518,0.00064944994,0.0005319707,0.0007869853,0.0007235553,0.00005703385,0.0017461397],"genre_scores_gemma":[0.995382,0.0013560534,0.00040324268,0.0003572883,0.00028664275,0.00087836647,0.00046358758,0.000009891245,0.0008629215],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962859,0.0024622201,0.00030139816,0.00040774653,0.0002454452,0.00029713174],"domain_scores_gemma":[0.99675316,0.0013801213,0.0008623361,0.00021201391,0.00014303954,0.00064932334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035090665,0.0012965859,0.0027827688,0.0005458757,0.00033770018,0.0011198513,0.00087004405,0.0021250693,0.0052728136],"category_scores_gemma":[0.008498054,0.0006967344,0.0054071154,0.00048683467,0.0006389094,0.0008205723,0.0010742889,0.0025372922,0.00039387902],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9388498,0.006718351,0.010934921,0.0033339404,0.013113849,0.00005907499,0.00010278885,0.0005076346,0.00046791276,0.00010354525,0.0011478146,0.024660341],"study_design_scores_gemma":[0.700822,0.13912383,0.117108114,0.0014003611,0.03540687,0.00016323666,0.00022723482,0.0027207616,0.0009246029,0.0006559405,0.0013663766,0.00008071735],"about_ca_topic_score_codex":0.003319874,"about_ca_topic_score_gemma":0.0034097815,"teacher_disagreement_score":0.0052728136,"about_ca_system_score_codex":0.00071357324,"about_ca_system_score_gemma":0.00097673,"threshold_uncertainty_score":0.018557906},"labels":[],"label_agreement":null},{"id":"W3039898484","doi":"10.1111/dom.14127","title":"Sotagliflozin added to optimized insulin therapy leads to <scp>HbA1c</scp> reduction without weight gain in adults with type 1 diabetes: A pooled analysis of <scp>inTandem1</scp> and <scp>inTandem2</scp>","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Placebo; Medicine; Insulin; Ketoacidosis; Internal medicine; Weight gain; Weight loss; Diabetes mellitus; Type 1 diabetes; Clinical trial; Gastroenterology; Body weight; Type 2 diabetes; Endocrinology; Obesity; Pathology","score_opus":0.013861662298813521,"score_gpt":0.2512247156702229,"score_spread":0.2373630533714094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039898484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8525636,0.13761331,0.0036400282,0.00049382437,0.00059675187,0.0010174018,0.0022406878,0.00019780695,0.0016365503],"genre_scores_gemma":[0.98265344,0.012966528,0.0019439259,0.0004299433,0.000207431,0.00037773108,0.0009850224,0.00001939426,0.0004164228],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99605197,0.0023376902,0.0005464864,0.0005478611,0.00040189686,0.000114121474],"domain_scores_gemma":[0.99777776,0.00099006,0.00077605346,0.00019002291,0.00016295395,0.00010307078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006404589,0.001342241,0.00559128,0.0008887859,0.00018045524,0.0013492358,0.0005241325,0.0009480968,0.0014344422],"category_scores_gemma":[0.005923191,0.0007978273,0.01192148,0.0009321167,0.00041353068,0.00067288807,0.0005643941,0.0011585806,0.00014325835],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5656787,0.0007042049,0.015799012,0.011601376,0.34061694,0.00012727793,0.00008908247,0.0018110304,0.005189563,0.00008543879,0.0011918988,0.057105497],"study_design_scores_gemma":[0.21774939,0.0472129,0.0944274,0.0011620587,0.6289563,0.0003587949,0.000118652184,0.003628728,0.003137388,0.00027509168,0.0028623308,0.000111015295],"about_ca_topic_score_codex":0.0014395631,"about_ca_topic_score_gemma":0.0037232065,"teacher_disagreement_score":0.006404589,"about_ca_system_score_codex":0.00065468164,"about_ca_system_score_gemma":0.0006823409,"threshold_uncertainty_score":0.033871114},"labels":[],"label_agreement":null},{"id":"W3041938457","doi":"10.1111/dom.14140","title":"Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 clinical trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Semaglutide; Medicine; Liraglutide; Type 2 diabetes; Hazard ratio; Internal medicine; Empagliflozin; Placebo; Disease; Diabetes mellitus; Macrovascular disease; Adverse effect; Clinical trial; Confidence interval; Surgery; Cardiology; Endocrinology; Pathology","score_opus":0.05417518927297947,"score_gpt":0.3188147998343146,"score_spread":0.2646396105613351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041938457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7525311,0.23242873,0.00080312276,0.0026453862,0.00056269026,0.0014626755,0.002913246,0.00006709439,0.0065859985],"genre_scores_gemma":[0.931434,0.05824208,0.0017782524,0.0019281056,0.0009595075,0.0015840454,0.0026426588,0.000019105139,0.0014123202],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979019,0.0013729822,0.00021771995,0.00016224505,0.0002484136,0.000096782045],"domain_scores_gemma":[0.9976578,0.0010924082,0.0006807441,0.000118855234,0.0002295119,0.00022064199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004469343,0.0006747838,0.0017920671,0.00025317326,0.00026780178,0.0008849693,0.00040260592,0.0007978475,0.0022350408],"category_scores_gemma":[0.005070218,0.00021381414,0.0027325896,0.0006397765,0.00037738332,0.00048917957,0.0003193896,0.0014111472,0.00018121548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73868006,0.0034762702,0.02204658,0.016339652,0.03547661,0.00014945571,0.00015396616,0.0009111233,0.002735043,0.00044140805,0.007719547,0.17187028],"study_design_scores_gemma":[0.6907402,0.115247466,0.12709507,0.0037124776,0.046961606,0.00046687672,0.00016401142,0.0012310293,0.0017975472,0.0011604133,0.011314117,0.00010921494],"about_ca_topic_score_codex":0.0007526944,"about_ca_topic_score_gemma":0.0027052755,"teacher_disagreement_score":0.004469343,"about_ca_system_score_codex":0.000416174,"about_ca_system_score_gemma":0.0008105985,"threshold_uncertainty_score":0.02363646},"labels":[],"label_agreement":null},{"id":"W3046517060","doi":"10.1111/dom.14158","title":"Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the <scp>EMPA‐REG OUTCOME</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Albuminuria; Renal function; Kidney disease; Internal medicine; Creatinine; Urology; Diabetes mellitus; Post-hoc analysis; Population; Type 2 diabetes; Endocrinology","score_opus":0.013615514011522918,"score_gpt":0.22350527547802146,"score_spread":0.20988976146649854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046517060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767144,0.0113938395,0.001524995,0.0017723492,0.00030166193,0.0007006776,0.0030890077,0.00007819863,0.004424801],"genre_scores_gemma":[0.99438393,0.0010976233,0.0007847442,0.0008265273,0.00026492937,0.00039608643,0.0017225405,0.00001342742,0.00051017356],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99547297,0.0033405751,0.00027842706,0.00042781548,0.00028751523,0.0001926955],"domain_scores_gemma":[0.99420774,0.0025339492,0.0016233484,0.0008250489,0.00029933412,0.00051047397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010146964,0.00066174817,0.002058719,0.0001872278,0.00025578222,0.0011204275,0.00053058664,0.00093066186,0.0020771518],"category_scores_gemma":[0.008880357,0.00023707653,0.002765963,0.0003154757,0.0005969034,0.0008273125,0.0006878731,0.0018440763,0.00022856421],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90677166,0.0012244101,0.023942433,0.0010407435,0.01814877,0.00009096505,0.0000978998,0.0011063301,0.0016945077,0.0004792237,0.0030665698,0.04233644],"study_design_scores_gemma":[0.6846186,0.07842389,0.1834911,0.00054794684,0.034983903,0.00034610325,0.00019314389,0.0044937036,0.0014923005,0.0033900158,0.00789506,0.00012428232],"about_ca_topic_score_codex":0.0005583312,"about_ca_topic_score_gemma":0.0013481143,"teacher_disagreement_score":0.010146964,"about_ca_system_score_codex":0.00031248262,"about_ca_system_score_gemma":0.00067239767,"threshold_uncertainty_score":0.053662896},"labels":[],"label_agreement":null},{"id":"W3046544717","doi":"10.1111/dom.14164","title":"Cardiometabolic risk factor control in black and white people in the United States initiating sodium‐glucose co‐transporter‐2 inhibitors: A real‐world study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; Toronto General Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Type 2 diabetes; Odds ratio; Confidence interval; Diabetes mellitus; Blood pressure; Endocrinology; Triglyceride; Cholesterol","score_opus":0.013923173439054394,"score_gpt":0.24194294683143033,"score_spread":0.22801977339237595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046544717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891174,0.00013291811,0.000038825143,0.000075062795,0.0000061836986,0.000009798669,0.00057950127,0.0000016245028,0.00024429717],"genre_scores_gemma":[0.9989967,0.00010651111,0.000060751547,0.00008943041,0.000011657924,0.000012857737,0.0006409419,0.0000012596082,0.00007989198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993032,0.00026044535,0.000071162554,0.0001516417,0.00011787768,0.00009558962],"domain_scores_gemma":[0.9982911,0.00019508043,0.0009471122,0.00008953026,0.00013927791,0.0003379283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089345453,0.00028309063,0.0004386109,0.00065426936,0.00055186107,0.0006985332,0.00041016092,0.00064980565,0.0008238488],"category_scores_gemma":[0.002140743,0.00034205042,0.0006147933,0.0011384928,0.00036245666,0.0007582656,0.00055660354,0.00077255955,0.00018155377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065307904,0.00006480616,0.99906677,0.0000058584715,0.00006233775,0.000029123168,0.00011299346,0.000019491494,0.00004320971,0.000007520633,0.00008955644,0.0004329029],"study_design_scores_gemma":[0.000008019955,0.00007474818,0.99918216,0.0000061048163,0.000023061715,0.00007139285,0.00037433018,0.00013792695,0.000015939291,0.000010708514,0.00009240782,0.0000031423372],"about_ca_topic_score_codex":0.020115841,"about_ca_topic_score_gemma":0.02449564,"teacher_disagreement_score":0.020115841,"about_ca_system_score_codex":0.00037705552,"about_ca_system_score_gemma":0.00028622276,"threshold_uncertainty_score":0.039997518},"labels":[],"label_agreement":null},{"id":"W3046891294","doi":"10.1111/dom.14160","title":"Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Semaglutide; Liraglutide; Medicine; Type 2 diabetes; Dulaglutide; Body mass index; Internal medicine; Lixisenatide; Placebo; Glucagon-like peptide 1 receptor; Overweight; Diabetes mellitus; Myocardial infarction; Glucagon-like peptide-1; Endocrinology; Receptor; Agonist","score_opus":0.013947813844310757,"score_gpt":0.24224426339219243,"score_spread":0.22829644954788167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046891294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384933,0.056262325,0.00045908257,0.00078807055,0.0002989325,0.0004598915,0.0013338983,0.000042577143,0.0018620234],"genre_scores_gemma":[0.98617727,0.009896722,0.00057539984,0.0007951556,0.0003129169,0.00043109828,0.0012675626,0.0000145489275,0.00052926084],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9976922,0.0014383442,0.00033712917,0.00023032563,0.00019336356,0.000108533975],"domain_scores_gemma":[0.99705684,0.0012933727,0.00080590975,0.00023639649,0.00027655554,0.0003309394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005037597,0.00096800184,0.0033359365,0.0003666584,0.00035051146,0.001280437,0.0005081667,0.0011365028,0.0012680752],"category_scores_gemma":[0.0046567074,0.0003316417,0.004967482,0.00062072807,0.0005879729,0.00080737623,0.00044621623,0.0021595294,0.00015131179],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9244609,0.0010501032,0.010366358,0.0034232773,0.024176322,0.000063470456,0.00009893926,0.0005777202,0.0025334333,0.00014140802,0.0013190367,0.031789042],"study_design_scores_gemma":[0.699053,0.10823973,0.107939534,0.0013403491,0.07398579,0.00030514976,0.00032678538,0.0016890563,0.0025134112,0.0010699354,0.003422695,0.00011447482],"about_ca_topic_score_codex":0.0006931964,"about_ca_topic_score_gemma":0.00222957,"teacher_disagreement_score":0.005037597,"about_ca_system_score_codex":0.00040814915,"about_ca_system_score_gemma":0.00060220255,"threshold_uncertainty_score":0.026641667},"labels":[],"label_agreement":null},{"id":"W3081300539","doi":"10.1111/dom.14179","title":"Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from <scp>DECLARE‐TIMI</scp> 58","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Dapagliflozin; Medicine; TIMI; Post-hoc analysis; Baseline (sea); Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.02102524981586148,"score_gpt":0.2515692520510866,"score_spread":0.23054400223522512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081300539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942947,0.00094935024,0.0009940855,0.0001076253,0.00018739492,0.00031780425,0.0020277002,0.000058328827,0.0010629741],"genre_scores_gemma":[0.99222976,0.0002949548,0.0012842224,0.00026246358,0.00022272725,0.001063724,0.0027218298,0.000053190208,0.001867184],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99635136,0.001943214,0.00021447935,0.0006797334,0.00035071746,0.0004604182],"domain_scores_gemma":[0.99480397,0.0029020198,0.00067016063,0.00091673026,0.000289118,0.00041804148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005987892,0.001621289,0.0040738643,0.00051185326,0.00025171734,0.0012350325,0.00095856894,0.00081819977,0.005527671],"category_scores_gemma":[0.004505402,0.00064452906,0.008617898,0.0005439283,0.0005220287,0.0007927087,0.0008253405,0.0023304394,0.00041706025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90567946,0.002547499,0.04047921,0.0006449529,0.029025592,0.00016907767,0.00009042207,0.0017546037,0.0042606792,0.00021981777,0.0028341454,0.01229447],"study_design_scores_gemma":[0.19225991,0.22179094,0.4826729,0.00017421394,0.07141784,0.00032089194,0.00024269398,0.015973942,0.008461648,0.0010125504,0.0054384707,0.00023389365],"about_ca_topic_score_codex":0.0012373385,"about_ca_topic_score_gemma":0.0012928292,"teacher_disagreement_score":0.005987892,"about_ca_system_score_codex":0.00050565583,"about_ca_system_score_gemma":0.0011082545,"threshold_uncertainty_score":0.03166741},"labels":[],"label_agreement":null},{"id":"W3083189092","doi":"10.1111/dom.14181","title":"Peri‐transplant glycaemic control as a predictor of pancreas transplant survival","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada; Medical Research Council; Royal College of Surgeons of Edinburgh","keywords":"Medicine; Confidence interval; Perioperative; Internal medicine; Area under the curve; Transplantation; Diabetes mellitus; Pancreas transplantation; Proportional hazards model; Urology; Surgery; Gastroenterology; Endocrinology; Kidney transplantation","score_opus":0.01239356902055796,"score_gpt":0.23086371399839406,"score_spread":0.2184701449778361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083189092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856013,0.0006839725,0.00040413378,0.000055463122,0.000008603031,0.0000024448218,0.000086900305,0.00000810862,0.00019031615],"genre_scores_gemma":[0.99969685,0.00009369426,0.00007425665,0.000010647445,0.000009220626,0.000001542646,0.00008178754,0.0000018456507,0.000030328192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994947,0.00015111633,0.000062200445,0.000092896706,0.00012406567,0.000075017335],"domain_scores_gemma":[0.99503654,0.0016203714,0.0021534772,0.000301609,0.0002629421,0.0006249752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001483782,0.00023287481,0.000246804,0.00037281003,0.0001764264,0.00064421,0.00021201873,0.00028055583,0.0010485532],"category_scores_gemma":[0.0046880883,0.00009000223,0.00039129445,0.0005432879,0.00030743165,0.00036923995,0.0004191785,0.0008670998,0.000110290785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003509549,0.000017052325,0.9971738,0.00000772812,0.000040358755,0.000025794989,0.000012986094,0.00014202285,0.0002102658,0.000009174044,0.000030933417,0.0019789846],"study_design_scores_gemma":[0.000004600195,0.00015224995,0.99844176,0.000005800779,0.000034556386,0.00015945574,0.000024629351,0.00090786326,0.00016275958,0.00003661963,0.000066433335,0.000003297499],"about_ca_topic_score_codex":0.0006762475,"about_ca_topic_score_gemma":0.00056145596,"teacher_disagreement_score":0.001483782,"about_ca_system_score_codex":0.00015988189,"about_ca_system_score_gemma":0.0002850667,"threshold_uncertainty_score":0.007847071},"labels":[],"label_agreement":null},{"id":"W3091408760","doi":"10.1111/dom.14204","title":"Differential effects of L‐ and D‐phenylalanine on pancreatic and gastrointestinal hormone release in humans: A randomized crossover study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Muscle metabolism and nutrition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Imperial Biomedical Research Centre; Biotechnology and Biological Sciences Research Council; Medical Research Council; Medical Research Council Canada; National Institute for Health and Care Research; Imperial College Healthcare NHS Trust; H2020 European Research Council; Imperial College London; Diabetes UK","keywords":"Medicine; Crossover study; Randomized controlled trial; Internal medicine; Gastroenterology; Endocrinology; Placebo; Pathology; Alternative medicine","score_opus":0.0052432918155434225,"score_gpt":0.20771271072459072,"score_spread":0.2024694189090473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091408760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698724,0.0026770514,0.003371211,0.00041359614,0.0010794502,0.019880835,0.0012349394,0.00018058083,0.0012899721],"genre_scores_gemma":[0.9578096,0.0019770453,0.0071083587,0.0011405188,0.0012876111,0.026546562,0.00088520907,0.00006415537,0.0031808245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99443203,0.003121825,0.00047537114,0.0009953531,0.0004340545,0.000541305],"domain_scores_gemma":[0.9967933,0.0007788762,0.00066648575,0.0006156011,0.00036625323,0.0007794829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066312705,0.002059165,0.0059529366,0.00075021386,0.0011369019,0.001433866,0.0011791252,0.0026940464,0.0060363566],"category_scores_gemma":[0.0042431485,0.0013311679,0.0019166879,0.00094723445,0.0025590116,0.002054115,0.00070964603,0.00247712,0.0010524162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97676283,0.013640661,0.00032586555,0.00030224185,0.00046817315,0.000027202002,0.000052354782,0.0000770125,0.0041605392,0.000052323237,0.00021500268,0.0039157737],"study_design_scores_gemma":[0.755335,0.24023513,0.0016950077,0.000020359848,0.000495104,0.000028316384,0.000032528056,0.00022665242,0.0009235784,0.00011469263,0.00086445385,0.000029226558],"about_ca_topic_score_codex":0.0008572416,"about_ca_topic_score_gemma":0.0013010689,"teacher_disagreement_score":0.0066312705,"about_ca_system_score_codex":0.000800878,"about_ca_system_score_gemma":0.0021342319,"threshold_uncertainty_score":0.035069942},"labels":[],"label_agreement":null},{"id":"W3092361090","doi":"10.1111/dom.14223","title":"Design and baseline characteristics of the <scp>AMPLITUDE‐O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Internal medicine; Placebo; Adverse effect; Diabetes mellitus; Renal function; Glucagon-like peptide 1 receptor; Stroke (engine); Myocardial infarction; Type 2 diabetes; Kidney disease; Agonist; Endocrinology; Receptor; Pathology","score_opus":0.017930540110283284,"score_gpt":0.21955812251201745,"score_spread":0.20162758240173417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092361090","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95698315,0.0034550985,0.0014013228,0.0012779903,0.00064726436,0.024524326,0.0046679387,0.000055458437,0.006987506],"genre_scores_gemma":[0.9490115,0.0010951372,0.002269321,0.0025938132,0.0006250171,0.03561542,0.0028357194,0.000022849437,0.0059311176],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9978357,0.0009553516,0.00017610601,0.00043985312,0.00017567123,0.0004174225],"domain_scores_gemma":[0.99889225,0.00016304015,0.00021689845,0.000085736545,0.000083942294,0.00055819185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036587252,0.0020180072,0.0024672106,0.00033369783,0.00080463703,0.0013180564,0.00063096406,0.0016917639,0.009315798],"category_scores_gemma":[0.0028763001,0.0008780399,0.0015442967,0.0005139509,0.0010191649,0.001066029,0.00057215244,0.0021261487,0.0014109489],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96989036,0.008215365,0.008918812,0.00033321636,0.00094957143,0.000091209076,0.000078420526,0.0002578419,0.002069627,0.00027689186,0.001186313,0.0077323103],"study_design_scores_gemma":[0.8337817,0.12877432,0.030048925,0.000111529116,0.0014501697,0.0001307223,0.00009157928,0.00070479495,0.00046633018,0.0010849742,0.0032880856,0.000066783745],"about_ca_topic_score_codex":0.00091017305,"about_ca_topic_score_gemma":0.0017110442,"teacher_disagreement_score":0.009315798,"about_ca_system_score_codex":0.00072490243,"about_ca_system_score_gemma":0.0014026079,"threshold_uncertainty_score":0.031164408},"labels":[],"label_agreement":null},{"id":"W3101372907","doi":"10.1111/dom.14254","title":"Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <scp>CAROLINA</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Boehringer Ingelheim","keywords":"Linagliptin; Glimepiride; Medicine; Hazard ratio; Type 2 diabetes; Mace; Internal medicine; Clinical endpoint; Diabetes mellitus; Randomized controlled trial; Lower risk; Dipeptidyl peptidase-4 inhibitor; Adverse effect; Myocardial infarction; Confidence interval; Endocrinology; Percutaneous coronary intervention","score_opus":0.006807630801666101,"score_gpt":0.19952963826545225,"score_spread":0.19272200746378615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101372907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98818153,0.009527222,0.00023855256,0.00018089236,0.00014711732,0.0003961212,0.0006790803,0.000012440595,0.0006369591],"genre_scores_gemma":[0.9956591,0.0021635802,0.0002531406,0.00024708424,0.00019494594,0.00033862473,0.0007584987,0.0000061729925,0.00037893694],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986582,0.00069484353,0.00023391342,0.00017971593,0.0001367753,0.00009657933],"domain_scores_gemma":[0.99901855,0.00033179327,0.0003151579,0.000107906686,0.000081052785,0.00014548334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027062846,0.0009953992,0.0025703693,0.00046884353,0.00022721075,0.0008477588,0.00038478972,0.00093753566,0.0013619615],"category_scores_gemma":[0.0026514728,0.00033346182,0.005645947,0.00045951063,0.00026720014,0.00035628522,0.00037490088,0.000907245,0.00013256831],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90199614,0.00077064923,0.030435214,0.0023265742,0.038926087,0.00020559612,0.00009147667,0.00070183806,0.0033992212,0.000080327765,0.0008288124,0.020238005],"study_design_scores_gemma":[0.5974761,0.09752113,0.18775693,0.00055751385,0.10776645,0.00050791755,0.00026826464,0.0024848736,0.0027725843,0.0006410266,0.002137173,0.00010998953],"about_ca_topic_score_codex":0.0017212156,"about_ca_topic_score_gemma":0.0041393484,"teacher_disagreement_score":0.0027062846,"about_ca_system_score_codex":0.0003799287,"about_ca_system_score_gemma":0.000702936,"threshold_uncertainty_score":0.0143123865},"labels":[],"label_agreement":null},{"id":"W3106244848","doi":"10.1111/dom.14252","title":"Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the <scp>SONAR</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Relypsa; National Institutes of Health; Servier; Novo Nordisk Fonden; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Duke Clinical Research Institute; Novo Nordisk; Novo Nordisk UK Research Foundation; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Post-hoc analysis; Post hoc; Sonar; Pharmacology; Internal medicine; Oceanography; Geology","score_opus":0.01942790409123715,"score_gpt":0.23874052931698814,"score_spread":0.21931262522575098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106244848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964071,0.0008645989,0.0013711314,0.00013731609,0.000057187517,0.00012661266,0.0004026345,0.00003238449,0.0006010438],"genre_scores_gemma":[0.9985864,0.000076797616,0.00040206834,0.000081712045,0.000048610287,0.00009760719,0.00034911768,0.000019068677,0.00033866605],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98790646,0.0089675635,0.0004863034,0.001457512,0.0006499626,0.0005323099],"domain_scores_gemma":[0.9849005,0.0091606425,0.0016083095,0.0033724727,0.00044983352,0.0005083403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016729355,0.00076837785,0.002359571,0.00018164261,0.00031301516,0.0011715323,0.00078812015,0.00072600134,0.0019316053],"category_scores_gemma":[0.0096919,0.00031800076,0.0054847053,0.00033743744,0.00056024094,0.0009163277,0.0005313658,0.0014227044,0.000261895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62623674,0.0012907358,0.2687914,0.00046748066,0.05528176,0.00034321792,0.0003007596,0.004244959,0.008607146,0.00036220936,0.0018883551,0.032185275],"study_design_scores_gemma":[0.020402772,0.06398634,0.8522662,0.000069853624,0.030741906,0.00050168287,0.00020734224,0.022120345,0.005109696,0.0010379833,0.0034421792,0.00011373971],"about_ca_topic_score_codex":0.0006924071,"about_ca_topic_score_gemma":0.0008144202,"teacher_disagreement_score":0.016729355,"about_ca_system_score_codex":0.00039382384,"about_ca_system_score_gemma":0.00086069363,"threshold_uncertainty_score":0.08847433},"labels":[],"label_agreement":null},{"id":"W3106995227","doi":"10.1111/dom.14269","title":"Proportion of newly diagnosed diabetes in <scp>COVID</scp> ‐19 patients: A systematic review and meta‐analysis","year":2020,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Meta-analysis; Diabetes mellitus; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Internal medicine; Virology; Disease; Endocrinology; Infectious disease (medical specialty)","score_opus":0.05036164860493033,"score_gpt":0.37291857437089015,"score_spread":0.32255692576595985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106995227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048851264,0.99182665,0.00036441788,0.00029742156,0.00016887198,0.00015666334,0.0019908738,0.000016804373,0.0002931779],"genre_scores_gemma":[0.12750822,0.86494434,0.0019129391,0.00069329754,0.00030237608,0.001088923,0.002964244,0.000031195083,0.00055455626],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941823,0.0025262982,0.001679461,0.0006853997,0.0007293301,0.000197159],"domain_scores_gemma":[0.98509836,0.011466005,0.001656806,0.0004345176,0.0011852776,0.00015899156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009960615,0.001216618,0.0076386738,0.0039456766,0.00038937587,0.001650571,0.0010040179,0.0010211014,0.004711549],"category_scores_gemma":[0.024834508,0.0008182107,0.015546589,0.006622218,0.00029396667,0.0010861927,0.0009919896,0.001159513,0.00035524485],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035389615,0.000036156147,0.018993732,0.5659645,0.36360908,0.00018737995,0.00012820594,0.0004153603,0.00035183565,0.0003262155,0.00711211,0.03933652],"study_design_scores_gemma":[0.0011093792,0.00030526205,0.030479804,0.08053203,0.8747491,0.0002842312,0.000118326316,0.0003782227,0.00027095422,0.00045270054,0.011266867,0.00005310754],"about_ca_topic_score_codex":0.0057003754,"about_ca_topic_score_gemma":0.014932125,"teacher_disagreement_score":0.009960615,"about_ca_system_score_codex":0.0014962401,"about_ca_system_score_gemma":0.0023862396,"threshold_uncertainty_score":0.052677453},"labels":[],"label_agreement":null},{"id":"W3108090279","doi":"10.1111/dom.14283","title":"Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes ( <scp> TRS‐HF <sub>DM</sub> </scp> ) in patients in the <scp>ACCORD</scp> trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; St. Michael's Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Heart failure; Internal medicine; Myocardial infarction; Cardiology; Diabetes mellitus; Thrombolysis; Framingham Risk Score; Creatinine; Clinical endpoint; Randomized controlled trial; Endocrinology; Disease","score_opus":0.0097584222737263,"score_gpt":0.20343287014692,"score_spread":0.19367444787319368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108090279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786645,0.0005217104,0.00027336102,0.000081397884,0.000053074775,0.0001280107,0.0004935949,0.000005465205,0.00057705713],"genre_scores_gemma":[0.99742633,0.00018419103,0.00038193486,0.000084918174,0.00011320798,0.0001258359,0.0014800582,0.000004068115,0.00019940753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733067,0.0017290444,0.00019626068,0.0003941033,0.00023965545,0.00011019068],"domain_scores_gemma":[0.9955449,0.0018617938,0.0010855481,0.0005542307,0.00031783144,0.0006356886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009143276,0.0010995636,0.0013908691,0.0004342814,0.00040587893,0.0014136294,0.0006964586,0.0010332213,0.0009831645],"category_scores_gemma":[0.006555244,0.00040965632,0.001326978,0.00054383447,0.0005245601,0.0007493018,0.00090007565,0.0011491522,0.00028985256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052042887,0.0011676789,0.9354796,0.00011416688,0.0024185549,0.000043765285,0.000093122195,0.0009763159,0.0007088192,0.00007193394,0.00053548097,0.006347755],"study_design_scores_gemma":[0.010189328,0.008211087,0.96974593,0.00006975031,0.0027611644,0.0001481903,0.00011609303,0.0073019736,0.0004624916,0.00024036964,0.00070235826,0.00005116121],"about_ca_topic_score_codex":0.0008514017,"about_ca_topic_score_gemma":0.0013301908,"teacher_disagreement_score":0.009143276,"about_ca_system_score_codex":0.00022456105,"about_ca_system_score_gemma":0.0003314116,"threshold_uncertainty_score":0.048354864},"labels":[],"label_agreement":null},{"id":"W3108268477","doi":"10.1111/dom.14284","title":"Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Bausch Health (Canada); LMC Diabetes & Endocrinology (Canada)","funders":"Orexigen Therapeutics","keywords":"Medicine; Post-hoc analysis; Weight loss; Internal medicine; Placebo; Overweight; Fatty liver; Bupropion; Gastroenterology; Body mass index; Obesity; Disease; Pathology","score_opus":0.022868737944642118,"score_gpt":0.2616724228823353,"score_spread":0.23880368493769316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108268477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7270229,0.23234133,0.008449459,0.0010446971,0.0031228897,0.014525338,0.00900824,0.0008290845,0.0036561012],"genre_scores_gemma":[0.9539037,0.027330883,0.0043149386,0.0009301545,0.00079504127,0.0072574345,0.0024264378,0.00014363664,0.0028976947],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98721087,0.008090975,0.0018459229,0.0011556431,0.0009994436,0.00069720997],"domain_scores_gemma":[0.9864298,0.0076409294,0.0033894812,0.00093327794,0.0011009168,0.00050560106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015819602,0.0036053564,0.013458915,0.0016537728,0.00047447803,0.0026894507,0.0011614149,0.0018426374,0.0062005897],"category_scores_gemma":[0.017622847,0.001439622,0.021857308,0.0017027874,0.0011647114,0.0017690975,0.0011559161,0.002197805,0.00048021413],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7352026,0.0005855352,0.0021966784,0.014428562,0.23346591,0.00011896924,0.000051914172,0.00084564125,0.0024139683,0.00006581293,0.0008727087,0.009751668],"study_design_scores_gemma":[0.5617433,0.029316638,0.014505735,0.0011387534,0.38806686,0.00011448113,0.00011438423,0.0012784997,0.0014376299,0.0002081746,0.0019611367,0.000114359354],"about_ca_topic_score_codex":0.0016197638,"about_ca_topic_score_gemma":0.0039482485,"teacher_disagreement_score":0.015819602,"about_ca_system_score_codex":0.0013256037,"about_ca_system_score_gemma":0.0015291877,"threshold_uncertainty_score":0.08366299},"labels":[],"label_agreement":null},{"id":"W3108278357","doi":"10.1111/dom.14275","title":"Genetically determined lean mass and dietary response","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Public Health Ontario; Diabetes Canada; University of Toronto; University Health Network","funders":"","keywords":"Weight loss; Lean body mass; Obesity; Preference; Food preference; Biology; Medicine; Physiology; Endocrinology; Body weight; Food science","score_opus":0.009817217134228194,"score_gpt":0.21388366514919424,"score_spread":0.20406644801496604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108278357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232775,0.0020785998,0.0021434848,0.001096269,0.000081702725,0.000012202223,0.00040518132,0.000034800436,0.0018199501],"genre_scores_gemma":[0.99744475,0.0005293724,0.00081788615,0.00027039062,0.00004041001,0.000009651179,0.00021381544,0.000010064834,0.00066360255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977666,0.00008719906,0.000014817542,0.000052264255,0.000046488425,0.000022609378],"domain_scores_gemma":[0.9992267,0.00026933255,0.0002709132,0.00009714844,0.000063075866,0.00007277511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005773712,0.0002512656,0.00021012056,0.0003442931,0.0001125376,0.00034923662,0.00016639857,0.00034290046,0.0011843477],"category_scores_gemma":[0.0023138686,0.00009747343,0.00019869165,0.00029220377,0.00029506625,0.00012523908,0.00019416223,0.00038541603,0.00013989168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003002287,0.00032399193,0.8470541,0.00014126771,0.0009915836,0.0013721974,0.00030898285,0.0011307427,0.0821321,0.0031046874,0.0016276004,0.058810394],"study_design_scores_gemma":[0.000027005799,0.00018106136,0.9933209,0.00001946543,0.000125579,0.0004960192,0.00004006961,0.0007471813,0.0021061634,0.0014740238,0.001450767,0.000011748883],"about_ca_topic_score_codex":0.0014454123,"about_ca_topic_score_gemma":0.0013033933,"teacher_disagreement_score":0.0014454123,"about_ca_system_score_codex":0.00019413797,"about_ca_system_score_gemma":0.00013247809,"threshold_uncertainty_score":0.00396204},"labels":[],"label_agreement":null},{"id":"W3110989969","doi":"10.1111/dom.14296","title":"Effects of <b>da</b> pagliflozin on prevention of major clinical events and recovery in patients with <b>re</b> spiratory failure because of COVID‐ <b>19</b> : Design and rationale for the DARE‐19 study","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; Kidney disease; Internal medicine; Clinical endpoint; Placebo; Respiratory failure; Population; Clinical trial; Intensive care medicine; Acute kidney injury; Type 2 diabetes; Diabetes mellitus; Pathology; Endocrinology","score_opus":0.029813648003676117,"score_gpt":0.27801396143111434,"score_spread":0.24820031342743823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110989969","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97068316,0.0077408194,0.0010647094,0.0017202288,0.0006751512,0.012644401,0.00127019,0.00009131558,0.0041099302],"genre_scores_gemma":[0.97344595,0.0030140865,0.0036370608,0.0021720573,0.00068156957,0.0144041,0.0009204818,0.000016455526,0.0017083634],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.998757,0.000677651,0.0001209965,0.00017762804,0.00008473041,0.0001819632],"domain_scores_gemma":[0.9988078,0.00027740875,0.0002901792,0.00011870413,0.0001007303,0.000405175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032662412,0.0015332819,0.0027633864,0.0004594712,0.0003856987,0.0009109535,0.0007392421,0.0019499515,0.0036772161],"category_scores_gemma":[0.0021614393,0.0006745247,0.0027361028,0.00037462683,0.0010241542,0.0008224734,0.00055098196,0.002718908,0.00048049114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9581278,0.016521825,0.001212091,0.00073488505,0.0010073337,0.00002467723,0.0000251893,0.00026360963,0.0027745052,0.00014434234,0.0005796131,0.0185843],"study_design_scores_gemma":[0.85960776,0.13347478,0.004687208,0.00006611816,0.0006206307,0.000017298922,0.000011004613,0.00031743152,0.00047199175,0.0001167513,0.0005926537,0.000016223921],"about_ca_topic_score_codex":0.0005415851,"about_ca_topic_score_gemma":0.0011813241,"teacher_disagreement_score":0.0036772161,"about_ca_system_score_codex":0.0006526818,"about_ca_system_score_gemma":0.0013514857,"threshold_uncertainty_score":0.017273784},"labels":[],"label_agreement":null},{"id":"W3112981338","doi":"10.1111/dom.14300","title":"Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Sinai Health System; University of Toronto","funders":"Institute of Chemical and Engineering Sciences; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Hazard ratio; Diabetic ketoacidosis; Internal medicine; Diabetes mellitus; Confidence interval; Cohort study; Rate ratio; Heart failure; Cohort; Endocrinology","score_opus":0.0051031615147639105,"score_gpt":0.2022933258319656,"score_spread":0.19719016431720168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112981338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989128,0.00023332286,0.000034445988,0.000039781316,0.0000070489255,0.000009993962,0.000606063,0.0000012790928,0.00015524137],"genre_scores_gemma":[0.9985884,0.00024729653,0.000057121564,0.000052217372,0.000013703908,0.000013041887,0.00081566273,0.0000014257224,0.0002110951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994136,0.00012045745,0.00006699788,0.00016155139,0.000114467315,0.000122933],"domain_scores_gemma":[0.9987405,0.00012164102,0.0005618823,0.000119552715,0.0001653313,0.00029112727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009204276,0.00032827552,0.00046292116,0.00061892543,0.0005789991,0.0007541181,0.0005002987,0.0006952742,0.000916483],"category_scores_gemma":[0.0017498577,0.00043847968,0.0010814654,0.0012966007,0.00027439633,0.0005448309,0.000534089,0.0006590067,0.00017302285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024136259,0.000039548635,0.99900216,0.000007420721,0.00015513714,0.000024678267,0.000050222145,0.000015943,0.000070675196,0.0000053892395,0.00006805952,0.00031940604],"study_design_scores_gemma":[0.00003398782,0.00009885329,0.99924845,0.00000840047,0.0001230621,0.000066431865,0.00015216255,0.00014901809,0.000013007229,0.0000058541636,0.00009714175,0.000003664022],"about_ca_topic_score_codex":0.15394562,"about_ca_topic_score_gemma":0.19032006,"teacher_disagreement_score":0.15394562,"about_ca_system_score_codex":0.0008926611,"about_ca_system_score_gemma":0.0008515303,"threshold_uncertainty_score":0.30609912},"labels":[],"label_agreement":null},{"id":"W3113276992","doi":"10.1111/dom.14294","title":"A retrospective observational population‐based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate &lt; 90 mL/min/1.73 m <sup>2</sup> in Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Renal function; Type 2 diabetes; Kidney disease; Population; Retrospective cohort study; Creatinine; Internal medicine; Diabetes mellitus; Dialysis; Health care; Emergency medicine; Environmental health; Endocrinology","score_opus":0.026243111032516787,"score_gpt":0.2519217443805053,"score_spread":0.22567863334798852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113276992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865317,0.00041356383,0.00023026286,0.00010717832,0.000013180562,0.00017996434,0.0112302685,0.000010973353,0.001282888],"genre_scores_gemma":[0.99456775,0.00026644094,0.00021759201,0.0001414349,0.000008944912,0.00009367507,0.0041121626,0.0000038141052,0.0005882682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987987,0.000091438385,0.00012293283,0.00028807687,0.00043830337,0.0002605518],"domain_scores_gemma":[0.9979705,0.0000877304,0.00072548864,0.000115838586,0.0007075978,0.00039279432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000592575,0.0005380023,0.0005931833,0.0010695206,0.0019044353,0.0010429855,0.0012061639,0.00053324894,0.0013141361],"category_scores_gemma":[0.0015014181,0.0006958403,0.0008230966,0.0039433762,0.00067269633,0.00045919212,0.00069930014,0.00064510305,0.00025419542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004947339,0.00002457367,0.99876046,0.000022343256,0.000078620076,0.00005427323,0.00015646969,0.00003068831,0.000087363675,0.000017507948,0.00040018477,0.00031809535],"study_design_scores_gemma":[0.000015434489,0.000029755978,0.9990803,0.000013457413,0.00003140823,0.000051151677,0.000255645,0.00012807074,0.00001864196,0.000008780328,0.00036205997,0.000005342386],"about_ca_topic_score_codex":0.9755392,"about_ca_topic_score_gemma":0.97881967,"teacher_disagreement_score":0.024460793,"about_ca_system_score_codex":0.01657913,"about_ca_system_score_gemma":0.015088005,"threshold_uncertainty_score":0.12029058},"labels":[],"label_agreement":null},{"id":"W3116633224","doi":"10.1111/dom.14308","title":"The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial","year":2020,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Dapagliflozin; Medicine; TIMI; Myocardial infarction; Placebo; Population; Unstable angina; Quality-adjusted life year; Stroke (engine); Heart failure; Internal medicine; Intensive care medicine; Cost effectiveness; Emergency medicine; Type 2 diabetes; Diabetes mellitus; Environmental health; Thrombolysis; Risk analysis (engineering); Alternative medicine","score_opus":0.045958767042678206,"score_gpt":0.2840855385992422,"score_spread":0.23812677155656398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116633224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9396318,0.02717166,0.007982874,0.0025159628,0.0003257553,0.0026900289,0.012809378,0.00007031638,0.006802169],"genre_scores_gemma":[0.98894054,0.0029187086,0.0021875435,0.00028040944,0.00007333623,0.0010477497,0.004149251,0.00001462925,0.0003878547],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98744303,0.010768817,0.0005417096,0.00029066546,0.00071764627,0.00023812366],"domain_scores_gemma":[0.98245656,0.014126772,0.0019900908,0.00040670202,0.00054368435,0.00047625866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01680572,0.0014322542,0.0023514302,0.0014055202,0.0002283958,0.0019385011,0.0009251195,0.0014108797,0.0029461822],"category_scores_gemma":[0.037664637,0.0004894452,0.0053331335,0.0015800423,0.0005710283,0.0014964566,0.0010153513,0.0016192695,0.00021061038],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5135803,0.004127046,0.067844465,0.01990075,0.051750712,0.0010716408,0.00036323303,0.21321806,0.001074332,0.008067536,0.009732155,0.10926968],"study_design_scores_gemma":[0.19935942,0.06712002,0.13900538,0.00685734,0.077226914,0.002260114,0.0008023716,0.4771405,0.0024465537,0.012040053,0.015138151,0.0006032885],"about_ca_topic_score_codex":0.0033911061,"about_ca_topic_score_gemma":0.0025167358,"teacher_disagreement_score":0.01680572,"about_ca_system_score_codex":0.002579115,"about_ca_system_score_gemma":0.0014078477,"threshold_uncertainty_score":0.088878214},"labels":[],"label_agreement":null},{"id":"W3120931056","doi":"10.1111/dom.14316","title":"Essential diabetes medicines and health outcomes in 127 countries","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University; St. Michael's Hospital","funders":"St. Michael's Hospital Foundation; Canadian Institutes of Health Research; Ontario SPOR SUPPORT Unit","keywords":"Medicine; Diabetes mellitus; Per capita; Population; Interquartile range; Gross domestic product; Confidence interval; Environmental health; Internal medicine; Demography; Endocrinology","score_opus":0.026657386207932794,"score_gpt":0.2758455092691804,"score_spread":0.2491881230612476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120931056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785428,0.002202432,0.00013247019,0.00024905836,0.000017373904,0.00004281166,0.017307863,0.000015868438,0.0014892631],"genre_scores_gemma":[0.9893273,0.00084062974,0.00025565585,0.00006284841,0.000017517437,0.00007116266,0.00928679,0.0000040047194,0.00013410779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780434,0.0008390398,0.00040766955,0.0002755425,0.00042938828,0.00024400634],"domain_scores_gemma":[0.99150217,0.0011799198,0.006196926,0.00019611455,0.00049713725,0.0004277645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019161244,0.00037009257,0.00057082885,0.002376242,0.00032489983,0.00077498954,0.00042191282,0.00036249487,0.0017742249],"category_scores_gemma":[0.0047274358,0.00036231018,0.0009783226,0.00582352,0.00040569928,0.00049795455,0.0012129142,0.00066731224,0.00021944624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014831465,0.000036379563,0.99624676,0.00016306974,0.00024268118,0.00004552931,0.000072762086,0.00025790103,0.000035577425,0.0000508219,0.00056373293,0.0021364307],"study_design_scores_gemma":[0.00003254802,0.00008035395,0.998667,0.00008542832,0.00009287405,0.00010454297,0.00014532928,0.00015579812,0.000045032673,0.000033820193,0.0005502493,0.0000070231454],"about_ca_topic_score_codex":0.01556469,"about_ca_topic_score_gemma":0.010025476,"teacher_disagreement_score":0.01556469,"about_ca_system_score_codex":0.0011322481,"about_ca_system_score_gemma":0.0009103869,"threshold_uncertainty_score":0.030948162},"labels":[],"label_agreement":null},{"id":"W3125150772","doi":"10.1111/dom.14326","title":"Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of <scp>EMPA‐REG OUTCOME</scp>","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Empagliflozin; Medicine; Internal medicine; Mace; Hazard ratio; Cardiology; Type 2 diabetes; Heart failure; Post-hoc analysis; Population; Diabetes mellitus; Proportional hazards model; Placebo; Confidence interval; Myocardial infarction; Endocrinology; Conventional PCI; Pathology","score_opus":0.01055226278675396,"score_gpt":0.249620035423218,"score_spread":0.23906777263646406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125150772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871457,0.0003365358,0.0002566353,0.000037736383,0.00005035322,0.000049849765,0.00030163108,0.000010055758,0.00024267197],"genre_scores_gemma":[0.99842584,0.00009006391,0.00028701904,0.00006633497,0.000066963905,0.00009388415,0.00053237664,0.000007078598,0.00043052857],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980326,0.0011210457,0.00008089824,0.00036360422,0.00015998479,0.00024174496],"domain_scores_gemma":[0.99751353,0.0011589408,0.000314328,0.0003391686,0.00016304292,0.00051108614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033129596,0.0010546368,0.0023583823,0.0002935698,0.00028937845,0.0010090177,0.00067194353,0.00063486653,0.001875399],"category_scores_gemma":[0.001900108,0.00032932157,0.0046571405,0.00032885786,0.0004815237,0.000589753,0.0006338747,0.0015046928,0.00017435553],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72186434,0.0036126908,0.22558802,0.00046129173,0.026887488,0.00037090562,0.00010114847,0.001614899,0.007186479,0.00013579767,0.0009783626,0.011198577],"study_design_scores_gemma":[0.016954714,0.0993561,0.84852326,0.00004330473,0.020273132,0.00034512853,0.00021931784,0.008887737,0.0037688913,0.00026126878,0.0012874483,0.000079627636],"about_ca_topic_score_codex":0.001705259,"about_ca_topic_score_gemma":0.0020124882,"teacher_disagreement_score":0.0033129596,"about_ca_system_score_codex":0.00037565484,"about_ca_system_score_gemma":0.0006950625,"threshold_uncertainty_score":0.017520845},"labels":[],"label_agreement":null},{"id":"W3126647711","doi":"10.1111/dom.14335","title":"Reducing the need for carbohydrate counting in type 1 diabetes using closed‐loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non‐inferiority, crossover pilot trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; McGill University; Sinai Health System; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Diabetes Canada","keywords":"Empagliflozin; Medicine; Insulin; Meal; Crossover study; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Placebo","score_opus":0.025204139370200652,"score_gpt":0.28779470572282884,"score_spread":0.2625905663526282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126647711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110764,0.0015466675,0.0010301946,0.0002705056,0.00042851767,0.004554716,0.0003041176,0.00007783581,0.0006797884],"genre_scores_gemma":[0.9875425,0.0011447986,0.0031702702,0.00047912743,0.00060845044,0.0056830845,0.00031996614,0.000016847167,0.0010349356],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979127,0.0011550309,0.00018717679,0.0003511843,0.00020253772,0.00019136208],"domain_scores_gemma":[0.997256,0.0011995737,0.00060341525,0.00024230231,0.00018829142,0.0005104459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038549916,0.0016170009,0.003448774,0.0005515802,0.00047857114,0.0012277061,0.0012098501,0.0024988926,0.005250574],"category_scores_gemma":[0.003794488,0.0009000628,0.0022467866,0.00045425812,0.0019146347,0.0014796639,0.0005783221,0.0027812952,0.00052895537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9797004,0.011575896,0.00022030834,0.00034982528,0.00041359453,0.000013446869,0.000028695355,0.00008325089,0.0012747155,0.00003775172,0.00010017669,0.0062020044],"study_design_scores_gemma":[0.90637445,0.09225267,0.00058738596,0.000016913567,0.00023213938,0.000009077415,0.0000069431685,0.00016708113,0.0002325757,0.000035120844,0.00007991192,0.0000057804145],"about_ca_topic_score_codex":0.0006183423,"about_ca_topic_score_gemma":0.00079726765,"teacher_disagreement_score":0.005250574,"about_ca_system_score_codex":0.0007080653,"about_ca_system_score_gemma":0.001135662,"threshold_uncertainty_score":0.020387352},"labels":[],"label_agreement":null},{"id":"W3127915609","doi":"10.1111/dom.14339","title":"The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: Results from the <scp>ADVANCE</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Health and Medical Research Council","keywords":"Medicine; Diabetes mellitus; Hazard ratio; Internal medicine; Confidence interval; Randomized controlled trial; Proportional hazards model; Relative risk; Clinical trial; Type 2 diabetes; Endocrinology","score_opus":0.012246029300390374,"score_gpt":0.24313643000418003,"score_spread":0.23089040070378966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127915609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762442,0.020310251,0.00035347827,0.00040507063,0.00021474573,0.00024443102,0.00082638237,0.000016696184,0.0013848104],"genre_scores_gemma":[0.99282855,0.003980753,0.00043899697,0.00048032278,0.00045291256,0.00022702543,0.0011333936,0.000007429586,0.00045065617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99785244,0.0015340127,0.00014597246,0.00020245288,0.00015075124,0.00011439374],"domain_scores_gemma":[0.9960581,0.001832203,0.0011298273,0.00038950334,0.00014818562,0.0004422668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004626645,0.00082558475,0.002364957,0.00030644724,0.00021328332,0.00081005454,0.0004951747,0.0008341053,0.0022250589],"category_scores_gemma":[0.0051417374,0.0002590441,0.0039318725,0.0004375398,0.00044733568,0.00069234706,0.00060178776,0.0016455632,0.00014025859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9417186,0.0011936979,0.015678072,0.0018885431,0.015911834,0.000075563046,0.00006973287,0.00083546643,0.0007249073,0.0002467362,0.0009592331,0.020697653],"study_design_scores_gemma":[0.6726009,0.10045253,0.16414958,0.0008034929,0.05353067,0.00029231192,0.00015684334,0.0027037112,0.00079704664,0.0013528914,0.0030536514,0.00010638654],"about_ca_topic_score_codex":0.0009774347,"about_ca_topic_score_gemma":0.001596558,"teacher_disagreement_score":0.004626645,"about_ca_system_score_codex":0.0003789483,"about_ca_system_score_gemma":0.0004654987,"threshold_uncertainty_score":0.024468362},"labels":[],"label_agreement":null},{"id":"W3128318125","doi":"10.1111/dom.14344","title":"Associations between attainment of incentivized primary care indicators and incident sight‐threatening diabetic retinopathy in England: A population‐based historical cohort study","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Primary Care and Health Outcomes","field":"Health Professions","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Global Challenges Research Fund; Moorfields Eye Hospital NHS Foundation Trust; Medical Research Council; National Institute for Health and Care Research; UK Research and Innovation","keywords":"Medicine; Diabetic retinopathy; Diabetes mellitus; Hazard ratio; Cohort; Type 2 diabetes; Cohort study; Concordance; Proportional hazards model; Demography; Quality and Outcomes Framework; Population; Propensity score matching; Educational attainment; Internal medicine; Primary care; Pediatrics; Confidence interval; Family medicine; Environmental health; Endocrinology","score_opus":0.019089989668730795,"score_gpt":0.31122246976242973,"score_spread":0.29213248009369897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128318125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833196,0.00030495127,0.00010217161,0.00005227037,0.000006441225,0.000012782448,0.0009373309,0.0000024452122,0.00024961666],"genre_scores_gemma":[0.99886936,0.00016364722,0.00007473696,0.000038574675,0.0000074547647,0.000015507856,0.0006544818,0.000001527246,0.00017466134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998923,0.00028549027,0.00013183041,0.00035589578,0.00015359373,0.00015014067],"domain_scores_gemma":[0.99620384,0.00048425517,0.0016989985,0.0006136201,0.0005532618,0.00044600913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001521163,0.00021588005,0.00041020845,0.00054134504,0.0004932767,0.0009966299,0.0005942372,0.00046429643,0.0015044829],"category_scores_gemma":[0.0041366173,0.00055518566,0.00057058025,0.0007645437,0.00035084106,0.0007178594,0.0009318264,0.0006551435,0.00025125337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010309447,0.000029592435,0.99887735,0.000015827125,0.000077447825,0.00007968361,0.00018598764,0.000020960259,0.00007424986,0.000020579779,0.00012490204,0.00039029174],"study_design_scores_gemma":[0.000008330755,0.000087846725,0.99925095,0.000011398417,0.000032252163,0.00012621838,0.00018608346,0.00008290181,0.00001737491,0.0000102468275,0.00018285046,0.0000035397707],"about_ca_topic_score_codex":0.039465986,"about_ca_topic_score_gemma":0.040842548,"teacher_disagreement_score":0.039465986,"about_ca_system_score_codex":0.00066745287,"about_ca_system_score_gemma":0.00045294277,"threshold_uncertainty_score":0.078472555},"labels":[],"label_agreement":null},{"id":"W3129758593","doi":"10.1111/dom.14290","title":"Obesity as a <scp>multisystem</scp> disease: Trends in obesity rates and <scp>obesity‐related</scp> complications","year":2021,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":408,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Diabetes Canada; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Obesity; Prediabetes; Weight loss; Type 2 diabetes; Disease; Body mass index; Diabetes mellitus; Comorbidity; Gerontology; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.025957243631668188,"score_gpt":0.30073740944117444,"score_spread":0.27478016580950626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129758593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012644105,0.99823016,0.0000515788,0.00048504514,0.00021407401,0.0000044432777,0.00004686818,0.000006686142,0.0008348231],"genre_scores_gemma":[0.0006249694,0.9986199,0.00009720803,0.0002216099,0.00010724175,0.0000043661908,0.000046199733,0.0000014727428,0.00027702557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996705,0.00006478456,0.00005837123,0.000046132132,0.00012547502,0.0000347091],"domain_scores_gemma":[0.999353,0.000338023,0.000113509326,0.00001434633,0.00014046933,0.000040620285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006142164,0.00065053406,0.0010981571,0.0032631843,0.00025900314,0.0011063957,0.0005994264,0.0008762234,0.0047569307],"category_scores_gemma":[0.0014411131,0.00019408931,0.0011191854,0.003391986,0.0003146035,0.0010603615,0.0006321721,0.0014223468,0.0012059021],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007999392,0.000049685703,0.0006923045,0.05658861,0.0003467237,0.00013036134,0.00011502549,0.00031290078,0.00054161635,0.0040191226,0.04980166,0.88732207],"study_design_scores_gemma":[0.000020133071,0.00009064985,0.004802073,0.04581789,0.00058752595,0.0016192434,0.00017090653,0.00015111185,0.00020957705,0.0023788586,0.94412553,0.000026416335],"about_ca_topic_score_codex":0.0031131567,"about_ca_topic_score_gemma":0.0052982243,"teacher_disagreement_score":0.0047569307,"about_ca_system_score_codex":0.0007793847,"about_ca_system_score_gemma":0.0018592762,"threshold_uncertainty_score":0.015913486},"labels":[],"label_agreement":null},{"id":"W3129981552","doi":"10.1111/dom.14352","title":"Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINE‐HF</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Ted Rogers Centre for Heart Research; University Health Network","funders":"Novo Nordisk; Eisai; Sanofi; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Dapagliflozin; Ejection fraction; Placebo; Heart failure; Medicine; Randomized controlled trial; Cardiology; Internal medicine; Urology; Endocrinology; Diabetes mellitus","score_opus":0.005336022667569256,"score_gpt":0.20323578025193384,"score_spread":0.1978997575843646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129981552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813043,0.0129786,0.00027691084,0.0010077521,0.00026221893,0.00036012215,0.0009649619,0.00004354502,0.002801563],"genre_scores_gemma":[0.99171877,0.0034764393,0.00049199315,0.0009976078,0.00031476803,0.00041014122,0.0014467436,0.000006184696,0.0011372631],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99980253,0.00009215777,0.00002213694,0.000026248386,0.000026078716,0.000030837386],"domain_scores_gemma":[0.99969995,0.00010064956,0.00007932606,0.000023053452,0.00002287143,0.000074099335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008570542,0.00050665357,0.0012829162,0.00014328132,0.00013649123,0.00064387673,0.0002359092,0.0005376696,0.0017184354],"category_scores_gemma":[0.000900523,0.00013941496,0.0009585114,0.00018314413,0.00024115643,0.00037454415,0.00023010334,0.0011655578,0.00019027232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87708396,0.004154566,0.013450625,0.0018385756,0.0042410633,0.00009438063,0.000085233434,0.00095265254,0.004279105,0.00028706682,0.0040767784,0.089456044],"study_design_scores_gemma":[0.82699746,0.06088455,0.096155904,0.0002800121,0.006041617,0.0001869103,0.00009609039,0.0020588576,0.0015324743,0.0005596101,0.005168248,0.000038259644],"about_ca_topic_score_codex":0.000511177,"about_ca_topic_score_gemma":0.0012512744,"teacher_disagreement_score":0.0017184354,"about_ca_system_score_codex":0.00027529223,"about_ca_system_score_gemma":0.0002760573,"threshold_uncertainty_score":0.005748749},"labels":[],"label_agreement":null},{"id":"W3130138560","doi":"10.1111/dom.14350","title":"Metformin and carotid intima‐media thickness in never‐smokers with type <scp>1</scp> diabetes: The <scp>REMOVAL</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; St Joseph's Health Care","funders":"Novo Nordisk; Juvenile Diabetes Research Foundation Australia; University of Glasgow; Steno Diabetes Center Copenhagen; Astellas Pharma; Mylan; Insulet Corporation; National Health and Medical Research Council; Leona M. and Harry B. Helmsley Charitable Trust; Juvenile Diabetes Research Foundation United States of America; Merck KGaA; Sanofi; GlaxoSmithKline; Amgen; Pfizer; NHS Greater Glasgow and Clyde; European Foundation for the Study of Diabetes; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Metformin; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.015960868952204336,"score_gpt":0.24489024886294186,"score_spread":0.22892937991073753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130138560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95447755,0.04205907,0.00022107494,0.0005938202,0.00047784072,0.00036386476,0.00052301475,0.000033234675,0.001250527],"genre_scores_gemma":[0.981584,0.0144996,0.00042740424,0.00071485573,0.00040426978,0.00040030497,0.0005444479,0.000012857075,0.0014123339],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996433,0.00019176379,0.00004399388,0.000047810594,0.00003673573,0.000036397192],"domain_scores_gemma":[0.9995278,0.00015242459,0.00016503345,0.000038594582,0.000039988787,0.0000761039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010886069,0.000934041,0.0021594502,0.00024634862,0.0002399711,0.0007627451,0.0003760918,0.00114919,0.0022545585],"category_scores_gemma":[0.0016408087,0.0003772175,0.0023356846,0.00027790532,0.0002560704,0.0003629778,0.00028543573,0.0013938454,0.00024094226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9194834,0.0014884581,0.0066850595,0.005668704,0.011731889,0.000106963846,0.000073029456,0.00038868724,0.0029133689,0.000118912816,0.0016102237,0.0497313],"study_design_scores_gemma":[0.87028414,0.05682407,0.040614914,0.0011026971,0.02372578,0.00031212706,0.00014015104,0.0013472263,0.001729952,0.0004459344,0.0034154442,0.00005755589],"about_ca_topic_score_codex":0.0014176429,"about_ca_topic_score_gemma":0.0029495026,"teacher_disagreement_score":0.0022545585,"about_ca_system_score_codex":0.0003547482,"about_ca_system_score_gemma":0.00054842955,"threshold_uncertainty_score":0.007542193},"labels":[],"label_agreement":null},{"id":"W3131254615","doi":"10.1111/dom.14360","title":"Applying <scp>REWIND</scp> cardiovascular disease criteria to <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6: An exploratory analysis of cardiovascular outcomes with semaglutide","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto; Toronto General Hospital; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Semaglutide; Mace; Hazard ratio; Medicine; Dulaglutide; Placebo; Internal medicine; Subgroup analysis; Type 2 diabetes; Confidence interval; Pooled analysis; Lower risk; Diabetes mellitus; Endocrinology; Exenatide; Myocardial infarction; Liraglutide","score_opus":0.013043416719402885,"score_gpt":0.23010970592467944,"score_spread":0.21706628920527657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131254615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592131,0.019451331,0.008398725,0.00048775345,0.00035368057,0.004733442,0.003936694,0.0001322718,0.0032930789],"genre_scores_gemma":[0.978204,0.0028700468,0.009044828,0.0008417635,0.0002485773,0.0027934976,0.0049215923,0.00008270378,0.0009929608],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9868227,0.008113093,0.001403768,0.001333596,0.0018056395,0.0005211218],"domain_scores_gemma":[0.9938537,0.002793842,0.0014447545,0.0009473848,0.00066429185,0.00029612242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016179454,0.0018048992,0.0049864035,0.00065036514,0.00033458913,0.00146216,0.0012332158,0.0010431524,0.002366921],"category_scores_gemma":[0.012162835,0.00056132436,0.0115797585,0.0008725804,0.0007360827,0.0009251468,0.0014002196,0.0019768088,0.00031302441],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7013187,0.0018271023,0.071549505,0.0069493703,0.10833941,0.0003370614,0.0003701348,0.0036690612,0.023598129,0.0018096282,0.0037307965,0.07650117],"study_design_scores_gemma":[0.29433885,0.11367352,0.4151732,0.0016920205,0.12707014,0.0009030609,0.00049574155,0.011265408,0.013374138,0.005454936,0.016024383,0.00053455547],"about_ca_topic_score_codex":0.0020994153,"about_ca_topic_score_gemma":0.0043523987,"teacher_disagreement_score":0.016179454,"about_ca_system_score_codex":0.0005806299,"about_ca_system_score_gemma":0.0013985636,"threshold_uncertainty_score":0.08556616},"labels":[],"label_agreement":null},{"id":"W3131978373","doi":"10.1111/dom.14351","title":"Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the <scp>ADVANCE</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; Servier; University of New South Wales","keywords":"Medicine; Post-hoc analysis; Renal function; Hazard ratio; Internal medicine; Type 2 diabetes; Proportional hazards model; Diabetes mellitus; Diabetic nephropathy; Creatinine; Nephropathy; Clinical trial; Confidence interval; Endocrinology","score_opus":0.011647337123727654,"score_gpt":0.27963635289626565,"score_spread":0.267989015772538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131978373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955064,0.0022382406,0.00033773613,0.00019325741,0.00010592056,0.00009165035,0.0010592097,0.000014860813,0.0004527251],"genre_scores_gemma":[0.99720794,0.00039613317,0.00024657368,0.00012465833,0.00019629154,0.00014958587,0.0013097258,0.000014894025,0.00035413055],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965988,0.0023158886,0.00022979276,0.00039958794,0.00023402798,0.0002219607],"domain_scores_gemma":[0.99085426,0.0048636408,0.0018501654,0.0012792746,0.00048681622,0.0006658255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008077668,0.0010046522,0.0022009632,0.00025461699,0.00033067312,0.0014292329,0.00066386786,0.00084422075,0.0021274236],"category_scores_gemma":[0.0065782513,0.00040194744,0.0042341743,0.0004998285,0.0004128398,0.000990606,0.00080305024,0.0020584331,0.00021165074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76526904,0.001229508,0.1716773,0.0010672177,0.04069958,0.00028423453,0.00017151618,0.0018476677,0.002304123,0.00019356291,0.0033106564,0.01194565],"study_design_scores_gemma":[0.11248261,0.05933794,0.7463744,0.00034615927,0.063180454,0.00048338008,0.00034201727,0.010722625,0.0020372092,0.0012038187,0.0033107968,0.00017852006],"about_ca_topic_score_codex":0.0007446411,"about_ca_topic_score_gemma":0.0010199235,"teacher_disagreement_score":0.008077668,"about_ca_system_score_codex":0.00023190898,"about_ca_system_score_gemma":0.0004858539,"threshold_uncertainty_score":0.042719305},"labels":[],"label_agreement":null},{"id":"W3134146806","doi":"10.1111/dom.14372","title":"Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Insulin glargine; Insulin degludec; Medicine; Type 2 diabetes; Confidence interval; Post-hoc analysis; Incidence (geometry); Internal medicine; Population; Hazard ratio; Diabetes mellitus; Endocrinology","score_opus":0.0135104133642412,"score_gpt":0.2568153891177615,"score_spread":0.24330497575352028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134146806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802727,0.015886186,0.00026766607,0.000694517,0.0002562805,0.00029511325,0.0006159097,0.000023877825,0.0016877922],"genre_scores_gemma":[0.99209166,0.003381959,0.0007119432,0.0012100473,0.0004343948,0.00045476024,0.00088671193,0.000009696306,0.0008189163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99864644,0.00089426385,0.000095552845,0.00014614518,0.00010707271,0.000110589615],"domain_scores_gemma":[0.99842703,0.00046409425,0.00050949614,0.00011728697,0.00007566913,0.00040634524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042778533,0.00058118603,0.0024966092,0.00021862569,0.00022787509,0.0010426079,0.00044356906,0.001064237,0.0023849788],"category_scores_gemma":[0.0029323574,0.0002998452,0.0021652994,0.0003002686,0.0005241228,0.0005853366,0.0004913997,0.0017042307,0.0002764432],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9643292,0.0014754072,0.009738222,0.0009800667,0.0027192447,0.000049391725,0.000063246946,0.0002285408,0.0013309605,0.00017643935,0.0012203498,0.017688908],"study_design_scores_gemma":[0.83176553,0.09112583,0.061638873,0.0006451944,0.008907054,0.00018660347,0.00012402596,0.0010461329,0.0007754259,0.0009960692,0.0027180063,0.00007128443],"about_ca_topic_score_codex":0.0006260703,"about_ca_topic_score_gemma":0.0011110451,"teacher_disagreement_score":0.0042778533,"about_ca_system_score_codex":0.00040673302,"about_ca_system_score_gemma":0.0006248716,"threshold_uncertainty_score":0.022623718},"labels":[],"label_agreement":null},{"id":"W3135935417","doi":"10.1111/dom.14382","title":"The J‐shaped relationship between body mass index and mortality in patients with <scp>COVID</scp> ‐19: A dose‐response meta‐analysis","year":2021,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Funnel plot; Body mass index; Coronavirus disease 2019 (COVID-19); Meta-analysis; Publication bias; Demography; Index (typography); Statistics; Plot (graphics); Medicine; Mathematics; Internal medicine; Computer science; Sociology","score_opus":0.0949946134359526,"score_gpt":0.4066922413542328,"score_spread":0.3116976279182802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135935417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006571705,0.9859336,0.0020148875,0.0013857927,0.00062687224,0.0004718177,0.0020213425,0.000052703803,0.00092133885],"genre_scores_gemma":[0.3090632,0.66839194,0.00641327,0.0050188825,0.0014474562,0.0028682712,0.0036116985,0.00019023394,0.0029951087],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9900455,0.006110313,0.0017171993,0.0010738628,0.0007625711,0.00029053102],"domain_scores_gemma":[0.9726949,0.022992184,0.0019990115,0.0009162241,0.0011643469,0.00023335556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021242326,0.0025510835,0.00931832,0.0028294094,0.000494422,0.003039125,0.0018663183,0.0021933652,0.009822813],"category_scores_gemma":[0.041571103,0.0011245544,0.037099853,0.0037531988,0.0005635271,0.0015441439,0.0012396672,0.0032195998,0.00081423786],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007986844,0.000057243284,0.009564881,0.17120866,0.7808279,0.00015642139,0.00010133922,0.0007347015,0.00035642806,0.0005325966,0.004208897,0.024264121],"study_design_scores_gemma":[0.002011348,0.00044659126,0.0083946865,0.015050385,0.96590394,0.00013619983,0.00005606014,0.0005745235,0.0001735825,0.0013096787,0.00589987,0.000043107346],"about_ca_topic_score_codex":0.0046204804,"about_ca_topic_score_gemma":0.008897492,"teacher_disagreement_score":0.021242326,"about_ca_system_score_codex":0.0015236209,"about_ca_system_score_gemma":0.002030274,"threshold_uncertainty_score":0.11234146},"labels":[],"label_agreement":null},{"id":"W3136693186","doi":"10.1111/dom.14386","title":"The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Mitsubishi Tanabe Pharma Corporation","keywords":"Canagliflozin; Medicine; Hazard ratio; Heart failure; Internal medicine; Empagliflozin; Proportional hazards model; Renal function; Type 2 diabetes; Diabetes mellitus; Kidney disease; Cardiology; Confidence interval; Endocrinology","score_opus":0.00925961364996951,"score_gpt":0.2186879114533947,"score_spread":0.20942829780342517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136693186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909444,0.003979826,0.0006982594,0.0003585659,0.00025400004,0.00037918705,0.0021003122,0.00002271479,0.0012627238],"genre_scores_gemma":[0.9948474,0.00038949025,0.00059604,0.0002822549,0.00018417422,0.00062067044,0.0021793204,0.000017284654,0.00088345306],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99140865,0.006421809,0.0003678253,0.0006580016,0.00074095355,0.00040281084],"domain_scores_gemma":[0.99231356,0.0044502653,0.0010871845,0.0009988119,0.00037388795,0.0007762214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013427212,0.0010514566,0.0034271243,0.00042558246,0.00046245786,0.001502908,0.0012129124,0.0018178851,0.0025142985],"category_scores_gemma":[0.01057212,0.0005612687,0.0072263395,0.0007787926,0.00069670816,0.001075003,0.0010661477,0.0030517932,0.00028266775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78566384,0.0017234777,0.15012144,0.0010427041,0.044236515,0.00023535622,0.0001521468,0.0019930622,0.0017427886,0.00041030103,0.0035297477,0.009148544],"study_design_scores_gemma":[0.14660256,0.049313877,0.7327932,0.00022417116,0.04721827,0.00041853398,0.00030115154,0.015508253,0.0012628685,0.0013751386,0.004769715,0.00021228452],"about_ca_topic_score_codex":0.0019341606,"about_ca_topic_score_gemma":0.0025989285,"teacher_disagreement_score":0.013427212,"about_ca_system_score_codex":0.0004768494,"about_ca_system_score_gemma":0.0006692111,"threshold_uncertainty_score":0.07101071},"labels":[],"label_agreement":null},{"id":"W3146265631","doi":"10.1111/dom.14391","title":"Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the <scp>ADVANCE</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; Servier; University of New South Wales","keywords":"Dementia; Odds ratio; Medicine; Diabetes mellitus; Waist; Internal medicine; Risk factor; Waist–hip ratio; Stroke (engine); Type 2 diabetes; Gerontology; Body mass index; Disease; Endocrinology","score_opus":0.029541246103450942,"score_gpt":0.29729966411366665,"score_spread":0.2677584180102157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146265631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632007,0.03134688,0.00030289564,0.00060015055,0.0003379224,0.00019071298,0.002344356,0.00001624626,0.001660245],"genre_scores_gemma":[0.9890304,0.0053403205,0.0004049613,0.0005122385,0.00055881834,0.00025180686,0.0030265984,0.000008072502,0.0008667199],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99858475,0.0008330749,0.0001332909,0.00019328496,0.00015695921,0.00009858134],"domain_scores_gemma":[0.9975242,0.0009249935,0.00078049756,0.00024602553,0.00018136323,0.00034289545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004117652,0.0007673023,0.0016547864,0.0002721437,0.0003604354,0.0011388959,0.0005681961,0.0010947374,0.0018212707],"category_scores_gemma":[0.004268885,0.0003353025,0.0032847093,0.00061619113,0.00031065135,0.000630311,0.00044270605,0.001670923,0.00013457301],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56934226,0.0015237177,0.33698618,0.0043500396,0.034245078,0.00023252475,0.00018751122,0.00089568854,0.0007818535,0.00049260876,0.0040351753,0.04692731],"study_design_scores_gemma":[0.18382673,0.028833082,0.7202754,0.0013137895,0.053416092,0.0007282922,0.0002965993,0.0034081219,0.0006666221,0.0014409916,0.005660702,0.00013359042],"about_ca_topic_score_codex":0.0029150986,"about_ca_topic_score_gemma":0.004862798,"teacher_disagreement_score":0.004117652,"about_ca_system_score_codex":0.00032134893,"about_ca_system_score_gemma":0.0005308798,"threshold_uncertainty_score":0.021776497},"labels":[],"label_agreement":null},{"id":"W3154836626","doi":"10.1111/dom.14401","title":"Prevalence and progression of chronic kidney disease among patients with type <scp>2</scp> diabetes: Insights from the <scp>DISCOVER</scp> study","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Interquartile range; Kidney disease; Renal function; Medicine; Creatinine; Internal medicine; Type 2 diabetes; Diabetes mellitus; Urology; Stage (stratigraphy); Observational study; Gastroenterology; Endocrinology; Biology","score_opus":0.005908242942561242,"score_gpt":0.21395183185815883,"score_spread":0.2080435889155976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154836626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995564,0.0002512727,0.00006767764,0.000054236738,0.000007638229,0.000008889015,0.0036141796,0.0000034466368,0.00042877896],"genre_scores_gemma":[0.99428564,0.00032584456,0.00013059193,0.00006491075,0.000028775801,0.000023115967,0.004889279,0.0000049776654,0.00024680485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992939,0.00019795018,0.00009508974,0.00015268655,0.00017386208,0.000086537104],"domain_scores_gemma":[0.99781597,0.00024368663,0.0010824326,0.0001831145,0.0002926837,0.0003820724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001143619,0.00035607725,0.00048218353,0.0008899617,0.00040662306,0.001062856,0.00045961796,0.00055159576,0.0007867324],"category_scores_gemma":[0.001953917,0.00033947034,0.0006847878,0.0021663764,0.00026952336,0.00064691255,0.00087125035,0.000669089,0.00020211864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058903213,0.000012558763,0.99928844,0.000006530853,0.00005404041,0.00002265725,0.000032543187,0.0000115902485,0.000037090493,0.0000054242264,0.00015493215,0.00031529323],"study_design_scores_gemma":[0.000010008248,0.000029984954,0.9994892,0.000004817003,0.000034886973,0.00007841908,0.00008541984,0.00006499223,0.000016756201,0.000007878453,0.00017432429,0.0000034044692],"about_ca_topic_score_codex":0.01774745,"about_ca_topic_score_gemma":0.026800025,"teacher_disagreement_score":0.01774745,"about_ca_system_score_codex":0.00037296003,"about_ca_system_score_gemma":0.00047152548,"threshold_uncertainty_score":0.035288334},"labels":[],"label_agreement":null},{"id":"W3157339478","doi":"10.1111/dom.14421","title":"Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes ( <scp>RESET‐IT Main</scp> ): A 2‐year randomized controlled trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; McMaster University; University of Toronto; St. Michael's Hospital; Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Randomized controlled trial; Insulin; Type 2 diabetes; Insulin resistance; Diabetes mellitus; Internal medicine; Type 1 diabetes; Endocrinology","score_opus":0.015840925882715986,"score_gpt":0.24326886958923857,"score_spread":0.22742794370652258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157339478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875711,0.007777865,0.00044163386,0.0004415553,0.0005901942,0.0018071621,0.00044440056,0.00007031931,0.00085575326],"genre_scores_gemma":[0.9861227,0.0042054984,0.0017801003,0.0010462924,0.00078670756,0.0037136283,0.0007084546,0.000015749305,0.001620891],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99903536,0.00051832,0.00008305634,0.00016767716,0.000078568766,0.000117066455],"domain_scores_gemma":[0.99838734,0.00054183486,0.00043092357,0.00012985633,0.00007850965,0.0004314861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024286106,0.0012485861,0.003504684,0.00041620815,0.00040210038,0.0010770649,0.0010481552,0.0019194832,0.005130656],"category_scores_gemma":[0.0020685182,0.0006545039,0.0029781528,0.00048650807,0.00094011356,0.0008703268,0.0005033464,0.0029650696,0.0005272703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9882554,0.0030076983,0.00033348016,0.00051674567,0.00088030496,0.000016694885,0.000015847572,0.00010635069,0.00065681484,0.000031037547,0.0001597381,0.006020037],"study_design_scores_gemma":[0.9535247,0.044158913,0.0011574153,0.000040760995,0.00063954975,0.00001480677,0.0000071128206,0.00015627699,0.00013892168,0.000030093592,0.00012535504,0.000006136402],"about_ca_topic_score_codex":0.0012181712,"about_ca_topic_score_gemma":0.0020351452,"teacher_disagreement_score":0.005130656,"about_ca_system_score_codex":0.00063097395,"about_ca_system_score_gemma":0.0010891617,"threshold_uncertainty_score":0.017163754},"labels":[],"label_agreement":null},{"id":"W3157970388","doi":"10.1111/dom.14415","title":"Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPA‐REG OUTCOME</scp> trial with a focus on Asia","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Empagliflozin; Medicine; Hazard ratio; Body mass index; Internal medicine; Proportional hazards model; Diabetes mellitus; Placebo; Diabetic nephropathy; Type 2 diabetes; Heart failure; Nephropathy; Cardiology; Confidence interval; Endocrinology","score_opus":0.010290191231539795,"score_gpt":0.26770079108212314,"score_spread":0.25741059985058334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157970388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97875255,0.016980866,0.00085811765,0.00041902758,0.00034134457,0.00038664968,0.0010921146,0.000034644447,0.0011346847],"genre_scores_gemma":[0.99602866,0.001460474,0.0003744946,0.00041530406,0.00023303246,0.0003335681,0.000683107,0.000011213017,0.00046012338],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99810576,0.0010035579,0.00028353525,0.00028403514,0.00015761335,0.0001654555],"domain_scores_gemma":[0.9986028,0.0005678805,0.0003228685,0.00025279383,0.000098023156,0.00015567419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004435443,0.0015396087,0.0045862775,0.000568558,0.0002849148,0.0013909864,0.00054752105,0.0010493192,0.0016833353],"category_scores_gemma":[0.002823974,0.00045320147,0.010790984,0.0006376587,0.0004303101,0.00068139384,0.00055825006,0.0014941961,0.00018253866],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7513467,0.0007701044,0.07162468,0.0036547496,0.13639969,0.00037981317,0.0001398441,0.0010711789,0.0045593474,0.00021818285,0.0018261196,0.028009623],"study_design_scores_gemma":[0.31713754,0.038795933,0.33307353,0.0008081006,0.29535043,0.0006471621,0.00042636695,0.0054100193,0.0027070292,0.001777489,0.0036544197,0.0002120016],"about_ca_topic_score_codex":0.0009457813,"about_ca_topic_score_gemma":0.002528547,"teacher_disagreement_score":0.0045862775,"about_ca_system_score_codex":0.00034434235,"about_ca_system_score_gemma":0.00055530627,"threshold_uncertainty_score":0.02345717},"labels":[],"label_agreement":null},{"id":"W3159368165","doi":"10.1111/dom.14416","title":"Patient‐reported outcomes in adults with type 1 diabetes in global real‐world clinical practice: The <scp>SAGE</scp> study","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"Sanofi","keywords":"Medicine; Worry; Diabetes mellitus; Hypoglycemia; Distress; Type 1 diabetes; Insulin; Observational study; Type 2 diabetes; Glycemic; Quality of life (healthcare); Diabetes management; Anxiety; Internal medicine; Clinical psychology; Psychiatry; Endocrinology; Nursing","score_opus":0.020961073199652302,"score_gpt":0.33468884320982034,"score_spread":0.31372777001016805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159368165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968389,0.00041805932,0.00007313581,0.00013207832,0.00001343346,0.00009207442,0.0017509303,0.0000037762534,0.0006775575],"genre_scores_gemma":[0.9961914,0.00028074876,0.00021319553,0.00023709491,0.00005342061,0.00023610434,0.00263748,0.0000051914453,0.00014539712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750537,0.0012004547,0.0002812215,0.00038953734,0.00042774883,0.00019570737],"domain_scores_gemma":[0.99372405,0.0010974781,0.0031886012,0.00033380373,0.00076359225,0.00089246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003152843,0.0004713224,0.00082138943,0.00116944,0.00046410353,0.0011141287,0.0004922804,0.00078666006,0.0014828764],"category_scores_gemma":[0.006847195,0.00026463973,0.0012394907,0.002916909,0.00040671072,0.0010949773,0.0013101652,0.001013783,0.0003288387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005708679,0.0002452442,0.995509,0.000111468406,0.00032521103,0.00006368486,0.00032319454,0.000051811927,0.000052234183,0.000020964639,0.00051956583,0.0022067875],"study_design_scores_gemma":[0.00014307359,0.0006140601,0.99778664,0.000048330945,0.00017150567,0.000119362354,0.0005747907,0.00013288647,0.000025421275,0.000025297932,0.0003483889,0.000010308059],"about_ca_topic_score_codex":0.005223103,"about_ca_topic_score_gemma":0.009347205,"teacher_disagreement_score":0.005223103,"about_ca_system_score_codex":0.0005823813,"about_ca_system_score_gemma":0.00087654364,"threshold_uncertainty_score":0.016674042},"labels":[],"label_agreement":null},{"id":"W3159474548","doi":"10.1111/dom.14411","title":"Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto; Diabetes Canada","keywords":"Dapagliflozin; Tubuloglomerular feedback; Renal function; Urology; Medicine; Internal medicine; Endocrinology; Placebo; Creatinine; Blood pressure; Chemistry; Cardiology; Diabetes mellitus; Type 2 diabetes; Pathology","score_opus":0.01623434562228844,"score_gpt":0.2629193872096659,"score_spread":0.24668504158737747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159474548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90041554,0.082351506,0.006161605,0.0009908921,0.0010503492,0.0050478,0.0018497695,0.00019026341,0.0019422625],"genre_scores_gemma":[0.9873159,0.0062090587,0.0021267831,0.00069269224,0.00026687334,0.0023366062,0.0005425562,0.000038206574,0.00047133738],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9764854,0.016232397,0.0028257181,0.0018788824,0.0017633492,0.0008143025],"domain_scores_gemma":[0.9767198,0.014969591,0.0046764854,0.0018348064,0.000977486,0.0008218112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0196753,0.0016845128,0.008901017,0.0008344981,0.0005451124,0.0023673906,0.0012604737,0.0023119508,0.0032503663],"category_scores_gemma":[0.024647959,0.0007938282,0.014034479,0.0014698327,0.0019043512,0.0014761258,0.00072791823,0.0025725376,0.00025025164],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89877224,0.000750664,0.0033544968,0.004902316,0.07950048,0.00007241947,0.000051578972,0.00044161253,0.0016797455,0.00015103983,0.00040976028,0.009913599],"study_design_scores_gemma":[0.8074149,0.037358582,0.021161556,0.00047407558,0.12914313,0.00010816547,0.0000635672,0.0014744487,0.0010077839,0.00051298743,0.0012030381,0.0000777442],"about_ca_topic_score_codex":0.0007401402,"about_ca_topic_score_gemma":0.0013707627,"teacher_disagreement_score":0.0196753,"about_ca_system_score_codex":0.0011540129,"about_ca_system_score_gemma":0.0011475808,"threshold_uncertainty_score":0.10405415},"labels":[],"label_agreement":null},{"id":"W3163402894","doi":"10.1111/dom.14443","title":"Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; Canadian Institutes of Health Research; National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Liraglutide; Semaglutide; Medicine; Mediation; Exploratory analysis; Type 2 diabetes; Endocrinology; Diabetes mellitus","score_opus":0.006874194599851394,"score_gpt":0.20026230806813572,"score_spread":0.19338811346828433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163402894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94621897,0.0057200836,0.03185658,0.0021268178,0.00034612382,0.0026994844,0.005970477,0.00037020887,0.004691128],"genre_scores_gemma":[0.9892301,0.00034499206,0.0061585745,0.00025774378,0.00009474904,0.0017370493,0.00066811655,0.00004083738,0.0014677651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.95659465,0.03614014,0.0008350439,0.0026826577,0.0014879241,0.0022595294],"domain_scores_gemma":[0.94933105,0.044031244,0.0021457588,0.0028758878,0.00093038287,0.0006856443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035784964,0.0030015036,0.0032424277,0.0008812958,0.0006323472,0.001746427,0.003260873,0.001676276,0.018055048],"category_scores_gemma":[0.045734428,0.000899443,0.0107596945,0.00093100144,0.0011069024,0.0016769249,0.0033646836,0.0027971577,0.00089156756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15762654,0.005674134,0.5098546,0.0071263444,0.1875483,0.0031990306,0.004062117,0.011074743,0.006869891,0.019420423,0.007306318,0.08023758],"study_design_scores_gemma":[0.024385097,0.043667473,0.48963767,0.00087393454,0.22529438,0.0016772103,0.003950561,0.15789975,0.007814182,0.03349604,0.010847401,0.0004562133],"about_ca_topic_score_codex":0.004120435,"about_ca_topic_score_gemma":0.0019231132,"teacher_disagreement_score":0.035784964,"about_ca_system_score_codex":0.0006437531,"about_ca_system_score_gemma":0.0021790648,"threshold_uncertainty_score":0.18925124},"labels":[],"label_agreement":null},{"id":"W3164661689","doi":"10.1111/dom.14447","title":"Alleviating carbohydrate counting with a <scp>FiASP‐plus‐pramlintide closed‐loop</scp> delivery system (artificial pancreas): Feasibility and pilot studies","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; McGill University; McGill University Health Centre","funders":"Breakthrough T1D Canada; Canada Research Chairs; Juvenile Diabetes Research Foundation United Kingdom; Juvenile Diabetes Research Foundation International","keywords":"SMA*; Medicine; Placebo; Psychological intervention; Bolus (digestion); Internal medicine; Nursing","score_opus":0.035123969872938025,"score_gpt":0.25256989133994434,"score_spread":0.2174459214670063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164661689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970065,0.00022126555,0.0016502246,0.000052137137,0.000019225121,0.00079223164,0.00005402705,0.00003206677,0.00017230946],"genre_scores_gemma":[0.9875307,0.00053334655,0.009812089,0.00012409216,0.00004719467,0.0013015869,0.00019051238,0.000013788121,0.00044677372],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990157,0.000484336,0.000069057576,0.00012328925,0.00019259025,0.000115014824],"domain_scores_gemma":[0.9991696,0.00032529904,0.00020433152,0.000079221616,0.00009011399,0.000131498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020837828,0.00060365186,0.0006008092,0.00027650144,0.00022204449,0.00050881103,0.00080297416,0.000624503,0.0020221274],"category_scores_gemma":[0.0019849562,0.00022347391,0.0007193318,0.00016192795,0.00065354235,0.0008835315,0.00048107776,0.00079335255,0.00027827043],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20128398,0.123189926,0.009980194,0.00428116,0.0006700611,0.0008492233,0.00084486196,0.0016155543,0.46423036,0.0004677952,0.0010010343,0.19158588],"study_design_scores_gemma":[0.00893069,0.897976,0.02003288,0.000079786165,0.00031267083,0.00049686065,0.000266264,0.0023023514,0.06743192,0.00006696906,0.0020660565,0.000037423775],"about_ca_topic_score_codex":0.00049672293,"about_ca_topic_score_gemma":0.00045540556,"teacher_disagreement_score":0.0020837828,"about_ca_system_score_codex":0.00035451457,"about_ca_system_score_gemma":0.0005285688,"threshold_uncertainty_score":0.011020184},"labels":[],"label_agreement":null},{"id":"W3166262312","doi":"10.1111/dom.14472","title":"Using machine learning to predict severe hypoglycaemia in hospital","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Public Health; Centre for Global Health Research; Sinai Health System; Public Health Ontario; University of Toronto","funders":"Canadian Institutes of Health Research; Canadian HIV Trials Network, Canadian Institutes of Health Research","keywords":"Medicine; Decile; Logistic regression; Lasso (programming language); Machine learning; Artificial intelligence; Retrospective cohort study; Psychological intervention; Cohort; Emergency medicine; Internal medicine; Statistics; Nursing","score_opus":0.012322720445825502,"score_gpt":0.25226130083368975,"score_spread":0.23993858038786425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166262312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639624,0.00024158302,0.0024414195,0.00023145745,0.000013963742,0.00001957557,0.0003001524,0.00002403782,0.00033153297],"genre_scores_gemma":[0.9981647,0.00008154181,0.0012033981,0.00003083188,0.000012712659,0.000008190745,0.0004247326,0.000002247136,0.000071670285],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993999,0.0002901143,0.000065042965,0.000079834106,0.00010596007,0.000059141366],"domain_scores_gemma":[0.99696547,0.0014602599,0.00096638175,0.00012941689,0.00027905253,0.00019947912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016248897,0.00044545194,0.00034616515,0.00069966784,0.00017850519,0.0007071108,0.00028285026,0.0003773412,0.00062684173],"category_scores_gemma":[0.008259773,0.00014973985,0.0003502891,0.0005164386,0.000193064,0.00035267806,0.0003404548,0.000555124,0.00013639391],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020225816,0.00007666267,0.9866062,0.000021239726,0.00008445345,0.00004797638,0.000036572266,0.005833126,0.00013645749,0.000029168024,0.0002224072,0.0067035514],"study_design_scores_gemma":[0.00004277301,0.00061727175,0.83623075,0.000059550493,0.00008452644,0.00022795405,0.00022387058,0.16103914,0.00053208135,0.0005687116,0.00035179872,0.000021460617],"about_ca_topic_score_codex":0.008362521,"about_ca_topic_score_gemma":0.011393155,"teacher_disagreement_score":0.008362521,"about_ca_system_score_codex":0.0006622485,"about_ca_system_score_gemma":0.00069964916,"threshold_uncertainty_score":0.016627729},"labels":[],"label_agreement":null},{"id":"W3168679049","doi":"10.1111/dom.14468","title":"Use of once‐weekly semaglutide in patients with type <scp>2</scp> diabetes in routine clinical practice: Results from the <scp>SURE C</scp> anada multicentre, prospective, observational study","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Boniface Hospital; Nova Scotia Health Authority; Western University; Montreal Clinical Research Institute; Professional Engineers Ontario; McGill University Health Centre","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Internal medicine; Clinical endpoint; Observational study; Confidence interval; Prospective cohort study; Waist; Glucagon-like peptide 1 receptor; Diabetes mellitus; Clinical trial; Agonist; Endocrinology; Obesity; Liraglutide","score_opus":0.040906573998949064,"score_gpt":0.2858680078196724,"score_spread":0.24496143382072336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168679049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873275,0.000615923,0.000034360324,0.000031174517,0.0000054376505,0.000016816684,0.00034454252,0.000002540606,0.00021629149],"genre_scores_gemma":[0.99881846,0.0003293723,0.0001031964,0.00007747281,0.00001640089,0.000013773606,0.00054032146,0.0000017393834,0.00009914651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988753,0.0003211862,0.00014838722,0.00026115193,0.00029581782,0.00009821715],"domain_scores_gemma":[0.99571395,0.0007621443,0.0023577851,0.00018461244,0.0004514182,0.00053011504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011921756,0.00026598191,0.0006268776,0.00047694074,0.00036718714,0.00094447867,0.00039286638,0.00059931015,0.0010355682],"category_scores_gemma":[0.0031232445,0.00030919322,0.00081087585,0.0013728635,0.00022398349,0.000443969,0.00028481567,0.00056305487,0.0001771629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011208596,0.00015648529,0.99547356,0.00004703185,0.00022389737,0.000047834626,0.00006241609,0.00001967832,0.00015175683,0.000005209728,0.00013943316,0.0025518253],"study_design_scores_gemma":[0.00018445945,0.0006954782,0.9982333,0.000018816476,0.0001547436,0.00018909185,0.00011009274,0.00016663951,0.00003483254,0.0000070399933,0.00019844722,0.000007012547],"about_ca_topic_score_codex":0.013525429,"about_ca_topic_score_gemma":0.020636315,"teacher_disagreement_score":0.9864746,"about_ca_system_score_codex":0.0006006469,"about_ca_system_score_gemma":0.00088996603,"threshold_uncertainty_score":0.026893377},"labels":[],"label_agreement":null},{"id":"W3173855870","doi":"10.1111/dom.14474","title":"Comparative effectiveness and safety of sodium‐glucose cotransporter‐2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sinai Health System; University of Toronto","funders":"National Institute on Aging; Canadian Institutes of Health Research","keywords":"Medicine; Metformin; Internal medicine; Hazard ratio; Diabetic ketoacidosis; Diabetes mellitus; Type 2 diabetes; Dapagliflozin; Propensity score matching; Lactic acidosis; Myocardial infarction; Stroke (engine); Confidence interval; Endocrinology; Insulin","score_opus":0.06893482035059344,"score_gpt":0.3041577007592252,"score_spread":0.23522288040863176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173855870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775285,0.0010900674,0.00015793764,0.00004536933,0.000018505389,0.00003289731,0.0007344373,0.000002564928,0.00016537271],"genre_scores_gemma":[0.99789584,0.0004107898,0.00020506012,0.00008800042,0.00004045482,0.000047075395,0.0012540582,0.0000026336593,0.000056015855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937116,0.0029946922,0.0009112154,0.0011908348,0.00090776413,0.00028397137],"domain_scores_gemma":[0.9799942,0.0060045677,0.011643018,0.0009893917,0.0006358193,0.0007329635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005068311,0.0004279989,0.0013162418,0.00090459065,0.0004805686,0.0010843369,0.00072275574,0.0009493388,0.0010260855],"category_scores_gemma":[0.018358162,0.0004953076,0.0030153221,0.0017432782,0.0004131613,0.00093813473,0.0005770056,0.0009408739,0.00012861984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009496037,0.00038503724,0.98155725,0.00016369561,0.004969934,0.000048474747,0.00007029129,0.00025460793,0.0001367312,0.00003243469,0.00019582834,0.002689583],"study_design_scores_gemma":[0.0018156285,0.0045605344,0.9879205,0.00006614959,0.0029421907,0.00023118618,0.00014659674,0.0015689565,0.00018906621,0.00010739381,0.00042057646,0.000031194748],"about_ca_topic_score_codex":0.0037336654,"about_ca_topic_score_gemma":0.004024888,"teacher_disagreement_score":0.005068311,"about_ca_system_score_codex":0.0008141979,"about_ca_system_score_gemma":0.00064394856,"threshold_uncertainty_score":0.02680415},"labels":[],"label_agreement":null},{"id":"W3176966268","doi":"10.1111/dom.14479","title":"Impact of pregnancy on the trajectories of cardiovascular risk factors in women with and without gestational diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Work & Health; Institute for Clinical Evaluative Sciences; Mount Sinai Hospital; Health Sciences Centre; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pregnancy; Gestational diabetes; Medicine; Obstetrics; Diabetes mellitus; Population; Gestation; Endocrinology; Internal medicine; Biology; Environmental health","score_opus":0.011348405558671702,"score_gpt":0.24361852812219556,"score_spread":0.23227012256352386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176966268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976146,0.00062909425,0.000049407165,0.00027455352,0.000009905945,0.000006095605,0.0006035971,0.000002439776,0.0008104096],"genre_scores_gemma":[0.999017,0.000360283,0.000053674616,0.000034835626,0.0000042960596,0.0000042797847,0.00034366298,0.0000013625956,0.00018071802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995283,0.000101306316,0.0000340859,0.00009337405,0.00008368782,0.00015926948],"domain_scores_gemma":[0.99890184,0.00022643075,0.0004366478,0.00007534908,0.000111823145,0.00024790506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000562855,0.00016033408,0.00021409444,0.0003684918,0.00053402584,0.0006521362,0.0003430556,0.000337668,0.00091712864],"category_scores_gemma":[0.00429565,0.00017333875,0.00036599522,0.0008605484,0.00034745975,0.0003754275,0.0006033053,0.0005568017,0.0000972036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011505715,0.0000115243,0.9978624,0.000004556891,0.000024189523,0.00004344454,0.00013159614,0.00003077713,0.000047772046,0.000025043548,0.000052499363,0.0016511932],"study_design_scores_gemma":[0.0000019449812,0.000023407862,0.99952793,0.0000067781325,0.000010760846,0.000045323093,0.0001758913,0.00008064049,0.000009439015,0.00002019037,0.00009564412,0.000001986443],"about_ca_topic_score_codex":0.22017473,"about_ca_topic_score_gemma":0.25239983,"teacher_disagreement_score":0.22017473,"about_ca_system_score_codex":0.0013949276,"about_ca_system_score_gemma":0.0017145306,"threshold_uncertainty_score":0.43778634},"labels":[],"label_agreement":null},{"id":"W3181430803","doi":"10.1111/dom.14494","title":"The modifying effects of adiposity on the cardiovascular safety of sulphonylureas","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University; Partners Healthcare","keywords":"Medicine; Internal medicine; Endocrinology; Pharmacology","score_opus":0.006655463016191803,"score_gpt":0.19336421319014394,"score_spread":0.18670875017395214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181430803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970798,0.0018021459,0.00023840355,0.00009386852,0.000016506228,0.000010123423,0.00018508406,0.0000040623445,0.0005699781],"genre_scores_gemma":[0.99948287,0.00022480833,0.00008377353,0.000036146394,0.00001575605,0.0000030735453,0.000047508507,0.000001392698,0.00010465382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987418,0.0007719414,0.000089478475,0.0001480995,0.00016180747,0.00008688761],"domain_scores_gemma":[0.9938567,0.0022020554,0.002683844,0.0007178182,0.00023282255,0.00030672434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020536839,0.0003491013,0.00042608095,0.00030269218,0.00016610514,0.0006802208,0.00022263786,0.0003352699,0.0018425304],"category_scores_gemma":[0.006639943,0.00023302963,0.0011219789,0.00033206912,0.00033118864,0.00034264245,0.00038745452,0.000720926,0.00012510801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017363414,0.00024766257,0.95599437,0.00019934704,0.0031240839,0.000115979725,0.00014929363,0.00054241525,0.003267483,0.00015020148,0.00011959322,0.018726211],"study_design_scores_gemma":[0.00016620148,0.0013950627,0.99606234,0.000018085728,0.0007712336,0.00008060044,0.000037624974,0.00055808254,0.0005907284,0.000087929926,0.00022448896,0.0000075560747],"about_ca_topic_score_codex":0.0012451683,"about_ca_topic_score_gemma":0.0014457846,"teacher_disagreement_score":0.0020536839,"about_ca_system_score_codex":0.00022172397,"about_ca_system_score_gemma":0.00023235606,"threshold_uncertainty_score":0.010861039},"labels":[],"label_agreement":null},{"id":"W3181897787","doi":"10.1111/dom.14489","title":"Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University Health Network; University of Toronto; Toronto General Hospital; Diabetes Canada","funders":"","keywords":"Empagliflozin; Metabolite; Type 2 diabetes; Urine; Internal medicine; Endocrinology; Diabetes mellitus; Chemistry; Medicine; Pharmacology","score_opus":0.006488083987414294,"score_gpt":0.1940352688528273,"score_spread":0.187547184865413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181897787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99816006,0.0011753712,0.00022710224,0.00003349442,0.00001020926,0.000011914931,0.000162405,0.0000088715915,0.00021061675],"genre_scores_gemma":[0.99887556,0.00024211717,0.00047900312,0.000058536174,0.000010681539,0.000013768036,0.00019122638,0.000002784865,0.0001261942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999577,0.00012940296,0.000043334974,0.00010714192,0.00010445676,0.000038586764],"domain_scores_gemma":[0.9992149,0.00019162858,0.0003881336,0.00003635943,0.00008352152,0.000085525906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069812156,0.00035492054,0.00076267245,0.00041116044,0.00024640333,0.00060013705,0.00017841159,0.00047007797,0.00082490686],"category_scores_gemma":[0.0017505469,0.00020275194,0.00038479557,0.00059093034,0.00015752486,0.00032000922,0.0002513684,0.00050095527,0.000103677696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0126576405,0.0003848887,0.95216525,0.00015159514,0.00063710654,0.0003230599,0.00019950976,0.00025781328,0.010982501,0.000016036833,0.00016276789,0.022061806],"study_design_scores_gemma":[0.000055664415,0.0010162136,0.9969319,0.000010865701,0.00016601391,0.00025061835,0.00008221005,0.00040513955,0.0009081011,0.000022451668,0.00014452607,0.0000062734066],"about_ca_topic_score_codex":0.0011158718,"about_ca_topic_score_gemma":0.0016852571,"teacher_disagreement_score":0.0011158718,"about_ca_system_score_codex":0.00027074516,"about_ca_system_score_gemma":0.00014763589,"threshold_uncertainty_score":0.003692031},"labels":[],"label_agreement":null},{"id":"W3186539542","doi":"10.1111/dom.14504","title":"Effect of insulin degludec versus insulin glargine <scp>U100</scp> on time in range: <scp>SWITCH PRO</scp> , a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Insulin degludec; Insulin glargine; Medicine; Internal medicine; Crossover study; Diabetes mellitus; Insulin; Endocrinology; Type 2 diabetes; Placebo","score_opus":0.009979427910325139,"score_gpt":0.2555264918040429,"score_spread":0.24554706389371778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186539542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775416,0.00091142755,0.0001522364,0.000060634862,0.00009996979,0.00047250072,0.00013001752,0.000019364656,0.00039978174],"genre_scores_gemma":[0.99696654,0.0006863583,0.0005972865,0.0001892072,0.0001350015,0.00060981617,0.00022941982,0.000010032033,0.00057635],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992743,0.00039721304,0.000064848995,0.00012855013,0.000051146584,0.00008405845],"domain_scores_gemma":[0.9982509,0.0006495614,0.00040864077,0.000113009344,0.0000711241,0.0005066742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015222628,0.0010819822,0.0019897656,0.00034582245,0.00029672304,0.0009408779,0.00053867087,0.0011997392,0.0031195248],"category_scores_gemma":[0.0019392503,0.0005545568,0.0017057689,0.00034795149,0.0006179452,0.0007584886,0.00032799275,0.0020043803,0.00040574704],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98423034,0.0069384794,0.00054286927,0.00016644283,0.00036514743,0.000011798237,0.000026952068,0.00012158743,0.0018805449,0.000016433569,0.000074429896,0.005624965],"study_design_scores_gemma":[0.63608795,0.35544276,0.005995205,0.000034485944,0.0006340501,0.000033175023,0.000032665583,0.00046696604,0.00091838936,0.00006675635,0.00026696862,0.00002059491],"about_ca_topic_score_codex":0.00084609236,"about_ca_topic_score_gemma":0.0011255029,"teacher_disagreement_score":0.0031195248,"about_ca_system_score_codex":0.00048799848,"about_ca_system_score_gemma":0.0005950766,"threshold_uncertainty_score":0.010435879},"labels":[],"label_agreement":null},{"id":"W3189855140","doi":"10.1111/dom.14513","title":"Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Placebo; Medicine; Renal function; Internal medicine; Clinical endpoint; Gastroenterology; Diabetes mellitus; Blood pressure; Confidence interval; Kidney disease; Type 2 diabetes; Adverse effect; Type 1 diabetes; Randomized controlled trial; Urology; Endocrinology; Pathology","score_opus":0.004508049062991897,"score_gpt":0.1942720261216524,"score_spread":0.1897639770586605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189855140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961188,0.0023694632,0.00024642327,0.00019352075,0.00006756448,0.00016651487,0.000151335,0.000017419208,0.0006688909],"genre_scores_gemma":[0.9979893,0.0006569527,0.00035060153,0.00033863145,0.00011742667,0.0001217291,0.0001967731,0.0000023483483,0.00022622886],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997009,0.00014766138,0.000030033782,0.000045400415,0.00004564344,0.000030430296],"domain_scores_gemma":[0.9993549,0.00022091153,0.00019884836,0.000024916124,0.000039009865,0.00016143286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010016012,0.00047298288,0.0017030808,0.00020762737,0.00016778389,0.00048656372,0.0002181605,0.0005910638,0.0015958522],"category_scores_gemma":[0.0011427489,0.00022844874,0.0010522025,0.0001962414,0.0003255885,0.0003468655,0.00015082619,0.0009684842,0.00013326248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88154143,0.005728415,0.027698245,0.00067101326,0.0021902735,0.00012163924,0.00006723299,0.0012411083,0.013416182,0.000114415176,0.0012128148,0.06599727],"study_design_scores_gemma":[0.6427503,0.21804368,0.12569086,0.00010022134,0.0024821407,0.00039600788,0.00009169004,0.005523709,0.002831935,0.00032134505,0.0017248747,0.000043141918],"about_ca_topic_score_codex":0.00047803312,"about_ca_topic_score_gemma":0.0010316485,"teacher_disagreement_score":0.0017030808,"about_ca_system_score_codex":0.00028252415,"about_ca_system_score_gemma":0.00042003274,"threshold_uncertainty_score":0.005338669},"labels":[],"label_agreement":null},{"id":"W3197785709","doi":"10.1111/dom.14535","title":"Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <scp>EMPA‐REG OUTCOME</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital","funders":"Eli Lilly and Company","keywords":"Empagliflozin; Medicine; Insulin; Placebo; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.011845454628464088,"score_gpt":0.21517571711972322,"score_spread":0.20333026249125913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197785709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97912276,0.01611112,0.00053442246,0.00087149517,0.00034239815,0.0004902205,0.0008558587,0.000047411795,0.0016243792],"genre_scores_gemma":[0.992069,0.0037871632,0.0006830081,0.0007525072,0.0005787713,0.0004722809,0.0010111214,0.000010548091,0.0006355647],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981579,0.0012971691,0.00012292383,0.00019585538,0.00012874826,0.000097361466],"domain_scores_gemma":[0.9980415,0.0008519612,0.00058663794,0.00018278981,0.00008398854,0.0002530868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045809993,0.0009825334,0.0021240674,0.00024354218,0.00019350465,0.0008636016,0.000479149,0.0010559356,0.002418353],"category_scores_gemma":[0.004122108,0.00032829182,0.0035305894,0.0003306753,0.0005846655,0.00066774775,0.0005246776,0.002027282,0.00024417808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95487994,0.001756188,0.007708889,0.00090748613,0.009040576,0.000034755216,0.000037533642,0.00051710923,0.00083611906,0.00008062578,0.0008906049,0.023310257],"study_design_scores_gemma":[0.8530722,0.066984855,0.0601158,0.0002695242,0.015384233,0.00012151987,0.000047516212,0.0014044682,0.00055066415,0.00036669237,0.0016444343,0.000038097933],"about_ca_topic_score_codex":0.00074593944,"about_ca_topic_score_gemma":0.0015148476,"teacher_disagreement_score":0.0045809993,"about_ca_system_score_codex":0.00044340378,"about_ca_system_score_gemma":0.00051650335,"threshold_uncertainty_score":0.024226964},"labels":[],"label_agreement":null},{"id":"W3199001556","doi":"10.1111/dom.14551","title":"Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); McMaster University; York University","funders":"","keywords":"Semaglutide; Weight loss; Tolerability; Overweight; Adverse effect; Medicine; Obesity; Weight management; Gastrointestinal system; Anti obesity; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.013496819939861935,"score_gpt":0.23526608980532987,"score_spread":0.22176926986546794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199001556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98721087,0.01149518,0.00029555982,0.00012519685,0.000023809209,0.000061194856,0.0002858303,0.000010773017,0.0004916526],"genre_scores_gemma":[0.997865,0.0013481053,0.00026683576,0.000116330026,0.00003814487,0.000039332685,0.00018059954,0.0000023221216,0.0001433565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905735,0.00045408396,0.0001427233,0.00012276243,0.00017800712,0.000045025106],"domain_scores_gemma":[0.9966718,0.0010935168,0.0018719477,0.000089903115,0.0001633378,0.00010949804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034136598,0.00028476273,0.0006668907,0.00033297803,0.00012463446,0.0003503773,0.00015357748,0.0003361023,0.00094838184],"category_scores_gemma":[0.0041171904,0.00020594573,0.0012256976,0.00046812007,0.00015191261,0.00034214385,0.00021026908,0.00052733667,0.00008675921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039086357,0.00047698338,0.8825613,0.0015031159,0.007675272,0.0001591649,0.00014372714,0.00046368112,0.0034766814,0.00004215351,0.00035916697,0.06405239],"study_design_scores_gemma":[0.0009750359,0.006725115,0.9880619,0.00009349179,0.0024698493,0.00028704002,0.000043150034,0.000453045,0.00039375215,0.000037916012,0.0004513388,0.000008425486],"about_ca_topic_score_codex":0.0006839729,"about_ca_topic_score_gemma":0.0015535607,"teacher_disagreement_score":0.0034136598,"about_ca_system_score_codex":0.00019694639,"about_ca_system_score_gemma":0.00022440481,"threshold_uncertainty_score":0.018053412},"labels":[],"label_agreement":null},{"id":"W3199091208","doi":"10.1111/dom.14552","title":"The ongoing evolution of basal insulin therapy over 100 years and its promise for the future","year":2021,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Context (archaeology); Insulin; Insulin degludec; Basal (medicine); Insulin glargine; Basal insulin; Medicine; Endocrinology; Bioinformatics; Internal medicine; Biology; Diabetes mellitus; Type 2 diabetes; Hypoglycemia","score_opus":0.02892116287858056,"score_gpt":0.31707443446232536,"score_spread":0.2881532715837448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199091208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007798712,0.9876208,0.00082103227,0.007052823,0.0008991166,0.0000045868014,0.000021424014,0.000016783026,0.002783618],"genre_scores_gemma":[0.006321753,0.98585945,0.001429793,0.0038670385,0.0012034061,0.000014573076,0.00004953828,0.0000109408475,0.0012436219],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991824,0.00023326611,0.00012138999,0.00010640257,0.00029121916,0.000065368185],"domain_scores_gemma":[0.99856323,0.0007026408,0.0001787175,0.0000487035,0.0003581415,0.00014864036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023879749,0.00037220863,0.0007328738,0.0007289404,0.00035482176,0.002011167,0.0006273988,0.0012999425,0.0018426585],"category_scores_gemma":[0.0030690841,0.00015653095,0.00040408372,0.0011460776,0.0012139428,0.0025926016,0.00088065665,0.003355028,0.0007622089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024038141,0.00007940609,0.0007610328,0.004928796,0.000052606094,0.00035691075,0.00041893544,0.00050645677,0.0014488077,0.023845106,0.02625219,0.9411094],"study_design_scores_gemma":[0.000013657095,0.00016601245,0.0014136496,0.0029261892,0.00004410557,0.0013227327,0.00023434227,0.0002248581,0.0005323157,0.010636153,0.98245054,0.00003551788],"about_ca_topic_score_codex":0.001279561,"about_ca_topic_score_gemma":0.0014043475,"teacher_disagreement_score":0.0023879749,"about_ca_system_score_codex":0.0012977466,"about_ca_system_score_gemma":0.0018095967,"threshold_uncertainty_score":0.0126289725},"labels":[],"label_agreement":null},{"id":"W3199674324","doi":"10.1111/dom.14559","title":"Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the <scp>EMPA‐REG OUTCOME</scp> trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; EMPA; Post-hoc analysis; Uric acid; Type 2 diabetes; Diabetes mellitus; Gout; Internal medicine; Pharmacology; Endocrinology; Chemistry","score_opus":0.011980052104121532,"score_gpt":0.24204910675745814,"score_spread":0.2300690546533366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199674324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739128,0.016403303,0.0011326965,0.00111098,0.00073824363,0.001274937,0.0025575028,0.00012133421,0.0027482088],"genre_scores_gemma":[0.9894967,0.0030608175,0.0009451869,0.0006174335,0.0005727567,0.0012509677,0.0018973084,0.00002853209,0.0021302209],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983209,0.0011978871,0.00008085712,0.00016021347,0.00008825546,0.00015192232],"domain_scores_gemma":[0.9983341,0.0008076235,0.00035229337,0.0001737945,0.000111475376,0.0002206722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004078235,0.0012949532,0.003614852,0.0002128358,0.00020394007,0.0011342824,0.00049658783,0.0008697109,0.004233179],"category_scores_gemma":[0.0035722891,0.0003289717,0.0043212194,0.00027430634,0.00039942208,0.0006672114,0.0004953997,0.001982916,0.00042450486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9753519,0.00072956935,0.0019416747,0.0008142642,0.008446982,0.000042599724,0.0000178071,0.0004621672,0.00072687195,0.000074978045,0.0010817493,0.010309429],"study_design_scores_gemma":[0.86166173,0.07980341,0.026250564,0.00023368526,0.025493952,0.00012379394,0.000055106015,0.0023671754,0.0009414029,0.0004440128,0.0025833559,0.000041811487],"about_ca_topic_score_codex":0.0007918955,"about_ca_topic_score_gemma":0.0014960207,"teacher_disagreement_score":0.004233179,"about_ca_system_score_codex":0.0004127202,"about_ca_system_score_gemma":0.00069523347,"threshold_uncertainty_score":0.02156806},"labels":[],"label_agreement":null},{"id":"W3203632442","doi":"10.1111/dom.14564","title":"Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine <scp>U300</scp> in people with type 2 diabetes: A post hoc analysis of the <scp>CONCLUDE</scp> trial","year":2021,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; National Institute for Health and Care Research","keywords":"Insulin degludec; Medicine; Insulin glargine; Internal medicine; Type 2 diabetes; Renal function; Insulin; Endocrinology; Diabetes mellitus; Kidney disease; Lixisenatide; Post-hoc analysis; Basal insulin","score_opus":0.01522354404536465,"score_gpt":0.25493959651881537,"score_spread":0.2397160524734507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203632442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818793,0.010204014,0.00049814075,0.0007955432,0.00082971575,0.001209811,0.0016314165,0.00006744386,0.0028846057],"genre_scores_gemma":[0.99256104,0.0016410133,0.00059067353,0.0008088381,0.0006092571,0.0009155959,0.0012336085,0.000029723175,0.0016102605],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99652785,0.002270573,0.00023541211,0.0003782791,0.00024071909,0.0003471794],"domain_scores_gemma":[0.9952845,0.0024947475,0.00084835966,0.00039723003,0.0003446302,0.0006305057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060522477,0.0017838946,0.0042992895,0.00031552985,0.0003587267,0.0016862089,0.00091490656,0.001517971,0.005208298],"category_scores_gemma":[0.0069019883,0.00044060437,0.007940318,0.0003736524,0.0009030281,0.0014081174,0.0007372929,0.0038519588,0.0006507368],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98866117,0.00076807634,0.00085711136,0.0003905251,0.0039208895,0.000019696694,0.000025990761,0.00019031657,0.00037806257,0.000037903388,0.00037612524,0.0043741846],"study_design_scores_gemma":[0.75034446,0.21185276,0.018230647,0.0002046576,0.014719762,0.00007326676,0.0000906675,0.0014477486,0.0009921358,0.00049807836,0.0014774889,0.00006837555],"about_ca_topic_score_codex":0.0008653129,"about_ca_topic_score_gemma":0.0016070924,"teacher_disagreement_score":0.0060522477,"about_ca_system_score_codex":0.0009066344,"about_ca_system_score_gemma":0.00076943776,"threshold_uncertainty_score":0.032007694},"labels":[],"label_agreement":null},{"id":"W3212829511","doi":"10.1111/dom.14591","title":"Restrictive versus liberal transfusion in patients with diabetes undergoing cardiac surgery: An o <scp>pen‐label,</scp> randomized, blinded outcome evaluation trial","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Blood transfusion and management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Libin Cardiovascular Institute of Alberta; Kingston General Hospital; University of Calgary; Centre Hospitalier de l’Université de Montréal; The Quebec Population Health Research Network; Health Sciences Centre; Mount Sinai Hospital; University of Toronto; St. Michael's Hospital","funders":"Health Research Council of New Zealand; National Health and Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; Canadian Blood Services","keywords":"Medicine; Diabetes mellitus; Randomized controlled trial; Internal medicine; Surgery; Blood transfusion; Stroke (engine); Myocardial infarction; Dialysis; Intensive care unit","score_opus":0.029934372663176,"score_gpt":0.2716096901452942,"score_spread":0.24167531748211818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212829511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802188,0.008154736,0.0011782188,0.0013816141,0.0012508745,0.0033981598,0.0013517442,0.00007942353,0.0029863552],"genre_scores_gemma":[0.98747617,0.002314141,0.0017866144,0.0018872317,0.00079033757,0.0035964334,0.00068085274,0.00001551663,0.0014527483],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981887,0.0012301321,0.00015001885,0.00020993332,0.00010307016,0.00011819656],"domain_scores_gemma":[0.9975176,0.0009864966,0.00076649495,0.00017714017,0.000133451,0.0004188745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030486218,0.001208251,0.0028065704,0.00024575862,0.0003945128,0.0015693338,0.0006323342,0.0019043838,0.0049009616],"category_scores_gemma":[0.0037723137,0.00046049154,0.0018220952,0.00037300395,0.0009250186,0.0010440327,0.0004354045,0.0023349093,0.00046017978],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99046844,0.0013476041,0.0005924224,0.0005007116,0.0008387381,0.0000138118185,0.000015636551,0.0000885386,0.0003052973,0.00006415891,0.00035266386,0.005411901],"study_design_scores_gemma":[0.9771986,0.019768728,0.0013190317,0.00009782856,0.0006836439,0.000018607414,0.000016825024,0.00033259537,0.00011151062,0.00018310644,0.00025803264,0.000011503285],"about_ca_topic_score_codex":0.00073630543,"about_ca_topic_score_gemma":0.0013685529,"teacher_disagreement_score":0.0049009616,"about_ca_system_score_codex":0.0005224835,"about_ca_system_score_gemma":0.0010165224,"threshold_uncertainty_score":0.01639533},"labels":[],"label_agreement":null},{"id":"W4200582462","doi":"10.1111/dom.14629","title":"Pushing the limits of insulin delivery 100 years later: A case study of a race across Canada","year":2021,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Race (biology); Insulin delivery; Insulin; Medicine; Demography; Sociology; Internal medicine; Gender studies; Endocrinology; Diabetes mellitus; Type 1 diabetes","score_opus":0.026244466748680813,"score_gpt":0.2752432618423576,"score_spread":0.24899879509367678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200582462","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70560354,0.0031379133,0.00051890966,0.2564877,0.0012552168,0.000076913275,0.00022875835,0.000026977299,0.03266403],"genre_scores_gemma":[0.9210459,0.0035107096,0.0006151655,0.060541462,0.00064187206,0.000025228734,0.000074820164,0.00008107901,0.013463778],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985903,0.00015054108,0.00005682864,0.00012807192,0.0002395701,0.000834738],"domain_scores_gemma":[0.9964065,0.0004969883,0.00034607935,0.00008017337,0.0006679257,0.0020022634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065001467,0.00035607352,0.0005329697,0.0006712218,0.019466337,0.0029256467,0.0015697394,0.0067719347,0.0042171814],"category_scores_gemma":[0.004349319,0.0004912337,0.0005381977,0.0020259107,0.002700005,0.0014482532,0.0018759266,0.012946861,0.00031330565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026231332,0.0007231946,0.21651797,0.00018033704,0.00012783331,0.5343125,0.12431131,0.00037623825,0.0017771525,0.011105593,0.07204026,0.038265295],"study_design_scores_gemma":[0.00008561297,0.00029004755,0.15244175,0.0013064165,0.00023856567,0.21839996,0.5114535,0.0019221271,0.00078630296,0.0055357073,0.10723743,0.000302557],"about_ca_topic_score_codex":0.92152816,"about_ca_topic_score_gemma":0.96162814,"teacher_disagreement_score":0.07847184,"about_ca_system_score_codex":0.02475652,"about_ca_system_score_gemma":0.043514613,"threshold_uncertainty_score":0.179622},"labels":[],"label_agreement":null},{"id":"W4200603578","doi":"10.1111/dom.14622","title":"Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis from 2010 to 2020","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Joseph's Health Care; Lawson Health Research Institute; Western University","funders":"Schulich School of Medicine and Dentistry; Western University; Ontario Ministry of Health and Long-Term Care; Academic Medical Organization of Southwestern Ontario; Lawson Health Research Institute","keywords":"Medicine; Insulin glargine; Kidney disease; Insulin degludec; Medical prescription; Diabetes mellitus; Internal medicine; Population; Type 2 diabetes; Intensive care medicine; Endocrinology; Pharmacology; Environmental health","score_opus":0.005974535116680456,"score_gpt":0.19893583274309798,"score_spread":0.19296129762641753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200603578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587427,0.0024526294,0.00020786538,0.00074087083,0.000027544085,0.00007356741,0.03491413,0.00002976766,0.0028109825],"genre_scores_gemma":[0.98976713,0.0011471248,0.0002178473,0.00021975614,0.00001674217,0.000035788977,0.007711423,0.0000064182755,0.00087784923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908364,0.000046519155,0.000115298855,0.00015487245,0.00038361072,0.00021604521],"domain_scores_gemma":[0.9967139,0.00010776222,0.0010475143,0.00007498061,0.0014094533,0.00064651173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043087674,0.00028923916,0.00045915946,0.0013139285,0.0010906834,0.0009798547,0.0009928842,0.0004584239,0.0013960486],"category_scores_gemma":[0.0017659866,0.00029363728,0.00087279204,0.0048365635,0.0003997922,0.000438088,0.0006140068,0.0005775911,0.00018033847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006932181,0.000017092501,0.9962048,0.00006816967,0.000076465396,0.00004386054,0.00013662862,0.00011345051,0.00009477463,0.00003188662,0.0012361922,0.0019074656],"study_design_scores_gemma":[0.000006652095,0.000013750795,0.99886703,0.000026821597,0.000026990592,0.00003252484,0.00019702752,0.00024195701,0.000019790761,0.000008000165,0.0005546014,0.00000477036],"about_ca_topic_score_codex":0.9864746,"about_ca_topic_score_gemma":0.9897187,"teacher_disagreement_score":0.018103553,"about_ca_system_score_codex":0.018103553,"about_ca_system_score_gemma":0.01988281,"threshold_uncertainty_score":0.13135111},"labels":[],"label_agreement":null},{"id":"W4205144121","doi":"10.1111/dom.14637","title":"<scp>Glucagon‐like peptide</scp> ‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?","year":2022,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Type 2 diabetes; Type 1 diabetes; Glucagon-like peptide-1; Narrative review; Adjunctive treatment; Diabetes mellitus; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.18476293404873256,"score_gpt":0.3183659521337006,"score_spread":0.13360301808496805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205144121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044641682,0.9971781,0.00018971373,0.00110977,0.00026495446,0.000032008364,0.0000781046,0.000008168973,0.0006928262],"genre_scores_gemma":[0.003357316,0.99401313,0.00047614277,0.0013386888,0.0003961778,0.00004349766,0.00008109285,0.0000042975907,0.0002896852],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917716,0.00031089634,0.0002122996,0.00008097255,0.00017563383,0.000042948253],"domain_scores_gemma":[0.99814296,0.0012096721,0.00036086282,0.00003171569,0.0002172923,0.000037456957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017784483,0.0005466184,0.0018353978,0.0010216701,0.00015957758,0.0014355212,0.000655442,0.00091039296,0.0057191025],"category_scores_gemma":[0.0034418849,0.00018020507,0.0017201736,0.00087064074,0.00035681957,0.0011759497,0.0005789158,0.0013847055,0.0010186781],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001110384,0.00009998957,0.00035402266,0.19380325,0.0016236467,0.00028753473,0.00012343084,0.00028047006,0.0018156471,0.00266843,0.015570411,0.78226274],"study_design_scores_gemma":[0.0009988894,0.0018567847,0.0037422318,0.18842424,0.008650801,0.002503444,0.0004074552,0.00036126355,0.0015599041,0.005275963,0.7861223,0.00009676959],"about_ca_topic_score_codex":0.00065274094,"about_ca_topic_score_gemma":0.0018499424,"teacher_disagreement_score":0.0057191025,"about_ca_system_score_codex":0.00039008347,"about_ca_system_score_gemma":0.0015339069,"threshold_uncertainty_score":0.019132257},"labels":[],"label_agreement":null},{"id":"W4205306193","doi":"10.1111/dom.14000","title":"Cover Image, Volume 22, Issue 3","year":2020,"lang":"en","type":"paratext","venue":"Diabetes Obesity and Metabolism","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital","funders":"","keywords":"Cover (algebra); Semaglutide; Type 2 diabetes; Front cover; Image (mathematics); Volume (thermodynamics); Medicine; Computer science; Artificial intelligence; Diabetes mellitus; Engineering; Physics; Mechanical engineering; Endocrinology","score_opus":0.005847285509191481,"score_gpt":0.22723898418700145,"score_spread":0.22139169867780997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205306193","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041910066,0.0022545818,0.000812186,0.007798595,0.041418992,0.00030449277,0.0059377546,0.003394047,0.9376603],"genre_scores_gemma":[0.0013301166,0.0010278581,0.00038453238,0.0025925247,0.007019086,0.00007554678,0.0020383534,0.00064720254,0.98488474],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997681,0.000020326204,0.000009557394,0.000032359243,0.00012377575,0.000045855897],"domain_scores_gemma":[0.998979,0.00020134673,0.000047004174,0.00006328476,0.00031124047,0.0003981443],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002836507,0.0011256111,0.0009065174,0.0015124918,0.0009023241,0.0043468312,0.00097295584,0.0022226728,0.89544976],"category_scores_gemma":[0.0022597397,0.00043730627,0.00087196735,0.0009871997,0.00046065266,0.0018836007,0.00140332,0.0023823243,0.7630238],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021098533,0.000010989611,0.000014204669,0.000044783144,9.026786e-7,0.000026055348,0.0000021258768,0.000012896807,0.00012213136,0.00015292475,0.9861615,0.013430442],"study_design_scores_gemma":[0.00002988171,0.000019944977,0.0002849725,0.00007746957,0.000001831919,0.00013914394,0.000011009496,0.00007400995,0.00013762021,0.0003357633,0.9988834,0.000004970548],"about_ca_topic_score_codex":0.0019006073,"about_ca_topic_score_gemma":0.0034148847,"teacher_disagreement_score":0.10455024,"about_ca_system_score_codex":0.0008250995,"about_ca_system_score_gemma":0.00064700353,"threshold_uncertainty_score":0.14912814},"labels":[],"label_agreement":null},{"id":"W4205423256","doi":"10.1111/dom.14652","title":"<scp>ZT</scp> ‐01: A novel somatostatin receptor 2 antagonist for restoring the glucagon response to hypoglycaemia in type 1 diabetes","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"iCo Therapeutics (Canada); York University","funders":"Leona M. and Harry B. Helmsley Charitable Trust; Juvenile Diabetes Research Foundation International","keywords":"Glucagon; Type 1 diabetes; Somatostatin; Antagonist; Receptor antagonist; Hypoglycemia; Glucagon-like peptide 1 receptor","score_opus":0.02058933680820301,"score_gpt":0.2716529716777969,"score_spread":0.2510636348695939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205423256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936434,0.0023705964,0.0019855483,0.0001276227,0.00004022392,0.000074105345,0.00041922604,0.0001134047,0.0012257365],"genre_scores_gemma":[0.9930125,0.0021370212,0.0028028865,0.00011732143,0.00002878987,0.000046886813,0.0008244854,0.000018183657,0.0010118593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999552,0.0000069094604,0.0000043382865,0.000007941008,0.0000131804545,0.000012427189],"domain_scores_gemma":[0.99994063,0.000009269954,0.000024141831,0.000003682659,0.00000589296,0.000016372582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001262625,0.0002998538,0.0001913406,0.00012559642,0.000068863534,0.00019147785,0.00023208637,0.00023687024,0.0016453156],"category_scores_gemma":[0.00009954009,0.00008608984,0.00017552318,0.00012601916,0.00016902384,0.00017443337,0.000082210914,0.00052688044,0.00039855507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032532623,0.0004026659,0.00063147745,0.00015932026,0.000018796887,0.00016723282,0.000011056644,0.00026365274,0.97681594,0.00009494803,0.00022182865,0.017959852],"study_design_scores_gemma":[0.0017700838,0.030095585,0.0152713405,0.000034553705,0.000088115135,0.0023374646,0.00004136953,0.002181325,0.9425326,0.00006542456,0.0055606076,0.000021592636],"about_ca_topic_score_codex":0.0004710677,"about_ca_topic_score_gemma":0.0007635939,"teacher_disagreement_score":0.0016453156,"about_ca_system_score_codex":0.00016216915,"about_ca_system_score_gemma":0.00020460442,"threshold_uncertainty_score":0.005504191},"labels":[],"label_agreement":null},{"id":"W4206145164","doi":"10.1111/dom.14634","title":"Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the <scp>REWIND</scp> randomized trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université Laval; Population Health Research Institute; Hamilton Health Sciences; University of Toronto; St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Atrial fibrillation; Post-hoc analysis; Internal medicine; Heart failure; Placebo; Atrial flutter; Cardiology; Stroke (engine); Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Exenatide; Endocrinology","score_opus":0.0062953249637689975,"score_gpt":0.20741575548699737,"score_spread":0.20112043052322837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206145164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887369,0.007174096,0.00039852477,0.00031327314,0.00030852132,0.00077790493,0.00090243365,0.00003750238,0.0013507773],"genre_scores_gemma":[0.9930484,0.0020326478,0.0009557199,0.0003737588,0.00033127595,0.00073323515,0.001236228,0.000015714042,0.0012730694],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99892586,0.0006383574,0.00009518063,0.00015854734,0.000067694484,0.00011448327],"domain_scores_gemma":[0.9987657,0.00045284556,0.0003782436,0.00013974335,0.00008832906,0.00017515612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023218223,0.0011996067,0.0030397722,0.00020462842,0.00021464773,0.0009866712,0.00057010324,0.00075582287,0.003446638],"category_scores_gemma":[0.0022369598,0.00038898966,0.0034718635,0.000241053,0.000397091,0.0005034469,0.00035428247,0.0014859771,0.000301253],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.973859,0.0008111285,0.0053328546,0.00093154516,0.0066460064,0.000053422737,0.000030410863,0.00028452766,0.0011384798,0.00009300223,0.0006711761,0.010148529],"study_design_scores_gemma":[0.9183051,0.04159253,0.023693081,0.00020200078,0.0130224405,0.00011669422,0.00007135606,0.00090121984,0.0006032913,0.000268416,0.0011920509,0.000031755328],"about_ca_topic_score_codex":0.0009434502,"about_ca_topic_score_gemma":0.0025754783,"teacher_disagreement_score":0.003446638,"about_ca_system_score_codex":0.00035400226,"about_ca_system_score_gemma":0.0006729503,"threshold_uncertainty_score":0.012279153},"labels":[],"label_agreement":null},{"id":"W4206528639","doi":"10.1111/dom.14645","title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Prediabetes; Placebo; Medicine; Internal medicine; Diabetes mellitus; Gastroenterology; Impaired fasting glucose; Type 2 diabetes; Post-hoc analysis; Endocrinology; Impaired glucose tolerance","score_opus":0.0415527206936868,"score_gpt":0.32807263884282367,"score_spread":0.28651991814913685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206528639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7986867,0.18738186,0.00517619,0.0008042261,0.001016366,0.0032916458,0.001705509,0.00020578338,0.0017317167],"genre_scores_gemma":[0.9815139,0.012849299,0.0020982046,0.00047955106,0.00045604748,0.0013357444,0.0008159243,0.000030474068,0.0004207714],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9878754,0.009233524,0.0012944924,0.0008157121,0.00046248638,0.0003184633],"domain_scores_gemma":[0.9905194,0.0053225853,0.0024540252,0.0007079135,0.00056956266,0.00042646067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017473353,0.0019421856,0.008635336,0.0011090398,0.00042121136,0.0018750303,0.0006529755,0.001360133,0.0023100872],"category_scores_gemma":[0.011480133,0.00076355017,0.013218274,0.0011392968,0.00073459494,0.0012759465,0.00073611736,0.0015077536,0.00020478205],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8585976,0.00048523367,0.0047818255,0.0040507503,0.11373724,0.0000631412,0.000048140446,0.0006392855,0.001890742,0.00005140275,0.00028724887,0.015367425],"study_design_scores_gemma":[0.5821367,0.09712551,0.03918497,0.00086526136,0.27253535,0.00022843204,0.00014342106,0.003095829,0.0019779075,0.00059038034,0.0019969768,0.000119221106],"about_ca_topic_score_codex":0.0005784685,"about_ca_topic_score_gemma":0.0017114889,"teacher_disagreement_score":0.017473353,"about_ca_system_score_codex":0.00074983435,"about_ca_system_score_gemma":0.0013618675,"threshold_uncertainty_score":0.092409015},"labels":[],"label_agreement":null},{"id":"W4211100132","doi":"10.1111/dom.14666","title":"Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A <scp>meta‐analysis</scp> and <scp>meta‐regression</scp> analysis","year":2022,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Mace; Medicine; Internal medicine; Meta-analysis; Myocardial infarction; Meta-regression; Hazard ratio; Semaglutide; Weight loss; Endocrinology; Diabetes mellitus; Type 2 diabetes; Obesity; Liraglutide; Confidence interval","score_opus":0.030950195687448515,"score_gpt":0.275676389128329,"score_spread":0.24472619344088048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211100132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019509945,0.970212,0.0037656492,0.0006984792,0.00068719307,0.001055972,0.0029295527,0.0002025629,0.0009386122],"genre_scores_gemma":[0.54019827,0.43630508,0.0102232,0.0025160785,0.0010265771,0.0042851586,0.0037147356,0.00016790228,0.0015630088],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9899995,0.005735023,0.0019445178,0.0010390268,0.0009801675,0.00030175556],"domain_scores_gemma":[0.9852415,0.011113078,0.0018635695,0.0007040729,0.00088679075,0.00019102187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017073775,0.0036421036,0.018756913,0.0051306756,0.00053022464,0.0036923022,0.0021305496,0.0024891354,0.00434089],"category_scores_gemma":[0.026027145,0.0017821853,0.060005724,0.0055060512,0.00061993586,0.0013809063,0.0012255873,0.002268687,0.00046778886],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019642366,0.000015657683,0.0020675655,0.057992075,0.93412316,0.000049681064,0.000016168504,0.00051558076,0.00015845492,0.000066004286,0.0003630947,0.002668315],"study_design_scores_gemma":[0.0006080838,0.000091270565,0.0013536965,0.0025292211,0.994507,0.000026869706,0.000007651557,0.00021188686,0.000066232955,0.0001030755,0.00048591202,0.0000089871855],"about_ca_topic_score_codex":0.0057663615,"about_ca_topic_score_gemma":0.008375846,"teacher_disagreement_score":0.018756913,"about_ca_system_score_codex":0.0017097847,"about_ca_system_score_gemma":0.0021292109,"threshold_uncertainty_score":0.09029585},"labels":[],"label_agreement":null},{"id":"W4213199527","doi":"10.1111/dom.14670","title":"Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Eurostars; Bundesministerium für Bildung und Forschung; European Regional Development Fund; Bundesministerium für Gesundheit; Boehringer Ingelheim","keywords":"Empagliflozin; Steatosis; Medicine; Internal medicine; Fatty liver; Fibrosis; Type 2 diabetes; Diabetes mellitus; Gastroenterology; Placebo; Disease; Endocrinology; Pathology","score_opus":0.007884611794065365,"score_gpt":0.2119760811619748,"score_spread":0.20409146936790945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213199527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390775,0.0042286757,0.00041286863,0.00016997909,0.00004484475,0.000118205615,0.00025991414,0.00002756002,0.0008303636],"genre_scores_gemma":[0.99786586,0.00072443386,0.0004822651,0.00013815191,0.000046080397,0.00008523273,0.00018397508,0.00000308773,0.0004708895],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994215,0.0003104082,0.000044541313,0.00008227933,0.00009298864,0.000048334477],"domain_scores_gemma":[0.9989773,0.0005035338,0.00027781722,0.00007827523,0.000060285307,0.00010277012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021875312,0.0004501866,0.00080517656,0.00021514503,0.00010735479,0.00038365295,0.00017295622,0.00037361323,0.0013765063],"category_scores_gemma":[0.0022466476,0.00016942142,0.0010467542,0.00016050739,0.00026950793,0.000296813,0.00023166498,0.00077433354,0.00009384474],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7469406,0.007621289,0.071389444,0.0011150623,0.005795049,0.00008602366,0.0000669382,0.0020770202,0.010762336,0.00015111393,0.0010226377,0.15297237],"study_design_scores_gemma":[0.11769937,0.18250524,0.66568094,0.00023990188,0.01021609,0.00025753147,0.00006032651,0.0055507803,0.014162165,0.0005391899,0.003030927,0.000057576697],"about_ca_topic_score_codex":0.00038450223,"about_ca_topic_score_gemma":0.0006670169,"teacher_disagreement_score":0.0021875312,"about_ca_system_score_codex":0.00021255917,"about_ca_system_score_gemma":0.00025449612,"threshold_uncertainty_score":0.011568904},"labels":[],"label_agreement":null},{"id":"W4214893005","doi":"10.1111/dom.14677","title":"The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp>","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Merck KGaA; Pfizer","keywords":"Natriuresis; Renal function; Medicine; Placebo; Internal medicine; Kidney disease; Albuminuria; Endocrinology; Uric acid; Diabetes mellitus; Urology; Confidence interval; Gastroenterology; Cardiology; Pathology","score_opus":0.012070645568670666,"score_gpt":0.23946648804927426,"score_spread":0.2273958424806036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214893005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693359,0.0052292617,0.0012528145,0.0005818699,0.00014982012,0.0038045847,0.012687289,0.00009246221,0.0068659214],"genre_scores_gemma":[0.97947854,0.0010336399,0.0019409892,0.0011422158,0.00014490695,0.0025401316,0.011224293,0.00004726755,0.0024480235],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99558556,0.0026358294,0.00039558375,0.00055641035,0.0005388693,0.00028776584],"domain_scores_gemma":[0.9951492,0.0017163162,0.0010038795,0.00085546565,0.00066264387,0.0006125666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005308885,0.0011319541,0.0024808424,0.00034718012,0.00047716906,0.0011765867,0.00076076225,0.0008541124,0.009060743],"category_scores_gemma":[0.0060710013,0.00042963316,0.0040541436,0.000720474,0.0007111101,0.0004255877,0.0008347724,0.0012836868,0.0005596973],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8204742,0.0026403982,0.07000397,0.0024061766,0.018449856,0.00033634042,0.00026035102,0.000981822,0.026684836,0.00043224177,0.008681158,0.048648655],"study_design_scores_gemma":[0.27771282,0.10841275,0.5632809,0.00060678634,0.02055508,0.0009304558,0.0002156109,0.001978872,0.008250996,0.0010667973,0.016804883,0.00018401805],"about_ca_topic_score_codex":0.0031901123,"about_ca_topic_score_gemma":0.014597079,"teacher_disagreement_score":0.009060743,"about_ca_system_score_codex":0.0010218429,"about_ca_system_score_gemma":0.0023584757,"threshold_uncertainty_score":0.030311167},"labels":[],"label_agreement":null},{"id":"W4220670177","doi":"10.1111/dom.14687","title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","year":2022,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; Western University","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Pioglitazone; Medicine; Stroke (engine); Diabetes mellitus; Insulin resistance; Adverse effect; Internal medicine; Placebo; Hazard ratio; Heart failure; Insulin; Myocardial infarction; Type 2 diabetes; Cardiology; Endocrinology; Confidence interval","score_opus":0.017495620797651955,"score_gpt":0.26119936239177355,"score_spread":0.2437037415941216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220670177","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699911,0.025003973,0.0003356023,0.0009601843,0.00027494648,0.00011666986,0.0004160335,0.0000486704,0.0028529228],"genre_scores_gemma":[0.99492633,0.0030868188,0.0003228083,0.00058430346,0.0002539562,0.000074112555,0.0004234269,0.0000055434393,0.00032266518],"study_design_codex":"randomized_trial","study_design_gemma":"systematic_review","domain_scores_codex":[0.99851125,0.00068022736,0.00025395246,0.00023565581,0.00018799304,0.00013095998],"domain_scores_gemma":[0.99714583,0.0011718423,0.0010016791,0.0002312085,0.00012986813,0.00031947388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002480602,0.00055687415,0.0030402967,0.00067824894,0.00030973606,0.0012101814,0.00045211927,0.0010220074,0.0030294778],"category_scores_gemma":[0.0052528055,0.00032221494,0.0025591955,0.00097596773,0.0002843021,0.00062233786,0.00039710672,0.0022945832,0.0003571846],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5751943,0.0071112635,0.1584993,0.0022310072,0.011345064,0.00031134498,0.00024338247,0.0016720262,0.0040159356,0.0003660942,0.0020183583,0.23699202],"study_design_scores_gemma":[0.199507,0.10905316,0.65857905,0.0012164979,0.016203668,0.00080908503,0.00027074153,0.0039011773,0.0022763822,0.0023938015,0.005634841,0.00015460445],"about_ca_topic_score_codex":0.00088604254,"about_ca_topic_score_gemma":0.001474753,"teacher_disagreement_score":0.0030402967,"about_ca_system_score_codex":0.00040939296,"about_ca_system_score_gemma":0.00040570894,"threshold_uncertainty_score":0.0131188035},"labels":[],"label_agreement":null},{"id":"W4220688079","doi":"10.1111/dom.14699","title":"Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready‐to‐use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin‐induced severe hypoglycaemia in adults with type 1 diabetes","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Tolerability; Family medicine; Pharmacology; Adverse effect","score_opus":0.017156926855270944,"score_gpt":0.2787632229340698,"score_spread":0.2616062960787989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220688079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872601,0.0040868684,0.0012076112,0.0003956949,0.00045146653,0.0031532163,0.001039045,0.00011487309,0.0022910465],"genre_scores_gemma":[0.98467225,0.002535933,0.0018193423,0.00072980835,0.00039869634,0.003701211,0.0014788623,0.00006811101,0.004595725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99919194,0.00039961477,0.00005419973,0.00011496536,0.00011465091,0.00012452254],"domain_scores_gemma":[0.9987872,0.0003746339,0.0002632545,0.00009777897,0.00009164057,0.00038548908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022076103,0.0010746005,0.0018217025,0.00034601105,0.00040983307,0.0014542851,0.0008743652,0.0011972517,0.0070495317],"category_scores_gemma":[0.0018388167,0.0005226576,0.0019395392,0.000352487,0.0010114523,0.0012812391,0.00026750908,0.0034102905,0.0013233785],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9119369,0.032318663,0.0005968274,0.0005012735,0.0006913432,0.00010116674,0.00014248141,0.00045955396,0.018156024,0.00018470813,0.0013256597,0.033585466],"study_design_scores_gemma":[0.37559906,0.6124944,0.0053383536,0.000051470954,0.0003669128,0.00011694291,0.00007963269,0.0008789664,0.0032071646,0.0001530978,0.0016715225,0.000042345477],"about_ca_topic_score_codex":0.0005365501,"about_ca_topic_score_gemma":0.0011849699,"teacher_disagreement_score":0.0070495317,"about_ca_system_score_codex":0.00071069435,"about_ca_system_score_gemma":0.0014123041,"threshold_uncertainty_score":0.023583055},"labels":[],"label_agreement":null},{"id":"W4220706492","doi":"10.1111/dom.14698","title":"Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"AstraZeneca Pharma Poland; AstraZeneca","keywords":"Medicine; Observational study; Multinational corporation; Type 2 diabetes; Disease; Diabetes mellitus; Health care; Intensive care medicine; Internal medicine; Endocrinology; Economic growth; Finance","score_opus":0.053073966119162624,"score_gpt":0.29522077216829157,"score_spread":0.24214680604912894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220706492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543166,0.00035620958,0.00010316682,0.000069284135,0.000008169098,0.000019225019,0.0037648876,0.0000034026175,0.00024403205],"genre_scores_gemma":[0.9949173,0.00032337845,0.00019829132,0.00007965328,0.000017777184,0.00005320062,0.0042878496,0.000004111686,0.000118460266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828196,0.0006175555,0.00031487807,0.00038729206,0.00022811312,0.00017022075],"domain_scores_gemma":[0.99641365,0.00040693328,0.0022519364,0.0003085981,0.000260063,0.00035887118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019839949,0.0005873781,0.00059456547,0.0015257043,0.00060507405,0.0012742535,0.0010285754,0.00075010885,0.0007516612],"category_scores_gemma":[0.0040181307,0.0006060125,0.0014527569,0.0035163537,0.00042602755,0.0010815313,0.001485549,0.00097227615,0.00018282504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048995214,0.000026544507,0.99931765,0.000011887707,0.00012903732,0.000015717264,0.000035926983,0.00005845712,0.000015524496,0.0000071311515,0.000094148316,0.00023896324],"study_design_scores_gemma":[0.000015057833,0.000050264196,0.9991104,0.000016593467,0.00008200575,0.00008877655,0.000190928,0.0002813277,0.000021251844,0.0000121679395,0.00012571474,0.000005522398],"about_ca_topic_score_codex":0.029455537,"about_ca_topic_score_gemma":0.023736501,"teacher_disagreement_score":0.029455537,"about_ca_system_score_codex":0.0009251601,"about_ca_system_score_gemma":0.0006486851,"threshold_uncertainty_score":0.05856818},"labels":[],"label_agreement":null},{"id":"W4220790895","doi":"10.1111/dom.14691","title":"Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from <scp>VERTIS CV</scp>","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck KGaA","keywords":"Medicine; Hazard ratio; Metformin; Mace; Internal medicine; Myocardial infarction; Diabetes mellitus; Type 2 diabetes; Confidence interval; Placebo; Stroke (engine); Insulin; Endocrinology; Percutaneous coronary intervention","score_opus":0.010409421984768243,"score_gpt":0.2339835748773109,"score_spread":0.22357415289254265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220790895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953827,0.0022243734,0.00017875957,0.00006046733,0.000031332394,0.0001312993,0.0011252243,0.000009678307,0.0008561566],"genre_scores_gemma":[0.99660826,0.00039132498,0.00018021939,0.000116508956,0.000068420464,0.00009640783,0.0022426783,0.0000075939906,0.0002885393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687046,0.0013784014,0.00031969164,0.00065170147,0.00051599107,0.00026384887],"domain_scores_gemma":[0.9957558,0.0014951705,0.0012577937,0.00060835347,0.00029701443,0.00058592943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028604427,0.00081506616,0.0018863147,0.0006232989,0.00032866915,0.0009710357,0.0005324805,0.0008258444,0.0032894507],"category_scores_gemma":[0.0037903877,0.0003816072,0.0031656162,0.0010211549,0.00057673926,0.000382695,0.00074376777,0.0010372654,0.00025808957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38274974,0.0012036362,0.55827844,0.0012130712,0.018431464,0.0004909847,0.00018689116,0.0008496932,0.0061611217,0.00029473062,0.0022636596,0.02787662],"study_design_scores_gemma":[0.04584154,0.014918651,0.9286218,0.00014171352,0.0059466907,0.0006211631,0.00010333237,0.0014375224,0.0006823274,0.00026145845,0.0013585868,0.00006516208],"about_ca_topic_score_codex":0.0027375575,"about_ca_topic_score_gemma":0.0040405598,"teacher_disagreement_score":0.0032894507,"about_ca_system_score_codex":0.00062954135,"about_ca_system_score_gemma":0.0007681641,"threshold_uncertainty_score":0.015127659},"labels":[],"label_agreement":null},{"id":"W4220949041","doi":"10.1111/dom.14700","title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Semaglutide; Liraglutide; Mace; Medicine; Hazard ratio; Type 2 diabetes; Internal medicine; Myocardial infarction; Placebo; Empagliflozin; Diabetes mellitus; Confidence interval; Gastroenterology; Surgery; Endocrinology; Percutaneous coronary intervention","score_opus":0.006453551494449718,"score_gpt":0.1985013044114067,"score_spread":0.192047752916957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220949041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9471563,0.04943517,0.00023779685,0.00044456223,0.00011938274,0.000084263746,0.00044753333,0.000025895339,0.0020490468],"genre_scores_gemma":[0.99115855,0.006579523,0.0004786472,0.0005521435,0.00021557372,0.00009551988,0.00056609063,0.0000031021038,0.00035092363],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.999332,0.00035206616,0.000073864394,0.00009427518,0.00010519513,0.00004256295],"domain_scores_gemma":[0.99889046,0.00041048654,0.00039139512,0.00004104374,0.00008297273,0.00018365501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017767864,0.00042190516,0.0014411784,0.00023599043,0.00015408853,0.0005972181,0.0002534493,0.0006604327,0.00095351576],"category_scores_gemma":[0.0015483762,0.0001681662,0.0010393838,0.00038884245,0.0002374919,0.00030961,0.00021825852,0.00076643337,0.00014567617],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39532894,0.0039393376,0.35832867,0.0040123495,0.010706111,0.000341512,0.00012649134,0.0014028777,0.007606111,0.00033955177,0.003167382,0.2147007],"study_design_scores_gemma":[0.08473081,0.16086921,0.7237588,0.0009062311,0.014064574,0.00152944,0.00022830519,0.0037969635,0.00336852,0.0009322476,0.005723082,0.00009187587],"about_ca_topic_score_codex":0.00044623198,"about_ca_topic_score_gemma":0.0010864991,"teacher_disagreement_score":0.0017767864,"about_ca_system_score_codex":0.0002598213,"about_ca_system_score_gemma":0.0003256773,"threshold_uncertainty_score":0.009396672},"labels":[],"label_agreement":null},{"id":"W4224218205","doi":"10.1111/dom.14725","title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":921,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; York University","funders":"Novo Nordisk; National Institute for Health and Care Research","keywords":"Semaglutide; Medicine; Placebo; Weight loss; Body mass index; Randomized controlled trial; Internal medicine; Physical therapy; Diabetes mellitus; Obesity; Type 2 diabetes; Endocrinology","score_opus":0.005126095142822623,"score_gpt":0.20570540382778232,"score_spread":0.2005793086849597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224218205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932934,0.0015131165,0.00023129275,0.00024094926,0.00009041114,0.0018021459,0.0011827139,0.00003494017,0.0016109876],"genre_scores_gemma":[0.9881761,0.001290243,0.00095376646,0.000531616,0.0001588953,0.003637349,0.0020590562,0.000020726233,0.003172277],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99950683,0.0002914852,0.00003526041,0.000050873383,0.000051614483,0.00006390305],"domain_scores_gemma":[0.9989936,0.00026767713,0.00030655696,0.00010117182,0.00012822438,0.00020280738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001903503,0.0007605025,0.0011646559,0.0001760102,0.00023986587,0.000560077,0.00040157195,0.0007464525,0.0051612435],"category_scores_gemma":[0.0018395967,0.00022440226,0.001203302,0.00017647586,0.00027624637,0.00038395938,0.0004086839,0.0015175324,0.00056138856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89935726,0.010031279,0.009647419,0.0021471537,0.0017912798,0.00018261347,0.0002108779,0.00047592798,0.008643096,0.00015293312,0.00348625,0.06387395],"study_design_scores_gemma":[0.6255878,0.29408115,0.06779289,0.00037213482,0.0026881057,0.0003474614,0.00014609437,0.00078723335,0.0027324483,0.00035761684,0.0050615785,0.000045479537],"about_ca_topic_score_codex":0.0005267351,"about_ca_topic_score_gemma":0.0016934066,"teacher_disagreement_score":0.0051612435,"about_ca_system_score_codex":0.000280505,"about_ca_system_score_gemma":0.00091286376,"threshold_uncertainty_score":0.017266095},"labels":[],"label_agreement":null},{"id":"W4225003979","doi":"10.1111/dom.14729","title":"Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; AstraZeneca; Juvenile Diabetes Research Foundation United States of America; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Boettcher Foundation; American Heart Association","keywords":"Dapagliflozin; Medicine; Kidney disease; Internal medicine; Endocrinology; Renal function; Albuminuria; Urology; Creatinine; Diabetes mellitus; Aldosterone; Excretion; Type 2 diabetes","score_opus":0.0035316257272561143,"score_gpt":0.18532639046903926,"score_spread":0.18179476474178313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225003979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992741,0.0003538246,0.000067759036,0.000022731765,0.000012747181,0.00003861254,0.000076705444,0.0000035805544,0.00014993454],"genre_scores_gemma":[0.99920255,0.00015083965,0.00020410647,0.00006166754,0.000031818745,0.00004510377,0.00020304567,0.000001499201,0.00009949633],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99956113,0.00019518599,0.000042910582,0.00009498645,0.00006071079,0.000045001267],"domain_scores_gemma":[0.9991136,0.0002550124,0.00015355348,0.000095765805,0.000052694184,0.00032942565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010264477,0.00048756704,0.0014931052,0.0001601257,0.00020565552,0.00040767685,0.0002153866,0.0004276021,0.0009798225],"category_scores_gemma":[0.0010463359,0.0002280707,0.0009957582,0.00019123373,0.0004051578,0.00034673142,0.00025928256,0.000894391,0.0001125332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7880848,0.017154329,0.08807344,0.0004167592,0.0024098584,0.00020225206,0.0002679705,0.0008960236,0.03894663,0.00007386754,0.0005966764,0.0628775],"study_design_scores_gemma":[0.1381642,0.33768016,0.5095438,0.000031658295,0.0021932975,0.00041840455,0.00015916933,0.002481316,0.0078297565,0.00012447937,0.0013045941,0.00006915223],"about_ca_topic_score_codex":0.00064344576,"about_ca_topic_score_gemma":0.0008961734,"teacher_disagreement_score":0.0014931052,"about_ca_system_score_codex":0.00030231668,"about_ca_system_score_gemma":0.00032699335,"threshold_uncertainty_score":0.0054284334},"labels":[],"label_agreement":null},{"id":"W4226335524","doi":"10.1111/dom.14703","title":"Healthcare costs and hospitalizations in <scp>US</scp> patients with type 2 diabetes and cardiovascular disease: A retrospective database study ( <scp>OFFSET</scp> )","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk; International Business Machines Corporation","keywords":"Medicine; Disease; Type 2 diabetes; Health care; Offset (computer science); Retrospective cohort study; Diabetes mellitus; Medical emergency; Emergency medicine; Internal medicine; Endocrinology","score_opus":0.006169460079034918,"score_gpt":0.21041075406453347,"score_spread":0.20424129398549856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226335524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919511,0.0005104594,0.00007918907,0.00007661636,0.000006932119,0.000029233279,0.006994636,0.0000038038672,0.00034799756],"genre_scores_gemma":[0.99237615,0.00034122998,0.00012299235,0.00010900126,0.00002385553,0.000053967357,0.0068681296,0.0000033966855,0.000101287565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877363,0.00026782247,0.0002800328,0.0002918937,0.00023485518,0.00015173618],"domain_scores_gemma":[0.99642414,0.00038475182,0.0023617742,0.00021792603,0.00028201187,0.0003294092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008675213,0.00033239886,0.00055935525,0.0017200052,0.00043148713,0.0010636876,0.00057092484,0.000649967,0.0014282145],"category_scores_gemma":[0.0029774522,0.00044376065,0.0011700925,0.00391028,0.00025329713,0.000756824,0.0008051244,0.0007875399,0.00020831008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019732618,0.000026707334,0.9984969,0.00003122365,0.0002372729,0.000047862908,0.000028393555,0.000059165402,0.000033767803,0.000018862544,0.00030697344,0.00051549054],"study_design_scores_gemma":[0.000035746278,0.00008767971,0.9984837,0.000026522355,0.00013372747,0.00032739856,0.00017352044,0.00032923714,0.0000408854,0.00001674072,0.00033820086,0.0000067095093],"about_ca_topic_score_codex":0.025004024,"about_ca_topic_score_gemma":0.025381576,"teacher_disagreement_score":0.025004024,"about_ca_system_score_codex":0.0011012973,"about_ca_system_score_gemma":0.0008159139,"threshold_uncertainty_score":0.04971695},"labels":[],"label_agreement":null},{"id":"W4280488682","doi":"10.1111/dom.14775","title":"Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Semaglutide; Type 2 diabetes; Internal medicine; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.01808116998617759,"score_gpt":0.24334209779018834,"score_spread":0.22526092780401075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765082,0.013106392,0.0021860022,0.00035571188,0.00089039473,0.0015600461,0.0018923974,0.00008744584,0.0034133492],"genre_scores_gemma":[0.9923481,0.0017946269,0.0024309533,0.00029088501,0.00021589358,0.0012531335,0.0007286016,0.0000167942,0.00092099747],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9927498,0.005180238,0.00061013794,0.0005816793,0.00061283703,0.00026528822],"domain_scores_gemma":[0.99478394,0.0028941177,0.0013833581,0.00038756392,0.00027017258,0.00028097254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053735464,0.0018480996,0.004416535,0.0007374658,0.00028483008,0.0012349825,0.0010585317,0.001625884,0.005314136],"category_scores_gemma":[0.008806729,0.0007971358,0.0072799325,0.000574084,0.00066798157,0.0012199937,0.00078912266,0.0026956403,0.00041130884],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94520754,0.0016017926,0.004444329,0.002131734,0.028203834,0.00004218377,0.00008921316,0.00092391064,0.0011005607,0.0002332022,0.00040294416,0.015618813],"study_design_scores_gemma":[0.56968516,0.29877573,0.046055775,0.00050821254,0.070969164,0.00026668422,0.00023934332,0.006191172,0.0025797302,0.0012518594,0.0032841142,0.00019303043],"about_ca_topic_score_codex":0.0009960571,"about_ca_topic_score_gemma":0.0018922016,"teacher_disagreement_score":0.0053735464,"about_ca_system_score_codex":0.0007534002,"about_ca_system_score_gemma":0.0006914048,"threshold_uncertainty_score":0.028418422},"labels":[],"label_agreement":null},{"id":"W4280523671","doi":"10.1111/dom.14760","title":"Efficacy and safety outcomes of dulaglutide by baseline <scp>HbA1c</scp> : A post hoc analysis of the <scp>REWIND</scp> trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Post-hoc analysis; Baseline (sea); Subgroup analysis; Body mass index; Internal medicine; Proportional hazards model; Placebo; Diabetes mellitus; Type 2 diabetes; Liraglutide; Confidence interval; Endocrinology","score_opus":0.00729499682094312,"score_gpt":0.2230150266327257,"score_spread":0.2157200298117826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280523671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894978,0.0056957435,0.0004190686,0.00025099728,0.00020375756,0.0009276377,0.0015437652,0.000033246302,0.0014281599],"genre_scores_gemma":[0.9927664,0.0013240936,0.0006414134,0.00026305724,0.00021567647,0.00092479214,0.0019576936,0.000022885179,0.0018840174],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99897206,0.00047533045,0.00009381179,0.00019063668,0.00010775132,0.00016034505],"domain_scores_gemma":[0.9984554,0.0004953946,0.0005066548,0.00017342684,0.00014356845,0.00022551017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026772665,0.0011614652,0.0032891505,0.00019354376,0.0002458943,0.0009905268,0.00060187955,0.0007688591,0.0035771537],"category_scores_gemma":[0.0019701219,0.00032302787,0.004728616,0.00021108321,0.00044652727,0.00069237046,0.0004227528,0.0015767127,0.0004224928],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9709283,0.0008663094,0.004928441,0.000908983,0.00756954,0.000062110834,0.000041902556,0.0003107509,0.002555675,0.00008257813,0.0007953357,0.010950128],"study_design_scores_gemma":[0.72571224,0.14911896,0.086271934,0.0004116771,0.028550306,0.00022931142,0.00013990948,0.0015460176,0.004349129,0.00049094984,0.0030804228,0.00009914201],"about_ca_topic_score_codex":0.0009562411,"about_ca_topic_score_gemma":0.0023851662,"teacher_disagreement_score":0.0035771537,"about_ca_system_score_codex":0.0005430505,"about_ca_system_score_gemma":0.0008922755,"threshold_uncertainty_score":0.014158905},"labels":[],"label_agreement":null},{"id":"W4281295175","doi":"10.1111/dom.14769","title":"Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute; Merck; National Institutes of Health; Pfizer","keywords":"Medicine; Internal medicine; Diabetes mellitus; Microalbuminuria; Glycated hemoglobin; Kidney disease; Type 2 Diabetes Mellitus; Renal function; Type 2 diabetes; Endocrinology","score_opus":0.0029302933040736517,"score_gpt":0.18838291019564649,"score_spread":0.18545261689157283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281295175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324787,0.0046485947,0.0003205558,0.0004907231,0.00003921915,0.000039237108,0.0004333638,0.00001038474,0.00077009073],"genre_scores_gemma":[0.99823654,0.0008257585,0.0002584008,0.0001110403,0.000051187984,0.000040643492,0.00026288364,0.00000175915,0.00021165822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988617,0.00060898764,0.00008271318,0.00016241039,0.00015194333,0.00013222104],"domain_scores_gemma":[0.9967264,0.0014220487,0.0012247314,0.00017710791,0.00015462085,0.00029504238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032239808,0.0005890606,0.0009486597,0.00040734335,0.00027613502,0.0012875256,0.0003588926,0.0005197461,0.0021090014],"category_scores_gemma":[0.0062946663,0.00021441618,0.0015877344,0.00059412164,0.00019341556,0.00046306392,0.00067611027,0.0011529976,0.0001258033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051268227,0.00041018077,0.98108345,0.00014578711,0.0014147053,0.000118500466,0.0001279075,0.00035033197,0.0004753477,0.00008951626,0.00017570765,0.010481748],"study_design_scores_gemma":[0.0003140967,0.0008623778,0.99531,0.000047573798,0.0013532089,0.00010027297,0.00010297414,0.0010092781,0.00036484865,0.00020912717,0.00031290468,0.000013360869],"about_ca_topic_score_codex":0.0017695861,"about_ca_topic_score_gemma":0.0015232685,"teacher_disagreement_score":0.0032239808,"about_ca_system_score_codex":0.0003655543,"about_ca_system_score_gemma":0.000754369,"threshold_uncertainty_score":0.017050266},"labels":[],"label_agreement":null},{"id":"W4281611212","doi":"10.1111/dom.14787","title":"Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to <scp>iGlarLixi</scp> in the <scp>LixiLan ONE CAN</scp> randomized trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada); McGill University Health Centre; Western University; St. Michael's Hospital; University of Toronto; Brampton Civic Hospital; McMaster University","funders":"Sanofi","keywords":"Basal insulin; Randomized controlled trial; Type 2 diabetes; Basal (medicine); Insulin; Algorithm; Computer science; Medicine; Diabetes mellitus; Gerontology; Internal medicine; Endocrinology","score_opus":0.020393817961443548,"score_gpt":0.24649940607671617,"score_spread":0.22610558811527262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281611212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99059945,0.002587368,0.0008464746,0.0005188538,0.0005977187,0.002720869,0.00029794726,0.00010897278,0.0017223592],"genre_scores_gemma":[0.98906565,0.0011237091,0.0033316463,0.0010802,0.00045406978,0.0035090756,0.00041221105,0.000019573796,0.001003817],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996563,0.0022542444,0.00027877127,0.00042626,0.00028480875,0.00019295563],"domain_scores_gemma":[0.99665904,0.0014547585,0.00083836494,0.0002968493,0.00020194924,0.00054906285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044776527,0.0010247256,0.0033253883,0.0004644567,0.0003996691,0.001044365,0.0010121255,0.0020387804,0.0048935027],"category_scores_gemma":[0.0059540654,0.00066544826,0.0027761145,0.00043067118,0.0006984603,0.0009972465,0.0005340053,0.0026542332,0.0004692625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.969402,0.005866367,0.0011457,0.00042312345,0.0014469385,0.000012363976,0.000044741126,0.0005535416,0.0004199436,0.00006136055,0.00034997202,0.020273829],"study_design_scores_gemma":[0.93088526,0.06336152,0.003172331,0.000063904336,0.00093670515,0.000016665863,0.000018950026,0.0010336427,0.00014469968,0.00014472162,0.00020513141,0.000016491176],"about_ca_topic_score_codex":0.0024371801,"about_ca_topic_score_gemma":0.0028353017,"teacher_disagreement_score":0.0048935027,"about_ca_system_score_codex":0.001006812,"about_ca_system_score_gemma":0.0015578831,"threshold_uncertainty_score":0.023680389},"labels":[],"label_agreement":null},{"id":"W4281734667","doi":"10.1111/dom.14792","title":"<scp>Long‐term</scp> clinical outcomes of oral antidiabetic drugs as <scp>fixed‐dose</scp> combinations: A nationwide retrospective cohort study","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Health Insurance Service; Ministry of Food and Drug Safety","keywords":"Medicine; Discontinuation; Hazard ratio; Internal medicine; Propensity score matching; Retrospective cohort study; Stroke (engine); Myocardial infarction; Proportional hazards model; Cohort; Confidence interval; Pill; Type 2 diabetes; Diabetes mellitus; Fixed-dose combination; Pharmacology","score_opus":0.022716543079221187,"score_gpt":0.3172238390351476,"score_spread":0.29450729595592645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281734667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99785894,0.0002497407,0.00015475668,0.000034199875,0.000006710583,0.000024257497,0.001501416,0.0000033518738,0.00016667777],"genre_scores_gemma":[0.99795544,0.00014337728,0.00020600305,0.0000551948,0.000010198742,0.000027783137,0.0014984912,0.0000025511886,0.00010088641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989507,0.00019882063,0.00019607112,0.0003749036,0.000173405,0.000106071144],"domain_scores_gemma":[0.9973502,0.00015679705,0.0015972019,0.00042305535,0.00025527508,0.00021746515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011025071,0.00030779,0.00037981156,0.0006679651,0.00057509745,0.00076640456,0.00049928133,0.0004174083,0.00083576766],"category_scores_gemma":[0.0020978455,0.00049368804,0.0007712814,0.0018530912,0.00024356517,0.0004958308,0.00044863127,0.00063350116,0.00023250697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075583775,0.000021546632,0.99893993,0.0000106712205,0.00014386913,0.00005650084,0.000022490798,0.000021853824,0.00008239599,0.000013255115,0.000109902765,0.00050191185],"study_design_scores_gemma":[0.000024916671,0.000099545294,0.9984775,0.000011269008,0.0001237914,0.0004407558,0.00009588993,0.00031192525,0.000059080638,0.000021910806,0.0003266926,0.0000066355137],"about_ca_topic_score_codex":0.010420413,"about_ca_topic_score_gemma":0.0128729595,"teacher_disagreement_score":0.010420413,"about_ca_system_score_codex":0.00052498275,"about_ca_system_score_gemma":0.0007200667,"threshold_uncertainty_score":0.020719528},"labels":[],"label_agreement":null},{"id":"W4281817250","doi":"10.1111/dom.14794","title":"In vivo and in vitro characterization of <scp>GL0034</scp> , a novel long‐acting <scp>glucagon‐like peptide</scp> ‐1 receptor agonist","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Medical Research Council; European Commission; Engineering and Physical Sciences Research Council; European Foundation for the Study of Diabetes; Innovative Medicines Initiative; Imperial College London; Wellcome Trust; Steno Diabetes Center Copenhagen; National Institute for Health and Care Research; Society for Endocrinology; Medical Research Council Canada; Diabetes UK; Juvenile Diabetes Research Foundation International; British Society for Neuroendocrinology; Horizon 2020 Framework Programme; Academy of Medical Sciences","keywords":"Agonist; Medicine; In vitro; In vivo; Receptor; Pharmacology; Internal medicine; Biochemistry; Biology; Biotechnology","score_opus":0.009129238576364142,"score_gpt":0.21480356351233348,"score_spread":0.20567432493596935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281817250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926784,0.0018140603,0.0032076195,0.0001412578,0.000017521208,0.000049046183,0.00072626624,0.00007535343,0.0012905096],"genre_scores_gemma":[0.98694116,0.002029852,0.005123812,0.00015152972,0.000024629748,0.000093967334,0.0028297578,0.00004439312,0.0027609372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992526,0.000020126921,0.0000050605327,0.00001028931,0.000021701315,0.000017670878],"domain_scores_gemma":[0.999938,0.000016392285,0.000017076372,0.000006116016,0.000008676197,0.000013763294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017843916,0.00037200007,0.00018940671,0.00012716811,0.000104611296,0.00017799274,0.0001988408,0.0002446157,0.0013004285],"category_scores_gemma":[0.00012486929,0.00007762118,0.00022331861,0.00011839252,0.00015421656,0.00014109012,0.000064754095,0.00040685167,0.0005977523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024168486,0.000052269865,0.0000897508,0.000035417717,0.0000039814654,0.000046314453,0.000005234127,0.000080281876,0.9982071,0.0000210135,0.000058886344,0.001158112],"study_design_scores_gemma":[0.000100796555,0.0022539266,0.0036614144,0.000005086534,0.000026232885,0.0008043681,0.000019854831,0.00074180105,0.98987925,0.000027289698,0.0024733753,0.000006626516],"about_ca_topic_score_codex":0.0006635474,"about_ca_topic_score_gemma":0.00067164004,"teacher_disagreement_score":0.0013004285,"about_ca_system_score_codex":0.0002889319,"about_ca_system_score_gemma":0.00021029594,"threshold_uncertainty_score":0.004350364},"labels":[],"label_agreement":null},{"id":"W4283260230","doi":"10.1111/dom.14802","title":"The association of <scp>long‐acting</scp> insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A <scp>population‐based</scp> cohort study","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Mace; Medicine; Insulin; Hazard ratio; Type 2 diabetes; Internal medicine; Diabetes mellitus; NPH insulin; Myocardial infarction; Population; Endocrinology; Protamine; Proportional hazards model; Cohort; Insulin glargine; Confidence interval; Percutaneous coronary intervention","score_opus":0.01259803569458863,"score_gpt":0.22803143163550596,"score_spread":0.21543339594091732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283260230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993161,0.00014855637,0.00005254436,0.000023199904,0.000004793734,0.000006519982,0.0003425841,0.0000015659241,0.00010410494],"genre_scores_gemma":[0.99926,0.00010479325,0.00007134499,0.000024999701,0.000012933053,0.0000074677796,0.0004130472,0.0000016718818,0.0001037346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993224,0.00019107727,0.000079395606,0.00019184012,0.00013862496,0.00007666294],"domain_scores_gemma":[0.99760854,0.00040326436,0.0011824358,0.00028996653,0.00017863195,0.0003371221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010731473,0.00028014687,0.00039866584,0.00048057106,0.00029453196,0.0009072255,0.00043411044,0.00053830957,0.0009665438],"category_scores_gemma":[0.0028272362,0.00038160026,0.00073651347,0.0007840534,0.00024382517,0.00043104496,0.00036109626,0.000863097,0.00015291538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007112164,0.000046845074,0.99795985,0.000010544471,0.00026081182,0.0000671952,0.00002489829,0.000035814377,0.00022163856,0.000008292377,0.00005914294,0.00059373345],"study_design_scores_gemma":[0.0000511071,0.00026610898,0.9987915,0.000004347129,0.00012044127,0.00026374465,0.000036740606,0.0002823607,0.000060657974,0.000012243266,0.00010627091,0.0000044046005],"about_ca_topic_score_codex":0.0046066674,"about_ca_topic_score_gemma":0.0040613045,"teacher_disagreement_score":0.0046066674,"about_ca_system_score_codex":0.0003309437,"about_ca_system_score_gemma":0.000312985,"threshold_uncertainty_score":0.009159684},"labels":[],"label_agreement":null},{"id":"W4285589669","doi":"10.1111/dom.14817","title":"<scp>TOTUM</scp> ‐63, a plant‐based polyphenol‐rich extract, improves glycaemic control in subjects with prediabetes or early stage newly‐diagnosed type 2 diabetes in a randomized, double‐blind, placebo‐controlled trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Phytochemicals and Antioxidant Activities","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prediabetes; Postprandial; Placebo; Glycemic; Internal medicine; Overweight; Tolerability; Type 2 diabetes; Body mass index; Waist; Gastroenterology; Diabetes mellitus; Randomized controlled trial; Endocrinology; Insulin; Adverse effect","score_opus":0.011754197695622087,"score_gpt":0.23174321875289136,"score_spread":0.21998902105726928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285589669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924735,0.0046338094,0.00027061268,0.00018180505,0.00021553203,0.0011748302,0.00039274347,0.000049801136,0.0006072671],"genre_scores_gemma":[0.9907197,0.00442347,0.00086555723,0.00051843346,0.00034728524,0.0012968719,0.00058736576,0.000011185238,0.0012300378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997707,0.00010840138,0.000024993691,0.000040033116,0.000027843282,0.000028009896],"domain_scores_gemma":[0.9996501,0.00007673139,0.00010229149,0.000023341592,0.00003094881,0.000116582596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008181464,0.0008413999,0.0016920441,0.00030332312,0.00037046394,0.00044566125,0.000420796,0.00104523,0.004128487],"category_scores_gemma":[0.00053821487,0.00037079447,0.0010891545,0.00031890642,0.0004982732,0.00028691234,0.00026174798,0.0011547392,0.0003537285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9667395,0.005676207,0.0009281171,0.001036797,0.0009786444,0.000036670157,0.000022888873,0.00007891078,0.009833146,0.000027253784,0.000296083,0.014345904],"study_design_scores_gemma":[0.8331889,0.15524624,0.0076202517,0.00008645468,0.0012525399,0.000057510337,0.00002171493,0.00021986337,0.0017522795,0.000035928693,0.0005066239,0.0000116916235],"about_ca_topic_score_codex":0.00054765807,"about_ca_topic_score_gemma":0.0011994295,"teacher_disagreement_score":0.004128487,"about_ca_system_score_codex":0.00021766436,"about_ca_system_score_gemma":0.0006101714,"threshold_uncertainty_score":0.013811171},"labels":[],"label_agreement":null},{"id":"W4287307425","doi":"10.1111/dom.14823","title":"The <scp>Real‐World</scp> Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes ( <scp>TROPHIES</scp> ): Patient disposition, clinical characteristics and treatment persistence at 12 months","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Medicine; Liraglutide; Dulaglutide; Observational study; Type 2 diabetes; Persistence (discontinuity); Internal medicine; Diabetes mellitus; Endocrinology","score_opus":0.020050611484245643,"score_gpt":0.24656024290133,"score_spread":0.22650963141708436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287307425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98789424,0.0002986065,0.00019055308,0.000105585146,0.000015981996,0.000096277116,0.010851611,0.000007946302,0.00053922884],"genre_scores_gemma":[0.97690445,0.0002736798,0.000761206,0.00023901525,0.00007558209,0.00025231516,0.020807972,0.000011122988,0.0006746244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883336,0.0004747458,0.00012615407,0.00029335063,0.00017908853,0.000093332266],"domain_scores_gemma":[0.9960306,0.00046687725,0.0019504705,0.00051104906,0.00028616286,0.0007547751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017008982,0.0005670716,0.00061873754,0.00060816464,0.00045270644,0.00096253253,0.00061216415,0.0007349335,0.0012453544],"category_scores_gemma":[0.0024493309,0.00049873244,0.0010218055,0.001439228,0.00041971853,0.00054837915,0.00088128657,0.0010155941,0.00036477103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028677958,0.0001887382,0.9926778,0.000068441506,0.0008081888,0.000108361724,0.00008888186,0.00013567427,0.00035047947,0.000039686187,0.0011119932,0.0015538497],"study_design_scores_gemma":[0.0006197042,0.00077651604,0.9965199,0.000030921863,0.00028838773,0.00030028677,0.00010011759,0.00030579264,0.0000970821,0.00002351857,0.00092369487,0.000014046956],"about_ca_topic_score_codex":0.011426939,"about_ca_topic_score_gemma":0.013906041,"teacher_disagreement_score":0.011426939,"about_ca_system_score_codex":0.0007033428,"about_ca_system_score_gemma":0.0006850688,"threshold_uncertainty_score":0.022720814},"labels":[],"label_agreement":null},{"id":"W4292332601","doi":"10.1111/dom.14844","title":"<scp>iGlarLixi</scp> versus basal plus <scp>Rapid‐Acting</scp> insulin in adults with type 2 diabetes advancing from basal insulin therapy: The <scp>SoliSimplify Real‐World</scp> study","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Medicine; Type 2 diabetes; Basal insulin; Confidence interval; Regimen; Observational study; Propensity score matching; Odds ratio; Basal (medicine); Internal medicine; Insulin; Diabetes mellitus; Endocrinology","score_opus":0.016820505435864087,"score_gpt":0.2597489733641618,"score_spread":0.24292846792829773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292332601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546164,0.0022592559,0.00030189124,0.00026499023,0.00011338187,0.0005497384,0.00032457808,0.000010966896,0.0007136453],"genre_scores_gemma":[0.99690187,0.000918455,0.0005957125,0.00035772246,0.00015337714,0.00038340501,0.00039836517,0.0000038610374,0.0002872623],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.996687,0.002304055,0.0002576931,0.00035332076,0.00023447274,0.00016354526],"domain_scores_gemma":[0.99670476,0.0010940804,0.0013870383,0.00025371238,0.000104750914,0.00045554803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005526211,0.00073050684,0.0013177966,0.0003009447,0.00025294357,0.0009843985,0.00063735887,0.0009237042,0.0022504593],"category_scores_gemma":[0.0049180933,0.00036767032,0.0038208028,0.0004173482,0.0006523631,0.00074646564,0.00070897886,0.0020870822,0.00029301085],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9288671,0.0064158537,0.027435832,0.00069465395,0.0071884315,0.000048803864,0.00008884382,0.0009295603,0.0007225432,0.00019619043,0.00058048207,0.02683171],"study_design_scores_gemma":[0.4926718,0.38219783,0.102115475,0.0004066329,0.013247731,0.0002557866,0.00019995254,0.0052386494,0.0010525616,0.000609726,0.0019396327,0.000064230524],"about_ca_topic_score_codex":0.0011276965,"about_ca_topic_score_gemma":0.0012767432,"teacher_disagreement_score":0.005526211,"about_ca_system_score_codex":0.00091631286,"about_ca_system_score_gemma":0.0008599513,"threshold_uncertainty_score":0.029225767},"labels":[],"label_agreement":null},{"id":"W4292696070","doi":"10.1111/dom.14825","title":"Hypoglycaemia events with <scp>iGlarLixi</scp> versus premix biphasic insulin aspart 30 ( <scp>BIAsp</scp> 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the <scp>SoliMix</scp> trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Medicine; Internal medicine; Incidence (geometry); Type 2 diabetes; Insulin aspart; Endocrinology; Logistic regression; Diabetes mellitus; Basal (medicine); Insulin; Basal insulin; Mathematics","score_opus":0.013486987864835407,"score_gpt":0.2444401437915788,"score_spread":0.2309531559267434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292696070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97945887,0.017558636,0.0002890737,0.000419311,0.000249266,0.0005350127,0.00036480467,0.000026336545,0.0010987074],"genre_scores_gemma":[0.9922086,0.0049804547,0.0006514851,0.00045957812,0.0001821791,0.0004868937,0.00046862618,0.0000081315975,0.0005540497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99825937,0.0012262082,0.00014459407,0.00015840257,0.00012312252,0.00008827099],"domain_scores_gemma":[0.99846184,0.00073560013,0.000464243,0.00007185343,0.0000662426,0.000200251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003832793,0.000753719,0.0020100705,0.0002954395,0.00016803844,0.0008489228,0.0005188007,0.00076022424,0.0022344454],"category_scores_gemma":[0.0033614151,0.000277609,0.0035827889,0.0004654282,0.00047933814,0.00040928565,0.00033133864,0.0017733807,0.00014669065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9570789,0.0010565288,0.0047159703,0.0030999861,0.0066213803,0.000050727114,0.00006135933,0.00052104174,0.0009290504,0.00014089653,0.0004917086,0.025232427],"study_design_scores_gemma":[0.8363135,0.11790881,0.026410775,0.0009330902,0.013528877,0.00019890619,0.00013080439,0.001847871,0.000927339,0.0005430167,0.0012100053,0.000046975736],"about_ca_topic_score_codex":0.00090104144,"about_ca_topic_score_gemma":0.0018594743,"teacher_disagreement_score":0.003832793,"about_ca_system_score_codex":0.0007250731,"about_ca_system_score_gemma":0.00086093316,"threshold_uncertainty_score":0.02026993},"labels":[],"label_agreement":null},{"id":"W4294397820","doi":"10.1111/dom.14856","title":"All‐cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the <scp>UK</scp>","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"National Institute for Health and Care Research; AstraZeneca","keywords":"Medicine; Type 2 diabetes; Cardiorenal syndrome; Diabetes mellitus; Gerontology; Demography; Environmental health; Internal medicine; Heart failure; Endocrinology","score_opus":0.012604358336796368,"score_gpt":0.22554937734763986,"score_spread":0.21294501901084348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294397820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776334,0.0024905112,0.00013945109,0.00015495194,0.000012961464,0.000021872564,0.018922104,0.000014740895,0.0006099742],"genre_scores_gemma":[0.9811484,0.001495987,0.00026902225,0.00007582072,0.00001257912,0.000023000257,0.01664295,0.000007704246,0.00032448323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990853,0.00009421749,0.000108672255,0.00023804458,0.00026366758,0.00021008764],"domain_scores_gemma":[0.99806434,0.0001448508,0.0004981569,0.00011903165,0.00088934513,0.0002842304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015739519,0.0003791293,0.000586639,0.0028679958,0.00064745656,0.001300652,0.0010352752,0.000587711,0.00072406634],"category_scores_gemma":[0.0025486373,0.0003088494,0.0010559708,0.0074602934,0.00044002515,0.0005342929,0.0007271431,0.00050838396,0.00014016782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018213263,0.000016573902,0.9965676,0.00006230593,0.00026769235,0.000054606033,0.00016869063,0.0001726566,0.000053775748,0.000038053557,0.00052937894,0.001886571],"study_design_scores_gemma":[0.000008334734,0.000013892661,0.9990877,0.000018509128,0.00007348705,0.000032002292,0.00027990108,0.00015374174,0.000012989432,0.0000068186546,0.00030884403,0.0000038511844],"about_ca_topic_score_codex":0.9319954,"about_ca_topic_score_gemma":0.9193793,"teacher_disagreement_score":0.06800461,"about_ca_system_score_codex":0.008018113,"about_ca_system_score_gemma":0.007456566,"threshold_uncertainty_score":0.13681012},"labels":[],"label_agreement":null},{"id":"W4295024043","doi":"10.1111/dom.14867","title":"External validation and extension of the <scp>TIMI</scp> risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the <scp>EXAMINE</scp> trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Acute coronary syndrome; Internal medicine; TIMI; Cardiology; Heart failure; Myocardial infarction; Type 2 diabetes; Creatinine; Framingham Risk Score; Confidence interval; Atrial fibrillation; Diabetes mellitus; Clinical endpoint; Natriuretic peptide; Randomized controlled trial; Thrombolysis; Endocrinology; Disease","score_opus":0.010888144472666407,"score_gpt":0.22904266183587868,"score_spread":0.21815451736321229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295024043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022245,0.0013085458,0.0014552862,0.00030320833,0.00017524385,0.001326416,0.0032151109,0.000028754435,0.001965013],"genre_scores_gemma":[0.98550224,0.0002951023,0.0012036001,0.00035511196,0.00024411306,0.0015959409,0.01029051,0.000044454213,0.00046890517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97273093,0.019992746,0.0017509103,0.0029220437,0.002033899,0.0005695066],"domain_scores_gemma":[0.9689567,0.01210118,0.0074528004,0.007496305,0.0026182132,0.0013746698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.040587906,0.0016321914,0.0017762294,0.0005757613,0.00071992184,0.002352324,0.0014564215,0.001516347,0.001692184],"category_scores_gemma":[0.03704079,0.0006624988,0.0031731036,0.0011709253,0.0016025282,0.0010287635,0.0031709054,0.0016321393,0.0007384852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13701314,0.0016855905,0.8236372,0.000664169,0.014660523,0.00016319386,0.00065257755,0.0018245586,0.0015576517,0.0005360114,0.0040964596,0.013508934],"study_design_scores_gemma":[0.036388136,0.009984467,0.93237865,0.00027162617,0.009292614,0.00031143994,0.00023102308,0.0038150137,0.0007589844,0.00067694037,0.0057878066,0.00010320489],"about_ca_topic_score_codex":0.001158899,"about_ca_topic_score_gemma":0.001794306,"teacher_disagreement_score":0.040587906,"about_ca_system_score_codex":0.000488642,"about_ca_system_score_gemma":0.0010979463,"threshold_uncertainty_score":0.21465188},"labels":[],"label_agreement":null},{"id":"W4295079843","doi":"10.1111/dom.14866","title":"Cross‐sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; National Center for Geriatrics and Gerontology","keywords":"Memory span; Trail Making Test; Montreal Cognitive Assessment; Cognition; Type 2 diabetes; Verbal fluency test; Medicine; Confounding; Cognitive test; Audiology; Effects of sleep deprivation on cognitive performance; Psychology; Diabetes mellitus; Internal medicine; Neuropsychology; Cognitive impairment; Psychiatry; Endocrinology; Working memory","score_opus":0.007217876421667732,"score_gpt":0.24215188303362248,"score_spread":0.23493400661195474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295079843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99875486,0.00048772997,0.000113625996,0.000022600232,0.0000129508735,0.0000062186987,0.0003867995,0.0000043385535,0.00021085383],"genre_scores_gemma":[0.9990376,0.00014662705,0.0001376882,0.000029082687,0.000014906745,0.0000101466685,0.00053332833,0.0000019051175,0.00008877245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993523,0.00017424273,0.00012169301,0.00016623408,0.00012666555,0.00005895531],"domain_scores_gemma":[0.9975255,0.0004721204,0.0011657099,0.00022406231,0.00034991247,0.00026258544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015064914,0.00047453548,0.00047102192,0.0007721695,0.00029069552,0.0007868831,0.00032430136,0.00071255903,0.00064285425],"category_scores_gemma":[0.004036304,0.00031339886,0.0005356641,0.0011025933,0.00015193984,0.0004365549,0.00041302858,0.00066663366,0.0001671243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011065953,0.000025826352,0.999172,0.0000056774693,0.00011234644,0.000014333476,0.000013693281,0.000018887431,0.00007061342,0.000002389915,0.000022726452,0.00043090948],"study_design_scores_gemma":[0.0000037102175,0.00008625235,0.99962366,0.0000025499733,0.000034046272,0.000066286164,0.000026647918,0.000092126604,0.000023108105,0.000005442407,0.00003432754,0.0000017204394],"about_ca_topic_score_codex":0.0033496162,"about_ca_topic_score_gemma":0.004385998,"teacher_disagreement_score":0.0033496162,"about_ca_system_score_codex":0.00019909085,"about_ca_system_score_gemma":0.0001594848,"threshold_uncertainty_score":0.007967174},"labels":[],"label_agreement":null},{"id":"W4295084553","doi":"10.1111/dom.14862","title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the <scp>FIGHT</scp> trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Heart, Lung, and Blood Institute; Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Ejection fraction; Liraglutide; Heart failure; Lightheadedness; Internal medicine; Placebo; Post-hoc analysis; Cardiology; Rate ratio; Hazard ratio; Myocardial infarction; Confidence interval; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.005161291033091831,"score_gpt":0.20780536470486644,"score_spread":0.20264407367177462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295084553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98560995,0.0074961293,0.0009583202,0.0005105962,0.00054101064,0.0013709601,0.0016829448,0.000113080816,0.0017169507],"genre_scores_gemma":[0.9899312,0.0018873536,0.0012791334,0.0004868951,0.00062756013,0.002129872,0.001997902,0.000044305358,0.0016157853],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99749583,0.0016339538,0.00020084927,0.00032192367,0.0001594194,0.00018801133],"domain_scores_gemma":[0.9958276,0.001909493,0.0010819583,0.00045757738,0.00031748932,0.00040597512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004546058,0.0020755474,0.0051344717,0.00031681423,0.0003064487,0.0012053589,0.0006838526,0.0011821622,0.0036174979],"category_scores_gemma":[0.0045717238,0.0004619549,0.005810931,0.00034090888,0.0006471669,0.0007946308,0.00050488353,0.001915694,0.00047014543],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97825956,0.00070920616,0.00290997,0.0012166447,0.008774594,0.0000660242,0.000025299512,0.00030377822,0.0013122461,0.000058568607,0.0007238181,0.0056402553],"study_design_scores_gemma":[0.80398303,0.12601607,0.03304927,0.00019576911,0.030838462,0.00016090833,0.00007676539,0.0017255603,0.0019002635,0.0003105955,0.0016763539,0.000066911605],"about_ca_topic_score_codex":0.0005062587,"about_ca_topic_score_gemma":0.0010798274,"teacher_disagreement_score":0.0051344717,"about_ca_system_score_codex":0.0005175536,"about_ca_system_score_gemma":0.0007344528,"threshold_uncertainty_score":0.02404213},"labels":[],"label_agreement":null},{"id":"W4295419496","doi":"10.1111/dom.14872","title":"Ethnicity and risks of severe <scp>COVID</scp> ‐19 outcomes associated with glucose‐lowering medications: A cohort study","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"NIHR Leicester Biomedical Research Centre; Medical Research Council; University of Oxford; National Institute for Health and Care Research; UK Research and Innovation; Public Health England; Department of Health and Social Care; Cancer Research UK; Wellcome Trust","keywords":"Medicine; Metformin; Pandemic; Diabetes mellitus; Ethnic group; Cohort; Cohort study; Type 2 diabetes; Population; Internal medicine; Observational study; Insulin; Coronavirus disease 2019 (COVID-19); Disease; Endocrinology; Environmental health; Infectious disease (medical specialty)","score_opus":0.023701621004731468,"score_gpt":0.2798515955079793,"score_spread":0.25614997450324783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295419496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958366,0.00041119862,0.00021772941,0.0000789179,0.00002539372,0.00010601007,0.002699914,0.000008564313,0.00061566336],"genre_scores_gemma":[0.9965636,0.00035267347,0.00035094138,0.00015350258,0.0000581618,0.000120503595,0.0018645024,0.0000122206275,0.00052374887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890256,0.00023188702,0.00012885353,0.0003340654,0.0001674481,0.00023517755],"domain_scores_gemma":[0.9974043,0.00020750072,0.0009264819,0.00054960174,0.00029235877,0.0006197286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013189669,0.000672094,0.00058555696,0.00087202183,0.0011859044,0.0012176544,0.00096689013,0.0011460982,0.0032392624],"category_scores_gemma":[0.0024380856,0.0008935614,0.0016883968,0.0014813,0.00047111395,0.00092015974,0.0015570319,0.0014966391,0.0008456515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009881525,0.00022410149,0.9957694,0.000032723376,0.00061567815,0.00017035952,0.00020375504,0.000042168504,0.00025671933,0.000058662426,0.0005379849,0.0011003665],"study_design_scores_gemma":[0.000102080296,0.00045369432,0.9975957,0.000028539971,0.0001933456,0.00043007094,0.0003014725,0.00025251048,0.000052657597,0.00004855308,0.00052030495,0.000021019103],"about_ca_topic_score_codex":0.021824138,"about_ca_topic_score_gemma":0.019198118,"teacher_disagreement_score":0.021824138,"about_ca_system_score_codex":0.0006489992,"about_ca_system_score_gemma":0.00067769684,"threshold_uncertainty_score":0.043394268},"labels":[],"label_agreement":null},{"id":"W4295907355","doi":"10.1111/dom.14871","title":"Rationale and design of the phase 3a development programme ( <scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Mount Sinai Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Diabetes mellitus; Insulin; Phase (matter); Medicine; Internal medicine; Endocrinology; Chemistry","score_opus":0.07775272463722106,"score_gpt":0.30364494058981084,"score_spread":0.2258922159525898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295907355","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005471421,0.010214129,0.029602384,0.008044577,0.0037012626,0.92362523,0.0054451935,0.00041177782,0.013484099],"genre_scores_gemma":[0.018005708,0.0031628544,0.059982434,0.009587038,0.0008797591,0.90373975,0.0012006226,0.000057569232,0.0033842598],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9299652,0.05759431,0.003280382,0.0028998621,0.005015871,0.0012443999],"domain_scores_gemma":[0.96805453,0.014898982,0.005394693,0.002996294,0.0056938464,0.0029616232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08567338,0.0034674713,0.0031854438,0.0018745502,0.0017759841,0.0036618742,0.004197894,0.0065009487,0.017672936],"category_scores_gemma":[0.06180334,0.0021632966,0.0038892175,0.0018574365,0.0038753927,0.0026866794,0.002050041,0.007508122,0.0075029926],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33813825,0.008371144,0.006070159,0.07607487,0.003492862,0.00097273116,0.0015060052,0.0068842038,0.012232431,0.07497727,0.13089426,0.3403858],"study_design_scores_gemma":[0.33642307,0.063583046,0.010487945,0.027433923,0.00521674,0.0008281742,0.00043993985,0.0066027483,0.007351256,0.035328887,0.50565135,0.0006529753],"about_ca_topic_score_codex":0.0011081573,"about_ca_topic_score_gemma":0.001925509,"teacher_disagreement_score":0.08567338,"about_ca_system_score_codex":0.002504728,"about_ca_system_score_gemma":0.016203936,"threshold_uncertainty_score":0.45308954},"labels":[],"label_agreement":null},{"id":"W4302292984","doi":"10.1111/dom.14890","title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: <scp>STEP</scp> 1 and 4 exploratory analyses","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Novo Nordisk","keywords":"Medicine; Overweight; Semaglutide; Obesity; Internal medicine; Gerontology; Type 2 diabetes; Endocrinology; Diabetes mellitus; Liraglutide","score_opus":0.014075579139428468,"score_gpt":0.23548500658293253,"score_spread":0.22140942744350406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302292984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897971,0.0045837243,0.0004216029,0.0002763218,0.00004428613,0.0011032273,0.0021620276,0.00007683518,0.0015349535],"genre_scores_gemma":[0.9902474,0.0023623707,0.0018435151,0.0003291507,0.000059333717,0.0014479343,0.002372836,0.000017926572,0.0013193919],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99940014,0.0003055403,0.00007477839,0.0000646805,0.00007786764,0.000076954006],"domain_scores_gemma":[0.99910897,0.00027453792,0.00027255813,0.0000672942,0.0001163071,0.00016024883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020486738,0.00093624846,0.0016453447,0.00034679094,0.00020740456,0.0007982262,0.0003576676,0.00048369318,0.004152874],"category_scores_gemma":[0.0017121817,0.0002639659,0.003553642,0.0003513984,0.00020674769,0.00039606102,0.00046827676,0.0008025886,0.00037034156],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70054257,0.0070606316,0.08491602,0.006886234,0.04546203,0.0003152241,0.00020256857,0.0031707822,0.014532472,0.00024987294,0.004250565,0.13241103],"study_design_scores_gemma":[0.3608112,0.20006597,0.37863436,0.000999473,0.041752193,0.000582916,0.00022685582,0.0037965127,0.007412798,0.00079771725,0.0047998615,0.00012021411],"about_ca_topic_score_codex":0.00074979005,"about_ca_topic_score_gemma":0.0033910996,"teacher_disagreement_score":0.004152874,"about_ca_system_score_codex":0.00037541927,"about_ca_system_score_gemma":0.000989734,"threshold_uncertainty_score":0.01389271},"labels":[],"label_agreement":null},{"id":"W4306166068","doi":"10.1111/dom.14893","title":"Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies","year":2022,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Oxford; National Institute for Health and Care Research","keywords":"Observational study; Meta-analysis; Medicine; Type 2 diabetes; Clinical trial; Systematic review; Randomized controlled trial; Internal medicine; Diabetes mellitus; Heart failure; Clinical Practice; MEDLINE; Intensive care medicine; Physical therapy; Endocrinology","score_opus":0.26656893213608385,"score_gpt":0.4697742417022192,"score_spread":0.20320530956613536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306166068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057012243,0.9920495,0.0006480675,0.00033252587,0.00022670324,0.0004317884,0.00039777887,0.000025021558,0.000187397],"genre_scores_gemma":[0.22578923,0.76524734,0.0037958228,0.0013441425,0.0004728846,0.0022489345,0.0007806235,0.000043101143,0.0002778225],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97802657,0.011853441,0.0063135773,0.0015299856,0.0019280202,0.00034841456],"domain_scores_gemma":[0.9574599,0.032085348,0.0068180603,0.0013381762,0.0019877993,0.00031068476],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.028769746,0.002327654,0.024690276,0.0052894866,0.00052975485,0.0040104915,0.0018825065,0.0027106006,0.002305032],"category_scores_gemma":[0.0638015,0.0016994186,0.039958775,0.00680347,0.000935709,0.0019996597,0.0013981423,0.002089801,0.00022981876],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025759377,0.000024935849,0.0035800834,0.28161138,0.7015624,0.000055179957,0.000069686976,0.00030195076,0.00013642591,0.00010473893,0.0003738362,0.009603501],"study_design_scores_gemma":[0.0011167862,0.00023057176,0.0030209844,0.025317539,0.9689941,0.00005073692,0.000038786657,0.0001591348,0.00008209968,0.00017291457,0.00079676753,0.000019632458],"about_ca_topic_score_codex":0.0047445693,"about_ca_topic_score_gemma":0.009446479,"teacher_disagreement_score":0.9753097,"about_ca_system_score_codex":0.0028193425,"about_ca_system_score_gemma":0.0037761203,"threshold_uncertainty_score":0.15215081},"labels":[],"label_agreement":null},{"id":"W4306167352","doi":"10.1111/dom.14891","title":"Effect of faecal microbial transplant via colonoscopy in patients with severe obesity and insulin resistance: A randomized double‐blind, placebo‐controlled Phase 2 trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Toronto Western Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Toronto General Hospital; Public Health Ontario","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research","keywords":"Insulin resistance; Internal medicine; Medicine; Gastroenterology; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.003674056461495466,"score_gpt":0.23014525126230398,"score_spread":0.22647119480080852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306167352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799069,0.011208029,0.0008167388,0.0009905776,0.0011013085,0.004118774,0.00059069117,0.00012544845,0.0011415019],"genre_scores_gemma":[0.98307335,0.0051143584,0.0016390383,0.0013909235,0.0006634241,0.0054936204,0.0004452838,0.000017312006,0.0021626805],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994849,0.0002611855,0.00003743274,0.00011310717,0.00003442406,0.000068989335],"domain_scores_gemma":[0.9992441,0.00020296313,0.00018509,0.000052499607,0.000054665765,0.00026065356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011383643,0.0014209787,0.003704617,0.0004548398,0.0005316004,0.0012030797,0.00067998806,0.0023691864,0.00663517],"category_scores_gemma":[0.0016047896,0.0006235184,0.0019226448,0.00041661205,0.00091565563,0.0010381453,0.0004676424,0.0023336266,0.0008823247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.983431,0.0051953206,0.0002352242,0.0007314966,0.00062662776,0.000021300599,0.000018428982,0.00009180721,0.0011551612,0.000028103788,0.00019744814,0.008268198],"study_design_scores_gemma":[0.9268502,0.07099594,0.0010998978,0.000056903264,0.00033651607,0.000016167796,0.00001931945,0.00015524763,0.0001524852,0.000055130917,0.0002525102,0.000009610387],"about_ca_topic_score_codex":0.00064007443,"about_ca_topic_score_gemma":0.0011407362,"teacher_disagreement_score":0.00663517,"about_ca_system_score_codex":0.00048342053,"about_ca_system_score_gemma":0.00080415304,"threshold_uncertainty_score":0.02219683},"labels":[],"label_agreement":null},{"id":"W4307773091","doi":"10.1111/dom.14911","title":"Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Nutrition Obesity Research Center, University of Alabama at Birmingham","keywords":"Medicine; Overweight; Weight loss; Body mass index; Type 2 diabetes; Randomized controlled trial; Obesity; Randomization; Diabetes mellitus; Placebo; Internal medicine; Type 1 diabetes; Endocrinology","score_opus":0.01488480251892933,"score_gpt":0.25579600854514506,"score_spread":0.24091120602621574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307773091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96821356,0.007431763,0.0020001298,0.0018803105,0.0011862284,0.013890864,0.0020274979,0.00017154047,0.0031982292],"genre_scores_gemma":[0.94693357,0.0035363738,0.008076396,0.0014189832,0.0006720987,0.034738455,0.0013493529,0.000037921738,0.0032367767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99784553,0.0015661457,0.00013007407,0.00020615055,0.00011766016,0.00013455805],"domain_scores_gemma":[0.99829596,0.000570884,0.0005395843,0.0001289414,0.00012036337,0.00034439232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035649543,0.0010497146,0.0027651084,0.0003594893,0.0003505201,0.00080150634,0.00057837693,0.0010163501,0.0054812627],"category_scores_gemma":[0.00557636,0.00031100016,0.0022732443,0.00038954776,0.0006156446,0.0008398743,0.0006156552,0.0016746002,0.00036785702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9724315,0.0045939353,0.0012874835,0.0009823522,0.001942351,0.000028889763,0.00005616296,0.00037271855,0.00040272382,0.00016642186,0.0010132628,0.016722115],"study_design_scores_gemma":[0.97571224,0.020113198,0.0023319488,0.00008572292,0.0007204244,0.000015721098,0.000017210372,0.000434077,0.000059712263,0.00016243786,0.00033968053,0.0000075950093],"about_ca_topic_score_codex":0.0020778528,"about_ca_topic_score_gemma":0.0040047034,"teacher_disagreement_score":0.0054812627,"about_ca_system_score_codex":0.0006197489,"about_ca_system_score_gemma":0.0014697263,"threshold_uncertainty_score":0.018853486},"labels":[],"label_agreement":null},{"id":"W4309244284","doi":"10.1111/dom.14923","title":"Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from <scp>VERTIS CV</scp> , a randomized trial of the <scp>sodium‐glucose cotransporter‐2</scp> inhibitor ertugliflozin","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"European Association for the Study of Diabetes; Pfizer; European Foundation for the Study of Diabetes; American Heart Association","keywords":"Medicine; Internal medicine; Hazard ratio; Steatosis; Mace; Gastroenterology; Heart failure; Quartile; Placebo; Kidney disease; Type 2 diabetes; Fatty liver; Diabetes mellitus; Confidence interval; Cardiology; Endocrinology; Disease; Pathology; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.011506921221839063,"score_gpt":0.21801209467513286,"score_spread":0.2065051734532938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309244284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932308,0.004312283,0.0002487422,0.00019454172,0.000098282166,0.00031796898,0.0007133989,0.000013828247,0.0008701834],"genre_scores_gemma":[0.9963192,0.00095633493,0.0004533292,0.00019656074,0.00014368682,0.00033453875,0.0010022317,0.000005116541,0.00058900076],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99785584,0.0014033631,0.0001367585,0.000275932,0.00016471182,0.00016333484],"domain_scores_gemma":[0.9973348,0.0010959497,0.0006569164,0.00033111376,0.00014276148,0.0004384545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045127543,0.0010600868,0.002189947,0.0003390617,0.00025325705,0.0008481276,0.0005785305,0.0007873537,0.0030552782],"category_scores_gemma":[0.0036275545,0.0004906324,0.003521892,0.00044962717,0.0005747793,0.00036499972,0.0005792378,0.00142519,0.00013479288],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9250668,0.0009828402,0.042061504,0.00086624076,0.01518745,0.0000928898,0.00006299028,0.0006701803,0.0027828487,0.00012280997,0.00079998584,0.011303443],"study_design_scores_gemma":[0.6005535,0.059261702,0.29063323,0.00027127494,0.04071574,0.00030124676,0.00015370296,0.0030724532,0.0020868497,0.0007203641,0.0021282686,0.00010167966],"about_ca_topic_score_codex":0.0028800126,"about_ca_topic_score_gemma":0.0076734773,"teacher_disagreement_score":0.0045127543,"about_ca_system_score_codex":0.00051430956,"about_ca_system_score_gemma":0.0009831735,"threshold_uncertainty_score":0.023865998},"labels":[],"label_agreement":null},{"id":"W4311480480","doi":"10.1111/dom.14943","title":"Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A <i>post hoc</i> analysis of the <scp>SURPASS</scp> ‐1 to ‐5 studies","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Toronto","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Semaglutide; Type 2 diabetes; Medicine; Weight loss; Internal medicine; Glucagon-like peptide 1 receptor; Placebo; Basal insulin; Basal (medicine); Hypoglycemia; Exenatide; Clinical endpoint; Endocrinology; Post-hoc analysis; Randomized controlled trial; Diabetes mellitus; Insulin; Agonist; Obesity; Liraglutide; Receptor","score_opus":0.00725095975743336,"score_gpt":0.21771508767922182,"score_spread":0.21046412792178845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311480480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927995,0.004307314,0.00054412463,0.000101067984,0.00007255818,0.000853318,0.00040839205,0.000019794217,0.0008938599],"genre_scores_gemma":[0.9955894,0.001798583,0.0006877851,0.00013206656,0.00008081148,0.00062563195,0.00050580734,0.000010106914,0.0005698131],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99742043,0.0017588632,0.00020963317,0.00020399851,0.00022643093,0.0001807587],"domain_scores_gemma":[0.99734676,0.0010750941,0.00075611525,0.00024448012,0.00021691261,0.00036059666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059743156,0.001028991,0.002338382,0.0003737837,0.00020197069,0.0011475262,0.0006114729,0.00076215836,0.00186362],"category_scores_gemma":[0.0029980668,0.00042721073,0.0046893787,0.00038247634,0.0006243379,0.000784952,0.00048330356,0.001570709,0.00019560418],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95654315,0.0023124092,0.005307576,0.0011028585,0.009599608,0.000036384645,0.00008070231,0.00051653443,0.004573807,0.000062534025,0.00021859516,0.019645777],"study_design_scores_gemma":[0.35865355,0.5430627,0.06349115,0.00025071262,0.02394736,0.0001855262,0.00015896326,0.001467533,0.0067002,0.00026106907,0.0017557187,0.00006545533],"about_ca_topic_score_codex":0.00060264644,"about_ca_topic_score_gemma":0.0016190785,"teacher_disagreement_score":0.0059743156,"about_ca_system_score_codex":0.0005219081,"about_ca_system_score_gemma":0.00091389375,"threshold_uncertainty_score":0.031595588},"labels":[],"label_agreement":null},{"id":"W4312093562","doi":"10.1111/dom.14949","title":"<scp>IMpact</scp> of flash glucose Monitoring in <scp>pEople</scp> with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic <scp>ThErapy</scp> ( <scp>IMMEDIATE</scp> ): A randomized controlled trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Abbott Diabetes Care","keywords":"Medicine; Randomized controlled trial; Type 2 diabetes; Diabetes mellitus; Insulin; Internal medicine; Blood Glucose Self-Monitoring; Diabetes management; Endocrinology; Glycemic; Continuous glucose monitoring","score_opus":0.010410676465415282,"score_gpt":0.24652758766846175,"score_spread":0.23611691120304648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312093562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754686,0.005382151,0.00027409178,0.0007076701,0.00040769958,0.0027570215,0.00085391273,0.000054670607,0.0020159585],"genre_scores_gemma":[0.991028,0.0026430748,0.0008922747,0.00074476167,0.0004914862,0.0024518387,0.00064088654,0.000006435627,0.0011012144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99915457,0.0004413709,0.0000903329,0.00012929871,0.000090981404,0.00009350351],"domain_scores_gemma":[0.99832255,0.00062855805,0.0005185233,0.00007861611,0.00009952898,0.00035220076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016928691,0.0008703641,0.0016881501,0.00031145324,0.00036815435,0.0008030969,0.0006248769,0.0016156128,0.007191057],"category_scores_gemma":[0.0024311638,0.0003717822,0.002391872,0.0003951947,0.0006594817,0.00050534983,0.00037849645,0.001951656,0.00045155894],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9708692,0.0042750495,0.0020908066,0.0014890833,0.0014940761,0.000029023835,0.000030654985,0.00017951505,0.00056945666,0.00006495747,0.00056564785,0.018342655],"study_design_scores_gemma":[0.9309259,0.060335867,0.006211166,0.00014422696,0.0013923029,0.00002863213,0.000024777888,0.0002781219,0.00022404916,0.00007135824,0.0003536983,0.000009851096],"about_ca_topic_score_codex":0.0015023035,"about_ca_topic_score_gemma":0.0026194332,"teacher_disagreement_score":0.007191057,"about_ca_system_score_codex":0.0005053,"about_ca_system_score_gemma":0.000985588,"threshold_uncertainty_score":0.024056494},"labels":[],"label_agreement":null},{"id":"W4313454138","doi":"10.1111/dom.14965","title":"Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the <scp>VERTIS CV</scp> population with type 2 diabetes and atherosclerotic cardiovascular disease","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Pfizer; American Diabetes Association","keywords":"Medicine; Type 2 diabetes; Residual risk; Internal medicine; Atherosclerotic cardiovascular disease; Population; Diabetes mellitus; Type 2 Diabetes Mellitus; Insulin resistance; Post-hoc analysis; Endocrinology; Obesity; Disease; Environmental health","score_opus":0.014742287592752942,"score_gpt":0.2366771745231051,"score_spread":0.22193488693035215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313454138","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852948,0.0034229849,0.0011433188,0.0019099178,0.00025016986,0.0013872584,0.0010102579,0.000049836963,0.0055314605],"genre_scores_gemma":[0.9945509,0.00051539927,0.0010325799,0.0014363495,0.00022599511,0.00076438836,0.0006591159,0.000018880934,0.00079635106],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9918276,0.005262851,0.00045657053,0.00076971407,0.0008450935,0.00083810085],"domain_scores_gemma":[0.9929472,0.0038752425,0.0013154059,0.000642327,0.00027478498,0.0009449622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007814906,0.0004916607,0.0017115462,0.00028114088,0.0004871357,0.0015792856,0.0006637182,0.001197214,0.0068071703],"category_scores_gemma":[0.013522534,0.0002068443,0.002274088,0.0006265855,0.00092992,0.00094160077,0.0011195606,0.002108943,0.0004594811],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.690815,0.007734642,0.16750549,0.0012419279,0.004899658,0.0005317007,0.00045768084,0.00084861706,0.003489007,0.0015335908,0.0041557103,0.11678697],"study_design_scores_gemma":[0.05009005,0.18640697,0.72656363,0.0005774124,0.01109125,0.0005164186,0.00078675436,0.005098575,0.0024041967,0.004378746,0.011933677,0.00015235809],"about_ca_topic_score_codex":0.0027814289,"about_ca_topic_score_gemma":0.0044303252,"teacher_disagreement_score":0.007814906,"about_ca_system_score_codex":0.000571178,"about_ca_system_score_gemma":0.0015624587,"threshold_uncertainty_score":0.041329622},"labels":[],"label_agreement":null},{"id":"W4313455221","doi":"10.1111/dom.14966","title":"Lifestyle intervention for the prevention of type 2 diabetes in women with prior gestational diabetes: A systematic review and meta‐analysis","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Gestational diabetes; Medicine; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Intervention (counseling); Obstetrics; Pregnancy; Gestation; Internal medicine; Endocrinology; Psychiatry","score_opus":0.04338813503796039,"score_gpt":0.34015320911502867,"score_spread":0.29676507407706826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313455221","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002654547,0.99615246,0.0002419075,0.00015386681,0.00012128022,0.00029138237,0.00018404896,0.000015174094,0.00018528297],"genre_scores_gemma":[0.06575538,0.9302838,0.00153161,0.00064688636,0.00021582308,0.0010085918,0.0003186384,0.000015197008,0.00022411766],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99422246,0.0025820218,0.0017940575,0.00050610065,0.0007011524,0.00019422238],"domain_scores_gemma":[0.9851135,0.010978321,0.0024674337,0.00033962124,0.0009034065,0.00019773126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010158404,0.0021806166,0.017666033,0.0057996116,0.00056623283,0.0031692854,0.0016718794,0.0023989254,0.0037354238],"category_scores_gemma":[0.027272923,0.0011310865,0.024753101,0.0062466054,0.0005689662,0.0014167165,0.0010480469,0.0015945914,0.00026848668],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022480867,0.00005352517,0.0021592905,0.6224041,0.34981328,0.00010780083,0.000078408295,0.00031850446,0.0002080394,0.00010666987,0.000571475,0.021930702],"study_design_scores_gemma":[0.00099139,0.000387747,0.00306778,0.07777059,0.9152554,0.00010876712,0.00004512515,0.00018024757,0.0001359947,0.0001407488,0.0018951385,0.000021069447],"about_ca_topic_score_codex":0.0055297134,"about_ca_topic_score_gemma":0.010469329,"teacher_disagreement_score":0.017666033,"about_ca_system_score_codex":0.0023162763,"about_ca_system_score_gemma":0.0040557226,"threshold_uncertainty_score":0.053723395},"labels":[],"label_agreement":null},{"id":"W4315752826","doi":"10.1111/dom.14973","title":"Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross‐sectional survey","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Sanofi","keywords":"Medicine; Cross-sectional study; Type 2 diabetes; Basal insulin; Basal (medicine); Diabetes mellitus; Family medicine; Endocrinology; Pathology","score_opus":0.019274948283101334,"score_gpt":0.252886190038437,"score_spread":0.23361124175533565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315752826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974521,0.00025205695,0.000053347456,0.00031839867,0.000008352486,0.000026944394,0.0011488948,0.000003915213,0.0007360534],"genre_scores_gemma":[0.9978119,0.00040817232,0.00018016933,0.0004388011,0.000013445367,0.000045007597,0.0009206933,0.0000028576485,0.00017891612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886787,0.00041688487,0.00020813783,0.00012868978,0.00023323273,0.0001451831],"domain_scores_gemma":[0.99591583,0.00091600773,0.0017692348,0.00011920845,0.0004953877,0.00078430213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019500063,0.00016594114,0.00031913695,0.0006759086,0.0007694095,0.0010716476,0.00043323854,0.00060577283,0.0015536515],"category_scores_gemma":[0.004553087,0.00034460885,0.000492513,0.0010253302,0.00042487204,0.0012478954,0.0009821843,0.0011680741,0.00024153083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056315097,0.00014287035,0.9942374,0.000034262797,0.000050020713,0.000057765596,0.0021535833,0.00003264939,0.00007753494,0.000025904463,0.0007489563,0.0023827495],"study_design_scores_gemma":[0.0000070157944,0.00015940823,0.9928477,0.000044213833,0.000017866761,0.00017629005,0.005695488,0.00018175672,0.000036009682,0.000021393364,0.0008005496,0.0000123396],"about_ca_topic_score_codex":0.02046484,"about_ca_topic_score_gemma":0.026244234,"teacher_disagreement_score":0.02046484,"about_ca_system_score_codex":0.0006565383,"about_ca_system_score_gemma":0.00065867545,"threshold_uncertainty_score":0.040691435},"labels":[],"label_agreement":null},{"id":"W4317871404","doi":"10.1111/dom.14987","title":"Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Placebo; Tolerability; Medicine; Nausea; Adverse effect; Vomiting; Type 1 diabetes; Insulin; Internal medicine; Diabetes mellitus; Type 2 diabetes; Anesthesia; Endocrinology","score_opus":0.02025264063125084,"score_gpt":0.2784638522499135,"score_spread":0.2582112116186627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317871404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73298013,0.20736541,0.025029175,0.0017222551,0.00033492644,0.0112509085,0.012274813,0.00036120712,0.008681219],"genre_scores_gemma":[0.95659345,0.017690448,0.013661661,0.0009658292,0.00039146707,0.0024382477,0.0072298306,0.000050363273,0.0009786579],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98556614,0.008522411,0.00148422,0.0009582383,0.0030598103,0.0004091385],"domain_scores_gemma":[0.9827472,0.006866722,0.0067243227,0.00079938344,0.0023424856,0.0005199331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028035365,0.0011672926,0.0033252367,0.0020562157,0.00026109346,0.0017120936,0.0006234712,0.0007646533,0.0027091727],"category_scores_gemma":[0.019310907,0.0004341686,0.0069861487,0.0017317769,0.00040182468,0.00090965774,0.0010108385,0.0009559943,0.0002324724],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2365487,0.002067606,0.12056751,0.027530003,0.16371594,0.0004281461,0.00047672816,0.01093031,0.026585698,0.0009423302,0.0031943351,0.40701276],"study_design_scores_gemma":[0.04717255,0.17323448,0.5615427,0.0037744222,0.15634519,0.001224706,0.0003765561,0.009886105,0.016306024,0.002376814,0.02749924,0.0002612488],"about_ca_topic_score_codex":0.000517578,"about_ca_topic_score_gemma":0.0011453715,"teacher_disagreement_score":0.028035365,"about_ca_system_score_codex":0.00086359837,"about_ca_system_score_gemma":0.002132435,"threshold_uncertainty_score":0.14826691},"labels":[],"label_agreement":null},{"id":"W4318168210","doi":"10.1111/dom.14990","title":"Safety and tolerability of semaglutide across the <scp>SUSTAIN</scp> and <scp>PIONEER</scp> phase <scp>IIIa</scp> clinical trial programmes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Tolerability; Placebo; Adverse effect; Dulaglutide; Internal medicine; Clinical trial; Diabetes mellitus; Type 2 diabetes; Pharmacology; Exenatide; Endocrinology; Liraglutide","score_opus":0.02576372130846005,"score_gpt":0.327358820115485,"score_spread":0.30159509880702495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318168210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890215,0.0045849066,0.00061506557,0.0002232278,0.00005493567,0.0018171424,0.0017148247,0.000062915555,0.001905626],"genre_scores_gemma":[0.9894002,0.0016787245,0.001449409,0.00040365322,0.00016344462,0.0024164275,0.003522765,0.000030730906,0.0009345442],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974343,0.0014367867,0.00026539003,0.00025723418,0.00045864642,0.00014765911],"domain_scores_gemma":[0.99616337,0.00083324715,0.0012782812,0.00040475873,0.00057529897,0.0007450647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008440265,0.00066522066,0.0017175587,0.00037044045,0.00039701723,0.0009610183,0.0005345178,0.0009088061,0.0032821],"category_scores_gemma":[0.005394667,0.00032095058,0.0014713171,0.0007094111,0.00067140703,0.0008758937,0.000502318,0.0015425575,0.0004631542],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8474361,0.007902418,0.019314675,0.0009782074,0.0021645247,0.00009425257,0.00021755477,0.00095008704,0.015800223,0.00027733034,0.0037033581,0.10116128],"study_design_scores_gemma":[0.43176305,0.4509471,0.10009185,0.00024441004,0.00232213,0.0005234176,0.00011423173,0.0010967903,0.0073007876,0.00046285344,0.005066175,0.000067157715],"about_ca_topic_score_codex":0.00078999845,"about_ca_topic_score_gemma":0.0012498492,"teacher_disagreement_score":0.008440265,"about_ca_system_score_codex":0.0008732017,"about_ca_system_score_gemma":0.0017278945,"threshold_uncertainty_score":0.044636965},"labels":[],"label_agreement":null},{"id":"W4318754175","doi":"10.1111/dom.14997","title":"Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Internal medicine; Hazard ratio; Heart failure; Placebo; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Confidence interval; Meta-analysis; Endocrinology; Pathology","score_opus":0.03912709330418561,"score_gpt":0.3085626076375541,"score_spread":0.2694355143333685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03653773,0.9585324,0.0016471167,0.0003978359,0.000589459,0.0006645152,0.00092545635,0.00008627814,0.0006190653],"genre_scores_gemma":[0.6730812,0.31669983,0.003726991,0.0014962623,0.0005782857,0.0020422274,0.0016346982,0.00008053106,0.00065998005],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98634654,0.008568811,0.0024376386,0.001404369,0.00088743155,0.00035533722],"domain_scores_gemma":[0.98722094,0.009005788,0.0022974035,0.00065056916,0.0006127259,0.00021269152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015211747,0.0033603373,0.020334523,0.0036691225,0.00054830255,0.00355579,0.001744408,0.0025692314,0.0027457478],"category_scores_gemma":[0.025392177,0.0016816998,0.048547845,0.0042748055,0.0007233339,0.0015834845,0.0012172068,0.0025476012,0.00022323772],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015045539,0.0000403811,0.0028938581,0.048248213,0.9283134,0.00006854653,0.000025500192,0.0006978453,0.00016099245,0.000073197334,0.0002910538,0.004141522],"study_design_scores_gemma":[0.0057793967,0.00038914612,0.0024594923,0.0024840788,0.98778605,0.00004823422,0.000018775698,0.00035094973,0.00008114719,0.00016624063,0.00042006068,0.000016309015],"about_ca_topic_score_codex":0.0047658226,"about_ca_topic_score_gemma":0.0057828366,"teacher_disagreement_score":0.020334523,"about_ca_system_score_codex":0.0019569984,"about_ca_system_score_gemma":0.0012642882,"threshold_uncertainty_score":0.08044839},"labels":[],"label_agreement":null},{"id":"W4318755799","doi":"10.1111/dom.15000","title":"Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Faculty of Medicine and Health, University of Sydney; McGill University","keywords":"Metformin; Medicine; Hazard ratio; Type 2 diabetes; Internal medicine; Confidence interval; Cohort; Proportional hazards model; Cohort study; Propensity score matching; Population; Diabetes mellitus; Combination therapy; Relative risk; Lower risk; Endocrinology; Insulin","score_opus":0.007082311232602926,"score_gpt":0.21893171097360017,"score_spread":0.21184939974099726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318755799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855167,0.00040628394,0.000099421275,0.00006558679,0.000023462782,0.000019581505,0.00063145586,0.0000029190285,0.00019966488],"genre_scores_gemma":[0.99852765,0.000346284,0.0001319178,0.00007773403,0.00003946709,0.000032820248,0.00059251586,0.000002991233,0.00024853428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998877,0.00035353936,0.00012069615,0.00028777294,0.000198791,0.00016221289],"domain_scores_gemma":[0.9977781,0.0003776302,0.0009889643,0.00031443776,0.00021155657,0.00032922605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018587594,0.0004173474,0.0005212148,0.0007098784,0.00056104065,0.001101619,0.0005880528,0.0010827343,0.0013281052],"category_scores_gemma":[0.004719117,0.0006031162,0.0018748046,0.0011791576,0.00024998502,0.0007058215,0.0006167302,0.0012317906,0.0002510089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012689835,0.00015618309,0.99613464,0.000021391623,0.00076904095,0.000092035785,0.000086598164,0.00005669506,0.00015691329,0.000018468998,0.00015103104,0.0010880283],"study_design_scores_gemma":[0.00021322332,0.00063649897,0.9974421,0.00001959477,0.00054786296,0.00020805492,0.00015088309,0.00045818943,0.000039130704,0.00003576747,0.0002360131,0.000012598744],"about_ca_topic_score_codex":0.009091732,"about_ca_topic_score_gemma":0.008136625,"teacher_disagreement_score":0.009091732,"about_ca_system_score_codex":0.00035910087,"about_ca_system_score_gemma":0.00044084722,"threshold_uncertainty_score":0.018077612},"labels":[],"label_agreement":null},{"id":"W4319059252","doi":"10.1111/dom.15002","title":"Effects of somatostatin receptor type 2 antagonism during insulin‐induced hypoglycaemia in male rats with prediabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"iCo Therapeutics (Canada); York University","funders":"Breakthrough T1D Canada; Canadian Glycomics Network; Natural Sciences and Engineering Research Council of Canada","keywords":"Internal medicine; Endocrinology; Glucagon; Medicine; Insulin; Prediabetes; Type 2 diabetes; Somatostatin; Streptozotocin; Diabetes mellitus","score_opus":0.008441693927555779,"score_gpt":0.23518134370661758,"score_spread":0.2267396497790618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319059252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99843925,0.00040266864,0.00025572718,0.000058954945,0.000052205443,0.000037815673,0.0002372099,0.0000490609,0.00046702652],"genre_scores_gemma":[0.9941109,0.0008432745,0.001002624,0.00016977063,0.000069476126,0.000191614,0.0008390077,0.00004036423,0.0027329796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967957,0.00005267503,0.000031163683,0.00006555338,0.00005971146,0.000111303205],"domain_scores_gemma":[0.9994592,0.000047535028,0.00016512067,0.000063752464,0.00003220743,0.00023223739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038894368,0.0011016211,0.00095476856,0.0007000967,0.0003408668,0.00044318722,0.00038958326,0.00052518246,0.0021066915],"category_scores_gemma":[0.00031787044,0.00055722514,0.000651343,0.0003623919,0.0005271495,0.0004736484,0.00030797996,0.0015550243,0.0005034241],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027172377,0.0035495092,0.0015479249,0.00011356685,0.00005822552,0.00038865703,0.00007182271,0.00019010434,0.9596609,0.000091379625,0.00021663752,0.00693888],"study_design_scores_gemma":[0.003000261,0.09676516,0.041987166,0.000040894276,0.00025090566,0.001278471,0.0003463302,0.0015527039,0.8518509,0.0001199499,0.0027311242,0.00007613399],"about_ca_topic_score_codex":0.001010388,"about_ca_topic_score_gemma":0.0019029776,"teacher_disagreement_score":0.0021066915,"about_ca_system_score_codex":0.00032061996,"about_ca_system_score_gemma":0.00045996485,"threshold_uncertainty_score":0.0070475936},"labels":[],"label_agreement":null},{"id":"W4319460681","doi":"10.1111/dom.15009","title":"Comparative efficacy of <scp>sodium‐glucose</scp> co‐transporter‐2 inhibitors, <scp>glucagon‐like</scp> peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network <scp>meta‐analysis</scp>","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Mace; Internal medicine; Type 2 diabetes; Kidney disease; Mineralocorticoid receptor; Glucagon-like peptide 1 receptor; Myocardial infarction; Endocrinology; Gastroenterology; Diabetes mellitus; Percutaneous coronary intervention; Receptor","score_opus":0.026744199475365646,"score_gpt":0.28922584845590626,"score_spread":0.2624816489805406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005683308,0.99240255,0.0002895246,0.00017425095,0.00013766834,0.00045053908,0.00054360344,0.00002325567,0.00029537044],"genre_scores_gemma":[0.17826428,0.81557256,0.0019388288,0.0011267782,0.00023212635,0.0014692538,0.00089080335,0.000028128392,0.00047725328],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99393684,0.002580747,0.0020289163,0.0005806914,0.0007018329,0.00017101022],"domain_scores_gemma":[0.98702955,0.00923148,0.0025257808,0.00021746593,0.00081678975,0.00017896654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008734094,0.0019565271,0.015799094,0.0055854553,0.00049520633,0.002797429,0.0014702632,0.0020397953,0.003045461],"category_scores_gemma":[0.020538399,0.00092140865,0.020165801,0.006013275,0.00065880764,0.0013792292,0.0010930789,0.0012927615,0.0002149853],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031356981,0.00002382714,0.0015874117,0.6508047,0.32904598,0.00009478132,0.000069780996,0.00024511758,0.00035431632,0.00011571425,0.0005877447,0.01393495],"study_design_scores_gemma":[0.0017447153,0.00040120335,0.0032413919,0.05409721,0.9374017,0.00012761711,0.000057374054,0.00014243319,0.00021727334,0.000172503,0.0023709768,0.000025703153],"about_ca_topic_score_codex":0.005842921,"about_ca_topic_score_gemma":0.014978874,"teacher_disagreement_score":0.015799094,"about_ca_system_score_codex":0.0025250847,"about_ca_system_score_gemma":0.0035431162,"threshold_uncertainty_score":0.046190858},"labels":[],"label_agreement":null},{"id":"W4320494607","doi":"10.1111/dom.15011","title":"A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa ( <scp>PACT‐MEA</scp> ): Study design and rationale","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Medicine; Reimbursement; Cross-sectional study; Guideline; Type 2 diabetes; Observational study; Family medicine; Epidemiology; Pact; Disease management; Diabetes mellitus; Disease; Health care; Internal medicine; Pathology","score_opus":0.03878253715765891,"score_gpt":0.25464470283110024,"score_spread":0.21586216567344133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320494607","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979274,0.0001517404,0.00025432173,0.000057522637,0.000009005909,0.00023407441,0.0009974226,0.0000027910394,0.00036572193],"genre_scores_gemma":[0.99728596,0.00011557039,0.00078164734,0.00020381233,0.000024634932,0.00050721515,0.0009225242,0.0000018101807,0.00015682343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986507,0.00071817794,0.00015157968,0.00021653315,0.00015689924,0.00010617367],"domain_scores_gemma":[0.9978987,0.00045581933,0.00082090177,0.0001851836,0.0003076691,0.00033178122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002356931,0.00041575643,0.00029452212,0.0007481064,0.0007415091,0.0005834923,0.00043838497,0.00060966716,0.0015518152],"category_scores_gemma":[0.00314158,0.00046096515,0.00044603168,0.0012859704,0.00043974337,0.0006654924,0.0005807525,0.00058917905,0.00032791615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011381831,0.00018979769,0.99871314,0.000019402336,0.0000728492,0.000028380646,0.00015571769,0.000014151529,0.00010282324,0.000013581801,0.000088151064,0.00048823497],"study_design_scores_gemma":[0.000063114545,0.00085676345,0.9977003,0.000014227037,0.00006159937,0.00019221802,0.00062985724,0.000119011835,0.000056608547,0.00001585882,0.00028583838,0.000004648672],"about_ca_topic_score_codex":0.0055520046,"about_ca_topic_score_gemma":0.0075593973,"teacher_disagreement_score":0.0055520046,"about_ca_system_score_codex":0.000441526,"about_ca_system_score_gemma":0.0006263338,"threshold_uncertainty_score":0.012464821},"labels":[],"label_agreement":null},{"id":"W4320709102","doi":"10.1111/dom.15019","title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; University of Toronto; Diabetes Canada; Heart and Stroke Foundation of Canada; Department of Medicine, University of Toronto; Sanofi","keywords":"Albuminuria; Medicine; Placebo; Renal function; Internal medicine; Kidney disease; Creatinine; Diabetes mellitus; Type 2 diabetes; Urology; Gastroenterology; Clinical trial; Endocrinology; Pathology","score_opus":0.005905114787099368,"score_gpt":0.21212779298316764,"score_spread":0.20622267819606827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320709102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99000823,0.007494184,0.00040932247,0.0003536474,0.00005672054,0.00014378071,0.00025262398,0.000022133758,0.0012592124],"genre_scores_gemma":[0.99615854,0.0018372891,0.0006444179,0.0005895886,0.000102085476,0.00009723662,0.00032553123,0.0000029437272,0.00024237267],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997235,0.000094381394,0.000031853768,0.000040548086,0.0000825804,0.000027133123],"domain_scores_gemma":[0.9993826,0.00019494187,0.0002615643,0.000019659159,0.000052133862,0.0000889802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011184585,0.0002475473,0.00085234694,0.0001811291,0.00015511794,0.000369276,0.00014458032,0.0004812424,0.00097386655],"category_scores_gemma":[0.0012277407,0.000098612996,0.0007923794,0.00021486457,0.00016957059,0.00025774655,0.00013432161,0.00068066624,0.000108585],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39114952,0.008205423,0.21532708,0.001967067,0.003350781,0.0002534502,0.00020637392,0.0029537466,0.021737527,0.00018287606,0.0028305387,0.3518357],"study_design_scores_gemma":[0.08781535,0.16602057,0.7239277,0.00031802515,0.00314273,0.0010074831,0.0001468687,0.006294686,0.005883971,0.0004086356,0.004963763,0.000070257665],"about_ca_topic_score_codex":0.00046203923,"about_ca_topic_score_gemma":0.0011476661,"teacher_disagreement_score":0.0011184585,"about_ca_system_score_codex":0.00030410057,"about_ca_system_score_gemma":0.00038099705,"threshold_uncertainty_score":0.005914986},"labels":[],"label_agreement":null},{"id":"W4321499324","doi":"10.1111/dom.15025","title":"Use of the <scp>FreeStyle Libre</scp> system and diabetes treatment progression in <scp>T2DM</scp> : Results from a retrospective cohort study using a <scp>Canadian</scp> private payer claims database","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"Abbott Diabetes Care","keywords":"Medicine; Diabetes mellitus; Retrospective cohort study; Cohort; Internal medicine; Database; Demography; Endocrinology","score_opus":0.03040760601775555,"score_gpt":0.26918374932032846,"score_spread":0.2387761433025729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321499324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966286,0.0003002462,0.00007696303,0.000057311296,0.0000040563295,0.000029289282,0.0025810422,0.0000049769865,0.00031760804],"genre_scores_gemma":[0.9974433,0.00019253154,0.00013577352,0.000028319675,0.0000050865447,0.000014286398,0.0019957179,0.000003514641,0.00018139386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985638,0.00019441711,0.00013848142,0.00031660407,0.0005704392,0.0002162976],"domain_scores_gemma":[0.99459684,0.00062176783,0.0024200368,0.00050053664,0.0011199291,0.0007408798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022002794,0.00031687526,0.00030131533,0.0012198095,0.0009892319,0.0012770888,0.0009985428,0.0004790209,0.0012513954],"category_scores_gemma":[0.005497632,0.00037551,0.0011667312,0.0028453872,0.00047294682,0.0004508757,0.0007822068,0.0007607351,0.000168937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011793335,0.000017017508,0.9989355,0.00000911889,0.00007292535,0.000015624248,0.00006643348,0.000038046466,0.00001974604,0.000011097566,0.00011554383,0.0005809377],"study_design_scores_gemma":[0.000014751641,0.00004707111,0.9990133,0.000014229658,0.00008365515,0.00006172258,0.00016209058,0.0003735176,0.000028279708,0.000009952659,0.00018564647,0.0000056649783],"about_ca_topic_score_codex":0.64404535,"about_ca_topic_score_gemma":0.6014694,"teacher_disagreement_score":0.35595465,"about_ca_system_score_codex":0.0036277126,"about_ca_system_score_gemma":0.0049172137,"threshold_uncertainty_score":0.7161019},"labels":[],"label_agreement":null},{"id":"W4321499386","doi":"10.1111/dom.15026","title":"Association between residual islet beta‐cell function and achieving the target of time in range in inpatients with type 2 diabetes undergoing antidiabetic treatment: An observation study","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Science Foundation of Shandong Province; National Natural Science Foundation of China","keywords":"Medicine; Insulin; Internal medicine; tar (computing); Diabetes mellitus; Logistic regression; Confounding; Type 2 diabetes; Endocrinology; Islet; Type 1 diabetes","score_opus":0.017127201436341492,"score_gpt":0.2306486240206104,"score_spread":0.2135214225842689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321499386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997342,0.00006745541,0.000033662553,0.000008454435,0.0000025990073,0.0000020415043,0.000070746544,0.0000011862322,0.00007964686],"genre_scores_gemma":[0.9996996,0.000047744707,0.000047301874,0.000009506799,0.0000049804107,0.0000031978022,0.00013894244,7.901721e-7,0.00004795828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995857,0.00010491372,0.000057602072,0.00010182395,0.000071408474,0.0000786119],"domain_scores_gemma":[0.9978928,0.00034258165,0.00106979,0.00015830697,0.00016191187,0.0003746809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006381743,0.0003324375,0.0005123258,0.00035984092,0.00030294768,0.00058623013,0.00025432123,0.00041077338,0.0010768283],"category_scores_gemma":[0.0018222114,0.0002574221,0.00059410976,0.0006093694,0.00017678879,0.00036266304,0.00030723444,0.00081342313,0.00018995073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016322505,0.00007013176,0.99914324,0.0000040795308,0.00003463417,0.00002376715,0.00002601558,0.000011146304,0.00008323993,0.0000020569746,0.000019693081,0.00041879143],"study_design_scores_gemma":[0.0000074068626,0.00028484277,0.9992861,0.0000026506875,0.000033191995,0.00010783599,0.0000933874,0.00010116931,0.000039275266,0.000004643233,0.00003689528,0.0000025542104],"about_ca_topic_score_codex":0.0025963525,"about_ca_topic_score_gemma":0.002783199,"teacher_disagreement_score":0.0025963525,"about_ca_system_score_codex":0.00027622242,"about_ca_system_score_gemma":0.0003258848,"threshold_uncertainty_score":0.005162537},"labels":[],"label_agreement":null},{"id":"W4328048371","doi":"10.1111/dom.15057","title":"Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the <scp>CANVAS</scp> programme and <scp>CREDENCE</scp>","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; University of Manitoba; NOSM University; McGill University Health Centre","funders":"Janssen Canada; Mitsubishi Tanabe Pharma Corporation","keywords":"Canagliflozin; Medicine; Empagliflozin; Internal medicine; Type 2 diabetes; Nephropathy; Type 2 Diabetes Mellitus; Diabetes mellitus; Diabetic nephropathy; Creatinine; Post-hoc analysis; Kidney disease; Endocrinology","score_opus":0.031398394816738076,"score_gpt":0.2413543484380646,"score_spread":0.20995595362132652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328048371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9023332,0.02047469,0.001140187,0.0006311991,0.00017139397,0.0006155105,0.06758385,0.0001534926,0.0068965373],"genre_scores_gemma":[0.918708,0.0031429967,0.0010580734,0.0006972401,0.00029304347,0.0005677395,0.074020706,0.000037939153,0.0014742116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968252,0.0007748983,0.0004009527,0.00060145976,0.0010759213,0.0003216293],"domain_scores_gemma":[0.99271214,0.0015490407,0.0029929043,0.0005651762,0.0011844123,0.0009962053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044293515,0.00073442067,0.0019520154,0.0013030854,0.0003362821,0.0013079197,0.000856156,0.0011738954,0.0015208328],"category_scores_gemma":[0.005690122,0.00038829833,0.0036555664,0.0027680944,0.00022450389,0.001042538,0.00086644903,0.0021219624,0.00053378823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.108269826,0.0018811206,0.80327046,0.001380045,0.012076026,0.00014453502,0.00020356712,0.0021461672,0.0004872055,0.00022715684,0.01570025,0.054213595],"study_design_scores_gemma":[0.0032747749,0.0019442586,0.98934746,0.0001090185,0.0022999207,0.00008036757,0.00003228201,0.00056987494,0.00014649227,0.00012495922,0.0020305538,0.00003994051],"about_ca_topic_score_codex":0.008363088,"about_ca_topic_score_gemma":0.01124048,"teacher_disagreement_score":0.008363088,"about_ca_system_score_codex":0.000883491,"about_ca_system_score_gemma":0.0007137355,"threshold_uncertainty_score":0.023424923},"labels":[],"label_agreement":null},{"id":"W4353021269","doi":"10.1111/dom.15058","title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of <scp>SOUL</scp> , a randomized trial","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Randomized controlled trial; Kidney disease; Disease; Diabetes mellitus; Internal medicine; Physical therapy; Endocrinology","score_opus":0.011004047311891228,"score_gpt":0.22011931855942451,"score_spread":0.2091152712475333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353021269","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570565,0.011797889,0.0013316589,0.0011305345,0.00069242175,0.020650506,0.0018006272,0.00009553346,0.0054442626],"genre_scores_gemma":[0.95223784,0.003992546,0.0032705495,0.0018173029,0.00093054114,0.033213396,0.0016124567,0.000024554176,0.0029009155],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968207,0.002213708,0.00022564051,0.00028905753,0.00021359751,0.00023723065],"domain_scores_gemma":[0.9984005,0.0004119873,0.0004386414,0.0001093212,0.00014029357,0.00049926346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005438344,0.0014292573,0.002516385,0.00043549662,0.0004833466,0.0013675797,0.0005732931,0.0017561051,0.0041782307],"category_scores_gemma":[0.0036698128,0.0006033499,0.0020796482,0.0005500721,0.0010606343,0.0009361526,0.00051909353,0.0015524923,0.00061326084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9835644,0.0034751114,0.0018440888,0.0006205824,0.0011455811,0.000016967218,0.000025201307,0.00022237435,0.00073292584,0.00017362653,0.00048657047,0.0076925606],"study_design_scores_gemma":[0.9511061,0.043243703,0.0029751554,0.00006405367,0.001087638,0.000015975635,0.000016510381,0.000323382,0.00023126348,0.00023214448,0.0006909104,0.000013160487],"about_ca_topic_score_codex":0.00040261645,"about_ca_topic_score_gemma":0.0010688875,"teacher_disagreement_score":0.005438344,"about_ca_system_score_codex":0.00052132417,"about_ca_system_score_gemma":0.0014556568,"threshold_uncertainty_score":0.02876103},"labels":[],"label_agreement":null},{"id":"W4361190342","doi":"10.1111/dom.15065","title":"Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of British Columbia","funders":"","keywords":"Medicine; Kidney disease; Diabetology; Library science; George (robot); Family medicine; Internal medicine; Diabetes mellitus; History; Art history; Endocrinology","score_opus":0.005120574803165702,"score_gpt":0.20186903255608327,"score_spread":0.19674845775291758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361190342","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2670544,0.06565783,0.0008629518,0.56268424,0.026844263,0.00082059106,0.026878057,0.00020428172,0.04899344],"genre_scores_gemma":[0.48373014,0.01208691,0.0020815548,0.43890405,0.038713373,0.0012172372,0.009929383,0.000073345596,0.013264098],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.996765,0.0018423864,0.00031701176,0.00027691846,0.00051199395,0.00028667937],"domain_scores_gemma":[0.98823035,0.0079202475,0.0012997253,0.00039172504,0.00086985494,0.0012880842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062587624,0.0005316297,0.002197393,0.0004511199,0.0005366392,0.0017350543,0.0006272906,0.0042723785,0.0043536695],"category_scores_gemma":[0.015473895,0.0003449515,0.0028338458,0.0010940535,0.000436849,0.00092748087,0.0005873484,0.004498841,0.0010346683],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19380324,0.00173575,0.100740835,0.0020287884,0.010814443,0.0011719586,0.00025916388,0.0012027386,0.0010430642,0.0016004231,0.452496,0.23310362],"study_design_scores_gemma":[0.27381313,0.016563088,0.46928015,0.0029626917,0.024421891,0.0010802163,0.00081146444,0.005063763,0.0011815045,0.007918362,0.1964777,0.00042611788],"about_ca_topic_score_codex":0.0055123367,"about_ca_topic_score_gemma":0.022929551,"teacher_disagreement_score":0.0062587624,"about_ca_system_score_codex":0.001977455,"about_ca_system_score_gemma":0.0022324189,"threshold_uncertainty_score":0.03309989},"labels":[],"label_agreement":null},{"id":"W4361191084","doi":"10.1111/dom.15063","title":"Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Eli Lilly and Company","keywords":"Insulin lispro; Postprandial; Medicine; Tolerability; Crossover study; Type 1 diabetes; Meal; Internal medicine; Diabetes mellitus; Bolus (digestion); Endocrinology; Insulin; Adverse effect; Placebo","score_opus":0.011533707238199057,"score_gpt":0.2382628710976963,"score_spread":0.22672916385949726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361191084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775094,0.0018642393,0.000067674344,0.000028553506,0.00001334931,0.000014710734,0.000060889222,0.0000063768625,0.0001932811],"genre_scores_gemma":[0.99816847,0.0009458068,0.00033202447,0.000087079134,0.000018512777,0.000025390653,0.00015239726,0.0000043237505,0.00026596658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99983835,0.000067422945,0.00001784097,0.000027233356,0.000030254827,0.00001877956],"domain_scores_gemma":[0.9994702,0.00016542243,0.0001909882,0.000020799287,0.000039303977,0.000113315284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000534432,0.00020987428,0.0006413913,0.00011928581,0.00008064454,0.00023847756,0.00012000195,0.00022399376,0.0013527058],"category_scores_gemma":[0.0007784887,0.00011694209,0.00036969638,0.00014258295,0.00014991958,0.00022990005,0.0001114598,0.00042291448,0.00011948538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3378077,0.007084728,0.31032258,0.0021163183,0.0019701177,0.0009310512,0.00097489817,0.0009431724,0.091906436,0.00020513378,0.0012761644,0.24446173],"study_design_scores_gemma":[0.008683458,0.25541285,0.71410173,0.00016309635,0.0011424132,0.0020668537,0.0005207136,0.0007875081,0.013114343,0.000063099586,0.0039117285,0.000032342035],"about_ca_topic_score_codex":0.0003768891,"about_ca_topic_score_gemma":0.00060556177,"teacher_disagreement_score":0.0013527058,"about_ca_system_score_codex":0.00015841296,"about_ca_system_score_gemma":0.00018053579,"threshold_uncertainty_score":0.0045252442},"labels":[],"label_agreement":null},{"id":"W4362601025","doi":"10.1111/dom.15081","title":"Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6 trials","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Post-hoc analysis; Type 2 diabetes; Medicine; Triglyceride; Diabetes mellitus; Adverse effect; Internal medicine; Baseline (sea); Post hoc; Endocrinology; Cholesterol; Liraglutide; Biology","score_opus":0.024800301952432297,"score_gpt":0.2642104988669024,"score_spread":0.2394101969144701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362601025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573014,0.02759633,0.0016149036,0.0010450254,0.001219784,0.0021911745,0.0049780095,0.00024191245,0.003811413],"genre_scores_gemma":[0.9858708,0.0042251307,0.0015942632,0.000856337,0.00058170606,0.001500405,0.0027462645,0.00007952409,0.002545459],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99614584,0.0024526108,0.0003436101,0.00051144464,0.00024061627,0.00030579593],"domain_scores_gemma":[0.99635124,0.0017384951,0.00066790206,0.0005191343,0.00029010006,0.00043316802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007870989,0.0027225553,0.0069530867,0.00052227534,0.0005072547,0.002029284,0.00081748434,0.0013931699,0.0047337557],"category_scores_gemma":[0.006469969,0.000811726,0.010416489,0.00079920964,0.0006928381,0.0015397773,0.0009550247,0.0032931003,0.00060928403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95554435,0.00066929683,0.0039301678,0.0009356202,0.030385885,0.00006039164,0.00004505551,0.0003762729,0.0007218307,0.00006299471,0.0010763813,0.006191764],"study_design_scores_gemma":[0.70660025,0.11206877,0.07713255,0.00030679614,0.094407246,0.00024939398,0.00021788076,0.002836904,0.0014224842,0.000919039,0.0036584977,0.00018013526],"about_ca_topic_score_codex":0.0011879151,"about_ca_topic_score_gemma":0.0034415645,"teacher_disagreement_score":0.007870989,"about_ca_system_score_codex":0.000611421,"about_ca_system_score_gemma":0.0008675589,"threshold_uncertainty_score":0.041626275},"labels":[],"label_agreement":null},{"id":"W4364352053","doi":"10.1111/dom.15083","title":"Control of human pancreatic beta cell kinome by glucagon‐like peptide‐1 receptor biased agonism","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; Diabetes UK; UK Research and Innovation; European Foundation for the Study of Diabetes; Eli Lilly and Company","keywords":"Kinome; Agonist; Medicine; Glucagon-like peptide 1 receptor; Receptor; Glucagon-like peptide-1; Internal medicine; Beta cell; Endocrinology; BETA (programming language); Beta adrenergic receptor kinase; Pharmacology; Cell biology; Kinase; G protein-coupled receptor; Biology; Diabetes mellitus; Type 2 diabetes","score_opus":0.010038426379119572,"score_gpt":0.22407242030774752,"score_spread":0.21403399392862793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364352053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967147,0.001241825,0.0010789945,0.000037538975,0.000012384649,0.000016158467,0.00037206977,0.000016869146,0.0005094729],"genre_scores_gemma":[0.9963003,0.0010918465,0.0011963162,0.000062484716,0.000008511624,0.000044225813,0.0005857055,0.000008025122,0.0007026147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998859,0.0000178677,0.000009745438,0.00003035598,0.000026126398,0.000029911813],"domain_scores_gemma":[0.99995255,0.00001054127,0.00001602512,0.0000063707057,0.000005393677,0.000009176563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012664063,0.00020982046,0.00022324304,0.000089356916,0.00007104331,0.00026172952,0.000072292314,0.00012970403,0.0016854265],"category_scores_gemma":[0.00014285337,0.00006869006,0.00019610334,0.00008805445,0.00009053964,0.00015909201,0.00018728618,0.00025280807,0.00031811994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042978142,0.000014726795,0.0005451139,0.000041277035,0.000005482206,0.00003203488,0.000008000102,0.000065305925,0.99716324,0.000011052751,0.000020275045,0.001663559],"study_design_scores_gemma":[0.000029820592,0.00090779824,0.040659297,0.000009943094,0.000031360865,0.00045994975,0.00008157338,0.0008865924,0.9553591,0.00004311782,0.0015217598,0.000009730684],"about_ca_topic_score_codex":0.000110653906,"about_ca_topic_score_gemma":0.00017486367,"teacher_disagreement_score":0.0016854265,"about_ca_system_score_codex":0.00013259234,"about_ca_system_score_gemma":0.00010362926,"threshold_uncertainty_score":0.005638361},"labels":[],"label_agreement":null},{"id":"W4365443628","doi":"10.1111/dom.15088","title":"Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6 cardiovascular outcomes trials","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Medicine; Post-hoc analysis; Type 2 diabetes; Post hoc; Diabetes mellitus; Lymphocyte; Internal medicine; Immunology; Endocrinology","score_opus":0.012677140490507957,"score_gpt":0.22541870464936944,"score_spread":0.21274156415886147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365443628","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84717876,0.021430861,0.0011950273,0.08189992,0.0074094892,0.0007113418,0.025246644,0.00007596877,0.014851981],"genre_scores_gemma":[0.9596151,0.0043107374,0.0017074876,0.0144952815,0.009018313,0.00071507064,0.005293948,0.00003104899,0.004812942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734384,0.0017121154,0.00027906554,0.00021313077,0.00030768782,0.000144235],"domain_scores_gemma":[0.9781568,0.01675182,0.001583816,0.0010330526,0.001602261,0.00087224477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052347924,0.00044842716,0.0013681581,0.00029410768,0.00038894833,0.0008888794,0.00049356197,0.0013716768,0.004513997],"category_scores_gemma":[0.022088757,0.00025452135,0.0014403461,0.0008337776,0.00024710962,0.00052433414,0.00025095124,0.002192295,0.00065302866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28964633,0.0010000828,0.4287373,0.0016641992,0.012532879,0.0025498124,0.0002367257,0.0009121742,0.00183199,0.00075885555,0.16610648,0.09402315],"study_design_scores_gemma":[0.07891174,0.018146662,0.7996855,0.00114118,0.028482068,0.0044815866,0.0007353061,0.010659121,0.0024623529,0.005202493,0.04982568,0.0002663506],"about_ca_topic_score_codex":0.0013639501,"about_ca_topic_score_gemma":0.0035828773,"teacher_disagreement_score":0.0052347924,"about_ca_system_score_codex":0.00037423847,"about_ca_system_score_gemma":0.0008959173,"threshold_uncertainty_score":0.02768457},"labels":[],"label_agreement":null},{"id":"W4365483438","doi":"10.1111/dom.15092","title":"Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the <scp>CVD‐REAL</scp> 2 study","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"Taipei Veterans General Hospital; Syddansk Universitet; Saint Luke's Health System; Novo Nordisk Fonden; AstraZeneca","keywords":"Medicine; Family medicine; Advisory committee; Management","score_opus":0.01354308518714901,"score_gpt":0.21625870016536491,"score_spread":0.2027156149782159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365483438","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931098,0.0041810204,0.00011375985,0.00016151229,0.00008226386,0.000032443855,0.0014977665,0.000006835864,0.00081458595],"genre_scores_gemma":[0.99552405,0.0010595461,0.00015643262,0.00020526357,0.00017872103,0.000046807498,0.002284651,0.000009091753,0.00053541525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987029,0.00051209825,0.00013934198,0.00027896013,0.00021847982,0.00014829737],"domain_scores_gemma":[0.9976744,0.0007433392,0.0007192138,0.00020540447,0.00012859853,0.00052915706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018536459,0.0005809632,0.0012698355,0.00051271904,0.00026449267,0.001070361,0.0005542173,0.00086248084,0.0018440008],"category_scores_gemma":[0.0026096709,0.00045597416,0.0040881825,0.0008255906,0.00024998552,0.0004988689,0.0004647406,0.0016910689,0.0001866994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086884245,0.0005333525,0.882207,0.0005138596,0.014806272,0.0003655589,0.00011233402,0.0005068927,0.0012060206,0.00016020119,0.0018011725,0.010903149],"study_design_scores_gemma":[0.004789585,0.0035831614,0.98178357,0.00006382581,0.0072197807,0.00022781173,0.000109350505,0.0010104534,0.00015000734,0.00015167112,0.0008696008,0.00004128299],"about_ca_topic_score_codex":0.0023953405,"about_ca_topic_score_gemma":0.004581006,"teacher_disagreement_score":0.0023953405,"about_ca_system_score_codex":0.00031427582,"about_ca_system_score_gemma":0.0004374418,"threshold_uncertainty_score":0.009803116},"labels":[],"label_agreement":null},{"id":"W4367843752","doi":"10.1111/dom.15115","title":"Cover Image","year":2023,"lang":"en","type":"paratext","venue":"Diabetes Obesity and Metabolism","topic":"Diet and metabolism studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cover (algebra); Medicine; Diabetes mellitus; Baseline (sea); Kidney disease; Front cover; Internal medicine; Political science; Engineering; Endocrinology","score_opus":0.014515633190999523,"score_gpt":0.26260200572308634,"score_spread":0.24808637253208682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367843752","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005131293,0.0013549008,0.001039453,0.00895909,0.04144973,0.00043788465,0.009929357,0.0038450356,0.9324714],"genre_scores_gemma":[0.0018564507,0.00074081577,0.00038007906,0.00257078,0.007350914,0.00012735947,0.0033941304,0.00081061845,0.98276895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995408,0.000041975432,0.00002046693,0.00006659379,0.00024565126,0.00008448251],"domain_scores_gemma":[0.99757165,0.00042917376,0.000108073036,0.00017611733,0.0010554481,0.0006595932],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038659046,0.0009845447,0.000815921,0.0015183476,0.000854609,0.0034380958,0.0012589919,0.0024836666,0.94698274],"category_scores_gemma":[0.00461756,0.00042994577,0.0007675293,0.0010011753,0.00043362466,0.0018106134,0.0016450124,0.0021107763,0.8437592],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017422233,0.00000873692,0.000015099168,0.000034466426,4.5044055e-7,0.00001984841,0.0000022466381,0.000009853583,0.000064237865,0.00013598276,0.9862192,0.01347255],"study_design_scores_gemma":[0.000025109557,0.000017167444,0.00027918114,0.00006784561,0.00000135646,0.00011767171,0.000014102686,0.00005942126,0.00010601141,0.0002717121,0.9990357,0.000004884898],"about_ca_topic_score_codex":0.0017275871,"about_ca_topic_score_gemma":0.0024061427,"teacher_disagreement_score":0.05301726,"about_ca_system_score_codex":0.00089035823,"about_ca_system_score_gemma":0.00069041445,"threshold_uncertainty_score":0.07562262},"labels":[],"label_agreement":null},{"id":"W4376121968","doi":"10.1111/dom.15091","title":"<scp>The sodium‐glucose cotransporter‐2</scp> inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> randomized double‐blind trials","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Hazard ratio; Placebo; Internal medicine; Proportional hazards model; Post-hoc analysis; Diabetes mellitus; Confidence interval; Type 2 diabetes; Urology; Surgery; Endocrinology; Pathology","score_opus":0.009550942729889354,"score_gpt":0.24690151203213107,"score_spread":0.23735056930224172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376121968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372204,0.04622573,0.0026524693,0.0012630777,0.0010467909,0.003461137,0.0030835967,0.00019245096,0.004854367],"genre_scores_gemma":[0.9907714,0.0041730497,0.0013734202,0.0006249112,0.00035537808,0.0010723165,0.00084619044,0.000018561579,0.0007647388],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964244,0.002377449,0.0004014548,0.0003588261,0.0002939056,0.00014401796],"domain_scores_gemma":[0.9957417,0.0022027853,0.001223388,0.0003573912,0.0002715971,0.00020323435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073631033,0.00075023354,0.0030287376,0.00043933734,0.00022624554,0.0011276546,0.00041218885,0.0010189144,0.003801636],"category_scores_gemma":[0.008860302,0.00041276135,0.006100744,0.0005145719,0.000624242,0.00049141684,0.00034002084,0.0010037017,0.0002248818],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8671046,0.0007637814,0.0065501933,0.008323512,0.08149412,0.00005594412,0.000051568422,0.0006474841,0.0023368455,0.00017146512,0.0019629966,0.03053748],"study_design_scores_gemma":[0.7324651,0.056741443,0.04302671,0.0010106874,0.15901421,0.00016535752,0.0000622336,0.0015881613,0.002229161,0.0005633741,0.0030797368,0.000053763448],"about_ca_topic_score_codex":0.00078342424,"about_ca_topic_score_gemma":0.0018228117,"teacher_disagreement_score":0.0073631033,"about_ca_system_score_codex":0.00044356738,"about_ca_system_score_gemma":0.00082427944,"threshold_uncertainty_score":0.03894025},"labels":[],"label_agreement":null},{"id":"W4376132684","doi":"10.1111/dom.15106","title":"Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; McGill University","keywords":"Medicine; Insulin; NPH insulin; Hazard ratio; Internal medicine; Type 2 diabetes; Diabetes mellitus; Insulin glargine; Population; Insulin detemir; Proportional hazards model; Endocrinology; Cohort; Confidence interval","score_opus":0.006036240404913996,"score_gpt":0.220107993074998,"score_spread":0.21407175267008402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376132684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825746,0.00042428338,0.00013879892,0.0000550229,0.000017299693,0.000021641434,0.0007703711,0.000005050917,0.0003101567],"genre_scores_gemma":[0.9982444,0.00039636117,0.0002158448,0.000075070115,0.000037246205,0.000029800914,0.0007209975,0.0000035577523,0.00027671602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994087,0.00014677792,0.00005384355,0.00018050084,0.00012992573,0.00008017679],"domain_scores_gemma":[0.9987226,0.00020283012,0.000516457,0.00020286262,0.00014237862,0.0002127832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010603378,0.00041900613,0.00053905713,0.00061900506,0.0005088113,0.0009401468,0.00047737354,0.0007901807,0.0011272137],"category_scores_gemma":[0.0022926126,0.0006625594,0.0010862341,0.0011642477,0.0001906853,0.0006008332,0.00034847218,0.0013354301,0.00025507621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039516645,0.00013582235,0.99790096,0.000010502881,0.00033050677,0.000076103745,0.000040353996,0.000040393963,0.00015397603,0.000010883049,0.0001169129,0.00078840164],"study_design_scores_gemma":[0.00011310164,0.00032737752,0.9981949,0.0000096466,0.00028415318,0.00034065358,0.00008508164,0.00032264277,0.00003654266,0.000021142152,0.00025424972,0.000010448681],"about_ca_topic_score_codex":0.0075795506,"about_ca_topic_score_gemma":0.0062864725,"teacher_disagreement_score":0.0075795506,"about_ca_system_score_codex":0.0002976345,"about_ca_system_score_gemma":0.00039996218,"threshold_uncertainty_score":0.015070915},"labels":[],"label_agreement":null},{"id":"W4376613148","doi":"10.1111/dom.15112","title":"Kidney protection with canagliflozin: A combined analysis of the randomized <scp>CANVAS</scp> program and <scp>CREDENCE</scp> trials","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"Janssen Research and Development; Mitsubishi Tanabe Pharma Corporation; American Society of Nephrology","keywords":"Canagliflozin; Medicine; Albuminuria; Renal function; Kidney disease; Empagliflozin; Internal medicine; Population; Urology; Creatinine; Kidney; Type 2 diabetes; Diabetes mellitus; Endocrinology","score_opus":0.019082076094144345,"score_gpt":0.25315936492035485,"score_spread":0.2340772888262105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8435052,0.13573052,0.005103795,0.0016786912,0.0020442826,0.0021405863,0.0052363384,0.0002965063,0.004264053],"genre_scores_gemma":[0.98766917,0.00630611,0.0013055782,0.0006444171,0.00065079564,0.00069591374,0.0017792044,0.000036016572,0.0009128763],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98736703,0.00949642,0.0008077893,0.0011360032,0.00071352255,0.00047926666],"domain_scores_gemma":[0.9910353,0.0049017007,0.0019380176,0.00095243537,0.00066693994,0.0005057702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01219203,0.0020097212,0.009998734,0.00088528264,0.00032630106,0.002489281,0.0007861228,0.0018529315,0.0038973247],"category_scores_gemma":[0.016010085,0.0009484455,0.017139172,0.0013025742,0.0006428531,0.0012357703,0.0011554813,0.001954249,0.0003903016],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7665197,0.0003300785,0.0056851264,0.004319616,0.20731777,0.00007631483,0.000038870814,0.00074055063,0.0008631803,0.00013521909,0.0012618736,0.012711663],"study_design_scores_gemma":[0.4365908,0.024322495,0.040935624,0.0006663893,0.49014437,0.00016691395,0.00009087477,0.002654793,0.0007826017,0.00088813907,0.0026483673,0.000108631415],"about_ca_topic_score_codex":0.001419447,"about_ca_topic_score_gemma":0.0029803114,"teacher_disagreement_score":0.01219203,"about_ca_system_score_codex":0.00066870614,"about_ca_system_score_gemma":0.0009334179,"threshold_uncertainty_score":0.06447834},"labels":[],"label_agreement":null},{"id":"W4377223615","doi":"10.1111/dom.15122","title":"Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Japan Society for the Promotion of Science","keywords":"Medicine; Renal function; Hazard ratio; Internal medicine; Meta-analysis; Meta-regression; Confidence interval; Heart failure; Diabetes mellitus; Type 2 diabetes; Placebo; Kidney disease; Blood pressure; Cardiology; Randomized controlled trial; Proportional hazards model; Endocrinology; Pathology","score_opus":0.029766468517735373,"score_gpt":0.28738270151207396,"score_spread":0.25761623299433856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377223615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049076337,0.9425129,0.0036235212,0.0005339556,0.0007416662,0.00080198963,0.0016322765,0.00021450313,0.000862858],"genre_scores_gemma":[0.70975506,0.27759373,0.005657338,0.0012291801,0.00063193624,0.0021138012,0.0016125808,0.00012101419,0.0012853625],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99216753,0.004937457,0.0011942136,0.00089378044,0.0004928516,0.0003141216],"domain_scores_gemma":[0.9898324,0.007638796,0.0011289496,0.0005531233,0.0006543031,0.00019241117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013973893,0.0039480315,0.019968983,0.0033758986,0.00054591964,0.0034337721,0.0024137397,0.0026031171,0.004319812],"category_scores_gemma":[0.020310357,0.0019043448,0.06775069,0.004145059,0.0006463798,0.0014663753,0.001258984,0.0030377626,0.000446648],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006787433,0.000036984704,0.0020367464,0.03200667,0.9551741,0.00006485356,0.000022206921,0.0008690714,0.00014991168,0.000060717557,0.0002417716,0.0025494997],"study_design_scores_gemma":[0.0011846765,0.00019002579,0.0014649885,0.0011072243,0.99517953,0.000023781864,0.000010095827,0.00041588934,0.00006525512,0.00008236168,0.0002642724,0.000011957644],"about_ca_topic_score_codex":0.007100488,"about_ca_topic_score_gemma":0.008202677,"teacher_disagreement_score":0.019968983,"about_ca_system_score_codex":0.0016995482,"about_ca_system_score_gemma":0.0014918048,"threshold_uncertainty_score":0.07390189},"labels":[],"label_agreement":null},{"id":"W4378348677","doi":"10.1111/dom.15099","title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator <scp>BI</scp> 685509 in patients with diabetic kidney disease: A randomized trial","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Kidney Foundation of Canada; University of Toronto; Diabetes Canada; Boehringer Ingelheim","keywords":"Placebo; Medicine; Renal function; Albuminuria; Internal medicine; Kidney disease; Tolerability; Creatinine; Pharmacodynamics; Urology; Endocrinology; Gastroenterology; Adverse effect; Pharmacokinetics; Pharmacology; Pathology","score_opus":0.004590596198653822,"score_gpt":0.21367781500390212,"score_spread":0.2090872188052483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378348677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991666,0.0040075253,0.00036236286,0.00045839604,0.00019777963,0.0013357162,0.0006467929,0.00006946407,0.0012559764],"genre_scores_gemma":[0.9947695,0.0014758816,0.0005231995,0.0006630755,0.00017771537,0.001062397,0.00048626095,0.000008993726,0.0008329765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99948066,0.00028279275,0.000046395213,0.000079460595,0.000040521114,0.00007022358],"domain_scores_gemma":[0.99929357,0.00015713072,0.00023877867,0.000041819745,0.000040760355,0.00022798569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013079547,0.0009853519,0.0018908782,0.00022482671,0.0002833223,0.00085466314,0.00051173475,0.0011313161,0.004064403],"category_scores_gemma":[0.0011360705,0.00039145787,0.0012487029,0.00032053256,0.0007147418,0.00049705995,0.00022964855,0.0017230986,0.00055889797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97380006,0.0025692694,0.001122521,0.0005712654,0.0009907811,0.00004152261,0.00003284464,0.0002553039,0.0039144466,0.000084207226,0.00079565076,0.015822077],"study_design_scores_gemma":[0.93093854,0.062313817,0.0041840402,0.000044049964,0.00075157423,0.00004837979,0.000017649963,0.0005655942,0.0004547206,0.00010035181,0.000565753,0.000015631602],"about_ca_topic_score_codex":0.0009522344,"about_ca_topic_score_gemma":0.0018556948,"teacher_disagreement_score":0.004064403,"about_ca_system_score_codex":0.0006060523,"about_ca_system_score_gemma":0.000748131,"threshold_uncertainty_score":0.013596833},"labels":[],"label_agreement":null},{"id":"W4378639993","doi":"10.1111/dom.15140","title":"Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the <scp>SURPASS</scp> clinical trial programme","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Eli Lilly and Company; American Diabetes Association","keywords":"Post-hoc analysis; Post hoc; Weight loss; Body weight; Weight change; Type 2 diabetes; Medicine; Clinical trial; Obesity; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.04520161446501675,"score_gpt":0.29709012449393574,"score_spread":0.251888510028919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378639993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956208,0.0012902825,0.00020584713,0.00014835098,0.00005571668,0.000851569,0.0008005795,0.000022348619,0.0010045137],"genre_scores_gemma":[0.9944916,0.00077861984,0.0006778486,0.00014070218,0.00012665801,0.00094482535,0.0013090845,0.000009305254,0.0015213548],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973099,0.0019089326,0.00019435806,0.00022582941,0.00022392289,0.00013706929],"domain_scores_gemma":[0.9955171,0.0016114644,0.0012494567,0.0006108059,0.00047529474,0.0005359494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070057595,0.0007933616,0.0019372201,0.00022353546,0.00024500082,0.0009391243,0.0004767858,0.000629872,0.003007624],"category_scores_gemma":[0.004614278,0.0003684974,0.0026487415,0.00034454773,0.00041998868,0.0005665087,0.0006359699,0.0012877806,0.0003114978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94873995,0.0029740126,0.018198458,0.00074769626,0.006469581,0.000033859247,0.00012470402,0.00049419707,0.0018954322,0.000077355566,0.0007498485,0.019494861],"study_design_scores_gemma":[0.31610918,0.36675474,0.29222757,0.00016247865,0.016075483,0.00014096184,0.00021426505,0.0021324274,0.0027378441,0.00019250668,0.0031772028,0.00007540741],"about_ca_topic_score_codex":0.001639436,"about_ca_topic_score_gemma":0.0032985336,"teacher_disagreement_score":0.0070057595,"about_ca_system_score_codex":0.00046333106,"about_ca_system_score_gemma":0.0011111717,"threshold_uncertainty_score":0.037050486},"labels":[],"label_agreement":null},{"id":"W4378640039","doi":"10.1111/dom.15119","title":"The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McMaster University; University of British Columbia; St. Michael's Hospital","funders":"University of Toronto; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Internal medicine; Cardiology; Type 2 diabetes; Waist; Body mass index; Coronary artery disease; Diabetes mellitus; Placebo; Anthropometry; Obesity; Endocrinology","score_opus":0.006149460745457394,"score_gpt":0.20428899293108377,"score_spread":0.19813953218562638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378640039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9076647,0.083672345,0.0012747793,0.0010754003,0.00044327253,0.00019591703,0.0014448793,0.000040524337,0.004188202],"genre_scores_gemma":[0.9853601,0.0101340925,0.0009665838,0.0007944057,0.0006662178,0.00014012055,0.0012433799,0.0000074097047,0.0006875871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994618,0.00020267733,0.000084058265,0.00009685562,0.0001156637,0.00003888233],"domain_scores_gemma":[0.9985287,0.0006170429,0.0004880222,0.000118579774,0.00012239642,0.00012528557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022475307,0.0003444581,0.0010338259,0.0003153419,0.00015955872,0.00049311947,0.00025712335,0.00051762094,0.0013445056],"category_scores_gemma":[0.003618433,0.00021885554,0.0016486085,0.00069166115,0.00017366813,0.00045819845,0.00025445025,0.001393097,0.00011400655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16540186,0.0016584058,0.5930587,0.0034211995,0.011088002,0.0002273389,0.000101985235,0.0010116978,0.0022920424,0.0002817474,0.003050758,0.21840622],"study_design_scores_gemma":[0.0075151175,0.006463345,0.97460234,0.0003095714,0.007145018,0.00025797272,0.00003876881,0.001065477,0.0003656646,0.00035894304,0.0018424238,0.00003535961],"about_ca_topic_score_codex":0.00074405584,"about_ca_topic_score_gemma":0.0014316358,"teacher_disagreement_score":0.0022475307,"about_ca_system_score_codex":0.00018070819,"about_ca_system_score_gemma":0.00020603294,"threshold_uncertainty_score":0.011886179},"labels":[],"label_agreement":null},{"id":"W4381598155","doi":"10.1111/dom.15148","title":"Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Eli Lilly and Company","keywords":"Semaglutide; Medicine; Regimen; Body weight; Weight loss; Weight change; Internal medicine; Propensity score matching; Mean difference; Obesity; Animal science; Confidence interval; Endocrinology; Diabetes mellitus; Type 2 diabetes; Liraglutide; Biology","score_opus":0.03178952701191406,"score_gpt":0.2765193998934975,"score_spread":0.24472987288158343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381598155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95074666,0.0297504,0.003552138,0.0006452464,0.0014126917,0.0037650873,0.0023322843,0.00013114659,0.007664467],"genre_scores_gemma":[0.98487085,0.004701778,0.0032822497,0.0004480499,0.00025397132,0.0031479304,0.0006726567,0.00002350259,0.0025990608],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99111396,0.007040913,0.0005269946,0.00054795475,0.00054073846,0.00022947592],"domain_scores_gemma":[0.9934906,0.0043074153,0.0014225916,0.00032564547,0.00022434453,0.00022949022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006507,0.0019779068,0.0041066282,0.00077448564,0.0002546427,0.0013534578,0.000925145,0.001899248,0.010018071],"category_scores_gemma":[0.009873606,0.0009774133,0.008584109,0.0004952807,0.00070316816,0.001128503,0.0009429102,0.0026801801,0.0007167838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9136421,0.0020484838,0.0029906712,0.0072518373,0.046872277,0.00007709442,0.00016061914,0.0013607001,0.0015717119,0.0006978787,0.00057766197,0.022748921],"study_design_scores_gemma":[0.6874584,0.18509586,0.018333726,0.0013512092,0.09344621,0.0003187478,0.00022778618,0.005053872,0.0029343262,0.0017919625,0.0038521858,0.00013572774],"about_ca_topic_score_codex":0.0009601337,"about_ca_topic_score_gemma":0.0016953705,"teacher_disagreement_score":0.010018071,"about_ca_system_score_codex":0.0007259,"about_ca_system_score_gemma":0.0007635873,"threshold_uncertainty_score":0.034412682},"labels":[],"label_agreement":null},{"id":"W4382363273","doi":"10.1111/dom.15073","title":"Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Internal medicine; Type 2 diabetes; Insulin glargine; Insulin resistance; Insulin; Diabetes mellitus; Endocrinology; Body mass index; Exenatide","score_opus":0.0135811436169266,"score_gpt":0.24927126617245227,"score_spread":0.23569012255552566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382363273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986552,0.00078981055,0.000114515686,0.00004500132,0.000008127811,0.000011451858,0.00012304443,0.0000037404213,0.00024920548],"genre_scores_gemma":[0.99966073,0.00005891639,0.00005796073,0.000018378953,0.000008867382,0.000006233791,0.00012219581,9.246309e-7,0.00006574661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994816,0.00022642026,0.00006480038,0.00009567161,0.000077325545,0.0000542128],"domain_scores_gemma":[0.99771655,0.00077668705,0.0008908022,0.000121902245,0.000100825906,0.00039316202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010398217,0.00020871407,0.0006346243,0.00021266662,0.00018087833,0.0004620514,0.00020218187,0.0004955631,0.0014190578],"category_scores_gemma":[0.0022033562,0.0001344463,0.00043921635,0.00029022447,0.00017569866,0.00033123282,0.00019366301,0.00050882297,0.00013159576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01951109,0.0005596334,0.96152955,0.00006980294,0.00038776934,0.00006564443,0.000061870116,0.00017618199,0.0027739808,0.000026024243,0.00013526157,0.014703159],"study_design_scores_gemma":[0.00013963073,0.0014860128,0.9976954,0.0000062155277,0.00008226305,0.00008266854,0.000026736257,0.00021971673,0.00016712489,0.000018389866,0.00007214227,0.0000035744208],"about_ca_topic_score_codex":0.00055240863,"about_ca_topic_score_gemma":0.0006909213,"teacher_disagreement_score":0.0014190578,"about_ca_system_score_codex":0.00016025033,"about_ca_system_score_gemma":0.00012573878,"threshold_uncertainty_score":0.0054991245},"labels":[],"label_agreement":null},{"id":"W4382918428","doi":"10.1111/dom.15196","title":"Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Food and Drug Administration; Novo Nordisk; McGill University; Brigham and Women's Hospital; Pfizer; National Institute on Aging; U.S. Food and Drug Administration; Patient-Centered Outcomes Research Institute; Bristol-Myers Squibb","keywords":"Metformin; Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; First line; Pharmacology; Endocrinology","score_opus":0.09025694862777887,"score_gpt":0.3301188495014631,"score_spread":0.2398619008736842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382918428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680568,0.019578803,0.000299144,0.002897145,0.000116257674,0.000015735432,0.005555798,0.00002803205,0.0034523755],"genre_scores_gemma":[0.9878973,0.0070328554,0.00035692612,0.0010749862,0.000077494056,0.000020906511,0.0030761166,0.000011144165,0.0004523028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984452,0.00023939415,0.0004501269,0.00034164684,0.00031232325,0.00021129622],"domain_scores_gemma":[0.9940507,0.00071522506,0.0036385779,0.00012469661,0.0008696866,0.0006011775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069717184,0.0001786845,0.00040200935,0.0011539843,0.00021694187,0.0012730943,0.00041257666,0.0006502873,0.0018153656],"category_scores_gemma":[0.004149915,0.00019168318,0.0007516078,0.0024415895,0.00022742728,0.0007285737,0.00066834554,0.00066995196,0.0002810447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018728533,0.0000356993,0.975327,0.00033217942,0.00020549663,0.0002956336,0.00052064005,0.00031834646,0.0006107261,0.0003226863,0.0028458165,0.018998537],"study_design_scores_gemma":[0.000010845762,0.000043131156,0.9958372,0.00015484502,0.0000334247,0.00044062533,0.00045681247,0.00023872967,0.000104325205,0.000020384989,0.0026502572,0.000009314282],"about_ca_topic_score_codex":0.06762961,"about_ca_topic_score_gemma":0.068693414,"teacher_disagreement_score":0.06762961,"about_ca_system_score_codex":0.001751026,"about_ca_system_score_gemma":0.0008852569,"threshold_uncertainty_score":0.1344719},"labels":[],"label_agreement":null},{"id":"W4383301637","doi":"10.1111/dom.15201","title":"Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Memorial University of Newfoundland","funders":"","keywords":"Canagliflozin; Dapagliflozin; Medicine; Kidney disease; Type 2 diabetes; Diabetes mellitus; Intensive care medicine; Disease; Internal medicine; Endocrinology","score_opus":0.013360940474585125,"score_gpt":0.24448621324006434,"score_spread":0.2311252727654792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383301637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96493495,0.007917775,0.012918943,0.0032488038,0.00013777398,0.00057208206,0.002889,0.00010683085,0.0072738873],"genre_scores_gemma":[0.9963231,0.0007430644,0.0016445962,0.000196551,0.000016549588,0.00008465026,0.00054328924,0.000004709149,0.0004434777],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99846977,0.0009327076,0.00006927769,0.00014928603,0.00017219986,0.000206683],"domain_scores_gemma":[0.99671835,0.0024256473,0.00043796896,0.0000635226,0.00014682993,0.00020760972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027651004,0.00072925066,0.0011826504,0.00071862945,0.00024496674,0.0012026854,0.0008601447,0.00091563864,0.0025455179],"category_scores_gemma":[0.011711368,0.00046502156,0.002853134,0.00060586113,0.00040111414,0.0009660366,0.0007430146,0.00096189626,0.00013041825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013080487,0.0008803604,0.055735413,0.00088950363,0.005344629,0.0001929684,0.000062986735,0.86881846,0.0007165325,0.0050539547,0.0019804542,0.047244336],"study_design_scores_gemma":[0.0024679005,0.0041651363,0.04214682,0.00042265758,0.005680766,0.00029734353,0.00015466358,0.93518096,0.0011684984,0.0056976094,0.002521694,0.00009596761],"about_ca_topic_score_codex":0.04316791,"about_ca_topic_score_gemma":0.030454848,"teacher_disagreement_score":0.04316791,"about_ca_system_score_codex":0.0060593914,"about_ca_system_score_gemma":0.0056828265,"threshold_uncertainty_score":0.08583331},"labels":[],"label_agreement":null},{"id":"W4383303146","doi":"10.1111/dom.15186","title":"Development and validation of a real‐world model to predict 1‐year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the <scp>iNPHORM</scp> study, United States)","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Sanofi","keywords":"Medicine; Diabetes mellitus; Gerontology; Pediatrics; Environmental health; Endocrinology","score_opus":0.024060529435662184,"score_gpt":0.2568736959968429,"score_spread":0.23281316656118073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383303146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8899291,0.00021107399,0.10251642,0.0010218305,0.00011105934,0.0006145656,0.00403324,0.00051301625,0.0010497638],"genre_scores_gemma":[0.9521635,0.00007485114,0.04165861,0.00013441966,0.000023616203,0.00058058056,0.004844913,0.000033971348,0.00048554075],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9970989,0.00216015,0.00014081354,0.00036644362,0.000102511854,0.00013113505],"domain_scores_gemma":[0.9907156,0.0067530842,0.00069389,0.00057291833,0.0009952263,0.00026925452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015253269,0.00088020944,0.00072834885,0.0011109726,0.00043863326,0.0017057679,0.0014796357,0.0010466255,0.0018999606],"category_scores_gemma":[0.018044889,0.0005400106,0.0015421603,0.00069742533,0.0004596745,0.00073649763,0.0011211209,0.0011280172,0.00045031836],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012917524,0.0014772718,0.5392825,0.00019046316,0.0013859867,0.00025724337,0.000757223,0.40892038,0.00065056107,0.0019016062,0.004646789,0.039238263],"study_design_scores_gemma":[0.00014180774,0.0004323694,0.03673945,0.000063378866,0.00012043998,0.000076453296,0.0001643984,0.96000266,0.00021173226,0.0011580756,0.00085240015,0.000036742458],"about_ca_topic_score_codex":0.013047289,"about_ca_topic_score_gemma":0.010536317,"teacher_disagreement_score":0.015253269,"about_ca_system_score_codex":0.0013626368,"about_ca_system_score_gemma":0.0018483388,"threshold_uncertainty_score":0.08066797},"labels":[],"label_agreement":null},{"id":"W4383710102","doi":"10.1111/dom.15211","title":"A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University","funders":"Novo Nordisk","keywords":"Semaglutide; Overweight; Weight loss; Medicine; Obesity; Demographics; Population; Dosing; Internal medicine; Diabetes mellitus; Type 2 diabetes; Demography; Endocrinology; Environmental health; Liraglutide","score_opus":0.014379455177132398,"score_gpt":0.22045006541803472,"score_spread":0.2060706102409023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383710102","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35194784,0.0025044908,0.6342847,0.0016690538,0.00012767452,0.0007466446,0.0030068837,0.0014095245,0.004303206],"genre_scores_gemma":[0.95071113,0.0006957487,0.04243603,0.00035428387,0.000060452996,0.0010261447,0.0017551777,0.000062502026,0.0028986267],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99903715,0.00052394636,0.000047653863,0.00021222794,0.000115773655,0.000063303116],"domain_scores_gemma":[0.9971404,0.0021854644,0.00034318122,0.00008843766,0.00017826704,0.00006428095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036637208,0.0012718182,0.0012889397,0.0012402359,0.00030522668,0.0013846587,0.0012327225,0.0013148793,0.002311135],"category_scores_gemma":[0.0070660734,0.0006106901,0.0020904148,0.0005918516,0.000329407,0.0006031613,0.00069571857,0.0015350042,0.0005002641],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050192233,0.00033204397,0.024945714,0.00015753329,0.0009087643,0.00012525904,0.000083930936,0.9370571,0.0013172752,0.0018435518,0.0009561354,0.03177079],"study_design_scores_gemma":[0.000048787067,0.0003177187,0.0041849636,0.000024860174,0.00014529431,0.00006110684,0.00001683841,0.9925795,0.00020511191,0.001848596,0.0005509417,0.00001617181],"about_ca_topic_score_codex":0.011297285,"about_ca_topic_score_gemma":0.0061589843,"teacher_disagreement_score":0.011297285,"about_ca_system_score_codex":0.0012218974,"about_ca_system_score_gemma":0.0013998456,"threshold_uncertainty_score":0.022463083},"labels":[],"label_agreement":null},{"id":"W4383711165","doi":"10.1111/dom.15203","title":"Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Department of Medicine, University of Toronto; Canadian Institutes of Health Research; Boston VA Research Institute; University of Toronto; Kidney Foundation of Canada; Heart and Stroke Foundation of Canada; Bristol-Myers Squibb","keywords":"Medicine; Albuminuria; Hazard ratio; Renal function; Kidney disease; Internal medicine; Type 2 diabetes; Clinical endpoint; Diabetes mellitus; Microalbuminuria; Dapagliflozin; Creatinine; Randomized controlled trial; Confidence interval; Urology; Endocrinology","score_opus":0.0035999479209241183,"score_gpt":0.20997615246005044,"score_spread":0.20637620453912633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383711165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989795,0.007247902,0.0002774429,0.0003536805,0.00027445314,0.00043760848,0.0003637144,0.000030205552,0.0012199859],"genre_scores_gemma":[0.994136,0.0029059446,0.00062161434,0.00078479777,0.00030021905,0.0002833472,0.00046963166,0.000005432885,0.0004929735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991346,0.00049231324,0.000084142055,0.00009567343,0.00010600915,0.00008733558],"domain_scores_gemma":[0.9988508,0.00041740944,0.0002616426,0.00007213949,0.00006725551,0.000330722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017468685,0.00083440146,0.0026231084,0.0004030085,0.0002557993,0.00061073666,0.00049324706,0.0008181366,0.0016144011],"category_scores_gemma":[0.002238116,0.00038139062,0.00253767,0.00038148405,0.0005433428,0.00049102725,0.00038775787,0.0017257944,0.00015718966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.939504,0.006000626,0.006542077,0.0005684264,0.0023506074,0.000039192368,0.000028474007,0.000560121,0.0023479736,0.00008128239,0.00058229046,0.04139491],"study_design_scores_gemma":[0.6164828,0.2987088,0.075486034,0.00011105316,0.003909983,0.00009439442,0.00003774324,0.0026378585,0.0009648461,0.0003430171,0.0011771277,0.000046351008],"about_ca_topic_score_codex":0.0014671491,"about_ca_topic_score_gemma":0.0038875884,"teacher_disagreement_score":0.0026231084,"about_ca_system_score_codex":0.00043119004,"about_ca_system_score_gemma":0.0008438343,"threshold_uncertainty_score":0.009238422},"labels":[],"label_agreement":null},{"id":"W4383998664","doi":"10.1111/dom.15202","title":"Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the <scp>GARFIELD‐AF</scp> registry","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Atrial fibrillation; Diabetes mellitus; Hazard ratio; Stroke (engine); Population; Proportional hazards model; Gastroenterology; Endocrinology; Confidence interval","score_opus":0.02280272397524157,"score_gpt":0.2761064568922203,"score_spread":0.2533037329169787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383998664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681747,0.0012163384,0.00011308332,0.00008180272,0.000012099086,0.000011847136,0.0012250326,0.0000055416053,0.0005166239],"genre_scores_gemma":[0.99748826,0.0006775425,0.00010888726,0.000060689967,0.000032101085,0.000015630265,0.0014875191,0.0000026651046,0.00012675428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988895,0.0002404752,0.00019665969,0.00028945168,0.00027668022,0.00010717929],"domain_scores_gemma":[0.9963391,0.00047268267,0.0024747015,0.00025486213,0.00017116804,0.00028752864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015142708,0.00020865718,0.00045790873,0.0008894171,0.00034558002,0.00068965397,0.00035849714,0.00034539393,0.00061873463],"category_scores_gemma":[0.0033939225,0.00017062855,0.000527454,0.0019449302,0.00019370495,0.00051161426,0.00041612462,0.00042918022,0.000119734825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009447369,0.000011277044,0.99828476,0.000007676771,0.00004586605,0.000032280368,0.000017037477,0.000022591299,0.000025141966,0.0000098057135,0.000105695886,0.0013433566],"study_design_scores_gemma":[0.000023269113,0.000038083337,0.9991868,0.000009986545,0.000044970173,0.00026280663,0.00005566336,0.00012621486,0.000032582608,0.0000144030655,0.00020150024,0.0000037312154],"about_ca_topic_score_codex":0.008046893,"about_ca_topic_score_gemma":0.011241873,"teacher_disagreement_score":0.008046893,"about_ca_system_score_codex":0.00039104425,"about_ca_system_score_gemma":0.00041622738,"threshold_uncertainty_score":0.016000092},"labels":[],"label_agreement":null},{"id":"W4385331114","doi":"10.1111/dom.15221","title":"Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Research Foundation of Korea; Ministry of Food and Drug Safety","keywords":"Medicine; Hazard ratio; Amputation; Cohort; Type 2 diabetes; Internal medicine; Retrospective cohort study; Propensity score matching; Cohort study; Diabetes mellitus; Proportional hazards model; Confidence interval; Surgery; Endocrinology","score_opus":0.008389640401609506,"score_gpt":0.21497732013791918,"score_spread":0.20658767973630968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385331114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839044,0.0006122426,0.00014864541,0.00004159414,0.000014371589,0.000016713218,0.00052173925,0.0000032199766,0.0002510604],"genre_scores_gemma":[0.99911207,0.00016814595,0.000077457604,0.000044866913,0.00001684227,0.000011630452,0.00049351796,0.0000011723376,0.000074355965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989635,0.0003426705,0.00014185085,0.0002718298,0.00017041298,0.000109802255],"domain_scores_gemma":[0.9972741,0.0006558846,0.001375056,0.0002598248,0.00017216695,0.000263039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020039654,0.00023384846,0.0005542619,0.00037071088,0.00031783647,0.0005852339,0.00027605155,0.00032883123,0.00086324674],"category_scores_gemma":[0.0041160663,0.0002043726,0.0014794363,0.00057025265,0.00019053918,0.0004964867,0.0003770343,0.00056648144,0.000102344056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007079473,0.00017380583,0.9856069,0.00005827143,0.00075895176,0.00003831273,0.00003169601,0.00016470584,0.00021845858,0.000023792389,0.00014053188,0.0057050977],"study_design_scores_gemma":[0.0005718533,0.0026154865,0.9940498,0.000024599385,0.0007316773,0.0001686524,0.0000762061,0.0011276854,0.00020402875,0.00008297781,0.0003363691,0.000010701083],"about_ca_topic_score_codex":0.0017975603,"about_ca_topic_score_gemma":0.0026645875,"teacher_disagreement_score":0.0020039654,"about_ca_system_score_codex":0.00028743994,"about_ca_system_score_gemma":0.00051770726,"threshold_uncertainty_score":0.010598123},"labels":[],"label_agreement":null},{"id":"W4385752248","doi":"10.1111/dom.15241","title":"Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval; Health Sciences Centre; University of Waterloo; Sunnybrook Health Science Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Discontinuation; Cohort; Medicine; Cotransporter; Cohort study; Internal medicine; Sodium; Chemistry","score_opus":0.022532548089796562,"score_gpt":0.25419073524909547,"score_spread":0.2316581871592989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385752248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99852437,0.00047995505,0.00005455215,0.000030477555,0.0000063194607,0.000015115596,0.00071321364,0.0000014263435,0.00017468011],"genre_scores_gemma":[0.99869186,0.00026347928,0.000053929863,0.000041832885,0.000007762209,0.000017049075,0.0008149226,0.0000020489492,0.00010715276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998123,0.00044939286,0.00029035052,0.00056047365,0.00028605168,0.00029077695],"domain_scores_gemma":[0.9958191,0.00063935213,0.001963483,0.00052566756,0.0006048279,0.0004475639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011941941,0.00044679295,0.00081379456,0.0009140192,0.0004427103,0.0009487031,0.0007531816,0.00077320467,0.0020044108],"category_scores_gemma":[0.0044337064,0.0006831181,0.0011583566,0.001522639,0.00037866947,0.0004875326,0.0011291434,0.00058542023,0.00031461337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030054126,0.000025855144,0.99804854,0.000033854732,0.00017205172,0.00019032008,0.00021321709,0.000034416775,0.00018257977,0.0000150796905,0.00012313138,0.0006603882],"study_design_scores_gemma":[0.000026652298,0.000107468084,0.9991436,0.000017042283,0.000062924206,0.00021240364,0.0001899612,0.000056733326,0.00002039066,0.0000030837034,0.0001552756,0.000004409129],"about_ca_topic_score_codex":0.059291888,"about_ca_topic_score_gemma":0.05490187,"teacher_disagreement_score":0.059291888,"about_ca_system_score_codex":0.000993928,"about_ca_system_score_gemma":0.00065709796,"threshold_uncertainty_score":0.11789358},"labels":[],"label_agreement":null},{"id":"W4385827492","doi":"10.1111/dom.15234","title":"Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Professional Engineers Ontario; Western University; Ottawa Hospital; University of Ottawa; Hamilton Health Sciences; McGill University; University of Calgary; Impact; LMC Diabetes & Endocrinology (Canada); McMaster University; Population Health Research Institute","funders":"Obesity Canada; Canadian Institutes of Health Research; Bayer Canada; National Institutes of Health; HLS Therapeutics; Bausch Health; Mitacs; Novo Nordisk; Dexcom; Insulet Corporation; Diabetes Canada; University of Calgary; Kowa Company; Sanofi; Hamilton Health Sciences; GlaxoSmithKline; McMaster University; Lawson Foundation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Alberta Health Services; Pfizer","keywords":"Medicine; Metformin; Diabetes mellitus; Type 2 diabetes; Insulin glargine; Internal medicine; Hazard ratio; Lixisenatide; Confidence interval; Insulin; Endocrinology; Liraglutide","score_opus":0.022017787339578987,"score_gpt":0.2561282778115219,"score_spread":0.23411049047194293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385827492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98693097,0.007182307,0.00058731774,0.0005390024,0.000624664,0.0025670019,0.00045141546,0.00008365818,0.0010336571],"genre_scores_gemma":[0.9866851,0.004044592,0.0014296209,0.0006826655,0.0007517468,0.004381947,0.0005264365,0.000017664779,0.0014802794],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99701667,0.0018602409,0.00032023565,0.00035159668,0.00019827548,0.00025305222],"domain_scores_gemma":[0.99703586,0.0013311025,0.0006419736,0.00024367383,0.00013015236,0.0006172387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035194093,0.0014918006,0.0043356232,0.00053262286,0.00043679844,0.000941315,0.00095682335,0.002322684,0.006543532],"category_scores_gemma":[0.004278985,0.0007701548,0.004812851,0.0006643162,0.0013135687,0.0008747398,0.00070930057,0.002471466,0.000607268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9861893,0.0038119243,0.00037503266,0.00074354757,0.001342856,0.000016291166,0.000027144808,0.00009925485,0.0003636907,0.000025343765,0.00011648152,0.0068891626],"study_design_scores_gemma":[0.95724106,0.039425436,0.0017096762,0.000068418354,0.0010528364,0.000014620205,0.000012944448,0.00017610351,0.0001129408,0.000052916115,0.00012356375,0.000009477399],"about_ca_topic_score_codex":0.0017219662,"about_ca_topic_score_gemma":0.0019907665,"teacher_disagreement_score":0.006543532,"about_ca_system_score_codex":0.0007954854,"about_ca_system_score_gemma":0.0012178116,"threshold_uncertainty_score":0.021890342},"labels":[],"label_agreement":null},{"id":"W4386084393","doi":"10.1111/dom.15243","title":"Impact of sarcosine on diabetic retinopathy: Findings based on weighted gene co‐expression network analysis and machine learning techniques","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"Zhejiang University; Anhui Medical University; Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China; Wenzhou Medical University","keywords":"Sarcosine; Odds ratio; Internal medicine; Medicine; Diabetic retinopathy; Logistic regression; Confidence interval; Interquartile range; Body mass index; Diabetes mellitus; Endocrinology; Bioinformatics; Oncology; Genetics; Biology","score_opus":0.009477936432036555,"score_gpt":0.2664616575259388,"score_spread":0.2569837210939023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386084393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569167,0.002865226,0.038451858,0.0002635158,0.00001715912,0.00002219253,0.0006731468,0.00007991731,0.0007103828],"genre_scores_gemma":[0.99143106,0.0005968801,0.007348879,0.000031043972,0.000014822564,0.000017883518,0.0003946514,0.000007987957,0.0001568744],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99947923,0.0002465491,0.00002256834,0.00014226149,0.00007268224,0.000036767236],"domain_scores_gemma":[0.9986376,0.0007173146,0.00038845337,0.00010360267,0.000097495715,0.000055493612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010404453,0.00036776395,0.0003540738,0.0014875967,0.00018836178,0.00045963726,0.00025316095,0.0002289138,0.000598054],"category_scores_gemma":[0.0026088383,0.00010435146,0.00061042997,0.001624684,0.00026264644,0.0003985777,0.00034349886,0.0002901924,0.0000873302],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013989063,0.00012789789,0.8255191,0.00039122743,0.0021763998,0.00035164744,0.00023812897,0.035423417,0.031060798,0.0014603676,0.0007063297,0.101145834],"study_design_scores_gemma":[0.000026092946,0.00024352553,0.75199646,0.000054041157,0.0007525154,0.0006383665,0.00018894766,0.23598114,0.0042565237,0.004374413,0.0014535204,0.000034497592],"about_ca_topic_score_codex":0.0032661934,"about_ca_topic_score_gemma":0.0034504512,"teacher_disagreement_score":0.0032661934,"about_ca_system_score_codex":0.0002741385,"about_ca_system_score_gemma":0.00025286592,"threshold_uncertainty_score":0.0064943433},"labels":[],"label_agreement":null},{"id":"W4386703896","doi":"10.1111/dom.15268","title":"Severe (level 3) hypoglycaemia occurrence in a real‐world cohort of adults with type 1 or 2 diabetes mellitus ( <scp>iNPHORM</scp> , United States)","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Center for Advancing Translational Sciences; Sanofi","keywords":"Medicine; Type 1 diabetes; Incidence (geometry); Type 2 Diabetes Mellitus; Diabetes mellitus; Epidemiology; Internal medicine; Prospective cohort study; Pediatrics; Demography; Endocrinology","score_opus":0.024700575008834137,"score_gpt":0.2713769618219571,"score_spread":0.24667638681312296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386703896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629515,0.00011600698,0.000088800196,0.000047230475,0.000006209634,0.000021968817,0.003016809,0.000003497059,0.00040422857],"genre_scores_gemma":[0.9959906,0.00014911374,0.00016092055,0.00010000793,0.0000117816835,0.000047058787,0.0033327173,0.0000019892234,0.00020583013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995987,0.00009979963,0.000068261346,0.000109086,0.00006763873,0.000056489218],"domain_scores_gemma":[0.9985857,0.00011353852,0.000897082,0.0001129019,0.00010807514,0.00018264719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007350858,0.00018236974,0.00019541572,0.0004560446,0.00035067557,0.00058277254,0.00024876223,0.00038658563,0.001475768],"category_scores_gemma":[0.0015716912,0.00023009129,0.00038122883,0.0008916295,0.00014390457,0.0005303141,0.0005139082,0.000527162,0.0002887215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040131654,0.00001663637,0.99917287,0.0000086595255,0.000018140096,0.000017464152,0.000040428095,0.000011518138,0.000044322205,0.000005225638,0.00017193684,0.000452719],"study_design_scores_gemma":[0.0000033688964,0.000043917516,0.9995788,0.0000057682673,0.0000068262034,0.00008603965,0.0000908291,0.00004190359,0.000013793006,0.0000065907852,0.0001205953,0.0000017152998],"about_ca_topic_score_codex":0.010404955,"about_ca_topic_score_gemma":0.014809509,"teacher_disagreement_score":0.010404955,"about_ca_system_score_codex":0.00024506016,"about_ca_system_score_gemma":0.00026500356,"threshold_uncertainty_score":0.020688772},"labels":[],"label_agreement":null},{"id":"W4387033838","doi":"10.1111/dom.15240","title":"Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross‐sectional surveys","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Sanofi","keywords":"Medicine; Basal insulin; Observational study; Pharmacy; Cross-sectional study; Family medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine","score_opus":0.01432211689660374,"score_gpt":0.2712706262229241,"score_spread":0.25694850932632035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990569,0.00014066964,0.0000363473,0.00018960173,0.000003784381,0.000011485936,0.00018394628,0.0000021118788,0.00037519974],"genre_scores_gemma":[0.99928623,0.00016239577,0.00009938023,0.00017104599,0.00000765217,0.000016256039,0.00017922201,0.000001082182,0.00007672072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759275,0.0013234741,0.00033728074,0.0001447905,0.00037510518,0.00022659448],"domain_scores_gemma":[0.98908,0.0036030822,0.0049616476,0.0001996202,0.0006924432,0.0014631096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030872077,0.00015038719,0.000248693,0.0005737421,0.000564297,0.00087694003,0.00032459333,0.0006135897,0.0012829083],"category_scores_gemma":[0.008681943,0.00028346118,0.0004287556,0.0006506128,0.00041061032,0.00085201894,0.00093715254,0.0008136713,0.00014559356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007291106,0.00016315868,0.99417084,0.000035586036,0.000051256742,0.0000627912,0.0027557395,0.000048495087,0.00009067129,0.000012117774,0.00028518596,0.0022512784],"study_design_scores_gemma":[0.000008973837,0.00021525052,0.99323434,0.000027793196,0.000015824402,0.00016544946,0.005739497,0.00016581688,0.00004519803,0.000009714641,0.00036348775,0.000008745433],"about_ca_topic_score_codex":0.0077993367,"about_ca_topic_score_gemma":0.009218646,"teacher_disagreement_score":0.0077993367,"about_ca_system_score_codex":0.00049905747,"about_ca_system_score_gemma":0.0005838572,"threshold_uncertainty_score":0.016326904},"labels":[],"label_agreement":null},{"id":"W4387357825","doi":"10.1111/dom.15301","title":"Breaking a feedback loop: A reassessment of an investigator initiated <scp>OS‐AID</scp> study","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Context-Aware Activity Recognition Systems","field":"Computer Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Medical Research Council","keywords":"Gateway (web page); Computer science; Loop (graph theory); World Wide Web; Combinatorics; Mathematics","score_opus":0.04574036661001977,"score_gpt":0.2687548718851961,"score_spread":0.22301450527517633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387357825","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005195593,0.0017932815,0.0006790317,0.96694505,0.028312024,0.00002761483,0.000044677465,0.000052807143,0.0016259921],"genre_scores_gemma":[0.013327976,0.0036782739,0.0029375146,0.880064,0.09376953,0.00017023768,0.00006719877,0.000111073874,0.005874211],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98706114,0.0054922947,0.0017158659,0.0012518198,0.0035628225,0.00091611553],"domain_scores_gemma":[0.8765299,0.07639853,0.0036369679,0.00612549,0.026689107,0.010620008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020868223,0.00060756033,0.0010943776,0.0007544143,0.0034824775,0.005261963,0.0026781121,0.026157223,0.0072316607],"category_scores_gemma":[0.13494855,0.00037941601,0.0015254841,0.00057444716,0.0037924463,0.0053409804,0.0018922754,0.033767983,0.007208252],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015308936,0.00007941013,0.000719821,0.00015953548,0.00003244649,0.0057490864,0.00050594466,0.00007658627,0.00025234296,0.005523588,0.93265027,0.05409797],"study_design_scores_gemma":[0.00014389775,0.000239351,0.00071328774,0.0009869973,0.000053835825,0.006862985,0.0010525411,0.00047989385,0.00039523287,0.016343785,0.9726504,0.00007768492],"about_ca_topic_score_codex":0.0024644297,"about_ca_topic_score_gemma":0.004716876,"teacher_disagreement_score":0.026157223,"about_ca_system_score_codex":0.004357228,"about_ca_system_score_gemma":0.0076910495,"threshold_uncertainty_score":0.110363066},"labels":[],"label_agreement":null},{"id":"W4387563674","doi":"10.1111/dom.15309","title":"Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from <scp>SUSTAIN</scp> 1‐5, 7‐10 and <scp>SUSTAIN</scp> China","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FSD Pharma (Canada)","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Post-hoc analysis; Type 2 diabetes; Internal medicine; Clinical endpoint; Placebo; Logistic regression; Covariate; Randomized controlled trial; Diabetes mellitus; Endocrinology; Mathematics; Statistics","score_opus":0.014177814722031596,"score_gpt":0.24719868808648404,"score_spread":0.23302087336445246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387563674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9321694,0.047503375,0.004775096,0.0003202007,0.00059463404,0.0031524142,0.008835605,0.00025268472,0.0023966024],"genre_scores_gemma":[0.9850566,0.004365812,0.002173036,0.00029668328,0.00018030601,0.0036352563,0.0030967898,0.000056408648,0.0011391889],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9898657,0.005811053,0.0015699917,0.0015163788,0.0008509205,0.00038591784],"domain_scores_gemma":[0.99393696,0.00303169,0.001551196,0.0006206734,0.00063925545,0.00022022112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015114039,0.0019550053,0.011666264,0.001356781,0.00022832354,0.0014098341,0.0009141541,0.0015771564,0.002426929],"category_scores_gemma":[0.011912092,0.00092462345,0.020196285,0.0017013241,0.00056649436,0.001176571,0.0010439995,0.0014920087,0.0002708283],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58663964,0.00043110014,0.021956647,0.012902218,0.34866852,0.000115082,0.00020231672,0.0016429749,0.0030857988,0.00012080889,0.001529038,0.022705821],"study_design_scores_gemma":[0.16105257,0.060150497,0.14668858,0.0012325213,0.619585,0.00025988906,0.00024220567,0.0036204783,0.003331817,0.00045879552,0.0031940476,0.00018372353],"about_ca_topic_score_codex":0.001994538,"about_ca_topic_score_gemma":0.002696066,"teacher_disagreement_score":0.015114039,"about_ca_system_score_codex":0.0007047585,"about_ca_system_score_gemma":0.0010156193,"threshold_uncertainty_score":0.07993162},"labels":[],"label_agreement":null},{"id":"W4387600391","doi":"10.1111/dom.15315","title":"Time trends towards earlier puberty in boys and girls with type 1 diabetes: Insights from the German Diabetes Prospective Follow‐up (DPV) registry, 2000 to 2021","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kirkland and District Hospital","funders":"","keywords":"Medicine; Type 1 diabetes; Diabetes mellitus; Body mass index; Type 2 diabetes; Prospective cohort study; Pediatrics; Population; Internal medicine; Endocrinology; Environmental health","score_opus":0.004603337045971016,"score_gpt":0.20816750624274769,"score_spread":0.20356416919677667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387600391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890015,0.0017108239,0.00008589217,0.00006817341,0.000011623842,0.000008690642,0.008485168,0.000010376537,0.00061762496],"genre_scores_gemma":[0.9904682,0.0009216589,0.00010637648,0.000030445008,0.000009815129,0.000013658873,0.008219632,0.0000044966214,0.0002257762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996284,0.000068334055,0.000055533048,0.00011166036,0.000060560822,0.000075475546],"domain_scores_gemma":[0.99893314,0.00011767905,0.0006448984,0.000053328065,0.00011871314,0.00013219709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006354129,0.00021872787,0.00026612115,0.0013929569,0.00020982226,0.0004935236,0.0002607534,0.0002793875,0.00090372487],"category_scores_gemma":[0.0011994861,0.00016963268,0.00038457484,0.0017477634,0.00013860058,0.0004237193,0.00039309674,0.00033543343,0.0002197517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007132091,0.000007494356,0.9982657,0.000018051574,0.000033764394,0.000030932548,0.00004484584,0.00003457947,0.000060575934,0.000010661943,0.0001647091,0.0012574395],"study_design_scores_gemma":[0.0000013607253,0.000012665605,0.9996762,0.000004900034,0.000009146003,0.000047005455,0.000051531595,0.0000216466,0.000013174441,0.0000018147961,0.00015965062,8.1785544e-7],"about_ca_topic_score_codex":0.018870464,"about_ca_topic_score_gemma":0.024389658,"teacher_disagreement_score":0.018870464,"about_ca_system_score_codex":0.00033717774,"about_ca_system_score_gemma":0.00031516608,"threshold_uncertainty_score":0.037521243},"labels":[],"label_agreement":null},{"id":"W4387764698","doi":"10.1111/dom.15333","title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the <scp>SURPASS</scp> clinical trials","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"European Foundation for the Study of Diabetes; Eli Lilly and Company","keywords":"Medicine; Nausea; Placebo; Adverse effect; Vomiting; Weight change; Weight loss; Semaglutide; Internal medicine; Type 2 diabetes; Gastroenterology; Clinical trial; Diabetes mellitus; Liraglutide; Obesity; Endocrinology","score_opus":0.03167783784088358,"score_gpt":0.2967542691922431,"score_spread":0.26507643135135955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387764698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8173867,0.16579765,0.0011779288,0.0019452627,0.0006126132,0.0040440713,0.0015050486,0.00006605625,0.0074646454],"genre_scores_gemma":[0.9662312,0.027222246,0.001272844,0.00089314906,0.00030658097,0.0026156611,0.0006692839,0.000007796372,0.00078120123],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994651,0.0039938684,0.0006051175,0.00023954573,0.00036937968,0.00014112188],"domain_scores_gemma":[0.9956108,0.0018862844,0.0018034894,0.00013676989,0.00028720507,0.0002755662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008506508,0.00064927054,0.0020431965,0.0003121438,0.00026496922,0.0010812139,0.00044949408,0.000869268,0.002864518],"category_scores_gemma":[0.007750911,0.000348428,0.003853154,0.00055223407,0.00036710748,0.0005539131,0.00046362093,0.001274583,0.00017099649],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72582227,0.001952304,0.030061662,0.04966805,0.06111295,0.00025407138,0.00047725416,0.0010744545,0.004665079,0.0008711365,0.0030682683,0.12097256],"study_design_scores_gemma":[0.61581105,0.13687381,0.14403762,0.006288275,0.07473892,0.0006833403,0.00041732655,0.0016054136,0.0026509806,0.001270072,0.0155140525,0.00010920658],"about_ca_topic_score_codex":0.0007274869,"about_ca_topic_score_gemma":0.0021910956,"teacher_disagreement_score":0.008506508,"about_ca_system_score_codex":0.0004168345,"about_ca_system_score_gemma":0.0009983268,"threshold_uncertainty_score":0.04498726},"labels":[],"label_agreement":null},{"id":"W4387865855","doi":"10.1111/dom.15331","title":"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; Université de Sherbrooke; McGill University Health Centre","funders":"McGill University Health Centre; McGill University","keywords":"Medicine; Metformin; Pioglitazone; Dementia; Cochrane Library; Meta-analysis; Internal medicine; Type 2 diabetes; Diabetes mellitus; CINAHL; Cohort study; Relative risk; Pharmacology; Endocrinology; Insulin; Confidence interval; Psychiatry; Disease; Psychological intervention","score_opus":0.04235189374697281,"score_gpt":0.3084662030670428,"score_spread":0.26611430932007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387865855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017672307,0.99565,0.00069214957,0.0002713471,0.00020943976,0.0005346727,0.0005268985,0.000022161481,0.0003260338],"genre_scores_gemma":[0.0825638,0.9047031,0.0051104752,0.0017005967,0.00046295498,0.0038460912,0.0010241991,0.000040074952,0.0005486811],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98022753,0.010696414,0.0051627834,0.0013626856,0.0020415813,0.0005090848],"domain_scores_gemma":[0.9727393,0.01944091,0.0049109217,0.0010829065,0.0015895605,0.00023641944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023399657,0.0033498867,0.021231484,0.011491124,0.00089134456,0.0045278943,0.002439457,0.0026856444,0.0047254995],"category_scores_gemma":[0.051526688,0.002304987,0.03855868,0.011223999,0.0006987978,0.0025303916,0.002257435,0.001931609,0.0004937029],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008430163,0.000023462373,0.0028444491,0.38980553,0.59380966,0.00010604675,0.00007332737,0.00038138204,0.00015377473,0.00019770561,0.0009432528,0.01081847],"study_design_scores_gemma":[0.00044354607,0.00015107771,0.002496957,0.062325284,0.93137836,0.00010585821,0.000039745126,0.00020712477,0.00009036797,0.0003041484,0.0024331536,0.000024331395],"about_ca_topic_score_codex":0.0067094695,"about_ca_topic_score_gemma":0.01709731,"teacher_disagreement_score":0.023399657,"about_ca_system_score_codex":0.0041137584,"about_ca_system_score_gemma":0.005388793,"threshold_uncertainty_score":0.12375069},"labels":[],"label_agreement":null},{"id":"W4387950612","doi":"10.1111/dom.15340","title":"Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Paul's Hospital; University of British Columbia; St. Michael's Hospital; McGill University Health Centre","funders":"Janssen Canada; Janssen Research and Development; McGill University Health Centre; Language Literacy and Culture, University of Maryland, Baltimore County","keywords":"Canagliflozin; Credence; Type 2 diabetes; Empagliflozin; Heart failure; Medicine; Diabetes mellitus; Clinical trial; Pharmacology; Internal medicine; Endocrinology; Computer science","score_opus":0.013380282846031787,"score_gpt":0.22747753760283193,"score_spread":0.21409725475680014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387950612","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86166495,0.07605717,0.006184295,0.010962683,0.0020884671,0.0005602344,0.0068878084,0.00030750924,0.035287008],"genre_scores_gemma":[0.98716265,0.003954768,0.0017660592,0.0018675231,0.001442739,0.00017404713,0.0019762125,0.000060558952,0.0015953493],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971119,0.0013920238,0.00022628663,0.0004899155,0.00053007586,0.00024974422],"domain_scores_gemma":[0.9840731,0.010835178,0.0024673063,0.000949839,0.00050988,0.0011647975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005939242,0.00037386976,0.0017021917,0.0004260858,0.0002146502,0.0017113774,0.00047445545,0.00071706186,0.0052596447],"category_scores_gemma":[0.022102557,0.0002468407,0.0022143405,0.00073819706,0.00034036476,0.00123712,0.00051826966,0.0025545075,0.0006498515],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37261474,0.0012675534,0.12347779,0.0018781292,0.009088917,0.00022416127,0.00019448278,0.004414646,0.0011180157,0.0031587712,0.021537112,0.4610257],"study_design_scores_gemma":[0.10745738,0.043240964,0.7296733,0.0018602523,0.024911921,0.00093891757,0.000335248,0.027803965,0.0017061724,0.023737134,0.037997466,0.00033713115],"about_ca_topic_score_codex":0.0012492018,"about_ca_topic_score_gemma":0.0023976145,"teacher_disagreement_score":0.005939242,"about_ca_system_score_codex":0.00067576364,"about_ca_system_score_gemma":0.0011351266,"threshold_uncertainty_score":0.031410098},"labels":[],"label_agreement":null},{"id":"W4388538144","doi":"10.1111/dom.15353","title":"Effects of <scp>CB1R</scp> inverse agonist, <scp>INV</scp> ‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Inversago Pharma (Canada)","funders":"American Diabetes Association","keywords":"Placebo; Medicine; Tolerability; Waist; Internal medicine; Gastroenterology; Confidence interval; Pharmacodynamics; Area under the curve; Body mass index; Metabolic syndrome; Adverse effect; Pharmacokinetics; Endocrinology; Obesity; Pathology","score_opus":0.008409374410353864,"score_gpt":0.2591078960781044,"score_spread":0.25069852166775053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388538144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995389,0.0025204094,0.0002510254,0.0001481125,0.00010288455,0.00061395485,0.00031172557,0.000039332346,0.0006235947],"genre_scores_gemma":[0.99521685,0.0014834604,0.0007022249,0.00045692205,0.000181153,0.0006501655,0.00047886575,0.000008999745,0.00082142506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996946,0.00015623547,0.000025468815,0.000049045677,0.000034948127,0.000039786566],"domain_scores_gemma":[0.99953365,0.0001118799,0.000106482614,0.000026917116,0.000036784564,0.00018426377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009008916,0.0010695684,0.0018972333,0.00027245266,0.00027366297,0.0004351954,0.00045410093,0.001113654,0.0031947705],"category_scores_gemma":[0.00063131173,0.000578894,0.0010831084,0.00022630444,0.0005240094,0.0004557206,0.00020121605,0.0014166475,0.00047431095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9383154,0.0126299765,0.0020647268,0.0007450894,0.0009224154,0.00012973038,0.00005322256,0.00029338422,0.021967273,0.000047607857,0.00051034556,0.022320949],"study_design_scores_gemma":[0.7361278,0.24837321,0.011085096,0.000032819535,0.0007991127,0.0001444988,0.00004023496,0.0006728241,0.0019888293,0.00005695095,0.0006537964,0.00002494691],"about_ca_topic_score_codex":0.0006211193,"about_ca_topic_score_gemma":0.0018012285,"teacher_disagreement_score":0.0031947705,"about_ca_system_score_codex":0.00029912,"about_ca_system_score_gemma":0.0006463348,"threshold_uncertainty_score":0.01068759},"labels":[],"label_agreement":null},{"id":"W4388946741","doi":"10.1111/dom.15362","title":"Obesity attenuates acute phosphate excretion after an oral challenge in females: A sex‐specific effect of obesity on phosphate handling","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Southeastern Ontario Academic Medical Organization; Canadian Institutes of Health Research","keywords":"Gateway (web page); Obesity; Table (database); Computer science; Medicine; Psychology; World Wide Web; Database; Internal medicine","score_opus":0.019590036974337796,"score_gpt":0.26804462252378053,"score_spread":0.24845458554944272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388946741","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494886,0.001718637,0.001102605,0.000097840864,0.00008331806,0.00007046851,0.0008479175,0.000046593275,0.0010838398],"genre_scores_gemma":[0.99017286,0.0010174263,0.0017246708,0.00024940036,0.00014529702,0.00023366202,0.0015045286,0.00008488593,0.004867323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968374,0.00006687572,0.000015386126,0.00007728492,0.00008986506,0.000066889894],"domain_scores_gemma":[0.9995109,0.0000619355,0.00012967296,0.00009536852,0.000075531825,0.00012665642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006754066,0.00072258327,0.00071044586,0.00051626464,0.00043957404,0.0004753864,0.0003253716,0.00034338445,0.0032492203],"category_scores_gemma":[0.0006273638,0.00025573466,0.00052373525,0.00036173468,0.00033679238,0.00027209392,0.00046261327,0.0007896112,0.00063905865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06522672,0.008593556,0.4378372,0.00042269472,0.00096766674,0.0010545576,0.00065421086,0.00028654272,0.3904512,0.00035225888,0.0022742175,0.09187919],"study_design_scores_gemma":[0.00015606853,0.012267554,0.95664644,0.000018670613,0.0003211631,0.0006832821,0.00014920795,0.00043646866,0.025708357,0.00008562475,0.0034994285,0.000027736374],"about_ca_topic_score_codex":0.0009948707,"about_ca_topic_score_gemma":0.0014380374,"teacher_disagreement_score":0.0032492203,"about_ca_system_score_codex":0.00016248444,"about_ca_system_score_gemma":0.0005326429,"threshold_uncertainty_score":0.010869741},"labels":[],"label_agreement":null},{"id":"W4388982295","doi":"10.1111/dom.15361","title":"<scp>S</scp> odium‐glucose co‐transporter‐2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"University of Alberta; Government of Alberta","keywords":"Albuminuria; Medicine; Renal function; Kidney disease; Diabetes mellitus; Internal medicine; Retrospective cohort study; Urology; Cohort; Endocrinology","score_opus":0.00805353841563022,"score_gpt":0.21127396958394334,"score_spread":0.20322043116831312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388982295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977719,0.0002940021,0.00020017389,0.0000377122,0.000014012444,0.000021190692,0.0014000529,0.0000036586077,0.00025719806],"genre_scores_gemma":[0.99874336,0.00012940854,0.0001145045,0.000050383827,0.000016658392,0.00002140151,0.00077580725,0.0000022929255,0.00014622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912184,0.0002202511,0.00014195453,0.00029110516,0.00013010649,0.00009478692],"domain_scores_gemma":[0.9979406,0.00023406031,0.0010047411,0.00037555853,0.00016359129,0.00028143972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013101159,0.0003636041,0.0004921713,0.0005240029,0.0004562289,0.00085678475,0.00044706455,0.00054254604,0.0014251039],"category_scores_gemma":[0.002139343,0.00057985977,0.0012146437,0.0010625791,0.00025047842,0.0005049107,0.00042679292,0.0007952156,0.00032750375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032771513,0.000034501216,0.9986507,0.0000092958535,0.0002882411,0.000036512454,0.000023300563,0.000031539585,0.00012525584,0.000017522809,0.00010962843,0.0003457907],"study_design_scores_gemma":[0.00007334379,0.0003365525,0.9979334,0.000011033558,0.00032876112,0.000323277,0.00012719055,0.00040875303,0.00009151159,0.000032585554,0.00032581558,0.0000078608955],"about_ca_topic_score_codex":0.0068243165,"about_ca_topic_score_gemma":0.005972427,"teacher_disagreement_score":0.0068243165,"about_ca_system_score_codex":0.00025900782,"about_ca_system_score_gemma":0.0003453954,"threshold_uncertainty_score":0.013569176},"labels":[],"label_agreement":null},{"id":"W4389097078","doi":"10.1111/dom.15385","title":"Insulin, hypoglycaemia and dementia: A causal mediation analysis showcasing challenges and potential opportunities","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Manitoba Health; Women's College Hospital; University of Toronto; University of Waterloo","funders":"Alzheimer Society Research Program; Alzheimer's Society","keywords":"Medicine; Dementia; Mediation; Insulin; Internal medicine; Disease","score_opus":0.03982752714907278,"score_gpt":0.269136602795444,"score_spread":0.2293090756463712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389097078","genre_codex":"methods","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036204,0.26100346,0.46083987,0.22516815,0.006533129,0.0021260339,0.0014124087,0.0005272159,0.0061857635],"genre_scores_gemma":[0.46725523,0.11406206,0.35775068,0.03450244,0.018067895,0.0048430995,0.0008082,0.00030874653,0.0024016777],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.93391037,0.059295435,0.001490887,0.002386837,0.002200228,0.0007161999],"domain_scores_gemma":[0.69291097,0.29452458,0.0028562872,0.006100006,0.002638814,0.00096941233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13329296,0.0032375278,0.0042658276,0.0036277026,0.0017773608,0.0040079476,0.005601148,0.0038945912,0.0097142],"category_scores_gemma":[0.15378235,0.0012869003,0.0072657107,0.0043353285,0.004357708,0.007877445,0.007496302,0.00966315,0.0006111699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036988868,0.0012637855,0.06881291,0.026221702,0.041640077,0.009366547,0.008688986,0.01142623,0.0015629187,0.41651174,0.024376838,0.38642937],"study_design_scores_gemma":[0.0011349324,0.0010292397,0.010563062,0.006107097,0.01102068,0.0017453611,0.0021086137,0.048472226,0.0004935851,0.8884665,0.028607821,0.0002508618],"about_ca_topic_score_codex":0.01102376,"about_ca_topic_score_gemma":0.014235883,"teacher_disagreement_score":0.13329296,"about_ca_system_score_codex":0.002304965,"about_ca_system_score_gemma":0.0077977497,"threshold_uncertainty_score":0.704929},"labels":[],"label_agreement":null},{"id":"W4389109661","doi":"10.1111/dom.15381","title":"A comment on tirzepatide versus glucagon‐like peptide‐1 receptor agonists and heart rate with regard to ‘Impact of a dual glucose‐dependent insulinotropic peptide/glucagon‐like peptide‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis’","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Diabetes mellitus; Type 2 diabetes; Receptor; Agonist; Medicine; Internal medicine; Chemistry; Endocrinology","score_opus":0.029839198786723593,"score_gpt":0.28017882106944203,"score_spread":0.25033962228271844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389109661","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002350649,0.020993313,0.00044505327,0.70628047,0.26801622,0.00019893273,0.0022755521,0.00015854176,0.001396879],"genre_scores_gemma":[0.0027878033,0.01014364,0.000644113,0.88542753,0.09624576,0.0005009903,0.00041833264,0.000088239096,0.0037435906],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9826233,0.0053167767,0.0044881403,0.0018787694,0.0048319055,0.0008610595],"domain_scores_gemma":[0.90380174,0.06543795,0.0070211585,0.0020236725,0.019806262,0.0019091757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027366245,0.0018817469,0.0036085614,0.0028569037,0.0019018023,0.0030122446,0.006155328,0.026318248,0.015381293],"category_scores_gemma":[0.13766915,0.0015019566,0.007203968,0.0034176072,0.0025931578,0.0041672434,0.0022269725,0.01885944,0.00867777],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002716517,0.000008904847,0.000175231,0.0045857746,0.00032319728,0.00018192768,0.00008962548,0.000046741075,0.0002128756,0.0007967723,0.9873125,0.0059947683],"study_design_scores_gemma":[0.0016820874,0.0002496491,0.0030197266,0.011429029,0.002031307,0.00093890814,0.00022314022,0.0003311366,0.00084607,0.007100883,0.9719685,0.00017953929],"about_ca_topic_score_codex":0.008958219,"about_ca_topic_score_gemma":0.010220354,"teacher_disagreement_score":0.027366245,"about_ca_system_score_codex":0.0040408247,"about_ca_system_score_gemma":0.0077893324,"threshold_uncertainty_score":0.1447283},"labels":[],"label_agreement":null},{"id":"W4389180501","doi":"10.1111/dom.15367","title":"Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies","year":2023,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"McGill University","keywords":"Medicine; Incretin; Meta-analysis; Type 2 diabetes; Observational study; Internal medicine; Confidence interval; Diabetic retinopathy; Cochrane Library; Diabetes mellitus; Retinopathy; Relative risk; Endocrinology","score_opus":0.06251447739997212,"score_gpt":0.31274015845991415,"score_spread":0.25022568105994203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389180501","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003370283,0.9952839,0.0003536826,0.00014621508,0.00011300522,0.0002698252,0.00031169236,0.000012484231,0.00013886802],"genre_scores_gemma":[0.09597581,0.8991315,0.00208602,0.0007070037,0.0002031405,0.0010864373,0.0006108276,0.000019767649,0.0001794782],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9823415,0.008305971,0.0058689844,0.0012886951,0.0018299692,0.00036480086],"domain_scores_gemma":[0.9551262,0.032923564,0.0075578205,0.0010823248,0.0029603385,0.00034978462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020202193,0.0024864292,0.01920493,0.008863392,0.0006909108,0.003418593,0.0021119276,0.0023010054,0.0020506624],"category_scores_gemma":[0.052639496,0.0017860034,0.03187071,0.010447467,0.0007723685,0.0015971154,0.0016161259,0.0018428232,0.00021486357],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010298553,0.000022463933,0.0044885604,0.5401486,0.44213787,0.00013992508,0.00010264548,0.0003912364,0.00014116245,0.000115777155,0.0005233894,0.010758476],"study_design_scores_gemma":[0.00041960704,0.0001768148,0.0038317738,0.05629777,0.93702936,0.00015118737,0.000066654306,0.00018238019,0.00012334884,0.00019436186,0.0014983105,0.000028530718],"about_ca_topic_score_codex":0.00704389,"about_ca_topic_score_gemma":0.014526012,"teacher_disagreement_score":0.020202193,"about_ca_system_score_codex":0.0031859027,"about_ca_system_score_gemma":0.0052698534,"threshold_uncertainty_score":0.10684067},"labels":[],"label_agreement":null},{"id":"W4389609315","doi":"10.1111/dom.15396","title":"Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Internal medicine; Post-hoc analysis; Population; Placebo; Myocardial infarction; Physical therapy; Stroke (engine); Cardiology; Diabetes mellitus; Endocrinology; Liraglutide; Pathology","score_opus":0.0060700517841647175,"score_gpt":0.20066669162208325,"score_spread":0.19459663983791853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389609315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98071563,0.0032814082,0.001667182,0.00057341915,0.0012562193,0.0037144858,0.004722205,0.0002117804,0.0038577423],"genre_scores_gemma":[0.97692525,0.0014089452,0.0027825164,0.0008936182,0.0010969151,0.0062539782,0.0033194027,0.00011890555,0.007200437],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9966197,0.001953409,0.00023168341,0.0005215281,0.00028264264,0.00039107073],"domain_scores_gemma":[0.9962698,0.0016071618,0.0005629559,0.0006216616,0.00043526347,0.00050311105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057317,0.002578096,0.005651191,0.00046818546,0.000522025,0.0015339163,0.0012941449,0.0015456834,0.009721812],"category_scores_gemma":[0.0063439514,0.00080959697,0.010655205,0.00060574076,0.0008112048,0.0015214041,0.0010895655,0.0029955946,0.0011381821],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97854084,0.002433601,0.0016446866,0.00048815782,0.008849484,0.000057970643,0.00005033014,0.00046990355,0.0009173377,0.0000760227,0.0011887978,0.005282739],"study_design_scores_gemma":[0.64992154,0.27126265,0.03326849,0.00012937686,0.03438681,0.00011610458,0.00014459208,0.0040206527,0.0024907799,0.0005585401,0.0035934711,0.000107047184],"about_ca_topic_score_codex":0.0014238742,"about_ca_topic_score_gemma":0.0019459865,"teacher_disagreement_score":0.009721812,"about_ca_system_score_codex":0.0006435273,"about_ca_system_score_gemma":0.0013818023,"threshold_uncertainty_score":0.032522738},"labels":[],"label_agreement":null},{"id":"W4390005477","doi":"10.1111/dom.15417","title":"Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Hazard ratio; Renal function; Kidney disease; Albuminuria; Internal medicine; Diabetes mellitus; Confidence interval; Mace; Type 2 diabetes; Proportional hazards model; Creatinine; Urology; Endocrinology; Myocardial infarction","score_opus":0.03638020386393328,"score_gpt":0.281562740278508,"score_spread":0.2451825364145747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390005477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566454,0.0025261745,0.00023742193,0.00008534222,0.000021616863,0.000041850904,0.0010752791,0.00000399659,0.00034367965],"genre_scores_gemma":[0.9969183,0.0006927953,0.00023804464,0.00008837935,0.000042961557,0.000072359035,0.0018262502,0.0000049256205,0.000115895695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99542063,0.002705272,0.000533777,0.0006495709,0.0005067625,0.0001839883],"domain_scores_gemma":[0.9914765,0.0029502097,0.0034724623,0.0013398123,0.0003875077,0.00037343666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071403985,0.00048497386,0.001497662,0.00080067734,0.0003371191,0.0012087512,0.00057971367,0.00093747093,0.0008974274],"category_scores_gemma":[0.009352935,0.0005063547,0.0023581367,0.0020742707,0.00031101823,0.0007671783,0.0011725405,0.0012166348,0.00012437826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014346599,0.00015297288,0.975366,0.0002678007,0.0059840237,0.00012081547,0.000112532965,0.00031519082,0.00027150736,0.000095173615,0.00041669654,0.0025506122],"study_design_scores_gemma":[0.0017933325,0.00083437446,0.9919316,0.000086851614,0.0031269742,0.00026641073,0.00013149143,0.0010509873,0.00007612934,0.00017202261,0.00050313317,0.00002662582],"about_ca_topic_score_codex":0.0018656568,"about_ca_topic_score_gemma":0.0028928516,"teacher_disagreement_score":0.0071403985,"about_ca_system_score_codex":0.00026058612,"about_ca_system_score_gemma":0.00032809438,"threshold_uncertainty_score":0.037762463},"labels":[],"label_agreement":null},{"id":"W4390016542","doi":"10.1111/dom.15415","title":"Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Gestational diabetes; Pregnancy; Medicine; Obstetrics; Body mass index; Prospective cohort study; Cohort study; Physical activity; Type 2 diabetes; Diabetes mellitus; Gestation; Gynecology; Endocrinology; Internal medicine; Physical therapy","score_opus":0.016389985540266026,"score_gpt":0.2970005244234828,"score_spread":0.28061053888321674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390016542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983645,0.0005986836,0.00006483136,0.00014405981,0.00001907626,0.000003887519,0.0002560831,0.000003054534,0.0005458919],"genre_scores_gemma":[0.99947757,0.00020390816,0.000037147398,0.000022231323,0.000008205196,0.0000029333382,0.00012953728,0.000001545709,0.000116916286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992218,0.00034499948,0.00005401393,0.00012376996,0.000120092445,0.00013541352],"domain_scores_gemma":[0.9966601,0.0013150924,0.0012321218,0.00019304843,0.00017493711,0.00042485583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079795165,0.00021620737,0.0002806746,0.00032178455,0.00026029116,0.0006063643,0.00031254074,0.0004195085,0.0012151274],"category_scores_gemma":[0.0064861793,0.0002244827,0.0005755175,0.0006240791,0.00023674426,0.00026107082,0.00036664496,0.00077233027,0.00013879631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020636454,0.00003707729,0.9973164,0.0000062186673,0.000053396543,0.00006449009,0.00003128089,0.000048342365,0.000102044025,0.000009435545,0.00004004021,0.0020848769],"study_design_scores_gemma":[0.0000017037992,0.00006658342,0.9996835,0.000004659147,0.000018918703,0.00005284329,0.00002663747,0.00008695111,0.000022422058,0.000005613941,0.000028824532,0.0000012920377],"about_ca_topic_score_codex":0.01319976,"about_ca_topic_score_gemma":0.012499406,"teacher_disagreement_score":0.01319976,"about_ca_system_score_codex":0.00037635362,"about_ca_system_score_gemma":0.00042785835,"threshold_uncertainty_score":0.026245832},"labels":[],"label_agreement":null},{"id":"W4390113202","doi":"10.1111/dom.15420","title":"Reduced incidence of diabetes during the <scp>COVID</scp> ‐19 pandemic in Alberta: A time‐segmented longitudinal study of Alberta's Tomorrow Project","year":2023,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"Health Canada; Alberta Health; Alberta Cancer Foundation; Alberta Health Services; Government of Alberta; Partenariat Canadien Contre Le Cancer","keywords":"Pandemic; Medicine; Diabetes mellitus; Incidence (geometry); Demography; Confidence interval; Population; Coronavirus disease 2019 (COVID-19); Cohort study; Rate ratio; Emergency medicine; Environmental health; Internal medicine; Disease; Infectious disease (medical specialty); Endocrinology","score_opus":0.010861913100466202,"score_gpt":0.24809346156743775,"score_spread":0.23723154846697156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390113202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496126,0.00038365368,0.00011765789,0.0003576663,0.00002266891,0.000026981013,0.0029653374,0.000011636183,0.0011530688],"genre_scores_gemma":[0.99661285,0.00022656974,0.00014381939,0.00012092226,0.000013474187,0.000015604192,0.0018547904,0.0000048563215,0.0010071663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992836,0.000099473466,0.000023914603,0.00012401366,0.00017428528,0.0002947116],"domain_scores_gemma":[0.9989373,0.000048728714,0.00025127555,0.000073613744,0.00031698233,0.00037211273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010044158,0.00051584013,0.00028052586,0.00076017826,0.0016000926,0.0012176833,0.0014379916,0.0007458936,0.0015463069],"category_scores_gemma":[0.0014483837,0.0003830719,0.0006050207,0.0017644395,0.0004921873,0.00039620712,0.0007735102,0.0009816721,0.00023006208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017343703,0.000058294812,0.9963111,0.000008166106,0.0000794498,0.000058727208,0.00033638324,0.00010151613,0.000118239615,0.000061905135,0.0008395954,0.0018531338],"study_design_scores_gemma":[0.0000069382377,0.000020725745,0.99898404,0.0000096708045,0.000022096006,0.000021536285,0.00044690384,0.00021398228,0.00001565124,0.00001562523,0.00023878917,0.0000040379055],"about_ca_topic_score_codex":0.95879084,"about_ca_topic_score_gemma":0.9611419,"teacher_disagreement_score":0.04120916,"about_ca_system_score_codex":0.007918222,"about_ca_system_score_gemma":0.009598073,"threshold_uncertainty_score":0.08290362},"labels":[],"label_agreement":null},{"id":"W4390311701","doi":"10.1111/dom.15431","title":"Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( <scp> ENDO <sup>2</sup> S‐RWD </scp> )","year":2023,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Medicine; Type 2 diabetes; Tolerability; Clinical trial; Internal medicine; Dulaglutide; Retrospective cohort study; Medical prescription; Cohort; Diabetes mellitus; Adverse effect; Pharmacology; Liraglutide; Endocrinology","score_opus":0.01697452754513942,"score_gpt":0.2486603731151771,"score_spread":0.23168584557003769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390311701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965405,0.0006432319,0.00012959585,0.000031760886,0.000011053436,0.0000729186,0.0022499883,0.00000422805,0.0003166932],"genre_scores_gemma":[0.99551386,0.0003477986,0.00027137573,0.00013337194,0.00003821334,0.000116722695,0.0034080008,0.0000060166176,0.00016461025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766314,0.0008219675,0.0004175197,0.0005675171,0.00034467314,0.00018515701],"domain_scores_gemma":[0.9941713,0.0009953685,0.0031337657,0.0006331742,0.00056921504,0.0004971766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031354928,0.0005547159,0.00084919715,0.0009770194,0.00046828587,0.0011688693,0.00061779533,0.0007996858,0.0010575308],"category_scores_gemma":[0.0038484363,0.00051625754,0.0016024366,0.0015759848,0.00046022824,0.0007300938,0.00080427405,0.0007163143,0.0003761126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013428333,0.00024207022,0.9962618,0.000076186756,0.00040398494,0.00006615553,0.00008846318,0.00005944033,0.00010078956,0.000010321115,0.0001755702,0.0011724425],"study_design_scores_gemma":[0.00023210437,0.001186736,0.99723154,0.000023885623,0.00022911212,0.00020540376,0.00018857754,0.00021628977,0.000059312813,0.00001468343,0.00039748842,0.000014786348],"about_ca_topic_score_codex":0.008507634,"about_ca_topic_score_gemma":0.0070474795,"teacher_disagreement_score":0.008507634,"about_ca_system_score_codex":0.00087356335,"about_ca_system_score_gemma":0.0007015253,"threshold_uncertainty_score":0.016916215},"labels":[],"label_agreement":null},{"id":"W4390502136","doi":"10.1111/dom.15419","title":"Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Metformin; Discontinuation; Medicine; Type 2 diabetes; Retrospective cohort study; Internal medicine; Cohort; Diabetes mellitus; Logistic regression; Cohort study; Pediatrics; Endocrinology","score_opus":0.0063257904242730615,"score_gpt":0.19644827907518556,"score_spread":0.1901224886509125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390502136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929357,0.000984997,0.000110276036,0.0004045509,0.000015802512,0.000035404304,0.0040257936,0.0000151343875,0.0014722521],"genre_scores_gemma":[0.996119,0.0005624613,0.00025098873,0.00012734164,0.000009808059,0.000013323741,0.0022491051,0.000005019738,0.00066282926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990465,0.00007099469,0.00006767936,0.00015394858,0.0003825631,0.0002783916],"domain_scores_gemma":[0.9979748,0.00012955483,0.00049373537,0.00005924748,0.0008712417,0.00047147818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000646531,0.00033340557,0.00039175674,0.0014764807,0.0018726367,0.001183357,0.0014870869,0.00042733358,0.0012054588],"category_scores_gemma":[0.0018984429,0.00032084013,0.00060781697,0.0043565994,0.0004835307,0.00030251622,0.00067879894,0.00061019644,0.00015016722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004595391,0.000018068931,0.9973443,0.000013670867,0.000026491281,0.00005791561,0.00018460848,0.00008699089,0.000052786603,0.000024960511,0.00047538648,0.0016688926],"study_design_scores_gemma":[0.000006330894,0.000013666427,0.99877805,0.000019495597,0.000019364887,0.00005482876,0.00045388733,0.00029874695,0.000022001252,0.000009854406,0.00031787925,0.000005860656],"about_ca_topic_score_codex":0.9920238,"about_ca_topic_score_gemma":0.9937709,"teacher_disagreement_score":0.020404527,"about_ca_system_score_codex":0.020404527,"about_ca_system_score_gemma":0.020999406,"threshold_uncertainty_score":0.1480459},"labels":[],"label_agreement":null},{"id":"W4390744416","doi":"10.1111/dom.15412","title":"Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the <scp>ORIGIN</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Sanofi","keywords":"Hazard ratio; Digit symbol substitution test; Confidence interval; Internal medicine; Placebo; Medicine; Insulin glargine; Post-hoc analysis; Proportional hazards model; Physical therapy; Psychology; Insulin; Hypoglycemia","score_opus":0.015012890294564029,"score_gpt":0.2985700707469004,"score_spread":0.28355718045233635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390744416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817855,0.014375054,0.00034956407,0.0003826448,0.00014113566,0.0005667236,0.0006651346,0.000020090849,0.0017140841],"genre_scores_gemma":[0.9946516,0.002883434,0.0004441182,0.00032225045,0.000134204,0.00047408426,0.0005649055,0.0000074949553,0.00051788415],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99761957,0.0017859442,0.00015783329,0.00015763818,0.0001441867,0.00013491458],"domain_scores_gemma":[0.9974312,0.001423646,0.00046459047,0.00023013147,0.00016379729,0.00028654668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047087832,0.0007015965,0.0021006204,0.00020594377,0.00020708605,0.0012733805,0.00048336573,0.00084631896,0.0019277739],"category_scores_gemma":[0.0048124897,0.00025328482,0.003406981,0.00041265847,0.00043577323,0.00061325793,0.00058874284,0.0014786539,0.00016872626],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95933264,0.0009538228,0.007243259,0.0020883714,0.010624226,0.00006474203,0.0001034632,0.00041541853,0.0006863537,0.00014954188,0.0005786627,0.017759593],"study_design_scores_gemma":[0.75593805,0.10863726,0.092047185,0.0013278692,0.03415178,0.00021228884,0.00029566415,0.0023348245,0.001088726,0.0010766383,0.0028098195,0.00007983146],"about_ca_topic_score_codex":0.0012312294,"about_ca_topic_score_gemma":0.0019963526,"teacher_disagreement_score":0.0047087832,"about_ca_system_score_codex":0.0004919488,"about_ca_system_score_gemma":0.0007943957,"threshold_uncertainty_score":0.024902701},"labels":[],"label_agreement":null},{"id":"W4390892305","doi":"10.1111/dom.15425","title":"The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"Sanofi","keywords":"Kidney disease; Type 2 diabetes; Medicine; Diabetes mellitus; Basal (medicine); Basal insulin; Disease; Renal function; Intensive care medicine; Internal medicine; Narrative review; Endocrinology","score_opus":0.01437076196548593,"score_gpt":0.301510869203142,"score_spread":0.2871401072376561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390892305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047284087,0.9993818,0.000030178464,0.00015707777,0.000091132555,0.000003953437,0.000013789473,0.0000020299515,0.00027273138],"genre_scores_gemma":[0.00030689372,0.9993168,0.00008151713,0.00013110363,0.000061204846,0.0000050326075,0.000014079263,6.0686745e-7,0.00008270495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996074,0.00009888333,0.00010235825,0.000054526077,0.0001133464,0.000023593597],"domain_scores_gemma":[0.9988393,0.00082180917,0.00016799124,0.000015486934,0.00012456815,0.000030876974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090093754,0.00069632556,0.0015447675,0.0021005175,0.00025058663,0.0013660677,0.00077446864,0.0010414425,0.004665864],"category_scores_gemma":[0.0025616165,0.00022893345,0.0011974969,0.002265793,0.00028688853,0.001115468,0.00069980585,0.001423576,0.000933634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015056423,0.000056337987,0.00017752327,0.15539935,0.000427948,0.00017679138,0.00013484152,0.00023547122,0.00044371528,0.0026878386,0.022975488,0.8171342],"study_design_scores_gemma":[0.00006462963,0.00018444099,0.0012853838,0.13546851,0.0017806184,0.0014770739,0.00018512986,0.0001248171,0.00021802771,0.0024954188,0.85668,0.000035928853],"about_ca_topic_score_codex":0.0014704375,"about_ca_topic_score_gemma":0.0023881746,"teacher_disagreement_score":0.004665864,"about_ca_system_score_codex":0.0004905831,"about_ca_system_score_gemma":0.0016216163,"threshold_uncertainty_score":0.015608847},"labels":[],"label_agreement":null},{"id":"W4390952355","doi":"10.1111/dom.15459","title":"Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Regional Municipality of Waterloo; University of Waterloo; University of Alberta","funders":"","keywords":"Exenatide; Semaglutide; Liraglutide; Dulaglutide; Lixisenatide; Weight loss; Medicine; Glucagon-like peptide 1 receptor; Adverse effect; Diabetes mellitus; Medical prescription; Obesity; Internal medicine; Type 2 diabetes; Endocrinology; Agonist; Pharmacology; Receptor","score_opus":0.013519707573142727,"score_gpt":0.2560227436641229,"score_spread":0.2425030360909802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390952355","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083927653,0.26443857,0.00023322919,0.6904034,0.04150363,0.0000256197,0.00021872068,0.000020937006,0.0023166484],"genre_scores_gemma":[0.012484156,0.40084285,0.00024370948,0.43917966,0.14485794,0.000069241716,0.00017000298,0.000027063466,0.002125376],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9964127,0.0017704989,0.00058021344,0.00031725562,0.0007182145,0.00020102036],"domain_scores_gemma":[0.97423357,0.016635085,0.0029570519,0.0001970616,0.0051558185,0.0008213383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003190317,0.00045888097,0.0012836563,0.00093027705,0.0012132347,0.0022596722,0.0015560293,0.008614966,0.0058480417],"category_scores_gemma":[0.036445055,0.00028834573,0.0009320741,0.001334127,0.002062402,0.0029090564,0.0010215144,0.0070368834,0.0013243153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025320935,0.000016950888,0.0020761979,0.006163424,0.00013893239,0.0009360572,0.0012548324,0.000091113216,0.000091176145,0.004929568,0.83752894,0.14651963],"study_design_scores_gemma":[0.00013768322,0.00021959585,0.005142718,0.035787888,0.00025748165,0.0025883894,0.0025616968,0.00025944592,0.00014539433,0.0077686505,0.94502425,0.00010681843],"about_ca_topic_score_codex":0.009189055,"about_ca_topic_score_gemma":0.018080596,"teacher_disagreement_score":0.009189055,"about_ca_system_score_codex":0.0021819344,"about_ca_system_score_gemma":0.00638026,"threshold_uncertainty_score":0.019563675},"labels":[],"label_agreement":null},{"id":"W4391116156","doi":"10.1111/dom.15450","title":"Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute on Minority Health and Health Disparities; National Center for Chronic Disease Prevention and Health Promotion; National Institute of Diabetes and Digestive and Kidney Diseases; Centers for Disease Control and Prevention; American Diabetes Association; American Heart Association; Centers for Disease Control and Prevention Foundation; Amgen","keywords":"Biostatistics; Family medicine; Medicine; Diabetes mellitus; Public health; Epidemiology; Gerontology; Library science; Nursing; Internal medicine","score_opus":0.018043709059800447,"score_gpt":0.26786741231575556,"score_spread":0.2498237032559551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391116156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77921724,0.015419144,0.004038675,0.004987403,0.00039331376,0.00028037466,0.18594387,0.00028459934,0.009435427],"genre_scores_gemma":[0.8582454,0.005881307,0.00793436,0.002616729,0.00078745704,0.00036296382,0.1228992,0.00009844448,0.0011741583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99079907,0.0018180504,0.00225275,0.0015886456,0.0030737487,0.00046776215],"domain_scores_gemma":[0.9649121,0.0062646503,0.02047621,0.0011784172,0.0054586097,0.0017100913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004598028,0.00049552345,0.00075449876,0.0063267453,0.0005332149,0.0018737414,0.0010885108,0.0010656564,0.0023097224],"category_scores_gemma":[0.03354653,0.00036416505,0.0010530325,0.0105091,0.00028561024,0.0017869906,0.0016563028,0.0015618273,0.00083495304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018307273,0.000061004426,0.9720214,0.0002447584,0.00037378902,0.00004201615,0.00026018664,0.00023950277,0.00011027044,0.00028030982,0.008551675,0.017632095],"study_design_scores_gemma":[0.000019698527,0.00008397514,0.9869877,0.00033025545,0.00010460148,0.00028018848,0.00040886525,0.0014326524,0.00015794653,0.00026423734,0.009903707,0.000026138254],"about_ca_topic_score_codex":0.034354974,"about_ca_topic_score_gemma":0.042823374,"teacher_disagreement_score":0.034354974,"about_ca_system_score_codex":0.0014224275,"about_ca_system_score_gemma":0.0013886113,"threshold_uncertainty_score":0.06831002},"labels":[],"label_agreement":null},{"id":"W4391151349","doi":"10.1111/dom.15463","title":"Postprandial glucose‐management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Postprandial; Type 2 diabetes; Medicine; Insulin; Diabetes mellitus; Meal; Internal medicine; Endocrinology; Intensive care medicine; Bioinformatics; Biology","score_opus":0.04824717584236721,"score_gpt":0.2997258717400016,"score_spread":0.2514786958976344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391151349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000987745,0.97895,0.00746568,0.009517708,0.0006118063,0.000035285408,0.00007267143,0.00006627343,0.002292887],"genre_scores_gemma":[0.01827546,0.9604735,0.0137986755,0.0052225683,0.0012498919,0.00013404543,0.00012869993,0.00002034411,0.0006967413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794275,0.0009246763,0.00024683113,0.000317538,0.00045629722,0.000111820234],"domain_scores_gemma":[0.9927291,0.005570301,0.0005430374,0.00020033662,0.0008101239,0.00014693032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059951018,0.0012210459,0.0021865405,0.0016022826,0.0004240367,0.0031132305,0.0013666162,0.0023552366,0.0026050678],"category_scores_gemma":[0.0079037985,0.0003552601,0.0022188036,0.0014800972,0.0015675058,0.003290709,0.0016794819,0.0037109705,0.0007173246],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034503048,0.00013943097,0.0015774765,0.024477743,0.00054827135,0.0002211413,0.00045848792,0.0021987753,0.0008650686,0.026576726,0.013141414,0.92945045],"study_design_scores_gemma":[0.00023290304,0.0013948425,0.005919697,0.05353286,0.0022804039,0.0015138225,0.0015221944,0.007171673,0.0030479417,0.12253982,0.8004884,0.00035531193],"about_ca_topic_score_codex":0.002666068,"about_ca_topic_score_gemma":0.0025589312,"teacher_disagreement_score":0.0059951018,"about_ca_system_score_codex":0.0015275045,"about_ca_system_score_gemma":0.003615247,"threshold_uncertainty_score":0.0317055},"labels":[],"label_agreement":null},{"id":"W4391317839","doi":"10.1111/dom.15455","title":"Obesity management from the perspectives of people living with obesity in Canada: A mixed‐methods study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Obesity and Health Practices","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Obesity Network; University of Alberta; University of Calgary","funders":"Novo Nordisk Canada","keywords":"Psychological intervention; Obesity; Overweight; Psychology; Medicine; Nursing","score_opus":0.021239392146482062,"score_gpt":0.3633803032925362,"score_spread":0.3421409111460541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391317839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620926,0.00044496387,0.00023115176,0.00034318364,0.000017587858,0.00061225763,0.00047093994,0.000002941284,0.0016677127],"genre_scores_gemma":[0.9938459,0.0012046419,0.0008322868,0.0009129822,0.000025610969,0.0010717097,0.00033046684,0.0000067350898,0.001769631],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99779284,0.0005738829,0.00015088492,0.00020628696,0.0004900766,0.0007860149],"domain_scores_gemma":[0.9971661,0.0008605499,0.00041436477,0.0000718394,0.0009539451,0.00053319626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032703483,0.0005212975,0.0007917975,0.0022643285,0.0094548315,0.0034166086,0.0011113166,0.0008437178,0.0024738677],"category_scores_gemma":[0.0049314783,0.000675016,0.0007583694,0.003828248,0.0015631864,0.0011773098,0.0024388928,0.0013870794,0.00023327215],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028911664,0.0010586547,0.2753496,0.00085577834,0.000068108166,0.0013511551,0.68164325,0.00008201737,0.0012099951,0.00049450307,0.0016146359,0.035983227],"study_design_scores_gemma":[0.00004429449,0.0003483696,0.18746193,0.00049463863,0.00005679947,0.00023934689,0.8049095,0.00023423988,0.00022121915,0.00013426694,0.005796401,0.000058929494],"about_ca_topic_score_codex":0.87362385,"about_ca_topic_score_gemma":0.9360472,"teacher_disagreement_score":0.12637615,"about_ca_system_score_codex":0.018453985,"about_ca_system_score_gemma":0.03620929,"threshold_uncertainty_score":0.25424075},"labels":[],"label_agreement":null},{"id":"W4391607301","doi":"10.1111/dom.15479","title":"Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"GlaxoSmithKline","keywords":"Medicine; Post-hoc analysis; Randomized controlled trial; Post hoc; Physical therapy; Internal medicine","score_opus":0.003015881425071274,"score_gpt":0.22961493926352047,"score_spread":0.2265990578384492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391607301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574661,0.01706574,0.004504833,0.0012756147,0.0029637415,0.009868964,0.0036662612,0.00028547764,0.0029031804],"genre_scores_gemma":[0.9782804,0.0022173251,0.004398604,0.0011905403,0.0013525558,0.008271995,0.0017625813,0.000088950845,0.0024370407],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98620516,0.010358316,0.0008935841,0.0012555935,0.0006466981,0.00064054783],"domain_scores_gemma":[0.9812088,0.012086293,0.0029242777,0.0018256971,0.0011168999,0.0008380681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018214267,0.0023296026,0.0067606196,0.0005738184,0.00046361957,0.0020840357,0.0010056496,0.0017968195,0.004753977],"category_scores_gemma":[0.02036612,0.00061221054,0.00922207,0.00061517715,0.001038672,0.0015332702,0.0007299947,0.0025446187,0.00050858635],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9635978,0.00079001056,0.0024370442,0.0015214105,0.024385724,0.00007781573,0.000041060164,0.00044223896,0.00086405285,0.00013019632,0.0008000322,0.004912705],"study_design_scores_gemma":[0.8598841,0.07120353,0.017448649,0.000265444,0.0442518,0.00009493715,0.00006538844,0.002701426,0.0012620023,0.0006112701,0.002141903,0.00006949619],"about_ca_topic_score_codex":0.00059764914,"about_ca_topic_score_gemma":0.0011109307,"teacher_disagreement_score":0.018214267,"about_ca_system_score_codex":0.00087583397,"about_ca_system_score_gemma":0.0016153343,"threshold_uncertainty_score":0.096327424},"labels":[],"label_agreement":null},{"id":"W4391652120","doi":"10.1111/dom.15485","title":"Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Diabetes Canada; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Intensive care medicine; Specialty; Disease; Health care; Internal medicine; Pathology","score_opus":0.04700399873108236,"score_gpt":0.30869696256568124,"score_spread":0.2616929638345989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391652120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005098928,0.9726332,0.0008032346,0.01704419,0.00042186526,0.000045348595,0.00012227552,0.000009663158,0.0038213308],"genre_scores_gemma":[0.1034708,0.8856112,0.0036661185,0.004721257,0.0017847973,0.00008307161,0.0002740047,0.000007781349,0.00038098212],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9948709,0.0025711218,0.00079930085,0.00046769294,0.0010458287,0.0002452013],"domain_scores_gemma":[0.95878136,0.0294886,0.0061291694,0.00087943487,0.003894516,0.0008268486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010686163,0.00078687526,0.0016764818,0.0028486282,0.00064429507,0.004507265,0.0016236525,0.001911321,0.0072885393],"category_scores_gemma":[0.026018482,0.00045890766,0.0022526563,0.0032137365,0.0014796103,0.0027980998,0.0023173497,0.0036212245,0.00068798556],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068257947,0.0007304571,0.08848181,0.037552055,0.007210731,0.00047702107,0.00050825044,0.00094660284,0.0004018901,0.015623943,0.011200347,0.83618444],"study_design_scores_gemma":[0.00077130843,0.0014617876,0.33795533,0.2967486,0.022700472,0.0030595341,0.0049508973,0.0033506923,0.0009430525,0.069210954,0.2585863,0.00026109966],"about_ca_topic_score_codex":0.0036957737,"about_ca_topic_score_gemma":0.008794637,"teacher_disagreement_score":0.010686163,"about_ca_system_score_codex":0.0018060672,"about_ca_system_score_gemma":0.0057989713,"threshold_uncertainty_score":0.0565145},"labels":[],"label_agreement":null},{"id":"W4392374089","doi":"10.1111/dom.15532","title":"Pre‐dinner walks may be superior to post‐dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed‐loop insulin delivery systems","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Insulin delivery; Type 2 diabetes; Closed loop; Range (aeronautics); Loop (graph theory); Medicine; Mathematics; Diabetes mellitus; Endocrinology; Type 1 diabetes; Materials science; Combinatorics; Engineering","score_opus":0.010478018655082858,"score_gpt":0.2346140597039238,"score_spread":0.22413604104884094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392374089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991449,0.00038391387,0.00012939835,0.000026082274,0.000024893316,0.00008070197,0.000023001969,0.000007583812,0.00017943658],"genre_scores_gemma":[0.99808323,0.00044670785,0.0007274825,0.000119809374,0.00005940759,0.00016187636,0.00010064331,0.0000029475198,0.0002978805],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.999752,0.00009928689,0.00003962046,0.000041988867,0.000033007764,0.000034141198],"domain_scores_gemma":[0.99955946,0.0001433308,0.00010112444,0.000018616409,0.000025337686,0.00015208412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078872347,0.00044823313,0.0009949157,0.00022312983,0.0002677954,0.0004427261,0.00031205153,0.0005030279,0.0017701463],"category_scores_gemma":[0.001025741,0.00023061113,0.00051396945,0.00020075002,0.00026580927,0.0004376883,0.00028799762,0.0006481184,0.00014158797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67858267,0.057809398,0.0498827,0.0013826413,0.0011547366,0.00013718102,0.0005114712,0.0006704584,0.040432375,0.00011693632,0.000503207,0.16881615],"study_design_scores_gemma":[0.043553177,0.77418166,0.1749715,0.00010126798,0.00077853916,0.000110363166,0.00030777653,0.0013868706,0.0036745663,0.000088130604,0.0008089861,0.000037115038],"about_ca_topic_score_codex":0.00063986465,"about_ca_topic_score_gemma":0.0013502095,"teacher_disagreement_score":0.0017701463,"about_ca_system_score_codex":0.0001433584,"about_ca_system_score_gemma":0.00018688891,"threshold_uncertainty_score":0.0059217215},"labels":[],"label_agreement":null},{"id":"W4392712963","doi":"10.1111/dom.15493","title":"Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study ( <scp>PIONEER REAL</scp> Canada)","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; University of Calgary; Western University; LMC Diabetes & Endocrinology (Canada); Diabetes Canada; University of British Columbia","funders":"Novo Nordisk Pharma; Novo Nordisk","keywords":"Semaglutide; Medicine; Clinical endpoint; Confidence interval; Type 2 diabetes; Prospective cohort study; Internal medicine; Diabetes mellitus; Clinical trial; Endocrinology","score_opus":0.01958254838142105,"score_gpt":0.29132823680404685,"score_spread":0.2717456884226258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392712963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99864954,0.0002979628,0.000032323038,0.000041542167,0.000003383407,0.0000770314,0.0006426257,0.0000025710826,0.00025312073],"genre_scores_gemma":[0.9985121,0.00021838643,0.00022537593,0.00008891033,0.000007939915,0.000044637647,0.00071873964,0.0000014692241,0.000182393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988669,0.00028405312,0.00008132424,0.00019324076,0.00039551445,0.00017895778],"domain_scores_gemma":[0.9962457,0.00041663635,0.001627555,0.00011764742,0.000914395,0.00067814114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001483608,0.0003699933,0.0005572514,0.0004250752,0.00087445934,0.0009277434,0.00059580273,0.00051542826,0.00085384876],"category_scores_gemma":[0.0028553065,0.00034659015,0.0005749991,0.001453914,0.000540627,0.00034115498,0.00043662815,0.0006205595,0.00011825566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007501378,0.00024197694,0.99577254,0.000060551552,0.00016751314,0.000023914632,0.00018930311,0.000056093395,0.0001286594,0.000008026487,0.00020082052,0.0024004707],"study_design_scores_gemma":[0.00011159317,0.00038251327,0.9988707,0.000014293681,0.000064832566,0.000033954533,0.00016995183,0.00017789326,0.00003019823,0.000004020472,0.00013211172,0.000008067078],"about_ca_topic_score_codex":0.6570297,"about_ca_topic_score_gemma":0.7511764,"teacher_disagreement_score":0.3429703,"about_ca_system_score_codex":0.005653241,"about_ca_system_score_gemma":0.0061990065,"threshold_uncertainty_score":0.68998027},"labels":[],"label_agreement":null},{"id":"W4392882969","doi":"10.1111/dom.15542","title":"Analyses of potential causal contributors to increased waist/hip ratio‐associated cardiometabolic disease: A combined and sex‐stratified Mendelian randomization study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Genetic Associations and Epidemiology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Mendelian randomization; Medicine; Internal medicine; Odds ratio; Waist–hip ratio; Type 2 diabetes; Endocrinology; Nonalcoholic fatty liver disease; Coronary artery disease; Diabetes mellitus; Body mass index; Waist; Fatty liver; Disease; Genetics; Biology; Genotype","score_opus":0.011430892367495041,"score_gpt":0.2735023999388374,"score_spread":0.26207150757134234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392882969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9461451,0.0017743714,0.048467953,0.00020672013,0.0001385593,0.00060962816,0.0014680078,0.00027705668,0.00091259705],"genre_scores_gemma":[0.9712904,0.0002545942,0.025720479,0.00017911606,0.000053475887,0.0009303849,0.0008079945,0.00006836618,0.0006950882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96899456,0.024258932,0.0011707061,0.003278833,0.0016490406,0.0006479172],"domain_scores_gemma":[0.98167944,0.010084471,0.0022528355,0.0047775656,0.0008304619,0.00037522544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018425241,0.001802637,0.002234825,0.001150266,0.0005675477,0.000770237,0.0011493017,0.0010620736,0.0031202768],"category_scores_gemma":[0.029376324,0.00062183716,0.0048498516,0.0013706244,0.000630202,0.00033563125,0.000800021,0.0007491051,0.00027602576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11897394,0.0014167312,0.66563976,0.0011830535,0.095213,0.0037164958,0.0011771545,0.008150747,0.02727164,0.005597123,0.0038791553,0.0677812],"study_design_scores_gemma":[0.019611804,0.030559955,0.7423452,0.00023865807,0.09595091,0.007128229,0.00054446195,0.07289915,0.011794967,0.009743775,0.008885986,0.00029693858],"about_ca_topic_score_codex":0.0025111923,"about_ca_topic_score_gemma":0.0017496004,"teacher_disagreement_score":0.018425241,"about_ca_system_score_codex":0.00038055368,"about_ca_system_score_gemma":0.0008385697,"threshold_uncertainty_score":0.09744316},"labels":[],"label_agreement":null},{"id":"W4393379443","doi":"10.1111/dom.15575","title":"An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Institute on Minority Health and Health Disparities; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health; Novo Nordisk; Sanofi; Centers for Disease Control and Prevention; AstraZeneca; Eli Lilly and Company","keywords":"Intensive care medicine; Diabetes mellitus; Medicine; Endocrinology","score_opus":0.017913273642689142,"score_gpt":0.3167492510886116,"score_spread":0.2988359774459225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393379443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001508077,0.9985079,0.00006443764,0.0004499284,0.00040410607,0.000010628466,0.000081250284,0.0000061304236,0.0003247951],"genre_scores_gemma":[0.0007583333,0.9980818,0.00016491009,0.0003758299,0.0003912732,0.000014761912,0.00009079407,0.0000016517026,0.00012060928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905926,0.00021786272,0.00036202488,0.00011798395,0.0001903893,0.000052374187],"domain_scores_gemma":[0.9967964,0.002020822,0.00058625435,0.00004240106,0.00045559666,0.000098432116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012445368,0.000947917,0.0023759129,0.006576095,0.00040912844,0.0020532638,0.0010746609,0.0013039942,0.005681789],"category_scores_gemma":[0.004679459,0.0003560905,0.00206315,0.00589058,0.0004142016,0.0018763454,0.0008399124,0.0014062291,0.0009221446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023795129,0.00008883164,0.0014323604,0.2764155,0.0010568006,0.0005685502,0.00041308446,0.0002780777,0.00062835886,0.0022204726,0.06674621,0.6499138],"study_design_scores_gemma":[0.00006001644,0.00022664313,0.0055721942,0.18235761,0.004535711,0.0044455417,0.00043725956,0.00015680677,0.00020327693,0.0016754745,0.80026245,0.00006700869],"about_ca_topic_score_codex":0.0025312414,"about_ca_topic_score_gemma":0.003975822,"teacher_disagreement_score":0.006576095,"about_ca_system_score_codex":0.001161764,"about_ca_system_score_gemma":0.0038274731,"threshold_uncertainty_score":0.019007444},"labels":[],"label_agreement":null},{"id":"W4393986738","doi":"10.1111/dom.15588","title":"A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Meta-analysis; Medicine; Randomized controlled trial; Thyroid cancer; Oncology; Internal medicine; Cancer","score_opus":0.03499213468690576,"score_gpt":0.32371052415221996,"score_spread":0.2887183894653142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393986738","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001721701,0.013159009,0.0005271732,0.784338,0.1983902,0.00019626696,0.0019709745,0.00019569506,0.0010504747],"genre_scores_gemma":[0.0016094517,0.0048009506,0.0008299385,0.9169004,0.0727576,0.00038496454,0.00031040868,0.000102137295,0.0023042166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95179486,0.016080435,0.011510249,0.0049283993,0.0139138615,0.0017722003],"domain_scores_gemma":[0.7892022,0.14587094,0.015554979,0.00587916,0.03981768,0.0036750971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.060468953,0.002510803,0.0047492166,0.0042930073,0.002891754,0.0045502544,0.007039209,0.03354457,0.013438063],"category_scores_gemma":[0.24332777,0.0021751462,0.009062207,0.0049993093,0.0045388737,0.006033085,0.0031837393,0.03126275,0.011166216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016189583,0.000008443179,0.00014820368,0.002905794,0.0002552993,0.00011821869,0.00008854433,0.000042728192,0.00014873763,0.00074324466,0.99119675,0.004182123],"study_design_scores_gemma":[0.001568179,0.0002323291,0.002557166,0.013380351,0.002156172,0.0009185578,0.00021306444,0.0004716785,0.00096663384,0.010056254,0.9672422,0.00023729171],"about_ca_topic_score_codex":0.010678363,"about_ca_topic_score_gemma":0.014079253,"teacher_disagreement_score":0.060468953,"about_ca_system_score_codex":0.0054279654,"about_ca_system_score_gemma":0.011892022,"threshold_uncertainty_score":0.31979424},"labels":[],"label_agreement":null},{"id":"W4394819668","doi":"10.1111/dom.15587","title":"Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non‐interventional study in Kenya","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Retinal Imaging and Analysis","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"AstraZeneca","keywords":"Fundus (uterus); Retinal; Optometry; Prospective cohort study; Artificial intelligence; Medicine; Deep learning; Computer science; Ophthalmology; Machine learning; Algorithm; Surgery","score_opus":0.010462281717212233,"score_gpt":0.2386104851687193,"score_spread":0.22814820345150708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394819668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987754,0.000042581865,0.00067571073,0.000041598312,0.000005188003,0.00013289947,0.00012101754,0.0000055782966,0.00019989768],"genre_scores_gemma":[0.996628,0.00006626486,0.0024386072,0.00005224484,0.000006642465,0.0001506875,0.00036977182,0.000003937554,0.00028380158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994748,0.0002783466,0.00003403422,0.000104281964,0.000051459534,0.000057040856],"domain_scores_gemma":[0.99741495,0.0011704004,0.00035785793,0.0002632393,0.0005557764,0.00023777719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033446962,0.00066675694,0.0003334469,0.000333038,0.00081123254,0.00059511093,0.0007604648,0.0007071411,0.0012548084],"category_scores_gemma":[0.0060827783,0.00039699127,0.00047612312,0.0001893594,0.0006084733,0.00043480043,0.0005923496,0.00091252633,0.0004324177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061094533,0.0063738385,0.9441865,0.00016181624,0.0002948882,0.00092640374,0.0014781422,0.006545285,0.0060588745,0.00026013496,0.0009707984,0.026633868],"study_design_scores_gemma":[0.0010546187,0.014252616,0.89393747,0.00016734269,0.00025912805,0.001064699,0.0019698355,0.081812546,0.003681097,0.00031010556,0.0014097696,0.00008083324],"about_ca_topic_score_codex":0.01466721,"about_ca_topic_score_gemma":0.016640233,"teacher_disagreement_score":0.01466721,"about_ca_system_score_codex":0.0009446978,"about_ca_system_score_gemma":0.0009877745,"threshold_uncertainty_score":0.029163659},"labels":[],"label_agreement":null},{"id":"W4396619349","doi":"10.1111/dom.15627","title":"Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Hazard ratio; Amoxicillin; Cohort; Cohort study; Population; Confidence interval; Propensity score matching; Antibiotics","score_opus":0.006595623636002181,"score_gpt":0.23920413350775688,"score_spread":0.2326085098717547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396619349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983931,0.00023141316,0.00012546834,0.000031436506,0.000008948439,0.000020890564,0.0010237076,0.0000041736757,0.0001608195],"genre_scores_gemma":[0.9987206,0.00018095358,0.00012602958,0.000033571447,0.000015829199,0.000020347845,0.0007647191,0.0000027018093,0.00013523786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990277,0.00026651178,0.00010120616,0.0003062133,0.00015582528,0.000142544],"domain_scores_gemma":[0.99789965,0.00029829782,0.0009269129,0.0004190821,0.00017781103,0.00027816644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015330433,0.0005428251,0.00058087066,0.0007372125,0.00048804196,0.000985998,0.0005768585,0.0008961025,0.0013197749],"category_scores_gemma":[0.002857292,0.00066788617,0.0016912733,0.0011586727,0.0002559298,0.0005457654,0.0005699918,0.0009957014,0.00024463085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090890285,0.00008767402,0.9969356,0.000016095966,0.0007128919,0.00009125772,0.0000623378,0.000086843866,0.00021205717,0.000016577571,0.00012293205,0.00074681046],"study_design_scores_gemma":[0.00010579534,0.00037663215,0.99812025,0.000010741336,0.0003335142,0.00021165071,0.00008047541,0.00049844454,0.00004763338,0.000027212474,0.00017485539,0.000012858664],"about_ca_topic_score_codex":0.012446177,"about_ca_topic_score_gemma":0.010707281,"teacher_disagreement_score":0.012446177,"about_ca_system_score_codex":0.00039382855,"about_ca_system_score_gemma":0.000464901,"threshold_uncertainty_score":0.024747431},"labels":[],"label_agreement":null},{"id":"W4396619388","doi":"10.1111/dom.15620","title":"Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the <scp>STEP</scp> 1–4 trials","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University; University of Alberta","funders":"Novo Nordisk","keywords":"Medicine; Semaglutide; Overweight; Obesity; Quality of life (healthcare); Gerontology; Physical therapy; Internal medicine; Endocrinology; Type 2 diabetes; Diabetes mellitus; Nursing","score_opus":0.023055780584326592,"score_gpt":0.28391158455474164,"score_spread":0.260855803970415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396619388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87500006,0.116635725,0.0005975443,0.0012007905,0.00041559283,0.0011335143,0.0013932032,0.00016402712,0.0034595383],"genre_scores_gemma":[0.96006507,0.032475248,0.0013368742,0.0019657582,0.00032770916,0.0011292781,0.0013112442,0.000019369232,0.001369533],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995629,0.00022218522,0.00006729909,0.000052461095,0.00006187096,0.000033206572],"domain_scores_gemma":[0.9995024,0.00016613258,0.00022117226,0.000015719226,0.0000406863,0.00005392856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014382915,0.0007799315,0.0017489234,0.00041205602,0.00019883626,0.00067167974,0.00039399922,0.0010178394,0.002123058],"category_scores_gemma":[0.0013695445,0.00024191664,0.0019745089,0.0003469384,0.00028878808,0.0005056298,0.00018165179,0.0012459619,0.00028397486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6672126,0.005036809,0.009318405,0.0206625,0.014393964,0.00028732696,0.0001572924,0.0016336577,0.015867824,0.00032147652,0.006129989,0.2589782],"study_design_scores_gemma":[0.7596384,0.14914443,0.058959868,0.002267833,0.012955582,0.0007698064,0.00014192033,0.0021718573,0.0051196064,0.0005596947,0.008171684,0.0000992942],"about_ca_topic_score_codex":0.00043317722,"about_ca_topic_score_gemma":0.0014567926,"teacher_disagreement_score":0.002123058,"about_ca_system_score_codex":0.00032906263,"about_ca_system_score_gemma":0.0004022267,"threshold_uncertainty_score":0.0076065063},"labels":[],"label_agreement":null},{"id":"W4396809585","doi":"10.1111/dom.15647","title":"Validation of the Individualized Metabolic Surgery score in predicting long‐term remission of diabetes after duodenal switch‐type procedures","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Type 2 diabetes; Cohort; Retrospective cohort study; Cohort study; Internal medicine; Receiver operating characteristic; Sleeve gastrectomy; Area under the curve; Body mass index; Surgery; Diabetes mellitus; Obesity; Gastric bypass; Weight loss; Endocrinology","score_opus":0.015223607877313423,"score_gpt":0.2484808302039205,"score_spread":0.2332572223266071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396809585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981956,0.0002577002,0.00058798294,0.000030652995,0.0000108740805,0.000019218704,0.00021714298,0.000011849913,0.000669117],"genre_scores_gemma":[0.99867356,0.00008068359,0.00064979587,0.000018189534,0.00001636653,0.00001206416,0.00047662106,0.0000032101138,0.00006948684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988918,0.0003422834,0.0001621989,0.00016502361,0.00031687994,0.000121921],"domain_scores_gemma":[0.99551386,0.0010612748,0.0021005888,0.00030465415,0.0005912963,0.00042835358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027750242,0.00042340963,0.00046559592,0.0010780381,0.00022228026,0.0007864918,0.0003222254,0.00037920487,0.0006624792],"category_scores_gemma":[0.006623075,0.00014216565,0.00068536366,0.00069460954,0.00023678307,0.00047178558,0.0006738016,0.00051468203,0.00020097695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028059547,0.000030734336,0.9953265,0.000008484149,0.00006493411,0.000016550404,0.000014367876,0.00023120895,0.00014843309,0.00001004278,0.000054154087,0.0038139895],"study_design_scores_gemma":[0.000030528958,0.00060584926,0.9957552,0.000016368767,0.00009143305,0.0002649824,0.000058838472,0.0025913485,0.00032372738,0.000028790066,0.0002241868,0.000008614044],"about_ca_topic_score_codex":0.0008762217,"about_ca_topic_score_gemma":0.0015896154,"teacher_disagreement_score":0.0027750242,"about_ca_system_score_codex":0.00024435602,"about_ca_system_score_gemma":0.00027951246,"threshold_uncertainty_score":0.014675915},"labels":[],"label_agreement":null},{"id":"W4396937622","doi":"10.1111/dom.15654","title":"Determinants of serious health <scp>outcome‐free</scp> status in <scp>middle‐aged</scp> and older people with dysglycaemia: Exploratory analysis of the <scp>ORIGIN</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"McMaster University; Hamilton Health Sciences; Sanofi","keywords":"Medicine; Internal medicine; Body mass index; Diabetes mellitus; Kidney disease; Type 2 diabetes; Endocrinology","score_opus":0.015330514339238082,"score_gpt":0.258766844180464,"score_spread":0.2434363298412259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396937622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975485,0.0009683681,0.00009137829,0.00010997168,0.000021067315,0.00010946838,0.0008698909,0.0000039281513,0.0002773281],"genre_scores_gemma":[0.9975702,0.0002986291,0.00017797078,0.000114056085,0.00005681988,0.000182545,0.0014346752,0.0000025899956,0.0001624752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816966,0.0011368181,0.00013176339,0.00022069436,0.00012746186,0.00021364907],"domain_scores_gemma":[0.99678564,0.00094958994,0.0010884383,0.00032574454,0.00018337763,0.00066726987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041090394,0.00064590346,0.0011975358,0.00028879885,0.0004216641,0.0011462835,0.0004930964,0.00097277603,0.0011110653],"category_scores_gemma":[0.0042583663,0.00029702333,0.003190024,0.00066761824,0.0004251958,0.0005982102,0.0014348897,0.0011898442,0.000114883194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18025191,0.0013272578,0.79037577,0.0009396632,0.010881604,0.00014603359,0.00026114442,0.00054101605,0.0005864886,0.0001282209,0.0011074641,0.013453463],"study_design_scores_gemma":[0.018981144,0.014838356,0.9554971,0.00020877675,0.007611451,0.000121145466,0.00022914972,0.0010316386,0.00027552934,0.0003214853,0.00084244215,0.00004178582],"about_ca_topic_score_codex":0.0037194355,"about_ca_topic_score_gemma":0.006862562,"teacher_disagreement_score":0.0041090394,"about_ca_system_score_codex":0.00037416356,"about_ca_system_score_gemma":0.0008228979,"threshold_uncertainty_score":0.02173096},"labels":[],"label_agreement":null},{"id":"W4397002346","doi":"10.1111/dom.15650","title":"Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the <scp>ORION</scp> ‐9, <scp>ORION</scp> ‐10 and <scp>ORION</scp> ‐11 Phase 3 randomized trials","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"NIHR Imperial Biomedical Research Centre; Imperial College London; Novartis Pharma; National Institute for Health and Care Research","keywords":"Medicine; Placebo; Prediabetes; Body mass index; Internal medicine; Post-hoc analysis; Type 2 diabetes; Obesity; Diabetes mellitus; Randomized controlled trial; Cholesterol; Adverse effect; Endocrinology; Gastroenterology; Pathology","score_opus":0.03341380485866252,"score_gpt":0.33047036542645913,"score_spread":0.2970565605677966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397002346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8131498,0.16829658,0.0066131656,0.00054566935,0.0011026383,0.003202222,0.0037375055,0.00030262407,0.0030498465],"genre_scores_gemma":[0.9815906,0.010576346,0.0028138277,0.0004480643,0.00025700565,0.001779863,0.0013541208,0.000055410004,0.0011247155],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9938711,0.0042205527,0.0007990895,0.0006122865,0.0002865638,0.00021028312],"domain_scores_gemma":[0.99460125,0.0029230788,0.0014136867,0.00053015095,0.00037117052,0.00016069194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010917671,0.0019981156,0.0068777497,0.0008556911,0.00027790244,0.0017190302,0.0005070889,0.00095024274,0.0027556769],"category_scores_gemma":[0.008978341,0.0006024537,0.016710022,0.0011294358,0.0003991924,0.000839268,0.0006531084,0.0011882744,0.00022935096],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48604226,0.00037231864,0.0077632107,0.01111848,0.4722211,0.00012410525,0.00009079354,0.0012841704,0.0029587683,0.00011829453,0.0010191004,0.016887434],"study_design_scores_gemma":[0.13333698,0.024440266,0.04320752,0.00090013637,0.790391,0.0001737036,0.00015764858,0.0021230925,0.0018390927,0.00063530804,0.002690175,0.00010507419],"about_ca_topic_score_codex":0.0009114675,"about_ca_topic_score_gemma":0.002367805,"teacher_disagreement_score":0.010917671,"about_ca_system_score_codex":0.00044449707,"about_ca_system_score_gemma":0.00078634714,"threshold_uncertainty_score":0.0577389},"labels":[],"label_agreement":null},{"id":"W4397012202","doi":"10.1111/dom.15657","title":"Development and first‐stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"MSD Sharp and Dohme","keywords":"Digit symbol substitution test; Cognition; Numerical digit; Correlation; Computer science; Psychology; Medicine; Mathematics; Arithmetic; Psychiatry; Pathology","score_opus":0.014431399278113799,"score_gpt":0.2546376924159936,"score_spread":0.2402062931378798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397012202","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95938027,0.0006698993,0.027832935,0.00030541854,0.00021055106,0.0056607183,0.0016761551,0.0002491829,0.004014898],"genre_scores_gemma":[0.8797408,0.0008165611,0.10655984,0.00036541466,0.000070267575,0.0060052145,0.0037474826,0.000072207135,0.0026221995],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9938951,0.0027182293,0.0010078789,0.000481142,0.0016978147,0.00019974995],"domain_scores_gemma":[0.9835321,0.0062632086,0.0014446529,0.0013095038,0.007006886,0.00044364537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014327215,0.0006555058,0.00048646796,0.0012405477,0.00038479795,0.001230422,0.0010824471,0.0007148931,0.0011124457],"category_scores_gemma":[0.030898334,0.00030846952,0.0010243118,0.0005801694,0.00044226824,0.00078636355,0.0012624689,0.0009172422,0.00058203284],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023918296,0.0029521016,0.6199363,0.00051179406,0.00035722082,0.0002846674,0.002455953,0.0026566256,0.0094765695,0.00051196857,0.0030831988,0.3553818],"study_design_scores_gemma":[0.00076528854,0.011327833,0.93056697,0.0007969852,0.00039464145,0.0014675481,0.0014790187,0.01723363,0.019458188,0.0005997963,0.015789602,0.00012048884],"about_ca_topic_score_codex":0.002595439,"about_ca_topic_score_gemma":0.0052150446,"teacher_disagreement_score":0.014327215,"about_ca_system_score_codex":0.00070100295,"about_ca_system_score_gemma":0.0022574586,"threshold_uncertainty_score":0.07577044},"labels":[],"label_agreement":null},{"id":"W4398252779","doi":"10.1111/dom.15682","title":"Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute on Aging","keywords":"Medicine; Hazard ratio; Adverse effect; Internal medicine; Diabetic ketoacidosis; Diabetes mellitus; Heart failure; Type 2 diabetes; Population; Intensive care medicine; Confidence interval; Endocrinology","score_opus":0.007096238374035541,"score_gpt":0.2402489686211598,"score_spread":0.23315273024712427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398252779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989174,0.008002148,0.00038877924,0.00020671473,0.00013939147,0.00020791306,0.0005961131,0.00001008785,0.0012749052],"genre_scores_gemma":[0.99735296,0.0011995537,0.00032219052,0.00021557802,0.000095889045,0.00020372128,0.00041796747,0.0000022895913,0.00018991953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99162686,0.0053806584,0.0007030784,0.00070439524,0.0012452318,0.0003397118],"domain_scores_gemma":[0.9836648,0.008178515,0.005242005,0.0006445314,0.0014729761,0.00079725904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010448354,0.00034574742,0.0008228383,0.000634809,0.0003394466,0.00073575304,0.00047926456,0.00079056894,0.0014424676],"category_scores_gemma":[0.022492481,0.00020677922,0.0020385494,0.00055185525,0.0005127689,0.0008137674,0.00061842863,0.0008244343,0.000099355835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3458214,0.009574942,0.37672168,0.004360747,0.017023092,0.00021356842,0.00053273723,0.0026825508,0.0013409525,0.0006167308,0.0031465932,0.237965],"study_design_scores_gemma":[0.03003319,0.24226822,0.7044972,0.0013627266,0.010336691,0.0004054286,0.0008005969,0.0034918133,0.002405805,0.0010838623,0.0032068652,0.000107616564],"about_ca_topic_score_codex":0.0019277628,"about_ca_topic_score_gemma":0.002558532,"teacher_disagreement_score":0.010448354,"about_ca_system_score_codex":0.0011203939,"about_ca_system_score_gemma":0.0011207493,"threshold_uncertainty_score":0.055256844},"labels":[],"label_agreement":null},{"id":"W4399138329","doi":"10.1111/dom.15678","title":"Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"Astellas Pharma; Novo Nordisk; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Kidney disease; Confidence interval; Credence; Medicine; Receiver operating characteristic; Renal function; Brier score; Internal medicine; Creatinine; Area under the curve; Albuminuria; Machine learning; Computer science","score_opus":0.01559221180745171,"score_gpt":0.273363173717535,"score_spread":0.2577709619100833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399138329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9193691,0.0061521702,0.0641299,0.0026963605,0.0002697919,0.0007470198,0.0024593843,0.0004752963,0.0037008864],"genre_scores_gemma":[0.976913,0.00049192604,0.018744754,0.00054989697,0.0001109855,0.00037138315,0.0021505316,0.000056357203,0.00061119214],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9806051,0.016909443,0.00039174737,0.0010184379,0.0008645497,0.00021070156],"domain_scores_gemma":[0.97364026,0.019644644,0.0021375269,0.0025285715,0.0015201591,0.0005288778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.049637273,0.0010883259,0.0017940105,0.0005729516,0.00024760087,0.0012092106,0.0009983382,0.0008666377,0.0010887204],"category_scores_gemma":[0.040144924,0.00029227536,0.002217355,0.00042224897,0.0005552396,0.0010190236,0.0011619555,0.0017798947,0.0003939821],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047590446,0.0017130184,0.41394153,0.0018076962,0.013850989,0.00033260733,0.00036416895,0.3409587,0.0020411913,0.0053596445,0.016242437,0.15579759],"study_design_scores_gemma":[0.005928069,0.009698427,0.077842176,0.0006759129,0.0036853317,0.0003696033,0.000107659725,0.88339186,0.0022415328,0.010347821,0.0055603827,0.00015116487],"about_ca_topic_score_codex":0.0014480589,"about_ca_topic_score_gemma":0.0018453221,"teacher_disagreement_score":0.049637273,"about_ca_system_score_codex":0.00070162024,"about_ca_system_score_gemma":0.0015634841,"threshold_uncertainty_score":0.26251012},"labels":[],"label_agreement":null},{"id":"W4399327175","doi":"10.1111/dom.15691","title":"Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the <scp>DECIDE</scp> ‐ <scp>CV</scp> clinical programme","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Janssen Research and Development; Novo Nordisk Foundation Center for Basic Metabolic Research; Boehringer Ingelheim","keywords":"Medicine; Type 2 diabetes; Internal medicine; Diabetes mellitus; Kidney disease; Mineralocorticoid receptor; Urology; Creatinine; Endocrinology; Aldosterone; Renal function; Outpatient clinic; Type 2 Diabetes Mellitus","score_opus":0.014026643978323644,"score_gpt":0.24731626414161395,"score_spread":0.2332896201632903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399327175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924931,0.0013428888,0.0009942009,0.00082463707,0.0002040933,0.0018306752,0.00045119162,0.00004478241,0.0018143236],"genre_scores_gemma":[0.9866917,0.0015565553,0.006920085,0.0010355483,0.00047107224,0.0019752064,0.00087594363,0.000014447467,0.00045941203],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981166,0.001153125,0.000074118696,0.00016828837,0.0002598046,0.0002280438],"domain_scores_gemma":[0.9962607,0.0012357282,0.0005495541,0.00020911901,0.00028938596,0.0014554424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031348178,0.00039949652,0.0005218919,0.00022236907,0.00033829987,0.0010938835,0.00057617447,0.00065931043,0.0024100156],"category_scores_gemma":[0.004649444,0.00016209882,0.0011118656,0.0002574842,0.00031060074,0.000428226,0.0012530163,0.0009920166,0.00013214476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07905905,0.10568536,0.13998361,0.0023680164,0.0022001693,0.0004208145,0.00081290136,0.0023856615,0.0062096543,0.00053925335,0.008704133,0.6516314],"study_design_scores_gemma":[0.16222036,0.2546083,0.5628162,0.00086227263,0.0022510358,0.000509041,0.0007083232,0.0038650774,0.0027116484,0.00044131366,0.008931261,0.00007518724],"about_ca_topic_score_codex":0.0025105532,"about_ca_topic_score_gemma":0.0039889463,"teacher_disagreement_score":0.0031348178,"about_ca_system_score_codex":0.00085143454,"about_ca_system_score_gemma":0.0032442068,"threshold_uncertainty_score":0.016578674},"labels":[],"label_agreement":null},{"id":"W4399385130","doi":"10.1111/dom.15687","title":"Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the <scp>VERTIS CV</scp> trial","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Pfizer","keywords":"Type 2 diabetes; Disease; Medicine; Diabetes mellitus; Atherosclerotic cardiovascular disease; Kidney disease; Internal medicine; Endocrinology","score_opus":0.03858505619028017,"score_gpt":0.2461420064499814,"score_spread":0.20755695025970122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399385130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89343715,0.06584691,0.000994786,0.0047272826,0.0018031083,0.002964656,0.013730104,0.000097028664,0.016398914],"genre_scores_gemma":[0.9578282,0.013590463,0.0013207637,0.003921468,0.0026702231,0.0035044616,0.014477276,0.00004988804,0.0026372396],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967056,0.001892027,0.00038386034,0.0003937804,0.00040529118,0.00021947468],"domain_scores_gemma":[0.9943305,0.0017227288,0.0017320759,0.000538475,0.0006157494,0.0010602934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008005459,0.00090326986,0.0023527292,0.00029615045,0.00076959684,0.0016980473,0.0008422072,0.002002508,0.0058830595],"category_scores_gemma":[0.010785167,0.00051150017,0.002925566,0.0010807393,0.00072862586,0.0014803833,0.0011274951,0.0037491536,0.00066263234],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8355937,0.0027578848,0.0874345,0.0041661407,0.013866544,0.00020534682,0.00032668948,0.0003976529,0.00083633227,0.0006084545,0.014210403,0.039596327],"study_design_scores_gemma":[0.550973,0.04178323,0.36675727,0.0020809975,0.019034786,0.0006440368,0.00045462075,0.0012205644,0.0004404054,0.002865908,0.01348263,0.0002625518],"about_ca_topic_score_codex":0.0023523432,"about_ca_topic_score_gemma":0.004747049,"teacher_disagreement_score":0.008005459,"about_ca_system_score_codex":0.000534019,"about_ca_system_score_gemma":0.0008918573,"threshold_uncertainty_score":0.042337418},"labels":[],"label_agreement":null},{"id":"W4399385154","doi":"10.1111/dom.15688","title":"The daunting task of recruiting insulin‐treated patients living with type 2 diabetes mellitus for intensive lifestyle interventions","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Consumer Attitudes and Food Labeling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute; Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Psychological intervention; Type 2 Diabetes Mellitus; Medicine; Task (project management); Diabetes mellitus; Insulin; Intensive care medicine; Internal medicine; Endocrinology; Nursing; Engineering","score_opus":0.020176957520881254,"score_gpt":0.2597668365144375,"score_spread":0.23958987899355624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399385154","genre_codex":"protocol","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28605434,0.043322157,0.042729106,0.051382467,0.017275376,0.5119148,0.011655223,0.00074801344,0.034918573],"genre_scores_gemma":[0.29524538,0.021888418,0.092373714,0.060247432,0.013699802,0.5048304,0.004842204,0.00017859484,0.006694041],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9734692,0.019642832,0.0033481834,0.0011958142,0.0016693273,0.00067459466],"domain_scores_gemma":[0.98203814,0.0056441794,0.003198382,0.0028453157,0.0018922843,0.0043816646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021389782,0.0013385759,0.0025857058,0.0011245555,0.002465866,0.002848162,0.0027853318,0.003239749,0.03433922],"category_scores_gemma":[0.021919752,0.0010392729,0.0018934717,0.0019318591,0.0015663973,0.002006859,0.0037375486,0.0029844616,0.009517482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057534467,0.0448155,0.048723944,0.011866836,0.0012214845,0.00078431854,0.00082268176,0.0011914566,0.0034411752,0.0023128486,0.05225092,0.77503437],"study_design_scores_gemma":[0.32018667,0.23461539,0.22260685,0.019356681,0.002452036,0.002972109,0.0045567215,0.0048604584,0.0026635223,0.01936723,0.16578965,0.0005726588],"about_ca_topic_score_codex":0.0015807217,"about_ca_topic_score_gemma":0.0029968754,"teacher_disagreement_score":0.03433922,"about_ca_system_score_codex":0.00088538637,"about_ca_system_score_gemma":0.005052399,"threshold_uncertainty_score":0.11487615},"labels":[],"label_agreement":null},{"id":"W4399500926","doi":"10.1111/dom.15703","title":"Cost–utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy—An Italian healthcare system perspective","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Perspective (graphical); Basal insulin; Flash (photography); Continuous glucose monitoring; Medicine; Type 2 Diabetes Mellitus; Intensive care medicine; Diabetes mellitus; Basal (medicine); Insulin; Critically ill; Type 1 diabetes; Type 2 diabetes; Computer science; Internal medicine; Endocrinology; Artificial intelligence; Art","score_opus":0.022812358994186856,"score_gpt":0.2949182100260869,"score_spread":0.27210585103190005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399500926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581994,0.005506092,0.015686616,0.0027670295,0.000079670644,0.00035306212,0.0037794812,0.00009274404,0.013535991],"genre_scores_gemma":[0.9961339,0.00052746304,0.0018248133,0.00013694176,0.000019195368,0.00007630866,0.0006185934,0.000010276421,0.00065253634],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9985421,0.0010435149,0.0000322568,0.00012407609,0.00010031357,0.00015775822],"domain_scores_gemma":[0.99722326,0.002097027,0.00029876904,0.000074666335,0.00014632098,0.00016002587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032486443,0.0011640193,0.0010413304,0.0009645283,0.00020245154,0.0015102417,0.00087872706,0.0011007268,0.0036811992],"category_scores_gemma":[0.0069157095,0.00049977866,0.002395747,0.0010026911,0.00046566472,0.00079837337,0.00086784,0.0008761382,0.00020568827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017079116,0.0001046774,0.013198851,0.00025693368,0.0006640144,0.00027083495,0.0000431096,0.9712567,0.00034552423,0.003103767,0.0010868561,0.00796087],"study_design_scores_gemma":[0.0005666646,0.0020367436,0.023961209,0.00024275303,0.0015092312,0.0003816824,0.0001573919,0.9657764,0.00035932456,0.0027729191,0.002169525,0.000066252935],"about_ca_topic_score_codex":0.022776516,"about_ca_topic_score_gemma":0.009362158,"teacher_disagreement_score":0.022776516,"about_ca_system_score_codex":0.006624618,"about_ca_system_score_gemma":0.0026192463,"threshold_uncertainty_score":0.048065245},"labels":[],"label_agreement":null},{"id":"W4399545973","doi":"10.1111/dom.15711","title":"No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Semaglutide; Medicine; Pneumonia; Diabetes mellitus; Surgery; General surgery; Internal medicine; Type 2 diabetes; Endocrinology","score_opus":0.0069880721845607605,"score_gpt":0.20729353006341633,"score_spread":0.20030545787885556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399545973","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947449,0.002238972,0.000119151664,0.00023671407,0.000105373736,0.000021379186,0.0011833633,0.0000071826203,0.0013430078],"genre_scores_gemma":[0.99822813,0.00078529964,0.00010011414,0.00015073482,0.000074043615,0.000015505162,0.00045381178,0.0000041335365,0.00018824144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934775,0.000095975614,0.00013341971,0.00016278382,0.00013492035,0.0001251031],"domain_scores_gemma":[0.99715036,0.0004625746,0.0013353012,0.00023223228,0.0003226013,0.00049693685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065336487,0.00023098414,0.00038343397,0.00077378115,0.00066267594,0.0006560917,0.00048786687,0.0006798886,0.0036581673],"category_scores_gemma":[0.0038527676,0.00036217622,0.00119664,0.0012621953,0.00025329858,0.00058757013,0.00049598276,0.0011150877,0.0003648418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012336808,0.000028146433,0.9986405,0.000031674783,0.00008175428,0.00008738826,0.000027993927,0.000008791567,0.000045016062,0.000011838891,0.00014575041,0.00076789065],"study_design_scores_gemma":[0.000016317823,0.0001972489,0.99839336,0.00003751784,0.000113762006,0.0005462374,0.00022130324,0.00010851334,0.000021217948,0.000031435826,0.0003043439,0.000008791497],"about_ca_topic_score_codex":0.007030425,"about_ca_topic_score_gemma":0.006872192,"teacher_disagreement_score":0.007030425,"about_ca_system_score_codex":0.00031462,"about_ca_system_score_gemma":0.0005505064,"threshold_uncertainty_score":0.013979018},"labels":[],"label_agreement":null},{"id":"W4399811711","doi":"10.1111/dom.15685","title":"Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the <scp>CREDENCE</scp> randomized trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Hazard ratio; Myocardial infarction; Internal medicine; Kidney disease; Proportional hazards model; Renal function; Stroke (engine); Heart failure; Confidence interval; Demography; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.00452194391986236,"score_gpt":0.20694754608862617,"score_spread":0.20242560216876382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399811711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923844,0.0022381828,0.0005532969,0.00046803005,0.00016892827,0.0006406785,0.0017483445,0.00002664478,0.0017715337],"genre_scores_gemma":[0.9956456,0.0003353916,0.00050021295,0.00045769752,0.00019913258,0.0005780972,0.0018084232,0.000006311899,0.00046900733],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9979113,0.0013064117,0.00013180544,0.00031907886,0.00019099223,0.00014041457],"domain_scores_gemma":[0.9974941,0.00075593556,0.00085502473,0.00034059206,0.00022650142,0.00032787825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003126364,0.0005164571,0.0012994498,0.0002742258,0.0003549681,0.00080411736,0.00039718492,0.0006998902,0.0029149044],"category_scores_gemma":[0.004876396,0.00019540825,0.002005737,0.0004806847,0.00038151076,0.00044837012,0.00037711463,0.00084605726,0.00021718752],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7976939,0.0033432543,0.13149574,0.0011043658,0.017609166,0.00015320796,0.0001371018,0.0012984604,0.001572002,0.0005608049,0.005280261,0.0397518],"study_design_scores_gemma":[0.44153112,0.035556342,0.48451617,0.00024456347,0.024121827,0.0003334174,0.0001984677,0.004456925,0.0012981412,0.0014357592,0.006231196,0.000076040946],"about_ca_topic_score_codex":0.0015292554,"about_ca_topic_score_gemma":0.0018770044,"teacher_disagreement_score":0.003126364,"about_ca_system_score_codex":0.00029342738,"about_ca_system_score_gemma":0.00066123344,"threshold_uncertainty_score":0.01653403},"labels":[],"label_agreement":null},{"id":"W4400262071","doi":"10.1111/dom.15726","title":"Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the <scp>ONWARDS</scp> 1–5 trials","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Medicine; Basal insulin; Type 2 diabetes; Meta-analysis; Insulin; Internal medicine; Basal (medicine); Diabetes mellitus; Endocrinology","score_opus":0.2422899538052596,"score_gpt":0.3831252561748905,"score_spread":0.1408353023696309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400262071","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07749909,0.9163345,0.001786698,0.0004553738,0.00078794593,0.00056973734,0.0010359338,0.00012522201,0.0014054494],"genre_scores_gemma":[0.7840327,0.20709004,0.0032010253,0.0016855629,0.00053201505,0.0009324955,0.0012475611,0.000080646016,0.0011979544],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9939889,0.0038842498,0.0008263479,0.00071272196,0.00039498528,0.00019287155],"domain_scores_gemma":[0.9938193,0.0043586483,0.0010675675,0.00030546487,0.00028631586,0.0001626862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008687345,0.002685936,0.012371169,0.001891322,0.00035297291,0.0031868885,0.0013051343,0.002087847,0.0033156234],"category_scores_gemma":[0.013033243,0.0011360721,0.036148373,0.0022856211,0.0005158367,0.0012645015,0.0010224764,0.0031638218,0.00028777885],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04611007,0.00007883027,0.0026473417,0.05485685,0.8844602,0.0000843573,0.00004918463,0.00091630407,0.000493661,0.00012619082,0.00048508734,0.009691968],"study_design_scores_gemma":[0.011714845,0.0013232259,0.0036552532,0.0031062334,0.9784411,0.00007035103,0.000028585535,0.00044258355,0.00016370963,0.00020825228,0.0008249571,0.000020949095],"about_ca_topic_score_codex":0.004771557,"about_ca_topic_score_gemma":0.007160229,"teacher_disagreement_score":0.012371169,"about_ca_system_score_codex":0.0013956724,"about_ca_system_score_gemma":0.0010008452,"threshold_uncertainty_score":0.045943618},"labels":[],"label_agreement":null},{"id":"W4400475255","doi":"10.1111/dom.15746","title":"The interaction effect between <scp>BMI</scp> , diabetes and age at diabetes onset on the risk of thyroid cancer: A population‐based cohort study in Shanghai, China","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Natural Science Foundation of China; Shanghai Municipal Health Commission","keywords":"Medicine; Thyroid cancer; Hazard ratio; Population; Internal medicine; Diabetes mellitus; Incidence (geometry); Cohort; Type 2 diabetes; Body mass index; Proportional hazards model; Cohort study; Cancer; Demography; Endocrinology; Confidence interval; Environmental health","score_opus":0.008275500570069656,"score_gpt":0.2595411814488906,"score_spread":0.25126568087882095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400475255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990658,0.00025353118,0.000074947755,0.000028182358,0.000006552916,0.0000052999103,0.00043148748,0.000004652931,0.00012952837],"genre_scores_gemma":[0.9993543,0.000091769136,0.000047001704,0.000012895059,0.0000067564592,0.0000046304817,0.00033338502,0.0000013530921,0.00014779021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996376,0.00008090556,0.000034760265,0.00010475501,0.00005952406,0.000082382394],"domain_scores_gemma":[0.99911326,0.00009943194,0.00023240334,0.0001131689,0.00015567282,0.00028611027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006179102,0.00059265486,0.00048278715,0.0009816922,0.0005390199,0.00062189176,0.00030417537,0.0003258994,0.0010443621],"category_scores_gemma":[0.00076111214,0.0005412641,0.0010517241,0.0014301384,0.0002836572,0.0002577001,0.00035441946,0.00040775945,0.000116131545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015773108,0.000013983031,0.9987293,0.0000087681665,0.00016715263,0.000078003955,0.000054978762,0.00003968387,0.00023278508,0.0000068917298,0.000063289044,0.0004473132],"study_design_scores_gemma":[0.000008019353,0.000034357046,0.99957603,0.0000016371082,0.000079340665,0.0000380997,0.00003341429,0.00015237817,0.000021923806,0.0000055870337,0.000046830726,0.0000024017047],"about_ca_topic_score_codex":0.076192215,"about_ca_topic_score_gemma":0.07023748,"teacher_disagreement_score":0.076192215,"about_ca_system_score_codex":0.00071618834,"about_ca_system_score_gemma":0.0009414196,"threshold_uncertainty_score":0.15149742},"labels":[],"label_agreement":null},{"id":"W4400696290","doi":"10.1111/dom.15770","title":"Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Natural Science Foundation of Tianjin City; National Natural Science Foundation of China; Eli Lilly and Company","keywords":"Offspring; Overweight; Gestational diabetes; Medicine; Diabetes mellitus; Obstetrics; Gestational age; Pregnancy; Obesity; Internal medicine; Gestation; Endocrinology; Biology","score_opus":0.0055565055311902825,"score_gpt":0.22163054203896906,"score_spread":0.2160740365077788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400696290","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602483,0.009685651,0.00009219128,0.019056708,0.00080852327,0.000045569366,0.0007583528,0.000015783415,0.0092889685],"genre_scores_gemma":[0.98633784,0.005681256,0.00037229835,0.003191913,0.0006788506,0.000062927735,0.00036444902,0.000005051987,0.0033053982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981576,0.00007755149,0.000013327137,0.000024483501,0.00003105951,0.00003780167],"domain_scores_gemma":[0.998789,0.00057374354,0.00021701632,0.00007586379,0.00009312079,0.0002512152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045581098,0.00014438701,0.00032158213,0.00027928362,0.00041023057,0.00022223659,0.0002285823,0.00074010954,0.006091242],"category_scores_gemma":[0.0034451135,0.00009285063,0.00054098497,0.0002925341,0.00013254506,0.00016923429,0.00016045262,0.00073149014,0.0002840347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040437806,0.0027537048,0.58184886,0.00046432245,0.0007333709,0.0048248433,0.0004684784,0.00026568637,0.0018805008,0.0006422737,0.025519772,0.34016037],"study_design_scores_gemma":[0.0014357143,0.0066071325,0.97736686,0.00051676395,0.001171021,0.0016752352,0.0005034153,0.00085262844,0.00049117365,0.0010444042,0.0082985265,0.000037064685],"about_ca_topic_score_codex":0.009045787,"about_ca_topic_score_gemma":0.01262467,"teacher_disagreement_score":0.009045787,"about_ca_system_score_codex":0.0005115026,"about_ca_system_score_gemma":0.00076574564,"threshold_uncertainty_score":0.020377219},"labels":[],"label_agreement":null},{"id":"W4400747098","doi":"10.1111/dom.15771","title":"Bariatric surgery and all‐cause mortality: A methodological review of studies using a non‐surgical comparator","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Atara Biotherapeutics; Kowa Company; Amarin Corporation; Novo Nordisk; Merck; Novartis; Pfizer; Seqirus; AstraZeneca; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim","keywords":"Medicine; Surgical procedures; Surgery; General surgery; Intensive care medicine","score_opus":0.36883434458384223,"score_gpt":0.46638567469115594,"score_spread":0.0975513301073137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400747098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012933015,0.99633944,0.00068270916,0.00046530928,0.00018874463,0.00058047264,0.00025048776,0.000007590429,0.00019190331],"genre_scores_gemma":[0.0607488,0.9249321,0.006550255,0.0019082893,0.0003445468,0.004577169,0.0007343627,0.000031333566,0.00017321714],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.86019045,0.055821486,0.06357086,0.005488045,0.014045611,0.0008836004],"domain_scores_gemma":[0.5796017,0.3340613,0.06373059,0.0068877395,0.014893661,0.00082500326],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10561095,0.0020707764,0.011256937,0.014250981,0.001177801,0.005153706,0.004476358,0.0038375456,0.003150479],"category_scores_gemma":[0.3272092,0.0020885656,0.019776514,0.014387123,0.002061462,0.003955005,0.0031306276,0.0020558694,0.0002991274],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008077614,0.00003033479,0.0039872145,0.91523165,0.04441147,0.000070623115,0.00026002293,0.00018138511,0.00015097864,0.00049032347,0.0009543645,0.033423968],"study_design_scores_gemma":[0.0009198011,0.00042225517,0.01117663,0.73338133,0.23655117,0.00037130117,0.00038653106,0.00024400293,0.00044524047,0.0014855518,0.014544659,0.00007151221],"about_ca_topic_score_codex":0.005148088,"about_ca_topic_score_gemma":0.011166858,"teacher_disagreement_score":0.89438903,"about_ca_system_score_codex":0.0064270976,"about_ca_system_score_gemma":0.012087755,"threshold_uncertainty_score":0.5585308},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch","metaepi_narrow","metaepi_broad"],"domain":"methods","study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4401033246","doi":"10.1111/dom.15769","title":"<scp>Glucagon‐like peptide</scp> ‐1 receptor agonists and <scp>sodium‐glucose cotransporter</scp> ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Toronto General and Western Hospital Foundation","keywords":"Medicine; Vildagliptin; Diabetes mellitus; Internal medicine; Combination therapy; Glucagon-like peptide-1; Gastroenterology; Body mass index; Glucagon-like peptide 1 receptor; Endocrinology; Pharmacology; Type 2 Diabetes Mellitus; Type 2 diabetes; Receptor","score_opus":0.013528296253285407,"score_gpt":0.24239407759248233,"score_spread":0.2288657813391969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401033246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879018,0.010634378,0.00033658347,0.000114907096,0.000024629117,0.00004436329,0.00052363216,0.000007449726,0.0004123459],"genre_scores_gemma":[0.99744356,0.0016148438,0.00040551065,0.0000858905,0.00005290117,0.0000380715,0.000285658,0.0000015889182,0.000071980176],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845433,0.0008629429,0.00020814234,0.00011994163,0.00030139837,0.00005322245],"domain_scores_gemma":[0.9955071,0.0013213409,0.0026279427,0.000114388786,0.00020835908,0.00022086961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028650505,0.0001506576,0.00060239545,0.0005863961,0.00011117744,0.0005841483,0.0002035851,0.00018287227,0.0008522994],"category_scores_gemma":[0.0030194533,0.0001085436,0.0009301016,0.00060108554,0.00017813317,0.0002851776,0.00022915116,0.00026003763,0.00008713912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027679766,0.0005386057,0.90775955,0.0009218805,0.003919167,0.00014358573,0.000046424604,0.0005168108,0.0023369573,0.0000987626,0.0005324242,0.055505954],"study_design_scores_gemma":[0.0020286343,0.00991889,0.97888523,0.00023947934,0.0031761718,0.00077812467,0.0001356235,0.0020562771,0.0016914916,0.00011685068,0.00095546583,0.000017842332],"about_ca_topic_score_codex":0.00044848936,"about_ca_topic_score_gemma":0.0011408944,"teacher_disagreement_score":0.0028650505,"about_ca_system_score_codex":0.00032327865,"about_ca_system_score_gemma":0.000557555,"threshold_uncertainty_score":0.015151978},"labels":[],"label_agreement":null},{"id":"W4401033736","doi":"10.1111/dom.15799","title":"Persistent disparities in insulin pump uptake despite a universal pump programme for type 1 diabetes in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; St. Michael's Hospital; Hospital for Sick Children; University of Toronto","funders":"Canadian Statistical Sciences Institute; Banting Research Foundation","keywords":"Medicine; Insulin pump; Odds; Odds ratio; Disadvantage; Type 1 diabetes; Logistic regression; Demography; Population; Gerontology; Diabetes mellitus; Environmental health; Internal medicine; Endocrinology","score_opus":0.02646375995055204,"score_gpt":0.24533920333769985,"score_spread":0.21887544338714782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401033736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98967314,0.0016235325,0.00012174881,0.0017549116,0.00003097755,0.00004346713,0.0036778755,0.000012107856,0.0030622345],"genre_scores_gemma":[0.99798656,0.00055588275,0.000103086066,0.00016424977,0.000008824967,0.00001375985,0.0007278485,0.000003109443,0.00043678287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869484,0.00008675908,0.0000794729,0.00018182838,0.00043043063,0.0005266805],"domain_scores_gemma":[0.99746406,0.000113491915,0.0006966107,0.00007034841,0.0007955756,0.0008599656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077386264,0.00021452374,0.0005182363,0.0007227114,0.0027280126,0.0012058998,0.0010496565,0.00035399164,0.0014412468],"category_scores_gemma":[0.0020283407,0.00024294756,0.00056074763,0.0029684275,0.0007782339,0.00048659922,0.0011436931,0.0007259256,0.00010214856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008655136,0.00003821267,0.9900637,0.000067577144,0.000074901734,0.00007432976,0.0012973958,0.00009808478,0.00014812917,0.00018371512,0.0015828203,0.0062845484],"study_design_scores_gemma":[0.00000658457,0.000010657391,0.9987429,0.00003162454,0.000016677584,0.000014427439,0.00053750235,0.00010454513,0.000013402861,0.000017760633,0.0004986494,0.000005323537],"about_ca_topic_score_codex":0.9970066,"about_ca_topic_score_gemma":0.9983364,"teacher_disagreement_score":0.035952866,"about_ca_system_score_codex":0.035952866,"about_ca_system_score_gemma":0.05001154,"threshold_uncertainty_score":0.26085752},"labels":[],"label_agreement":null},{"id":"W4401033823","doi":"10.1111/dom.15798","title":"Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Esperion Therapeutics; Kowa Company; National Institutes of Health; Amarin Corporation; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute; Pfizer; Amgen; AstraZeneca; Eli Lilly and Company; Eisai; American Heart Association","keywords":"Medicine; Pharmacotherapy; Weight loss; Diabetes mellitus; Intensive care medicine; Type 2 diabetes; Internal medicine; Obesity; Endocrinology","score_opus":0.012279429574224746,"score_gpt":0.2620909850618799,"score_spread":0.24981155548765516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401033823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94660133,0.0009433969,0.049061604,0.0010205262,0.000060655602,0.00015444963,0.0008658256,0.00016286381,0.0011292748],"genre_scores_gemma":[0.9938943,0.00014231418,0.0049801264,0.00007675275,0.00002323357,0.00006269822,0.0005258253,0.000008171796,0.00028663964],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998985,0.0005444411,0.00006324008,0.00018615604,0.00014615261,0.00007504618],"domain_scores_gemma":[0.9961935,0.002650854,0.00063639885,0.00017978586,0.00020498967,0.00013442858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004202194,0.0007069612,0.00069324794,0.0007403702,0.00016505978,0.0010571192,0.0006786408,0.00065912755,0.0011250596],"category_scores_gemma":[0.01015154,0.00026460894,0.0009912763,0.00032727214,0.00024368666,0.00036122967,0.0004132361,0.0007969596,0.00028331854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001918279,0.00039450362,0.83880055,0.00009543929,0.0012569071,0.00023129008,0.0000841198,0.12629548,0.0010964706,0.00086214277,0.0013093246,0.027655514],"study_design_scores_gemma":[0.00019107903,0.00062244624,0.14642853,0.000040121347,0.00045292397,0.00037961194,0.000036407953,0.8490087,0.0004328335,0.0016528826,0.00073154183,0.00002290377],"about_ca_topic_score_codex":0.0019057193,"about_ca_topic_score_gemma":0.0011269238,"teacher_disagreement_score":0.004202194,"about_ca_system_score_codex":0.00043591927,"about_ca_system_score_gemma":0.0006076307,"threshold_uncertainty_score":0.022223532},"labels":[],"label_agreement":null},{"id":"W4401434535","doi":"10.1111/dom.15834","title":"Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk Canada; Novo Nordisk","keywords":"Medicine; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Endocrinology; Cohort; Basal (medicine); Albuminuria; Diabetes mellitus; Insulin; Kidney disease; Liraglutide; Renal function; Population; Agonist; Receptor","score_opus":0.0077060772296730215,"score_gpt":0.24782676468415807,"score_spread":0.24012068745448506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401434535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970061,0.0009190036,0.00006629639,0.00016745135,0.00003717713,0.000095748896,0.0011553251,0.000004922908,0.000548077],"genre_scores_gemma":[0.99796695,0.00034206855,0.00016372405,0.0001621775,0.00003492255,0.00006200974,0.0011339823,0.0000017197383,0.00013242994],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984326,0.0006111755,0.00012950676,0.00034033458,0.00025621246,0.00023012383],"domain_scores_gemma":[0.99800843,0.00040759507,0.0007569228,0.00012054614,0.00015992172,0.00054667646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021823624,0.0005202881,0.0008242163,0.00024228782,0.00044190537,0.00096375064,0.0005434067,0.00078480766,0.0011634734],"category_scores_gemma":[0.0040915227,0.000257565,0.002539498,0.0006136599,0.00035252582,0.00047881412,0.00056176085,0.0012025051,0.00011037263],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20104921,0.0053730123,0.74231493,0.0007343487,0.0112582855,0.00013258355,0.000212717,0.002221282,0.0010140161,0.00019541691,0.0025526895,0.032941453],"study_design_scores_gemma":[0.018513963,0.033420134,0.9334975,0.0001694894,0.008624329,0.00011652225,0.00038288682,0.003027264,0.0005434689,0.00017979839,0.0014390065,0.00008568622],"about_ca_topic_score_codex":0.058509376,"about_ca_topic_score_gemma":0.07094206,"teacher_disagreement_score":0.058509376,"about_ca_system_score_codex":0.0021674084,"about_ca_system_score_gemma":0.0024105648,"threshold_uncertainty_score":0.11633766},"labels":[],"label_agreement":null},{"id":"W4401447115","doi":"10.1111/dom.15794","title":"Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Real world data; Pooled analysis; Diabetes mellitus; Internal medicine; Meta-analysis; Endocrinology; Data science; Liraglutide","score_opus":0.029476314409815265,"score_gpt":0.28172118628095005,"score_spread":0.2522448718711348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401447115","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41426057,0.54703027,0.008821861,0.0011235742,0.0004639838,0.0034098944,0.021125473,0.000192421,0.0035719767],"genre_scores_gemma":[0.94896513,0.03483201,0.0053113806,0.0007303072,0.00027024705,0.001816977,0.007590507,0.00006306915,0.0004204239],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9485794,0.030133814,0.012168267,0.0032057061,0.005446082,0.0004667528],"domain_scores_gemma":[0.92161137,0.043981012,0.026014,0.003924797,0.003839435,0.0006293872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.052076183,0.0011813388,0.0065545086,0.005019313,0.00029088877,0.0029873021,0.0008842971,0.0014760548,0.0024186163],"category_scores_gemma":[0.06841802,0.0007483649,0.019507192,0.004214689,0.0005708245,0.0015241911,0.002043382,0.0012113075,0.00025065758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040007107,0.00020301536,0.06701952,0.0670657,0.78104407,0.00017016215,0.00028204004,0.0016020603,0.0010915578,0.00022072298,0.001261651,0.040032383],"study_design_scores_gemma":[0.01212098,0.009938424,0.17883122,0.011750364,0.7750613,0.0007792097,0.00029050023,0.0011599078,0.0010693115,0.00066033297,0.008165004,0.00017336168],"about_ca_topic_score_codex":0.00067170087,"about_ca_topic_score_gemma":0.001240809,"teacher_disagreement_score":0.052076183,"about_ca_system_score_codex":0.00069235626,"about_ca_system_score_gemma":0.0010353881,"threshold_uncertainty_score":0.27540845},"labels":[],"label_agreement":null},{"id":"W4401463253","doi":"10.1111/dom.15844","title":"Cystic fibrosis‐related diabetes develops from a combination of insulin secretion defects and insulin resistance","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital du Sacré-Cœur de Montréal; University of Alberta; Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Insulin resistance; Medicine; Internal medicine; Insulin; Endocrinology; Cystic fibrosis-related diabetes; Diabetes mellitus; Glucose tolerance test; Impaired glucose tolerance","score_opus":0.006704654826958133,"score_gpt":0.23817626737813097,"score_spread":0.23147161255117282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401463253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979522,0.000847039,0.0007679409,0.000042422667,0.0000050162735,0.000006062159,0.00006682028,0.000013599257,0.00029889334],"genre_scores_gemma":[0.9991953,0.00027125812,0.00033897566,0.000018311135,0.000012146676,0.000003377826,0.00009197154,0.0000024250598,0.0000662407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996921,0.00008487592,0.000039233826,0.000072829775,0.000067298424,0.000043690216],"domain_scores_gemma":[0.99871635,0.00037303232,0.00065075734,0.00007427181,0.000054903547,0.00013073203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006652479,0.00041885977,0.000544624,0.0005607979,0.00023326659,0.0004078825,0.00018243896,0.00033700597,0.0009848207],"category_scores_gemma":[0.0015794076,0.00018260498,0.0004286068,0.00051268603,0.00037048743,0.00026613765,0.00042965592,0.0004855671,0.00016591029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004797041,0.000032254633,0.9879516,0.00003174331,0.00013814226,0.0004283933,0.000024191171,0.00022495781,0.00498216,0.000047426343,0.000046672634,0.005612817],"study_design_scores_gemma":[0.000017478123,0.0002881302,0.99203604,0.000029537274,0.000110900975,0.0050929114,0.00004604674,0.0011280619,0.0008609382,0.00017950672,0.00020236237,0.000008173399],"about_ca_topic_score_codex":0.00045438955,"about_ca_topic_score_gemma":0.00039428874,"teacher_disagreement_score":0.0009848207,"about_ca_system_score_codex":0.00015676787,"about_ca_system_score_gemma":0.00017818651,"threshold_uncertainty_score":0.0035182238},"labels":[],"label_agreement":null},{"id":"W4401684784","doi":"10.1111/dom.15829","title":"Opportunities to optimize lifestyle interventions in combination with <scp>glucagon‐like peptide</scp> ‐1‐based therapy","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Weight loss; Medicine; Type 2 diabetes; Discontinuation; Psychological intervention; Obesity; Disease; Diabetes mellitus; Intensive care medicine; Gerontology; Internal medicine; Endocrinology; Psychiatry","score_opus":0.06778202109263012,"score_gpt":0.310770133213144,"score_spread":0.24298811212051388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401684784","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05248735,0.33003452,0.046348747,0.3282094,0.015633646,0.0023494354,0.0026246728,0.002273383,0.22003876],"genre_scores_gemma":[0.27144462,0.37771216,0.14718276,0.11653434,0.020075334,0.0045694932,0.003703062,0.00059935846,0.05817886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988783,0.00056239084,0.000082314175,0.000103224724,0.00023485986,0.00013901232],"domain_scores_gemma":[0.99819463,0.0006241769,0.00021573195,0.00009227282,0.00035485992,0.0005184074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020167285,0.0006387341,0.00068778265,0.000589674,0.00031177557,0.0017327846,0.00072582805,0.0015215455,0.027610824],"category_scores_gemma":[0.0050850087,0.00012617128,0.0015215599,0.0002692126,0.00035522218,0.0012782332,0.0012413664,0.002648685,0.0065244674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011900833,0.0027971587,0.0021481398,0.0034044469,0.00037129168,0.0004172612,0.00017131209,0.0010398336,0.0024161886,0.008214826,0.088867836,0.8889616],"study_design_scores_gemma":[0.0018352648,0.0029883473,0.013106769,0.009107506,0.00060463906,0.0012413363,0.0006170983,0.0016636782,0.0020351664,0.023727419,0.9429768,0.00009599662],"about_ca_topic_score_codex":0.0011046407,"about_ca_topic_score_gemma":0.0031714025,"teacher_disagreement_score":0.027610824,"about_ca_system_score_codex":0.00064017996,"about_ca_system_score_gemma":0.0023542596,"threshold_uncertainty_score":0.09236735},"labels":[],"label_agreement":null},{"id":"W4402012272","doi":"10.1111/dom.15899","title":"Optimizing physician‐encounter frequency for type 2 diabetes patients in primary care based on cardiovascular risk assessment: A target trial emulation study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Primary Care and Health Outcomes","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Bruyère; University of Ottawa","funders":"Young Scientists Fund; University of Hong Kong; National Natural Science Foundation of China","keywords":"Medicine; Type 2 diabetes; Emulation; Primary care; Risk assessment; Diabetes mellitus; Internal medicine; Family medicine; Intensive care medicine","score_opus":0.02478251503964235,"score_gpt":0.3467474885368992,"score_spread":0.32196497349725683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402012272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951196,0.0003333501,0.0025603413,0.00023386076,0.000048220056,0.0009770347,0.00016311188,0.00003131679,0.0005332846],"genre_scores_gemma":[0.99612075,0.00011633839,0.001967137,0.0001832749,0.00005317529,0.0010804989,0.00020952479,0.0000054555812,0.000263902],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9934077,0.0055117644,0.00022714182,0.00044331836,0.00015923385,0.00025082412],"domain_scores_gemma":[0.99045724,0.005939114,0.0017267792,0.0009376252,0.00032363913,0.00061559584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013871592,0.0007336634,0.0016043633,0.000253358,0.00018851343,0.0007953399,0.0008373429,0.000915657,0.002036024],"category_scores_gemma":[0.015743759,0.0003013745,0.0017087425,0.00033326543,0.0005697569,0.0007399603,0.0006880032,0.0010680442,0.00022429485],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81630766,0.037960906,0.04296551,0.0008150446,0.0056270454,0.0001508849,0.0003896746,0.028775236,0.0033564656,0.0010608017,0.0011000171,0.061490756],"study_design_scores_gemma":[0.25528967,0.5844708,0.054264717,0.000112019006,0.005949302,0.0001932291,0.00018222317,0.093246765,0.002809308,0.0015255716,0.0018601571,0.00009617049],"about_ca_topic_score_codex":0.0009017036,"about_ca_topic_score_gemma":0.0006323414,"teacher_disagreement_score":0.013871592,"about_ca_system_score_codex":0.00097217207,"about_ca_system_score_gemma":0.0014905228,"threshold_uncertainty_score":0.07336086},"labels":[],"label_agreement":null},{"id":"W4402140134","doi":"10.1111/dom.15895","title":"Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from <scp>VERTIS CV</scp>","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"European Foundation for the Study of Diabetes; American Society of Nephrology; Pfizer; American Diabetes Association","keywords":"Medicine; Post-hoc analysis; Gout; Type 2 diabetes; Disease; Uric acid; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.006852900927880108,"score_gpt":0.2233089835908114,"score_spread":0.2164560826629313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402140134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112904,0.0034498367,0.000468807,0.00022751863,0.00022267927,0.0010757463,0.0019126886,0.000046585836,0.001467138],"genre_scores_gemma":[0.9932029,0.00077952433,0.0008272018,0.00028950372,0.00019127932,0.00093433744,0.001947763,0.000017832193,0.0018095968],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9971449,0.0018430445,0.00016931538,0.00036189155,0.00015984233,0.000321052],"domain_scores_gemma":[0.99739033,0.0010756666,0.0004908044,0.0004179624,0.0002311265,0.0003941483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00537238,0.0013195241,0.003980364,0.0003273389,0.00029262307,0.00093026867,0.0006367945,0.0009227141,0.0052766693],"category_scores_gemma":[0.0039569857,0.0005173664,0.0055630147,0.00037234102,0.0005317108,0.0006021983,0.00061130594,0.0015265689,0.00039858092],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96930045,0.0016161924,0.0057071196,0.00049537077,0.009470555,0.000046480574,0.000038364455,0.00049059815,0.0019212125,0.000045167704,0.0007891633,0.01007922],"study_design_scores_gemma":[0.650656,0.20022677,0.11336372,0.00013508943,0.028505929,0.00012008732,0.0000799392,0.0016079594,0.0026546656,0.00028394148,0.0022879792,0.00007791163],"about_ca_topic_score_codex":0.0025307622,"about_ca_topic_score_gemma":0.0062270877,"teacher_disagreement_score":0.00537238,"about_ca_system_score_codex":0.00069437927,"about_ca_system_score_gemma":0.0012068782,"threshold_uncertainty_score":0.028412163},"labels":[],"label_agreement":null},{"id":"W4402318599","doi":"10.1111/dom.15926","title":"Evaluating remission of type 2 diabetes using a metabolic intervention including fixed‐ratio insulin degludec and liraglutide: A randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; University of Calgary; Ottawa Hospital; University of Ottawa; Western University; Capital District Health Authority; McMaster University; University of Alberta; Population Health Research Institute","funders":"Novo Nordisk Foundation Center for Basic Metabolic Research","keywords":"Medicine; Liraglutide; Hazard ratio; Type 2 diabetes; Internal medicine; Diabetes mellitus; Randomized controlled trial; Regimen; Confidence interval; Body mass index; Metformin; Insulin; Endocrinology","score_opus":0.04193998720789953,"score_gpt":0.3412835895633655,"score_spread":0.299343602355466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402318599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97600126,0.012021551,0.0011349631,0.0007425949,0.0012201928,0.00642975,0.0008964895,0.00018053249,0.0013727333],"genre_scores_gemma":[0.97818017,0.0050970186,0.0035979056,0.0011045826,0.00083366025,0.008764989,0.0008455147,0.000023815062,0.0015523242],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99716884,0.001695405,0.00028148128,0.00044030996,0.00019946558,0.0002144773],"domain_scores_gemma":[0.9979658,0.00073412765,0.00059626467,0.00017069899,0.000144523,0.0003885995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038121156,0.0017730827,0.0046883356,0.0006452266,0.00054707006,0.0013077691,0.0012721997,0.002527768,0.0057473634],"category_scores_gemma":[0.0038160288,0.00087094447,0.003394089,0.00068640005,0.0011216529,0.0008703986,0.0006065972,0.0023827031,0.0006671072],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99031866,0.00238907,0.0003142082,0.00073927786,0.0013249292,0.00001092771,0.000013192426,0.00007790836,0.0004108388,0.000023755676,0.00011447551,0.0042627854],"study_design_scores_gemma":[0.9788102,0.018786585,0.0009138547,0.00005508905,0.0009837197,0.000011462206,0.000007715526,0.0001707759,0.000111300986,0.00002775054,0.0001146348,0.000006909362],"about_ca_topic_score_codex":0.0019665218,"about_ca_topic_score_gemma":0.0025419802,"teacher_disagreement_score":0.0057473634,"about_ca_system_score_codex":0.00097525096,"about_ca_system_score_gemma":0.0013078675,"threshold_uncertainty_score":0.020160675},"labels":[],"label_agreement":null},{"id":"W4402370027","doi":"10.1111/dom.15917","title":"Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alliance for Canadian Health Outcomes Research in Diabetes; University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta","keywords":"Medicine; Gliclazide; Acute coronary syndrome; Odds ratio; Internal medicine; Cardiac catheterization; Confidence interval; Diabetes mellitus; Type 2 diabetes; Logistic regression; Retrospective cohort study; Cohort; Cardiology; Myocardial infarction; Endocrinology; Insulin","score_opus":0.013000125573673261,"score_gpt":0.2507554099865906,"score_spread":0.23775528441291738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402370027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993667,0.00014057232,0.000045331297,0.000029757497,0.00000696743,0.000007299854,0.00027596104,0.0000019386014,0.000125581],"genre_scores_gemma":[0.99930954,0.00012577974,0.0000731063,0.000025199957,0.000012331888,0.000007699308,0.00033001858,0.000001688329,0.000114610935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994616,0.00011134878,0.00005085837,0.00016831791,0.00010216897,0.00010568201],"domain_scores_gemma":[0.9985228,0.00014692526,0.0006743921,0.00017760911,0.00016350168,0.00031470874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007893987,0.00044359147,0.00038955483,0.00067819335,0.0005757435,0.0009306308,0.0005486094,0.0006626112,0.0012355503],"category_scores_gemma":[0.0019689165,0.00053870835,0.0011390136,0.0010090475,0.0002688048,0.0004065768,0.00044633707,0.0009429951,0.00016821334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011039438,0.000024771305,0.9994031,0.0000032123241,0.0000945899,0.00003131903,0.00003128014,0.000011020235,0.00007042556,0.0000039424335,0.00002989355,0.00018587393],"study_design_scores_gemma":[0.000011667282,0.00009550466,0.99938965,0.0000041105613,0.000060683593,0.00011114716,0.000106176674,0.00013939194,0.00001639014,0.000006514663,0.000055234283,0.0000034534332],"about_ca_topic_score_codex":0.04836539,"about_ca_topic_score_gemma":0.04472146,"teacher_disagreement_score":0.04836539,"about_ca_system_score_codex":0.0005159508,"about_ca_system_score_gemma":0.0007080113,"threshold_uncertainty_score":0.09616774},"labels":[],"label_agreement":null},{"id":"W4402381722","doi":"10.1111/dom.15811","title":"Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to <scp>iGlarLixi</scp> : A participant‐level pooled analysis of three phase 3 <scp>LixiLan</scp> randomized controlled trials","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Type 2 diabetes; Diabetes mellitus; Internal medicine; Endocrinology; Exenatide","score_opus":0.021043760299329518,"score_gpt":0.2644955457325564,"score_spread":0.24345178543322687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402381722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67646164,0.30905956,0.0045439177,0.00057467923,0.00073547394,0.002677591,0.004119897,0.0001973494,0.0016299614],"genre_scores_gemma":[0.97171426,0.021216061,0.0026419254,0.0005339435,0.00018326237,0.0017771047,0.0014093716,0.000027766995,0.00049639225],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993396,0.0042917463,0.0009187002,0.00069106225,0.0005052059,0.00019730353],"domain_scores_gemma":[0.9951916,0.0021863517,0.001804851,0.00030782569,0.00035214893,0.00015733192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011330013,0.0014446244,0.006262052,0.0011128675,0.00022270942,0.0017045212,0.00059972645,0.0013111338,0.0016475447],"category_scores_gemma":[0.008905629,0.0006409037,0.013796,0.0014885128,0.0003919777,0.00066327624,0.0006462236,0.0011788259,0.00015369336],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44143504,0.00049620814,0.018351408,0.024168173,0.47929227,0.0000905697,0.00012010604,0.00094640465,0.002052239,0.00009090814,0.0008544682,0.032102205],"study_design_scores_gemma":[0.19732703,0.028826157,0.070328794,0.0025291457,0.6949682,0.00019606018,0.00014707228,0.0013060517,0.0014053966,0.00034612868,0.0025183859,0.00010153161],"about_ca_topic_score_codex":0.0013024582,"about_ca_topic_score_gemma":0.0027248582,"teacher_disagreement_score":0.011330013,"about_ca_system_score_codex":0.00063402846,"about_ca_system_score_gemma":0.00086107745,"threshold_uncertainty_score":0.059919536},"labels":[],"label_agreement":null},{"id":"W4402463578","doi":"10.1111/dom.15935","title":"Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the <scp>ADVANCE</scp> study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Health and Medical Research Council; Medical Research Council; Servier","keywords":"Medicine; Hazard ratio; Apolipoprotein B; Internal medicine; Type 2 diabetes; Diabetes mellitus; Apolipoprotein A1; Endocrinology; Cholesterol; Proportional hazards model; Lipoprotein; Confounding; Confidence interval","score_opus":0.006155913341831345,"score_gpt":0.22707495390146615,"score_spread":0.2209190405596348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402463578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983045,0.0007677754,0.00007448585,0.000064182896,0.000018845225,0.000014097135,0.00041808785,0.0000034088694,0.0003346729],"genre_scores_gemma":[0.99815255,0.00036116963,0.00015249659,0.00009107655,0.00007689921,0.000027418972,0.00073154503,0.0000032458445,0.0004036565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995801,0.00014013368,0.000031888587,0.0001171638,0.000080755366,0.000049939663],"domain_scores_gemma":[0.99910396,0.00013763957,0.00035423195,0.00013472738,0.000062979874,0.00020646074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013109315,0.0005839048,0.00074275164,0.00040116138,0.00044485828,0.0008131454,0.00039897114,0.00064019614,0.0011075794],"category_scores_gemma":[0.0015415796,0.000556872,0.0009840867,0.00076607993,0.00025864234,0.0003831115,0.0004889144,0.00094345066,0.00018341275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032329701,0.00014161668,0.9937835,0.000026351803,0.00050656946,0.00012225597,0.000067395405,0.00004869949,0.00032421944,0.000031634376,0.00022797943,0.0014867855],"study_design_scores_gemma":[0.00028145028,0.0004589881,0.997898,0.00001051213,0.0003738238,0.00021203628,0.00008002787,0.00021746138,0.000090335176,0.0000484795,0.0003216888,0.000007160068],"about_ca_topic_score_codex":0.0035547616,"about_ca_topic_score_gemma":0.0050743213,"teacher_disagreement_score":0.0035547616,"about_ca_system_score_codex":0.00024989495,"about_ca_system_score_gemma":0.00027874013,"threshold_uncertainty_score":0.007068157},"labels":[],"label_agreement":null},{"id":"W4402499648","doi":"10.1111/dom.15924","title":"The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Obesity, Physical Activity, Diet","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Liver Centre","funders":"","keywords":"Medicine; Overweight; Obesity; Body mass index; Demography; Public health; Gerontology; Psychological intervention; Environmental health","score_opus":0.012499480336630599,"score_gpt":0.29211565015362334,"score_spread":0.2796161698169927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402499648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9446186,0.021096421,0.0005739717,0.0072057643,0.000319925,0.000057921174,0.019805806,0.000049843446,0.006271807],"genre_scores_gemma":[0.98755604,0.0043206615,0.00026378958,0.0006414597,0.00010055797,0.000033863387,0.0066557596,0.0000043040072,0.0004235383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995654,0.000116051924,0.00004309359,0.000051876446,0.00012252395,0.00010103606],"domain_scores_gemma":[0.9990922,0.00009318336,0.00044963582,0.000028391903,0.00018573053,0.00015097152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011764292,0.00028246248,0.00021269097,0.0010085439,0.00021480191,0.0006256686,0.00024236013,0.00037997236,0.0009847465],"category_scores_gemma":[0.002372912,0.00010328249,0.0006167831,0.0012167083,0.0002112155,0.00054784206,0.0008638013,0.0007234742,0.00017224245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001054384,0.00006710432,0.9782552,0.00012923549,0.00022465568,0.000057911508,0.00008166988,0.0006778815,0.00013443826,0.0002096953,0.0026357705,0.017421063],"study_design_scores_gemma":[0.000004813284,0.00005929055,0.9977787,0.0000918719,0.000068440735,0.00006371821,0.00010571941,0.0003013441,0.000040720002,0.00010421725,0.0013776087,0.0000035178286],"about_ca_topic_score_codex":0.04106591,"about_ca_topic_score_gemma":0.05254238,"teacher_disagreement_score":0.04106591,"about_ca_system_score_codex":0.0009526164,"about_ca_system_score_gemma":0.0011326639,"threshold_uncertainty_score":0.081653714},"labels":[],"label_agreement":null},{"id":"W4402516471","doi":"10.1111/dom.15938","title":"The association of glycaemic risk factors and diabetes duration with risk of heart failure in people with type 2 diabetes: A systematic review and meta‐analysis","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Health and Medical Research Council; La Trobe University","keywords":"Medicine; Type 2 diabetes; Meta-analysis; Diabetes mellitus; Hazard ratio; Internal medicine; Publication bias; Odds ratio; Confidence interval; Endocrinology","score_opus":0.00996980483077645,"score_gpt":0.24551313731623933,"score_spread":0.2355433324854629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402516471","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004069732,0.9946504,0.00030629904,0.00018645085,0.00011246308,0.00022996814,0.00028709718,0.000013985748,0.00014372208],"genre_scores_gemma":[0.12055823,0.8745456,0.0020395229,0.0007037071,0.0002771983,0.0010898274,0.00053735933,0.00001666338,0.00023180939],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9916831,0.0035403934,0.0027760456,0.0007806375,0.00096234196,0.00025756712],"domain_scores_gemma":[0.97603786,0.017810535,0.0037885157,0.00062108954,0.0015017309,0.00024024966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013326471,0.0020554026,0.015626667,0.006073335,0.00060019246,0.0030287188,0.0017167422,0.0022424175,0.002166497],"category_scores_gemma":[0.033171266,0.0012995605,0.023713801,0.007209348,0.0007014678,0.001438082,0.0010697504,0.0012457145,0.00018263493],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009969391,0.000031799016,0.0078275325,0.59796965,0.37746176,0.0001854655,0.00009562654,0.0005075916,0.0002765818,0.00012476573,0.0007111884,0.013811128],"study_design_scores_gemma":[0.0003776736,0.00026231186,0.008948285,0.06825899,0.9190705,0.00020456844,0.000063517924,0.0002735492,0.00015186079,0.00018297778,0.0021726403,0.000033163582],"about_ca_topic_score_codex":0.006589516,"about_ca_topic_score_gemma":0.01307986,"teacher_disagreement_score":0.015626667,"about_ca_system_score_codex":0.0022707786,"about_ca_system_score_gemma":0.0046074265,"threshold_uncertainty_score":0.0704779},"labels":[],"label_agreement":null},{"id":"W4402557297","doi":"10.1111/dom.15957","title":"Do nonglycaemic effects such as weight loss account for <scp>HbA1c</scp> lowering with efpeglenatide?: Insights from the <scp>AMPLITUDE‐</scp> O trial","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Sanofi","keywords":"Medicine; Weight loss; Food science; Internal medicine; Obesity","score_opus":0.008594574529834389,"score_gpt":0.22687970568778146,"score_spread":0.21828513115794707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402557297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64646673,0.28864753,0.003390871,0.032305226,0.0018724507,0.0010803201,0.0028554648,0.000116106705,0.02326531],"genre_scores_gemma":[0.9388739,0.04313641,0.0017104351,0.010122006,0.0022708126,0.00036839547,0.0015070178,0.00005892335,0.0019521108],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.998769,0.0006603684,0.00013713165,0.00011482369,0.00017900595,0.00013966388],"domain_scores_gemma":[0.99629176,0.0021474601,0.00088599033,0.0002654564,0.00015243849,0.00025690667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051137125,0.00060630793,0.0022133042,0.00027096237,0.00024725692,0.0013299027,0.0007975363,0.0017824585,0.005277893],"category_scores_gemma":[0.008201005,0.0002772612,0.0033537643,0.0004841187,0.0007047276,0.0012914157,0.0005057718,0.0018523311,0.0005385194],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33861753,0.0020515295,0.08471845,0.0084265545,0.021463068,0.00097180135,0.0002852147,0.001962723,0.003778962,0.007743363,0.014521264,0.51545954],"study_design_scores_gemma":[0.24726945,0.04098591,0.45744982,0.0064981636,0.077672906,0.003525636,0.0012008179,0.022603482,0.0042242254,0.062418528,0.075755954,0.00039508092],"about_ca_topic_score_codex":0.001210238,"about_ca_topic_score_gemma":0.002448371,"teacher_disagreement_score":0.005277893,"about_ca_system_score_codex":0.0005250951,"about_ca_system_score_gemma":0.00087618374,"threshold_uncertainty_score":0.027044177},"labels":[],"label_agreement":null},{"id":"W4402659510","doi":"10.1111/dom.15768","title":"Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; McGill University Health Centre; Sunnybrook Health Science Centre; Ontario Brain Institute; University of Ottawa; Wilfrid Laurier University; McGill University","funders":"Ministry of Colleges and Universities; Canada Research Chairs; Mach-Gaensslen Foundation of Canada","keywords":"Canagliflozin; Medicine; Phenotype; Type 2 diabetes; Hazard ratio; Internal medicine; Clinical endpoint; Proportional hazards model; Latent class model; Empagliflozin; Diabetes mellitus; Clinical trial; Endocrinology; Confidence interval; Biology; Genetics","score_opus":0.012888779664216043,"score_gpt":0.23788790500090937,"score_spread":0.22499912533669333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402659510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872149,0.0023005751,0.004805655,0.00065240765,0.00013627137,0.0004236483,0.0030608925,0.00005175267,0.0013538476],"genre_scores_gemma":[0.99412966,0.0003042506,0.0014730296,0.00017003,0.00010436227,0.00046584473,0.0028910795,0.000014895063,0.00044683783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939353,0.004872057,0.00015840773,0.0004679327,0.000291375,0.0002749354],"domain_scores_gemma":[0.99457884,0.0021790406,0.0013285644,0.0012050107,0.00028406715,0.000424378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010909688,0.0007095253,0.0014472696,0.0003714722,0.00036945913,0.001198991,0.0005556812,0.00064161816,0.002375817],"category_scores_gemma":[0.007323517,0.0002326409,0.0034812547,0.000670563,0.0004279332,0.00065777876,0.0008648525,0.0014762986,0.00018055628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39814618,0.0020337915,0.49864957,0.00085199025,0.029310506,0.00009350436,0.00019486403,0.005740734,0.0019998443,0.0014530943,0.0058744233,0.055651534],"study_design_scores_gemma":[0.08630228,0.019706523,0.8013699,0.0003814235,0.025416443,0.00030277256,0.00033021357,0.05266385,0.0012852277,0.0068862564,0.005185695,0.00016936804],"about_ca_topic_score_codex":0.0018764017,"about_ca_topic_score_gemma":0.002189994,"teacher_disagreement_score":0.010909688,"about_ca_system_score_codex":0.00046579813,"about_ca_system_score_gemma":0.0008275999,"threshold_uncertainty_score":0.05769664},"labels":[],"label_agreement":null},{"id":"W4402722805","doi":"10.1111/dom.15940","title":"A novel, centrally acting mammalian aminosterol, <scp>ENT</scp> ‐03, induces weight loss in obese and lean rodents","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Weston Family Foundation; Weston Brain Institute","keywords":"Medicine; Weight loss; Pharmacology; Cell biology; Endocrinology; Internal medicine; Obesity; Biology","score_opus":0.008218874300047111,"score_gpt":0.2178197142001367,"score_spread":0.2096008399000896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402722805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981,0.00031894934,0.00082360127,0.000060296163,0.00001620761,0.000016002266,0.00015477251,0.00005506519,0.00045513693],"genre_scores_gemma":[0.99410146,0.00055462064,0.0021382386,0.000096686366,0.000014971886,0.00004991362,0.00056708313,0.000041661417,0.0024352418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998554,0.000023466277,0.000015065641,0.000029571791,0.00003136313,0.00004521876],"domain_scores_gemma":[0.9997185,0.000030406753,0.00008638212,0.000032058953,0.000023144308,0.00010947407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014701833,0.0004970254,0.00035185984,0.0004892521,0.00020140666,0.00028852804,0.0002792474,0.00037268546,0.0014476727],"category_scores_gemma":[0.00013856635,0.00023358775,0.0002682124,0.00019043492,0.00053973374,0.00025678723,0.0001692493,0.0009094467,0.0002399585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009810776,0.00009703118,0.000283223,0.000018963618,0.000008473382,0.000066153676,0.000009572991,0.000025914604,0.99735177,0.00005547075,0.000023015255,0.0010793819],"study_design_scores_gemma":[0.00012737981,0.0028161844,0.0066974573,0.000006047795,0.000031623695,0.00031063615,0.000044373493,0.00028499187,0.9885296,0.000053102445,0.0010916695,0.000006895649],"about_ca_topic_score_codex":0.0008484801,"about_ca_topic_score_gemma":0.0023271502,"teacher_disagreement_score":0.0014476727,"about_ca_system_score_codex":0.00039999594,"about_ca_system_score_gemma":0.0002960127,"threshold_uncertainty_score":0.004842937},"labels":[],"label_agreement":null},{"id":"W4403469908","doi":"10.1111/dom.15999","title":"Use of continuous glucose monitoring and hybrid closed‐loop therapy in pregnancy","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary","funders":"Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Pregnancy; Randomized controlled trial; Type 1 diabetes; Type 2 diabetes; Gestational diabetes; Population; Insulin; Continuous glucose monitoring; Insulin pump; Diabetes mellitus; Obstetrics; Intensive care medicine; Gestation; Internal medicine; Endocrinology","score_opus":0.06510419955570805,"score_gpt":0.3303641960014682,"score_spread":0.26525999644576015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403469908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16532241,0.74422526,0.024818182,0.021542797,0.0035005098,0.0005692983,0.00083132426,0.00032019545,0.03886997],"genre_scores_gemma":[0.6799248,0.28133446,0.022756148,0.00953058,0.002114397,0.0010830988,0.0007196076,0.000060154227,0.002476792],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954406,0.0029901185,0.00027453556,0.00041190072,0.00076162774,0.00012111869],"domain_scores_gemma":[0.993443,0.0048420853,0.0008789568,0.00025796122,0.0003491505,0.00022886903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004700384,0.000332015,0.0007741433,0.000480221,0.00018207158,0.001023548,0.0006400284,0.00078648835,0.0028817689],"category_scores_gemma":[0.015106857,0.00016908268,0.00076594413,0.000713912,0.00061916996,0.0007998899,0.00077748345,0.0013526756,0.00022689623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041977707,0.0003651067,0.008268995,0.004578805,0.000444632,0.00019420587,0.00017968475,0.0006572062,0.0009323611,0.00319092,0.0048381086,0.9721522],"study_design_scores_gemma":[0.012641814,0.06030143,0.2664886,0.062490165,0.0058671185,0.014180294,0.0013383433,0.017966505,0.017552111,0.035969753,0.5045026,0.0007014086],"about_ca_topic_score_codex":0.0019696513,"about_ca_topic_score_gemma":0.0011869994,"teacher_disagreement_score":0.004700384,"about_ca_system_score_codex":0.00074189465,"about_ca_system_score_gemma":0.001082245,"threshold_uncertainty_score":0.024858296},"labels":[],"label_agreement":null},{"id":"W4403610206","doi":"10.1111/dom.16020","title":"Body mass index trajectories and time in target range after delivery and long‐term type 2 diabetes risk in women with a history of gestational diabetes mellitus","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Chinese Diabetes Society; European Foundation for the Study of Diabetes; Eli Lilly and Company","keywords":"Medicine; Gestational diabetes; Body mass index; Hazard ratio; Type 2 diabetes; Diabetes mellitus; Confidence interval; Proportional hazards model; Pregnancy; Obstetrics; Internal medicine; Family history; Type 2 Diabetes Mellitus; Endocrinology; Gestation","score_opus":0.004958246095399305,"score_gpt":0.2064604280609,"score_spread":0.2015021819655007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403610206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99940586,0.00012899481,0.00014690717,0.000045347948,0.0000036757751,0.0000025821964,0.0001472601,0.0000019275753,0.00011748943],"genre_scores_gemma":[0.9995421,0.000072564144,0.00007139127,0.000008854381,0.0000027480494,0.0000038548474,0.00018034186,0.0000012119685,0.00011685138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998202,0.00005495264,0.000014229203,0.000047861573,0.000020387934,0.00004248971],"domain_scores_gemma":[0.9991172,0.00021567984,0.00035277687,0.00010857813,0.00006334823,0.00014237035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005191732,0.00018135582,0.00018177288,0.00030283362,0.00026640497,0.0005675959,0.00029971346,0.00032191648,0.0012880052],"category_scores_gemma":[0.0020323494,0.0002229852,0.0006158897,0.00059323246,0.00014584018,0.00031758478,0.00038190506,0.0005781449,0.00013897139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000128524,0.000014955077,0.99879116,0.0000029631774,0.00003181553,0.00002572167,0.000049927858,0.000056911835,0.000090724396,0.000017262917,0.00002704427,0.00076305744],"study_design_scores_gemma":[0.0000037870975,0.00005091353,0.9985305,0.0000051738166,0.000026074613,0.00006113738,0.00015923967,0.0010261495,0.00003234348,0.000041288604,0.000060881735,0.0000025209183],"about_ca_topic_score_codex":0.00854389,"about_ca_topic_score_gemma":0.0064533986,"teacher_disagreement_score":0.00854389,"about_ca_system_score_codex":0.00023595014,"about_ca_system_score_gemma":0.00032843612,"threshold_uncertainty_score":0.016988277},"labels":[],"label_agreement":null},{"id":"W4404547136","doi":"10.1111/dom.16079","title":"Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Merck Canada; University of Toronto; Diabetes Canada; Banting and Best Diabetes Centre, University of Toronto; Heart and Stroke Foundation of Canada; Gilead Sciences; Department of Medicine, University of Toronto; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Kidney disease; Internal medicine; Renal function; Placebo; Diabetes mellitus; Erythropoietin; Type 2 diabetes; Anemia; Adverse effect; Clinical trial; Endocrinology; Pathology","score_opus":0.0033236803224837904,"score_gpt":0.19446411755313533,"score_spread":0.19114043723065155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404547136","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9426373,0.049242225,0.0022280326,0.0006955557,0.0004311032,0.00064865046,0.0020998504,0.00007649179,0.0019407225],"genre_scores_gemma":[0.9925437,0.003702939,0.0014469869,0.00058116234,0.00016986273,0.00023481643,0.0009189578,0.000012108202,0.00038938722],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99575907,0.0028512788,0.00035435767,0.00046890066,0.00030868137,0.00025780228],"domain_scores_gemma":[0.99476504,0.0035270774,0.0009145699,0.00034322252,0.00021480098,0.00023533702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006364735,0.0007571522,0.0027011635,0.00046039847,0.00024989902,0.0007160082,0.0004910965,0.0010032672,0.001969029],"category_scores_gemma":[0.010088306,0.00050056126,0.011473794,0.00048406725,0.0003701122,0.00048967364,0.0006042079,0.0014306144,0.00012295201],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6668043,0.0020971103,0.092534274,0.0057895835,0.11695518,0.00026614667,0.00016561915,0.00581455,0.0032804948,0.0004660394,0.002113425,0.10371329],"study_design_scores_gemma":[0.12182573,0.11450847,0.56561756,0.0013903127,0.16162558,0.000553213,0.00018387417,0.021586189,0.003061647,0.0026207918,0.006803637,0.00022305778],"about_ca_topic_score_codex":0.0033359113,"about_ca_topic_score_gemma":0.005270816,"teacher_disagreement_score":0.006364735,"about_ca_system_score_codex":0.00067651144,"about_ca_system_score_gemma":0.0009761894,"threshold_uncertainty_score":0.033660352},"labels":[],"label_agreement":null},{"id":"W4404829385","doi":"10.1111/dom.16104","title":"The effect of altered sleep timing on glycaemic outcomes: Systematic review of human intervention studies","year":2024,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Sleep and related disorders","field":"Psychology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Impact; Université Laval; Centre Hospitalier Universitaire de Sherbrooke; McMaster University; Université de Sherbrooke","funders":"Canadian Institutes of Health Research; Diabetes Fonds; ZonMw; Health~Holland","keywords":"Medicine; Sleep (system call); Sleep deprivation; Postprandial; Population; Intervention (counseling); Randomized controlled trial; MEDLINE; Weight loss; Physical therapy; Internal medicine; Diabetes mellitus; Obesity; Circadian rhythm; Psychiatry; Endocrinology; Environmental health","score_opus":0.035291748644090876,"score_gpt":0.38718610493173883,"score_spread":0.351894356287648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404829385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010795407,0.9975708,0.00019824874,0.0001277556,0.00010520811,0.00038256912,0.00033755813,0.000009584082,0.00018866833],"genre_scores_gemma":[0.018048262,0.97913206,0.00091971405,0.0003978363,0.00008377404,0.0009973444,0.00030458404,0.000009788877,0.00010663545],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9879765,0.004798166,0.004673604,0.0008107283,0.0014713975,0.00026966853],"domain_scores_gemma":[0.96386945,0.027469927,0.005699322,0.0006552061,0.002031061,0.00027501635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013684187,0.0018795192,0.011078804,0.0070159235,0.00060598593,0.0026348575,0.0019640455,0.0018564962,0.0051890975],"category_scores_gemma":[0.047517423,0.0011029379,0.010042556,0.008288999,0.0010275758,0.0015932331,0.0015510243,0.0011972488,0.00036175555],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003296428,0.000015672716,0.00028174525,0.9703782,0.011909531,0.000042439275,0.00007864178,0.00006132612,0.00012802884,0.00007845017,0.00040640478,0.016289877],"study_design_scores_gemma":[0.00075171347,0.000515217,0.004135501,0.76506865,0.216243,0.00019268887,0.00018063419,0.00007835836,0.00033233233,0.00025299768,0.012208063,0.00004089434],"about_ca_topic_score_codex":0.007118186,"about_ca_topic_score_gemma":0.01788537,"teacher_disagreement_score":0.013684187,"about_ca_system_score_codex":0.0031304446,"about_ca_system_score_gemma":0.009877957,"threshold_uncertainty_score":0.072369754},"labels":[],"label_agreement":null},{"id":"W4404869373","doi":"10.1111/dom.16099","title":"Role of the liver in the sustained normalisation of A1c over 2 years following short‐term insulin therapy in early type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; McMaster University; Western University; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; McMaster University; Sanofi","keywords":"Medicine; Metformin; Internal medicine; Waist; Type 2 diabetes; Odds ratio; Diabetes mellitus; Insulin; Body mass index; Insulin resistance; Insulin glargine; Logistic regression; Endocrinology","score_opus":0.008941085984602894,"score_gpt":0.2288545028136899,"score_spread":0.21991341682908702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404869373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968612,0.0024259465,0.0001128941,0.000101816004,0.000007213666,0.000008132129,0.00004011946,0.000003973459,0.00043861364],"genre_scores_gemma":[0.9995223,0.00019440302,0.00008293856,0.000024726414,0.000012912758,0.0000037813809,0.0000333219,0.0000015515501,0.00012405467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996536,0.0001971424,0.000026098913,0.000040628474,0.00003479983,0.0000478047],"domain_scores_gemma":[0.99733526,0.0008352786,0.0010349278,0.00013875046,0.00017417718,0.00048158044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014666741,0.00029234283,0.00032506062,0.00043872217,0.00017070651,0.0008283534,0.00023744097,0.00048689055,0.0010962558],"category_scores_gemma":[0.0026081472,0.00019185597,0.0002584853,0.0003109222,0.00042017526,0.00038403628,0.00037569727,0.0004986497,0.00017206598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0151872765,0.00054801145,0.9449675,0.00012309143,0.0001511229,0.0004267329,0.00027265726,0.00033586743,0.010504831,0.000088836336,0.000105994746,0.027288096],"study_design_scores_gemma":[0.000039188446,0.0011628247,0.9975222,0.000013605705,0.00005309068,0.00028526018,0.00007063318,0.00023945721,0.0004546555,0.000046709505,0.00010729092,0.0000052078185],"about_ca_topic_score_codex":0.0012810944,"about_ca_topic_score_gemma":0.0013743613,"teacher_disagreement_score":0.0014666741,"about_ca_system_score_codex":0.00030369437,"about_ca_system_score_gemma":0.0003770706,"threshold_uncertainty_score":0.007756591},"labels":[],"label_agreement":null},{"id":"W4405012042","doi":"10.1111/dom.16112","title":"The effect of <scp>HbA1c</scp> variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; Health Sciences Centre; University of Calgary","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Internal medicine; Blood pressure; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Stroke (engine); Myocardial infarction; Confidence interval; Endocrinology","score_opus":0.004920806540793517,"score_gpt":0.20467399816139045,"score_spread":0.19975319162059693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405012042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079037,0.007340944,0.00027728098,0.00030113928,0.00005534013,0.000034777353,0.00016261693,0.000014408386,0.0010230287],"genre_scores_gemma":[0.9988072,0.00064876257,0.00017015316,0.000121046556,0.00007831999,0.000018534169,0.00011211344,0.0000024403757,0.00004141924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973896,0.0016660532,0.00019923423,0.00020028467,0.0004318029,0.00011293391],"domain_scores_gemma":[0.99127895,0.0050340905,0.0021713192,0.00064588594,0.00023076644,0.0006388931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043803207,0.00037479668,0.0010705997,0.0003021631,0.00019560604,0.00064249075,0.00032350124,0.00057000027,0.0006695285],"category_scores_gemma":[0.00852706,0.00014322968,0.0014840475,0.0005898139,0.00032346207,0.00036144807,0.0003404675,0.0011168858,0.000063352265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25743338,0.003231061,0.57963616,0.0010303564,0.01663772,0.00021192804,0.0001769201,0.003388059,0.0026915325,0.00019164005,0.0010341278,0.13433714],"study_design_scores_gemma":[0.004236876,0.017430075,0.97134686,0.00007918886,0.0031366416,0.00011358403,0.000044299886,0.0023840156,0.00058053865,0.00030143405,0.00031990232,0.000026401483],"about_ca_topic_score_codex":0.00072842726,"about_ca_topic_score_gemma":0.00087707915,"teacher_disagreement_score":0.0043803207,"about_ca_system_score_codex":0.0003355129,"about_ca_system_score_gemma":0.00035877235,"threshold_uncertainty_score":0.023165584},"labels":[],"label_agreement":null},{"id":"W4405452583","doi":"10.1111/dom.16115","title":"Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University","keywords":"Medicine; Gestational diabetes; Metformin; Obstetrics; Pregnancy; Cohort; Cohort study; Population; Diabetes mellitus; Gynecology; Gestation; Internal medicine; Environmental health; Endocrinology","score_opus":0.014996314846974277,"score_gpt":0.2693624350464781,"score_spread":0.25436612019950383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405452583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969037,0.0013940106,0.00008009863,0.00012484775,0.000013672024,0.000022930506,0.0011291637,0.0000033473625,0.00032808067],"genre_scores_gemma":[0.9983215,0.00077479024,0.00011518937,0.000080747115,0.000010397321,0.0000263677,0.0005603665,0.0000019659265,0.00010869112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873334,0.00037701358,0.00023097821,0.00030999072,0.00018816114,0.00016057419],"domain_scores_gemma":[0.99696225,0.0004482038,0.0016061598,0.00035308313,0.00030291145,0.00032742633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009369383,0.00036165418,0.00061641936,0.0007468598,0.00046427324,0.00093187613,0.0005129989,0.000701284,0.0010774358],"category_scores_gemma":[0.0047465237,0.0006984297,0.0008135302,0.00199172,0.0002791662,0.00053559314,0.00076431927,0.0006930303,0.00019707094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116418654,0.000017255476,0.99854714,0.000024489284,0.00012068288,0.00011715675,0.00010800069,0.000027303024,0.00007818148,0.000014995562,0.00014342043,0.0006848835],"study_design_scores_gemma":[0.000022460335,0.000066224005,0.99901307,0.00003487122,0.000089671776,0.00026659935,0.00015035266,0.000113943184,0.00001709517,0.000011706467,0.00020800278,0.0000060490047],"about_ca_topic_score_codex":0.05670753,"about_ca_topic_score_gemma":0.047809176,"teacher_disagreement_score":0.05670753,"about_ca_system_score_codex":0.00096620363,"about_ca_system_score_gemma":0.0007103772,"threshold_uncertainty_score":0.11275494},"labels":[],"label_agreement":null},{"id":"W4405600257","doi":"10.1111/dom.16050","title":"Long‐term weight loss and cardiorenal outcomes by baseline <scp>BMI</scp> in the <scp>VERTIS CV</scp> trial","year":2024,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Pfizer","keywords":"Medicine; Weight loss; Cardiorenal syndrome; Body mass index; Baseline (sea); Term (time); Internal medicine; Cardiology; Heart failure; Obesity","score_opus":0.008480813377605586,"score_gpt":0.2372306698724115,"score_spread":0.22874985649480592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405600257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98258,0.012628841,0.00023397741,0.0007844152,0.00028324663,0.0002517067,0.0005424482,0.000035611192,0.0026597804],"genre_scores_gemma":[0.99378175,0.003136518,0.00040405412,0.0005999343,0.0002593454,0.00027630012,0.0005897897,0.000005611004,0.00094676623],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994885,0.00027842712,0.000044976456,0.00006739697,0.000056247223,0.00006454523],"domain_scores_gemma":[0.9991549,0.00022000332,0.0002562795,0.000060740775,0.000056179357,0.00025177601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001160229,0.00050511415,0.0013846628,0.00016110954,0.00017273538,0.00071769493,0.00039462734,0.00075050595,0.002871448],"category_scores_gemma":[0.0015138809,0.00017535556,0.0013850321,0.00028219545,0.0004492531,0.00034650887,0.00029881645,0.0015862143,0.00022044909],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92011,0.0015826074,0.011557515,0.0020122046,0.004945903,0.00011698089,0.00006245613,0.0006263708,0.0046600644,0.0002849561,0.0025097926,0.05153101],"study_design_scores_gemma":[0.8387226,0.07555202,0.06891225,0.00070156885,0.008087636,0.00029219536,0.0001116936,0.0024173642,0.0016166259,0.00066081824,0.002876221,0.00004897359],"about_ca_topic_score_codex":0.0018564739,"about_ca_topic_score_gemma":0.0047146576,"teacher_disagreement_score":0.002871448,"about_ca_system_score_codex":0.0004713242,"about_ca_system_score_gemma":0.000612837,"threshold_uncertainty_score":0.009605944},"labels":[],"label_agreement":null},{"id":"W4405829028","doi":"10.1111/dom.16169","title":"Impact of the timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes","year":2024,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Royal Adelaide Hospital; University of Adelaide; Hospital Research Foundation","keywords":"Medicine; Metformin; Type 2 diabetes; Internal medicine; Plasma glucose; Diabetes mellitus; Endocrinology; Plasma concentration; Continuous glucose monitoring; Pharmacology; Type 1 diabetes","score_opus":0.01272841719396867,"score_gpt":0.2564239995365676,"score_spread":0.24369558234259892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405829028","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870051,0.0102742445,0.00081007445,0.00030178766,0.00045483484,0.00015504388,0.00024893673,0.000028161794,0.00072167383],"genre_scores_gemma":[0.99478084,0.0023860224,0.0013801504,0.00039513208,0.00026163427,0.00015179098,0.00026791284,0.000015549416,0.00036096232],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994036,0.00025644794,0.00008024338,0.00009257703,0.00008906272,0.00007793039],"domain_scores_gemma":[0.998678,0.0005181218,0.00036333638,0.00006818729,0.00007599149,0.00029628954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016379054,0.0005728711,0.0012740083,0.00020752425,0.0001981379,0.0008344019,0.00033129947,0.00066741917,0.0019087801],"category_scores_gemma":[0.00250584,0.00023990819,0.0007940968,0.00035004073,0.00022795526,0.00058182265,0.00030120817,0.0013519292,0.00025290402],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63151896,0.021987094,0.072373845,0.0020718013,0.0014795233,0.0006160993,0.00017946327,0.0022673532,0.10652134,0.00022381761,0.0009013495,0.15985928],"study_design_scores_gemma":[0.023929631,0.31420553,0.5787255,0.0005233993,0.003273752,0.00081875414,0.00030839109,0.0066767475,0.064870514,0.0005278732,0.0059480006,0.00019193276],"about_ca_topic_score_codex":0.0004974519,"about_ca_topic_score_gemma":0.00069214613,"teacher_disagreement_score":0.0019087801,"about_ca_system_score_codex":0.0004690342,"about_ca_system_score_gemma":0.00047618916,"threshold_uncertainty_score":0.008662164},"labels":[],"label_agreement":null},{"id":"W4406106519","doi":"10.1111/dom.16154","title":"Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Servier; University of Toronto","keywords":"Medicine; Type 2 diabetes; Adjunctive treatment; Psychological intervention; Intensive care medicine; Diabetes mellitus; Internal medicine; Endocrinology; Psychiatry","score_opus":0.08353014946425638,"score_gpt":0.41418216357173954,"score_spread":0.3306520141074831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406106519","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009294058,0.9986002,0.00009462971,0.0008994847,0.00012356433,0.0000071224445,0.000014805738,0.0000044075637,0.00016290267],"genre_scores_gemma":[0.001429811,0.996786,0.00035555512,0.0009857161,0.0003235653,0.000025160401,0.000024891737,0.0000027140213,0.00006655272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982936,0.0007285059,0.00038012498,0.0002364057,0.00026953817,0.00009190256],"domain_scores_gemma":[0.9847912,0.012486624,0.0011340969,0.00018048572,0.0011777029,0.00022992087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060547893,0.0011379102,0.004126627,0.0023210403,0.00035592096,0.0027716851,0.0014500328,0.0025830716,0.0047718473],"category_scores_gemma":[0.008783321,0.00047799462,0.0031515874,0.002595217,0.0009578809,0.0025751952,0.0013249145,0.003540794,0.0007766078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082013436,0.00014803527,0.0006904719,0.13112183,0.0018273738,0.00013275266,0.00016655723,0.00038727175,0.0005880874,0.00539681,0.010064838,0.8486558],"study_design_scores_gemma":[0.0006407275,0.0015940712,0.0048155976,0.26227608,0.015189284,0.0010566299,0.00063912274,0.0009578603,0.00073870533,0.02083039,0.6910961,0.00016541732],"about_ca_topic_score_codex":0.0014284947,"about_ca_topic_score_gemma":0.0033838237,"teacher_disagreement_score":0.0060547893,"about_ca_system_score_codex":0.0009616851,"about_ca_system_score_gemma":0.0028376037,"threshold_uncertainty_score":0.032021165},"labels":[],"label_agreement":null},{"id":"W4406225861","doi":"10.1111/dom.16190","title":"Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Canagliflozin; Medicine; Tolerability; Internal medicine; Adverse effect; Renal function; Kidney disease; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.005007696488987766,"score_gpt":0.21690827824916928,"score_spread":0.2119005817601815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406225861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90394735,0.080094755,0.0025318505,0.000537428,0.00041338342,0.0005830792,0.009465285,0.000111205954,0.0023156512],"genre_scores_gemma":[0.98638874,0.0046881367,0.000912232,0.00035140174,0.0003339141,0.00039896235,0.0062436666,0.000024402956,0.00065847876],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99456644,0.0029545943,0.00068000593,0.0007535811,0.00077534904,0.00026999274],"domain_scores_gemma":[0.99476224,0.002198113,0.001343755,0.0006603732,0.00072891114,0.00030658423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010709311,0.0011142503,0.00496099,0.0010794202,0.00024455134,0.0014779241,0.0004456804,0.0008866176,0.00173316],"category_scores_gemma":[0.009508482,0.0004949201,0.0120884385,0.0018259534,0.00020393968,0.0006861034,0.00089110504,0.0010648749,0.00018309386],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30445278,0.00041900275,0.22299014,0.0076043964,0.40570986,0.00027850762,0.00018013455,0.0021430673,0.0023187723,0.00018136116,0.0047225645,0.048999447],"study_design_scores_gemma":[0.034345776,0.0084202215,0.55006456,0.0006544395,0.39862838,0.00027987055,0.00013696802,0.0023680667,0.00092301774,0.0004513284,0.003622929,0.00010446884],"about_ca_topic_score_codex":0.0030963465,"about_ca_topic_score_gemma":0.0062078605,"teacher_disagreement_score":0.010709311,"about_ca_system_score_codex":0.00039102524,"about_ca_system_score_gemma":0.0006533898,"threshold_uncertainty_score":0.05663693},"labels":[],"label_agreement":null},{"id":"W4406252582","doi":"10.1111/dom.16176","title":"Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the <scp>SURMOUNT</scp> ‐1 to ‐4 trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Nausea; Placebo; Tolerability; Weight loss; Overweight; Adverse effect; Vomiting; Internal medicine; Type 2 diabetes; Antiemetic; Weight management; Diabetes mellitus; Clinical endpoint; Clinical trial; Obesity; Gastroenterology; Endocrinology; Alternative medicine","score_opus":0.01263508857942536,"score_gpt":0.2473143678169976,"score_spread":0.23467927923757223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406252582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9216867,0.07142795,0.0005083902,0.0007126841,0.00019917412,0.0011720322,0.0012174387,0.00005099676,0.0030247075],"genre_scores_gemma":[0.982496,0.0142712975,0.00067717704,0.0004603669,0.00013251259,0.00077054603,0.0007272651,0.000009829077,0.00045502494],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99823475,0.0011013363,0.00025107033,0.00015493935,0.00016376909,0.00009410712],"domain_scores_gemma":[0.9977355,0.00092016015,0.0009386887,0.00008874143,0.00015774569,0.00015916601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034939742,0.0005720461,0.0015766383,0.00034401522,0.000215325,0.0007826687,0.00034661626,0.0005517598,0.0020842012],"category_scores_gemma":[0.0040949695,0.00027080893,0.0039902725,0.0004580218,0.00031183832,0.0005217713,0.0003108072,0.0010840332,0.00014449541],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7716537,0.0013376198,0.027865231,0.026019156,0.044161897,0.00022878476,0.00027173836,0.001099719,0.010490601,0.00032907765,0.0024016383,0.11414074],"study_design_scores_gemma":[0.6176347,0.13716817,0.16648227,0.0031708824,0.059142303,0.001172254,0.00030451556,0.0012941221,0.003788641,0.0007293821,0.009012554,0.00010010467],"about_ca_topic_score_codex":0.00067731686,"about_ca_topic_score_gemma":0.0027747867,"teacher_disagreement_score":0.0034939742,"about_ca_system_score_codex":0.00034956503,"about_ca_system_score_gemma":0.00055177923,"threshold_uncertainty_score":0.018478155},"labels":[],"label_agreement":null},{"id":"W4406382034","doi":"10.1111/dom.16197","title":"Long‐term blood glucose control via glucose‐activated transcriptional regulation of insulin analogue in type 1 diabetes mice","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College; University of Toronto","funders":"National Natural Science Foundation of China","keywords":"Medicine; Insulin; Type 2 diabetes; Internal medicine; Term (time); Endocrinology; Blood sugar regulation; Diabetes mellitus","score_opus":0.00739398338393703,"score_gpt":0.2198384020662056,"score_spread":0.21244441868226857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406382034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679354,0.0020441525,0.024436982,0.00043722434,0.00017024834,0.0002105535,0.001341551,0.00064514275,0.0027786929],"genre_scores_gemma":[0.96727365,0.0022059712,0.020249987,0.00029267743,0.00006479256,0.00045472197,0.001758268,0.00016991857,0.0075300913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973744,0.00004163076,0.000024536417,0.00008493727,0.00006362236,0.000047747562],"domain_scores_gemma":[0.9997906,0.000014953391,0.000105952575,0.000022416763,0.000013896814,0.00005210955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031162341,0.00077610544,0.00033467752,0.00046358735,0.00015951142,0.00038822318,0.00044457125,0.0005402744,0.001479075],"category_scores_gemma":[0.00011714198,0.00021484432,0.0005077304,0.0002441411,0.0005152866,0.00032543985,0.0002133777,0.0013270583,0.00039334976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046944912,0.00013939249,0.00016226553,0.000065278015,0.000007802997,0.000039670256,0.000011714646,0.000105431514,0.996431,0.0001817298,0.000079618505,0.0023066574],"study_design_scores_gemma":[0.00032945615,0.0026736488,0.0037818705,0.0000318329,0.00007027248,0.0003576207,0.000038567294,0.0017037083,0.9855214,0.00012345276,0.0053490777,0.000019073084],"about_ca_topic_score_codex":0.0002158177,"about_ca_topic_score_gemma":0.00031606483,"teacher_disagreement_score":0.001479075,"about_ca_system_score_codex":0.00037560202,"about_ca_system_score_gemma":0.00022170559,"threshold_uncertainty_score":0.00494802},"labels":[],"label_agreement":null},{"id":"W4406917166","doi":"10.1111/dom.16206","title":"Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Type 2 diabetes; Insulin resistance; Narrative review; Intensive care medicine; Weight loss; Obesity; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.01211267877879356,"score_gpt":0.29370002212965113,"score_spread":0.28158734335085756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406917166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000060263108,0.9990933,0.00005277292,0.00025916405,0.00014590497,0.0000069610614,0.000022014956,0.0000036453443,0.0003560318],"genre_scores_gemma":[0.00042709557,0.9990023,0.0001291581,0.00020792756,0.000078892626,0.000008458758,0.000022287199,8.629735e-7,0.00012310832],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995925,0.00009417141,0.00010662993,0.00005788629,0.00011925438,0.000029518853],"domain_scores_gemma":[0.99868625,0.0008525644,0.00022590418,0.000019686348,0.00016794418,0.00004756381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000974683,0.000869184,0.0015389982,0.0027136055,0.00033320475,0.0015999144,0.0008625778,0.0011620141,0.0046398942],"category_scores_gemma":[0.0027947277,0.00027305284,0.0013826808,0.0031018208,0.00032105588,0.0013464821,0.00076396286,0.0014850802,0.00091573544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012934528,0.000056286575,0.0002273599,0.24658294,0.0005880587,0.00021010895,0.00019610662,0.00031269903,0.00055215455,0.003536397,0.037559155,0.7100494],"study_design_scores_gemma":[0.000057955684,0.00015450531,0.00163258,0.18371852,0.0021656705,0.001648011,0.00024500006,0.0001476813,0.00024949224,0.0026187778,0.80732155,0.000040175368],"about_ca_topic_score_codex":0.0018562513,"about_ca_topic_score_gemma":0.0035119988,"teacher_disagreement_score":0.0046398942,"about_ca_system_score_codex":0.00069197564,"about_ca_system_score_gemma":0.0027454344,"threshold_uncertainty_score":0.015522003},"labels":[],"label_agreement":null},{"id":"W4407183248","doi":"10.1111/dom.16214","title":"Effect of <scp>iGlarLixi</scp> on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Sanofi-Aventis Deutschland; Sanofi","keywords":"Medicine; Lixisenatide; Insulin glargine; Type 2 diabetes; Postprandial; Insulin; Glucagon-like peptide 1 receptor; Hypoglycemia; Diabetes mellitus; Internal medicine; Type 1 diabetes; Endocrinology; Basal insulin; Receptor; Agonist","score_opus":0.0044178126924421385,"score_gpt":0.2323221658458761,"score_spread":0.22790435315343394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407183248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466705,0.002519283,0.00012231497,0.00023414643,0.00007498236,0.00039539198,0.00046742614,0.000062653984,0.0014567864],"genre_scores_gemma":[0.9964858,0.0008175036,0.0005415355,0.0005506206,0.000097525764,0.00044168817,0.00057579286,0.0000076279243,0.00048183542],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99931014,0.0003716043,0.00008744594,0.000103983264,0.00006893795,0.00005790356],"domain_scores_gemma":[0.99857616,0.0004160364,0.0004457043,0.000103116865,0.00009489964,0.00036416965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018056957,0.0006949145,0.001658993,0.00025688272,0.0002355963,0.0005312741,0.0004141163,0.00093167456,0.0024752966],"category_scores_gemma":[0.0024529567,0.0002574221,0.0015092554,0.00034462675,0.0002727219,0.0005053641,0.00036901538,0.0013504653,0.00034244082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8685458,0.011039492,0.02008278,0.0007092274,0.0017415808,0.00004416443,0.00009537788,0.0005209095,0.002617487,0.000045906396,0.0012832093,0.09327406],"study_design_scores_gemma":[0.33568737,0.41474852,0.23977308,0.0003675482,0.0029860635,0.00018695362,0.00011863894,0.0025106682,0.0015419336,0.00013866396,0.0018785028,0.00006203595],"about_ca_topic_score_codex":0.0016765482,"about_ca_topic_score_gemma":0.0026452434,"teacher_disagreement_score":0.0024752966,"about_ca_system_score_codex":0.0004798058,"about_ca_system_score_gemma":0.0004806327,"threshold_uncertainty_score":0.009549558},"labels":[],"label_agreement":null},{"id":"W4407192481","doi":"10.1111/dom.16230","title":"Effectiveness of gemigliptin on risk of major adverse kidney events in people with type 2 diabetes: A Korean cohort study","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LG Chem","keywords":"Medicine; Type 2 diabetes; Cohort; Adverse effect; Internal medicine; Cohort study; Diabetes mellitus; Endocrinology","score_opus":0.004209678543887113,"score_gpt":0.2166906158163506,"score_spread":0.21248093727246348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407192481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969253,0.0012962964,0.00009392104,0.00007019228,0.000023394517,0.00006898021,0.0012796695,0.0000040473155,0.00023817188],"genre_scores_gemma":[0.99776316,0.00049831305,0.00018208906,0.00012348841,0.000032370135,0.00006814607,0.0011724286,0.0000036741912,0.00015626306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990827,0.0002111418,0.00014085021,0.00033359235,0.00010378871,0.00012799523],"domain_scores_gemma":[0.9983581,0.00015378074,0.0006610323,0.00027631476,0.00020177252,0.00034911744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017392567,0.0007582454,0.0011289755,0.0006276952,0.0005647676,0.00079500227,0.00059022504,0.0007978361,0.0013471282],"category_scores_gemma":[0.0020865044,0.00055443787,0.0032452215,0.0012840764,0.0002470957,0.0006634621,0.0006148952,0.0010171187,0.00018922151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010468552,0.000504635,0.97988105,0.00016506351,0.004510645,0.00017074161,0.00011057389,0.00014855126,0.00039351903,0.000040812698,0.0003713805,0.0032345448],"study_design_scores_gemma":[0.0013639039,0.0014572919,0.9919661,0.000028395943,0.0037230738,0.00019111893,0.00017164694,0.0005311434,0.0001039048,0.000042730782,0.00039293466,0.00002772908],"about_ca_topic_score_codex":0.007660319,"about_ca_topic_score_gemma":0.0086020045,"teacher_disagreement_score":0.007660319,"about_ca_system_score_codex":0.0006669966,"about_ca_system_score_gemma":0.00070427207,"threshold_uncertainty_score":0.01523149},"labels":[],"label_agreement":null},{"id":"W4407192491","doi":"10.1111/dom.16220","title":"Efficacy of high‐intensity interval training in individuals with type 2 diabetes mellitus: An umbrella review of systematic reviews and meta‐analyses","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Cardiovascular and exercise physiology","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; High-intensity interval training; Cardiorespiratory fitness; Meta-analysis; Systematic review; Interval training; Physical therapy; Confidence interval; Internal medicine; Type 2 diabetes; Guideline; Diabetes mellitus; MEDLINE; Endocrinology; Pathology","score_opus":0.11198731395931047,"score_gpt":0.365820510315809,"score_spread":0.2538331963564985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407192491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00088272116,0.996597,0.00058612553,0.0002713406,0.00018964188,0.000837019,0.0003745118,0.000017972588,0.00024374663],"genre_scores_gemma":[0.034264002,0.95407575,0.0038339782,0.00144956,0.0003012889,0.005198059,0.00058532454,0.000024085293,0.0002680243],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9644247,0.016643085,0.012148185,0.002220924,0.0039569545,0.0006061367],"domain_scores_gemma":[0.9490913,0.03600387,0.00986463,0.0014593959,0.003278045,0.00030276176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032931767,0.0031445273,0.021664873,0.01353523,0.0009836626,0.005270793,0.002961018,0.0028600825,0.0035278192],"category_scores_gemma":[0.09641011,0.002067193,0.026042398,0.013792802,0.00103787,0.0036688086,0.0030384604,0.0018222391,0.0004112304],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042735058,0.000015076677,0.00087137544,0.84921783,0.13131903,0.000076560435,0.0001201829,0.00021380954,0.00016843254,0.0002567004,0.0008941206,0.016419413],"study_design_scores_gemma":[0.00057320076,0.00025001686,0.0028361846,0.39898288,0.58853126,0.00013928278,0.00012215169,0.0002191876,0.00023154334,0.0005296692,0.007540983,0.000043726373],"about_ca_topic_score_codex":0.007005454,"about_ca_topic_score_gemma":0.01633278,"teacher_disagreement_score":0.032931767,"about_ca_system_score_codex":0.0053518945,"about_ca_system_score_gemma":0.0083323065,"threshold_uncertainty_score":0.17416185},"labels":[],"label_agreement":null},{"id":"W4407348979","doi":"10.1111/dom.16235","title":"Characterization of the effect of naltrexone/bupropion on body composition","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada); McGill University Health Centre","funders":"Health Canada; Bausch Health; Orexigen Therapeutics","keywords":"Lean body mass; Placebo; Medicine; Bupropion; Internal medicine; Body mass index; Naltrexone; Weight loss; Endocrinology; Animal science; Obesity; Antagonist; Body weight; Smoking cessation; Biology","score_opus":0.003677726107854942,"score_gpt":0.2417478207140669,"score_spread":0.23807009460621195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407348979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969875,0.0019539995,0.0005428278,0.00004452175,0.000006623773,0.000094325995,0.00009059286,0.000009539743,0.00026997947],"genre_scores_gemma":[0.9975731,0.00076749723,0.0009764582,0.00006354119,0.000023530318,0.00010761305,0.00017005412,0.0000044535977,0.0003137298],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997459,0.000090717454,0.000020075391,0.00004135893,0.00008242969,0.000019531657],"domain_scores_gemma":[0.9995987,0.0001240949,0.00017040528,0.00003523286,0.000032918837,0.00003869705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006326275,0.00029677115,0.00046080616,0.00014562285,0.00006487827,0.00018408238,0.00021177004,0.00031641277,0.0018751196],"category_scores_gemma":[0.0007605039,0.00010846207,0.00027053073,0.00007167808,0.00024992737,0.00018013566,0.00011550083,0.00033173087,0.00011735587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04226454,0.00299874,0.036666762,0.0015270036,0.00057848217,0.00012430822,0.00013663479,0.00051838584,0.81229067,0.00005428377,0.00014588344,0.102694295],"study_design_scores_gemma":[0.0034694758,0.08245429,0.8012655,0.00015598755,0.00052571093,0.00085110986,0.0001382259,0.0017072163,0.108121805,0.00008203324,0.0012080747,0.000020575173],"about_ca_topic_score_codex":0.00024987065,"about_ca_topic_score_gemma":0.00043216694,"teacher_disagreement_score":0.0018751196,"about_ca_system_score_codex":0.00011983329,"about_ca_system_score_gemma":0.00013085,"threshold_uncertainty_score":0.0062729716},"labels":[],"label_agreement":null},{"id":"W4407379624","doi":"10.1111/dom.16242","title":"Mechanisms of diabetic cardiomyopathy: Focus on inflammation","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Cardiovascular Function and Risk Factors","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Diabetic cardiomyopathy; Medicine; Cardiomyopathy; Coronary artery disease; Heart failure; Inflammation; Diabetes mellitus; Disease; Bioinformatics; Therapeutic approach; Insulin resistance; Cardiology; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.012505314081733516,"score_gpt":0.2510559400740218,"score_spread":0.2385506259922883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407379624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000069521586,0.99873656,0.000057284436,0.00023745303,0.00037579285,0.0000031974835,0.000014086166,0.0000055718588,0.00050057616],"genre_scores_gemma":[0.00036759634,0.99874336,0.000066066175,0.0002050721,0.000286437,0.0000036437166,0.000022140332,0.0000011487341,0.00030455543],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998228,0.000035396504,0.000034363,0.000030484318,0.00005560925,0.000021307538],"domain_scores_gemma":[0.99962556,0.00017151512,0.00006295509,0.000009437335,0.000097596916,0.000032948243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043915876,0.00091506046,0.0014495827,0.001877059,0.00025407597,0.0010807007,0.0006573839,0.00085194455,0.0041552554],"category_scores_gemma":[0.00077472883,0.00019775779,0.0006375244,0.0016811586,0.00036862883,0.0011715931,0.00072092493,0.0015636963,0.0015356438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012391411,0.00006702072,0.00025396806,0.0476024,0.0001760127,0.00023906492,0.00009712199,0.0003754993,0.0016915204,0.0039481735,0.060309283,0.885116],"study_design_scores_gemma":[0.000019884268,0.00012067108,0.0010924923,0.012262622,0.00021588193,0.0014174907,0.00009737923,0.000086938424,0.00038468605,0.002069433,0.98221093,0.00002159994],"about_ca_topic_score_codex":0.0006826411,"about_ca_topic_score_gemma":0.000961615,"teacher_disagreement_score":0.0041552554,"about_ca_system_score_codex":0.00045853684,"about_ca_system_score_gemma":0.0012003222,"threshold_uncertainty_score":0.013900697},"labels":[],"label_agreement":null},{"id":"W4407384717","doi":"10.1111/dom.16231","title":"Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the <scp>ONWARDS</scp> 1–5 trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Trillium Health Centre","funders":"Novo Nordisk","keywords":"Medicine; Post-hoc analysis; Basal insulin; Internal medicine; Insulin; Type 2 diabetes; Basal (medicine); Diabetes mellitus; Endocrinology; Renal function","score_opus":0.040088998702929604,"score_gpt":0.29897232845642047,"score_spread":0.2588833297534909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407384717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727358,0.019890519,0.0006039844,0.00026174547,0.00028137298,0.0016025476,0.0021240786,0.000035057208,0.0024649014],"genre_scores_gemma":[0.9911164,0.003511067,0.0010356063,0.00038047862,0.00013886923,0.0011581064,0.0014234754,0.00001873328,0.0012173307],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99774146,0.0013345786,0.0002457255,0.00026886194,0.00018618673,0.00022323219],"domain_scores_gemma":[0.99725,0.0013963919,0.00076903246,0.00018529687,0.00019081745,0.00020841516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034996432,0.0011338071,0.003347495,0.00037891738,0.00018319392,0.0011182075,0.0005089714,0.00094522233,0.003963663],"category_scores_gemma":[0.003908529,0.00034656056,0.009566236,0.0004273849,0.00033788037,0.0007083211,0.0007115873,0.0018618326,0.00026364523],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9184892,0.0009483579,0.008967597,0.007031348,0.037036378,0.00008421804,0.0001487994,0.0008062057,0.00375669,0.00017970797,0.0008205225,0.021731023],"study_design_scores_gemma":[0.5167125,0.21333306,0.12820126,0.0022940754,0.12579016,0.00024927707,0.00028849245,0.0015026007,0.004830699,0.00064656255,0.006035386,0.00011597237],"about_ca_topic_score_codex":0.0012204214,"about_ca_topic_score_gemma":0.0043283324,"teacher_disagreement_score":0.003963663,"about_ca_system_score_codex":0.00063844863,"about_ca_system_score_gemma":0.00083055545,"threshold_uncertainty_score":0.018508077},"labels":[],"label_agreement":null},{"id":"W4408026290","doi":"10.1111/dom.16278","title":"What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Biosimilar; Simple (philosophy); Intensive care medicine; Medical physics; Internal medicine; Epistemology","score_opus":0.09275575179041569,"score_gpt":0.381834232375524,"score_spread":0.2890784805851083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408026290","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075643073,0.01693189,0.0027558836,0.96762824,0.0048938426,0.00016718953,0.00026584038,0.00011697987,0.0064837798],"genre_scores_gemma":[0.057947997,0.06491123,0.097059675,0.7591317,0.011701584,0.001116682,0.0013130204,0.0005456607,0.0062724263],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9265032,0.02618955,0.016538974,0.0026775808,0.022655455,0.005435215],"domain_scores_gemma":[0.6981013,0.05501582,0.017411496,0.010133124,0.18120506,0.03813319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.089438386,0.0013902216,0.004019818,0.005929223,0.008688704,0.016360559,0.012017458,0.02500689,0.006314305],"category_scores_gemma":[0.2459013,0.0013872088,0.003619728,0.0077532,0.01345754,0.013816944,0.00663584,0.024177093,0.002618337],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011872928,0.00017056821,0.008432385,0.0030964704,0.0002515969,0.0008281741,0.005163893,0.00078040495,0.000432055,0.025289075,0.7691993,0.18623728],"study_design_scores_gemma":[0.00026118848,0.00013382187,0.0138688125,0.027873255,0.00041851675,0.0011645801,0.011226482,0.0016043005,0.0004177097,0.05307205,0.8893996,0.00055961177],"about_ca_topic_score_codex":0.48091865,"about_ca_topic_score_gemma":0.52704835,"teacher_disagreement_score":0.51908135,"about_ca_system_score_codex":0.047774598,"about_ca_system_score_gemma":0.21513826,"threshold_uncertainty_score":0.95623875},"labels":[],"label_agreement":null},{"id":"W4408244332","doi":"10.1111/dom.16315","title":"The coordinated changes in insulin sensitivity and insulin secretion associated with the remission of type 2 diabetes following short‐term insulin therapy","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Insulin; Type 2 diabetes; Internal medicine; Insulin sensitivity; Term (time); Endocrinology; Diabetes mellitus; Type 1 diabetes; Insulin resistance","score_opus":0.014500087350177777,"score_gpt":0.2512828135866966,"score_spread":0.2367827262365188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408244332","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045005314,0.006128729,0.0014976101,0.89544684,0.012502963,0.000056952696,0.00017682952,0.000116731804,0.039067954],"genre_scores_gemma":[0.4517411,0.0113383,0.0024487309,0.4416153,0.04780842,0.00010891803,0.00019692238,0.00010151405,0.044640858],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99893993,0.0004093208,0.00013493889,0.00009106942,0.00027314379,0.00015156865],"domain_scores_gemma":[0.997436,0.0013600515,0.0003285368,0.0001892537,0.00041208416,0.00027405628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001018385,0.00013996132,0.00038261712,0.000293914,0.0011294488,0.0010245211,0.00038623807,0.006053708,0.002050252],"category_scores_gemma":[0.008975663,0.00012227248,0.0003171403,0.00047915333,0.0011023592,0.00068245764,0.0003680991,0.0056498004,0.0019045261],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079930585,0.00022117412,0.030402197,0.00027630661,0.000043815955,0.16931362,0.0011755659,0.00030001582,0.0041443724,0.0104890475,0.62418157,0.15865304],"study_design_scores_gemma":[0.00021238667,0.00068263477,0.07611084,0.0009822506,0.000051385246,0.27846885,0.0025472527,0.0016995228,0.0020648495,0.029123716,0.60795027,0.0001060388],"about_ca_topic_score_codex":0.0017296539,"about_ca_topic_score_gemma":0.0035521295,"teacher_disagreement_score":0.006053708,"about_ca_system_score_codex":0.0014059453,"about_ca_system_score_gemma":0.00071979326,"threshold_uncertainty_score":0.010200858},"labels":[],"label_agreement":null},{"id":"W4408585020","doi":"10.1111/dom.16328","title":"Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of <scp>ONWARDS</scp> 1–5","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Medicine; Internal medicine; Basal (medicine); Type 2 diabetes; Insulin; Hypoglycemia; Diabetes mellitus; Endocrinology; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Post-hoc analysis; Agonist; Receptor","score_opus":0.011744945684002967,"score_gpt":0.25189143007267056,"score_spread":0.2401464843886676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408585020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181443,0.0061116754,0.00013484055,0.0000975038,0.0000986412,0.0003151174,0.00041738167,0.000011706589,0.0009986775],"genre_scores_gemma":[0.99655056,0.0015841088,0.00029642685,0.00016367875,0.000069030866,0.0002867254,0.00056327466,0.000007077347,0.0004791299],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9985442,0.0008270089,0.00016879034,0.0001918268,0.00011255995,0.0001555922],"domain_scores_gemma":[0.9978719,0.000928658,0.0006123794,0.00013287703,0.00012546817,0.00032870073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002593086,0.00069203007,0.0027952339,0.00043870774,0.00017473701,0.0010369932,0.00040979692,0.0007438613,0.0027834412],"category_scores_gemma":[0.0026739442,0.00030502392,0.0040419744,0.00050752284,0.00037796516,0.0006620134,0.00047027518,0.0015451338,0.00018145874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96065044,0.0018465798,0.0061998013,0.0012024889,0.005218621,0.000024839868,0.00008233687,0.00046596106,0.0018155621,0.00006755165,0.00027640973,0.022149336],"study_design_scores_gemma":[0.542442,0.33179963,0.10097967,0.00065538834,0.01748736,0.00013376056,0.0002410938,0.0015022842,0.0024786685,0.00032263575,0.0018792823,0.00007824986],"about_ca_topic_score_codex":0.0011884618,"about_ca_topic_score_gemma":0.002887256,"teacher_disagreement_score":0.0027952339,"about_ca_system_score_codex":0.00061024964,"about_ca_system_score_gemma":0.00055084284,"threshold_uncertainty_score":0.013713717},"labels":[],"label_agreement":null},{"id":"W4408745570","doi":"10.1111/dom.16266","title":"<scp>FRONTIER</scp> : <scp>FReeStyle</scp> Libre system use in Ontario among people with diabetes in the <scp>IC</scp> / <scp>ES</scp> database—Evidence from real‐world practice: Patients on basal insulin, glucagon‐like peptide 1 receptor agonist or oral therapies","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbott (Canada); Diabetes Canada; Montreal Clinical Research Institute; Western University","funders":"Abbott Diabetes Care","keywords":"Medicine; Basal (medicine); Insulin; Basal insulin; Diabetes mellitus; Liraglutide; Type 2 diabetes; Type 2 Diabetes Mellitus; Hypoglycemia; Internal medicine; Endocrinology","score_opus":0.01834633413073169,"score_gpt":0.2501892040016411,"score_spread":0.23184286987090938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408745570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63131785,0.0027019554,0.00015337912,0.0007239354,0.000039812152,0.00045345508,0.35942996,0.00003970258,0.005139932],"genre_scores_gemma":[0.88118404,0.0015752299,0.00046845563,0.00045534645,0.00005061077,0.00043310976,0.11407239,0.000015962714,0.0017447161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998728,0.00011964588,0.00023256421,0.00020606248,0.00050091546,0.00021289536],"domain_scores_gemma":[0.99248004,0.0004341256,0.0033891152,0.00035018683,0.0024197642,0.0009268259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007774697,0.00038593682,0.000616496,0.0019610696,0.0010007456,0.0011116771,0.0012826455,0.0004046822,0.0038482298],"category_scores_gemma":[0.0054204515,0.0003839182,0.0010281516,0.008034712,0.00045420113,0.0005605769,0.0010023625,0.00036020385,0.00044481267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048360004,0.000037413516,0.9813508,0.0007519696,0.00034434063,0.000058086785,0.00032429307,0.00010787591,0.00008820392,0.00006854434,0.012677765,0.0037071651],"study_design_scores_gemma":[0.00008772696,0.000026277085,0.9971361,0.00013789152,0.00012995112,0.000025603487,0.00022492287,0.00010822342,0.000027810194,0.000009846597,0.0020785981,0.0000070048395],"about_ca_topic_score_codex":0.97118664,"about_ca_topic_score_gemma":0.9735218,"teacher_disagreement_score":0.028813362,"about_ca_system_score_codex":0.012559447,"about_ca_system_score_gemma":0.018533045,"threshold_uncertainty_score":0.09112555},"labels":[],"label_agreement":null},{"id":"W4408745647","doi":"10.1111/dom.16341","title":"A meta‐analysis of adverse offspring health outcomes in patients with gestational diabetes mellitus","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gestational diabetes; Meta-analysis; Offspring; Confidence interval; Odds ratio; Overweight; Publication bias; Subgroup analysis; Obesity; Internal medicine; Blood pressure; Diabetes mellitus; Obstetrics; Pregnancy; Endocrinology; Gestation","score_opus":0.03191254537991806,"score_gpt":0.31505639557028775,"score_spread":0.2831438501903697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408745647","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016754458,0.9806348,0.0011266146,0.00024097317,0.0003349364,0.0001640532,0.00043132185,0.00003677443,0.00027612457],"genre_scores_gemma":[0.4345515,0.5565719,0.0046928967,0.0011736347,0.0005257293,0.00081420457,0.0010970006,0.000046539604,0.00052669964],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9907126,0.0054208753,0.0020185942,0.00089375844,0.0006831497,0.00027107736],"domain_scores_gemma":[0.98810333,0.008600231,0.0015716671,0.00074636063,0.0008018652,0.00017643525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014047708,0.0028667606,0.014020154,0.0055327294,0.00058429316,0.003291044,0.0015968599,0.0020335421,0.001744575],"category_scores_gemma":[0.027348036,0.0014101833,0.048413172,0.00585682,0.00042763553,0.0011462737,0.0013909095,0.0019187023,0.00018875588],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020499385,0.000022052558,0.0076400843,0.04747608,0.9365133,0.00013664535,0.0000382944,0.0005810433,0.00020469747,0.00007516559,0.00025543498,0.0050073443],"study_design_scores_gemma":[0.000323217,0.00014680905,0.0041078953,0.0026552824,0.99177814,0.00007621483,0.000017425285,0.00021430536,0.00007253629,0.000119256714,0.00047746106,0.000011534602],"about_ca_topic_score_codex":0.00582129,"about_ca_topic_score_gemma":0.010307046,"teacher_disagreement_score":0.014047708,"about_ca_system_score_codex":0.0015734739,"about_ca_system_score_gemma":0.0022149687,"threshold_uncertainty_score":0.0742923},"labels":[],"label_agreement":null},{"id":"W4409691646","doi":"10.1111/dom.16371","title":"The interplay between heart failure and chronic kidney disease","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Bayer","keywords":"Medicine; Kidney disease; Heart failure; Mineralocorticoid receptor; Intensive care medicine; Disease; Diabetes mellitus; Blood pressure; Internal medicine; Hyperkalemia; Endocrinology; Cardiology; Aldosterone","score_opus":0.010128089709059636,"score_gpt":0.28731579467443796,"score_spread":0.2771877049653783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409691646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008264897,0.9985623,0.000052524363,0.0003368505,0.00020916502,0.000003003921,0.000013364168,0.000004125923,0.00073612714],"genre_scores_gemma":[0.00063717924,0.99854386,0.00009194936,0.00024157189,0.00015442504,0.000004291651,0.00001938477,8.5407027e-7,0.0003065043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996804,0.00008605298,0.000056834822,0.000037144735,0.000111619214,0.000027933957],"domain_scores_gemma":[0.9996126,0.00021193261,0.000048641545,0.000008764505,0.00009139794,0.000026645872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051542855,0.00062133034,0.0012377193,0.0014751365,0.00028993658,0.0010096596,0.0005143,0.0007930615,0.0036792553],"category_scores_gemma":[0.0010431171,0.00019294255,0.0007180674,0.0016483017,0.00033781436,0.00092883833,0.0006773375,0.0015717631,0.0010573218],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007969665,0.00005857942,0.00035762996,0.04164909,0.0002760168,0.00019778644,0.00012575548,0.0002918353,0.00068192126,0.0045286403,0.04225134,0.9095016],"study_design_scores_gemma":[0.000018571607,0.00007882698,0.0018762447,0.014354291,0.00027695074,0.0011440191,0.00008662208,0.000076178585,0.00012954867,0.0021426813,0.9797987,0.000017394077],"about_ca_topic_score_codex":0.0020982309,"about_ca_topic_score_gemma":0.0035579773,"teacher_disagreement_score":0.0036792553,"about_ca_system_score_codex":0.000624762,"about_ca_system_score_gemma":0.001844436,"threshold_uncertainty_score":0.0123083},"labels":[],"label_agreement":null},{"id":"W4409893677","doi":"10.1111/dom.16415","title":"Clinically meaningful improvements in treatment satisfaction in insulin‐naïve people with type 2 diabetes post initiation of insulin glargine 300 U/ <scp>mL</scp> : A post hoc analysis of real‐world <scp>ATOS</scp> study","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Sanofi","keywords":"Medicine; Insulin glargine; Post-hoc analysis; Type 2 diabetes; Insulin; Internal medicine; Endocrinology; Type 2 Diabetes Mellitus; Diabetes mellitus","score_opus":0.01288432946621716,"score_gpt":0.27468092034625646,"score_spread":0.2617965908800393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409893677","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628556,0.0007074764,0.00019439241,0.000103089915,0.00005581405,0.00026699077,0.0017096056,0.000012787404,0.00066423893],"genre_scores_gemma":[0.9967398,0.00021790173,0.00021889003,0.00014665886,0.00007244571,0.00037778268,0.001764788,0.000005752927,0.00045596782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975896,0.001396244,0.0002245,0.00023803097,0.00033559106,0.00021607422],"domain_scores_gemma":[0.99543226,0.0016024696,0.001470238,0.0002670426,0.00051988114,0.0007080954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004134763,0.00052055647,0.0013877163,0.00036236734,0.00041660925,0.0008910138,0.00044076465,0.00060559646,0.003423519],"category_scores_gemma":[0.0055145775,0.00029855076,0.0031803998,0.00085394434,0.0003648696,0.00073080906,0.0007893024,0.0014815439,0.0003269556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27546445,0.0060890503,0.6644768,0.0010192909,0.009983795,0.00011359646,0.00070379715,0.00056732,0.0007776106,0.00010651757,0.002447284,0.03825048],"study_design_scores_gemma":[0.007538229,0.030740712,0.95696425,0.00005095142,0.0024664663,0.00007096627,0.00033724753,0.0008030413,0.00018723156,0.000074687385,0.0007298019,0.000036443213],"about_ca_topic_score_codex":0.0020317596,"about_ca_topic_score_gemma":0.0027257965,"teacher_disagreement_score":0.004134763,"about_ca_system_score_codex":0.00052891026,"about_ca_system_score_gemma":0.00058122596,"threshold_uncertainty_score":0.021866977},"labels":[],"label_agreement":null},{"id":"W4409979848","doi":"10.1111/dom.16426","title":"Social disadvantage and technology use among adults with type 1 diabetes in Quebec: A cross‐sectional study using data from the Canadian <scp>T1D</scp> ( <scp>BETTER</scp> ) Registry","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Diabetes Canada; Montreal Clinical Research Institute; McGill University Health Centre; University of Ottawa; McGill University; Université Laval; University of Toronto; Public Health Ontario; Université de Montréal; Hospital for Sick Children; University Health Network; Ottawa Hospital; Centre hospitalier universitaire de Québec; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Breakthrough T1D Canada; Novo Nordisk; Sanofi; Diabetes Canada; Eli Lilly and Company; Canadian Institutes of Health Research; Diabetes Action Research and Education Foundation","keywords":"Medicine; Odds ratio; Disadvantage; Odds; Insulin pump; Cross-sectional study; Type 1 diabetes; Demography; Insulin; Logistic regression; Confidence interval; Diabetes mellitus; Gerontology; Environmental health; Internal medicine; Endocrinology","score_opus":0.023483228402835045,"score_gpt":0.2922524543133965,"score_spread":0.26876922591056146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409979848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98766124,0.0005443301,0.00018741156,0.00024004022,0.000011131052,0.00009504324,0.009854543,0.000012822812,0.0013934025],"genre_scores_gemma":[0.9950435,0.00029189105,0.00022934817,0.00017928741,0.0000099152185,0.00007187754,0.0034811466,0.000004273908,0.0006886987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993839,0.0000871289,0.000057905738,0.00011931367,0.00018776012,0.00016391494],"domain_scores_gemma":[0.9982364,0.00012143049,0.00056807994,0.00008351401,0.00064287934,0.00034765326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008181573,0.00036865586,0.00037061883,0.0012600962,0.0016104262,0.0010088908,0.0008625741,0.00055731484,0.0019130928],"category_scores_gemma":[0.0016325978,0.00027887625,0.0006419824,0.0032422643,0.0004655839,0.0005667779,0.00070369005,0.00066262926,0.00031523968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021305095,0.000035241825,0.9982315,0.000015579026,0.00004962884,0.000016342787,0.00015562448,0.00003603767,0.000048665403,0.000016420354,0.00047750422,0.00089616026],"study_design_scores_gemma":[0.000004293685,0.000015763733,0.9993268,0.000013389816,0.000014915555,0.000013015423,0.00019233374,0.00013756462,0.000011168518,0.000004184501,0.00026298434,0.0000035795451],"about_ca_topic_score_codex":0.97736686,"about_ca_topic_score_gemma":0.9808637,"teacher_disagreement_score":0.022633135,"about_ca_system_score_codex":0.009600847,"about_ca_system_score_gemma":0.005990938,"threshold_uncertainty_score":0.06965935},"labels":[],"label_agreement":null},{"id":"W4410132355","doi":"10.1111/dom.16431","title":"Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( <scp>RACELINES</scp> ): A randomised, double‐blind trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Amsterdam University Medical Centers; Boehringer Ingelheim","keywords":"Empagliflozin; Medicine; Linagliptin; Postprandial; Renal function; Type 2 diabetes; Gliclazide; Internal medicine; Endocrinology; Urology; Metformin; Diabetes mellitus; Glycosuria; Effective renal plasma flow; Renal blood flow","score_opus":0.0077083763909527505,"score_gpt":0.24274227196848683,"score_spread":0.23503389557753407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410132355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515814,0.0023564217,0.00026680843,0.00018015548,0.0002520756,0.0009148274,0.00027339754,0.00004177871,0.00055625907],"genre_scores_gemma":[0.99340254,0.0012045697,0.0009276317,0.0003049381,0.00043934333,0.0021674975,0.00038395307,0.000012897351,0.0011566834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988582,0.0005523306,0.00010667829,0.00024030605,0.000096296884,0.0001461883],"domain_scores_gemma":[0.9989568,0.00022818636,0.00024176884,0.00009183373,0.00007132524,0.00041013226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020501602,0.0016812971,0.004702383,0.0005159601,0.00042387767,0.001168557,0.0009007508,0.0020778568,0.004400439],"category_scores_gemma":[0.0014509376,0.0010362546,0.002864454,0.00046239767,0.0010643394,0.0010612777,0.0005781672,0.002766951,0.00068456435],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98963165,0.0040934854,0.00026496593,0.00015758442,0.00048043096,0.000008059942,0.00001075012,0.000079402416,0.001210897,0.0000123394575,0.00007339014,0.0039770654],"study_design_scores_gemma":[0.889631,0.10585151,0.0024957214,0.000018516024,0.0009314324,0.000017517403,0.000010154608,0.0003062091,0.00052044843,0.000040657884,0.00016118168,0.000015693979],"about_ca_topic_score_codex":0.0006720732,"about_ca_topic_score_gemma":0.0010423741,"teacher_disagreement_score":0.004702383,"about_ca_system_score_codex":0.00074060546,"about_ca_system_score_gemma":0.0009701895,"threshold_uncertainty_score":0.014720917},"labels":[],"label_agreement":null},{"id":"W4410871301","doi":"10.1111/dom.16469","title":"Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Eli Lilly Canada; National Institutes of Health; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; Novartis; Novo Nordisk; Esperion Therapeutics; Arrowhead Pharmaceuticals; Merck; NewAmsterdam Pharma; Boehringer Ingelheim; Amgen; Eli Lilly and Company; 89bio","keywords":"Medicine; Disease; Atherosclerotic cardiovascular disease; Lipoprotein(a); Statin; Guideline; Intensive care medicine; Familial hypercholesterolemia; Risk factor; PCSK9; Epidemiology; Narrative review; Bioinformatics; Internal medicine; Lipoprotein; Pathology; Cholesterol; LDL receptor","score_opus":0.10622161136636724,"score_gpt":0.37055368627367347,"score_spread":0.26433207490730626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410871301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000093290415,0.993711,0.0002277961,0.0051534926,0.0004607615,0.000007869755,0.000036014266,0.0000069084304,0.00030289896],"genre_scores_gemma":[0.0011330951,0.99383765,0.0006999278,0.0034277013,0.00066884654,0.000024952125,0.00004708518,0.000006691218,0.00015403928],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99520075,0.0017015907,0.0014189637,0.0006606199,0.0008706413,0.00014728506],"domain_scores_gemma":[0.98025995,0.014762756,0.0015878406,0.00027205376,0.0028240797,0.00029331932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007580946,0.0010048476,0.0029285066,0.0034022166,0.0004640471,0.003754361,0.0016367984,0.0033193645,0.0023865313],"category_scores_gemma":[0.025446422,0.00059158145,0.0018898714,0.003115617,0.0016163783,0.004621027,0.0011119896,0.004094219,0.0015057592],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003072483,0.000045437093,0.0011779182,0.067230076,0.00073784153,0.0002230226,0.00038243757,0.00025353197,0.0004813242,0.0050588944,0.048901163,0.87520105],"study_design_scores_gemma":[0.00009396911,0.00018863988,0.0035687801,0.16059652,0.002185334,0.0014596242,0.0007828154,0.0002678238,0.00053284486,0.012640044,0.8175711,0.000112553644],"about_ca_topic_score_codex":0.00448167,"about_ca_topic_score_gemma":0.006175257,"teacher_disagreement_score":0.007580946,"about_ca_system_score_codex":0.0020623833,"about_ca_system_score_gemma":0.003971719,"threshold_uncertainty_score":0.04009241},"labels":[],"label_agreement":null},{"id":"W4410901256","doi":"10.1111/dom.16478","title":"Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The <scp>DAPASALT</scp> trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca; AstraZeneca Mölndal","keywords":"Dapagliflozin; Medicine; Type 2 diabetes; Kidney disease; Blood pressure; Diabetes mellitus; Internal medicine; Excretion; Endocrinology; Sodium; Urology","score_opus":0.0032523616165991685,"score_gpt":0.19932043480933004,"score_spread":0.19606807319273087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410901256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314356,0.0037618384,0.0003003315,0.00038178786,0.00016728292,0.0005835951,0.00065172534,0.000023925304,0.0009858909],"genre_scores_gemma":[0.994609,0.0014271482,0.00063779956,0.0005352028,0.000273425,0.00079238426,0.0010796303,0.0000065251274,0.00063878566],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998939,0.0006333074,0.000084718056,0.00015975606,0.00010741217,0.000075865195],"domain_scores_gemma":[0.9988426,0.00031131433,0.00038353752,0.00015514134,0.00009396527,0.0002134262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029897331,0.0009517477,0.0020524354,0.00018647879,0.00025471603,0.0008324692,0.0005269874,0.0010638995,0.0014892508],"category_scores_gemma":[0.0026796728,0.00033368732,0.0019408367,0.00024814112,0.0005780912,0.0006182483,0.00048957026,0.0016515873,0.00022438812],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9543797,0.002869319,0.011776768,0.0007758947,0.0037590642,0.000041256764,0.00006863479,0.0005375626,0.001991549,0.00009930461,0.0008245029,0.022876488],"study_design_scores_gemma":[0.8458156,0.08282409,0.062381677,0.00014685802,0.004590353,0.00014371883,0.000045588564,0.0013926399,0.0007370677,0.00033348615,0.0015534332,0.000035563917],"about_ca_topic_score_codex":0.0007815556,"about_ca_topic_score_gemma":0.0013413394,"teacher_disagreement_score":0.0029897331,"about_ca_system_score_codex":0.00042288023,"about_ca_system_score_gemma":0.000683319,"threshold_uncertainty_score":0.015811443},"labels":[],"label_agreement":null},{"id":"W4411078217","doi":"10.1111/dom.16513","title":"A1c versus oral glucose tolerance test for chronic glycemic surveillance in women with previous gestational diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Gestational Diabetes Research and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gestational diabetes; Internal medicine; Diabetes mellitus; Insulin resistance; Glycemic; Type 2 diabetes; Endocrinology; Glucose tolerance test; Pregnancy; Glycemic index; Insulin; Gestation","score_opus":0.008721685529246128,"score_gpt":0.2612230939032517,"score_spread":0.2525014083740056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411078217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972113,0.002064232,0.000065216336,0.00012537804,0.000034110337,0.0000104386045,0.000078857454,0.0000034587792,0.00040698764],"genre_scores_gemma":[0.99884003,0.00055057084,0.00024860897,0.00008557237,0.000040009774,0.000015020961,0.00012994902,0.0000015909758,0.00008873078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927205,0.00035023672,0.000087745015,0.00012829118,0.00008728955,0.0000742644],"domain_scores_gemma":[0.99800104,0.0008688695,0.0006055014,0.00008806713,0.00011384806,0.00032274626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021913084,0.0002483662,0.0004249735,0.0004402855,0.00030080043,0.00049219106,0.00024852564,0.000542984,0.00088462536],"category_scores_gemma":[0.0058430815,0.0001519868,0.00044372134,0.00052157114,0.0002620531,0.00039703766,0.0003911604,0.0003848596,0.00015360105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067961453,0.00013434172,0.98119444,0.00003875537,0.00009993297,0.000071719056,0.00006429449,0.00005272696,0.00018331803,0.00001247213,0.000092073984,0.011259848],"study_design_scores_gemma":[0.00026693652,0.0068550888,0.9901382,0.00007423206,0.00032028256,0.0004437317,0.00029360442,0.00066621706,0.0003101761,0.00004546942,0.00057676877,0.000009407697],"about_ca_topic_score_codex":0.0019461596,"about_ca_topic_score_gemma":0.0031655682,"teacher_disagreement_score":0.0021913084,"about_ca_system_score_codex":0.00038372868,"about_ca_system_score_gemma":0.00036300824,"threshold_uncertainty_score":0.0115888715},"labels":[],"label_agreement":null},{"id":"W4411214651","doi":"10.1111/dom.16528","title":"A simplified protocol based on a standardized meal‐stimulated beta‐cell response to stratify people living with non‐insulin‐treated type 2 diabetes","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; Université de Montréal; Ottawa Hospital; University of Ottawa","funders":"Ottawa Hospital Research Institute","keywords":"Medicine; Insulin; Beta cell; BETA (programming language); Type 2 diabetes; Diabetes mellitus; Internal medicine; Type 1 diabetes; Meal; Oncology; Endocrinology; Islet","score_opus":0.00905740798181033,"score_gpt":0.2502071142431937,"score_spread":0.24114970626138338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411214651","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05477111,0.011531599,0.097335055,0.46856362,0.06993588,0.083080046,0.016458964,0.0031425573,0.19518118],"genre_scores_gemma":[0.2340436,0.015343949,0.12550424,0.31445605,0.045329,0.1204467,0.011246206,0.00079748145,0.13283283],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938875,0.00403369,0.00086490577,0.00028541536,0.00057629624,0.00035224235],"domain_scores_gemma":[0.99048,0.0043755253,0.00057717593,0.0012976098,0.0025182771,0.00075144233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060780435,0.00071865035,0.0009982141,0.0011129805,0.0012655593,0.0010232077,0.00090437185,0.003986172,0.027194275],"category_scores_gemma":[0.022367138,0.00034025477,0.0007455447,0.0008714835,0.000544794,0.00072944735,0.0012222554,0.004322233,0.014662456],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027722432,0.0011658458,0.0057896604,0.0006006986,0.00006594223,0.004909574,0.00038560558,0.00037511397,0.0035050588,0.0030511273,0.8180046,0.15937448],"study_design_scores_gemma":[0.0036652545,0.0036583852,0.05641084,0.0026406897,0.00015538612,0.009534257,0.0009527068,0.0030972497,0.004412072,0.011216721,0.90399235,0.000264037],"about_ca_topic_score_codex":0.0020177094,"about_ca_topic_score_gemma":0.0025349546,"teacher_disagreement_score":0.027194275,"about_ca_system_score_codex":0.0013537626,"about_ca_system_score_gemma":0.0017073341,"threshold_uncertainty_score":0.090973854},"labels":[],"label_agreement":null},{"id":"W4411349501","doi":"10.1111/dom.16511","title":"Continuous glucose monitoring‐derived time in range is associated with changes in cognitive function test scores in Japanese patients with type 2 diabetes mellitus","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Medicine; Type 2 Diabetes Mellitus; Continuous glucose monitoring; Cognition; Internal medicine; Diabetes mellitus; Test (biology); Endocrinology; Type 1 diabetes; Psychiatry","score_opus":0.007333343211527844,"score_gpt":0.2366238890478479,"score_spread":0.22929054583632005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411349501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99923456,0.0003929623,0.000059308575,0.000026176818,0.000008670126,0.0000025075892,0.000088884764,0.0000032071453,0.00018372248],"genre_scores_gemma":[0.99961746,0.00010176176,0.00005736291,0.000017609646,0.000009426682,0.0000032219298,0.000120997305,0.0000014574197,0.00007068164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996313,0.00009379352,0.00006157333,0.00009914972,0.00006569409,0.000048467973],"domain_scores_gemma":[0.9980379,0.00029893126,0.0010324185,0.000150589,0.00020185119,0.00027830474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077372434,0.0005024715,0.00053879205,0.00075059215,0.0004499187,0.0006414687,0.0003552127,0.00046781226,0.0007220075],"category_scores_gemma":[0.0022856188,0.00034445513,0.0007564728,0.0013124457,0.00024592408,0.00028904923,0.00036940927,0.00072422513,0.00012961365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115424366,0.000021843776,0.9989654,0.000006309164,0.00008428825,0.00006249385,0.00003681684,0.00002104989,0.00015595127,0.0000025672766,0.00002520195,0.000502651],"study_design_scores_gemma":[0.000003502143,0.000037441612,0.99963415,0.0000021982332,0.000038812224,0.0000941731,0.000042290045,0.00010017764,0.000015192014,0.000004053482,0.000025661413,0.0000023448367],"about_ca_topic_score_codex":0.01134562,"about_ca_topic_score_gemma":0.012408332,"teacher_disagreement_score":0.01134562,"about_ca_system_score_codex":0.00026278093,"about_ca_system_score_gemma":0.00024114749,"threshold_uncertainty_score":0.022559166},"labels":[],"label_agreement":null},{"id":"W4411450861","doi":"10.1111/dom.16535","title":"Interaction between dietary omega‐3 polyunsaturated fatty acids, obesity and gut microbiota in preclinical models: A systematic review of randomized controlled trials","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diet and metabolism studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Natural Science Foundation of China","keywords":"Medicine; Gut flora; Polyunsaturated fatty acid; Randomized controlled trial; Obesity; Bioinformatics; Internal medicine; Fatty acid; Immunology; Biochemistry; Biology","score_opus":0.06835631774634332,"score_gpt":0.3650874740205751,"score_spread":0.2967311562742318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411450861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011893706,0.99772114,0.00017002455,0.00014169984,0.000091938644,0.00028808237,0.0002493017,0.000009181426,0.00013923131],"genre_scores_gemma":[0.021351898,0.9756715,0.00089636486,0.00060310314,0.00013755866,0.0009104219,0.00029619163,0.000010574679,0.00012233657],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9927731,0.0027780265,0.0027722556,0.0006403827,0.00085630425,0.00017989744],"domain_scores_gemma":[0.97580373,0.01755764,0.0045230794,0.0004348198,0.0014500982,0.00023060347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009685165,0.0017051023,0.012222131,0.0037679726,0.00056411576,0.002191104,0.0017479897,0.0018383564,0.0045765527],"category_scores_gemma":[0.03239346,0.00081102503,0.011223978,0.004912622,0.0008807195,0.001590726,0.0011580961,0.0014563383,0.0003119626],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027773606,0.000054527583,0.000647725,0.9177874,0.03348564,0.00005718781,0.000059369584,0.00011545008,0.00032163467,0.00015842401,0.0008412043,0.04369415],"study_design_scores_gemma":[0.0043633166,0.0019182151,0.0064334534,0.52153516,0.44585553,0.00028475624,0.00016777369,0.00018793113,0.0005283966,0.00057797553,0.018072024,0.000075483265],"about_ca_topic_score_codex":0.0034155548,"about_ca_topic_score_gemma":0.008991022,"teacher_disagreement_score":0.012222131,"about_ca_system_score_codex":0.0020920816,"about_ca_system_score_gemma":0.0058372375,"threshold_uncertainty_score":0.051220655},"labels":[],"label_agreement":null},{"id":"W4411592381","doi":"10.1111/dom.16547","title":"Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; St. Michael's Hospital; Hospital for Sick Children; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"Canadian Statistical Sciences Institute; Banting Research Foundation","keywords":"Medicine; Type 2 diabetes; Disadvantage; Diabetes mellitus; Insulin; Intensive care medicine; Gerontology; Environmental health; Internal medicine; Endocrinology","score_opus":0.02236670991544468,"score_gpt":0.3367042641964723,"score_spread":0.3143375542810276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411592381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894811,0.001193893,0.00014727497,0.00077956246,0.000021991935,0.00007603794,0.005780741,0.000010092329,0.0025093816],"genre_scores_gemma":[0.99773824,0.00043075142,0.0001346969,0.0000971525,0.000007692687,0.00002464481,0.0010841044,0.000003252217,0.00047940432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864167,0.00014047662,0.000107592285,0.0001865071,0.0004366286,0.0004870558],"domain_scores_gemma":[0.9971935,0.00016086787,0.0008523328,0.000089082314,0.0008963569,0.0008079312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010926984,0.00032746192,0.0005216495,0.0011658908,0.0028323922,0.0012189971,0.0011353126,0.000357375,0.0018389174],"category_scores_gemma":[0.002858314,0.00034098528,0.00095401926,0.0034508512,0.00081435073,0.00041002964,0.0014481175,0.00062727026,0.00011227189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055377095,0.000020024587,0.9960145,0.00003741906,0.00005863586,0.00004461028,0.0005863147,0.00008677587,0.000039391827,0.00006668722,0.00084905804,0.002141213],"study_design_scores_gemma":[0.0000060753496,0.000009658329,0.9989587,0.00003316492,0.000021677652,0.000016487793,0.00042412415,0.00016284572,0.000010200801,0.000014982199,0.00033623003,0.000005850876],"about_ca_topic_score_codex":0.99687356,"about_ca_topic_score_gemma":0.9979632,"teacher_disagreement_score":0.031231299,"about_ca_system_score_codex":0.031231299,"about_ca_system_score_gemma":0.043148506,"threshold_uncertainty_score":0.22659999},"labels":[],"label_agreement":null},{"id":"W4411926911","doi":"10.1111/dom.16586","title":"Male–female differences in insulin sensitivity and β‐cell function in <scp>US</scp> elders with and without abdominal obesity: An exploratory study with an in‐depth race/ethnicity analysis","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Obesity and Health Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Ethnic group; Race (biology); Insulin sensitivity; Exploratory analysis; Obesity; Internal medicine; Endocrinology; Gerontology; Insulin resistance; Gender studies","score_opus":0.0348069362960227,"score_gpt":0.3221611709363408,"score_spread":0.28735423464031806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411926911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8520448,0.002128741,0.0003982405,0.11917452,0.0015929239,0.00009674396,0.006078981,0.00002966146,0.018455379],"genre_scores_gemma":[0.9290206,0.0014283061,0.0005577643,0.0515863,0.0017735587,0.00024208208,0.0010976162,0.000019985453,0.014273871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993618,0.00023988694,0.00007026051,0.000070688904,0.00014524437,0.000112111746],"domain_scores_gemma":[0.99747485,0.0012484157,0.00035138876,0.00011896884,0.00051983725,0.00028650564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011427351,0.00012076705,0.0002562296,0.00045627196,0.0008241421,0.00036933145,0.00018823735,0.0010508063,0.0058959965],"category_scores_gemma":[0.0056492058,0.00013374533,0.0002140622,0.000742075,0.00025346671,0.0003560625,0.00028561213,0.00079270947,0.0012546972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057559804,0.00018698092,0.87167853,0.000052912736,0.00003444086,0.0016715599,0.0010632816,0.00002629161,0.0003394649,0.0003097101,0.094258435,0.02980273],"study_design_scores_gemma":[0.000084124105,0.00046398284,0.96585935,0.0001589753,0.000044880828,0.0036109595,0.0032677292,0.00022688397,0.00025104906,0.00088237727,0.025119796,0.000029812516],"about_ca_topic_score_codex":0.009959275,"about_ca_topic_score_gemma":0.022858245,"teacher_disagreement_score":0.009959275,"about_ca_system_score_codex":0.0004895565,"about_ca_system_score_gemma":0.0005915191,"threshold_uncertainty_score":0.01980263},"labels":[],"label_agreement":null},{"id":"W4412039181","doi":"10.1111/dom.16556","title":"<scp>GABA</scp> ameliorates diet‐induced hepatic steatosis and insulin resistance by inhibiting macrophage activation","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"GABA and Rice Research","field":"Agricultural and Biological Sciences","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Natural Science Foundation of China","keywords":"Internal medicine; Endocrinology; Insulin resistance; Steatosis; TLR4; Inflammation; Tumor necrosis factor alpha; Fatty liver; Downregulation and upregulation; Medicine; Insulin; Biology; Biochemistry","score_opus":0.010259452201056266,"score_gpt":0.22263661944470367,"score_spread":0.2123771672436474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412039181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766783,0.009590402,0.0029650237,0.0013594131,0.00035221258,0.00012667246,0.0022647716,0.0007500265,0.0059131877],"genre_scores_gemma":[0.9771499,0.0057576504,0.0035971233,0.00071758893,0.00010847185,0.00018663437,0.0017771618,0.0001281769,0.010577334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990916,0.000017175997,0.000011867142,0.000014615486,0.000023056144,0.00002415353],"domain_scores_gemma":[0.9999186,0.000006837119,0.00002445771,0.000008990223,0.000013582149,0.00002757541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008770951,0.00054920505,0.0005885016,0.00046315492,0.00019075077,0.0002491439,0.00027507555,0.00043335982,0.003867436],"category_scores_gemma":[0.000093609495,0.00014810993,0.0003311009,0.00024398888,0.00030349728,0.00024400682,0.00019107116,0.0012201541,0.000790384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039696135,0.00047641018,0.00020564595,0.00045166904,0.00009473233,0.00023070163,0.000014304693,0.00017704575,0.97952133,0.00027643907,0.0011290326,0.0134530645],"study_design_scores_gemma":[0.0011617212,0.007914367,0.008666919,0.00012152061,0.00021476446,0.0012109008,0.00008823436,0.0014882862,0.95580965,0.0004751743,0.022810098,0.00003826632],"about_ca_topic_score_codex":0.0012085768,"about_ca_topic_score_gemma":0.0017614741,"teacher_disagreement_score":0.003867436,"about_ca_system_score_codex":0.00021649286,"about_ca_system_score_gemma":0.00036620203,"threshold_uncertainty_score":0.012937903},"labels":[],"label_agreement":null},{"id":"W4412137963","doi":"10.1111/dom.16589","title":"Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Postprandial; Adipose tissue; Internal medicine; Subcutaneous adipose tissue; Endocrinology; Glucagon-like peptide-1; Glucagon; Subcutaneous tissue; Diabetes mellitus; Type 2 diabetes; Insulin; Pathology","score_opus":0.006408039506782344,"score_gpt":0.22035362042486573,"score_spread":0.21394558091808338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412137963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983909,0.00077233725,0.0004250554,0.000035030404,0.000007638829,0.0000068895783,0.000037018326,0.000009617563,0.0003156304],"genre_scores_gemma":[0.9990926,0.00018377558,0.00025338135,0.000019040246,0.000013475391,0.000010360772,0.000044879944,0.000002434222,0.0003801351],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999187,0.000035224584,0.0000042725173,0.000018115916,0.000011210175,0.000012432342],"domain_scores_gemma":[0.9998704,0.000029914318,0.000041008967,0.000011133671,0.000009900924,0.00003767475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026940388,0.00023064435,0.0002092872,0.00017793455,0.000117801756,0.00018783091,0.00009745252,0.00015081526,0.0016921584],"category_scores_gemma":[0.00020272836,0.00013969294,0.00017552233,0.00009107052,0.00018555702,0.00011829637,0.000110135144,0.00025769812,0.00016959969],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014712386,0.0003264758,0.041653484,0.00015435822,0.00007349864,0.00083273434,0.00019798095,0.0001557228,0.9144195,0.00015689657,0.00020373908,0.027113251],"study_design_scores_gemma":[0.0003719183,0.004290861,0.92252326,0.0000177132,0.00012720417,0.0019879017,0.00023667794,0.0016877097,0.06758779,0.00036553957,0.0007832014,0.000020281557],"about_ca_topic_score_codex":0.00027496513,"about_ca_topic_score_gemma":0.00013726561,"teacher_disagreement_score":0.0016921584,"about_ca_system_score_codex":0.00009545377,"about_ca_system_score_gemma":0.000061022405,"threshold_uncertainty_score":0.0056607723},"labels":[],"label_agreement":null},{"id":"W4412387251","doi":"10.1111/dom.16604","title":"Persisting plasma proinsulin levels in a cohort of 482 individuals with long‐standing type 1 diabetes mellitus","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"H2020 European Research Council; Canadian Institutes of Health Research; Novo Nordisk; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Nierstichting; Amsterdam University Medical Centers","keywords":"Proinsulin; Medicine; Internal medicine; C-peptide; Endocrinology; Type 2 Diabetes Mellitus; Insulin; Diabetes mellitus; Prohormone; Insulin resistance; Cohort; Hormone","score_opus":0.006606379954291627,"score_gpt":0.2191964284383908,"score_spread":0.21259004848409918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412387251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996176,0.000111720605,0.000035901045,0.000008761582,0.000003336656,0.0000030447657,0.00012349714,0.000001658419,0.00009438147],"genre_scores_gemma":[0.9995121,0.00007077496,0.000045582063,0.000016168591,0.000007896628,0.000005640038,0.00020170967,0.000001483905,0.00013882274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997731,0.000034765573,0.000022369453,0.00009617647,0.000037631475,0.000035882254],"domain_scores_gemma":[0.99928194,0.000103577426,0.00027173787,0.00009506992,0.00006586067,0.00018181073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039036787,0.0003304046,0.00035239157,0.00058383966,0.0005867265,0.0006665273,0.00028365693,0.00049268716,0.0013299217],"category_scores_gemma":[0.0009923952,0.00037573004,0.00029855815,0.00066917186,0.00027275467,0.00045001262,0.00038830886,0.0006675772,0.00032630636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010231631,0.000019239356,0.9988034,0.0000041692074,0.000022841725,0.00007704467,0.00006382283,0.000012131703,0.00036070205,0.0000031290965,0.000024527384,0.00050664647],"study_design_scores_gemma":[0.000005035918,0.00013100108,0.999223,0.0000029070457,0.000019131852,0.00033740417,0.00012160511,0.00004484182,0.0000407635,0.000007104127,0.000064660104,0.0000024914104],"about_ca_topic_score_codex":0.0030255471,"about_ca_topic_score_gemma":0.002347009,"teacher_disagreement_score":0.0030255471,"about_ca_system_score_codex":0.00015733302,"about_ca_system_score_gemma":0.00014224144,"threshold_uncertainty_score":0.006015897},"labels":[],"label_agreement":null},{"id":"W4412389382","doi":"10.1111/dom.16605","title":"Differential effects of a multidomain intervention on cognitive decline in older adults with type 2 diabetes according to white matter hyperintensity status: A secondary analysis of the J‐ <scp>MIND</scp> ‐Diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Japan Society for the Promotion of Science; National Center for Geriatrics and Gerontology; Japan Agency for Medical Research and Development","keywords":"Medicine; Type 2 diabetes; Dementia; Randomized controlled trial; Cognitive decline; Physical therapy; Neuropsychology; Diabetes mellitus; Cognition; Hyperintensity; Gerontology; Internal medicine; Psychiatry; Disease; Magnetic resonance imaging","score_opus":0.003608446829115093,"score_gpt":0.24624485721727485,"score_spread":0.24263641038815975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412389382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773717,0.00061873754,0.00014602575,0.000054277323,0.000062343424,0.000636127,0.00044023394,0.0000112498,0.00029393326],"genre_scores_gemma":[0.996031,0.0003739972,0.0004989831,0.00016297333,0.00010885735,0.0015416752,0.00069605117,0.0000043563828,0.0005820097],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982743,0.00089661585,0.00020153887,0.000239442,0.00015306541,0.0002349418],"domain_scores_gemma":[0.9981377,0.000624033,0.00050603825,0.00017445038,0.00025450057,0.0003032128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023374455,0.0009922392,0.0023917833,0.0007471467,0.000508621,0.00072350935,0.0004791456,0.0010478162,0.0023865802],"category_scores_gemma":[0.003243576,0.0003562117,0.0049867583,0.00060416094,0.00035990097,0.00035332472,0.0007530532,0.0010923751,0.00018084815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8538076,0.033621,0.060352586,0.002254728,0.017323608,0.00010488679,0.0002727373,0.00063083286,0.0025158478,0.000080243284,0.00078714173,0.028248785],"study_design_scores_gemma":[0.25681117,0.24239436,0.4720381,0.0002580143,0.02252746,0.00007963701,0.0001980131,0.0017238741,0.002592351,0.00020358377,0.0011121829,0.00006120778],"about_ca_topic_score_codex":0.004202158,"about_ca_topic_score_gemma":0.0063919113,"teacher_disagreement_score":0.004202158,"about_ca_system_score_codex":0.0006301948,"about_ca_system_score_gemma":0.0011879711,"threshold_uncertainty_score":0.012361705},"labels":[],"label_agreement":null},{"id":"W4412487404","doi":"10.1111/dom.16608","title":"Prevalence of <scp>SGLT2</scp> inhibitor and <scp>GLP1</scp> receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Faculty of Medicine and Health, University of Sydney; Eli Lilly Australia; George Institute for Global Health; University of Melbourne; Boehringer Ingelheim; Australian Government; Australian Commission on Safety and Quality in Health Care; University of New South Wales; Ian Potter Foundation; David and Elaine Potter Foundation; Eli Lilly and Company","keywords":"Medicine; Renal function; Kidney disease; Internal medicine; Type 2 diabetes; Population; Medical prescription; Diabetes mellitus; Creatinine; Endocrinology; Urology; Gastroenterology; Pharmacology","score_opus":0.006482020705146322,"score_gpt":0.2306823558687402,"score_spread":0.22420033516359386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412487404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941216,0.00025917197,0.00007432912,0.00009677099,0.0000046784035,0.000038876813,0.005065517,0.000005138956,0.00033391136],"genre_scores_gemma":[0.995181,0.00023281395,0.00018775258,0.00010381059,0.000009214496,0.00007096423,0.0040176287,0.00000353269,0.00019325837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764675,0.0006171288,0.00043691217,0.00057687535,0.00046353127,0.00025865878],"domain_scores_gemma":[0.9943615,0.00079207454,0.0030617958,0.00045695514,0.0006774721,0.00065013196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016235582,0.00034673637,0.0008585876,0.0017848501,0.00064865727,0.0011284336,0.001173834,0.0008688043,0.0012748095],"category_scores_gemma":[0.0055348943,0.0007259623,0.001439993,0.004094975,0.0004929164,0.0007489306,0.0022816577,0.0010509302,0.0002476814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006342872,0.000025955042,0.9985061,0.000054834745,0.000144101,0.000060219074,0.00023298844,0.00007402786,0.00009203924,0.000019211506,0.0002529688,0.0004741408],"study_design_scores_gemma":[0.0000056430413,0.000021818996,0.9993569,0.000011356527,0.000029848443,0.00008420203,0.00013145256,0.00023769456,0.000013716155,0.0000074139743,0.00009671145,0.0000032768987],"about_ca_topic_score_codex":0.14314345,"about_ca_topic_score_gemma":0.11914273,"teacher_disagreement_score":0.14314345,"about_ca_system_score_codex":0.0012962383,"about_ca_system_score_gemma":0.0011638852,"threshold_uncertainty_score":0.28462052},"labels":[],"label_agreement":null},{"id":"W4412514208","doi":"10.1111/dom.16627","title":"A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Obesity; Intensive care medicine; Internal medicine","score_opus":0.029851293783844077,"score_gpt":0.2933600414834586,"score_spread":0.2635087476996145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412514208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88498497,0.04001044,0.0020294446,0.00419129,0.00022936244,0.0023758165,0.048781946,0.000107181455,0.017289544],"genre_scores_gemma":[0.9813183,0.0076034674,0.0015866312,0.00046290504,0.00003986274,0.00030809906,0.0072799083,0.000016047743,0.0013846941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696845,0.00078732806,0.0002073442,0.00022467389,0.001098445,0.00071377656],"domain_scores_gemma":[0.9963887,0.001125671,0.0005365333,0.00006926144,0.0012801503,0.00059970206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002092959,0.00088965567,0.0013779026,0.0027268208,0.0010024336,0.0017193281,0.0013907419,0.0008174463,0.0045544854],"category_scores_gemma":[0.00930278,0.00047420518,0.004088256,0.0060312436,0.0007116741,0.00046416768,0.0007785247,0.0012135318,0.000115072755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044150084,0.0029391511,0.42179248,0.013328351,0.02411281,0.0009419227,0.0004520261,0.21102805,0.0019128887,0.013868436,0.036502536,0.22897129],"study_design_scores_gemma":[0.0133854635,0.0051378272,0.76947093,0.0027280904,0.02169975,0.00078232464,0.0012574024,0.162703,0.0012287252,0.002910998,0.018299874,0.00039567903],"about_ca_topic_score_codex":0.9800624,"about_ca_topic_score_gemma":0.97517437,"teacher_disagreement_score":0.10748589,"about_ca_system_score_codex":0.10748589,"about_ca_system_score_gemma":0.07952694,"threshold_uncertainty_score":0.77986836},"labels":[],"label_agreement":null},{"id":"W4412514240","doi":"10.1111/dom.16623","title":"Improved glycemic regulation on exercise compared to non‐exercise days in a real‐world setting in individuals recently diagnosed with type 2 diabetes: A secondary analysis of the <scp>MOTIVATE T2D</scp> randomised controlled trial","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Okanagan University College; Kelowna General Hospital; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"Medical Research Council; Canadian Institutes of Health Research","keywords":"Medicine; Type 2 diabetes; Glycemic; Physical therapy; Diabetes mellitus; Physical medicine and rehabilitation; Endocrinology","score_opus":0.010300296114305461,"score_gpt":0.25189338613509543,"score_spread":0.24159309002078996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412514240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9316634,0.0138351,0.002216077,0.0008438552,0.0016785098,0.03423858,0.010466194,0.00018989912,0.004868365],"genre_scores_gemma":[0.9432239,0.002802303,0.003335144,0.0011351125,0.00090737664,0.041892726,0.0044566207,0.000043334137,0.0022035358],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954489,0.002504192,0.0005758164,0.0006392355,0.00051149854,0.00032046592],"domain_scores_gemma":[0.99572927,0.0016645398,0.0011616858,0.00045180542,0.0005462833,0.00044642677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062412675,0.0018243551,0.0049701836,0.00069326506,0.00066053245,0.0014945342,0.0009073002,0.0019022713,0.007967108],"category_scores_gemma":[0.010327656,0.00059071125,0.006159743,0.0011566724,0.0009234934,0.0010824172,0.0008749565,0.0022508532,0.0007704062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9752098,0.0025650274,0.0021488213,0.0042985156,0.007848908,0.000037222573,0.00007662301,0.00013631316,0.0006509412,0.00013898298,0.0010309662,0.0058579776],"study_design_scores_gemma":[0.9001974,0.06196636,0.022174135,0.00046782833,0.011963164,0.000058749487,0.00007206668,0.0004560699,0.00043222282,0.00037151572,0.0017920403,0.000048468533],"about_ca_topic_score_codex":0.002072613,"about_ca_topic_score_gemma":0.0032806885,"teacher_disagreement_score":0.007967108,"about_ca_system_score_codex":0.0008483123,"about_ca_system_score_gemma":0.0014803283,"threshold_uncertainty_score":0.033007324},"labels":[],"label_agreement":null},{"id":"W4412638791","doi":"10.1111/dom.16621","title":"Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"Novo Nordisk","keywords":"Mace; Semaglutide; Medicine; Placebo; Myocardial infarction; Internal medicine; Population; Body mass index; Post-hoc analysis; Heart failure; Type 2 diabetes; Cardiology; Diabetes mellitus; Endocrinology; Percutaneous coronary intervention","score_opus":0.0035217352849685655,"score_gpt":0.22256093028326052,"score_spread":0.21903919499829194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412638791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654166,0.021623204,0.0020711327,0.0003000315,0.00091267086,0.0014590392,0.00503226,0.0002545215,0.0029305753],"genre_scores_gemma":[0.9915787,0.0022307124,0.0012188519,0.0003359573,0.00027210594,0.0011121808,0.0014990183,0.00004010445,0.001712345],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99726546,0.0014552163,0.00031807538,0.0005028867,0.00023168632,0.00022664589],"domain_scores_gemma":[0.99782556,0.001044371,0.0005031202,0.00026914474,0.00019597828,0.000161711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005271973,0.0018456578,0.006875389,0.00049307407,0.00024305945,0.0012857364,0.0006918503,0.0011980776,0.0039042654],"category_scores_gemma":[0.0041929535,0.0006396591,0.011508339,0.0005531626,0.0005512525,0.0008738838,0.00068581256,0.0018655175,0.00039614367],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9079201,0.0006171792,0.003679202,0.002581847,0.07319969,0.000060823222,0.00003567965,0.0005713208,0.0028052703,0.00007569276,0.0007798194,0.0076734037],"study_design_scores_gemma":[0.33189762,0.16795914,0.1391061,0.0006069916,0.34005973,0.00024313596,0.00018053631,0.00737588,0.0067082467,0.0010739506,0.0045762234,0.00021239585],"about_ca_topic_score_codex":0.0012594806,"about_ca_topic_score_gemma":0.0027788298,"teacher_disagreement_score":0.006875389,"about_ca_system_score_codex":0.00053929735,"about_ca_system_score_gemma":0.00071037107,"threshold_uncertainty_score":0.027881205},"labels":[],"label_agreement":null},{"id":"W4412726703","doi":"10.1111/dom.16660","title":"Evaluating biased agonism of glucagon‐like peptide‐1 ( <scp>GLP</scp> ‐1) receptors to improve cellular bioenergetics: A systematic review","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Receptor Mechanisms and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Medicine; Agonism; Glucagon-like peptide-1; Receptor; Bioenergetics; Exenatide; Pharmacology; Endocrinology; Internal medicine; Cell biology; Diabetes mellitus; Type 2 diabetes; Biology","score_opus":0.01946024597199198,"score_gpt":0.294103723815944,"score_spread":0.27464347784395204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412726703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011947122,0.99711406,0.00020100709,0.00018911486,0.000090402486,0.00040191237,0.00047697677,0.000010502629,0.00032142844],"genre_scores_gemma":[0.0098789185,0.98792773,0.00049525575,0.0005630204,0.00006999565,0.00059208705,0.00027667847,0.0000071351787,0.00018929003],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971046,0.0007902582,0.0012229712,0.00024763774,0.0005090489,0.00012541402],"domain_scores_gemma":[0.99020505,0.006568118,0.0019066405,0.00013932693,0.0010354486,0.00014548116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048358585,0.0014305825,0.008887222,0.0058909543,0.00054072775,0.0022527848,0.0017950756,0.0017174688,0.0060936217],"category_scores_gemma":[0.015814124,0.0006680399,0.007811512,0.0069728564,0.00070698484,0.0018688177,0.0012274354,0.0008680199,0.00050398585],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002795186,0.00001381076,0.00028981993,0.96783763,0.0065639066,0.00007086646,0.00007254376,0.00006205795,0.00026129218,0.00011959749,0.000825658,0.023603184],"study_design_scores_gemma":[0.00048643284,0.00039981422,0.0023488763,0.8636187,0.113548614,0.00037526438,0.0001692551,0.000085069805,0.00034469066,0.0003273028,0.018256625,0.00003944913],"about_ca_topic_score_codex":0.0054027885,"about_ca_topic_score_gemma":0.017294632,"teacher_disagreement_score":0.008887222,"about_ca_system_score_codex":0.0023029197,"about_ca_system_score_gemma":0.008391707,"threshold_uncertainty_score":0.025574744},"labels":[],"label_agreement":null},{"id":"W4412727804","doi":"10.1111/dom.16649","title":"Lack of evidence for obesity paradox in patients with cardiovascular disease: A <scp>UK BioBank</scp> cohort study","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Genetic Associations and Epidemiology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary; Alberta Health Services","funders":"National Natural Science Foundation of China","keywords":"Medicine; Biobank; Cohort; Disease; Obesity; Cohort study; Internal medicine; Bioinformatics","score_opus":0.025935746169836713,"score_gpt":0.2775707495157185,"score_spread":0.25163500334588174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412727804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896507,0.0021754848,0.0004146548,0.0008196049,0.000078473335,0.000062123996,0.0054906206,0.000021436785,0.0012868778],"genre_scores_gemma":[0.99451256,0.00053022726,0.0003328197,0.0005015602,0.000086410175,0.00009512191,0.003512634,0.00001990146,0.00040882002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564314,0.0019795334,0.00051837077,0.0009988867,0.00057659706,0.00028355682],"domain_scores_gemma":[0.98561966,0.0031336022,0.005223199,0.003331776,0.0013249604,0.0013667662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044655404,0.0006530477,0.0011746354,0.0012016246,0.0011445753,0.0020403264,0.0013488599,0.001412103,0.0054628123],"category_scores_gemma":[0.0163664,0.00066922925,0.0009262206,0.002772136,0.0008704479,0.00092077977,0.0017477876,0.0010511185,0.00079570414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020602364,0.000058790552,0.98899287,0.00014866714,0.0012624871,0.00058982143,0.00038422729,0.00006585084,0.0005408545,0.00020162408,0.0030997957,0.0025947327],"study_design_scores_gemma":[0.0002836367,0.00021104823,0.9959674,0.00008808923,0.0005715193,0.0008652024,0.00018502292,0.00020520716,0.000062866464,0.00013357848,0.0014054634,0.00002104548],"about_ca_topic_score_codex":0.018296663,"about_ca_topic_score_gemma":0.019869335,"teacher_disagreement_score":0.018296663,"about_ca_system_score_codex":0.000701153,"about_ca_system_score_gemma":0.00093162525,"threshold_uncertainty_score":0.03638035},"labels":[],"label_agreement":null},{"id":"W4412943684","doi":"10.1111/dom.70008","title":"Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; University of British Columbia; McGill University; Jewish General Hospital; Trillium Health Centre; University of Toronto; Western University; St. Michael's Hospital; LMC Diabetes & Endocrinology (Canada)","funders":"Abbott Canada","keywords":"Medicine; Observational study; Meta-analysis; Randomized controlled trial; Type 2 diabetes; Internal medicine; Continuous glucose monitoring; Subgroup analysis; Systematic review; Type 2 Diabetes Mellitus; Diabetes mellitus; MEDLINE; Insulin; Glycemic; Endocrinology","score_opus":0.09041100860655103,"score_gpt":0.39798537852435506,"score_spread":0.307574369917804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412943684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048321064,0.998126,0.0003108982,0.0003085735,0.00020603549,0.00030965247,0.00015900022,0.00001121281,0.00008539987],"genre_scores_gemma":[0.02374883,0.9693979,0.0031308196,0.0012659637,0.0003378892,0.0016452085,0.000341093,0.000022309376,0.000110005974],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96063834,0.017578762,0.014457724,0.0023313127,0.004400702,0.0005931228],"domain_scores_gemma":[0.9044264,0.06569942,0.01853355,0.002032623,0.008749868,0.00055809057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04524095,0.0030132844,0.020766702,0.010728369,0.0007077357,0.004764398,0.0034268247,0.003162061,0.0038750102],"category_scores_gemma":[0.11686441,0.0022089605,0.021763908,0.010056123,0.0011937306,0.0038380418,0.0022571418,0.002544691,0.00034087215],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087295816,0.000021174368,0.00086341664,0.85541636,0.109399915,0.0000750363,0.000120892255,0.0002530515,0.0001365583,0.00028537758,0.0017833097,0.030771827],"study_design_scores_gemma":[0.0013136646,0.00032968234,0.0030123307,0.45259646,0.53009653,0.00020131544,0.00012639625,0.00029316486,0.00022998588,0.00078856223,0.0109305,0.0000813398],"about_ca_topic_score_codex":0.006236857,"about_ca_topic_score_gemma":0.012980402,"teacher_disagreement_score":0.04524095,"about_ca_system_score_codex":0.005451557,"about_ca_system_score_gemma":0.010592579,"threshold_uncertainty_score":0.2392599},"labels":[],"label_agreement":null},{"id":"W4412943903","doi":"10.1111/dom.70013","title":"Glucagon‐like peptide‐1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta‐analysis of observational studies","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Intraoperative Neuromonitoring and Anesthetic Effects","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bruyère; Queensway-Carleton Hospital; LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Anterior ischemic optic neuropathy; Observational study; Meta-analysis; Optic neuropathy; Internal medicine; Ophthalmology; Optic nerve","score_opus":0.0428331031382486,"score_gpt":0.33048534707194094,"score_spread":0.2876522439336923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412943903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024617207,0.9962633,0.00021833203,0.00021515692,0.00011235051,0.00007811313,0.00049442385,0.0000083369405,0.00014823354],"genre_scores_gemma":[0.054742616,0.9424861,0.0007519533,0.00040217143,0.00022652766,0.00036839195,0.0008078749,0.00001306013,0.00020130981],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9948472,0.0023769513,0.0013819415,0.0005598035,0.00064489513,0.00018920153],"domain_scores_gemma":[0.9821175,0.013921564,0.002170611,0.00039947656,0.0012301278,0.00016074411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008826818,0.0016121354,0.008324894,0.004163252,0.00042140053,0.0019684657,0.0012412143,0.0012707417,0.0033457533],"category_scores_gemma":[0.022229712,0.0009420265,0.018568719,0.0069377613,0.0003412194,0.0009880564,0.0008830774,0.0011848226,0.00025915305],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020932646,0.000036488957,0.010634046,0.50253785,0.44041064,0.00019987416,0.00010121709,0.00052573596,0.00028510153,0.00022540508,0.0036404268,0.03930998],"study_design_scores_gemma":[0.0005703565,0.00021017308,0.013738227,0.057490584,0.92123425,0.0002042939,0.00007538063,0.00027842456,0.0001633597,0.00038554196,0.005610833,0.000038622125],"about_ca_topic_score_codex":0.0045427317,"about_ca_topic_score_gemma":0.011093425,"teacher_disagreement_score":0.008826818,"about_ca_system_score_codex":0.0011497242,"about_ca_system_score_gemma":0.002653009,"threshold_uncertainty_score":0.046681225},"labels":[],"label_agreement":null},{"id":"W4413117037","doi":"10.1111/dom.16597","title":"Adherence to app‐based dose guidance for once‐weekly insulin icodec in insulin‐naive individuals with type 2 diabetes: Post hoc analysis of <scp>ONWARDS</scp> 5","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk","keywords":"Medicine; Insulin; Type 2 diabetes; Post-hoc analysis; Diabetes mellitus; Post hoc; Internal medicine; Endocrinology","score_opus":0.025197492805653105,"score_gpt":0.357253434947003,"score_spread":0.3320559421413499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413117037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689806,0.00027344102,0.00031194667,0.00007711677,0.000053265576,0.00049205817,0.0012112685,0.000022926528,0.00066008285],"genre_scores_gemma":[0.99502003,0.000136412,0.0006472717,0.00018942037,0.00004642654,0.0011790033,0.0015205194,0.000019385383,0.0012414942],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969105,0.001804316,0.00021915813,0.00046430566,0.00032377275,0.00027798058],"domain_scores_gemma":[0.9950623,0.0022059327,0.001092406,0.00080401,0.00041388033,0.0004215052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043758354,0.0007115317,0.0013826947,0.000200817,0.00039099168,0.00090594444,0.0006724281,0.0009707618,0.004523295],"category_scores_gemma":[0.008562001,0.00047793947,0.0041785142,0.00037871787,0.0003735972,0.0006508705,0.00076348905,0.002027228,0.00052071974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8601801,0.009119618,0.06873908,0.0014299963,0.010648312,0.0000857994,0.0008439827,0.0008111782,0.0025113437,0.000110014276,0.0034010382,0.04211959],"study_design_scores_gemma":[0.10338793,0.2297941,0.633802,0.00038142432,0.02045309,0.00012855834,0.0005495298,0.004714141,0.0025940104,0.0003093684,0.0037389856,0.00014687481],"about_ca_topic_score_codex":0.0054715914,"about_ca_topic_score_gemma":0.005874354,"teacher_disagreement_score":0.0054715914,"about_ca_system_score_codex":0.00058170897,"about_ca_system_score_gemma":0.0010438389,"threshold_uncertainty_score":0.023141861},"labels":[],"label_agreement":null},{"id":"W4413358799","doi":"10.1111/dom.16652","title":"Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel <scp>GLP</scp> ‐ <scp>1R</scp> / <scp>GIPR</scp> dual agonist, <scp>HISHS</scp> ‐2001","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Division of Diabetes, Endocrinology, and Metabolic Diseases; Institute of Nutrition, Metabolism and Diabetes; National Institute of Diabetes and Digestive and Kidney Diseases; Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; Eli Lilly and Company; Society for Endocrinology; Diabetes UK; Wellcome Trust; Canada Foundation for Innovation","keywords":"Receptor; Incretin; Agonist; Internalization; Internal medicine; Endocrinology; G protein-coupled receptor; Insulin; In vivo; Downregulation and upregulation; Glucagon-like peptide-1; Medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Pharmacology; Diabetes mellitus; Chemistry; Biology; Biochemistry","score_opus":0.011660221750556832,"score_gpt":0.23365995100454845,"score_spread":0.2219997292539916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413358799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969637,0.0005653653,0.0012961768,0.000040436847,0.000009515754,0.000022326576,0.00022512152,0.0000179485,0.00085953873],"genre_scores_gemma":[0.99231076,0.00074037374,0.0028839589,0.000054341213,0.000008348648,0.000036186764,0.0006570511,0.000015391375,0.0032936032],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998264,0.000049091363,0.000017231112,0.000029770079,0.000041908457,0.00003557301],"domain_scores_gemma":[0.99985397,0.00006059413,0.00003353287,0.000015719912,0.000014774012,0.00002141297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025934732,0.00023480783,0.00016691328,0.00009791025,0.00009535361,0.00021694621,0.00018060156,0.00025363592,0.0010718987],"category_scores_gemma":[0.00019051175,0.00015487763,0.00015951277,0.000123444,0.00013186029,0.00014958472,0.00007044029,0.0003640854,0.00038629776],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002841856,0.000035816916,0.00006576748,0.0000253301,0.000004936335,0.000022466493,0.000012771354,0.00017970102,0.9984353,0.000050591956,0.000034297875,0.0008487762],"study_design_scores_gemma":[0.00002158605,0.00068280986,0.0011638033,0.0000026453038,0.000010003687,0.00010657307,0.00001312747,0.0012586842,0.9960418,0.000009472502,0.0006842763,0.000005298649],"about_ca_topic_score_codex":0.00050239224,"about_ca_topic_score_gemma":0.00041100898,"teacher_disagreement_score":0.0010718987,"about_ca_system_score_codex":0.00031630992,"about_ca_system_score_gemma":0.00012552601,"threshold_uncertainty_score":0.003585875},"labels":[],"label_agreement":null},{"id":"W4413800920","doi":"10.1111/dom.70063","title":"Impact of tirzepatide treatment on participant‐reported food craving and food preference: Secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diet and metabolism studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Almond Board of California; Patient-Centered Outcomes Research Institute; Eli Lilly and Company; National Institute for Health and Care Research; WW International; Henry M. Jackson Foundation; Leona M. and Harry B. Helmsley Charitable Trust; National Institutes of Health; National Science Foundation","keywords":"Medicine; Placebo; Weight loss; Craving; Appetite; Obesity; Calorie; Internal medicine; Weight management; Type 2 diabetes; Randomized controlled trial; Glucagon-like peptide-1; Diabetes mellitus; Endocrinology; Psychiatry; Alternative medicine","score_opus":0.0654914884206259,"score_gpt":0.3232958927812491,"score_spread":0.2578044043606232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413800920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537961,0.008221098,0.0017221202,0.00046706683,0.00063820014,0.023761533,0.0081188595,0.00021260387,0.0030624743],"genre_scores_gemma":[0.9580699,0.002705764,0.0025487505,0.0007533431,0.0004179157,0.029205853,0.0038074127,0.000054169566,0.0024369322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966286,0.0017215325,0.000393261,0.0005280494,0.00035169287,0.00037690965],"domain_scores_gemma":[0.99599826,0.001180293,0.0013332916,0.0004641162,0.0005243631,0.00049980346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063369065,0.002615042,0.0052096597,0.00081425294,0.00075407285,0.0014555411,0.0012989164,0.0020901223,0.009141164],"category_scores_gemma":[0.007701978,0.0009319742,0.0076454035,0.00095809647,0.0010465009,0.0012381768,0.0007754283,0.00318121,0.00096205814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98046416,0.0029439065,0.0016422078,0.0016572373,0.006531641,0.000034875935,0.000060396917,0.0001780374,0.0011614076,0.000044985976,0.0005420638,0.004739114],"study_design_scores_gemma":[0.88629067,0.08223314,0.01908131,0.00012952813,0.009654089,0.00006159364,0.00005872958,0.00044397058,0.000706885,0.00024435957,0.0010352713,0.000060386414],"about_ca_topic_score_codex":0.0016364012,"about_ca_topic_score_gemma":0.0033643062,"teacher_disagreement_score":0.009141164,"about_ca_system_score_codex":0.0008743306,"about_ca_system_score_gemma":0.0014313918,"threshold_uncertainty_score":0.03351319},"labels":[],"label_agreement":null},{"id":"W4414023851","doi":"10.1111/dom.70103","title":"Olfactory training improves cognition and modifies brain networks in type 2 diabetes patients with mild cognitive impairment: A 16‐week randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Olfactory and Sensory Function Studies","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fundamental Research Funds for the Central Universities","keywords":"Medicine; Cognition; Montreal Cognitive Assessment; Population; Effects of sleep deprivation on cognitive performance; Neuropsychology; Neuroimaging; Cognitive training; Audiology; Internal medicine; Psychiatry; Cognitive impairment","score_opus":0.038471055822457,"score_gpt":0.23091209854980024,"score_spread":0.19244104272734325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414023851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891216,0.005520903,0.0002977909,0.0003962329,0.0006105659,0.00250516,0.00059594767,0.000066711145,0.000885049],"genre_scores_gemma":[0.98419106,0.0046340716,0.0010347114,0.00094689295,0.0006859698,0.0048035122,0.0006614723,0.000012779806,0.0030294347],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99948275,0.00020967133,0.00005322796,0.00011475879,0.000043127642,0.00009642476],"domain_scores_gemma":[0.9992887,0.0001914367,0.0001692582,0.00006329804,0.000059632694,0.00022757183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014230419,0.0017499777,0.0033986468,0.00048336663,0.000586067,0.0011716383,0.0010280125,0.0023085512,0.0064957123],"category_scores_gemma":[0.0015756282,0.0006850978,0.002386099,0.00053417403,0.00095571735,0.00095571554,0.0005709822,0.002238048,0.00068929844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9812516,0.0074343043,0.0005450713,0.0006872169,0.0010330328,0.000024644612,0.000028954413,0.00010166354,0.0008544914,0.000020216965,0.00020752104,0.0078113424],"study_design_scores_gemma":[0.938868,0.056766987,0.003029782,0.000052844767,0.0005994716,0.000012919477,0.000022185093,0.00016075277,0.00015151495,0.000056902973,0.00026486994,0.000013807208],"about_ca_topic_score_codex":0.0017778592,"about_ca_topic_score_gemma":0.0028105727,"teacher_disagreement_score":0.0064957123,"about_ca_system_score_codex":0.0005521544,"about_ca_system_score_gemma":0.00071265816,"threshold_uncertainty_score":0.021730304},"labels":[],"label_agreement":null},{"id":"W4414083764","doi":"10.1111/dom.70081","title":"The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population‐based modelling study","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Hospital Authority; Hong Kong Government; Health Bureau","keywords":"Type 2 diabetes; Risk factor; Health care; Population; Control (management); Diabetes mellitus","score_opus":0.0198883013953585,"score_gpt":0.27086259360661497,"score_spread":0.25097429221125644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414083764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489474,0.00017284529,0.0017074974,0.000197969,0.000015638527,0.00006734214,0.0022958862,0.000020249436,0.00062788004],"genre_scores_gemma":[0.996252,0.00018777385,0.0012061226,0.00005553502,0.0000073504375,0.00012196349,0.0016232823,0.000007248276,0.0005387404],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9994012,0.0002920498,0.00004756882,0.00010785027,0.000032294472,0.000119025586],"domain_scores_gemma":[0.9976609,0.0012823852,0.00033225399,0.0002479612,0.00028099242,0.00019545546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030376662,0.0009287276,0.0009568608,0.00077867607,0.00047406805,0.0012187962,0.0014550104,0.00086082314,0.002481271],"category_scores_gemma":[0.0033051842,0.00063040684,0.002829279,0.0010492571,0.00044419363,0.0007172395,0.00087529636,0.0010539151,0.00027220004],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013026971,0.0008470261,0.6515512,0.0002445054,0.0030850973,0.00086137635,0.00063825614,0.33094817,0.00024814252,0.0015294383,0.0024932513,0.0062509608],"study_design_scores_gemma":[0.00043540576,0.0006851971,0.26949477,0.0001471895,0.00092572655,0.00029986733,0.0011766403,0.7243951,0.0001685514,0.00095308723,0.0012099801,0.0001085359],"about_ca_topic_score_codex":0.3255179,"about_ca_topic_score_gemma":0.1257392,"teacher_disagreement_score":0.3255179,"about_ca_system_score_codex":0.003991846,"about_ca_system_score_gemma":0.0028493013,"threshold_uncertainty_score":0.64724636},"labels":[],"label_agreement":null},{"id":"W4414085673","doi":"10.1111/dom.70121","title":"Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to <scp>HbA1c</scp> lowering in type 2 diabetes: An updated meta‐regression analysis incorporating <scp>FLOW</scp> and <scp>SOUL</scp> trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University and Génome Québec Innovation Centre; McGill Genome Centre","funders":"Canadian Institutes of Health Research; Japan Student Services Organization; Fonds de Recherche du Québec - Santé; TD Bank","keywords":"Mace; Type 2 diabetes; Clinical trial; Surrogate endpoint; Agonist","score_opus":0.01665137745857425,"score_gpt":0.25970634202639736,"score_spread":0.2430549645678231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414085673","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024520634,0.96945167,0.0020723469,0.00063672627,0.0006199477,0.00038606898,0.0012613422,0.00012851672,0.00092266547],"genre_scores_gemma":[0.60585266,0.38085443,0.005073668,0.0023623025,0.001092911,0.0012478972,0.0021618537,0.00015527598,0.0011989775],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98922765,0.006213859,0.0021343443,0.0012164955,0.00093837606,0.0002693588],"domain_scores_gemma":[0.98111767,0.014020647,0.0028812801,0.0007393545,0.0010142351,0.0002267716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016955901,0.002737201,0.013224832,0.0032290374,0.00040090084,0.0040877494,0.0017472145,0.0018720012,0.0040578917],"category_scores_gemma":[0.029269278,0.0015301382,0.04719661,0.0036551827,0.00063166535,0.0016228913,0.0011940628,0.0027254426,0.00048315173],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010912228,0.000034017936,0.003907281,0.06933169,0.90457326,0.000050678696,0.000035360405,0.0006619645,0.00026055743,0.00009996129,0.00060613605,0.009526937],"study_design_scores_gemma":[0.0032577072,0.00026360128,0.0031493239,0.002922125,0.9889783,0.000035553843,0.000014557964,0.0003498466,0.00009364206,0.00014759091,0.00076962105,0.000018195686],"about_ca_topic_score_codex":0.0039076456,"about_ca_topic_score_gemma":0.004877167,"teacher_disagreement_score":0.016955901,"about_ca_system_score_codex":0.0012288569,"about_ca_system_score_gemma":0.0013150239,"threshold_uncertainty_score":0.089672446},"labels":[],"label_agreement":null},{"id":"W4414159630","doi":"10.1111/dom.70134","title":"Association of point‐of‐care ultrasound‐derived subcutaneous fat thickness with <scp>DXA</scp> ‐measured body fat percentage in older adults","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Body Composition Measurement Techniques","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"British Columbia Centre of Excellence for Women's Health; Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"Vancouver Coastal Health Research Institute","keywords":"Ultrasound; Institutional review board; Subcutaneous fat; Magnetic resonance imaging; Body fat percentage; Hydrostatic pressure; Fat mass; Gold standard (test)","score_opus":0.004921113158432123,"score_gpt":0.20975459324745632,"score_spread":0.2048334800890242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414159630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954136,0.0028567335,0.00026191733,0.00008623157,0.000019465426,0.0000172938,0.0005834301,0.000008331451,0.000753054],"genre_scores_gemma":[0.99839324,0.00057929347,0.00026405544,0.000035658333,0.0000405997,0.000015153214,0.00041876372,0.000001989626,0.00025119595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963415,0.000097420976,0.00006604858,0.00008455771,0.000073730385,0.00004412445],"domain_scores_gemma":[0.9981975,0.0004777754,0.0007671102,0.000112397,0.00029194183,0.00015334597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009206824,0.00039064873,0.00036441756,0.00058644754,0.00024276554,0.0005231991,0.00047399168,0.0007054974,0.0015471646],"category_scores_gemma":[0.003744999,0.00021431992,0.00040308558,0.00087706244,0.00019355946,0.00037338393,0.0004200185,0.00067034026,0.00036582552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021500609,0.00002917207,0.99745136,0.000032472053,0.00006689007,0.000035447716,0.000047331887,0.000023260154,0.00009464414,0.000013562237,0.00007487354,0.0019158697],"study_design_scores_gemma":[0.0000046002215,0.00011055747,0.9992944,0.000013795185,0.000036488593,0.00016299881,0.00006595062,0.00018363801,0.000016752378,0.000018916066,0.00008961418,0.0000021896412],"about_ca_topic_score_codex":0.0059308214,"about_ca_topic_score_gemma":0.0054730084,"teacher_disagreement_score":0.0059308214,"about_ca_system_score_codex":0.00019876253,"about_ca_system_score_gemma":0.00019870832,"threshold_uncertainty_score":0.0117926},"labels":[],"label_agreement":null},{"id":"W4414160028","doi":"10.1111/dom.70117","title":"A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Diabetes Canada; University of Toronto; Trillium Health Centre; Université Laval; University of Alberta; University of Calgary","funders":"Novo Nordisk","keywords":"Multidisciplinary approach; Steatohepatitis; Disease; Multisystem disease; Disease management; Primary care; Type 2 diabetes; Identification (biology); MEDLINE","score_opus":0.008767295967723358,"score_gpt":0.2520402595369037,"score_spread":0.24327296356918032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414160028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035444074,0.9992987,0.000021485885,0.00020445985,0.00012563007,0.000004848834,0.000019025658,0.0000022191748,0.00028815895],"genre_scores_gemma":[0.00024678907,0.9993716,0.000068274814,0.00014317122,0.000061351675,0.000005470964,0.000020700436,6.809033e-7,0.000082018654],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99924976,0.00018505045,0.00018326155,0.00009080942,0.000230004,0.00006111641],"domain_scores_gemma":[0.9980494,0.0010682134,0.000303413,0.000024036612,0.00043679596,0.00011818672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012799754,0.0010435858,0.001655926,0.005748608,0.00053204823,0.0014544195,0.0011790178,0.0012015634,0.0060216403],"category_scores_gemma":[0.0037434408,0.00041499143,0.0013377405,0.0080365855,0.0004474227,0.0013257557,0.0010809994,0.0013947138,0.0009616017],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008670176,0.000061200015,0.00035232728,0.14928225,0.00030389082,0.00012971634,0.00021958225,0.0003276051,0.0001987269,0.0018827139,0.05438205,0.7927732],"study_design_scores_gemma":[0.000049541664,0.000113263864,0.004018234,0.19008692,0.00090549496,0.0011452583,0.00028394183,0.00013519154,0.000085435895,0.00095772266,0.8021783,0.000040611914],"about_ca_topic_score_codex":0.018836444,"about_ca_topic_score_gemma":0.039359972,"teacher_disagreement_score":0.98116356,"about_ca_system_score_codex":0.0024905931,"about_ca_system_score_gemma":0.0063898675,"threshold_uncertainty_score":0.03745359},"labels":[],"label_agreement":null},{"id":"W4414292494","doi":"10.1111/dom.70135","title":"Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Heart and Stroke Foundation; University of Toronto","funders":"","keywords":"Enteroendocrine cell; Clinical trial; Endogeny; Adverse effect; Glucagon-like peptide-1; Endocrine system; Hormone; In vitro","score_opus":0.02251802642745963,"score_gpt":0.3321211460644948,"score_spread":0.30960311963703513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414292494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95085853,0.022456545,0.003086002,0.002212266,0.00087969087,0.010873802,0.003188984,0.0004861319,0.005957974],"genre_scores_gemma":[0.9553555,0.013360281,0.006742026,0.00395168,0.00071642327,0.009631224,0.0046053226,0.000110393834,0.005527098],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992084,0.0003625395,0.000051602074,0.00010451259,0.00012770176,0.00014532542],"domain_scores_gemma":[0.99935,0.0001351277,0.00021064331,0.00005117661,0.00008983642,0.00016317463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025108652,0.001492907,0.0014910791,0.0004127078,0.000303701,0.0011210884,0.0007440697,0.0018371511,0.004860159],"category_scores_gemma":[0.0015641743,0.0004047038,0.0015031849,0.00047035652,0.0006284884,0.00084619026,0.0002742904,0.0023255742,0.00076357456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6386594,0.05173169,0.0035078428,0.0040998515,0.0030409673,0.0002907747,0.0002343308,0.0021429877,0.062404804,0.00076182367,0.015363682,0.2177619],"study_design_scores_gemma":[0.60872966,0.36547017,0.007164588,0.00020584553,0.0007813321,0.0001904648,0.00004259855,0.000904157,0.008228601,0.00028519955,0.007954579,0.00004282604],"about_ca_topic_score_codex":0.00043179386,"about_ca_topic_score_gemma":0.0011918684,"teacher_disagreement_score":0.004860159,"about_ca_system_score_codex":0.000794079,"about_ca_system_score_gemma":0.0009563003,"threshold_uncertainty_score":0.016258836},"labels":[],"label_agreement":null},{"id":"W4414333164","doi":"10.1111/dom.70146","title":"Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Empagliflozin; Randomized controlled trial; Gestation; Gestational age; Benzhydryl compounds; Pregnancy","score_opus":0.00959530191378957,"score_gpt":0.23369041963445186,"score_spread":0.2240951177206623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414333164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93591195,0.041815035,0.002044694,0.002616698,0.0028207225,0.009681695,0.0015370932,0.00026643497,0.0033056876],"genre_scores_gemma":[0.9628555,0.015213959,0.0027716274,0.0023193972,0.0015438873,0.0110925,0.0007141007,0.000025569783,0.0034635102],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99920976,0.00042300217,0.00007902861,0.00014165272,0.00006717722,0.00007936432],"domain_scores_gemma":[0.9992447,0.00030929493,0.0001874688,0.00006172716,0.00006019538,0.00013672127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020478356,0.0012260543,0.0033132383,0.00053253095,0.00038734297,0.0009737395,0.00074255565,0.0026987419,0.006397435],"category_scores_gemma":[0.0027557504,0.0006131226,0.0022006712,0.00046940785,0.0009713276,0.00089456927,0.00033545564,0.0018698963,0.0006229835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9812169,0.002442494,0.00025718877,0.0016663782,0.0010410738,0.000036015932,0.000021646736,0.00011593467,0.0012254184,0.00007303949,0.0003934438,0.011510522],"study_design_scores_gemma":[0.983247,0.01522158,0.00045775485,0.000057574605,0.00045934532,0.000013730026,0.0000063076286,0.000112775815,0.000106323045,0.00004396542,0.00026913136,0.000004605988],"about_ca_topic_score_codex":0.0006841841,"about_ca_topic_score_gemma":0.0010241478,"teacher_disagreement_score":0.006397435,"about_ca_system_score_codex":0.0004878734,"about_ca_system_score_gemma":0.00085963384,"threshold_uncertainty_score":0.021401525},"labels":[],"label_agreement":null},{"id":"W4414371052","doi":"10.1111/dom.70142","title":"Optimizing cardiovascular health with a type 2 diabetes remission program: Ultraprocessed food‐intake reduction, Mediterranean diet, chrononutrition and physical training—The <scp>DIABEPIC</scp> ‐2 pilot study","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Dietary Effects on Health","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Gériatrie de Montréal; Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Type 2 diabetes; Cardiovascular health; Randomized controlled trial; Diabetes mellitus; MEDLINE; Physical activity","score_opus":0.0277901829991459,"score_gpt":0.27876272054409107,"score_spread":0.2509725375449452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414371052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984994,0.00012083638,0.0001445137,0.00005983581,0.000015820231,0.00075954426,0.000087988,0.000012726166,0.00029939367],"genre_scores_gemma":[0.9907313,0.0004019884,0.0038519846,0.0002711567,0.00014062125,0.003146979,0.0005003738,0.000009093015,0.0009464745],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991202,0.00045640016,0.00005933737,0.00011082901,0.00011021987,0.00014310819],"domain_scores_gemma":[0.9990376,0.00018593537,0.00012941209,0.00008103509,0.000059103466,0.0005069304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021835775,0.00061472115,0.00064074615,0.0004497178,0.00049429527,0.00046414914,0.0007093803,0.0007637438,0.0025577536],"category_scores_gemma":[0.0012349738,0.00033924973,0.00086000166,0.0003383992,0.00030551548,0.00034390698,0.0009143592,0.0011257383,0.00028042906],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18673865,0.565657,0.02813486,0.0010473406,0.00094622397,0.00018311558,0.0006701544,0.0009867268,0.014950686,0.000111430934,0.0010481348,0.19952556],"study_design_scores_gemma":[0.19109713,0.62415415,0.17907844,0.00012047175,0.0006053493,0.00014258933,0.00019816816,0.0013852938,0.0020656157,0.000055596323,0.0010606394,0.00003664002],"about_ca_topic_score_codex":0.00229134,"about_ca_topic_score_gemma":0.0027681931,"teacher_disagreement_score":0.0025577536,"about_ca_system_score_codex":0.00038467546,"about_ca_system_score_gemma":0.001098674,"threshold_uncertainty_score":0.011547983},"labels":[],"label_agreement":null},{"id":"W4414972078","doi":"10.1111/dom.70185","title":"Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post‐hoc analysis from a double‐blinded randomized controlled trial","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canada Research Chairs","keywords":"Semaglutide; Randomized controlled trial; Placebo; Insulin pump; Type 1 diabetes; Glycemic; Diabetes mellitus; Crossover study","score_opus":0.008097921347696638,"score_gpt":0.2304328707177119,"score_spread":0.22233494937001527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414972078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9599227,0.014402883,0.0036406345,0.0007991237,0.0027308392,0.013075829,0.002840179,0.00030939313,0.0022784725],"genre_scores_gemma":[0.9681523,0.0045253364,0.00530686,0.00120966,0.0014154083,0.013893761,0.001953557,0.00012675973,0.0034163855],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9867006,0.009119988,0.0011945665,0.0012726479,0.00088141375,0.00083082204],"domain_scores_gemma":[0.9863594,0.0072859186,0.002654431,0.0014593998,0.0013054276,0.00093542377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014889224,0.0032669615,0.010860275,0.0008888333,0.0006305718,0.00200524,0.0012807912,0.0023171206,0.007940676],"category_scores_gemma":[0.014567566,0.0008944661,0.009591203,0.00092623656,0.0015409756,0.0020814291,0.0008003657,0.0031479986,0.0008822843],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9897176,0.0011857386,0.00025513794,0.00054438715,0.004344372,0.00002302021,0.00002610839,0.00011113141,0.0006454399,0.000029788065,0.00023150072,0.0028856583],"study_design_scores_gemma":[0.9003991,0.08565814,0.0032515852,0.00008577274,0.008449863,0.000028362234,0.00004439497,0.00064162933,0.0005827334,0.00016158319,0.0006497919,0.000046975747],"about_ca_topic_score_codex":0.0007045463,"about_ca_topic_score_gemma":0.001499046,"teacher_disagreement_score":0.014889224,"about_ca_system_score_codex":0.0012368159,"about_ca_system_score_gemma":0.0018185887,"threshold_uncertainty_score":0.07874268},"labels":[],"label_agreement":null},{"id":"W4415235069","doi":"10.1111/dom.70209","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the <scp>TRIUMPH</scp> registrational clinical trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Obstructive sleep apnea; Clinical trial; Disease; Obesity; Sleep apnea; MEDLINE","score_opus":0.044380771340370294,"score_gpt":0.3089905578648763,"score_spread":0.264609786524506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415235069","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049449988,0.13972844,0.059970073,0.023860618,0.0064482093,0.6843371,0.0063604014,0.0005125552,0.029332671],"genre_scores_gemma":[0.14520225,0.040438306,0.13994752,0.019025803,0.0040201475,0.6421147,0.0024172275,0.00013195706,0.0067020906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9611328,0.029876979,0.002945974,0.0018373355,0.0034060376,0.00080084347],"domain_scores_gemma":[0.9831981,0.0068747057,0.003884768,0.0017432768,0.002579226,0.0017198906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05862295,0.0016991048,0.0034438074,0.0015039794,0.0011437589,0.0038412935,0.002868713,0.0043634176,0.0051729013],"category_scores_gemma":[0.042365015,0.0011371055,0.002580369,0.0017820421,0.0023464833,0.0019751329,0.0014687888,0.00390684,0.002144056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23322569,0.008835545,0.010053504,0.04942357,0.005282236,0.00072089006,0.0010075311,0.0048302584,0.018730903,0.062578015,0.04067487,0.564637],"study_design_scores_gemma":[0.5343426,0.088293426,0.0140686575,0.019428216,0.007395815,0.0014137788,0.00038683988,0.008534161,0.008116075,0.036477275,0.28115487,0.0003883487],"about_ca_topic_score_codex":0.0005548846,"about_ca_topic_score_gemma":0.0011921637,"teacher_disagreement_score":0.05862295,"about_ca_system_score_codex":0.0014558072,"about_ca_system_score_gemma":0.0077019455,"threshold_uncertainty_score":0.31003147},"labels":[],"label_agreement":null},{"id":"W4415278127","doi":"10.1111/dom.70201","title":"Effects of <scp>GLP</scp> ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized controlled trials","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":true,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Shandong First Medical University","keywords":"Cognition; Randomized controlled trial; Type 2 diabetes; Type 2 Diabetes Mellitus; Receptor; Clinical trial","score_opus":0.013704273603037687,"score_gpt":0.2685342083474067,"score_spread":0.25482993474436905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415278127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028671445,0.99593484,0.00030769448,0.0001231618,0.00009620506,0.00025955483,0.00025346104,0.000013931597,0.00014397685],"genre_scores_gemma":[0.09844496,0.89693254,0.0019067731,0.00074694236,0.00022911988,0.0010045621,0.00053425494,0.00002061426,0.00018021544],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9910863,0.0040507214,0.0029064252,0.0008342229,0.00089098705,0.0002313694],"domain_scores_gemma":[0.98401964,0.01175413,0.002638482,0.0003993826,0.0010001891,0.0001882069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012759043,0.0030460896,0.022051722,0.0068637165,0.00062148937,0.0033489987,0.002057817,0.00227645,0.0033355134],"category_scores_gemma":[0.026125308,0.0014912764,0.03402322,0.007271688,0.0007671816,0.0016270361,0.0013643795,0.0017360648,0.00025059067],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021695471,0.000042716318,0.0017348387,0.47099382,0.50951666,0.00008693658,0.00005787598,0.00036218538,0.00023942873,0.00011090744,0.00037884232,0.014306238],"study_design_scores_gemma":[0.0007027999,0.00023367442,0.0019633125,0.030226242,0.96515,0.00006302375,0.00003406182,0.00013422608,0.00010986475,0.00015045487,0.0012122713,0.000020078582],"about_ca_topic_score_codex":0.004848432,"about_ca_topic_score_gemma":0.010574659,"teacher_disagreement_score":0.022051722,"about_ca_system_score_codex":0.0021156732,"about_ca_system_score_gemma":0.0035344886,"threshold_uncertainty_score":0.06747711},"labels":[],"label_agreement":null},{"id":"W4415603722","doi":"10.1111/dom.70213","title":"Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canada Research Chairs","keywords":"Insulin pump; Type 1 diabetes; Semaglutide; Insulin; Bolus (digestion); Crossover study","score_opus":0.016742660790223504,"score_gpt":0.2860849597777098,"score_spread":0.2693422989874863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415603722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938292,0.0022639027,0.00076978304,0.00010529712,0.0002788698,0.0017758582,0.00044795361,0.000049915034,0.0004792833],"genre_scores_gemma":[0.99224246,0.0009858882,0.0018855622,0.00015298251,0.00029290808,0.0029650298,0.00057650486,0.000028374965,0.0008703212],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99306774,0.004363657,0.00072638755,0.00078670983,0.00061338826,0.00044214862],"domain_scores_gemma":[0.98844343,0.0054294695,0.0030559239,0.00126719,0.000962832,0.0008411709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011388397,0.002091995,0.005829389,0.00059641234,0.00039117155,0.00145129,0.00089524535,0.001402835,0.003197268],"category_scores_gemma":[0.00983136,0.0006175045,0.005382354,0.0005997228,0.0011423957,0.0010936143,0.0005593808,0.0019580696,0.00044858662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9890666,0.0016289377,0.0011144174,0.00032274736,0.0024376332,0.000014947144,0.000047935617,0.0001754312,0.00126586,0.000018139213,0.000103795806,0.003803644],"study_design_scores_gemma":[0.6729383,0.29486915,0.020055125,0.00008710335,0.007841022,0.000048958504,0.00008562269,0.0010791826,0.0021940833,0.00014103432,0.0005992687,0.00006116645],"about_ca_topic_score_codex":0.00058486447,"about_ca_topic_score_gemma":0.00092906534,"teacher_disagreement_score":0.011388397,"about_ca_system_score_codex":0.0010220273,"about_ca_system_score_gemma":0.0012011457,"threshold_uncertainty_score":0.06022829},"labels":[],"label_agreement":null},{"id":"W4415617104","doi":"10.1111/dom.70240","title":"Diabetes management in maternally inherited diabetes and deafness ( <scp>MIDD</scp> ): A review and a proposed treatment algorithm","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Breakthrough T1D Canada","keywords":"Heteroplasmy; Diabetes mellitus; Pathophysiology; Oxidative stress; Type 2 diabetes; Insulin resistance; Diabetes management","score_opus":0.015172358154213203,"score_gpt":0.2733554057617461,"score_spread":0.2581830476075329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415617104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015110079,0.99754936,0.00024320459,0.001149904,0.0003203062,0.000017166147,0.000034810164,0.000013019337,0.0005211941],"genre_scores_gemma":[0.00079839403,0.99722594,0.00057215575,0.00075015414,0.00038979997,0.000025684742,0.00006625006,0.0000024607023,0.0001691508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995927,0.0000877258,0.00015663996,0.00005900291,0.000075786455,0.000028087024],"domain_scores_gemma":[0.9990834,0.0004843192,0.00020503943,0.00001345612,0.00016471124,0.000049056194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009168993,0.0009799065,0.0015962496,0.0033873841,0.00034934265,0.001097527,0.0011505794,0.0012939539,0.00302285],"category_scores_gemma":[0.0017176642,0.00025283892,0.0011983064,0.002336437,0.00041497857,0.0015019501,0.0007513167,0.0017327921,0.00091056124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017478835,0.000094663264,0.00046211702,0.059016183,0.00024527757,0.000566135,0.00014705354,0.00051850616,0.00052010803,0.0032877922,0.041221917,0.8937454],"study_design_scores_gemma":[0.0001032407,0.00040005616,0.0026221352,0.08072882,0.0011857981,0.0068694837,0.00026932114,0.00042644562,0.00030820657,0.0041222014,0.9028997,0.00006455132],"about_ca_topic_score_codex":0.0012346092,"about_ca_topic_score_gemma":0.0020445124,"teacher_disagreement_score":0.0033873841,"about_ca_system_score_codex":0.0007540682,"about_ca_system_score_gemma":0.0016352992,"threshold_uncertainty_score":0.010112464},"labels":[],"label_agreement":null},{"id":"W4415647739","doi":"10.1111/dom.70234","title":"Blood pressure and adverse cardiovascular outcomes in older people with type 2 diabetes and chronic kidney disease: Findings based on the Clinical Practice Research Datalink databases in England","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"NIHR Leicester Biomedical Research Centre; University of Leicester; Department of Health and Social Care; British Heart Foundation; National Institute for Health and Care Research","keywords":"Mace; Blood pressure; Type 2 diabetes; Clinical Practice; Older people; Type 2 Diabetes Mellitus; Adverse effect","score_opus":0.03171958744217211,"score_gpt":0.3215363430491205,"score_spread":0.28981675560694836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415647739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567987,0.011380358,0.00034910894,0.00090469926,0.000022581296,0.0001067171,0.029142002,0.000014077868,0.0012817628],"genre_scores_gemma":[0.98854816,0.0025055036,0.0003402025,0.00024119909,0.000026600572,0.00012686357,0.008057048,0.0000056043677,0.00014878606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9851826,0.0061619696,0.004572961,0.001535517,0.002023385,0.0005235234],"domain_scores_gemma":[0.9307538,0.022032613,0.036647122,0.0035880364,0.0054250164,0.0015533398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008078772,0.00035862104,0.0014113912,0.0038917882,0.00043374556,0.0017883067,0.00090213935,0.0007144868,0.001681157],"category_scores_gemma":[0.049105402,0.0006207458,0.0013701291,0.008889642,0.00039841566,0.001863166,0.003627046,0.0007322189,0.00026207013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026713265,0.000021102056,0.99449253,0.0006218275,0.00044969964,0.00013837767,0.0007749097,0.00010941189,0.000048895177,0.000093773284,0.00068104663,0.0023013402],"study_design_scores_gemma":[0.000041945015,0.000044565244,0.9973117,0.00033850738,0.00021290002,0.00028655003,0.00060539343,0.00032185137,0.000023976165,0.000050554976,0.00074727356,0.000014872536],"about_ca_topic_score_codex":0.06484249,"about_ca_topic_score_gemma":0.05194813,"teacher_disagreement_score":0.06484249,"about_ca_system_score_codex":0.0014121595,"about_ca_system_score_gemma":0.0011354348,"threshold_uncertainty_score":0.12893015},"labels":[],"label_agreement":null},{"id":"W4415655700","doi":"10.1111/dom.70253","title":"An indirect treatment comparison of tirzepatide 10 and 15 mg versus high‐dose semaglutide 7.2 mg in people with obesity and type 2 diabetes","year":2025,"lang":"en","type":"letter","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Semaglutide; Type 2 diabetes; Placebo; Obesity; Clinical trial; Weight loss; Trial registration","score_opus":0.013812651318188382,"score_gpt":0.25427623198390936,"score_spread":0.240463580665721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415655700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9137341,0.05799929,0.0018114636,0.0015215166,0.0035571961,0.0038352688,0.0026329295,0.00014475256,0.014763529],"genre_scores_gemma":[0.9741933,0.011017813,0.0025197547,0.001923098,0.0009633931,0.002563224,0.0012224825,0.000037293048,0.0055595455],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969223,0.0022771622,0.00021675082,0.00021519291,0.00026139632,0.00010705852],"domain_scores_gemma":[0.9968419,0.0018034461,0.0006679117,0.0001734262,0.0002099516,0.00030334143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030878494,0.001523758,0.0031748929,0.00059508934,0.00030147767,0.0011705154,0.00073875615,0.0017657755,0.012913371],"category_scores_gemma":[0.005332064,0.0007095591,0.005596391,0.0004817597,0.00060355174,0.0010485431,0.0007858925,0.0034645428,0.0011781371],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9617732,0.002668283,0.0008771666,0.0023734532,0.0078791445,0.000033404947,0.00007196234,0.00022576646,0.0009810945,0.00027831152,0.00077497726,0.022063252],"study_design_scores_gemma":[0.76821136,0.1919054,0.01249239,0.0007609619,0.018908676,0.00013660331,0.00012729818,0.0008537276,0.0011584283,0.0007710716,0.004585316,0.00008869115],"about_ca_topic_score_codex":0.0010425564,"about_ca_topic_score_gemma":0.002201045,"teacher_disagreement_score":0.012913371,"about_ca_system_score_codex":0.000734323,"about_ca_system_score_gemma":0.00070282485,"threshold_uncertainty_score":0.04319954},"labels":[],"label_agreement":null},{"id":"W4415818676","doi":"10.1111/dom.70252","title":"Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( <scp>iNPHORM</scp> , United States)","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Montgomery County Government","keywords":"Incidence (geometry); Type 2 diabetes; Diabetes mellitus; Hypoglycemia; Type 1 diabetes; MEDLINE","score_opus":0.014857774270946355,"score_gpt":0.25894904067679003,"score_spread":0.24409126640584367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415818676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98170257,0.0008936678,0.00040154404,0.00021060693,0.000021913307,0.000031745716,0.015932946,0.000014499484,0.0007905688],"genre_scores_gemma":[0.9891271,0.0003249885,0.0004550604,0.00012124712,0.00003014251,0.000058645313,0.00974052,0.0000049588816,0.0001372798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989496,0.00041606935,0.0001786072,0.00024689012,0.0001175585,0.0000912741],"domain_scores_gemma":[0.99561995,0.0007308865,0.0028650858,0.00033231537,0.00023000907,0.00022166065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016519388,0.0002411222,0.00026904145,0.00059534976,0.00019992843,0.00057572266,0.0003260094,0.00053457083,0.0014937331],"category_scores_gemma":[0.004137979,0.00024003357,0.0007601408,0.0013507284,0.0001583832,0.00047997045,0.0005883154,0.0006963498,0.0002454467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013922183,0.000019273457,0.9976313,0.00003349159,0.000081908554,0.000023229077,0.000034511388,0.00009301835,0.00003333354,0.000021494288,0.000712141,0.0011770902],"study_design_scores_gemma":[0.000010261042,0.00005650812,0.9989209,0.000028526963,0.000035207224,0.000122025645,0.00008270452,0.00034972955,0.000023601893,0.0000334653,0.00033160712,0.000005438623],"about_ca_topic_score_codex":0.009335172,"about_ca_topic_score_gemma":0.009745906,"teacher_disagreement_score":0.009335172,"about_ca_system_score_codex":0.00035643997,"about_ca_system_score_gemma":0.00024686896,"threshold_uncertainty_score":0.018561661},"labels":[],"label_agreement":null},{"id":"W4415896261","doi":"10.1111/dom.70196","title":"Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( <scp>SYNCHRONIZE</scp> ™‐1)","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Tolerability; Cohort; Weight loss; Baseline (sea); Cohort study; Obesity","score_opus":0.028426785054407305,"score_gpt":0.30824914136559417,"score_spread":0.27982235631118685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415896261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830215,0.0038339354,0.0008251808,0.00037678744,0.0002035056,0.0062188557,0.0034867139,0.000043447264,0.0019900014],"genre_scores_gemma":[0.97793305,0.0013926316,0.0017490734,0.0010842619,0.00016427881,0.0132883685,0.002440709,0.000018505969,0.0019290139],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99876106,0.0006419753,0.00014171933,0.00018465752,0.00012372468,0.00014691857],"domain_scores_gemma":[0.9990357,0.000220129,0.0002806772,0.000059470975,0.000088176006,0.00031582825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034369538,0.0010129059,0.001643131,0.0003034142,0.00055170956,0.0007888062,0.00039256574,0.0013438085,0.004408169],"category_scores_gemma":[0.0025662258,0.00045273366,0.0012119222,0.00037426825,0.0006858433,0.00077003264,0.00026080388,0.001384293,0.00052889285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9579415,0.0071336515,0.011582914,0.0006170347,0.0010175655,0.00006560162,0.00010297822,0.00031756604,0.0056415224,0.000088280576,0.0016999618,0.0137914745],"study_design_scores_gemma":[0.7333106,0.18614188,0.071645506,0.00016679605,0.0018454746,0.00018651737,0.00014248073,0.0010611373,0.001473763,0.00032655915,0.0036257887,0.000073531046],"about_ca_topic_score_codex":0.00050641166,"about_ca_topic_score_gemma":0.0010031201,"teacher_disagreement_score":0.004408169,"about_ca_system_score_codex":0.00031267156,"about_ca_system_score_gemma":0.0010602257,"threshold_uncertainty_score":0.018176556},"labels":[],"label_agreement":null},{"id":"W4416093687","doi":"10.1111/dom.70289","title":"Effects of <scp>SGLT2</scp> inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Janssen Research and Development; Canadian Institutes of Health Research; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Fundação para a Ciência e a Tecnologia; Boehringer Ingelheim; McGill University; Yale University; Eli Lilly and Company","keywords":"Albuminuria; Pooled analysis; Meta-analysis; Kidney disease; Kidney; Clinical trial","score_opus":0.006465847211660236,"score_gpt":0.2536120545076286,"score_spread":0.24714620729596834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416093687","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11406362,0.86711013,0.0054570567,0.0011066031,0.0015888507,0.00386573,0.004407077,0.00027287027,0.0021281112],"genre_scores_gemma":[0.81950134,0.1595912,0.007932976,0.0016519092,0.0007422731,0.0057129767,0.0035399816,0.00013184048,0.0011955332],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9734163,0.01653416,0.0060943244,0.001883515,0.0014823365,0.00058932696],"domain_scores_gemma":[0.98175323,0.010893147,0.0047223098,0.0010244722,0.0012373378,0.00036949947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028155956,0.0031466777,0.020003172,0.0031936427,0.00036614356,0.003413984,0.0012066374,0.0023118265,0.0029259014],"category_scores_gemma":[0.034183167,0.00123754,0.043737028,0.0032291277,0.00081566133,0.0019832407,0.0016513814,0.0020770857,0.00032544142],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078886814,0.00008461638,0.0031968812,0.062452532,0.8393325,0.00005834358,0.00005665661,0.0009795506,0.00036863747,0.000136248,0.0007674098,0.013679777],"study_design_scores_gemma":[0.040854733,0.0030445745,0.008974697,0.005768401,0.937669,0.0000867082,0.000077358745,0.00085768744,0.00028729544,0.0006652064,0.0016565777,0.00005778556],"about_ca_topic_score_codex":0.0033927325,"about_ca_topic_score_gemma":0.004706156,"teacher_disagreement_score":0.028155956,"about_ca_system_score_codex":0.0019577397,"about_ca_system_score_gemma":0.0016713676,"threshold_uncertainty_score":0.14890468},"labels":[],"label_agreement":null},{"id":"W4416093819","doi":"10.1111/dom.70264","title":"Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Deutsche Forschungsgemeinschaft; McGill University","keywords":"Cohort study; Type 2 diabetes; Cohort; Type 2 Diabetes Mellitus; Sodium; Dipeptidyl peptidase-4","score_opus":0.0034519751134909848,"score_gpt":0.2028476780419693,"score_spread":0.1993957029284783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416093819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989537,0.00022822265,0.00009787859,0.000036001133,0.000014081611,0.000014308385,0.0004992741,0.0000029204236,0.00015363083],"genre_scores_gemma":[0.9987453,0.00021557244,0.00012757344,0.000055311913,0.000028423652,0.000024283398,0.00057478173,0.0000037619632,0.00022491446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991698,0.00021963156,0.00007969509,0.0002714875,0.00012322339,0.00013617077],"domain_scores_gemma":[0.9983816,0.0002806189,0.0005823766,0.0002741942,0.00013964274,0.0003416586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015443299,0.00049465866,0.0006235131,0.0006945166,0.000595876,0.0013407667,0.00056175067,0.001049948,0.0013283632],"category_scores_gemma":[0.0026179461,0.0007231051,0.0016136443,0.0012201949,0.00030316526,0.0008531725,0.00054601487,0.0013182153,0.00029652508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010369489,0.00015325674,0.99715626,0.00001140746,0.00048856786,0.00007119153,0.00006399668,0.000049026283,0.00021911204,0.000012684673,0.00009327504,0.00064421986],"study_design_scores_gemma":[0.00019427846,0.00072650926,0.9972894,0.0000111058525,0.0004725649,0.00027268313,0.00017972651,0.0005409944,0.00006322288,0.000034263838,0.00020188032,0.000013316948],"about_ca_topic_score_codex":0.0063141165,"about_ca_topic_score_gemma":0.0058267424,"teacher_disagreement_score":0.0063141165,"about_ca_system_score_codex":0.00035773392,"about_ca_system_score_gemma":0.00047952047,"threshold_uncertainty_score":0.012554765},"labels":[],"label_agreement":null},{"id":"W4416133916","doi":"10.1111/dom.70263","title":"Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Tolerability; Type 2 diabetes; Baseline (sea); Obesity; Glucagon-like peptide 1 receptor; Diabetes mellitus; Glucagon-like peptide-1; Randomized controlled trial","score_opus":0.009285637839900903,"score_gpt":0.2505621433897121,"score_spread":0.2412765055498112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416133916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94574606,0.0054146145,0.0016690716,0.001116463,0.00038270978,0.010252169,0.025780141,0.000086827335,0.009551841],"genre_scores_gemma":[0.94700736,0.0013885943,0.0024830564,0.0020045703,0.0001930528,0.018937191,0.017845018,0.000039921226,0.0101013575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991906,0.00028369162,0.00009103755,0.0001732853,0.00012865195,0.0001327025],"domain_scores_gemma":[0.99937254,0.0001261731,0.00016492774,0.00003539241,0.00007829641,0.00022279826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019269794,0.00086133886,0.001169952,0.00030666118,0.0005968132,0.0005992245,0.00033128716,0.00095920713,0.011130181],"category_scores_gemma":[0.0016409322,0.00039979522,0.000993927,0.00056653,0.00034100283,0.00066256925,0.00020217492,0.0016237305,0.0010869012],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88370985,0.013001905,0.044733036,0.0009591228,0.0020307829,0.0002445881,0.00014006026,0.0010627625,0.007603639,0.00030825648,0.01302643,0.033179544],"study_design_scores_gemma":[0.5701717,0.15265821,0.24993075,0.00029833373,0.002859903,0.000703537,0.00019358103,0.0016222924,0.0029216988,0.0010381329,0.017454954,0.00014687981],"about_ca_topic_score_codex":0.0007134519,"about_ca_topic_score_gemma":0.001578988,"teacher_disagreement_score":0.011130181,"about_ca_system_score_codex":0.0005139124,"about_ca_system_score_gemma":0.0011835722,"threshold_uncertainty_score":0.037234187},"labels":[],"label_agreement":null},{"id":"W4416306192","doi":"10.1111/dom.70290","title":"The value and impact of weight reduction from the perspective of people with type 2 diabetes in the <scp>United States</scp>","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Perspective (graphical); Type 2 diabetes; Weight loss; Value (mathematics); Reduction (mathematics); Type 2 Diabetes Mellitus","score_opus":0.005560948907691396,"score_gpt":0.23543700322753458,"score_spread":0.22987605431984318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416306192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95282173,0.0039486913,0.00050403294,0.02405617,0.0002328704,0.000023820901,0.00017510068,0.000007122783,0.01823057],"genre_scores_gemma":[0.9956862,0.0015173706,0.00026013696,0.002024405,0.000040428808,0.00001054583,0.00003820458,0.0000030613326,0.0004195422],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9970366,0.002208787,0.000084112915,0.000062264255,0.0003550826,0.00025306668],"domain_scores_gemma":[0.99715984,0.0011396047,0.00056189735,0.000057309426,0.0003698377,0.0007114981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034032043,0.0001846044,0.00017549373,0.00049495057,0.0012861773,0.0021903329,0.00034051214,0.0006465674,0.002074016],"category_scores_gemma":[0.005989027,0.00015458063,0.00053559494,0.00041544207,0.0015756282,0.0014370839,0.0017944342,0.0018044963,0.00013445091],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059225556,0.000443303,0.41591188,0.0015366448,0.0005144082,0.0027630685,0.38294253,0.000694427,0.0030921267,0.0058075055,0.020543272,0.16515861],"study_design_scores_gemma":[0.00006117953,0.0007703913,0.23476245,0.0016727939,0.00019832436,0.0022068722,0.7150083,0.0007156028,0.0007615989,0.002976706,0.040792484,0.00007325291],"about_ca_topic_score_codex":0.009232245,"about_ca_topic_score_gemma":0.016188134,"teacher_disagreement_score":0.009232245,"about_ca_system_score_codex":0.0015658574,"about_ca_system_score_gemma":0.0019213485,"threshold_uncertainty_score":0.018357038},"labels":[],"label_agreement":null},{"id":"W4416340615","doi":"10.1111/dom.70299","title":"Despite lower haemoglobin A1c with second‐generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A <scp>BETTER</scp> registry analysis","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ste. Anne's Hospital; Centre Hospitalier de l’Université de Montréal; McGill University; Université de Montréal; Montreal Clinical Research Institute","funders":"Breakthrough T1D Canada; Canadian Institutes of Health Research; Institut de Recherche Clinique De Montréal; Juvenile Diabetes Research Foundation Canada","keywords":"Diabetes mellitus; Type 2 diabetes; Insulin delivery; Type 1 diabetes; Insulin; MEDLINE","score_opus":0.008780291928723458,"score_gpt":0.23852788126642827,"score_spread":0.2297475893377048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416340615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810476,0.0006609543,0.00018102342,0.00020633775,0.000013401227,0.00012392555,0.008975456,0.000014332337,0.0017198044],"genre_scores_gemma":[0.98935986,0.0007124035,0.0005194197,0.00014862802,0.000026725133,0.00012573219,0.008605355,0.0000070607525,0.0004948627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799407,0.00029841255,0.00018858464,0.00028994336,0.0009246031,0.00030444885],"domain_scores_gemma":[0.9955621,0.00039851366,0.0022056971,0.00036588943,0.0010440695,0.0004237858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00186707,0.00027579375,0.00044294642,0.0010712867,0.00072376215,0.0009842751,0.0006081174,0.00026271355,0.0028220706],"category_scores_gemma":[0.0043249633,0.00022172356,0.0009719581,0.003196914,0.00022143623,0.00048146222,0.00067925063,0.00048521435,0.0002557259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015036634,0.000036211582,0.9943474,0.000037091886,0.00012368361,0.000016968628,0.000040690255,0.000033153363,0.00003222556,0.00002697458,0.0009860222,0.004169325],"study_design_scores_gemma":[0.000029563631,0.00006881588,0.9987953,0.000023934303,0.000113056405,0.00005291762,0.00014463086,0.00016538656,0.000039382423,0.000006589502,0.0005562982,0.000004039653],"about_ca_topic_score_codex":0.4227587,"about_ca_topic_score_gemma":0.5617352,"teacher_disagreement_score":0.4227587,"about_ca_system_score_codex":0.0027933645,"about_ca_system_score_gemma":0.0050355066,"threshold_uncertainty_score":0.84059596},"labels":[],"label_agreement":null},{"id":"W4416614007","doi":"10.1111/dom.70309","title":"Sensory network dysregulation in type 2 diabetes: Linking olfactory, visual, and cognitive function","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Olfactory and Sensory Function Studies","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Nanjing Drum Tower Hospital; Nanjing University; National Natural Science Foundation of China; Jiangsu Commission of Health","keywords":"Sensory system; Cognition; Olfaction; Sensory processing; Olfactory system; Cognitive impairment","score_opus":0.05179596970855555,"score_gpt":0.2601387451670569,"score_spread":0.20834277545850133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416614007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739945,0.0013951202,0.00038531542,0.000049210594,0.0000051995657,0.000009225485,0.00012859952,0.000004982855,0.00062289054],"genre_scores_gemma":[0.9987318,0.0006135946,0.00039079107,0.00003878629,0.000009060249,0.000010368969,0.00009366444,0.0000012645694,0.00011067187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999007,0.000029684175,0.0000072393736,0.000028545088,0.000015611628,0.000018230374],"domain_scores_gemma":[0.99975806,0.00006356939,0.00011292637,0.000017414524,0.000021092927,0.000026849673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045514817,0.00059833995,0.00025506088,0.0004378675,0.00021789566,0.0005666418,0.00018710895,0.00024643837,0.0011078877],"category_scores_gemma":[0.0006530048,0.0001117692,0.00034826476,0.000441934,0.00028589575,0.00026292077,0.00037724985,0.00031038022,0.000044149347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028560169,0.000490111,0.92946404,0.00037250138,0.00095764035,0.00060475396,0.00038640742,0.0010123118,0.021930194,0.0002556729,0.00024562908,0.041424695],"study_design_scores_gemma":[0.000021071583,0.00027042764,0.99709415,0.000027552878,0.00015578643,0.00027677807,0.00013372807,0.0007327167,0.0008139227,0.00033902048,0.0001286324,0.0000062814806],"about_ca_topic_score_codex":0.0031098258,"about_ca_topic_score_gemma":0.005009633,"teacher_disagreement_score":0.0031098258,"about_ca_system_score_codex":0.00030158894,"about_ca_system_score_gemma":0.00022637263,"threshold_uncertainty_score":0.0061834455},"labels":[],"label_agreement":null},{"id":"W4416677995","doi":"10.1111/dom.70302","title":"A nationwide 12‐month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Hyperglycemia and glycemic control in critically ill and hospitalized patients","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Société Francophone du Diabète","keywords":"Continuous glucose monitoring; Insulin; Insulin delivery; Diabetes mellitus","score_opus":0.006234940366201611,"score_gpt":0.23634416803472066,"score_spread":0.23010922766851905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416677995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991497,0.00009931701,0.00005959052,0.000044710687,0.0000069418707,0.000015083736,0.00038944822,0.0000043284504,0.00023089518],"genre_scores_gemma":[0.9988832,0.00008450305,0.00015074601,0.000063427746,0.000012227376,0.000025509205,0.0006446869,0.0000019699385,0.00013376746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835676,0.00057692424,0.00017061479,0.00033117624,0.0002834043,0.0002810651],"domain_scores_gemma":[0.99507207,0.00042779534,0.0033148304,0.0002764787,0.00035639413,0.00055241113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018276176,0.00025574613,0.0002695881,0.00056024035,0.000517979,0.0010300095,0.00045192862,0.0005173999,0.0010260239],"category_scores_gemma":[0.0043542897,0.0003301971,0.0005155671,0.0011789259,0.0003528168,0.00082120433,0.0008066534,0.0008349236,0.00022726276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024971258,0.00029812843,0.99616647,0.000018690867,0.000054322947,0.000022175178,0.00009140098,0.00002723632,0.000120070086,0.000006359356,0.00015980248,0.0027855872],"study_design_scores_gemma":[0.000013289093,0.00030913734,0.9993482,0.0000052937953,0.000016310361,0.000034432687,0.00009144002,0.000059247763,0.000025763153,0.0000026757025,0.00009155957,0.0000024490344],"about_ca_topic_score_codex":0.01610799,"about_ca_topic_score_gemma":0.019325767,"teacher_disagreement_score":0.01610799,"about_ca_system_score_codex":0.00086017005,"about_ca_system_score_gemma":0.0009977701,"threshold_uncertainty_score":0.032028437},"labels":[],"label_agreement":null},{"id":"W4416766283","doi":"10.1111/dom.70317","title":"<scp>PIONEER REAL</scp> Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk","keywords":"Semaglutide; Type 2 diabetes; Population; Diabetes mellitus; Patient satisfaction","score_opus":0.009816013317230697,"score_gpt":0.23889823068596952,"score_spread":0.22908221736873882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416766283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855787,0.0002165698,0.00006353142,0.00005953046,0.0000056879035,0.00014985353,0.00074525503,0.000002831021,0.00019887667],"genre_scores_gemma":[0.99735,0.00019763973,0.000630229,0.0001834239,0.000034228135,0.00022439707,0.0010728525,0.0000024325616,0.0003048385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99959475,0.00022384273,0.000037197984,0.000055450524,0.000058113925,0.000030694206],"domain_scores_gemma":[0.99828976,0.0002163814,0.00076521555,0.0001051898,0.00029561762,0.00032778762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012508247,0.00042386557,0.0003365465,0.0002588128,0.00032676864,0.0004433032,0.00031408115,0.00044131436,0.0019540137],"category_scores_gemma":[0.0012633782,0.00024151633,0.00041013613,0.0004528543,0.00022130263,0.00033505293,0.0003962755,0.00033246732,0.00043634354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007877196,0.0013163639,0.9747182,0.0002788602,0.00057123357,0.00014529946,0.0005535343,0.00015883778,0.0020482743,0.00003534277,0.0011163314,0.011180522],"study_design_scores_gemma":[0.0022019306,0.006176831,0.98845005,0.000058138347,0.00024904503,0.00036773522,0.0003976071,0.00048043748,0.0004399972,0.000019162997,0.0011354784,0.000023575272],"about_ca_topic_score_codex":0.0067281816,"about_ca_topic_score_gemma":0.008091257,"teacher_disagreement_score":0.0067281816,"about_ca_system_score_codex":0.00042891255,"about_ca_system_score_gemma":0.000550413,"threshold_uncertainty_score":0.013378024},"labels":[],"label_agreement":null},{"id":"W4416943866","doi":"10.1111/dom.70318","title":"Evaluating the use of virtual reality for weight management: A systematic review and meta‐analysis","year":2025,"lang":"en","type":"review","venue":"Diabetes Obesity and Metabolism","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Winnipeg Regional Health Authority; Seven Oaks General Hospital; Manitoba Health; University of Manitoba","funders":"","keywords":"Virtual reality; Weight loss; Clinical trial; Behaviour change; MEDLINE","score_opus":0.22602604883332192,"score_gpt":0.49227600908563357,"score_spread":0.2662499602523116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416943866","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004155263,0.99333924,0.0008371174,0.00016814897,0.00022664884,0.0007947064,0.00021683941,0.000020771895,0.00024133227],"genre_scores_gemma":[0.14017144,0.8489066,0.005350464,0.00095252483,0.00034293113,0.0035975839,0.00039236344,0.00002660372,0.0002595915],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9790653,0.011627812,0.005599292,0.0012893616,0.0020864317,0.0003318243],"domain_scores_gemma":[0.9670037,0.025420988,0.0044973055,0.0008578594,0.0019473381,0.00027289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023375785,0.0029371951,0.019021332,0.008008773,0.0007940612,0.0043302993,0.002313534,0.0026013139,0.0036545226],"category_scores_gemma":[0.054523665,0.00170302,0.038476527,0.0075181243,0.0010141386,0.0024491816,0.0017807626,0.0022957113,0.00023629866],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014983255,0.000055330533,0.0012741069,0.51027554,0.47125015,0.00007381412,0.00010180589,0.00036057885,0.00019775228,0.00013486948,0.00023199116,0.014545808],"study_design_scores_gemma":[0.00085019914,0.0005372822,0.001903527,0.056375496,0.93816227,0.00008307352,0.000077873745,0.0002083304,0.0001677728,0.00017808011,0.0014283942,0.00002767949],"about_ca_topic_score_codex":0.0058712414,"about_ca_topic_score_gemma":0.012583426,"teacher_disagreement_score":0.023375785,"about_ca_system_score_codex":0.00312729,"about_ca_system_score_gemma":0.0049547357,"threshold_uncertainty_score":0.123624444},"labels":[],"label_agreement":null},{"id":"W4417194820","doi":"10.1111/dom.70350","title":"Clinical implications of intentional weight loss in people living with type 2 diabetes: A real‐world database study","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; University of British Columbia","funders":"Novo Nordisk","keywords":"Weight loss; Obesity; Type 2 diabetes; Excess weight; Body weight; MEDLINE; Population","score_opus":0.018258725063390387,"score_gpt":0.30766603273482757,"score_spread":0.2894073076714372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417194820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868947,0.0016351547,0.0003677383,0.0006891418,0.00004274193,0.00008641076,0.009369048,0.000009348145,0.0009057514],"genre_scores_gemma":[0.9951776,0.00039652621,0.0003145912,0.00028661505,0.000037084465,0.00008330877,0.0036335953,0.0000041700932,0.00006646022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927471,0.003943916,0.0011562792,0.0010843369,0.00078769284,0.00028073977],"domain_scores_gemma":[0.98253596,0.0055724354,0.008801491,0.0015350636,0.0008964995,0.0006585201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044301758,0.00027037936,0.0006425437,0.0011293472,0.00037991005,0.0018922674,0.0008695008,0.00072577444,0.0011181085],"category_scores_gemma":[0.021774549,0.00034870897,0.0015415906,0.0038774807,0.00033212488,0.0011451555,0.0010501397,0.00091663765,0.00012678091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033411887,0.00006440054,0.996727,0.0000934324,0.00069692725,0.00006266381,0.00006293331,0.00011983671,0.000021739112,0.000052172752,0.00043105124,0.0013337495],"study_design_scores_gemma":[0.00009416221,0.00010187054,0.9963076,0.00007932642,0.00053847954,0.0002730386,0.00034457116,0.0014460171,0.00003354532,0.0001051907,0.00065976585,0.000016447737],"about_ca_topic_score_codex":0.011828679,"about_ca_topic_score_gemma":0.013250295,"teacher_disagreement_score":0.011828679,"about_ca_system_score_codex":0.000679329,"about_ca_system_score_gemma":0.0006318836,"threshold_uncertainty_score":0.023519695},"labels":[],"label_agreement":null},{"id":"W4417290268","doi":"10.1111/dom.70358","title":"Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline <scp>HbA1c</scp> , <scp>BMI</scp> and duration of type 2 diabetes subgroups: A post hoc analysis of <scp>ONWARDS</scp> 1–5","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"Novo Nordisk","keywords":"Basal insulin; Post-hoc analysis; Type 2 diabetes; Post hoc; Basal (medicine); Baseline (sea); Insulin; Diabetes mellitus","score_opus":0.016734233936958613,"score_gpt":0.2936411475909479,"score_spread":0.2769069136539893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417290268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934323,0.002420398,0.0004667008,0.0000960133,0.00011966599,0.000821715,0.0011918838,0.000024356525,0.0014270003],"genre_scores_gemma":[0.996101,0.0005760568,0.0007089506,0.00014139205,0.00006535978,0.0007759672,0.00090790604,0.000011111677,0.0007123963],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9982174,0.0009957874,0.00020876243,0.0002470604,0.00015599019,0.00017505596],"domain_scores_gemma":[0.9969273,0.0014338094,0.00077768706,0.00020308976,0.00026568855,0.00039230383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034962595,0.00088529993,0.003245044,0.00040003713,0.00021831616,0.0011078698,0.0004533378,0.00065000233,0.0028193642],"category_scores_gemma":[0.0032432491,0.00036677308,0.0042028483,0.0005127848,0.0004577861,0.00075930654,0.0004330767,0.0021535493,0.00020864185],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9711288,0.0020440272,0.0051734485,0.0006236684,0.006140887,0.000016977609,0.00004662451,0.0008166395,0.0026993465,0.0000692445,0.00037706867,0.010863198],"study_design_scores_gemma":[0.41112396,0.45834354,0.08974288,0.0002698385,0.025399424,0.00012322442,0.00019828649,0.004205392,0.007245669,0.00044005646,0.0028103876,0.000097407734],"about_ca_topic_score_codex":0.00085352216,"about_ca_topic_score_gemma":0.0017751111,"teacher_disagreement_score":0.0034962595,"about_ca_system_score_codex":0.0005469496,"about_ca_system_score_gemma":0.00075432484,"threshold_uncertainty_score":0.018490195},"labels":[],"label_agreement":null},{"id":"W4417292863","doi":"10.1111/dom.70375","title":"Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Trillium Health Centre; Women's College Hospital; University of Toronto; University of British Columbia","funders":"Ministry of Health, British Columbia","keywords":"Type 2 Diabetes Mellitus; Type 2 diabetes; Diabetes mellitus; Disease; Kidney disease","score_opus":0.0049636346903255005,"score_gpt":0.19019516505616174,"score_spread":0.18523153036583623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417292863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888948,0.0020257449,0.000086435066,0.00047998078,0.000023880091,0.000044656026,0.0058590826,0.000014403508,0.0025708273],"genre_scores_gemma":[0.9941029,0.0016025761,0.00020018307,0.00039800984,0.000012087445,0.00003312821,0.0024274753,0.0000056583326,0.0012180199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942064,0.00004774136,0.00007678257,0.00009082088,0.00020680389,0.0001572954],"domain_scores_gemma":[0.9983645,0.00010049229,0.0004120015,0.000046916794,0.0006478393,0.00042821892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044512821,0.00023658585,0.00033997835,0.0011492267,0.0014507185,0.00093148014,0.0007693201,0.00041505098,0.0017118321],"category_scores_gemma":[0.0015554768,0.00027328098,0.00036538113,0.003135256,0.00033431654,0.00028595625,0.00062499515,0.0006098008,0.00025120596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029468853,0.000029855344,0.9942516,0.00005217134,0.000028831157,0.000060198494,0.00018962966,0.000052370735,0.00009750246,0.000019178564,0.0011524772,0.0040366515],"study_design_scores_gemma":[0.0000061350306,0.000010757687,0.99862194,0.00006812809,0.000016825581,0.00006203198,0.00038087263,0.00013082744,0.000030485155,0.000009664285,0.00065684057,0.0000054965585],"about_ca_topic_score_codex":0.97479486,"about_ca_topic_score_gemma":0.9862314,"teacher_disagreement_score":0.025205135,"about_ca_system_score_codex":0.0076714265,"about_ca_system_score_gemma":0.010625298,"threshold_uncertainty_score":0.055660367},"labels":[],"label_agreement":null},{"id":"W4417319772","doi":"10.1111/dom.70385","title":"Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the <scp>PSMMC NephraRisk</scp> model","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Prince Sultan Military Medical City","keywords":"Software deployment; Ensemble learning; Ensemble forecasting; Predictive modelling; Risk assessment; Disease; Clinical decision making; Kidney disease","score_opus":0.009021138665120606,"score_gpt":0.22723824409419288,"score_spread":0.21821710542907227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417319772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7640992,0.0017311834,0.22803679,0.0013701089,0.00011218864,0.00030318924,0.0016139473,0.00091279077,0.0018205967],"genre_scores_gemma":[0.95332575,0.00026939358,0.043914896,0.00019932362,0.000048582337,0.00016036215,0.0015062735,0.000036104288,0.0005393223],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99829775,0.0011170678,0.00009881153,0.00023403313,0.00016146275,0.00009085615],"domain_scores_gemma":[0.9935061,0.00453261,0.00044227758,0.0004799433,0.0008698968,0.00016925266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0111094965,0.00076211995,0.0011602793,0.001025002,0.0003642069,0.0008595024,0.0011797481,0.0006125858,0.00088924926],"category_scores_gemma":[0.015113896,0.000308807,0.0012677357,0.00071151444,0.00022045978,0.000584794,0.0009772354,0.0012163984,0.00025435735],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009326387,0.0004925399,0.117003486,0.000116488874,0.0013058957,0.00012079358,0.00015615848,0.7245899,0.0009906646,0.0011626869,0.0030223837,0.15010639],"study_design_scores_gemma":[0.000027717613,0.00015947648,0.0051888246,0.0000257029,0.00010564763,0.000026290278,0.0000149002735,0.9929952,0.00027641683,0.00085906364,0.00030836172,0.0000122935535],"about_ca_topic_score_codex":0.010112138,"about_ca_topic_score_gemma":0.0104106525,"teacher_disagreement_score":0.0111094965,"about_ca_system_score_codex":0.0008504385,"about_ca_system_score_gemma":0.0016164228,"threshold_uncertainty_score":0.05875337},"labels":[],"label_agreement":null},{"id":"W4417319939","doi":"10.1111/dom.70382","title":"Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence","year":2025,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Exenatide; MEDLINE; Clinical trial; Randomized controlled trial; Glucagon-like peptide 1 receptor; Meta-analysis","score_opus":0.031821337890528704,"score_gpt":0.28201902779756494,"score_spread":0.2501976899070362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417319939","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009394041,0.98285204,0.0045244074,0.0006603866,0.00035472962,0.0005474726,0.0010296482,0.00007115197,0.00056604],"genre_scores_gemma":[0.5014329,0.47716528,0.012375727,0.0022439368,0.00067396474,0.0032081036,0.002224156,0.00016326598,0.0005126231],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.92308277,0.053329013,0.014581428,0.00402738,0.0042296476,0.0007497841],"domain_scores_gemma":[0.8633959,0.115360156,0.012794288,0.004596101,0.0033576433,0.00049592735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.071969144,0.003899945,0.021226944,0.008137076,0.00041201792,0.0055690613,0.0025558637,0.0028473795,0.0036619545],"category_scores_gemma":[0.1313467,0.0017974977,0.059243154,0.007993203,0.00097089,0.0026030752,0.002148442,0.002742445,0.00039414008],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016558879,0.000017109001,0.0029322105,0.08313755,0.9046246,0.000060756436,0.000042517087,0.0008007351,0.000102247854,0.00020096496,0.00029543962,0.006130085],"study_design_scores_gemma":[0.00071274367,0.0001699807,0.0026867834,0.010167765,0.9836586,0.00005921093,0.000037343867,0.00047704944,0.00013223146,0.00080182444,0.0010714636,0.000024914934],"about_ca_topic_score_codex":0.002558329,"about_ca_topic_score_gemma":0.003636018,"teacher_disagreement_score":0.071969144,"about_ca_system_score_codex":0.002358628,"about_ca_system_score_gemma":0.0023629037,"threshold_uncertainty_score":0.38061374},"labels":[],"label_agreement":null}]}